2023-12-29 04:38:51,957 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2023-12-29 04:38:51,957 - INFO - NumExpr defaulting to 8 threads.
2023-12-29 04:38:54,946 - INFO - openai_wrapper loaded
2023-12-29 04:38:55,252 - INFO - Starting
2023-12-29 04:38:56,580 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2023-12-29 04:43:48,886 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2023-12-29 04:43:48,886 - INFO - NumExpr defaulting to 8 threads.
2023-12-29 04:44:04,089 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2023-12-29 04:44:04,089 - INFO - NumExpr defaulting to 8 threads.
2023-12-29 04:44:04,410 - INFO - openai_wrapper loaded
2023-12-29 04:44:04,710 - INFO - Starting
2023-12-29 04:44:07,005 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-01 09:33:47,028 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-01 09:33:47,028 - INFO - NumExpr defaulting to 8 threads.
2024-01-01 09:33:49,909 - INFO - openai_wrapper loaded
2024-01-01 09:33:50,212 - INFO - Starting
2024-01-01 09:35:00,334 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-01 09:35:00,334 - INFO - NumExpr defaulting to 8 threads.
2024-01-01 09:35:00,662 - INFO - openai_wrapper loaded
2024-01-01 09:35:00,964 - INFO - Starting
2024-01-01 09:45:20,786 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-01 09:45:20,786 - INFO - NumExpr defaulting to 8 threads.
2024-01-01 09:45:21,110 - INFO - openai_wrapper loaded
2024-01-01 09:45:21,409 - INFO - Starting
2024-01-01 09:49:53,707 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-01 09:49:53,707 - INFO - NumExpr defaulting to 8 threads.
2024-01-01 09:49:54,025 - INFO - openai_wrapper loaded
2024-01-01 09:49:54,335 - INFO - Starting
2024-01-01 09:55:37,952 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-01 09:55:37,952 - INFO - NumExpr defaulting to 8 threads.
2024-01-01 09:55:38,283 - INFO - openai_wrapper loaded
2024-01-01 09:55:38,592 - INFO - Starting
2024-01-01 09:56:27,025 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-01 09:56:27,025 - INFO - NumExpr defaulting to 8 threads.
2024-01-01 09:56:27,372 - INFO - openai_wrapper loaded
2024-01-01 09:56:27,682 - INFO - Starting
2024-01-01 09:59:51,282 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-01 09:59:51,282 - INFO - NumExpr defaulting to 8 threads.
2024-01-01 09:59:51,644 - INFO - openai_wrapper loaded
2024-01-01 09:59:51,936 - INFO - Starting
2024-01-01 10:00:45,833 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-01 10:00:45,833 - INFO - NumExpr defaulting to 8 threads.
2024-01-01 10:00:46,193 - INFO - openai_wrapper loaded
2024-01-01 10:00:46,502 - INFO - Starting
2024-01-01 10:01:38,059 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-01 10:01:38,059 - INFO - NumExpr defaulting to 8 threads.
2024-01-01 10:01:38,436 - INFO - openai_wrapper loaded
2024-01-01 10:01:38,726 - INFO - Starting
2024-01-01 10:02:16,412 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-01 10:02:16,412 - INFO - NumExpr defaulting to 8 threads.
2024-01-01 10:02:16,782 - INFO - openai_wrapper loaded
2024-01-01 10:02:17,087 - INFO - Starting
2024-01-01 10:03:29,472 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-01 10:03:29,472 - INFO - NumExpr defaulting to 8 threads.
2024-01-01 10:03:29,822 - INFO - openai_wrapper loaded
2024-01-01 10:03:30,135 - INFO - Starting
2024-01-01 10:04:19,076 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-01 10:04:19,076 - INFO - NumExpr defaulting to 8 threads.
2024-01-01 10:04:19,463 - INFO - openai_wrapper loaded
2024-01-01 10:04:19,793 - INFO - Starting
2024-01-01 10:05:46,700 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-01 10:05:46,700 - INFO - NumExpr defaulting to 8 threads.
2024-01-01 10:05:47,015 - INFO - openai_wrapper loaded
2024-01-01 10:05:47,316 - INFO - Starting
2024-01-01 10:08:24,712 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-01 10:08:24,712 - INFO - NumExpr defaulting to 8 threads.
2024-01-01 10:08:25,032 - INFO - openai_wrapper loaded
2024-01-01 10:08:25,332 - INFO - Starting
2024-01-01 10:10:14,619 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-01 10:10:14,619 - INFO - NumExpr defaulting to 8 threads.
2024-01-01 10:10:14,957 - INFO - openai_wrapper loaded
2024-01-01 10:10:15,266 - INFO - Starting
2024-01-01 10:10:33,976 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-01 10:10:33,976 - INFO - NumExpr defaulting to 8 threads.
2024-01-01 10:10:34,283 - INFO - openai_wrapper loaded
2024-01-01 10:10:34,588 - INFO - Starting
2024-01-01 10:11:53,502 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-01 10:11:53,502 - INFO - NumExpr defaulting to 8 threads.
2024-01-01 10:11:53,851 - INFO - openai_wrapper loaded
2024-01-01 10:11:54,162 - INFO - Starting
2024-01-01 10:15:49,725 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-01 10:15:49,725 - INFO - NumExpr defaulting to 8 threads.
2024-01-01 10:15:50,043 - INFO - openai_wrapper loaded
2024-01-01 10:15:50,343 - INFO - Starting
2024-01-01 10:16:06,112 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-01 10:16:06,112 - INFO - NumExpr defaulting to 8 threads.
2024-01-01 10:16:06,472 - INFO - openai_wrapper loaded
2024-01-01 10:16:06,773 - INFO - Starting
2024-01-01 10:17:52,432 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-01 10:17:52,432 - INFO - NumExpr defaulting to 8 threads.
2024-01-01 10:17:52,813 - INFO - openai_wrapper loaded
2024-01-01 10:17:53,133 - INFO - Starting
2024-01-01 10:18:07,052 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-01 10:18:07,052 - INFO - NumExpr defaulting to 8 threads.
2024-01-01 10:18:07,442 - INFO - openai_wrapper loaded
2024-01-01 10:18:07,752 - INFO - Starting
2024-01-01 10:23:55,722 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-01 10:23:55,722 - INFO - NumExpr defaulting to 8 threads.
2024-01-01 10:23:56,072 - INFO - openai_wrapper loaded
2024-01-01 10:23:56,362 - INFO - Starting
2024-01-01 10:24:16,632 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-01 10:24:16,632 - INFO - NumExpr defaulting to 8 threads.
2024-01-01 10:24:16,995 - INFO - openai_wrapper loaded
2024-01-01 10:24:17,292 - INFO - Starting
2024-01-01 10:50:11,799 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-01 10:50:11,799 - INFO - NumExpr defaulting to 8 threads.
2024-01-01 10:50:12,122 - INFO - openai_wrapper loaded
2024-01-01 10:50:12,437 - INFO - Starting
2024-01-01 10:51:33,116 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-01 10:51:33,116 - INFO - NumExpr defaulting to 8 threads.
2024-01-01 10:51:33,472 - INFO - openai_wrapper loaded
2024-01-01 10:51:33,772 - INFO - Starting
2024-01-01 10:52:16,098 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-01 10:52:16,098 - INFO - NumExpr defaulting to 8 threads.
2024-01-01 10:52:16,411 - INFO - openai_wrapper loaded
2024-01-01 10:52:16,701 - INFO - Starting
2024-01-01 11:06:49,336 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-01 11:06:49,336 - INFO - NumExpr defaulting to 8 threads.
2024-01-01 11:06:49,662 - INFO - openai_wrapper loaded
2024-01-01 11:06:49,960 - INFO - Starting
2024-01-01 11:07:55,344 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-01 11:07:55,344 - INFO - NumExpr defaulting to 8 threads.
2024-01-01 11:07:55,651 - INFO - openai_wrapper loaded
2024-01-01 11:07:55,961 - INFO - Starting
2024-01-01 11:13:32,772 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-01 11:13:32,772 - INFO - NumExpr defaulting to 8 threads.
2024-01-01 11:13:33,075 - INFO - openai_wrapper loaded
2024-01-01 11:13:33,371 - INFO - Starting
2024-01-01 11:14:05,621 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-01 11:14:05,621 - INFO - NumExpr defaulting to 8 threads.
2024-01-01 11:14:05,923 - INFO - openai_wrapper loaded
2024-01-01 11:14:06,224 - INFO - Starting
2024-01-01 11:16:30,431 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-01 11:16:30,431 - INFO - NumExpr defaulting to 8 threads.
2024-01-01 11:16:30,759 - INFO - openai_wrapper loaded
2024-01-01 11:16:31,051 - INFO - Starting
2024-01-01 11:16:49,564 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-01 11:16:49,564 - INFO - NumExpr defaulting to 8 threads.
2024-01-01 11:16:49,878 - INFO - openai_wrapper loaded
2024-01-01 11:16:50,176 - INFO - Starting
2024-01-01 11:17:08,656 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-01 11:17:08,656 - INFO - NumExpr defaulting to 8 threads.
2024-01-01 11:17:08,968 - INFO - openai_wrapper loaded
2024-01-01 11:17:09,260 - INFO - Starting
2024-01-01 11:17:30,802 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-01 11:17:30,802 - INFO - NumExpr defaulting to 8 threads.
2024-01-01 11:17:31,096 - INFO - openai_wrapper loaded
2024-01-01 11:17:31,406 - INFO - Starting
2024-01-01 11:18:24,122 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-01 11:18:24,122 - INFO - NumExpr defaulting to 8 threads.
2024-01-01 11:18:24,443 - INFO - openai_wrapper loaded
2024-01-01 11:18:24,749 - INFO - Starting
2024-01-01 11:18:39,604 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-01 11:18:39,604 - INFO - NumExpr defaulting to 8 threads.
2024-01-01 11:18:39,917 - INFO - openai_wrapper loaded
2024-01-01 11:18:40,210 - INFO - Starting
2024-01-01 11:19:08,684 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-01 11:19:08,684 - INFO - NumExpr defaulting to 8 threads.
2024-01-01 11:19:08,994 - INFO - openai_wrapper loaded
2024-01-01 11:19:09,297 - INFO - Starting
2024-01-01 11:20:27,762 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-01 11:20:27,766 - INFO - NumExpr defaulting to 8 threads.
2024-01-01 11:20:28,082 - INFO - openai_wrapper loaded
2024-01-01 11:20:28,372 - INFO - Starting
2024-01-01 19:39:17,361 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-01 19:39:17,361 - INFO - NumExpr defaulting to 8 threads.
2024-01-01 19:39:20,073 - INFO - openai_wrapper loaded
2024-01-01 19:39:20,379 - INFO - Starting
2024-01-01 19:40:39,616 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-01 19:40:39,616 - INFO - NumExpr defaulting to 8 threads.
2024-01-01 19:40:39,963 - INFO - openai_wrapper loaded
2024-01-01 19:40:40,263 - INFO - Starting
2024-01-01 19:40:51,695 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-01 19:40:51,695 - INFO - NumExpr defaulting to 8 threads.
2024-01-01 19:40:52,051 - INFO - openai_wrapper loaded
2024-01-01 19:40:52,353 - INFO - Starting
2024-01-01 19:41:05,919 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-01 19:41:05,919 - INFO - NumExpr defaulting to 8 threads.
2024-01-01 19:41:06,293 - INFO - openai_wrapper loaded
2024-01-01 19:41:06,612 - INFO - Starting
2024-01-01 19:42:10,030 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-01 19:42:10,030 - INFO - NumExpr defaulting to 8 threads.
2024-01-01 19:42:10,399 - INFO - openai_wrapper loaded
2024-01-01 19:42:10,693 - INFO - Starting
2024-01-01 19:42:23,162 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-01 19:42:23,162 - INFO - NumExpr defaulting to 8 threads.
2024-01-01 19:42:23,547 - INFO - openai_wrapper loaded
2024-01-01 19:42:23,861 - INFO - Starting
2024-01-01 19:43:13,133 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-01 19:43:13,133 - INFO - NumExpr defaulting to 8 threads.
2024-01-01 19:43:13,493 - INFO - openai_wrapper loaded
2024-01-01 19:43:13,797 - INFO - Starting
2024-01-01 20:18:20,461 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-01 20:18:20,461 - INFO - NumExpr defaulting to 8 threads.
2024-01-01 20:18:20,819 - INFO - openai_wrapper loaded
2024-01-01 20:18:21,125 - INFO - Starting
2024-01-01 20:19:00,438 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-01 20:19:00,438 - INFO - NumExpr defaulting to 8 threads.
2024-01-01 20:19:00,759 - INFO - openai_wrapper loaded
2024-01-01 20:19:01,061 - INFO - Starting
2024-01-01 20:19:36,092 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-01 20:19:36,092 - INFO - NumExpr defaulting to 8 threads.
2024-01-01 20:19:36,404 - INFO - openai_wrapper loaded
2024-01-01 20:19:36,699 - INFO - Starting
2024-01-01 20:19:55,839 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-01 20:19:58,682 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-01 20:19:59,859 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-01 20:19:59,889 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-01 20:19:59,893 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-01 20:19:59,948 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-01 20:20:04,029 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-01 20:20:04,052 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-01 20:20:07,020 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-01 20:20:13,078 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-01 20:20:46,818 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-01 20:20:46,874 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-01 20:20:48,481 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-01 20:20:48,489 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-01 20:20:53,641 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-01 20:20:54,059 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-01 20:20:54,138 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-01 20:20:56,458 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-01 20:20:59,819 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-01 20:21:03,446 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-01 22:53:53,560 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-01 22:53:53,560 - INFO - NumExpr defaulting to 8 threads.
2024-01-01 22:53:56,265 - INFO - openai_wrapper loaded
2024-01-01 22:53:56,573 - INFO - Starting
2024-01-01 22:55:38,783 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-01 22:55:38,783 - INFO - NumExpr defaulting to 8 threads.
2024-01-01 22:55:39,098 - INFO - openai_wrapper loaded
2024-01-01 22:55:39,393 - INFO - Starting
2024-01-01 22:56:23,123 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-01 22:56:23,123 - INFO - NumExpr defaulting to 8 threads.
2024-01-01 22:56:23,436 - INFO - openai_wrapper loaded
2024-01-01 22:56:23,736 - INFO - Starting
2024-01-01 22:57:44,989 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-01 22:57:44,989 - INFO - NumExpr defaulting to 8 threads.
2024-01-01 22:57:45,304 - INFO - openai_wrapper loaded
2024-01-01 22:57:45,608 - INFO - Starting
2024-01-01 22:58:26,893 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-01 22:58:26,893 - INFO - NumExpr defaulting to 8 threads.
2024-01-01 22:58:27,213 - INFO - openai_wrapper loaded
2024-01-01 22:58:27,505 - INFO - Starting
2024-01-01 22:59:25,314 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-01 22:59:25,314 - INFO - NumExpr defaulting to 8 threads.
2024-01-01 22:59:25,633 - INFO - openai_wrapper loaded
2024-01-01 22:59:25,932 - INFO - Starting
2024-01-01 23:00:18,774 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-01 23:00:18,774 - INFO - NumExpr defaulting to 8 threads.
2024-01-01 23:00:19,093 - INFO - openai_wrapper loaded
2024-01-01 23:00:19,388 - INFO - Starting
2024-01-01 23:49:34,816 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-01 23:49:34,816 - INFO - NumExpr defaulting to 8 threads.
2024-01-01 23:49:35,139 - INFO - openai_wrapper loaded
2024-01-01 23:49:35,436 - INFO - Starting
2024-01-01 23:49:42,520 - INFO - "GET /?state=Cg7fhN0StMpCLOXrBFvgedoB5RJUiw&code=4/0AfJohXmO25HxxlzvplMo3yK9Pv0zrpFXHvaIyH6rzp-PlR7Maxr5XcMGSI5xLJZ7Yv0WDg&scope=https://www.googleapis.com/auth/spreadsheets HTTP/1.1" 200 65
2024-01-01 23:49:42,914 - INFO - file_cache is only supported with oauth2client<4.0.0
2024-01-01 23:49:49,089 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-01 23:49:49,376 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-01 23:49:51,467 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-01 23:49:52,626 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-01 23:49:54,734 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-01 23:52:12,697 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-01 23:52:12,698 - INFO - NumExpr defaulting to 8 threads.
2024-01-01 23:52:13,019 - INFO - openai_wrapper loaded
2024-01-01 23:52:13,316 - INFO - Starting
2024-01-01 23:52:13,324 - INFO - file_cache is only supported with oauth2client<4.0.0
2024-01-01 23:52:19,935 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-01 23:52:20,019 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-01 23:52:21,279 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-01 23:52:22,339 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-01 23:52:22,588 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:03:18,317 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-02 00:03:18,317 - INFO - NumExpr defaulting to 8 threads.
2024-01-02 00:03:18,649 - INFO - openai_wrapper loaded
2024-01-02 00:03:18,946 - INFO - Starting
2024-01-02 00:03:18,956 - INFO - file_cache is only supported with oauth2client<4.0.0
2024-01-02 00:03:25,538 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:03:26,644 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:03:26,999 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:03:27,203 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:03:30,958 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:05:00,358 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-02 00:05:00,358 - INFO - NumExpr defaulting to 8 threads.
2024-01-02 00:05:00,680 - INFO - openai_wrapper loaded
2024-01-02 00:05:00,979 - INFO - Starting
2024-01-02 00:05:00,983 - INFO - file_cache is only supported with oauth2client<4.0.0
2024-01-02 00:05:07,624 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:05:08,644 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:05:11,588 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:05:13,942 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:05:14,042 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:07:40,906 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-02 00:07:40,906 - INFO - NumExpr defaulting to 8 threads.
2024-01-02 00:07:41,223 - INFO - openai_wrapper loaded
2024-01-02 00:07:41,517 - INFO - Starting
2024-01-02 00:07:41,522 - INFO - file_cache is only supported with oauth2client<4.0.0
2024-01-02 00:07:46,858 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:07:48,210 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:07:49,823 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:07:49,886 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:07:51,335 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:10:40,496 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-02 00:10:40,496 - INFO - NumExpr defaulting to 8 threads.
2024-01-02 00:10:40,812 - INFO - openai_wrapper loaded
2024-01-02 00:10:41,107 - INFO - Starting
2024-01-02 00:10:41,111 - INFO - file_cache is only supported with oauth2client<4.0.0
2024-01-02 00:10:48,485 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:10:49,691 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:10:49,840 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:10:50,958 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:10:52,516 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:11:50,125 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-02 00:11:50,125 - INFO - NumExpr defaulting to 8 threads.
2024-01-02 00:11:50,450 - INFO - openai_wrapper loaded
2024-01-02 00:11:50,756 - INFO - Starting
2024-01-02 00:11:50,761 - INFO - file_cache is only supported with oauth2client<4.0.0
2024-01-02 00:11:55,560 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:11:56,634 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:11:58,272 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:11:58,522 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:11:59,038 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:12:22,334 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-02 00:12:22,334 - INFO - NumExpr defaulting to 8 threads.
2024-01-02 00:12:22,674 - INFO - openai_wrapper loaded
2024-01-02 00:12:22,981 - INFO - Starting
2024-01-02 00:12:22,985 - INFO - file_cache is only supported with oauth2client<4.0.0
2024-01-02 00:12:29,140 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:12:30,096 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:12:30,198 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:12:31,670 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:12:35,724 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:14:36,612 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-02 00:14:36,612 - INFO - NumExpr defaulting to 8 threads.
2024-01-02 00:14:36,945 - INFO - openai_wrapper loaded
2024-01-02 00:14:37,240 - INFO - Starting
2024-01-02 00:14:37,244 - INFO - file_cache is only supported with oauth2client<4.0.0
2024-01-02 00:14:43,514 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:14:43,662 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:14:43,691 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:14:44,872 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:14:45,677 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:17:30,936 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-02 00:17:30,937 - INFO - NumExpr defaulting to 8 threads.
2024-01-02 00:17:31,260 - INFO - openai_wrapper loaded
2024-01-02 00:17:31,563 - INFO - Starting
2024-01-02 00:17:31,568 - INFO - file_cache is only supported with oauth2client<4.0.0
2024-01-02 00:17:36,890 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:17:38,842 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:17:40,611 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:17:40,816 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:17:42,418 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:18:56,751 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-02 00:18:56,751 - INFO - NumExpr defaulting to 8 threads.
2024-01-02 00:18:57,069 - INFO - openai_wrapper loaded
2024-01-02 00:18:57,367 - INFO - Starting
2024-01-02 00:18:57,372 - INFO - file_cache is only supported with oauth2client<4.0.0
2024-01-02 00:19:03,172 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:19:03,573 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:19:03,591 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:19:03,678 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:19:03,705 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:21:06,028 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-02 00:21:06,028 - INFO - NumExpr defaulting to 8 threads.
2024-01-02 00:21:06,397 - INFO - openai_wrapper loaded
2024-01-02 00:21:06,710 - INFO - Starting
2024-01-02 00:21:06,715 - INFO - file_cache is only supported with oauth2client<4.0.0
2024-01-02 00:21:13,666 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:21:13,858 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:21:17,210 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:21:17,544 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:21:18,032 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:23:02,344 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-02 00:23:02,344 - INFO - NumExpr defaulting to 8 threads.
2024-01-02 00:23:02,700 - INFO - openai_wrapper loaded
2024-01-02 00:23:03,020 - INFO - Starting
2024-01-02 00:23:03,023 - INFO - file_cache is only supported with oauth2client<4.0.0
2024-01-02 00:23:09,550 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:23:10,190 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:23:11,021 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:23:12,698 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:23:12,840 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:23:18,656 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:23:18,781 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:23:19,387 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:23:19,638 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:23:19,961 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:24:51,439 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-02 00:24:51,439 - INFO - NumExpr defaulting to 8 threads.
2024-01-02 00:24:51,785 - INFO - openai_wrapper loaded
2024-01-02 00:24:52,109 - INFO - Starting
2024-01-02 00:24:52,113 - INFO - file_cache is only supported with oauth2client<4.0.0
2024-01-02 00:24:57,652 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:24:57,662 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:24:57,793 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:24:57,937 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:24:57,945 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:24:58,356 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:24:58,417 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:24:58,427 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:24:58,454 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:24:58,468 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:24:58,570 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:24:58,575 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:24:58,576 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:24:58,606 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:24:58,636 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:24:58,728 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:24:58,735 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:24:58,735 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:24:58,761 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:24:58,766 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:24:58,801 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:24:58,807 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:24:58,808 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:24:58,832 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:24:58,837 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:24:58,840 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:24:58,898 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:24:58,964 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:24:58,966 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:24:58,970 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:24:58,994 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:24:59,020 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:24:59,026 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:24:59,098 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:24:59,119 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:24:59,151 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:24:59,163 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:24:59,175 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:24:59,236 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:24:59,239 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:24:59,252 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:24:59,263 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:24:59,271 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:24:59,294 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:24:59,309 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:24:59,358 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:24:59,613 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:24:59,615 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:24:59,635 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:24:59,675 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:24:59,704 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:24:59,821 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:24:59,840 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:24:59,877 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:24:59,883 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:24:59,917 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:24:59,951 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:24:59,962 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:00,006 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:00,008 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:00,010 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:00,067 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:00,071 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:00,114 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:00,122 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:00,144 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:00,149 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:00,180 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:00,277 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:00,344 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:00,352 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:00,403 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:00,676 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:00,736 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:00,738 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:00,836 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:00,965 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:01,036 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:01,092 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:01,092 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:01,101 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:01,116 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:01,163 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:01,210 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:01,236 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:01,329 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:01,355 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:01,369 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:01,398 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:01,518 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:01,663 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:01,715 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:01,887 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:02,033 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:02,035 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:02,045 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:02,087 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:02,159 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:02,178 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:02,186 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:02,213 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:02,351 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:02,384 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:02,410 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:02,418 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:02,534 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:02,540 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:02,585 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:02,635 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:02,700 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:02,702 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:02,708 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:02,776 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:02,819 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:02,877 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:02,929 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:02,949 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:02,970 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:03,053 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:03,145 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:03,277 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:03,292 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:03,476 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:03,517 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:03,521 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:03,522 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:03,638 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:03,719 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:03,776 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:03,886 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:03,912 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:03,935 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:03,954 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:03,988 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:04,025 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:04,062 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:04,094 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:04,128 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:04,201 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:04,245 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:04,388 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:04,435 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:04,528 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:04,529 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:04,584 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:04,587 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:04,605 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:04,713 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:04,830 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:04,876 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:04,941 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:04,944 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:04,967 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:04,995 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:05,078 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:05,128 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:05,162 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:05,166 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:05,244 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:05,256 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:05,258 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:05,345 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:05,371 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:05,419 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:05,428 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:05,437 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:05,570 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:05,686 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:05,709 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:06,042 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:06,251 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:06,330 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:06,441 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:06,532 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:06,534 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:06,649 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:06,650 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:06,654 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:06,822 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:06,839 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:07,008 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:07,067 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:07,447 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:07,453 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:07,613 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:07,670 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:07,779 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:07,901 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:08,049 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:08,250 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:08,423 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:08,904 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:08,998 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:09,078 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:09,299 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:09,772 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:10,616 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:10,684 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:11,887 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:14,307 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:19,124 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:19,608 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:19,656 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:19,715 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:19,883 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:19,946 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:19,993 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:20,005 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:20,090 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:20,124 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:20,273 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:20,415 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:20,432 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:20,466 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:20,558 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:20,590 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:20,598 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:20,624 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:20,634 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:20,639 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:20,640 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:20,743 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:20,763 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:20,800 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:20,810 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:20,813 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:20,851 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:20,874 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:20,900 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:20,908 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:20,910 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:20,969 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:21,026 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:21,056 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:21,073 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:21,074 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:21,082 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:21,096 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:21,125 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:21,139 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:21,162 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:21,182 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:21,192 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:21,193 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:21,197 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:21,199 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:21,206 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:21,223 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:21,226 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:21,227 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:21,232 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:21,235 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:21,241 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:21,259 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:21,268 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:21,322 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:21,450 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:21,460 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:21,507 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:21,525 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:21,648 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:21,674 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:21,682 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:21,692 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:21,693 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:21,726 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:21,731 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:21,770 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:21,796 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:21,841 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:21,859 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:21,906 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:21,907 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:22,025 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:22,117 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:22,241 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:22,256 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:22,272 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:22,315 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:22,317 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:22,360 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:22,379 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:22,415 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:22,549 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:22,566 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:22,624 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:22,669 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:22,724 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:22,746 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:22,825 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:22,841 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:22,932 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:22,952 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:23,035 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:23,151 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:23,171 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:23,215 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:23,373 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:23,501 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:23,552 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:23,557 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:23,778 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:24,033 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:24,039 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:24,194 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:24,244 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:24,308 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:24,418 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:24,454 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:24,467 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:24,544 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:24,591 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:24,600 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:24,608 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:24,618 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:24,618 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:24,661 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:24,665 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:24,716 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:24,785 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:24,806 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:24,855 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:24,860 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:24,901 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:24,918 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:24,949 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:24,955 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:25,046 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:25,117 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:25,182 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:25,274 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:25,361 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:25,362 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:25,362 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:25,375 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:25,394 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:25,416 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:25,426 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:25,432 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:25,446 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:25,476 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:25,550 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:25,568 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:25,580 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:25,608 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:25,901 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:25,918 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:25,924 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:25,943 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:25,945 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:25,974 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:26,068 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:26,218 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:26,238 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:26,240 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:26,249 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:26,269 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:26,320 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:26,367 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:26,377 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:26,484 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:26,499 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:26,625 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:26,637 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:26,642 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:26,650 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:26,672 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:26,679 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:26,794 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:26,865 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:26,976 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:27,011 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:27,041 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:27,060 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:27,070 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:27,103 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:27,134 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:27,166 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:27,290 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:27,317 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:27,369 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:27,384 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:27,607 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:27,676 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:27,690 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:27,742 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:27,787 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:27,848 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:27,888 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:27,908 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:28,196 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:28,330 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:28,346 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:28,417 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:28,683 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:29,137 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:31,052 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:32,038 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:32,510 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:32,518 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:38,007 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:38,055 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:38,275 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:38,356 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:38,379 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:38,384 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:38,395 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:38,438 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:38,497 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:38,543 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:38,550 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:38,596 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:38,605 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:38,660 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:38,667 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:38,775 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:38,784 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:38,786 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:38,799 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:38,803 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:38,818 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:38,825 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:38,869 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:38,924 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:38,947 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:38,957 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:39,013 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:39,047 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:39,072 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:39,258 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:39,270 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:39,280 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:39,325 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:39,381 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:39,402 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:39,406 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:39,420 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:39,448 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:39,515 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:39,541 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:39,571 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:39,576 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:39,580 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:39,583 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:39,588 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:39,613 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:39,642 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:39,681 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:39,696 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:39,723 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:39,774 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:39,795 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:39,800 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:39,808 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:39,810 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:39,906 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:39,914 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:39,916 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:39,926 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:39,964 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:39,996 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:40,006 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:40,020 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:40,040 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:40,092 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:40,118 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:40,130 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:40,139 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:40,293 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:40,298 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:40,372 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:40,416 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:40,443 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:40,576 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:40,597 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:40,625 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:40,684 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:40,732 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:40,747 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:40,819 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:40,823 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:41,018 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:41,032 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:41,113 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:41,118 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:41,265 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:41,315 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:41,342 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:41,400 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:41,454 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:41,462 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:41,502 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:41,526 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:41,555 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:41,965 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:41,965 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:42,127 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:42,248 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:42,275 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:42,300 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:42,417 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:42,605 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:42,653 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:42,734 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:42,873 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:43,006 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:43,023 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:43,150 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:43,248 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:43,265 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:43,272 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:43,275 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:43,313 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:43,323 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:43,348 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:43,365 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:43,401 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:43,441 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:43,535 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:43,565 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:43,596 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:43,679 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:43,775 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:43,776 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:43,806 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:43,831 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:43,858 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:43,878 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:43,892 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:43,909 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:43,918 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:43,948 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:43,976 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:44,001 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:44,067 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:44,101 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:44,156 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:44,196 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:44,225 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:44,252 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:44,277 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:44,372 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:44,398 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:44,406 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:44,427 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:44,433 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:44,468 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:44,520 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:44,526 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:44,558 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:44,582 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:44,583 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:44,585 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:44,626 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:44,640 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:44,665 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:44,899 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:44,950 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:44,951 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:44,966 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:44,994 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:45,135 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:45,406 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:45,406 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:45,459 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:45,466 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:45,492 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:45,500 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:45,501 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:45,503 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:45,551 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:45,675 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:45,777 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:45,780 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:45,903 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:45,905 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:46,203 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:46,229 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:46,476 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:46,488 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:46,526 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:46,559 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:46,677 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:46,711 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:46,824 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:47,074 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:47,144 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:47,424 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:47,501 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:47,631 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:47,647 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:47,775 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:47,869 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:48,094 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:48,151 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:48,402 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:48,536 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:49,069 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:49,143 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:50,531 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:53,392 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:53,397 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:53,398 - INFO - Retrying request to /chat/completions in 0.923782 seconds
2024-01-02 00:25:53,401 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:53,401 - INFO - Retrying request to /chat/completions in 0.781053 seconds
2024-01-02 00:25:53,402 - INFO - Retrying request to /chat/completions in 0.765693 seconds
2024-01-02 00:25:53,420 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:53,422 - INFO - Retrying request to /chat/completions in 0.811901 seconds
2024-01-02 00:25:53,454 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:53,458 - INFO - Retrying request to /chat/completions in 0.867208 seconds
2024-01-02 00:25:53,482 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:53,484 - INFO - Retrying request to /chat/completions in 0.902285 seconds
2024-01-02 00:25:53,489 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:53,490 - INFO - Retrying request to /chat/completions in 0.801208 seconds
2024-01-02 00:25:53,493 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:53,495 - INFO - Retrying request to /chat/completions in 0.816679 seconds
2024-01-02 00:25:53,579 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:53,581 - INFO - Retrying request to /chat/completions in 0.886179 seconds
2024-01-02 00:25:53,631 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:53,633 - INFO - Retrying request to /chat/completions in 0.966519 seconds
2024-01-02 00:25:53,645 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:53,646 - INFO - Retrying request to /chat/completions in 0.844377 seconds
2024-01-02 00:25:53,661 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:53,662 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:53,663 - INFO - Retrying request to /chat/completions in 0.946249 seconds
2024-01-02 00:25:53,664 - INFO - Retrying request to /chat/completions in 0.872313 seconds
2024-01-02 00:25:53,714 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:53,753 - INFO - Retrying request to /chat/completions in 0.938535 seconds
2024-01-02 00:25:53,756 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:53,757 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:53,759 - INFO - Retrying request to /chat/completions in 0.981010 seconds
2024-01-02 00:25:53,759 - INFO - Retrying request to /chat/completions in 0.953347 seconds
2024-01-02 00:25:53,767 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:53,769 - INFO - Retrying request to /chat/completions in 0.865617 seconds
2024-01-02 00:25:53,778 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:53,780 - INFO - Retrying request to /chat/completions in 0.808719 seconds
2024-01-02 00:25:53,880 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:53,884 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:53,885 - INFO - Retrying request to /chat/completions in 0.794362 seconds
2024-01-02 00:25:53,888 - INFO - Retrying request to /chat/completions in 0.956160 seconds
2024-01-02 00:25:53,893 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:53,894 - INFO - Retrying request to /chat/completions in 0.867820 seconds
2024-01-02 00:25:53,922 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:53,925 - INFO - Retrying request to /chat/completions in 0.770397 seconds
2024-01-02 00:25:53,946 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:53,948 - INFO - Retrying request to /chat/completions in 0.984945 seconds
2024-01-02 00:25:53,996 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:53,998 - INFO - Retrying request to /chat/completions in 0.879413 seconds
2024-01-02 00:25:54,019 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:54,020 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:54,023 - INFO - Retrying request to /chat/completions in 0.913491 seconds
2024-01-02 00:25:54,024 - INFO - Retrying request to /chat/completions in 0.847135 seconds
2024-01-02 00:25:54,075 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:54,076 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:54,077 - INFO - Retrying request to /chat/completions in 0.953067 seconds
2024-01-02 00:25:54,078 - INFO - Retrying request to /chat/completions in 0.937577 seconds
2024-01-02 00:25:54,131 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:54,133 - INFO - Retrying request to /chat/completions in 0.780379 seconds
2024-01-02 00:25:54,147 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:54,148 - INFO - Retrying request to /chat/completions in 0.941730 seconds
2024-01-02 00:25:54,158 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:54,159 - INFO - Retrying request to /chat/completions in 0.978804 seconds
2024-01-02 00:25:54,203 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:54,206 - INFO - Retrying request to /chat/completions in 0.768736 seconds
2024-01-02 00:25:54,251 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:54,254 - INFO - Retrying request to /chat/completions in 0.814061 seconds
2024-01-02 00:25:54,282 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:54,284 - INFO - Retrying request to /chat/completions in 0.849531 seconds
2024-01-02 00:25:54,286 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:54,287 - INFO - Retrying request to /chat/completions in 0.838904 seconds
2024-01-02 00:25:54,336 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:54,340 - INFO - Retrying request to /chat/completions in 0.864905 seconds
2024-01-02 00:25:54,404 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:54,406 - INFO - Retrying request to /chat/completions in 0.995672 seconds
2024-01-02 00:25:54,410 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:54,412 - INFO - Retrying request to /chat/completions in 0.912686 seconds
2024-01-02 00:25:54,470 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:54,473 - INFO - Retrying request to /chat/completions in 0.844046 seconds
2024-01-02 00:25:54,537 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:54,541 - INFO - Retrying request to /chat/completions in 0.997739 seconds
2024-01-02 00:25:54,546 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:54,547 - INFO - Retrying request to /chat/completions in 0.912560 seconds
2024-01-02 00:25:54,595 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:54,596 - INFO - Retrying request to /chat/completions in 0.995782 seconds
2024-01-02 00:25:54,678 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:54,682 - INFO - Retrying request to /chat/completions in 1.699269 seconds
2024-01-02 00:25:54,721 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:54,722 - INFO - Retrying request to /chat/completions in 0.913873 seconds
2024-01-02 00:25:54,810 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:54,815 - INFO - Retrying request to /chat/completions in 0.956942 seconds
2024-01-02 00:25:54,936 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:54,940 - INFO - Retrying request to /chat/completions in 0.969391 seconds
2024-01-02 00:25:55,071 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:55,074 - INFO - Retrying request to /chat/completions in 0.968408 seconds
2024-01-02 00:25:55,297 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:55,597 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:55,771 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:55,786 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:56,028 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:56,094 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:56,101 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:56,114 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:56,255 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:56,260 - INFO - Retrying request to /chat/completions in 0.960195 seconds
2024-01-02 00:25:56,295 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:56,322 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:56,380 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:56,389 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:56,397 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:56,413 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:56,457 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:56,473 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:56,514 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:56,515 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:56,520 - INFO - Retrying request to /chat/completions in 0.898576 seconds
2024-01-02 00:25:56,523 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:56,525 - INFO - Retrying request to /chat/completions in 0.939922 seconds
2024-01-02 00:25:56,529 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:56,529 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:56,532 - INFO - Retrying request to /chat/completions in 0.802113 seconds
2024-01-02 00:25:56,532 - INFO - Retrying request to /chat/completions in 0.886432 seconds
2024-01-02 00:25:56,607 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:56,612 - INFO - Retrying request to /chat/completions in 0.793869 seconds
2024-01-02 00:25:56,615 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:56,615 - INFO - Retrying request to /chat/completions in 0.823303 seconds
2024-01-02 00:25:56,631 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:56,638 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:56,639 - INFO - Retrying request to /chat/completions in 0.810426 seconds
2024-01-02 00:25:56,656 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:56,658 - INFO - Retrying request to /chat/completions in 1.666378 seconds
2024-01-02 00:25:56,660 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:56,662 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:56,663 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:56,667 - INFO - Retrying request to /chat/completions in 0.839670 seconds
2024-01-02 00:25:56,668 - INFO - Retrying request to /chat/completions in 1.668485 seconds
2024-01-02 00:25:56,737 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:56,740 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:56,746 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:56,747 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:56,750 - INFO - Retrying request to /chat/completions in 0.996958 seconds
2024-01-02 00:25:56,760 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:56,770 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:56,772 - INFO - Retrying request to /chat/completions in 0.949929 seconds
2024-01-02 00:25:56,774 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:56,775 - INFO - Retrying request to /chat/completions in 1.531678 seconds
2024-01-02 00:25:56,802 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:56,806 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:56,807 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:56,809 - INFO - Retrying request to /chat/completions in 0.899371 seconds
2024-01-02 00:25:56,825 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:56,827 - INFO - Retrying request to /chat/completions in 0.940028 seconds
2024-01-02 00:25:56,846 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:56,866 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:56,869 - INFO - Retrying request to /chat/completions in 0.844001 seconds
2024-01-02 00:25:56,871 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:56,873 - INFO - Retrying request to /chat/completions in 0.751474 seconds
2024-01-02 00:25:56,874 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:56,891 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:56,893 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:56,895 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:56,898 - INFO - Retrying request to /chat/completions in 0.824141 seconds
2024-01-02 00:25:56,901 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:56,902 - INFO - Retrying request to /chat/completions in 0.828888 seconds
2024-01-02 00:25:56,903 - INFO - Retrying request to /chat/completions in 0.913785 seconds
2024-01-02 00:25:56,913 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:56,915 - INFO - Retrying request to /chat/completions in 0.938211 seconds
2024-01-02 00:25:56,937 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:56,938 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:56,941 - INFO - Retrying request to /chat/completions in 0.770632 seconds
2024-01-02 00:25:56,941 - INFO - Retrying request to /chat/completions in 0.818928 seconds
2024-01-02 00:25:56,942 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:56,942 - INFO - Retrying request to /chat/completions in 0.821936 seconds
2024-01-02 00:25:56,964 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:56,964 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:56,965 - INFO - Retrying request to /chat/completions in 0.819238 seconds
2024-01-02 00:25:56,966 - INFO - Retrying request to /chat/completions in 1.629209 seconds
2024-01-02 00:25:56,981 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:56,982 - INFO - Retrying request to /chat/completions in 0.773521 seconds
2024-01-02 00:25:56,989 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:56,994 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:56,995 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:57,007 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:57,009 - INFO - Retrying request to /chat/completions in 0.905335 seconds
2024-01-02 00:25:57,028 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:57,029 - INFO - Retrying request to /chat/completions in 0.983267 seconds
2024-01-02 00:25:57,043 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:57,044 - INFO - Retrying request to /chat/completions in 0.814626 seconds
2024-01-02 00:25:57,045 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:57,045 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:57,046 - INFO - Retrying request to /chat/completions in 0.764220 seconds
2024-01-02 00:25:57,047 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:57,047 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:57,050 - INFO - Retrying request to /chat/completions in 0.876832 seconds
2024-01-02 00:25:57,050 - INFO - Retrying request to /chat/completions in 0.823298 seconds
2024-01-02 00:25:57,055 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:57,056 - INFO - Retrying request to /chat/completions in 0.995609 seconds
2024-01-02 00:25:57,079 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:57,082 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:57,084 - INFO - Retrying request to /chat/completions in 0.947453 seconds
2024-01-02 00:25:57,084 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:57,085 - INFO - Retrying request to /chat/completions in 0.952234 seconds
2024-01-02 00:25:57,096 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:57,099 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:57,101 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:57,104 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:57,105 - INFO - Retrying request to /chat/completions in 0.986079 seconds
2024-01-02 00:25:57,105 - INFO - Retrying request to /chat/completions in 0.915987 seconds
2024-01-02 00:25:57,121 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:57,122 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:57,123 - INFO - Retrying request to /chat/completions in 0.837807 seconds
2024-01-02 00:25:57,124 - INFO - Retrying request to /chat/completions in 1.791270 seconds
2024-01-02 00:25:57,127 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:57,128 - INFO - Retrying request to /chat/completions in 1.634275 seconds
2024-01-02 00:25:57,131 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:57,132 - INFO - Retrying request to /chat/completions in 0.808118 seconds
2024-01-02 00:25:57,162 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:57,163 - INFO - Retrying request to /chat/completions in 0.864476 seconds
2024-01-02 00:25:57,188 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:57,189 - INFO - Retrying request to /chat/completions in 1.692053 seconds
2024-01-02 00:25:57,196 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:57,197 - INFO - Retrying request to /chat/completions in 1.715122 seconds
2024-01-02 00:25:57,203 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:57,204 - INFO - Retrying request to /chat/completions in 1.608028 seconds
2024-01-02 00:25:57,211 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:57,215 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:57,215 - INFO - Retrying request to /chat/completions in 1.841153 seconds
2024-01-02 00:25:57,223 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:57,224 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:57,224 - INFO - Retrying request to /chat/completions in 1.798823 seconds
2024-01-02 00:25:57,225 - INFO - Retrying request to /chat/completions in 1.827739 seconds
2024-01-02 00:25:57,227 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:57,228 - INFO - Retrying request to /chat/completions in 1.834926 seconds
2024-01-02 00:25:57,230 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:57,230 - INFO - Retrying request to /chat/completions in 1.978761 seconds
2024-01-02 00:25:57,231 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:57,232 - INFO - Retrying request to /chat/completions in 1.953548 seconds
2024-01-02 00:25:57,239 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:57,256 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:57,257 - INFO - Retrying request to /chat/completions in 1.661755 seconds
2024-01-02 00:25:57,261 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:57,262 - INFO - Retrying request to /chat/completions in 1.737813 seconds
2024-01-02 00:25:57,273 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:57,273 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:57,274 - INFO - Retrying request to /chat/completions in 1.596432 seconds
2024-01-02 00:25:57,274 - INFO - Retrying request to /chat/completions in 1.500030 seconds
2024-01-02 00:25:57,289 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:57,290 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:57,291 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:57,291 - INFO - Retrying request to /chat/completions in 1.560294 seconds
2024-01-02 00:25:57,292 - INFO - Retrying request to /chat/completions in 1.935704 seconds
2024-01-02 00:25:57,292 - INFO - Retrying request to /chat/completions in 1.501737 seconds
2024-01-02 00:25:57,333 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:57,336 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:57,337 - INFO - Retrying request to /chat/completions in 1.817089 seconds
2024-01-02 00:25:57,340 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:57,340 - INFO - Retrying request to /chat/completions in 1.956992 seconds
2024-01-02 00:25:57,355 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:57,372 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:57,373 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:57,374 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:57,374 - INFO - Retrying request to /chat/completions in 1.932591 seconds
2024-01-02 00:25:57,375 - INFO - Retrying request to /chat/completions in 1.787476 seconds
2024-01-02 00:25:57,375 - INFO - Retrying request to /chat/completions in 1.820957 seconds
2024-01-02 00:25:57,384 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:57,385 - INFO - Retrying request to /chat/completions in 1.621659 seconds
2024-01-02 00:25:57,388 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:57,389 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:57,391 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:57,391 - INFO - Retrying request to /chat/completions in 1.863009 seconds
2024-01-02 00:25:57,392 - INFO - Retrying request to /chat/completions in 1.934442 seconds
2024-01-02 00:25:57,392 - INFO - Retrying request to /chat/completions in 1.927764 seconds
2024-01-02 00:25:57,406 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:57,407 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:57,411 - INFO - Retrying request to /chat/completions in 1.893578 seconds
2024-01-02 00:25:57,413 - INFO - Retrying request to /chat/completions in 1.808306 seconds
2024-01-02 00:25:57,438 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:57,442 - INFO - Retrying request to /chat/completions in 1.938546 seconds
2024-01-02 00:25:57,448 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:57,450 - INFO - Retrying request to /chat/completions in 1.576287 seconds
2024-01-02 00:25:57,453 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:57,455 - INFO - Retrying request to /chat/completions in 1.568674 seconds
2024-01-02 00:25:57,457 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:57,464 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:57,466 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:57,467 - INFO - Retrying request to /chat/completions in 1.567361 seconds
2024-01-02 00:25:57,468 - INFO - Retrying request to /chat/completions in 1.632461 seconds
2024-01-02 00:25:57,472 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:57,472 - INFO - Retrying request to /chat/completions in 1.926714 seconds
2024-01-02 00:25:57,498 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:57,500 - INFO - Retrying request to /chat/completions in 1.764495 seconds
2024-01-02 00:25:57,505 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:57,506 - INFO - Retrying request to /chat/completions in 1.587272 seconds
2024-01-02 00:25:57,506 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:57,507 - INFO - Retrying request to /chat/completions in 1.863372 seconds
2024-01-02 00:25:57,514 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:57,515 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448998, Requested 1578. Please try again in 76ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:25:57,515 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>5-Bromo-3,4-dihydroxybenzaldehyde stabilizes diabetic retinal neurovascular units by inhibiting the inflammatory microenvironment.\nDiabetic retinopathy (DR) is a leading cause of blindness characterized by damage to the retinal neurovascular unit, which is caused by hyperglycemia-induced metabolic and inflammatory responses. 5-Bromo-3,4-dihydroxybenzaldehyde (BDB) is a compound derived from marine red algae and known for its anti-inflammatory effects.This study aimed to investigate the potential protective effects of BDB on DR using primary human retinal vascular endothelial cells and retinal tissue explants. The analysis involved assessing vascular integrity, expression of tight junction protein, hyperglycemia-induced permeability, and retinal ganglion cell (RGC) apoptosis. The protective effect of BDB in maintaining the diabetic retinal neurovascular units was verified using type 1 diabetic mouse models. Additionally, the inhibitory effect of BDB on the levels of inflammatory cytokines TNF-\u03b1, IL-1\u03b2, and IL-6 were examined.In vitro experiments revealed that BDB promoted vascular integrity, inhibited the transcription of pro-inflammatory factors, and alleviated hyperglycemia-induced permeability. BDB also protected RGC from hyperglycemia-induced apoptosis. In diabetic mice models, BDB treatment maintained the integrity of diabetic retinal neurovascular units and inhibited the secretion of TNF-\u03b1, IL-1\u03b2, and IL-6.BDB demonstrated a protective effect on DR by inhibiting the secretion of inflammatory factors, suggesting its potential as a therapeutic agent for the treatment of DR. Further research is warranted to validate its safety and efficacy for clinical application.</ABSTRACT>'}]
2024-01-02 00:25:57,524 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:57,535 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:57,535 - INFO - Retrying request to /chat/completions in 1.765274 seconds
2024-01-02 00:25:57,548 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:57,555 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:57,556 - INFO - Retrying request to /chat/completions in 1.631986 seconds
2024-01-02 00:25:57,557 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:57,558 - INFO - Retrying request to /chat/completions in 1.940939 seconds
2024-01-02 00:25:57,560 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:57,560 - INFO - Retrying request to /chat/completions in 1.905319 seconds
2024-01-02 00:25:57,581 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:57,582 - INFO - Retrying request to /chat/completions in 1.930634 seconds
2024-01-02 00:25:57,583 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:57,596 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:57,597 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:57,597 - INFO - Retrying request to /chat/completions in 1.951543 seconds
2024-01-02 00:25:57,618 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:57,628 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:57,653 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:57,666 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:57,684 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:57,707 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:57,769 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:57,834 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:57,835 - INFO - Retrying request to /chat/completions in 1.992554 seconds
2024-01-02 00:25:57,837 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:57,838 - INFO - Retrying request to /chat/completions in 1.592285 seconds
2024-01-02 00:25:57,844 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:57,846 - INFO - Retrying request to /chat/completions in 1.993051 seconds
2024-01-02 00:25:57,856 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:57,858 - INFO - Retrying request to /chat/completions in 1.832322 seconds
2024-01-02 00:25:57,862 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:57,863 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:57,864 - INFO - Retrying request to /chat/completions in 1.730234 seconds
2024-01-02 00:25:57,864 - INFO - Retrying request to /chat/completions in 1.569652 seconds
2024-01-02 00:25:57,881 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:57,888 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:57,892 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:57,892 - INFO - Retrying request to /chat/completions in 1.635062 seconds
2024-01-02 00:25:57,894 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:57,895 - INFO - Retrying request to /chat/completions in 1.724588 seconds
2024-01-02 00:25:57,897 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:57,899 - INFO - Retrying request to /chat/completions in 1.660489 seconds
2024-01-02 00:25:57,912 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:57,913 - INFO - Retrying request to /chat/completions in 1.659684 seconds
2024-01-02 00:25:57,916 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:57,931 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:57,936 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:57,938 - INFO - Retrying request to /chat/completions in 1.769535 seconds
2024-01-02 00:25:57,938 - INFO - Retrying request to /chat/completions in 1.703156 seconds
2024-01-02 00:25:57,963 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:57,964 - INFO - Retrying request to /chat/completions in 1.709663 seconds
2024-01-02 00:25:57,981 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:57,983 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:57,990 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:58,001 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:58,006 - INFO - Retrying request to /chat/completions in 1.926542 seconds
2024-01-02 00:25:58,015 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:58,017 - INFO - Retrying request to /chat/completions in 1.905308 seconds
2024-01-02 00:25:58,036 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:58,064 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:58,065 - INFO - Retrying request to /chat/completions in 1.860417 seconds
2024-01-02 00:25:58,087 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:58,090 - INFO - Retrying request to /chat/completions in 1.802126 seconds
2024-01-02 00:25:58,105 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:58,108 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:58,141 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:58,142 - INFO - Retrying request to /chat/completions in 1.781374 seconds
2024-01-02 00:25:58,147 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:58,147 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:58,149 - INFO - Retrying request to /chat/completions in 1.711467 seconds
2024-01-02 00:25:58,149 - INFO - Retrying request to /chat/completions in 1.597320 seconds
2024-01-02 00:25:58,154 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:58,154 - INFO - Retrying request to /chat/completions in 1.574586 seconds
2024-01-02 00:25:58,164 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:58,164 - INFO - Retrying request to /chat/completions in 1.757405 seconds
2024-01-02 00:25:58,219 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:58,228 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:58,228 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:58,228 - INFO - Retrying request to /chat/completions in 1.815488 seconds
2024-01-02 00:25:58,288 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:58,346 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:58,373 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:58,391 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:58,410 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:58,445 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:58,538 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:58,590 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:58,615 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:58,748 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:58,766 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:58,911 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:58,912 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449075, Requested 1681. Please try again in 100ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:25:58,912 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Molecular analyses of ADAMTS-1, -4, -5, and IL-17\xa0a cytokine relationship in patients with ulcerative colitis.\nUlcerative colitis (UC) is a chronic inflammatory bowel disease that develops due to the impaired immune response in genetically susceptible individuals, and its etiopathogenesis is not fully elucidated. IL-17\xa0A is a cytokine that is produced by a type of immune cell called Th17 cells and is involved in the immune response and inflammation. On the other hand, ADAMTS-1, -4, and -\u20095 are enzymes that are involved in the breakdown of extracellular matrix proteins, including proteoglycans, which are important components of the intestinal wall. This study aimed to evaluate the relationship between interleukin 17 (IL-17\xa0A) cytokine, which plays a role in the pathogenesis of ulcerative colitis, and the inflammation-controlled a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS)-1, -4, and -\u20095 protein members.Bowel tissue samples and blood serum from 51 patients with UC and 51 healthy controls were included in this study. mRNA expression levels of the ADAMTS-1, -4, -5, and IL-17\xa0A were analyzed by RT-qPCR, and immunohistochemical analyses were performed to evaluate ADAMTS-1, -4, -5, and IL-17\xa0A proteins in tissue samples. In addition, ELISA analysis determined serum levels of the ADAMTS-1, -4, -5, and IL-17\xa0A.RT-qPCR results reveal that the expression of ADAMTS-1, -4, -5, and IL-17\xa0A genes in the UC tissue samples were significantly high according to the control tissue samples. Also, ADAMTS-1, -4, -5, and IL-17\xa0A proteins revealed enhanced expression pattern UC groups according to the control. Also, ADAMTS-1, -4, -5, and IL-17\xa0A protein showed cytoplasmic localization patterns in both control and UC groups. The serum levels of ADAMTS-1,-5, and IL-17\xa0A were significantly higher in UC samples than in the control group.We observed a positive correlation between the ADAMTS-1, -5 and IL17A cytokine expression in UC samples. These results provide a new understanding of controlling crucial ADAMTS family protein members by IL-17\xa0A cytokines with UC.</ABSTRACT>'}]
2024-01-02 00:25:58,922 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:58,923 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:58,924 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448601, Requested 1514. Please try again in 15ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:25:58,924 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Involvement of Epithelial-Mesenchymal Transition (EMT) in Autoimmune Diseases.\nEpithelial-mesenchymal transition (EMT) is a complex reversible biological process characterized by the loss of epithelial features and the acquisition of mesenchymal features. EMT was initially described in developmental processes and was further associated with pathological conditions including metastatic cascade arising in neoplastic progression and organ fibrosis. Fibrosis is delineated by an excessive number of myofibroblasts, resulting in exuberant production of extracellular matrix (ECM) proteins, thereby compromising organ function and ultimately leading to its failure. It is now well acknowledged that a significant number of myofibroblasts result from the conversion of epithelial cells via EMT. Over the past two decades, evidence has accrued linking fibrosis to many chronic autoimmune and inflammatory diseases, including systemic sclerosis (SSc), rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), Sjgren\'s syndrome (SS), and inflammatory bowel diseases (IBD). In addition, chronic inflammatory states observed in most autoimmune and inflammatory diseases can act as a potent trigger of EMT, leading to the development of a pathological fibrotic state. In the present review, we aim to describe the current state of knowledge regarding the contribution of EMT to the pathophysiological processes of various rheumatic conditions.</ABSTRACT>'}]
2024-01-02 00:25:58,985 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:58,991 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449708, Requested 1722. Please try again in 190ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:25:58,991 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Sexual health in women with Sjogren\'s syndrome: A review.\nRheumatic diseases, mainly affecting women, including rheumatoid arthritis, Sjogren\'s syndrome, systemic lupus erythematosus, etc., are chronic, inflammatory, autoimmune disorders that may involve multiple organs or systems and are closely related to sexual health, which is an important aspect of human physical and mental health. Sjogren\'s syndrome (SS) is the second most common rheumatic illnesses after rheumatoid arthritis with a female predominance. At present, the research on sexual health of female SS patients is still scarce and difficult to summarize.The objective of our study was to systematically review the literature for the influence of maternal SS on sexual health, such as sexual function, sex hormones, fertility, and pregnancy outcomes.We performed a comprehensive literature search based on PubMed and Web of science databases from inception to 1 November 2022. Outcomes were divided into 4 categories: sex hormones, sexual function, fertility, and pregnancy and offspring outcomes.A total of 756 potentially eligible papers were retrieved. After eliminating duplicate articles and reviewing the titles and abstracts to exclude records, we read the remaining 92 articles in full for further evaluation, and selected 42 studies. Results on sex hormones, sexual function, fertility and pregnancy and offspring outcomes were reported in 13, 12, 3 and 14 SS-related articles, respectively. The levels of some sex hormones in SS patients may have undergone changes. Female patients with SS have a high prevalence of sexual dysfunction compared with controls. Most studies suggested SS had an adverse impact on maternal and fetal outcomes following pregnancy. However, there is insufficient evidence that directly indicating the fertility of SS women is diminished.In summary, certain aspects of sexual health (sexual function, sex hormones and pregnancy outcomes) are impaired in SS women. Screening for sexual health problems in SS female should become an integral part of medical clinical practice. Rheumatologists should be aware of this association and collaborate with gynecologists, obstetricians, psychologists, and other experts on this issue to determine appropriate therapeutic approaches.</ABSTRACT>'}]
2024-01-02 00:25:59,005 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:59,008 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449599, Requested 1524. Please try again in 149ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:25:59,009 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>A Canadian case control study investigating demographic and environmental factors associated with MOGAD.\nLittle is known about demographic and environmental factors associated with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD).To investigate factors associated with MOGAD using a case-control design and validated questionnaire from the Environmental Risk Factors in Multiple Sclerosis Study (EnvIMS).We enrolled patients with positive MOG antibody serology and diagnosis of MOGAD at six Canadian centres. MOGAD participants completed the EnvIMS questionnaire, and were compared to unaffected controls from the Canadian arm of EnvIMS. We calculated crude and adjusted odds ratios (OR) using logistic regression models and Firth\'s procedure for rare events.We enrolled 39 MOGAD participants with mean (SD) age 45.0 (14.4) years, 28 (71.8\xa0%) women, 25 (64.1\xa0%) White, 26 (66.7\xa0%) residents of Ontario, and mean BMI 28.6 (7.1). They were compared to 956 controls. Using multivariable logistic regression, larger body size at age 10 years (OR: 3.57, 95\xa0% CI:1.23 - 10.33) and non-White ethnicity (OR:3.81, 95\xa0% CI:1.93-7.54) were associated with higher odds of MOGAD. Among Ontario residents, current BMI \u226530 was associated with higher odds of MOGAD (OR:2.79, 95\xa0% CI:1.03-7.53).Our findings are hypothesis-generating due to the sample size, but suggest that obesity and ethnicity should be explored as potential risk factors for MOGAD in other settings.</ABSTRACT>'}]
2024-01-02 00:25:59,028 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:59,034 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:59,035 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449497, Requested 1621. Please try again in 149ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:25:59,035 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Genetic insights into PHARC syndrome: identification of a novel frameshift mutation in ABHD12.\nMutations in ABHD12 (OMIM: 613,599) are associated with polyneuropathy, hearing loss, ataxia, retinitis pigmentosa, and cataract (PHARC) syndrome (OMIM: 612674), which is a rare autosomal recessive neurodegenerative disease. PHARC syndrome is easily misdiagnosed as other neurologic disorders, such as retinitis pigmentosa, Charcot-Marie-Tooth disease, and Refsum disease, due to phenotype variability and slow progression. This paper presents a novel mutation in ABHD12 in two affected siblings with PHARC syndrome phenotypes. In addition, we summarize genotype-phenotype information of the previously reported patients with ABHD12 mutation.Following a thorough medical evaluation, whole-exome sequencing was done on the proband to look for potential genetic causes. This was followed by confirmation of identified variant in the proband and segregation analysis in the family by Sanger sequencing. The variants were interpreted based on the American College of Medical Genetics and Genomics (ACMG) guidelines.A novel pathogenic homozygous frameshift variant, NM_001042472.3:c.601dup, p.(Val201GlyfsTer4), was identified in exon 6 of ABHD12 (ACMG criteria: PVS1 and PM2, PM1, PM4, PP3, and PP4). Through Sanger sequencing, we showed that this variant is co-segregated with the disease in the family. Further medical evaluations confirmed the compatibility of the patients\' phenotype with PHARC syndrome.Our findings expand the spectrum of mutations in the ABHD12 and emphasize the significance of multidisciplinary diagnostic collaboration among clinicians and geneticists to solve the differential diagnosis of related disorders. Moreover, a summary based on mutations found so far in the ABHD12 gene did not suggest a clear genotype-phenotype correlation for PHARC syndrome.</ABSTRACT>'}]
2024-01-02 00:25:59,037 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449317, Requested 1752. Please try again in 142ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:25:59,037 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>A single-center study of clinical features of pediatric Sjgren\'s syndrome.\nSjgren\'s syndrome (SS) is a rare disease with unclear diagnostic criteria among the children and adolescents. The purpose of this study is to describe the clinical features of pediatric Sjgren\'s syndrome and validate with Japanese diagnostic guidelines criteria of 2018.We conducted a retrospective analysis of the clinical data of a cohort of 54 patients with pediatric Sjgren\'s syndrome admitted to our hospital over a total of 10\xa0years from September 2013 to September 2022.The ratio of females to males was 49:5 among the 54 children (34 cases of primary SS and 20 cases of secondary SS), the average age of onset of symptoms for the first time was 9.9\xa0years, and the average age at diagnosis was 10.2\xa0years. In terms of subjective symptoms, 7 cases (13.0%) presented with dry mouth and 5 cases (9.3%) reported dry eyes. The positive rates were 9.3% for Schirmer I test, 70.4% for salivary gland function test, and 55.6% for salivary gland ultrasonography. The positive rates were 94.4% for Anti-Ro/SSA antibodies, 66.7% for Anti-La/SSB antibodies, 88.9% for ANA, 59.3% for RF, and the elevation rate of IgG was 63.0%. Among the EULAR Sjgren\'s syndrome disease activity index (ESSDAI) domains, the biological, constitutional, glandular, cutaneous, and lymphadenopathy domains were most involved. Treatment consisted of glucocorticoids in 88.9% of the patients in our study and hydroxychloroquine in 92.6%. As per the Japanese version of the clinical practice guidance for Sjgren\'s Syndrome in pediatric patients (2018), 5 cases were identified as Definite SS, 35 cases as Probable SS, and 14 cases as Possible SS. With respect to primary and secondary SS, there was essentially no significant difference between the groups in any of the above aspects.Patients with pediatric SS presented with a wide spectrum of clinical features, a low prevalence of reported symptoms of dry mouth and dry eyes, and various clinical manifestations with multi-system involvement. These are similar to other pediatric study cohorts in terms of epidemiology, auxiliary investigation results, disease activity scores, and treatment. The coincidence between our study and the Japanese version of the clinical practice guidance for Sjgren\'s Syndrome in pediatric patients (2018) is good for the diagnosis of pediatric SS.</ABSTRACT>'}]
2024-01-02 00:25:59,037 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:59,038 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449303, Requested 2039. Please try again in 178ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:25:59,038 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>DIAGNOSTIC VALUE OF LABORATORY MARKERS OF SYNTROPIC LESIONS OF THE CIRCULATORY SYSTEM ORGANS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS.\nSystemic lupus erythematosus (SLE) is a chronic autoimmune disease that affects almost all internal organs, among which circulatory system organs (CSO) lesions are not only among the most common but also at the top of the list of causes of mortality. The tactics of treatment of patients with SLE without and in combination with CSO lesions are fundamentally different, and therefore, improving diagnostic methods will help to enhance the effectiveness of the management of this category of patients. The aim of the study - to determine the diagnostic value of laboratory markers of syntropic lesions of the circulatory system organs in patients with systemic lupus erythematosus. The research included 125 patients with SLE with CSO lesions, among whom the vast majority were young women. Patients were stratified according to syntropy. Syntropic lesions were those whose frequency significantly increased with increasing severity of SLE: retinal angiopathy, capillaritis, Raynaud\'s syndrome, livedo reticularis, atherosclerosis, mitral valve insufficiency, mitral valve thickening, pericardial effusion, pulmonary hypertension, myocarditis, endocarditis, symptomatic arterial hypertension, and vein thrombosis. During the study, the diagnostic value of individual laboratory markers and their constellations in terms of sensitivity, specificity, and accuracy in patients with SLE with syntropic lesions of CSO was determined step by step, and the one with the highest diagnostic value for the diagnosis of these lesions was chosen. The difference was considered statistically significant if p<0.050. The association coefficient and the contingent coefficient were used to determine the closeness of the relationship between the marker and the syntropic lesion. The relationship was considered confirmed if the association coefficient was \u2265 0.50 or the contingent coefficient was \u2265 0.30. We studied the diagnostic value of individual laboratory markers and their constellations in terms of sensitivity, specificity, and accuracy in patients with SLE with syntropic CSO lesions. It was found that the best diagnostic value for the diagnosis of retinal angiopathy is the constellation of \u2191 LDL + \u2191 IA + \u2191 anti-ds DNA + \u2191 ANA; capillaritis - \u2191 \u03b2-globulins + \u2191 IA + \u2191 anti-ds DNA + \u2191 antiphospholipid antibodies Ig M + \u2191 anti-Sm + \u2193 C4; Raynaud\'s syndrome - a separate marker \u2193 C3; livedo reticularis - \u2191 ESR + \u2191 small CIC + \u2191 anti-ds DNA + \u2191 anti-Sm; atherosclerosis - \u2193 hemoglobin + \u2191 LDL + \u2191 ANA + \u2193 C4; mitral valve insufficiency - \u2191 ESR + \u2191 anti-ds DNA + \u2191 ANA + \u2191 antiphospholipid antibodies Ig M; mitral valve stenosis - \u2191 ESR+\u2191 LDL + \u2191 small CK + \u2191 ANA; pericardial effusion - erythropenia + \u2191 C-RP + \u2191 lupus anticoagulant; pulmonary hypertension - hypercholesterolemia + \u2191 LDL + \u2191 anti-ds DNA + \u2191 ANA; myocarditis - an individual marker \u2193 C4; endocarditis - \u2191 ESR + \u2191 total fibrinogen + \u2191 \u03b3-globulins + hypercholesterolemia + \u2191 anti-Sm; symptomatic arterial hypertension - \u2191 LDL + \u2191 anti-ds DNA + \u2191 ANA + \u2191 anti-SSA (Ro); vein thrombosis - erythropenia + \u2193 hemoglobin + \u2191 LDL + \u2191 ANA. For each syntropic lesion in patients with systemic lupus erythematosus, an individual laboratory marker or constellations have been identified that having the best diagnostic value for the diagnosis of these lesions.</ABSTRACT>'}]
2024-01-02 00:25:59,073 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:59,086 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:59,119 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:59,120 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449446, Requested 1496. Please try again in 125ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:25:59,120 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>1\u2005Retreatment for reactivation of ROP following initial anti-VEGF injections. A 5-year retrospective study.\nTo present the retreatment rates and the characteristics of ROP reactivation, as well as the differences between bevacizumab and ranibizumab injections in premature babies treated in our department over the past 5 years.A retrospective analysis of babies with treated ROP was performed. 89 babies who required treatment from 2017 to 2022 were examined. We studied the severity of their disease with regards to their gestational age, treatment time and type and the need of further treatment. We also focused on the comparison of anti-VEGF agents for ROP.22 out of 89 babies (14 boys and 8 girls) with aggressive posterior retinopathy of prematurity (APROP) and mean gestational age of 25+3w received initially anti-VEGF injections. 16 of those (11 boys and 5 girls) required retreatment with diode laser. 9 out of these 16 babies were treated with ranibizumab (Lucentis) and 7 with bevacizumab (Avastin). It is also of note that only 2 out of 67 babies who initially received laser treatment needed a complementary laser session.The majority of babies with aggressive ROP who receive anti-VEGF agents will most probably require further laser treatment. At an equal level of retinal damage, it seems that their response to ranibizumab and bevacizumab is similar.</ABSTRACT>'}]
2024-01-02 00:25:59,145 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:59,147 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448994, Requested 1737. Please try again in 97ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:25:59,147 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>The incidence, risk factors, management and prognosis of postoperative systemic complications after ophthalmic surgery: a retrospective study at a tertiary, academic referral hospital over a decade.\nTo explore the incidence, risk factors, management and prognosis of systemic complications after ophthalmic surgeries.A retrospective review of hospitalized patients undergoing ophthalmic surgeries between 2012 and 2022 at Peking Union Medical College Hospital was performed to summarize and analyse the postoperative systemic complications. Multivariate logistic and linear regression analyses were conducted to clarify the risk factors of postoperative systemic complications and factors associated with the severity of adverse events.A total of 34,841 patients underwent inpatient ophthalmic surgery, among which 162 systemic complications occurred in 150 patients during postoperative hospitalization. The overall incidence rate was 0.4%, with cardiovascular events (48.1%), digestive events (13.6%) and fever (12.3%) being the leading causes. About 17.3% of the cases had conditions improved after observation, 19.1% after symptomatic treatment, 54.9% had consultation with specific intervention and 8.6% were transferred to the corresponding departments for specialized treatment. For the prognosis, 93.8% had condition improved, 5.6% chose voluntary discharge without improvement, and one patient died of respiratory failure caused by postoperative pulmonary infection. The worse ADL (activities of daily living) grading, indication of primary intraocular lymphoma or intraocular tumour, surgery of simple pars plana vitrectomy (PPV), PPV with silicone oil tamponade, PPV with gas tamponade, general anaesthesia, history of diabetes mellitus (DM), chronic heart failure and digestive system disease were the risk factors positively correlated with postoperative systemic complications (p\xa0<\xa0.05). The worse ADL grading, history of DM and respiratory system disease were also positively correlated with the severity of the adverse events (p\xa0<\xa0.05).The incidence of postoperative systemic complications was low among patients undergoing ophthalmic surgery, most were mild and could be relieved after observation, symptomatic or specialist consultation. Patients with worse ADL and history of DM should be paid extra attention.</ABSTRACT>'}]
2024-01-02 00:25:59,169 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:59,171 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448824, Requested 1822. Please try again in 86ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:25:59,171 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Remote management of worsening heart failure to avoid hospitalization in a real-world setting.\nFrom a patient and health system perspective, managing worsening heart failure (WHF) as an outpatient has become a priority. Remote management allows early detection of WHF, enabling timely intervention with the aim of preventing hospitalization. The objective of the study was to evaluate the feasibility and safety of remotely managing WHF events using a multiparametric platform.All patients enrolled in the heart failure remote management programme of the Bordeaux University Hospital Telemedicine Center between 1 January and 31 December 2021 were included in the study. Follow-up data were collected until 1 March 2022. Inclusion criteria were chronic heart failure (HF) with New York Heart Association \u2265II symptoms and an elevated B-type natriuretic peptide (BNP\xa0>\xa0100\xa0pg/mL or N-terminal-pro-BNP\xa0>\xa01000\xa0pg/mL). Patient assessments were performed remotely and included measurements of body weight, blood pressure, heart rate, symptoms, biochemical parameters, and data from cardiac implantable electronic devices when available. In total, 161 patients (71\xa0\xa011\xa0years old, 79% male) were followed for a mean of 291\xa0\xa066\xa0days with a mean adherence to the remote monitoring system of 80\xa0\xa020%. Over this period, 52 (32.3%) patients had 105 WHF events, of which 66 (63%) were successfully managed remotely, the remaining requiring hospitalization. Freedom from WHF events and hospitalization at 300\xa0days were 66% and 85%, respectively (P\xa0<\xa00.001 for the difference). Increased level of BNP was associated with an increased risk of WHF event [hazard ratio (HR) per unit increase in BNP: 1.001; 95% confidence interval (CI) 1-1.002; P\xa0=\xa00.001] and hospitalization (HR 1.002; 95% CI 1.002-1.003; P\xa0=\xa00.002). A decrease in the level of glomerular filtration rate was associated with an increased risk of hospitalization (HR per unit decrease in estimated glomerular filtration rate: 0.946; 95% CI 0.906-0.989; P\xa0=\xa00.014). WHF event recurrence and (re)hospitalization rates at 1-month were similar among patients managed remotely (18% and 12%, respectively) and those requiring hospitalization (21% and 10%, respectively). Iatrogenic complications occurred more often during hospitalization than remote management (26% vs. 3%, P\xa0<\xa00.001).Our study suggests that remote management of WHF events based on a multiparametric approach led by a telemedical centre is feasible and safe. Adopting such a strategy for patients with chronic HF could reduce HF-related hospitalizations with expected benefits for patients, care providers, and health care systems.</ABSTRACT>'}]
2024-01-02 00:25:59,173 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:59,174 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448756, Requested 1618. Please try again in 49ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:25:59,174 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Incremental Value of Global Longitudinal Strain for Confirming Heart Failure-Related Symptoms in Severe Aortic Stenosis.\nThe indications or timing of aortic valve replacement for symptomatic aortic stenosis (AS) are based on a patient\'s life expectancy and symptoms. However, clinical decision-making may be difficult because symptoms are subjective and cannot be quantitatively assessed and confirmed. This study aimed to evaluate the association between heart failure (HF)-related symptoms and cardiac hemodynamic left ventricular deformations in patients with severe AS using transthoracic echocardiographic assessments of left ventricular global longitudinal strain (LV-GLS). The medical records of patients hospitalized for AS between February 2017 and September 2019 were retrospectively screened. Independent cardiologists analyzed the transthoracic echocardiographic images of a digital echocardiography database. The cohort comprised 177 hospitalized patients with severe AS and no history of HF. The subgroup with HF-related symptoms included 87 patients, whereas that without HF-related symptoms included 90 patients. In 145 patients without atrial fibrillation, the left atrial volume index (LAVI) and LV-GLS were significantly associated with HF-related symptoms (odds ratio 1.033, 95% confidence interval 1.008 to 1.059, p\xa0=\xa00.011 and odds ratio 1.224, 95% confidence interval 1.118 to 1.340, p <0.0001, respectively). Moreover, the combination of brain natriuretic peptide level, LAVI, and LV-GLS showed better diagnostic accuracy than the combination of brain natriuretic peptide level and LAVI (p\xa0=\xa00.005). However, there were no such tendencies in 32 patients with atrial fibrillation. The HF-related symptoms in patients with severe AS were strongly linked to LV-GLS. LV-GLS showed incremental value for confirming HF-related symptoms.</ABSTRACT>'}]
2024-01-02 00:25:59,182 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:59,183 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:59,183 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:59,185 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448788, Requested 1694. Please try again in 64ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:25:59,185 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Presumed Silicone Oil Droplets After Intravitreal Pegcetacoplan Injections.\nRecently, intravitreal pegcetacoplan became the first drug to gain US Food and Drug Administration approval for the treatment of geographic atrophy associated with nonexudative age-related macular degeneration, but the administration of this medication may be associated with unanticipated posttreatment complications.To assess the prevalence of presumed silicone oil droplets in the vitreous cavity after intravitreal injection of pegcetacoplan.This case series study involved a retrospective record review of all 55 patients treated with intravitreal pegcetacoplan, 0.1 mL in 150-mg/mL solution, between March 24 and June 5, 2023, at a single specialty retina practice. All injections were done using needles from the kit supplied by Apellis Pharmaceuticals on a 1-mL McKesson Luer lock syringe.The presence or absence of presumed silicone bubbles detected during dilated biomicroscopic fundus examination and/or on color fundus photographs, the presence or absence of symptoms, change in visual acuity, and/or increase in intraocular pressure.A total of 62 intravitreal pegcetacoplan injections were given to 55 patients (mean [SD] age, 83.8 [7.8] years; 33 women [60%]) from March 24 to June 5, 2023. Of the 55 patients, 16 (29%; mean [SD] age, 83.8 [7.4] years; 9 women [56%]) had presumed intravitreal silicone droplets discovered 2 to 4 weeks after treatment, 3 of which were documented on color fundus photographs. Of the 16 patients, 14 (88%) were symptomatic for new floaters that they described as persistent, while 2 (13%) were asymptomatic. There were no signs of inflammation or infection, no increases in intraocular pressure, and no changes in visual acuity for all 16 patients.A substantial percentage of patients had symptomatic floaters from presumed intravitreal silicone oil droplets after injections of pegcetacoplan using a McKesson 1-mL Luer lock syringe. These findings support consideration of informing patients of this potential adverse effect, avoiding use of the McKesson syringe, and considering use of silicone-free syringes for pegcetacoplan injections.</ABSTRACT>'}]
2024-01-02 00:25:59,186 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448689, Requested 1667. Please try again in 47ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:25:59,186 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Assessment of amino-terminal C-type natriuretic peptide serum level and its correlation with high-density lipoprotein structure and function in patients with end stage renal disease before and after kidney transplantation.\nWe aimed to investigate serum amino-terminal C-type natriuretic peptide (NT-proCNP) and its relationship with quantitative and qualitative HDL-parameters in patients with end-stage renal disease (ESRD) before, then 1 and 6 months after kidney transplantation (TX). Seventy patients (47 males, 23 females, mean age 51.7\xa0\xa012.4 years) were enrolled in a prospective follow-up study. We examined serum creatinine, C-reactive protein, procalcitonin, fasting glucose and lipid parameters before, then 1 and 6 months after TX. High-density lipoprotein- (HDL)-associated paraoxonase-1 (PON1) paraoxonase and arylesterase activities were measured spectrophotometrically. Lipoprotein subfractions were determined by Lipoprint. NT-proCNP and oxidized low-density lipoprotein (oxLDL) levels were measured by ELISA. Mean NT-proCNP was 45.8\xa0\xa021.9\xa0pmol/L before renal transplantation and decreased markedly 1 month and 6 months after transplantation (5.3\xa0\xa02.5 and 7.7\xa0\xa04.9\xa0pmol/L, respectively, P\xa0=\xa01\xa0\xa010-4). During the 6 months\' follow-up, PON1 arylesterase, paraoxonase and salt-stimulated paraoxonase activities improved. NT-proCNP positively correlated with procalcitonin and creatinine and negatively with GFR, LDL-cholesterol (LDL-C) and HDL-cholesterol (HDL-C). There was a negative correlation between serum NT-proCNP and PON1 arylesterase activity. According to the multiple regression analysis, the best predicting variables of NT-proCNP were serum procalcitonin, creatinine and PON1 arylesterase activity. NT-proCNP might be a novel link between HDL dysfunction and impaired vascular function in ESRD, but not after kidney transplantation. Further studies in larger populations are needed to clarify the exact role of NT-proCNP in the risk prediction for cardiovascular comorbidities and complications in ESRD.</ABSTRACT>'}]
2024-01-02 00:25:59,188 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448631, Requested 1617. Please try again in 33ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:25:59,188 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Physical activity in childhood and later risk of inflammatory bowel disease: A Scandinavian birth cohort study.\nRetrospective data have linked adult physical activity (PA) to reduced risk of inflammatory bowel disease (IBD). We aimed to prospectively examine the association of PA and screen time (ST) in childhood with later risk of IBD, for which data are scarce.Using two population-based birth cohorts (All Babies in Southeast Sweden [ABIS] and Norwegian Mother, Father, and Child Cohort Study [MoBa]), we retrieved parent-reported data on PA and ST degree at ages 3 and 8\xa0years. Data were modelled as binary (high vs. low) and numerical (hours/day) exposures. Inflammatory bowel disease was defined as \u22652 diagnostic records in national health registers. Cox regression estimated hazard ratios adjusted for potential confounding from parental IBD, country of origin, education, and smoking habits (Adjusted hazard ratio (aHR)). Our 8-year analyses included a 2-year lag period to reduce the risk of reverse causation. Cohort-specific estimates were pooled using random-effects model.Among 65,978 participants from ABIS (n\xa0=\xa08810) and MoBa (n\xa0=\xa057,168) with available data, 266 developed IBD. At 3\xa0years, children with high versus low PA had an aHR of 1.12 for IBD (95%CI\xa0=\xa00.87-1.43); high versus low ST showed an aHR of 0.91 (95%CI\xa0=\xa00.71-1.17). Conversely, at 8\xa0years, high versus low ST was associated with increased risk of later IBD (aHR\xa0=\xa01.51; 95%CI\xa0=\xa01.02-2.25), but PA at 8\xa0years, was not linked to IBD (aHR\xa0=\xa01.19; 95%CI\xa0=\xa00.80-1.76). Subtype-specific analyses for Crohn\'s disease and ulcerative colitis did not differ appreciably.Acknowledging possible confounding variables, children with high versus low ST at 8\xa0years were at increased risk of IBD. In contrast, PA degree was not linked to IBD at any age category.</ABSTRACT>'}]
2024-01-02 00:25:59,195 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:59,196 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448603, Requested 1726. Please try again in 43ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:25:59,196 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Simultaneous detection method for two cardiac disease protein biomarkers on a single chip modified with mixed aptamers using surface plasmon resonance.\nA simultaneous detection method for two cardiac disease protein biomarkers present in serum samples on a single planar gold chip using surface plasmon resonance (SPR) is described. The detection of N-terminal pro-brain natriuretic peptide (NT-proBNP) and tumor necrosis factor \u03b1 (TNF-\u03b1), which are known as acute myocardial infarction (AMI) biomarkers, with predetermined clinically relevant concentrations was performed using mixed aptamers specific to each protein tethered on a single gold surface. After the binding of NT-proBNP and/or TNF-\u03b1 to the mixed aptamers, an antibody specific to each target protein was injected to form a surface sandwich complex to improve selectivity. In order to adjust the dynamic ranges in the known clinically relevant concentration significantly different for NT-proBNP (0.13-0.24\xa0nM) and TNF-\u03b1 (0.5-3 pM), the surface density ratios of the corresponding pair of aptamer and antibody were first systematically determined, which were the 1:1 mixed aptamer chip with 40\xa0nM anti-NT-proBNP and 100\xa0nM anti-TNF-\u03b1. This allowed to establish the distinct dynamic ranges of 0.05-0.5\xa0nM for NT-proBNP and 0.1-5 pM for TNF-\u03b1 in a buffer, along with detection and quantification limits of 0.03 and 0.19\xa0nM for NT-proBNP and 0.06 and 0.21 pM for TNF-\u03b1, respectively. The changes in refractive unit (RU) values observed when exposing both proteins at different concentrations alongside the corresponding fixed concentration of antibodies onto the 1:1 mixed aptamer chip were then correlated to the sum of RU values measured when using the injection of individual protein for evaluating each protein concentration. With a complete characterization of the simultaneous quantification of two protein concentrations in the buffer, the mixed aptamer chip was finally employed for direct measurements of NT-proBNP and TNF-\u03b1 concentrations in undiluted serum samples from healthy controls and AMI patients. The results of simultaneous SPR measurements for the two proteins in the serum samples were further compared to the individual protein concentration results using an enzyme-linked immunosorbent assay.</ABSTRACT>'}]
2024-01-02 00:25:59,196 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:59,221 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:59,222 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449682, Requested 1609. Please try again in 172ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:25:59,222 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Long non-coding RNAs: The hidden players in diabetes mellitus-related complications.\nLong non-coding RNAs (lncRNAs) have been recognized as important regulators of gene expression in various human diseases. Diabetes mellitus (DM) is a long-term metabolic disorder associated with serious macro and microvascular complications. This review discusses the potential lncRNAs involved in DM-related complications such as dysfunction of pancreatic beta islets, nephropathy, retinopathy, cardiomyopathy, and peripheral neuropathy.An extensive literature search was conducted in the Scopus database to find information from reputed biomedical articles published on lncRNAs and diabetic complications from 2014 to 2023. All review articles were collected and statistically analyzed, and the findings were summarized. In addition, the potential lncRNAs involved in DM-related complications, molecular mechanisms, and gene targets were discussed in detail.The lncRNAs ANRIL, E33, MALAT1, PVT1, Erbb4-IR, Gm4419, Gm5524, MIAT, MEG3, KNCQ1OT1, Uc.48+, BC168687, HOTAIR, and NONRATT021972 were upregulated in several diabetic complications. However, \u03b2linc1, H19, PLUTO, MEG3, GAS5, uc.322, HOTAIR, MIAT, TUG1, CASC2, CYP4B1-PS1-001, SOX2OT, and Crnde were downregulated. Remarkably, lncRNAs MALAT1, ANRIL, MIAT, MEG3, H19, and HOTAIR were overlapping in more than one diabetic complication and were considered potential lncRNAs.Several lncRNAs are identified as regulators of DM-related complications. The expression of lncRNAs is up or downregulated depending on the disease context, target genes, and regulatory partners. However, most lncRNAs target oxidative stress, inflammation, apoptosis, fibrosis, and angiogenesis pathways to mediate their protective/pathogenic mechanism of action and contribute to DM-related complications.</ABSTRACT>'}]
2024-01-02 00:25:59,223 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:59,230 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:59,234 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:59,239 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:59,263 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:59,282 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:59,296 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:59,296 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:59,300 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449395, Requested 1723. Please try again in 149ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:25:59,301 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Vitamin D deficiency and its associated factors among patients with type 2 diabetes mellitus: a systematic review and meta-analysis.\nThe study intended to assess the pooled prevalence of vitamin D deficiency (VDD) and its associated factors among patients with type 2 diabetes mellitus (T2DM).The Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were employed to plan and conduct this systematic review and meta-analysis.PubMed, Medline, Google Scholar, Web of Science, Science Direct and the Worldwide Science database were searched from their inception to 31 January 2023.Data were extracted using a standardised data extraction format prepared in Microsoft Excel. The inverse variance (I2) test was used to evaluate the presence of heterogeneity across the included studies. To identify the possible source of heterogeneity, subgroup analysis was carried out. Funnel plot symmetry, Begg\'s and Egger\'s tests were used to evaluate the existence of publication bias. In addition, factors associated with VDD among patients with T2DM were examined. All statistical analyses were carried out with STATA V.14 software.A total of 54 studies with 38\u2009016 study participants were included in the study. The pooled prevalence of VDD among patients with T2DM was found to be 64.2% (95% CI 60.6% to 67.8%) with a substantial level of heterogeneity (I2=98.2%; p<0.001). Results of the subgroup analysis indicated that the pooled prevalence of VDD among patients with T2DM was highest (70.9%) in African nations and lowest (57.1%) in Middle East countries. Being female (pooled OR (POR) 1.60, 95% CI 1.29 to 1.97), having poor glycaemic control (POR 2.50; 95% CI 1.74 to 3.59), hypertension (POR 1.21; 95% CI 1.08 to 1.36), obesity (body mass index \u226525) (POR 1.68; 95% CI 1.16 to 2.44), dyslipidaemia (POR 2.54, 95% CI 1.37 to 4.73), albuminuria (POR 2.22, 95% CI 1.71 to 2.95), nephropathy (POR 1.58; 95% CI 1.08 to 2.31) and retinopathy (POR 1.48: 95% CI 1.17 to 1.89) were predictors of VDD among patients with T2DM.More than half of patients with T2DM were suffering from VDD. Being female, having poor glycaemic control, hypertension, obesity, dyslipidaemia, albuminuria, nephropathy and retinopathy were the predictors of VDD among patients with T2DM.</ABSTRACT>'}]
2024-01-02 00:25:59,304 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:59,305 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449270, Requested 1751. Please try again in 136ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:25:59,305 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Development and evaluation of a point-of-care ocular ultrasound curriculum for medical students - a proof-of-concept study.\nPoint-of-care Ocular Ultrasound (POCOUS) has gained importance in emergency medicine and intensive care in recent years. This work aimed to establish and evaluate a dedicated ultrasound education program for learning POCOUS-specific skills during medical studies at a university hospital.The blended learning-based program (6 teaching units) based on recent scientific publications and recommendations was developed for students in the clinical part of their medical studies. Experts and trainers consisted of physicians from the Ear-Nose-Throat, radiology, ophthalmology and neurology specialties as well as university educational specialists. Lecture notes containing digital video links for preparation was produced as teaching material. In total, 33 students participated in the study. The education program, including the teaching materials, motivation and subjective gain in competency, was evaluated with the aid of a questionnaire (7-point Likert response format). Objective learning success was assessed on the basis of pre- and post-tests. These covered the skill areas: "anatomical basics", "ultrasound basics", "understanding of cross-sectional images", "normal findings" and "pathology recognition".In the objective assessment of image interpretation, the participants improved significantly (p\u2009<\u20090.001) from pre- to post-test with a large effect size (Cohen\'s d\u2009=\u20091.78, effect size r\u2009=\u20090.66). The evaluations revealed a high level of satisfaction with the course concept, teaching materials and the tutors. In addition, a high level of motivation was recorded in relation to continuing to study "ultrasound diagnostics" and "ophthalmologic diseases". A significant (p\u2009<\u20090.01) positive gain was also achieved in terms of the subjective assessment of competency. This covers areas such as expertise, sonographic anatomy and performing a POCOUS examination as well as recognizing retinal detachment, globe perforation and increased optic nerve sheath diameter.The results of this feasibility study show that medical students accept and support a POCOUS-specific education program and are able to develop a higher objective and subjective level of competency. Future transfer to other sites and larger groups of participants seems feasible.</ABSTRACT>'}]
2024-01-02 00:25:59,316 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:59,321 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449175, Requested 1656. Please try again in 110ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:25:59,321 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Study protocol of OmegaROP-2 prospective study: expression of placental fatty acid receptors in preterm newborns with retinopathy of prematurity.\nIncomplete vascularization of the retina in preterm infants carries a risk of retinopathy of prematurity (ROP). Progress in neonatal resuscitation in developing countries has led to the survival of an increasing number of premature infants, resulting in an increased rate of ROP and consequently in visual disability. Strategies to reduce ROP involve optimizing oxygen saturation, nutrition, and normalizing factors such as insulin-like growth factor 1 and n-3 long-chain polyunsaturated fatty acids (LC-PUFA). Our previous study, OmegaROP, showed that there is an accumulation or retention of docosahexaenoic acid (DHA) in mothers of infants developing ROP, suggesting abnormalities in the LC-PUFA placental transfer via fatty acid transporting proteins. The present study aims to better understand the LC-PUFA transport dysfunction in the fetoplacental unit during pregnancy and to find a novel target for the prevention of ROP development.The study protocol is designed to evaluate the correlation between the expression level of placental fatty acid receptors and ROP occurrence. This ongoing study will include 100 mother-infant dyads: mother-infant dyads born before 29\xa0weeks of gestational age (GA) and mother-infant dyads with full-term pregnancies. Recruitment is planned over a period of 46\xa0months. Maternal and cord blood samples as well as placental tissue samples will be taken following delivery. ROP screening will be performed using wide-field camera imaging according to the International Classification of ROP consensus statement.The results of this study will have a tangible impact on public health. Indeed, if we show a correlation between the expression level of placental omega-3 receptors and the occurrence of ROP, it would be an essential step in discovering novel pathophysiological mechanisms involved in this retinopathy.NCT04819893.</ABSTRACT>'}]
2024-01-02 00:25:59,325 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:59,326 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:59,326 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449166, Requested 1724. Please try again in 118ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:25:59,326 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Safety and Performance of the Aortix Device in Acute Decompensated Heart\xa0Failure and Cardiorenal Syndrome.\nCardiorenal syndrome (CRS) complicates 33% of acute decompensated heart failure (ADHF) admissions, and patients with persistent congestion at discharge have high 30-day event rates.The purpose of this study was to evaluate a novel catheter-deployed intra-aortic entrainment pump (IAEP) in patients with ADHF with CRS and persistent congestion.A multicenter (n\xa0=\xa014), nonrandomized, single-arm, safety and feasibility study of IAEP therapy was conducted. Within patient changes (post-pre IAEP therapy) in fluid loss, hemodynamics, patient-reported dyspnea, and serum biomarkers were assessed using Wilcoxon signed-rank testing.Of 21 enrolled patients, 18 received Aortix therapy. Mean  SD patient age was 60.3  7.9 years. The median left ventricular ejection fraction was 22.5% (25th-75th percentile: 10.0%-53.5%); 27.8% had a left ventricular ejection fraction\xa0\u226550%. Pre-therapy, patients received 8.7  4.1\xa0days of loop diuretic agents and 44% were on inotropes. Pump therapy averaged 4.6  1.6\xa0days, yielding net fluid losses of 10.7  6.5\xa0L (P\xa0< 0.001) and significant (P\xa0< 0.01) reductions in central venous pressure (change from baseline:\xa0-8.5\xa0mm\xa0Hg [25th-75th percentile:\xa0-3.5 to\xa0-10.0 mm\xa0Hg]), pulmonary capillary wedge pressure (-11.0\xa0mm\xa0Hg [25th-75th percentile:\xa0-5.0 to\xa0-14.0 mm Hg]), and serum creatinine (-0.2\xa0mg/dL [25th-75th percentile:\xa0-0.1 to\xa0-0.5 mg/dL]) with improved estimated glomerular filtration rate (+5.0\xa0mL/min/1.73\xa0m2 [25th-75th percentile: 2.0-9.0 mL/min/1.73 m2]) and patient-reported dyspnea score (+16 [25th-75th percentile: 3-37]). Dyspnea scores, natriuretic peptides, and renal function improvements persisted through 30\xa0days.This pilot study of patients with ADHF, persistent congestion, and worsening renal function due to CRS supports the potential for safely achieving decongestion using IAEP therapy. These initial promising results provide the basis for future randomized clinical trials of this novel pump. (An Evaluation of the Safety and Performance of the Aortix System for Intra-Aortic Mechanical Circulatory Support in Patients with Cardiorenal Syndrome [The Aortix CRS Pilot Study]; NCT04145635).</ABSTRACT>'}]
2024-01-02 00:25:59,327 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449150, Requested 1555. Please try again in 94ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:25:59,327 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>In vivo measurement of T1 in the vitreous humor of patients with ischemic retinal disease.\nTo demonstrate MR T1 mapping in vivo as a method to non-invasively estimate vitreous oxygen concentration in ischemic eye disease.Patients with ischemic eye disease (central retinal vein occlusion, ocular ischemic syndrome, and proliferative diabetic retinopathy) were prospectively recruited. MRI was performed on each patient before any treatment, with T1 mapping acquired using an inversion recovery TrueFISP sequence at several inversion times, from a single slice positioned through the center of both eyes in the axial oblique plane. A phantom study measuring seven different concentrations of vitronectin, a protein released in ischemic eye disease, was undertaken to determine its potential confounding effect on T1 .Ten participants were recruited (eight central retinal vein occlusion, one ocular ischemic syndrome, and one proliferative diabetic retinopathy). Of the eight central retinal vein occlusion cases, there was a statistically different vitreous T1 in the diseased eye compared to the healthy control eye (4.306 vs. 4.518\u2009s, p\u2009=\u20090.008). T1 times did not significantly alter across the range of vitronectin concentrations.Ischemic eye disease decreases vitreous T1 , potentially implying an increase in vitreous partial pressure of oxygen (pO2 ) concentration given what is known from the relationship between 1/T1 and pO2 . Potential theories for this unexpected result are discussed. This study provides further data on this technique, with potential clinical application in eye disease.</ABSTRACT>'}]
2024-01-02 00:25:59,328 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:59,339 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:59,340 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:59,341 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448640, Requested 1529. Please try again in 22ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:25:59,341 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Risk of incident autoimmune diseases in patients with newly diagnosed psoriatic disease: a nationwide population-based study.\nThere are limited large population-based cohort studies on the risk of incident autoimmune diseases among patients with newly diagnosed psoriatic disease. The objective of this study was to assess the risk of autoimmune diseases in patients with newly diagnosed psoriatic disease. Using the Korean National Health Insurance Service database, patients with newly diagnosed psoriatic disease between 2007 and 2019 were included. Comparators were randomly selected and matched according to age and sex. A total of 321,354 patients with psoriatic disease and 321,354 matched comparators were included in this study. Patients with psoriatic disease had a significantly higher risk of Crohn\'s disease [adjusted hazard ratio (aHR), 1.95; 95% confidence interval (CI) 1.42-2.67], ulcerative colitis (aHR, 1.65; 95% CI 1.39-1.96), systemic lupus erythematosus (aHR, 1.86; 95% CI 1.34-2.57), rheumatoid arthritis (aHR, 1.63; 95% CI 1.52-1.76), ankylosing spondylitis (aHR, 2.32; 95% CI 1.95-2.77), alopecia areata (aHR, 1.41; 95% CI 1.35-1.46), and type 1 diabetes (aHR, 1.23; 95% CI 1.11-1.37). However, the risk of Graves\' disease, Hashimoto\'s disease, Sjgren\'s syndrome, and systemic sclerosis was not significantly different between the groups. In conclusion, patients with newly diagnosed psoriatic disease may have a significantly increased risk of incident autoimmune diseases.</ABSTRACT>'}]
2024-01-02 00:25:59,342 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448619, Requested 1706. Please try again in 43ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:25:59,342 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Metagenomic analysis of microbiological changes on the ocular surface of diabetic children and adolescents with a dry eye.\nMicrobiome changes on the ocular surface may cause dry eyes. A metagenome assay was used to compare the microbiome composition and function of the ocular surface between diabetic children and adolescents with dry eye, diabetic children and adolescents without dry eye, and normal children.Twenty children and adolescents aged 8 to 16 with diabetes were selected from the Shanghai Children and Adolescent Diabetes Eye Study. Ten healthy children and adolescents belonging to the same age group were selected from the outpatient clinic during the same period. The participants were classified into the dry eye group (DM-DE group, n\u2009=\u200910), the non-dry eye group (DM-NDE group, n\u2009=\u200910) and the normal group (NDM group, n\u2009=\u200910). A conjunctival sac swab was collected for metagenomic sequencing, and the relationship between the microbiome composition and functional gene differences on the ocular surface with dry eye was studied.The classification composition and metabolic function of the microorganisms on the ocular surface of children in the 3 groups were analyzed. It was found that children\'s ocular microbiota was composed of bacteria, viruses and fungi. There were significant differences in \u03b1 diversity and \u03b2 diversity of microbial composition of ocular surface between DM-DE group and NDM group(P<0.05). There were significant differences in \u03b1 and \u03b2 diversity of metabolic pathways between the two groups(P<0.05). The functional pathways of ocular surface microorganisms in diabetic children with dry eyes were mainly derived from human disease, antibiotic resistance genes, carbohydrate, coenzyme and lipid transport and metabolism-related functional genes; In normal children, the functional pathways were mainly derived from replication, recombination, repair, signal transduction and defense-related functional genes.The DM-DE group have unique microbial composition and functional metabolic pathways. The dominant species and unique metabolic pathways of the ocular surface in the DM-DE group may be involved in the pathogenesis of dry eye in diabetic children.</ABSTRACT>'}]
2024-01-02 00:25:59,342 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:59,369 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:59,381 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:59,382 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449184, Requested 1181. Please try again in 48ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:25:59,382 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Editorial: Advanced approaches in the diagnosis and treatment of diabetes mellitus and secondary complications.\n</ABSTRACT>'}]
2024-01-02 00:25:59,405 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:59,407 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449054, Requested 1486. Please try again in 72ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:25:59,407 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Clinical Reasoning: A Woman With Progressive Painless Sequential Monocular Vision Loss.\nA 68-year-old woman with a history of diabetes mellitus type 2, depression, and migraines presented with painless, acute, consecutive vision loss affecting the right eye for 1 week and the left eye for 2 weeks. Neuro-ophthalmic examination was notable for visual acuities of finger-counting peripherally, a central scotoma, anterior uveitis, vitritis, and placoid macular pigmentary changes in each eye (OU). Proprioception was diminished in the bilateral lower extremities. Optical coherence tomography (OCT) revealed hyper-reflectivity and attenuation of the outer retina OU with normal inner retinal architecture and reflectivity. Fluorescein angiography (FA) demonstrated normal filling of the central retinal arteries with patchy choroidal perfusion in the right eye and targetoid punctate foci of leakage in the macula OU. Before the recognition of intraocular inflammation and findings on OCT and FA, the patient was treated for presumed central retinal artery occlusion at an outside hospital. Additional diagnostic testing at our institution revealed an alternate diagnosis. This case highlights a rare presentation of a well-known disease entity and underscores the importance of avoiding diagnostic anchoring in clinical practice.</ABSTRACT>'}]
2024-01-02 00:25:59,411 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:59,412 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449023, Requested 1527. Please try again in 73ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:25:59,412 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Retinal vascular occlusion risks during the COVID-19 pandemic and after SARS-CoV-2 infection.\nThe coronavirus disease 2019 (COVID-19) has been reported to affect vascular networks including the eye. However, evidence on the causal relationship between COVID-19 infection and retinal vascular occlusions remains limited. This study aimed to determine the change in retinal vascular occlusion incidence during COVID-19 era and whether severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection induces retinal vascular occlusion. Retinal vein occlusion (RVO) and retinal artery occlusion (RAO) incidences during 2018-2019 and 2020-July 2021 were compared, those in confirmed and suspected COVID-19 patients diagnosed from 2020 to January 2021 were calculated, and those in COVID-19 patients during 180\xa0days prior and 180\xa0days after diagnosis were assessed. Additionally, the standardized incidence ratio of RVOs in COVID-19 patients was analyzed. Incidence rates per 100,000 people/year of RVO during 2018-2019 and 2020-2021 was 102.0 and 98.8, respectively. RAO incidence rates during 2018-2019 and 2020-2021 were 11.7 and 12.0, respectively. In both confirmed and suspected COVID-19 patients, the incidence of RVO and RAO did not change significantly from 180\xa0days before to after diagnosis in the adjusted model. RVO incidence slightly decreased while RAO incidence increased during the COVID-19 pandemic. SARS-CoV-2 infection did not significantly increase RVO or RAO incidence.</ABSTRACT>'}]
2024-01-02 00:25:59,438 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:59,442 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448912, Requested 1599. Please try again in 68ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:25:59,442 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>The association between plasma N-terminal pro-brain natriuretic peptide concentration and metabolic disturbances in women with depressive symptoms.\nThe relationship between brain natriuretic peptides and depression was studied in patients with cardiovascular diseases (CVD), but the data in people without CVD are limited. Metabolic disturbances can be associated with natriuretic peptides\' levels. The study aimed to assess serum N-terminal pro-brain natriuretic peptide (NT-proBNP) level in women with depressive symptoms and its relationship with metabolic disturbances.The analysis included 347 women (20-60 years old) from Bialystok PLUS cohort study: 98 with depressive symptoms and 249 controls. Clinical examination, oral glucose tolerance test (OGTT) and assessment of lipid, sex hormone binding globulin (SHBG) and NT-proBNP concentrations in the blood were performed. The participants completed Beck Depression Inventory questionnaire.Metabolic syndrome was more frequent in the group of women with depressive symptoms compared to women without depressive symptoms. Women with depressive symptoms had lower NT-proBNP level than the control group - 45.88 (27.80-67.04) vs 56.49 (32.42-94.25) pg/mL, p\xa0=\xa00.027. Multiple linear regression analysis of all women showed that NT-proBNP level was reversely associated with the presence of depressive symptoms, waist circumference and heart rate and positively connected with age. In the group of women with depressive symptoms, we observed negative correlations between NT-proBNP level and insulin concentration at 60\xa0min of OGTT, diastolic blood pressure and a positive correlation with SHBG.NT-proBNP level is decreased in women with depressive symptoms, which might be connected with metabolic disturbances in this group.</ABSTRACT>'}]
2024-01-02 00:25:59,446 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:59,447 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:59,447 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448848, Requested 1573. Please try again in 56ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:25:59,447 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>5\u2005Tear proteins in premature babies at risk of retinopathy of prematurity.\nThis feasibility study aimed to investigate the feasibility of collecting and analysing tear proteins from preterm infants at risk of retinopathy of prematurity (ROP). Additionally, we sought to identify any tear proteins which might be implicated in the pathophysiology of ROP.Eligible infants were those undergoing ROP screening without other ocular pathology. Tear samples were obtained by Schirmer\'s test strips coincident with routine ROP screening. Mass spectrometry was used for proteomic analysis. All participants\' parents gave written, informed consent.Samples were collected from 12 infants, including two sets of twins. Gestation ranged from 25+6 to 31+1 weeks. Median postnatal age at sampling was 30.5 days (range 19 to 66). One infant developed self-limiting ROP. An adequate sample for protein analysis was obtained from each infant. 701 proteins were identified; 261 proteins identified in the majority of tear samples, including several common tear proteins, were used for analyses.Increased risk of ROP as determined by G-ROP prediction criteria was associated with an increase in lactate dehydrogenase B (LDH-B) chain protein in tears. Older, more mature infants demonstrated increased concentration of immunoglobulin complexes within their tear samples and two sets of twins in the cohort showed exceptionally similar proteomes, supporting validity of the analysis.Tear sampling by Schirmer test strips and subsequent proteomic analysis in preterm infants is feasible. A larger study is required to investigate the potential use of tear proteomics in early identification of ROP.</ABSTRACT>'}]
2024-01-02 00:25:59,448 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448796, Requested 1390. Please try again in 24ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:25:59,448 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Ultrasound Concave 2-D Ring Array for Retinal Stimulation.\nAn ultrasound concave 2-D ring array transducer was designed for applications in visual stimulation of the retina with a long-term goal to restore vision in individuals with intact neurons but suffering blindness due to retinopathies. The array was synthesized and has a frequency of 20 MHz (0.075-mm wavelengths in water), 18-mm focal length (the curvature of the concave array), 1004 elements (with a pitch of 4.0 wavelengths), and inner and outer diameters of 9 and 14 mm, respectively. Wave patterns produced with the array at the focal distance were simulated. Results show that the wave patterns obtained can achieve a full-width-at-half-maximum (FWHM) resolution of 0.147 mm that is very close to the FWHM diffraction limit (0.136 mm). In addition, a scaled experiment at a lower frequency of 2.5 MHz was performed. The result is very close to those obtained with the simulations.</ABSTRACT>'}]
2024-01-02 00:25:59,491 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:59,491 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449586, Requested 1878. Please try again in 195ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:25:59,492 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Risk of cardiac rupture among elderly patients with diabetes presenting with first acute myocardial infarction.\nWe aimed to analyze the risk of cardiac rupture (CR) in aged diabetic patients with acute ST-segment elevated myocardial infarction (STEMI) who were followed up for one month, and analyze its independent risk factors.A total of 3063 aged patients with first onset STEMI admitted to Beijing Anzhen Hospital from January 2001 to December 2020 were retrospectively included. There were 2020 patients without diabetes mellitus (DM) and 1043 patients with DM. We used propensity scores matching (PSM) method to balance baseline exposure factors between patients with or without DM, and all were divided the DM group (1043 cases) and the non-DM group (1043 cases) after the PSM. The primary outcome was CR (the composite rate of papillary muscle rupture, ventricular septum perforation, free wall rupture), which was diagnosed based on clinical manifestations and/or echocardiographic findings. Kaplan-meier survival analyses and log-rank test was used to evaluate the risk of CR between the two groups, and Cox regression analysis was used to evaluate the independent risk factors for CR.After PSM, the baseline clinical data were similar between the DM and non-DM group (all P>0.05). However, level of glycated hemoglobin was significantly higher in the DM group (P<0.05). During 1 month of follow-up, there were 55 (2.64%) cases of CR, most occurred within 48h after admission (40 cases). Among the 55 cases, 11(0.53%) had papillary muscle rupture, 18(0.86%) had ventricular septum perforation, and 26(1.25%) had free wall rupture. Kaplan-meier survival analyses detected that the DM group was associated with significantly increased risk of CR (3.36% vs. 1.92%, HR=1.532, 95% CI: 1.054-2.346, P=0.030), ventricular septum perforation (1.05% vs. 0.67%, HR=1.464, 95% CI: 1.021-2.099, P=0.038) and free wall rupture (1.63% vs. 0.86%, HR=1.861, 95% CI: 1.074-3.225, P=0.027) than those in the non-DM group. Among the 2031 aged STEMI patients without CR, 144 cases (6.90%, 144/2086) died; and among the 55 patients with CR, 37 cases (1.77%, 37/2086) died due to CR. Therefore, twenty percent (20.44%, 37/181) of death was due to CR. Multivariate Cox regression analysis indicated that DM (HR=1.532, 95%CI: 1.054-2.346), age (HR=1.390, 95%CI: 1.079-1.791), female (HR=1.183, 95%CI: 1.049-1.334), troponin I (HR=1.364, 95%CI: 1.108-1.679), brain natriuretic peptide (HR=1.512, 95%CI: 1.069-2.139), revascularization (HR=0.827, 95%CI: 0.731-0.936) and \u03b2-receptor blocker (HR=0.849, 95%CI: 0.760-0.948) were independent risk factors of CR (all P<0.05).DM as well as a few other factors, are independent determinants of CR. CR is not a rare event among the aged STEMI patients and twenty percent of deaths are due to CR. However, large sample-sized studies are warranted to confirm these findings.</ABSTRACT>'}]
2024-01-02 00:25:59,496 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:59,523 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:59,525 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449020, Requested 1577. Please try again in 79ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:25:59,525 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Case Report: Spectrum of interesting ocular manifestations following COVID-19 vaccination: a case series of real-world presentations.\nWe report the ocular findings that patients experienced after receiving the coronavirus disease 2019 (COVID-19) vaccination in three different eye centers in Malaysia.A total of four cases were reported. Three patients received the Pfizer-BioNTech vaccine, while the other received the Oxford AstraZeneca type. Ocular symptoms occurred after the first vaccine dose in two patients and after the second vaccine dose in the other two. Three out of four patients required active treatment for their vision complications postvaccination. The first patient had acute-onset retinal pigment epitheliitis within 3\xa0h of vaccination and was treated conservatively. The second patient developed unilateral choroidal neovascularization 3 days after vaccination and required intravitreal antivascular endothelial growth factor injection. The third patient presented with bilateral acute multifocal placoid pigment epitheliopathy a week after vaccination and responded to intravenous methylprednisolone. The fourth patient presented with herpes zoster infection and unilateral anterior nongranulomatous uveitis 2 weeks after vaccination and was treated with oral acyclovir and topical corticosteroids. All patients reported some amount of visual recovery.Visual symptoms and various ocular adverse events can occur following COVID-19 vaccination, which warrants further investigation and urgent intervention if necessary. We would suggest patients receiving the COVID-19 vaccination be aware of possible ocular complications and report any symptoms, regardless of severity.</ABSTRACT>'}]
2024-01-02 00:25:59,535 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:59,538 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448904, Requested 1617. Please try again in 69ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:25:59,538 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>8\u2005Unexpected retinopathy in a patient presenting with bilateral optic disc swelling.\nA 12-year-old boy presented with 5 day history of blurry vision, \'wobbly eyes\', tinnitus and difficulty seeing at night. Local ophthalmology noted bilateral optic disc swelling and referred him urgently for neurological investigations.Clinical Findings: At presentation VA was RE 0.00 and LE 0.2 with normal Ishihara colour vision. His extraocular movements were full without manifest strabismus. Fundoscopy showed bilateral optic disc swelling. Electrophysiology unexpectedly revealed a functionally cone isolated retina with markedly abnormal rod function. Pattern VEPs indicated bilateral macular pathway dysfunction affecting left eye more than right eye. Wide field imaging showed bilateral diffusely scattered yellow-white flecks in the midperiphery of each eye. His kinetic visual fields were moderately restricted bilaterally. MRI showed a Chiari 1 malformation with cerebellar tonsil herniation, but LP opening pressure was normal.Differential diagnosis included RDH5 retinopathy or vitamin A deficiency. On questioning he reported a diet restricted to only meat and biscuits. His vitamin A levels were subnormal at 0.14 umol/L (reference range 0.9-2.5umol/l) and he was started on high-dose Vitamin A supplements.Four months after supplementation retinal appearances had normalised, the rod ERGs recovered, nyctalopia and visual field restriction resolved. PVEPs had improved but an element of LE macular pathway dysfunction remained. Optic disc swelling settled leaving mild temporal pallor, particularly of the LE with some RNFL loss.It is important to recognise nutritional Vitamin A deficiency in children as prompt recognition and treatment can improve symptoms, reverse retinal pathology which we have demonstrated with electrophysiological findings.</ABSTRACT>'}]
2024-01-02 00:25:59,545 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:59,566 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:59,568 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448440, Requested 1616. Please try again in 7ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:25:59,568 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>[Salivary gland ultrasound or biopsy? : Comparison of methods based on case examples].\nUltrasound examination of the salivary glands (SG) is a\xa0quick and noninvasive method to detect and semiquantitatively estimate typical changes in the large SG in Sjgren\'s syndrome (SS). The differential diagnosis of SS is difficult because several diseases and adverse effects of treatment have a similar clinical picture as SS with sicca syndrome and can even induce alterations in the SG (mimic diseases). Hence, for a long time an SG biopsy was regarded as the diagnostic procedure of choice, especially in SS\u2011A negative patients, whereas the significance of SD sonography is still controversially discussed.Comparison of typical and atypical changes for SS in the salivary glands in ultrasound and associated histological sections.This article describes six patient cases with antibody positive or negative SS with and without typical SS ultrasound patterns, SS-associated lymphoma, sarcoidosis and IgG4-associated disease. The findings of the sonographic examination of the parotid glands and the associated histology of the SD are explained and put into context.The SSA antibody positive patients with SS show a\xa0typical sonographic pattern with hypoechoic foci, especially if the disease has been present for a\xa0long time. This pattern can help support the diagnosis of SS. The ultrasound patterns of the mimic diseases sometimes differ significantly from the typical patterns of pSS. The histological examination of the SG helps to corroborate the diagnosis but low histological focus scores, in particular, require a\xa0critical synopsis of the clinical, serological and imaging findings.Both salivary gland ultrasound and the histological examination of SG biopsies are justified in the diagnostics and differential diagnosis of SS and sicca syndrome.</ABSTRACT>'}]
2024-01-02 00:25:59,582 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:59,588 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:59,589 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449436, Requested 1615. Please try again in 140ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:25:59,589 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Optical Density Ratio of Subretinal Fluid in Choroidal Melanomas Versus Choroidal Naevi Assessed by Optical Coherence Tomography.\nThe purpose of this study was to determine whether optical density ratio (ODR) of subretinal fluid (SRF) on optical coherence tomography (OCT) differs between choroidal naevi and melanomas.One hundred ninety-nine patients (one eye per patient) presenting choroidal melanoma or choroidal naevus with SRF on OCT, evaluated between February and June 2019, were retrospectively included. Other retinal conditions, opaque media, and low-quality OCT were excluded. Mean pixel intensity of SRF (range = 0-255) was quantified using a semi-automated procedure by a masked observer on standard horizontal OCT sections. Mean vitreous intensity served as the reference for ODR.One hundred twenty-eight patients with choroidal melanoma and 71 patients with choroidal naevus were included in this study. ODR (mean  SD) was higher in melanomas (181  64) than in naevi (78  48, P < 0.0001). ODR was correlated to lesion thickness (P < 0.0001, r = 0.27), largest basal diameter (P\xa0=\xa00.028, r = 0.16) and, among naevi, to the number of risk factors for growth into melanoma (P\xa0=\xa00.032, r = 0.22). Among 110 patients with naevi or melanoma who underwent fluorescein angiography, ODR was 120.7  550.1 in eyes presenting angiographic pinpoints versus 14.19  26.0 in eyes that did not (P\xa0=\xa00.06). Fourteen eyes with naevi that transformed into melanoma over 3\xa0years had a mean baseline ODR of 94.7  243.5 compared to 4.01  9.74 in 28 matched naevi eyes of similar size that did not transform (P\xa0=\xa00.027).SRF ODR is higher in choroidal melanoma compared to choroidal naevi. This OCT-derived imaging marker is also higher in choroidal naevi with the potential to transform into melanoma, compared to stationary naevi.</ABSTRACT>'}]
2024-01-02 00:25:59,611 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:59,614 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449201, Requested 1537. Please try again in 98ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:25:59,614 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Fibroblasts mediate endothelium response to angiogenic cues in a newly developed 3D stroma engineered model.\nThree-dimensional stroma engineered models would enable fundamental and applicative studies of human tissues interaction and remodeling in both physiological and pathological conditions. In this work, we propose a 3D vascularized stroma model to be used as in vitro platform for drug testing. A pullulan/dextran-based porous scaffold containing pre-patterned microchannels of 100\xa0\u03bcm diameter is used for co-culturing of fibroblasts within the matrix pores and endothelial cells to form the lumen. Optical clearing of the constructs by hyperhydration allows for in-depth imaging of the model up to 1\xa0mm by lightsheet and confocal microscopy. Our 3D vascularized stroma model allows for higher viability, metabolism and cytokines expression compared to a monocultured vascular model. Stroma-endothelium cross-talk is then investigated by exposing the system to pro and anti-angiogenic molecules. The results highlight the protective role played by fibroblasts on the vasculature, as demonstrated by decreased cytotoxicity, restoration of nitric oxide levels upon challenge, and sustained expression of endothelial markers CD31, vWF and VEGF. Our tissue model provides a 3D engineered platform for in vitro studies of stroma remodeling in angiogenesis-driven events, known to be a leading mechanism in diseased conditions, such as metastatic cancers, retinopathies and ischemia, and to investigate related potential therapies.</ABSTRACT>'}]
2024-01-02 00:25:59,639 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:59,639 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448999, Requested 1715. Please try again in 95ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:25:59,640 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Establishment of an LC-MS/MS method for quantification of lifitegrast in rabbit plasma and ocular tissues and its application to pharmacokinetic study.\nLifitegrast, a lymphocyte function-associated antigen 1 antagonist, was approved by the FDA for the treatment of dry eye disease. Cornea and conjunctiva have been reported to be the sites of action of lifitegrast. To investigate the pharmacokinetics of lifitegrast, a sensitive analytical method for the determination of lifitegrast in various biological matrices such as plasma and ocular tissues is required. However, only limited information about the analytical method for lifitegrast in biological samples is available. In the present study, we aimed to develop a new liquid chromatography-tandem mass spectrometry method for the determination of lifitegrast in rabbit plasma, cornea, conjunctiva, and sclera. Lifitegrast-d6 was used as an internal standard (IS). To prepare the biological samples, protein precipitation using acetonitrile was utilized. Analytes were separated from endogenous interferences on an Atlantis dC18 (5\xa0m, 2.1\xa0\xa0150 mm), and a mixture of 0.1\xa0% formic acid and acetonitrile was used as the mobile phase. The mass transition of precursor to product ion was monitored at 615.2\xa0\u2192\xa0145.0 for lifitegrast and 621.2\xa0\u2192\xa0145.1 for IS. The calibration curves were linear over the concentration range from 2 to 500\xa0ng/mL for plasma and 5 to 500\xa0ng/mL in ocular tissue homogenates. Intra- and inter-day accuracy ranged from 95.76 to 106.80\xa0% in the plasma and 94.42 to 112.80\xa0% in the ocular tissues. Precision was within 8.56\xa0% in the plasma and 9.72\xa0% in the ocular tissues. The short-term, long-term, auto-sampler, and freeze-thaw stabilities of lifitegrast were validated. The developed method was applied to a pharmacokinetic study of lifitegrast in rabbits. Following ophthalmic administration, only 3.26\xa0% of administered lifitegrast was absorbed into the systemic circulation. Peak tissue concentrations were observed at 0.5\xa0h after dosing, and topically administered lifitegrast was mainly distributed in the cornea and conjunctiva. The finding of this study is expected to be used in further pharmacokinetic studies and formulation development.</ABSTRACT>'}]
2024-01-02 00:25:59,662 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:59,664 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:59,665 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448814, Requested 1751. Please try again in 75ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:25:59,665 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Fecal short chain fatty acids and urinary 3-indoxyl sulfate do not discriminate between patients with Crohns disease and ulcerative colitis and are not of diagnostic utility for predicting disease severity.\nUrinary 3-indoxyl sulfate levels as well as fecal short chain fatty acid (SCFA) concentrations are surrogate markers for gut microbiota diversity. Patients with inflammatory bowel diseases (IBDs) and patients with primary sclerosing cholangitis (PSC), a disease closely associated with IBD, have decreased microbiome diversity. In this paper, the fecal SCFAs propionate, acetate, butyrate and isobutyrate of patients with IBD and patients with PSC-IBD and urinary 3-indoxyl sulfate of IBD patients were determined to study associations with disease etiology and severity.SCFA levels in feces of 64 IBD patients and 20 PSC-IBD patients were quantified by liquid chromatography with tandem mass spectrometry (LC-MS/MS). Urinary 3-indoxyl sulfate levels of 45 of these IBD patients were analysed by means of reversed-phase liquid chromatography-electrospray ionization-tandem mass spectrometry. Feces of 17 healthy controls and urine of 13 of these controls were analyzed in parallel. These cohorts had comparable sex distribution and age.Urinary 3-indoxyl sulfate concentrations (normalized to urinary creatinine levels) was increased (P\u2009=\u20090.030) and fecal isobutyrate levels (normalized to dry weight of the stool sample) of IBD patients were decreased (P\u2009=\u20090.035) in comparison to healthy controls. None of the analyzed metabolites differed between patients with Crohns disease (CD) and patients with ulcerative colitis (UC). Fecal acetate and butyrate positively correlated with fecal calprotectin (P\u2009=\u20090.040 and P\u2009=\u20090.005, respectively) and serum C-reactive protein (P\u2009=\u20090.024 and P\u2009=\u20090.025, respectively) in UC but not CD patients. UC patients with fecal calprotectin levels above 150\xa0g/g, indicating intestinal inflammatory activity, had higher fecal acetate (P\u2009=\u20090.016), butyrate (P\u2009=\u20090.007) and propionate (P\u2009=\u20090.046) in comparison to patients with fecal calprotectin levels\u2009<\u200950\xa0g/g. Fecal SCFA levels of PSC-IBD and IBD patients were comparable.Current findings suggest that analysis of urinary 3-indoxyl-sulfate as well as fecal SCFAs has no diagnostic value for IBD and PSC-IBD diagnosis or monitoring of disease severity.</ABSTRACT>'}]
2024-01-02 00:25:59,665 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448753, Requested 1519. Please try again in 36ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:25:59,665 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Ectopic adrenocorticotropic hormone (ACTH) syndrome: two case reports.\nClinically, the incidence of ectopic adrenocorticotropic hormone (ACTH) syndrome (EAS) is often obscured, making it difficult to identify the primary lesion. This can pose challenges in both diagnosing and treating the disease. Therefore, this paper presents two cases of EAS to share insights and guide diagnosis and treatment approaches.Case 1 is a male patient aged 71, and Case 2 is a female patient aged 61. EAS was considered for both patients according to the medical history and auxiliary examination results. After the blood glucose and blood potassium were slightly stable, Case 1 received the total right adrenalectomy and the left subtotal adrenalectomy. After the surgery, a positron emission tomography-computed tomography (PET-CT) was used to identify the primary lesion in Case 1, and the result showed primary neuroendocrine tumors originating from the thymus with metastasis. A chest CT scan with contrast for Case 2 confirmed the presence of multiple soft tissue nodules in both lungs, suspected of being tumor lesions, along with mediastinal lymph node enlargement. A CT-guided lung puncture was not performed due to a progressive decrease in platelets, and the patient died due to severe lung infection eventually.PET-CT can be an effective method for diagnosing EAS. Early control of hypercortisolism is vital in preventing life-threatening infections in EAS patients.</ABSTRACT>'}]
2024-01-02 00:25:59,681 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:59,682 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448576, Requested 1532. Please try again in 14ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:25:59,682 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Efficacy of a single injection of brolucizumab in neovascular age-related macular degeneration on visual acuity and micromorphometry.\nTo assess short-term efficacy of a single injection of brolucizumab in neovascular AMD.This was a multicenter, retrospective chart review of 25 eyes of 25 patients who received a single injection of brolucizumab. Visual acuity (VA) and optical coherence tomography (OCT) features such as central subfield thickness (CSFT), subretinal fluid (SRF), intraretinal fluid, and pigment epithelial detachment (PED) were recorded at baseline, first month, and third month.Of the 25 eyes, 14 eyes were treatment-nave and 11 eyes had received previous injections. VA improved from 0.68  0.59 log MAR at baseline to 0.31  0.43 log MAR at the end of 3 months. SRF height in first and third month was significantly reduced from baseline (P < 0.001). Subretinal hyperreflective material height significantly reduced from baseline (P value 0.008 at first month and 0.01 at third month, respectively). CSFT was 464.16  247.97 microns at baseline and showed a significant reduction in first month (P < 0.001) and third month (P < 0.001). There was a significant reduction of PED height from baseline at both follow-ups. None of the eyes showed a recurrence of fluid at the end of 3 months.Our study demonstrated sustained improvement in VA and OCT parameters after a single injection of brolucizumab at 3 months. A longer follow-up may demonstrate even farther effects of a single injection.</ABSTRACT>'}]
2024-01-02 00:25:59,687 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:59,689 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448579, Requested 1591. Please try again in 22ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:25:59,690 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Disease Severity Impairs Generation of Intestinal Organoid Cultures From Inflammatory Bowel Disease Patients.\nChronic inflammation of the intestinal epithelium is an underlying cause of the two main types of inflammatory bowel disease (IBD), ulcerative colitis (UC), and Crohn\'s disease (CD). Ex\xa0vivo organoids derived from the intestinal epithelium are a useful model to study IBD. Whether such cultures can be established from surgically resected diseased IBD intestinal tissues has not been fully explored. In this study, we tested our ability to establish organoids from nondiseased and diseased IBD intestinal tissues.From 12 UC patients (n\xa0=\xa054 tissues) and 20 CD patients (n\xa0=\xa049 tissues), tissues were collected from multiple colonic regions, and for CD, the terminal ileum was also surveyed. Organoids were cultured in Matrigel domes using defined media. In primary tissues, we conducted immunohistochemical analysis for mucin 2 (MUC2) and Alcian blue staining for goblet cells. Organoids were stained for Ki67, E-cadherin, and MUC2.For UC, we were highly successful establishing organoids from nondiseased tissue (n\xa0=\xa012 of 13, 92%). This success rates dropped from tissues with mild (n\xa0=\xa06 of 9, 67%), moderate (n\xa0=\xa02 of 9, 22%), or severe disease (n\xa0=\xa01 of 23, 4%). The rates from nondiseased CD tissues were reduced (n\xa0=\xa011 of 23, 48%) in comparison to such tissues from UC patients. In UC, goblet cells and MUC2 were reduced in diseased tissues and these phenotypes were retained in organoids.Organoids can be readily derived from nondiseased surgically resected IBD tissues. While more work is needed to improve their derivation from diseased tissue, our study supports the use of organoids to study IBD pathophysiology.</ABSTRACT>'}]
2024-01-02 00:25:59,706 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:59,708 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448597, Requested 1600. Please try again in 26ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:25:59,708 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Ocular fundal changes in children suffering from cerebral malaria.\nTo assess the frequency and distribution of retinal changes in children suffering from cerebral malaria (CM), study the correlation between fundal changes and severity of disease, visual outcome, and survival of patients.An observational, cross-sectional study was done on pediatric patients, suffering from CM in a tertiary care center in eastern India. A complete ophthalmological examination was done and findings were tabulated. Their hospital admission records were checked for severity of coma, recovery, and prognosis. Data were analyzed with SPSS software, and P value < 0.05 was considered statistically significant.Total 113 children of age group 0-18 years (mean age 7.88  0.56 years) were enrolled in the study. Seventy-seven children (68.14%) had retinal changes. Most common retinal signs associated with malarial retinopathy were white centered hemorrhage and papilledema (53.09% each), followed by retinal whitening (51.33%) and vessel changes (39.82%). The correlation between the presence of white centered retinal hemorrhages and visual prognosis was found to be statistically significant (P = 0.001). Patients with Grade 4 parasitemia showed maximum retinal signs with a significant correlation between the severity of papilledema and parasite load (P = 0.037). Eighty-six patients (76.11%) survived and 27 patients (23.89%) died. All 27 patients who died showed all four signs of malarial retinopathy. Out of these, patients with retinal whitening suffered from severe coma, and this correlation was found to be statistically significant (P = 0.002).Presence of retinal signs in patients with CM is associated with severe disease (high parasite load), poor visual outcome, and increased mortality.</ABSTRACT>'}]
2024-01-02 00:25:59,722 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:59,741 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:59,742 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449598, Requested 1563. Please try again in 154ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:25:59,742 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Perilipin 2-positive mononuclear phagocytes accumulate in the diabetic retina and promote PPAR\u03b3-dependent vasodegeneration.\nType 2 diabetes mellitus (T2DM), characterized by hyperglycemia and dyslipidemia, leads to nonproliferative diabetic retinopathy (NPDR). NPDR is associated with blood-retina barrier disruption, plasma exudates, microvascular degeneration, elevated inflammatory cytokine levels, and monocyte (Mo) infiltration. Whether and how the diabetes-associated changes in plasma lipid and carbohydrate levels modify Mo differentiation remains unknown. Here, we show that mononuclear phagocytes (MPs) in areas of vascular leakage in DR donor retinas expressed perilipin 2 (PLIN2), a marker of intracellular lipid load. Strong upregulation of PLIN2 was also observed when healthy donor Mos were treated with plasma from patients with T2DM or with palmitate concentrations typical of those found in T2DM plasma, but not under high-glucose conditions. PLIN2 expression correlated with the expression of other key genes involved in lipid metabolism (ACADVL, PDK4) and the DR biomarkers ANGPTL4 and CXCL8. Mechanistically, we show that lipid-exposed MPs induced capillary degeneration in ex vivo explants that was inhibited by pharmaceutical inhibition of PPAR\u03b3 signaling. Our study reveals a mechanism linking dyslipidemia-induced MP polarization to the increased inflammatory cytokine levels and microvascular degeneration that characterize NPDR. This study provides comprehensive insights into the glycemia-independent activation of Mos in T2DM and identifies MP PPAR\u03b3 as a target for inhibition of lipid-activated MPs in DR.</ABSTRACT>'}]
2024-01-02 00:25:59,796 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:59,797 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449287, Requested 1747. Please try again in 137ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:25:59,797 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Cost-effectiveness of NT-proBNP-supported screening of chronic heart failure in patients with or without type 2 diabetes in Austria and Switzerland.\nHeart failure (HF) is a clinical syndrome with a global burden. Signs and symptoms of HF are nonspecific and often shared with other conditions. The N-terminal prohormone of brain natriuretic peptide (NT-proBNP) serves as a useful biomarker for the diagnosis of HF not only in patients with acute symptoms but also in outpatients with an ambiguous clinical presentation. The aim of the analysis is to evaluate the cost-effectiveness of implementing NT-proBNP in the diagnostic algorithm in patients with/without type 2 diabetes mellitus (T2DM), compared with a diagnosis based primarily on clinical signs or symptoms from the perspective of the Austrian and Swiss healthcare system.A time-discrete Markov model was developed to simulate the effect/improvement (lifetime-costs, quality-adjusted life-years [QALYs], and life-years [LYs]) due to an NT-proBNP screening in undetected HF patients. Undetected HF patients are included in the model according to a distribution of New York Heart Association (NYHA) classes. The model considers disease progression by transition of NYHA classes. Undetected patients may remain undetected or be detected with the help of NT-proBNP or symptoms. Patients with known HF exhibit a slower disease progression. The probability of dying is influenced by the respective NYHA class. Direct costs (2021  or CHF) were derived from published sources. QALYs, LYs, and costs were discounted (3% p.a.).In the per-patient analysis (at age 60 over lifetime), the incremental cost-utility ratio (ICUR)/QALY of NT-proBNP vs. no screening was 3,042 for HF patients in Austria. Considering the total cohort of undetected HF patients (n\u2009=\u20099,377) with the corresponding age structure over a lifetime, the ICUR increases to 4,356. In Switzerland, the per-patient results show an ICUR of CHF 897. Considering the total cohort of undetected HF patients (n\u2009=\u20096,826) the ICUR amounts to CHF 4,513. If indirect costs are considered, NT-proBNP screening becomes the dominant strategy in both countries.Overall, the analysis concludes that screening with NT-proBNP is a highly cost-effective or cost-saving diagnostic option for patients with HF, and a sensitivity analysis confirmed these findings.</ABSTRACT>'}]
2024-01-02 00:25:59,813 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:59,815 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449128, Requested 1503. Please try again in 84ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:25:59,815 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Convergent evolution of dim light vision in owls and deep-diving whales.\nAnimals with enhanced dim-light sensitivity are at higher risk of light-induced retinal degeneration when exposed to bright light conditions.1,2,3,4 This trade-off is mediated by the rod photoreceptor sensory protein, rhodopsin (RHO), and its toxic vitamin A chromophore by-product, all-trans retinal.5,6,7,8 Rod arrestin (Arr-1) binds to RHO and promotes sequestration of excess all-trans retinal,9,10 which has recently been suggested as a protective mechanism against photoreceptor cell death.2,11 We investigated Arr-1 evolution in animals at high risk of retinal damage due to periodic bright-light exposure of rod-dominated retinas. Here, we find the convergent evolution of enhanced Arr-1/RHO all-trans-retinal sequestration in owls and deep-diving whales. Statistical analyses reveal a parallel acceleration of Arr-1 evolutionary rates in these lineages, which is associated with the introduction of a rare Arr-1 mutation (Q69R) into the RHO-Arr-1 binding interface. Using in\xa0vitro assays, we find that this single mutation significantly enhances RHO-all-trans-retinal sequestration by \u223c30%. This functional convergence across 300 million years of evolutionary divergence suggests that Arr-1 and RHO may play an underappreciated role in the photoprotection of the eye, with potentially vast clinical significance.</ABSTRACT>'}]
2024-01-02 00:25:59,841 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:59,845 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:59,845 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448570, Requested 1583. Please try again in 20ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:25:59,846 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>A natural history study of autosomal dominant GUCY2D-associated cone-rod dystrophy.\nTo describe the natural history of autosomal dominant (AD) GUCY2D-associated cone-rod dystrophies (CRDs), and evaluate associated structural and functional biomarkers.Retrospective analysis was conducted on 16 patients with AD GUCY2D-CRDs across two sites. Assessments included central macular thickness (CMT) and length of disruption to the ellipsoid zone (EZ) via optical coherence tomography (OCT), electroretinography (ERG) parameters, best corrected visual acuity (BCVA), and fundus autofluorescence (FAF).At first visit, with a mean age of 30\xa0years (range 5-70\xa0years), 12 patients had a BCVA below Australian driving standard (LogMAR\u2009\u2265\u20090.3 bilaterally), and 1 patient was legally blind (LogMAR\u2009\u2265\u20091). Longitudinal analysis demonstrated a deterioration of LogMAR by - 0.019 per year (p\u2009<\u20090.001). This accompanied a reduction in CMT of - 1.4\xa0m per year (p\u2009<\u20090.0001), lengthened EZ disruption by 42\xa0m per year (p\u2009=\u2009\u2009<\u20090.0001) and increased area of FAF by 0.05 mm2 per year (p\u2009=\u20090.027). Similarly, cone function decreased with increasing age, as demonstrated by decreasing b-wave amplitude of the light-adapted 30\xa0Hz flicker and fused flicker (p\u2009=\u20090.005 and p\u2009=\u20090.018, respectively). Reduction in CMT and increased EZ disruption on OCT were associated with functional changes including poorer BCVA and decreased cone function on ERG.We have described the natural long-term decline in vision and cone function associated with mutations in GUCY2D and identified a set of functional and structural biomarkers that may be useful as outcome parameters for future therapeutic clinical trials.</ABSTRACT>'}]
2024-01-02 00:25:59,863 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:59,865 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449631, Requested 1554. Please try again in 158ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:25:59,865 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>NT-proBNP and cardiovascular event risk in individuals with prediabetes undergoing cardiovascular evaluation.\nCardiovascular risk assessment beyond traditional risk factors in subjects with prediabetes is not well-established. Here, we evaluated the utility of N-terminal pro-B-type natriuretic peptide (NT-proBNP) in predicting incident adverse cardiovascular outcomes in prediabetic subjects.NT-proBNP was analyzed in 3,235 stable subjects with prediabetes undergoing cardiovascular risk evaluation and followed for both 3-year major adverse cardiac events (MACE; death, myocardial infarction, stroke), and 5-year all-cause mortality.Using Cox proportional hazard models, we found that plasma NT-proBNP was associated with incident (3-year) MACE risk (Q4 vs Q1, HR 6.04 [95%CI 4.17-8.76], P\xa0<\xa00.001) and 5-year mortality risk (HR 8.64 [95%CI 5.78-12.9], P\xa0<\xa00.001). These associations remained significant after adjustments for traditional cardiovascular risk factors, multiple indices of glycemic control, cardiovascular disease (CVD), left ventricular ejection fraction (LVEF), and medication (e.g. diuretic) use (adjusted HR for 3-year MACE 2.65 [95% CI 1.16-6.05], P\xa0<\xa00.05; and adjusted HR for 5-year mortality 3.45 [95% CI 1.42-8.39], P\xa0<\xa00.01). NT-proBNP significantly improved the clinical prognostic value (C-statistic, NRI, IDI) for both 3-year MACE and 5-year death when added to models.NT-proBNP independently predicts increased long-term MACE and mortality risks in prediabetic subjects, and may help identify those for whom more aggressive global preventive efforts are indicated.</ABSTRACT>'}]
2024-01-02 00:25:59,906 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:25:59,958 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:59,958 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:59,958 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448573, Requested 1637. Please try again in 28ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:25:59,958 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Blood concentrations of anterior pituitary hormones in drug-nave people with first-episode psychosis: A systematic review and meta-analysis.\nThe role of anterior pituitary hormones - i.e., adrenocorticotropic hormone (ACTH), luteinizing and follicle stimulating hormones (LH and FSH), growth hormone (GH), prolactin (PRL), and thyroid-stimulating hormone (TSH) - in early schizophrenia and psychoses unclear. We thus performed a systematic review and meta-analysis on the blood concentrations of ACTH, LH and FSH, GH, PRL, and TSH in drug-nave people with first-episode psychosis (FEP) as compared with healthy controls.We searched Embase, MEDLINE, and PsycInfo for articles indexed until September 2022. Data quality was appraised. Random-effects meta-analyses were carried out, generating pooled standardized mean differences (SMDs). Between-study heterogeneity was estimated using the I2 statistic. Sensitivity and meta-regression analyses were performed.Twenty-six studies were included. Drug-nave people with FEP, compared to healthy subjects, had higher blood concentrations of ACTH (k\xa0=\xa07; N\xa0=\xa0548; SMD\xa0=\xa00.62; 95%CI: 0.29 to 0.94; p\xa0<\xa00.001; I2 =\xa060.9%) and PRL (k\xa0=\xa017; N\xa0=\xa01757; SMD\xa0=\xa00.85; 95%CI: 0.56 to 1.14; p\xa0<\xa00.001; I2 =\xa085.5%) as well as lower levels of TSH (k\xa0=\xa06; N\xa0=\xa0677; SMD\xa0=\xa0-0.34; 95%CI: -0.54 to -0.14; p\xa0=\xa00.001; I2 =\xa029.1%). Meta-regressions did not show any moderating effect of age (p\xa0=\xa00.78), sex (p\xa0=\xa00.21),\xa0or symptom severity (p\xa0=\xa00.87) on PRL concentrations in drug-nave FEP. Available data were not sufficient to perform meta-analyses on FSH, LH, and GH.Drug-nave people with FEP have altered ACTH, PRL, and TSH blood concentrations, supporting the hypothesis that an abnormal anterior pituitary hormone secretion may be involved in the onset of schizophrenia and psychoses. Further research is needed to elucidate the role of pituitary hormones in FEP.</ABSTRACT>'}]
2024-01-02 00:25:59,959 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448640, Requested 1648. Please try again in 38ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:25:59,959 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Exposure to low-intensity noise exacerbates nonalcoholic fatty liver disease by activating hypothalamus pituitary adrenal axis.\nNoise exposure induces metabolic disorders, in a latent, chronic and complex way. However, there is no direct evidence elucidating the relationship between low-intensity noise exposure and nonalcoholic fatty liver disease (NAFLD). Male mice (n\xa0=\xa05) on high-fat diet (HFD) were exposed to an average of 75\xa0dB SPL noise for 3\xa0months to reveal the effect of noise exposure on NAFLD, where the potential mechanisms were explored. In vivo (n\xa0=\xa05) and in vitro models challenged with dexamethasone (DEX) were used to verify the role of hypothalamus pituitary adrenal (HPA) axis activation in hepatic lipid metabolism. Typical chronic-restraint stress (CRS, n\xa0=\xa08) was used to explore the role of depression in modifying activity of HPA axis. Finally, animal experiment (n\xa0=\xa08) was repeated to validate the roles of depression and HPA axis activation in NAFLD development. Chronic low-intensity noise exposure exacerbated NAFLD in mice on HFD characterized by hepatocyte steatosis, modified lipid metabolism and inflammation level. Plasma ACTH in H\xa0+\xa0N group was 1.5-fold higher than that in HFD group. Transcription of glucocorticoid receptor target genes was increased by chronic low-intensity noise exposure in HFD-treated mice. Excessive glucocorticoids mimicking HPA axis activation induced NAFLD in vivo and in vitro. Plasma ACTH increase and lipid storage also occurred in depressive mice stressed by CRS. More interestingly, the same noise exposure simultaneously induced depression in mice, disrupted the HPA axis homeostasis and exacerbated NAFLD in a repeated experiment. Thus, three-month exposure to 75\xa0dB SPL noise was sufficient to exacerbate NAFLD progress in mice, where activation of HPA axis played a critical role. Depression played an intermediate role and contributed to HPA axis activation up-stream of the exacerbation.</ABSTRACT>'}]
2024-01-02 00:25:59,963 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:25:59,963 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448534, Requested 1510. Please try again in 5ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:25:59,963 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>TBC1D32 variants disrupt retinal ciliogenesis and cause retinitis pigmentosa.\nRetinitis pigmentosa (RP) is the most common inherited retinal disease (IRD) and is characterized by photoreceptor degeneration and progressive vision loss. We report 4 patients presenting with RP from 3 unrelated families with variants in TBC1D32, which to date has never been associated with an IRD. To validate TBC1D32 as a putative RP causative gene, we combined Xenopus in vivo approaches and human induced pluripotent stem cell-derived (iPSC-derived) retinal models. Our data showed that TBC1D32 was expressed during retinal development and that it played an important role in retinal pigment epithelium (RPE) differentiation. Furthermore, we identified a role for TBC1D32 in ciliogenesis of the RPE. We demonstrated elongated ciliary defects that resulted in disrupted apical tight junctions, loss of functionality (delayed retinoid cycling and altered secretion balance), and the onset of an epithelial-mesenchymal transition-like phenotype. Last, our results suggested photoreceptor differentiation defects, including connecting cilium anomalies, that resulted in impaired trafficking to the outer segment in cones and rods in TBC1D32 iPSC-derived retinal organoids. Overall, our data highlight a critical role for TBC1D32 in the retina and demonstrate that TBC1D32 mutations lead to RP. We thus identify TBC1D32 as an IRD-causative gene.</ABSTRACT>'}]
2024-01-02 00:26:00,023 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:00,024 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449694, Requested 1514. Please try again in 161ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:00,024 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Correlation between tear levels of vascular endothelial growth factor and vitamin D at retinopathy of prematurity stages in preterm infants.\nDeregulation of vascular endothelial growth factor (VEGF) levels leads to retinopathy of prematurity (ROP). Vitamin D (VIT-D) is known to regulate VEGF in an oxygen dependent manner. The purpose of this study was to correlate tear levels of VEGF and VIT-D with different ROP stages in preterm infants. In this prospective cross-sectional study, we enrolled 104 pre-term infants. They were grouped into: Group-1 (Classical ROP) and Group-2 (Aggressive ROP), which were further subdivided into Group-1A (progressing), Group-1B (regressing), Group-2A (pre-treatment), and Group-2B (post-treatment). Tear VEGF and VIT-D levels and their association with different ROP stages were assessed. Stage 1 and stage 2 had higher whereas stage 3 had lower VEGF levels in Group-1B compared to Group-1A. Stage 1 and stage 3 showed higher levels of VIT-D with no difference in stage 2 in Group-1B compared to Group-1A., Group-2B showed higher VEGF and lower VIT-D levels compared to Group-2A. Presence of a positive correlation at an early stage (stage 1) of ROP and a negative correlation at a more advanced stage (stage 3) of ROP with VIT-D and VEGF implies stage-specific distinct signaling crosstalk. These findings suggest that VIT-D supplementation may have the potential to modify the course and outcome of ROP.</ABSTRACT>'}]
2024-01-02 00:26:00,026 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:00,028 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449737, Requested 1421. Please try again in 154ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:00,028 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Relationship of atrial fibrillation and N terminal pro brain natriuretic peptide in heart failure patients.\nN terminal pro brain natriuretic peptide (NT-proBNP) plays an important role in the diagnosis and prognosis of heart failure (HF). The plasma level of NT-proBNP in atrial fibrillation (AF) patients was higher than of sinus rhythm patients. In HF, NT-proBNP levels are affected by the concomitant presence of AF, making it difficult to distinguish between HF and AF in patients with elevated NT-proBNP. Several other diseases, such as renal failure and pulmonary embolism, are known to further increase NT-proBNP levels in patients with concomitant HF. Therefore, NT-proBNP is a sensitive but non-specific marker for the detection of HF. AF is very important in this regard because among patients with HF regardless of ejection fraction, symptoms such as shortness of breath and atrial enlargement develop and can mimic HF. In the present study, we investigated whether the prognostic value of natriuretic peptides in HF holds true for patients with concomitant AF.</ABSTRACT>'}]
2024-01-02 00:26:00,029 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:00,030 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449704, Requested 1580. Please try again in 171ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:00,030 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Experimental and mathematical approaches for drug delivery for the treatment of wet age-related macular degeneration.\nSeveral chronic eye diseases affect the posterior segment of the eye. Among them age-related macular degeneration can cause vision loss if left untreated and is one of the leading causes of visual impairment in the world. Most treatments are based on intravitreally injected therapeutics that inhibit the action of vascular endothelial growth factor. However, due to the need for monthly injections, this method is associated with poor patient compliance. To address this problem, numerous drug delivery systems (DDSs) have been developed. This review covers a selection of particulate systems, non-stimuli responsive hydrogels, implants, and composite systems that have been developed in the last few decades. Depending on the type of DDS, polymer material, and preparation method, different mechanical properties and drug release profiles can be achieved. Furthermore, DDS development can be optimized by implementing mathematical modeling of both drug release and pharmacokinetic aspects. Several existing mathematical models for diffusion-controlled, swelling-controlled, and erosion-controlled drug delivery from polymeric systems are summarized. Compartmental and physiologically based models for ocular drug transport and pharmacokinetics that have studied drug concentration profiles after intravitreal delivery or release from a DDS are also reviewed. The coupling of drug release models with ocular pharmacokinetic models can lead to obtaining much more efficient DDSs for the treatment of age-related macular degeneration and other diseases of the posterior segment of the eye.</ABSTRACT>'}]
2024-01-02 00:26:00,055 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:00,056 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449494, Requested 1629. Please try again in 149ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:00,056 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Therapeutic drug monitoring of methotrexate in patients with Crohn\'s disease.\nTherapeutic drug monitoring (TDM) has the potential to improve efficacy and diminish side effects. Measuring methotrexate-polyglutamate (MTX-PG) in erythrocytes might enable TDM for methotrexate in patients with Crohn\'s disease (CD).To investigate the relationship between MTX-PGs and methotrexate drug survival, efficacy and toxicity METHODS: In a multicentre prospective cohort study, patients with CD starting subcutaneous methotrexate without biologics were included and followed for 12\u2009months. Primary outcome was subcutaneous methotrexate discontinuation or requirement for step-up therapy. Secondary outcomes included faecal calprotectin (FCP), Harvey Bradshaw Index (HBI), hepatotoxicity and gastrointestinal intolerance. Erythrocyte MTX-PGs were analysed at weeks 8, 12, 24 and 52 or upon treatment discontinuation.We included 80 patients with CD (mean age 55\u2009\u200913y, 35% male) with a median FCP of 268\u2009\u03bcg/g (IQR 73-480). After the 12-month visit, 21 patients (26%) were still on subcutaneous methotrexate monotherapy. Twenty-one patients stopped because of disease activity, 29 because of toxicity, and four for both reasons. Five patients ended study participation or stopped methotrexate for another reason. A higher MTX-PG3 concentration was associated with a higher rate of methotrexate drug survival (HR 0.86, 95% CI 0.75-0.99), lower FCP (\u03b2 -3.7, SE 1.3, p\u2009<\u20090.01) and with biochemical response (FCP \u2264250 if baseline >250\u2009\u03bcg/g; OR 1.1, 95% CI 1.0-1.3). Higher MTX-PGs were associated with less gastrointestinal intolerance. There was no robust association between MTX-PGs and HBI or hepatotoxicity.Higher MTX-PG3 concentrations are related to better methotrexate drug survival and decreased FCP levels. Therefore, MTX-PG3 could be used for TDM if a target concentration can be established.</ABSTRACT>'}]
2024-01-02 00:26:00,064 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:00,067 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449442, Requested 1604. Please try again in 139ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:00,067 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Conditional loss of Ube3d in the retinal pigment epithelium accelerates age-associated alterations in the retina of mice.\nSeveral studies have suggested a correlation between the ubiquitin-proteasome system (UPS) and age-related macular degeneration (AMD), with its phenotypic severity ranging from mild visual impairment to blindness, but the mechanism for UPS dysfunction contributing to disease progression is unclear. In this study, we investigated the role of ubiquitin protein ligase E3D (UBE3D) in aging and degeneration in mouse retina. Conditional knockout of Ube3d in the retinal pigment epithelium (RPE) of mice led to progressive and irregular fundus lesions, attenuation of the retinal vascular system, and age-associated deterioration of rod and cone responses. Simultaneously, RPE-specific Ube3d knockout mice also presented morphological changes similar to the histopathological characteristics of human AMD, in which a defective UPS led to RPE abnormalities such as phagocytosis or degradation of metabolites, the interaction with photoreceptor outer segment, and the transport of nutrients or waste products with choroidal capillaries via Bruch\'s membrane. Moreover, conditional loss of Ube3d resulted in aberrant molecular characterizations associated with the autophagy-lysosomal pathway, oxidative stress damage, and cell-cycle regulation, which are implicated in AMD pathology. Thus, our findings strengthen and expand the impact of UPS dysfunction on retinal pathophysiology during aging, indicating that genetic Ube3d deficiency in the RPE could lead to the abnormal formation of pigment deposits and secondary fundus alterations.  2023 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.</ABSTRACT>'}]
2024-01-02 00:26:00,150 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:00,153 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448846, Requested 1666. Please try again in 68ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:00,153 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>The regulatory effect of Angelicae Sinensis Radix on neuroendocrine-immune network and sphingolipid metabolism in CUMS-induced model of depression.\nConventional antidepressants therapy remains unsatisfactory due to the disadvantages of delayed clinical onset of action and side effects. Traditional Chinese Medicine (TCM) with good efficacy and higher safety have received much attention. Angelicae Sinensis Radix (AS), a well-known TCM, has been proved to exhibit the efficacy of antidepression recently.The purpose of this study was to investigate the potential anti-depressant mechanisms of AS based on chronic unpredictable mild stress (CUMS) rat model.In this study, behavioral experiments, molecular biology techniques, and ultra performance liquid chromatography-triple-time of flight mass spectrometer (UPLC-Triple-TOF/MS) were combined to explore the potential antidepressant mechanisms of AS based on CUMS rat model.The results demonstrated that AS could reduce the contents of serum hypothalamic-pituitary-adrenal (HPA) axis hormones in CUMS rats, including corticotropin-releasing hormone (CRH), adrenocorticotropic hormone (ACTH) and cortisol (CORT). In addition, AS regulated the percentage of CD4+ T lymphocytes, the ratio of CD4+/CD8+, and the levels of serum cytokines such as IL-1\u03b2, IL-4, IL-6, and TNF-\u03b1 in CUMS rats. Lipidomics showed that 31 lipids were related to depression and AS could regulate the lipid metabolism alteration induced by CUMS, particularly sphingolipid metabolism. Finally, the key proteins in sphingolipid metabolic pathways in hippocampus of CUMS rats could be back-regulated by AS, including serine palmitoyl transferase (SPTLC2), ceramide synthase (CerS2), sphingomyelinase (SPHK1), and neutral sphingomyelinase (nSMase).AS could alleviate NEI network disorder and restore the levels of sphingolipid metabolites and key proteins in CUMS rats. The underlying mechanism by which AS relieved depression-like behavior in CUMS rats may be through modulation of NEI and disturbances in sphingolipid metabolism.</ABSTRACT>'}]
2024-01-02 00:26:00,368 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:00,509 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:00,620 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:00,989 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:00,998 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:01,126 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:01,218 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:01,250 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:01,259 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:01,488 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:01,666 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:01,707 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:01,751 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:01,831 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:01,865 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:01,983 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:02,005 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:02,071 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:02,114 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:02,131 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:02,306 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:02,352 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:02,357 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:02,374 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:02,417 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:02,449 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:02,491 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:02,796 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:02,927 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:03,113 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:03,166 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:03,168 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:03,225 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:03,303 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:03,406 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:03,575 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:03,599 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:03,600 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:03,688 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:03,767 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:04,134 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:04,167 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:04,349 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:04,408 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:04,573 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:04,732 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:04,926 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:05,110 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:05,447 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:07,582 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:09,500 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:12,298 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,298 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,299 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,300 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,301 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,303 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,303 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,303 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,304 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,304 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,305 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,306 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,306 - INFO - Retrying request to /chat/completions in 0.956108 seconds
2024-01-02 00:26:12,306 - INFO - Retrying request to /chat/completions in 0.900001 seconds
2024-01-02 00:26:12,307 - INFO - Retrying request to /chat/completions in 0.903680 seconds
2024-01-02 00:26:12,307 - INFO - Retrying request to /chat/completions in 0.860923 seconds
2024-01-02 00:26:12,307 - INFO - Retrying request to /chat/completions in 0.960678 seconds
2024-01-02 00:26:12,307 - INFO - Retrying request to /chat/completions in 0.754264 seconds
2024-01-02 00:26:12,307 - INFO - Retrying request to /chat/completions in 0.848554 seconds
2024-01-02 00:26:12,307 - INFO - Retrying request to /chat/completions in 0.851001 seconds
2024-01-02 00:26:12,307 - INFO - Retrying request to /chat/completions in 0.816796 seconds
2024-01-02 00:26:12,307 - INFO - Retrying request to /chat/completions in 0.908277 seconds
2024-01-02 00:26:12,307 - INFO - Retrying request to /chat/completions in 0.755379 seconds
2024-01-02 00:26:12,308 - INFO - Retrying request to /chat/completions in 0.866961 seconds
2024-01-02 00:26:12,308 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,309 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,312 - INFO - Retrying request to /chat/completions in 0.806249 seconds
2024-01-02 00:26:12,312 - INFO - Retrying request to /chat/completions in 0.861901 seconds
2024-01-02 00:26:12,320 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,321 - INFO - Retrying request to /chat/completions in 0.800344 seconds
2024-01-02 00:26:12,336 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,337 - INFO - Retrying request to /chat/completions in 0.999667 seconds
2024-01-02 00:26:12,339 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,341 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,342 - INFO - Retrying request to /chat/completions in 0.821313 seconds
2024-01-02 00:26:12,343 - INFO - Retrying request to /chat/completions in 0.834806 seconds
2024-01-02 00:26:12,343 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,344 - INFO - Retrying request to /chat/completions in 0.891568 seconds
2024-01-02 00:26:12,348 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,349 - INFO - Retrying request to /chat/completions in 0.858450 seconds
2024-01-02 00:26:12,353 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,354 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,356 - INFO - Retrying request to /chat/completions in 0.922662 seconds
2024-01-02 00:26:12,356 - INFO - Retrying request to /chat/completions in 0.899760 seconds
2024-01-02 00:26:12,393 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,394 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,396 - INFO - Retrying request to /chat/completions in 0.873750 seconds
2024-01-02 00:26:12,397 - INFO - Retrying request to /chat/completions in 0.954988 seconds
2024-01-02 00:26:12,410 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,412 - INFO - Retrying request to /chat/completions in 0.778247 seconds
2024-01-02 00:26:12,418 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,419 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,419 - INFO - Retrying request to /chat/completions in 0.937961 seconds
2024-01-02 00:26:12,420 - INFO - Retrying request to /chat/completions in 0.828565 seconds
2024-01-02 00:26:12,433 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,437 - INFO - Retrying request to /chat/completions in 0.928068 seconds
2024-01-02 00:26:12,441 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,444 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,445 - INFO - Retrying request to /chat/completions in 0.858115 seconds
2024-01-02 00:26:12,446 - INFO - Retrying request to /chat/completions in 0.902357 seconds
2024-01-02 00:26:12,449 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,451 - INFO - Retrying request to /chat/completions in 0.828001 seconds
2024-01-02 00:26:12,476 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,477 - INFO - Retrying request to /chat/completions in 0.787822 seconds
2024-01-02 00:26:12,478 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,479 - INFO - Retrying request to /chat/completions in 0.875324 seconds
2024-01-02 00:26:12,483 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,483 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,484 - INFO - Retrying request to /chat/completions in 0.930889 seconds
2024-01-02 00:26:12,485 - INFO - Retrying request to /chat/completions in 0.935524 seconds
2024-01-02 00:26:12,486 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,487 - INFO - Retrying request to /chat/completions in 0.769952 seconds
2024-01-02 00:26:12,490 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,492 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,494 - INFO - Retrying request to /chat/completions in 0.949389 seconds
2024-01-02 00:26:12,494 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,494 - INFO - Retrying request to /chat/completions in 0.789889 seconds
2024-01-02 00:26:12,495 - INFO - Retrying request to /chat/completions in 0.759823 seconds
2024-01-02 00:26:12,514 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,516 - INFO - Retrying request to /chat/completions in 0.798005 seconds
2024-01-02 00:26:12,520 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,521 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,521 - INFO - Retrying request to /chat/completions in 0.833730 seconds
2024-01-02 00:26:12,522 - INFO - Retrying request to /chat/completions in 0.899825 seconds
2024-01-02 00:26:12,525 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,526 - INFO - Retrying request to /chat/completions in 0.781150 seconds
2024-01-02 00:26:12,528 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,529 - INFO - Retrying request to /chat/completions in 0.870175 seconds
2024-01-02 00:26:12,535 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,535 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,535 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,536 - INFO - Retrying request to /chat/completions in 0.892251 seconds
2024-01-02 00:26:12,537 - INFO - Retrying request to /chat/completions in 0.876886 seconds
2024-01-02 00:26:12,537 - INFO - Retrying request to /chat/completions in 0.835953 seconds
2024-01-02 00:26:12,539 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,541 - INFO - Retrying request to /chat/completions in 0.869392 seconds
2024-01-02 00:26:12,566 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,567 - INFO - Retrying request to /chat/completions in 0.997382 seconds
2024-01-02 00:26:12,569 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,570 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,570 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,572 - INFO - Retrying request to /chat/completions in 0.847044 seconds
2024-01-02 00:26:12,572 - INFO - Retrying request to /chat/completions in 0.792476 seconds
2024-01-02 00:26:12,572 - INFO - Retrying request to /chat/completions in 0.940112 seconds
2024-01-02 00:26:12,577 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,579 - INFO - Retrying request to /chat/completions in 0.933378 seconds
2024-01-02 00:26:12,584 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,585 - INFO - Retrying request to /chat/completions in 0.929546 seconds
2024-01-02 00:26:12,609 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,610 - INFO - Retrying request to /chat/completions in 0.872775 seconds
2024-01-02 00:26:12,611 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,612 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,613 - INFO - Retrying request to /chat/completions in 0.799474 seconds
2024-01-02 00:26:12,613 - INFO - Retrying request to /chat/completions in 0.977640 seconds
2024-01-02 00:26:12,625 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,626 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,627 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,631 - INFO - Retrying request to /chat/completions in 0.979358 seconds
2024-01-02 00:26:12,632 - INFO - Retrying request to /chat/completions in 0.906947 seconds
2024-01-02 00:26:12,634 - INFO - Retrying request to /chat/completions in 0.921536 seconds
2024-01-02 00:26:12,635 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,636 - INFO - Retrying request to /chat/completions in 0.846039 seconds
2024-01-02 00:26:12,644 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,645 - INFO - Retrying request to /chat/completions in 0.971365 seconds
2024-01-02 00:26:12,653 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,653 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,654 - INFO - Retrying request to /chat/completions in 0.922442 seconds
2024-01-02 00:26:12,655 - INFO - Retrying request to /chat/completions in 0.809063 seconds
2024-01-02 00:26:12,658 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,658 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,660 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,660 - INFO - Retrying request to /chat/completions in 0.931578 seconds
2024-01-02 00:26:12,661 - INFO - Retrying request to /chat/completions in 0.961123 seconds
2024-01-02 00:26:12,662 - INFO - Retrying request to /chat/completions in 0.848108 seconds
2024-01-02 00:26:12,676 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,681 - INFO - Retrying request to /chat/completions in 0.818512 seconds
2024-01-02 00:26:12,682 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,686 - INFO - Retrying request to /chat/completions in 0.763274 seconds
2024-01-02 00:26:12,701 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,702 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,703 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,704 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,704 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,705 - INFO - Retrying request to /chat/completions in 0.844333 seconds
2024-01-02 00:26:12,708 - INFO - Retrying request to /chat/completions in 0.804663 seconds
2024-01-02 00:26:12,709 - INFO - Retrying request to /chat/completions in 0.887506 seconds
2024-01-02 00:26:12,709 - INFO - Retrying request to /chat/completions in 0.872881 seconds
2024-01-02 00:26:12,710 - INFO - Retrying request to /chat/completions in 0.923726 seconds
2024-01-02 00:26:12,718 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,719 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,720 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,721 - INFO - Retrying request to /chat/completions in 0.822032 seconds
2024-01-02 00:26:12,721 - INFO - Retrying request to /chat/completions in 0.991394 seconds
2024-01-02 00:26:12,721 - INFO - Retrying request to /chat/completions in 0.767124 seconds
2024-01-02 00:26:12,722 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,723 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,726 - INFO - Retrying request to /chat/completions in 0.999138 seconds
2024-01-02 00:26:12,726 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,727 - INFO - Retrying request to /chat/completions in 0.849018 seconds
2024-01-02 00:26:12,730 - INFO - Retrying request to /chat/completions in 0.797956 seconds
2024-01-02 00:26:12,733 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,735 - INFO - Retrying request to /chat/completions in 0.990365 seconds
2024-01-02 00:26:12,749 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,750 - INFO - Retrying request to /chat/completions in 0.792527 seconds
2024-01-02 00:26:12,776 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,777 - INFO - Retrying request to /chat/completions in 0.844454 seconds
2024-01-02 00:26:12,783 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,784 - INFO - Retrying request to /chat/completions in 0.992324 seconds
2024-01-02 00:26:12,787 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,791 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,796 - INFO - Retrying request to /chat/completions in 0.811365 seconds
2024-01-02 00:26:12,797 - INFO - Retrying request to /chat/completions in 0.830003 seconds
2024-01-02 00:26:12,801 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,801 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,801 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,802 - INFO - Retrying request to /chat/completions in 0.927655 seconds
2024-01-02 00:26:12,802 - INFO - Retrying request to /chat/completions in 0.889547 seconds
2024-01-02 00:26:12,802 - INFO - Retrying request to /chat/completions in 0.973201 seconds
2024-01-02 00:26:12,807 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,807 - INFO - Retrying request to /chat/completions in 0.804413 seconds
2024-01-02 00:26:12,816 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,817 - INFO - Retrying request to /chat/completions in 0.990589 seconds
2024-01-02 00:26:12,819 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,820 - INFO - Retrying request to /chat/completions in 0.860125 seconds
2024-01-02 00:26:12,824 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,824 - INFO - Retrying request to /chat/completions in 0.912085 seconds
2024-01-02 00:26:12,844 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,845 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,848 - INFO - Retrying request to /chat/completions in 0.808340 seconds
2024-01-02 00:26:12,848 - INFO - Retrying request to /chat/completions in 0.773244 seconds
2024-01-02 00:26:12,867 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,867 - INFO - Retrying request to /chat/completions in 0.854149 seconds
2024-01-02 00:26:12,884 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,886 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,887 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,887 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,888 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,890 - INFO - Retrying request to /chat/completions in 0.893060 seconds
2024-01-02 00:26:12,890 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,890 - INFO - Retrying request to /chat/completions in 0.881059 seconds
2024-01-02 00:26:12,890 - INFO - Retrying request to /chat/completions in 0.950168 seconds
2024-01-02 00:26:12,891 - INFO - Retrying request to /chat/completions in 0.753673 seconds
2024-01-02 00:26:12,891 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,891 - INFO - Retrying request to /chat/completions in 0.879223 seconds
2024-01-02 00:26:12,891 - INFO - Retrying request to /chat/completions in 0.802952 seconds
2024-01-02 00:26:12,892 - INFO - Retrying request to /chat/completions in 0.862753 seconds
2024-01-02 00:26:12,906 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,906 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,907 - INFO - Retrying request to /chat/completions in 0.750649 seconds
2024-01-02 00:26:12,908 - INFO - Retrying request to /chat/completions in 0.955525 seconds
2024-01-02 00:26:12,909 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,910 - INFO - Retrying request to /chat/completions in 0.937822 seconds
2024-01-02 00:26:12,936 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,940 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,941 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,942 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,943 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,944 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,944 - INFO - Retrying request to /chat/completions in 0.756613 seconds
2024-01-02 00:26:12,945 - INFO - Retrying request to /chat/completions in 0.800604 seconds
2024-01-02 00:26:12,945 - INFO - Retrying request to /chat/completions in 0.789929 seconds
2024-01-02 00:26:12,945 - INFO - Retrying request to /chat/completions in 0.997483 seconds
2024-01-02 00:26:12,945 - INFO - Retrying request to /chat/completions in 0.785483 seconds
2024-01-02 00:26:12,945 - INFO - Retrying request to /chat/completions in 0.924412 seconds
2024-01-02 00:26:12,963 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,963 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,964 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,965 - INFO - Retrying request to /chat/completions in 0.988696 seconds
2024-01-02 00:26:12,965 - INFO - Retrying request to /chat/completions in 0.793017 seconds
2024-01-02 00:26:12,965 - INFO - Retrying request to /chat/completions in 0.922068 seconds
2024-01-02 00:26:12,986 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:12,987 - INFO - Retrying request to /chat/completions in 0.759583 seconds
2024-01-02 00:26:13,011 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,013 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,015 - INFO - Retrying request to /chat/completions in 0.900760 seconds
2024-01-02 00:26:13,016 - INFO - Retrying request to /chat/completions in 0.928120 seconds
2024-01-02 00:26:13,028 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,031 - INFO - Retrying request to /chat/completions in 0.976883 seconds
2024-01-02 00:26:13,042 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,042 - INFO - Retrying request to /chat/completions in 0.965367 seconds
2024-01-02 00:26:13,053 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,055 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,058 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,060 - INFO - Retrying request to /chat/completions in 0.817544 seconds
2024-01-02 00:26:13,060 - INFO - Retrying request to /chat/completions in 0.936907 seconds
2024-01-02 00:26:13,060 - INFO - Retrying request to /chat/completions in 0.769453 seconds
2024-01-02 00:26:13,133 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,134 - INFO - Retrying request to /chat/completions in 0.963213 seconds
2024-01-02 00:26:13,201 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,203 - INFO - Retrying request to /chat/completions in 1.859673 seconds
2024-01-02 00:26:13,312 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,315 - INFO - Retrying request to /chat/completions in 1.699232 seconds
2024-01-02 00:26:13,345 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,346 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,347 - INFO - Retrying request to /chat/completions in 1.609856 seconds
2024-01-02 00:26:13,347 - INFO - Retrying request to /chat/completions in 1.729184 seconds
2024-01-02 00:26:13,392 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,397 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,398 - INFO - Retrying request to /chat/completions in 1.663738 seconds
2024-01-02 00:26:13,399 - INFO - Retrying request to /chat/completions in 1.651968 seconds
2024-01-02 00:26:13,420 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,421 - INFO - Retrying request to /chat/completions in 1.695281 seconds
2024-01-02 00:26:13,424 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,424 - INFO - Retrying request to /chat/completions in 1.896260 seconds
2024-01-02 00:26:13,426 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,427 - INFO - Retrying request to /chat/completions in 1.936391 seconds
2024-01-02 00:26:13,436 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,437 - INFO - Retrying request to /chat/completions in 1.645022 seconds
2024-01-02 00:26:13,441 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,443 - INFO - Retrying request to /chat/completions in 1.761285 seconds
2024-01-02 00:26:13,444 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,445 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,446 - INFO - Retrying request to /chat/completions in 1.788461 seconds
2024-01-02 00:26:13,446 - INFO - Retrying request to /chat/completions in 1.599477 seconds
2024-01-02 00:26:13,450 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,451 - INFO - Retrying request to /chat/completions in 1.790601 seconds
2024-01-02 00:26:13,492 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,496 - INFO - Retrying request to /chat/completions in 1.781580 seconds
2024-01-02 00:26:13,512 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,515 - INFO - Retrying request to /chat/completions in 1.770631 seconds
2024-01-02 00:26:13,518 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,518 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,518 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,519 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,520 - INFO - Retrying request to /chat/completions in 1.906134 seconds
2024-01-02 00:26:13,520 - INFO - Retrying request to /chat/completions in 1.587875 seconds
2024-01-02 00:26:13,520 - INFO - Retrying request to /chat/completions in 1.772524 seconds
2024-01-02 00:26:13,520 - INFO - Retrying request to /chat/completions in 1.508586 seconds
2024-01-02 00:26:13,527 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,527 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,528 - INFO - Retrying request to /chat/completions in 1.834167 seconds
2024-01-02 00:26:13,528 - INFO - Retrying request to /chat/completions in 1.590811 seconds
2024-01-02 00:26:13,533 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,533 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,534 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,534 - INFO - Retrying request to /chat/completions in 1.569200 seconds
2024-01-02 00:26:13,535 - INFO - Retrying request to /chat/completions in 1.618241 seconds
2024-01-02 00:26:13,535 - INFO - Retrying request to /chat/completions in 1.527860 seconds
2024-01-02 00:26:13,556 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,556 - INFO - Retrying request to /chat/completions in 1.600265 seconds
2024-01-02 00:26:13,569 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,569 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,570 - INFO - Retrying request to /chat/completions in 1.506197 seconds
2024-01-02 00:26:13,572 - INFO - Retrying request to /chat/completions in 1.795202 seconds
2024-01-02 00:26:13,601 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,602 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,603 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,603 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,604 - INFO - Retrying request to /chat/completions in 1.835765 seconds
2024-01-02 00:26:13,605 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,609 - INFO - Retrying request to /chat/completions in 1.700203 seconds
2024-01-02 00:26:13,609 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,609 - INFO - Retrying request to /chat/completions in 1.941174 seconds
2024-01-02 00:26:13,610 - INFO - Retrying request to /chat/completions in 1.538218 seconds
2024-01-02 00:26:13,610 - INFO - Retrying request to /chat/completions in 1.726860 seconds
2024-01-02 00:26:13,611 - INFO - Retrying request to /chat/completions in 1.707336 seconds
2024-01-02 00:26:13,635 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,636 - INFO - Retrying request to /chat/completions in 1.927307 seconds
2024-01-02 00:26:13,643 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,643 - INFO - Retrying request to /chat/completions in 1.763901 seconds
2024-01-02 00:26:13,648 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,648 - INFO - Retrying request to /chat/completions in 1.663224 seconds
2024-01-02 00:26:13,654 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,655 - INFO - Retrying request to /chat/completions in 1.692758 seconds
2024-01-02 00:26:13,658 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,659 - INFO - Retrying request to /chat/completions in 1.992568 seconds
2024-01-02 00:26:13,681 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,681 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,683 - INFO - Retrying request to /chat/completions in 1.630794 seconds
2024-01-02 00:26:13,683 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,684 - INFO - Retrying request to /chat/completions in 1.564725 seconds
2024-01-02 00:26:13,685 - INFO - Retrying request to /chat/completions in 1.575570 seconds
2024-01-02 00:26:13,694 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,694 - INFO - Retrying request to /chat/completions in 1.532140 seconds
2024-01-02 00:26:13,696 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,697 - INFO - Retrying request to /chat/completions in 1.609448 seconds
2024-01-02 00:26:13,699 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,699 - INFO - Retrying request to /chat/completions in 1.790119 seconds
2024-01-02 00:26:13,718 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,721 - INFO - Retrying request to /chat/completions in 1.659658 seconds
2024-01-02 00:26:13,726 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,727 - INFO - Retrying request to /chat/completions in 1.784320 seconds
2024-01-02 00:26:13,739 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,742 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,742 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,743 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,746 - INFO - Retrying request to /chat/completions in 1.989947 seconds
2024-01-02 00:26:13,747 - INFO - Retrying request to /chat/completions in 1.690181 seconds
2024-01-02 00:26:13,747 - INFO - Retrying request to /chat/completions in 1.618590 seconds
2024-01-02 00:26:13,747 - INFO - Retrying request to /chat/completions in 1.907941 seconds
2024-01-02 00:26:13,767 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,770 - INFO - Retrying request to /chat/completions in 1.789780 seconds
2024-01-02 00:26:13,777 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,778 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,778 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,783 - INFO - Retrying request to /chat/completions in 1.874993 seconds
2024-01-02 00:26:13,784 - INFO - Retrying request to /chat/completions in 1.939898 seconds
2024-01-02 00:26:13,784 - INFO - Retrying request to /chat/completions in 1.674544 seconds
2024-01-02 00:26:13,788 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,790 - INFO - Retrying request to /chat/completions in 1.840397 seconds
2024-01-02 00:26:13,792 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,792 - INFO - Retrying request to /chat/completions in 1.534708 seconds
2024-01-02 00:26:13,799 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,800 - INFO - Retrying request to /chat/completions in 1.820681 seconds
2024-01-02 00:26:13,827 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,829 - INFO - Retrying request to /chat/completions in 1.823255 seconds
2024-01-02 00:26:13,835 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,835 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,835 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,837 - INFO - Retrying request to /chat/completions in 1.694214 seconds
2024-01-02 00:26:13,837 - INFO - Retrying request to /chat/completions in 1.776787 seconds
2024-01-02 00:26:13,837 - INFO - Retrying request to /chat/completions in 1.994324 seconds
2024-01-02 00:26:13,840 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,841 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,842 - INFO - Retrying request to /chat/completions in 1.551369 seconds
2024-01-02 00:26:13,843 - INFO - Retrying request to /chat/completions in 1.985964 seconds
2024-01-02 00:26:13,866 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,866 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,869 - INFO - Retrying request to /chat/completions in 1.500862 seconds
2024-01-02 00:26:13,870 - INFO - Retrying request to /chat/completions in 1.601708 seconds
2024-01-02 00:26:13,891 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,892 - INFO - Retrying request to /chat/completions in 1.990663 seconds
2024-01-02 00:26:13,900 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,901 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,901 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,902 - INFO - Retrying request to /chat/completions in 1.568993 seconds
2024-01-02 00:26:13,903 - INFO - Retrying request to /chat/completions in 1.793872 seconds
2024-01-02 00:26:13,903 - INFO - Retrying request to /chat/completions in 1.919116 seconds
2024-01-02 00:26:13,904 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,905 - INFO - Retrying request to /chat/completions in 1.798536 seconds
2024-01-02 00:26:13,907 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,908 - INFO - Retrying request to /chat/completions in 1.980455 seconds
2024-01-02 00:26:13,931 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,934 - INFO - Retrying request to /chat/completions in 1.505384 seconds
2024-01-02 00:26:13,937 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,938 - INFO - Retrying request to /chat/completions in 1.660525 seconds
2024-01-02 00:26:13,939 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,940 - INFO - Retrying request to /chat/completions in 1.564145 seconds
2024-01-02 00:26:13,952 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,953 - INFO - Retrying request to /chat/completions in 1.823588 seconds
2024-01-02 00:26:13,976 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,977 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,978 - INFO - Retrying request to /chat/completions in 1.986343 seconds
2024-01-02 00:26:13,979 - INFO - Retrying request to /chat/completions in 1.655533 seconds
2024-01-02 00:26:13,991 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,992 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,993 - INFO - Retrying request to /chat/completions in 1.694210 seconds
2024-01-02 00:26:13,993 - INFO - Retrying request to /chat/completions in 1.864816 seconds
2024-01-02 00:26:13,994 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:13,994 - INFO - Retrying request to /chat/completions in 1.851230 seconds
2024-01-02 00:26:14,002 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:14,003 - INFO - Retrying request to /chat/completions in 1.596658 seconds
2024-01-02 00:26:14,028 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:14,029 - INFO - Retrying request to /chat/completions in 1.911428 seconds
2024-01-02 00:26:14,033 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:14,033 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:14,034 - INFO - Retrying request to /chat/completions in 1.705850 seconds
2024-01-02 00:26:14,034 - INFO - Retrying request to /chat/completions in 1.728222 seconds
2024-01-02 00:26:14,044 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:14,045 - INFO - Retrying request to /chat/completions in 1.514425 seconds
2024-01-02 00:26:14,050 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:14,050 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:14,051 - INFO - Retrying request to /chat/completions in 1.597731 seconds
2024-01-02 00:26:14,051 - INFO - Retrying request to /chat/completions in 1.795454 seconds
2024-01-02 00:26:14,069 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:14,070 - INFO - Retrying request to /chat/completions in 1.684832 seconds
2024-01-02 00:26:14,074 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:14,075 - INFO - Retrying request to /chat/completions in 1.749662 seconds
2024-01-02 00:26:14,080 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:14,080 - INFO - Retrying request to /chat/completions in 1.993202 seconds
2024-01-02 00:26:14,086 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:14,087 - INFO - Retrying request to /chat/completions in 1.590132 seconds
2024-01-02 00:26:14,110 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:14,111 - INFO - Retrying request to /chat/completions in 1.635521 seconds
2024-01-02 00:26:14,129 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:14,129 - INFO - Retrying request to /chat/completions in 1.564211 seconds
2024-01-02 00:26:14,132 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:14,132 - INFO - Retrying request to /chat/completions in 1.541350 seconds
2024-01-02 00:26:14,139 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:14,139 - INFO - Retrying request to /chat/completions in 1.887986 seconds
2024-01-02 00:26:14,147 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:14,147 - INFO - Retrying request to /chat/completions in 1.583620 seconds
2024-01-02 00:26:14,148 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:14,149 - INFO - Retrying request to /chat/completions in 1.827697 seconds
2024-01-02 00:26:14,150 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:14,151 - INFO - Retrying request to /chat/completions in 1.959889 seconds
2024-01-02 00:26:14,157 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:14,158 - INFO - Retrying request to /chat/completions in 1.618676 seconds
2024-01-02 00:26:14,172 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:14,175 - INFO - Retrying request to /chat/completions in 1.993412 seconds
2024-01-02 00:26:14,181 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:14,185 - INFO - Retrying request to /chat/completions in 1.605640 seconds
2024-01-02 00:26:14,187 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:14,190 - INFO - Retrying request to /chat/completions in 1.501192 seconds
2024-01-02 00:26:14,200 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:14,201 - INFO - Retrying request to /chat/completions in 1.517250 seconds
2024-01-02 00:26:14,204 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:14,204 - INFO - Retrying request to /chat/completions in 1.543046 seconds
2024-01-02 00:26:14,206 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:14,206 - INFO - Retrying request to /chat/completions in 1.964135 seconds
2024-01-02 00:26:14,208 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:14,208 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:14,210 - INFO - Retrying request to /chat/completions in 1.757494 seconds
2024-01-02 00:26:14,210 - INFO - Retrying request to /chat/completions in 1.877955 seconds
2024-01-02 00:26:14,221 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:14,221 - INFO - Retrying request to /chat/completions in 1.768538 seconds
2024-01-02 00:26:14,226 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:14,226 - INFO - Retrying request to /chat/completions in 1.528817 seconds
2024-01-02 00:26:14,255 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:14,255 - INFO - Retrying request to /chat/completions in 1.506498 seconds
2024-01-02 00:26:14,269 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:14,270 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:14,271 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:14,271 - INFO - Retrying request to /chat/completions in 1.579494 seconds
2024-01-02 00:26:14,272 - INFO - Retrying request to /chat/completions in 1.928065 seconds
2024-01-02 00:26:14,272 - INFO - Retrying request to /chat/completions in 1.803543 seconds
2024-01-02 00:26:14,276 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:14,277 - INFO - Retrying request to /chat/completions in 1.870082 seconds
2024-01-02 00:26:14,288 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:14,290 - INFO - Retrying request to /chat/completions in 1.672271 seconds
2024-01-02 00:26:14,291 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:14,291 - INFO - Retrying request to /chat/completions in 1.583898 seconds
2024-01-02 00:26:14,310 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:14,310 - INFO - Retrying request to /chat/completions in 1.919899 seconds
2024-01-02 00:26:14,725 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:14,809 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:14,825 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:14,882 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:14,902 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:14,999 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:15,133 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:15,134 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:15,183 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:15,184 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:15,185 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:15,187 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448685, Requested 1768. Please try again in 60ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:15,187 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Electrolyte Disorders in Mitochondrial Cytopathies: A Systematic Review.\nSeveral recent studies identified mitochondrial mutations in patients with Gitelman or Fanconi syndrome. Mitochondrial cytopathies are generally not considered in the diagnostic workup of patients with electrolyte disorders. In this systematic review, we investigated the presence of electrolyte disorders in patients with mitochondrial cytopathies to determine the relevance of mitochondrial mutation screening in this population. Our analysis demonstrates that electrolyte disorders are commonly reported in mitochondrial cytopathies, often as presenting symptoms. Consequently, more clinical attention should be raised for mitochondrial disease as cause for disturbances in electrolyte homeostasis. Further prospective cohort studies are required to determine the exact prevalence of electrolyte disorders in mitochondrial cytopathies.Electrolyte reabsorption in the kidney has a high energy demand. Proximal and distal tubular epithelial cells have a high mitochondrial density for energy release. Recently, electrolyte disorders have been reported as the primary presentation of some mitochondrial cytopathies. However, the prevalence and the pathophysiology of electrolyte disturbances in mitochondrial disease are unknown. Therefore, we systematically investigated electrolyte disorders in patients with mitochondrial cytopathies.We searched PubMed, Embase, and Google Scholar for articles on genetically confirmed mitochondrial disease in patients for whom at least one electrolyte is reported. Patients with a known second genetic anomaly were excluded. We evaluated 214 case series and reports (362 patients) as well as nine observational studies. Joanna Briggs Institute criteria were used to evaluate the quality of included studies.Of 362 reported patients, 289 had an electrolyte disorder, with it being the presenting or main symptom in 38 patients. The average number of different electrolyte abnormalities per patient ranged from 2.4 to 1.0, depending on genotype. Patients with mitochondrial DNA structural variants seemed most affected. Reported pathophysiologic mechanisms included renal tubulopathies and hormonal, gastrointestinal, and iatrogenic causes.Mitochondrial diseases should be considered in the evaluation of unexplained electrolyte disorders. Furthermore, clinicians should be aware of electrolyte abnormalities in patients with mitochondrial disease.</ABSTRACT>'}]
2024-01-02 00:26:15,208 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:15,208 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:15,210 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449080, Requested 1439. Please try again in 69ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:15,210 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Retinal detachment following retinopathy of prematurity in France: Screening and treatment pathways.\nPreterm children are highly vulnerable to sensorial impairments through Retinopathy Of Prematurity (ROP). The objective was to determine whether some cases of ROP requiring surgery could be secondary to deficiencies in care pathways.Descriptive study of neonatal characteristics and the screening/treatment pathways of children treated for stage \u22654A ROP from 2009 to 2020 in a referral unit in France.Twenty-five preterm children (44 eyes) were included: median gestational age was 25\u2009weeks, and median birthweight was 700 grams. Eighty-four per cent had received at least one fundus examination, 50% of which were completed on time. At the time of retinal detachment diagnosis, only 36% of the children had received laser or anti-vascular endothelial growth factor (VEGF) intra-vitreal injection. ROP stage was only reported in 8%, and the zone or type was reported in 16% of the files.The risk of blindness and the effectiveness of laser or anti-VEGF treatment highlight the need to enhance screening and treatment practices in France.</ABSTRACT>'}]
2024-01-02 00:26:15,211 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448993, Requested 1529. Please try again in 69ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:15,211 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Bilateral macular hole in a patient with CAPN5-related neovascular inflammatory vitreoretinopathy.\nTo characterize the genotype and phenotype of a patient with CAPN5-related neovascular inflammatory vitreoretinopathy (NIV) who have undergone surgery for macular holes.We observed a patient presenting with retinitis pigmentosa and posterior uveitis who later developed vitreoretinal macular traction and a macular hole. Genetic testing was performed using a targeted gene panel. Fundus photography and spectral-domain optical coherence tomography were also performed.In a targeted gene panel, a monoallelic pathogenic variant, c.750G\u2009>\u2009T, p.Lys250Asn, in the CAPN5 gene was identified, and CAPN5-NIV was diagnosed. At the first visit, peripheral retinal degeneration and mild posterior uveitis were observed. At that time, neovascularization, epiretinal or fibrous membranes were not observed. After 5 years, vitreomacular traction developed and progressed to a full-thickness macular hole in both eyes. After pars plana vitrectomy, the macular hole was successfully closed without aggravation of uveitis.In this case, a pathogenic variant of CAPN5 lead to a distinct phenotype of retinitis pigmentosa, posterior uveitis, vitreomacular traction, and macular hole without typical inflammatory neovascularization or tractional membranes. Therefore, the clinical variability of CAPN5-NIV and genetic diagnosis should be considered in cases of atypical retinitis pigmentosa with bilateral macular hole.</ABSTRACT>'}]
2024-01-02 00:26:15,214 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:15,216 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:15,217 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448977, Requested 1193. Please try again in 22ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:15,217 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Targeted Probiotics Against Bacterial-Fungal Biofilms: A New Concept Seems to Bring Us Closer to Microbiome-modulating Therapy for Inflammatory Bowel Disease.\n</ABSTRACT>'}]
2024-01-02 00:26:15,220 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449041, Requested 1718. Please try again in 101ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:15,220 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Corticosteroid Use and Adherence in Patients Treated with Acthar Gel for Advanced Sarcoidosis.\nLong-term corticosteroid use in immune-mediated diseases is associated with increased risk of adverse events (AEs) and worsened health-related quality of life (HRQoL). Previous studies report chronic high-dose corticosteroid therapy results in higher rates of healthcare resource use and AE-related medical costs. Recent studies suggest Acthar Gel (repository corticotropin injection) is an effective steroid-sparing therapy for sarcoidosis. This study compares the corticosteroid-sparing effect between Acthar Gel and comparators and evaluates the impact of Acthar Gel adherence on reduction of corticosteroid burden.A retrospective analysis of a large administrative pharmacy and medical claims database (Symphony Health Solutions) was conducted. Patients were included with confirmed ICD-9/10 diagnosis for sarcoidosis in the study period (2014-2020), followed by\u2009\u2265\u20092 Acthar Gel claims or comparators (janus kinase inhibitor (JAKi)/rituximab),\u2009\u2265\u200918\xa0years old, with 12\xa0months coverage pre/post index. Outcomes were compared as change from baseline. Acthar Gel adherence was determined by proportion of days covered in the follow-up period.The Acthar Gel (n\u2009=\u2009735) and comparator (n\u2009=\u2009626) cohorts were mostly female (68-72%) between 55 and 58\xa0years old. Compared to the comparator cohort at baseline, Acthar Gel patients had greater any corticosteroid use (80% vs. 56%, p\u2009<\u20090.001), extended use (61% vs. 32%, p\u2009<\u20090.001), and mean average daily dose (6.72 vs. 3.03, p\u2009<\u20090.001). After treatment, Acthar Gel patients had greater reduction from baseline in any corticosteroid use (-\xa09.0% vs. -\xa03.2%) and extended use (-\xa010.0% vs. -\xa03.0%). In the Acthar Gel adherence cohorts, patients with above average adherence had greater reduction in both measures (-\xa011.2% vs. -\xa06.1%; -\xa011.6% vs. -\xa07.6%, respectively) than patients with below average adherence. Acthar Gel patients had greater reduction of extended use at all dose levels.Acthar Gel is associated with reductions in corticosteroid use compared to alternatives. Better adherence is associated with greater reduction in corticosteroid exposure. Key Summary Points.</ABSTRACT>'}]
2024-01-02 00:26:15,226 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:15,228 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:15,229 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448896, Requested 1665. Please try again in 74ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:15,229 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Deep learning algorithms to detect diabetic kidney disease from\xa0retinal photographs in multiethnic populations with diabetes.\nTo develop a deep learning algorithm (DLA) to detect diabetic kideny disease (DKD) from retinal photographs of patients with diabetes, and evaluate performance in multiethnic populations.We trained 3 models: (1) image-only; (2) risk factor (RF)-only multivariable logistic regression (LR) model adjusted for age, sex, ethnicity, diabetes duration, HbA1c, systolic blood pressure; (3) hybrid multivariable LR model combining RF data and standardized z-scores from image-only model. Data from Singapore Integrated Diabetic Retinopathy Program (SiDRP) were used to develop (6066 participants with diabetes, primary-care-based) and internally validate (5-fold cross-validation) the models. External testing on 2 independent datasets: (1) Singapore Epidemiology of Eye Diseases (SEED) study (1885 participants with diabetes, population-based); (2) Singapore Macroangiopathy and Microvascular Reactivity in Type 2 Diabetes (SMART2D) (439 participants with diabetes, cross-sectional) in Singapore. Supplementary external testing on 2 Caucasian cohorts: (3) Australian Eye and Heart Study (AHES) (460 participants with diabetes, cross-sectional) and (4) Northern Ireland Cohort for the Longitudinal Study of Ageing (NICOLA) (265 participants with diabetes, cross-sectional).In SiDRP validation, area under the curve (AUC) was 0.826(95% CI 0.818-0.833) for image-only, 0.847(0.840-0.854) for RF-only, and 0.866(0.859-0.872) for hybrid. Estimates with SEED were 0.764(0.743-0.785) for image-only, 0.802(0.783-0.822) for RF-only, and 0.828(0.810-0.846) for hybrid. In SMART2D, AUC was 0.726(0.686-0.765) for image-only, 0.701(0.660-0.741) in RF-only, 0.761(0.724-0.797) for hybrid.There is potential for DLA using retinal images as a screening adjunct for DKD among individuals with diabetes. This can value-add to existing DLA systems which diagnose diabetic retinopathy from retinal images, facilitating primary screening for DKD.</ABSTRACT>'}]
2024-01-02 00:26:15,230 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448917, Requested 1717. Please try again in 84ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:15,231 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Clinical significance of the expression levels of serum transforming growth factor-\u03b2 and CXC type chemokine ligand 13 in primary Sjogren\'s syndrome patients.\nThe aim of this study was to investigate the expression levels of the serum transforming growth factor-\u03b21 (TGF-\u03b21) CXC type chemokine ligand 13 (CXCL13) in primary Sjogren\'s syndrome (pSS) patients and its correlation with disease severity.Thirty patients with pSS admitted to Nanjing Traditional Chinese Medicine Affiliated Hospital of Nanjing University of Traditional Chinese Medicine from January 2021 to December 2022 were included as the pSS group, while 30 patients who underwent physical examination during the same period were included as the control group. The levels of TGF-\u03b21 and CXCL13 were detected. The diagnostic value of TGF-\u03b21 and CXCL13 for pSS was analyzed. Detection of serum TGF-\u03b21 and CXCL13 levels in pSS patients with different disease activities and lip gland pathological grading of pSS was done. We compared the correlation between TGF-\u03b21 and CXCL13 levels and disease activity and labial gland pathological grading in pSS patients.The TGF-\u03b21 and CXCL13 levels in the pSS group were higher than those in the control group. The area under the receiver operating characteristic (ROC) curve (AUC) for TGF-\u03b21 and CXCL13 diagnosis of pSS was 0.790 (95% confidence interval (CI): 0.720~0.861) and 0.838 (95% CI: 0.778~0.898), respectively. The serum TGF-\u03b21 and CXCL13 levels of pSS patients significantly increase with the increase of disease activity and lip gland pathological grading. The TGF-\u03b21 and CXCL13 levels in pSS patients were positively correlated with disease activity and lip gland pathological grading.The levels of TGF-\u03b21 and CXCL13 in pSS patients were increased, and it was closely related to disease activity and lip gland pathological grading, which can be used as an effective indicator for the diagnosis of pSS. Key Points  The TGF-\u03b21 and CXCL13 levels in the pSS group were higher than those in the control group.  The TGF-\u03b21 and CXCL13 levels in pSS patients were positively correlated with disease activity and lip gland pathological grading.  TGF-\u03b21 and CXCL13 can be used as an effective indicator for the diagnosis of pSS.</ABSTRACT>'}]
2024-01-02 00:26:15,237 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:15,238 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448847, Requested 1577. Please try again in 56ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:15,238 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>The complement system: a novel therapeutic target for age-related macular degeneration.\nWith the recent FDA approvals of pegcetacoplan (SYFOVRE, Apellis Pharmaceuticals) and avacincaptad pegol (IZERVAY, Astellas Pharmaceuticals), modulation of the complement system has emerged as a promising therapeutic approach for slowing progression of geographic atrophy (GA) in AMD.This article reviews the current understanding of the complement system, its role in AMD, and the various complement-targeting therapies in development for the treatment of GA, including monoclonal antibodies, aptamers, protein analogs, and gene therapies. Approved and investigational agents have largely focused on interfering with the activity of complement components 3 and 5, owing to their central roles in the classical, lectin, and alternative complement pathways. Other investigational therapies have targeted formation of membrane attack complex (a terminal step in the complement cascade which leads to cell lysis), complement factors H and I (which serve regulatory functions in the alternative pathway), complement factors B and D (within the alternative pathway), and complement component 1 (within the classical pathway). Clinical trials investigating these agents are summarized, and the potential benefits and limitations of these therapies are discussed.Targeting the complement system is a promising therapeutic approach for slowing the progression of GA in AMD, potentially improving visual outcomes. However, increased risk of exudative conversion must be considered, and further research is required to identify clinical criteria and best practices for initiating complement inhibitor therapy for GA.</ABSTRACT>'}]
2024-01-02 00:26:15,240 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:15,266 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:15,267 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:15,268 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449417, Requested 1648. Please try again in 142ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:15,268 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Prevalence of geographic atrophy in Nordic countries and number of patients potentially eligible for intravitreal complement inhibitor treatment: A systematic review with meta-analyses and forecasting study.\nWe systematically reviewed the literature on the prevalence of geographic atrophy (GA) in Nordic populations, conducted meta-analyses on age-stratified estimates, and calculated current and future number of patients and those potentially eligible for intravitreal complement inhibitor treatment. We followed the PRISMA guidelines, and our protocol was registered in PROSPERO. Ten databases were searched on 22 April 2023 for population-based studies of GA prevalence. Based on clinical descriptive analyses of GA and eligibility criteria of the phase III studies for intravitreal pegcetacoplan (complement C3 and C3b inhibitor), we were able to calculate the proportion of patients with GA potentially eligible for therapy. Finally, we extracted population data for Nordic countries (Denmark, Finland, Iceland, Norway, and Sweden) from Eurostat, applied prevalence statistics to the extracted census and forecasting data to estimate the number of patients with GA, and then applied the proportion eligible for intravitreal pegcetacoplan therapy. We identified six studies with a total of 10\u2009159 individuals. Prevalence of GA was estimated to 0.4% (95% confidence intervals [CI]: 0.2%-0.8%), 1.5% (95% CI: 0.7%-2.6%), and 7.6% (95% CI: 4.6%-11.3%) for individuals aged 60-69, 70-79, and 80+ years, respectively. In Nordic countries, we estimate a total of 166\u2009307 individuals with GA in 2023, increasing to 277\u2009893 in 2050. Of these, 90\u2009803 individuals in 2023, increasing to 151\u2009730 in 2050, are potentially eligible for intravitreal complement inhibitor treatment. Considering these large numbers, our study highlights the importance of this topic in the coming years and its potential to significantly impact our clinical practice, organization, and staffing.</ABSTRACT>'}]
2024-01-02 00:26:15,281 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:15,285 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:15,286 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449401, Requested 1523. Please try again in 123ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:15,286 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Erythrocyte transfusions are associated with retinopathy of prematurity in extremely low gestational age newborns.\nRetinopathy of prematurity (ROP) is a major morbidity in preterm infants causing visual impairment including blindness. Prevention and timely treatment are critical. We investigated the potential role of red blood cell (RBC) transfusions as risk factor for ROP development.Retrospective cohort study of data from 68 tertiary level neonatal intensive care units in Germany. Preterm infants born at 22\u2009+\u20090 to 28\u2009+\u20096\u2009weeks of gestation between January 2009 and December 2021 were enrolled.We included n\u2009=\u200912\u2009565 infants. Prevalence of any ROP was 49.2% with most infants being diagnosed with stage 1 (21.5%) and 2 disease (17.2%). ROP stage 3 was present in 10.2%, stage 4 in 0.3%, and ROP requiring treatment in 6.6%. Infants with ROP had significantly more frequently a history of RBC transfusions. Adjusting for confounders, RBC transfusions were associated with increased odds of ROP (OR 1.4, p\u2009<\u20090.001), ROP progression (OR 2.1, p\u2009<\u20090.01) and ROP requiring treatment (OR 3.6, p\u2009<\u20090.001). Restrictive transfusion approaches correlated with decreased (OR 0.7, p\u2009<\u20090.001), liberal regimes with increased odds (OR 1.2, p\u2009=\u20090.001).The present study confirmed an association of RBC transfusions and ROP. Our findings emphasise the need for anaemia prevention and critical re-evaluation of transfusion practices in preterm infants.</ABSTRACT>'}]
2024-01-02 00:26:15,291 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:15,297 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:15,306 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:15,318 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:15,323 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:15,357 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:15,358 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448942, Requested 1527. Please try again in 62ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:15,358 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Immunoregulation mechanism of VEGF signaling pathway inhibitors and its efficacy on the kidney.\nAngiogenesis and immunosuppression are closely related pathophysiologic processes. Widely prescribed in malignant tumor and proliferative retinal lesions, VEGF signaling pathway inhibitors may cause hypertension and renal injury in some patients, presenting with proteinuria, nephrotic syndrome, renal failure and thrombotic microangiopathy. VEGF signaling pathway inhibitors block the action of both VEGF-A and VEGF-C. However, VEGF-A and VEGF-C produced by podocytes are vital to maintain the physiological function of glomerular endothelial cells and podocytes. There is still no effective treatment for kidney disease associated with VEGF signaling pathway inhibitors and some patients have progressive renal failure even after withdrawal of the drug. Recent studies reveal that blocking of VEGF-A and VEGF-C can activate CD4 +and CD8+ T cells, augment antigen-presenting function of dendritic cells, enhance cytotoxicity of macrophages and initiate complement cascade activation. VEGF and VEGFR are expressed in immune cells, which are involved in the immunosuppression and cross-talk among immune cells. This review summarizes the expression and function of VEGF-A and VEGF-C in the kidney. The current immunoregulation mechanisms of VEGF signaling pathway inhibitors are reviewed. Finally, combinate strategies are summarized to highlight the proposal for VEGF signaling pathway inhibitors.</ABSTRACT>'}]
2024-01-02 00:26:15,359 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:15,360 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448952, Requested 1562. Please try again in 68ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:15,360 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Automatic Segmentation of Retinal Layers in Multiple Neurodegenerative Disorder Scenarios.\nRetinal Optical Coherence Tomography (OCT) allows the non-invasive direct observation of the central nervous system, enabling the measurement and extraction of biomarkers from neural tissue that can be helpful in the assessment of ocular, systemic and Neurological Disorders (ND). Deep learning models can be trained to segment the retinal layers for biomarker extraction. However, the onset of ND can have an impact on the neural tissue, which can lead to the degraded performance of models not exposed to images displaying signs of disease during training. We present a fully automatic approach for the retinal layer segmentation in multiple neurodegenerative disorder scenarios, using an annotated dataset of patients of the most prevalent NDs: Alzheimer\'s disease, Parkinson\'s disease, multiple sclerosis and essential tremor, along with healthy control patients. Furthermore, we present a two-part, comprehensive study on the effects of ND on the performance of these models. The results show that images of healthy patients may not be sufficient for the robust training of automated segmentation models intended for the analysis of ND patients, and that using images representative of different NDs can increase the model performance. These results indicate that the presence or absence of patients of ND in datasets should be taken into account when training deep learning models for retinal layer segmentation, and that the proposed approach can provide a valuable tool for the robust and reliable diagnosis in multiple scenarios of ND.</ABSTRACT>'}]
2024-01-02 00:26:15,366 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:15,367 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448919, Requested 1563. Please try again in 64ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:15,367 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Predictors of 30-day mortality in patients diagnosed with hepatic encephalopathy on admission to the emergency department.\nThe aim of this study is to compare the laboratory findings and disease severity scores of patients diagnosed with hepatic encephalopathy (HE) in the emergency department (ED) to predict 30-day mortality.The patients over 18 years old and diagnosed HE in the ED of a tertiary hospital were included in the study. Demographic and clinical characteristics, laboratory parameters, predisposing causes and outcomes of the patients included in the study were recorded in the data form. Severity of liver disease was assessed by Child Pugh Score (CPS), End-stage liver disease model (MELD), MELD-Na and MELD-Lactate scores.Two hundred fifty-four patients diagnosed with HE were included in the study. 59.1% of the patients were male. The mean age of the patients was 65.2\u2005\u200512.6 years. The mortality rate of the patients was 47.2%. When the receiver operating characteristic (ROC) analysis, which determines the predictive properties of laboratory parameters and disease severity scores, was examined, the area under curve value of the MELD-Lactate score (0.858 95% CI 0.812-0.904, P \u2005<\u20050.001) was the highest. Binary logistic regression analysis for the estimation of patients\' 30-day mortality showed that CPS and MELD-Lactate scores and blood ammonia and B-type natriuretic peptide levels were independent predictors of mortality.According to the study data, MELD-Lactate and BNP levels in patients diagnosed with HE in the ED may help the clinician in the prediction of 30-day mortality in the early period.</ABSTRACT>'}]
2024-01-02 00:26:15,373 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:15,375 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448847, Requested 1645. Please try again in 65ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:15,375 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>[Diagnostics and management of patients with inherited retinal diseases in Germany : Results of a nationwide survey of university and non-university eye departments and specialized practices].\nInherited retinal diseases (IRDs) refer to a\xa0heterogeneous group of rare disorders that potentially lead to blindness. Emerging therapeutic options have led to a\xa0growing interest in IRDs; however, there are insufficient systematic studies on IRDs in Germany characterizing the demographics and management in clinical practice.To characterize the care for IRD patients in Germany, to assess the applied diagnostics, the use of databases and the implementation of education in ophthalmic genetics.The anonymous online survey (SoSci Survey GmbH) was sent to all German ophthalmology departments listed on the website of the German Ophthalmological Society and to three practices focusing on IRDs.The overall response rate was 44.8%. Almost all institutions (93.6%) reported seeing IRD patients, but university and non-university hospitals differed in the number of patients. Databases are used in 60% of universities but only in 5.9% of non-university hospitals. Regarding the number of patients with genetic diagnostics, 53% of the non-university and 12% of the university sites reported that 20% at most of their patients had received a\xa0molecular genetic diagnosis. The results of the IRD practices are comparable with the university hospitals. Patients with biallelic RPE65 mutations-associated IRD, potential candidates for treatment with voretigene neparvovec (Luxturna), were followed in 9/25 participating university departments.This survey highlights the deficits in the management of IRD patients. In particular, we found a\xa0clear difference between university and non-university hospitals in the rate of patients with known molecular genetic results. Improvements should be initiated in the latter, especially because of existing and emerging therapeutic options.</ABSTRACT>'}]
2024-01-02 00:26:15,388 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:15,400 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:15,401 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449839, Requested 1929. Please try again in 235ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:15,401 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Cardiac Remodeling in Subclinical Hypertrophic Cardiomyopathy: The VANISH Randomized Clinical Trial.\nValsartan has shown promise in attenuating cardiac remodeling in patients with early-stage sarcomeric hypertrophic cardiomyopathy (HCM). Genetic testing can identify individuals at risk of HCM in a subclinical stage who could benefit from therapies that prevent disease progression.To explore the potential for valsartan to modify disease development, and to characterize short-term phenotypic progression in subclinical HCM.The multicenter, double-blind, placebo-controlled Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) randomized clinical trial was conducted from April 2014 to July 2019 at 17 sites in 4 countries (Brazil, Canada, Denmark, and the US), with 2 years of follow-up. The prespecified exploratory VANISH cohort studied here included sarcomere variant carriers with subclinical HCM and early phenotypic manifestations (reduced E\' velocity, electrocardiographic abnormalities, or an increased left ventricular [LV] wall thickness [LVWT] to cavity diameter ratio) but no LV hypertrophy (LVH). Data were analyzed between March and December 2022.Treatment with placebo or valsartan (80 mg/d for children weighing <35 kg, 160 mg/d for children weighing \u226535 kg, or 320 mg/d for adults aged \u226518 years).The primary outcome was a composite z score incorporating changes in 9 parameters of cardiac remodeling (LV cavity volume, LVWT, and LV mass; left atrial [LA] volume; E\' velocity and S\' velocity; and serum troponin and N-terminal prohormone of brain natriuretic peptide levels).This study included 34 participants, with a mean (SD) age of 16\u2009(5) years (all were White). A total of 18 participants (8 female [44%] and 10 male [56%]) were randomized to valsartan and 16 (9 female [56%] and 7 male [44%]) were randomized to placebo. No statistically significant effects of valsartan on cardiac remodeling were detected (mean change in composite z score compared with placebo: -0.01 [95% CI, -0.29 to 0.26]; P\u2009=\u2009.92). Overall, 2-year phenotypic progression was modest, with only a mild increase in LA volume detected (increased by 3.5 mL/m2 [95% CI, 1.4-6.0 mL/m2]; P\u2009=\u2009.002). Nine participants (26%) had increased LVWT, including 6 (18%) who developed clinically overt HCM. Baseline LA volume index (LAVI; 35 vs 28 mL/m2; P\u2009=\u2009.01) and average interventricular septum thickness (8.5 vs 7.0 mm; P\u2009=\u2009.009) were higher in participants who developed HCM.In this exploratory cohort, valsartan was not proven to slow progression of subclinical HCM. Minimal changes in markers of cardiac remodeling were observed, although nearly one-fifth of patients developed clinically overt HCM. Transition to disease was associated with greater baseline interventricular septum thickness and LAVI. These findings highlight the importance of following sarcomere variant carriers longitudinally and the critical need to improve understanding of factors that drive disease penetrance and progression.ClinicalTrials.gov Identifier: NCT01912534.</ABSTRACT>'}]
2024-01-02 00:26:15,403 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:15,404 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449899, Requested 1561. Please try again in 194ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:15,404 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Incidence of Inflammatory Bowel Disease in New Zealand Remains High, Findings in the Manawat\u016b Region.\nNew Zealand (NZ) has one of the world\'s highest rates of inflammatory bowel diseases (IBD), however available data are limited to southern, urban regions.To determine the incidence and prevalence of IBD in the Manawat\u016b region of NZ.Patients in the Manawat\u016b region, with a diagnosis of IBD made between 2011 and 2015 were identified. Demographic, diagnostic and disease data were collected, fulfilment of diagnostic criteria was assessed, and incidence rates were calculated. Comparison of disease phenotype and observed diagnostic criteria was made between diagnosis and 12-months following diagnosis. All resident patients with a diagnosis of IBD current on 5 March 2013 were identified, and prevalence rates were calculated.The mean annual age-standardised incidence rates of UC, CD, and IBD were 10.2, 17.0, and 27.2 per 100,000. IBD incidence was highest among those of European ethnicity (24.8 per 100,000), followed by Asian (1.4), and M\u0101ori (1.1). IBD incidence in the urban population was 34.0 per 100,000 (95% CI 24.1-46.0) compared to the rural population of 5.6 (95% CI 0.4-22.4). The age-standardised point prevalence of UC, CD, and IBD on 5 March 2013 was 157.7, 231.8, and 397.9 per 100,000, respectively.The incidence and prevalence of IBD in the Manawat\u016b region are comparable to those reported in other Australasian studies. Incidence was lower in M\u0101ori, and in the rural population. Follow-up is required to identify any changes in incidence and phenotype, and whether rural residence remains protective.</ABSTRACT>'}]
2024-01-02 00:26:15,417 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:15,419 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449753, Requested 1594. Please try again in 179ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:15,419 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Protective Effect of Quercetin and p-Coumaric Acid (p-CA) Against Cardiotoxicity: An In Silico Study.\nHydroxychloroquine (HCQ) is a common antimalarial drug that has been used effectively in the treatment of various rheumatic and auto-immunity diseases. The major side effects and drawbacks associated with HCQ are cardiotoxicity, retinopathy, gastrointestinal upset, and neuromyopathy however, cardiotoxicity is an increasing concern and it is critical to avoid heart dysfunction induced by HCQ. The present work is focused on receptor and signaling molecules associated with pathways attributing to drug-induced cardiotoxicity. We analyzed the therapeutic efficacy of selected natural products in HCQ-induced cardiotoxicity through insilico. We selected Syzygium cumini polyphenols, quercetin, and p-coumaric acid. The motivation behind selecting quercetin, and p-coumaric acid is their wide applicability as an antioxidative, anti-inflammatory, antiapoptotic, and cardioprotective.For predicting quercetin, p-coumaric acid, and HCQ toxicity and physicochemical properties, in silico studies were performed using ProTox II and Swiss ADME. We further performed molecular docking using Autodock Vina and Discovery Studio visualizer to find the affinity of selected polyphenols against signaling molecules and receptors. Then we performed network pharmacological studies of selected signaling molecules.We analyzed that the computational method indicated quercetin (\u0394 G -9.3 kcal/mol) has greater binding affinity than p-Coumaric acid for prevention and restoration of the disease while hydroxychloroquine was taken as a control.It can be concluded that Syzygium cumini, polyphenols may aid in the future therapeutic potential against HCQ-induced cardiotoxicity.</ABSTRACT>'}]
2024-01-02 00:26:15,432 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:15,432 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:15,434 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449677, Requested 1571. Please try again in 166ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:15,434 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Variants of the CASP9 gene as candidate markers for primary response to anti-TNF therapy in Crohn\'s disease patients.\nAnti-tumor necrosis factor (TNF) therapy is used to induce and maintain remission in Crohn\'s disease (CD) patients. However, primary non-responders to initial treatment constitute 20-40% of cases. The causes of this phenomenon are still unknown. We aim to investigate the impact of the caspase 9 (CASP9) gene variants on the variable reactions of CD patients to anti-TNF therapy. The study group included 196 diagnosed and clinically characterized CD Polish patients following anti-TNF therapy. The sequence of the CASP9 gene was analyzed using next-generation and Sanger sequencing and was analyzed with the response to biological treatment. Using the RT-qPCR analysis, we estimated the CASP9 gene mRNA level in colon biopsies material from inflamed and non-inflamed tissue (21 CD patients: 14 responders and seven non-responders to anti-TNF therapy and six controls), as well as in vitro in a peripheral blood mononuclear cells (PBMCs) from CD patients (seven responders and seven non-responders to anti-TNF therapy) and eight controls. Our findings indicated association of variants rs1052571 and rs4645978 with response to anti-TNF monoclonal antibodies (mAbs). Moreover, we observed tendency for reduced expression after incubation with anti-TNF in the group of CD patients, in contrast to the control group. Our results suggest that response to anti-TNF therapy in CD patients may be an effect of variants of the CASP9 gene as a key effector of the internal pathway of apoptosis; however, further population and functional research are necessary.</ABSTRACT>'}]
2024-01-02 00:26:15,434 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449621, Requested 1715. Please try again in 178ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:15,434 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Crohn\'s Disease Features in Anastomotic Biopsies from Patients With and Without Crohn\'s Disease: Diagnostic and Prognostic Value.\nEndoscopic evidence of disease activity is a critical predictor of clinical relapse in patients with Crohn\'s disease (CD), and histologic disease activity is evolving as a similarly important end point for patient management. However, classical morphologic features of CD may overlap with postoperative inflammatory changes, confounding the evaluation of anastomotic biopsies. There is a clear unmet need for better characterization of diagnostic and clinically significant histologic features of CD in these surgically altered sites. We evaluated ileocolonic and colocolonic/rectal anastomotic biopsies performed at 3 academic institutions in patients with and without CD. The biopsies were blindly assessed for CD histologic features and correlated to clinical and endoscopic characteristics. In CD patients, the presence of each feature was correlated with the subsequent clinical exacerbation or relapse. We obtained anastomotic biopsies from 208 patients, of which 109 were operated on for CD and 99 for another indication (neoplasia [80%], diverticular disease (11%), and other [9%]). Mean time since surgery was 10 years (0-59; 14 years for CD [1-59], 6 years for non-CD [0-33]). Endoscopic inflammation was noted in 52% of cases (68% for CD and 35% for non-CD). Microscopic inflammation was present in 74% of cases (82% for CD and 67% for non-CD). Only discontinuous lymphoplasmacytosis (P < .001) and pyloric gland metaplasia (P\xa0= .04) occurred significantly more often in CD patients. However, none of the histologic features predicted clinical disease progression. In subset analysis, the presence of histologic features of CD in nonanastomotic biopsies obtained concurrently in CD patients was significantly associated with relapse (P\xa0= .03). Due to extensive morphologic overlap between CD and postoperative changes and the lack of specific histologic features of relapse, biopsies from anastomotic sites are of no value in predicting clinical CD progression. Instead, CD activity in biopsies obtained away from anastomotic sites should be used for guiding endoscopic sampling and clinical management.</ABSTRACT>'}]
2024-01-02 00:26:15,435 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:15,436 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449538, Requested 1751. Please try again in 171ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:15,436 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Monocyte/macrophage mediates the impact of depression on Crohn\'s disease.\nDepression increases the risk of Crohn\'s disease (CD) and worsens its prognosis. Monocytes/macrophages, immune modulate cells, play vital roles in both depression and CD.We investigated whether monocyte/macrophage could mediate the impact of depression on CD through induction of CD4\u2009+\u2009T lymphocyte differentiation and epithelial barrier dysfunction, in addition to the alteration of their own phagocytic ability and cytokines production.Circulating monocytes and intestinal macrophages were isolated from eligible CD patients, divided into depressed and non-depressed groups. Phagocytosis was determined using flow cytometry while in vitro cytokine production was quantified using Luminex assay and qPCR. CD4\u2009+\u2009T cells were cocultured with monocytes, then Type 1 Helper T Lymphocytes Th1/Type 2 Helper T Lymphocytes (Th2) /Type 17 Helper T Lymphocytes (Th17)/Treg subsets were analyzed using flow cytometry and qPCR. Caco-2 monolayers simulating epithelial barrier were cocultured with macrophages, and integrity and proliferation were evaluated. Tight junction protein expression was detected using immunofluorescence and western blot.Decreased monocyte/macrophage phagocytosis and enhanced production of pro-inflammatory cytokines including Tumor necrosis factor-\u03b1 (TNF-\u03b1), Interleukin-6 (IL-6) and Interleukin-1\u03b2 (IL-1\u03b2) were revealed in the depressed versus non-depressed CD groups. Higher proportions of Th1 and Th17 cells with a lower proportion of Treg cell were observed after cocultured with monocytes from the depressed versus non-depressed CD patients. So were the expressions of their corresponding transcription factors T-bet, Retinoic Acid Related Orphan Nuclear Receptor gamma T (ROR\u03b3t) and Forkhead box protein P3 (FoxP3). Caco-2 cells cocultured with macrophages from depressed CD displayed lower Transepithelial electric resistance (TEER), reduced proliferation activity, and decreased tight junction protein expressions compared with their counterpart cocultured with macrophages from non-depressed CD.Monocyte/macrophage may underlie the impact of depression upon CD via decreased phagocytosis, increased pro-inflammatory cytokine production, inducing CD4\u2009+\u2009T cell differentiation toward Th1/Th17 cells rather than Treg cell, and impairing macrophage-enhanced epithelial barrier.</ABSTRACT>'}]
2024-01-02 00:26:15,441 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:15,444 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449572, Requested 1607. Please try again in 157ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:15,444 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Does inflammatory bowel disease promote kidney diseases: a mendelian randomization study with populations of European ancestry.\nThis study aimed to investigate a causal relationship between IBD and multiple kidney diseases using two-sample Mendelian randomization (MR) analyses.We selected a group of single nucleotide polymorphisms (SNPs) specific to IBD as instrumental variables from a published genome-wide association study (GWAS) with 86,640 individuals of European ancestry. Summary statistics for multiple kidney diseases were obtained from the publicly available GWAS. Genetic data from one GWAS involving 210 extensive T-cell traits was used to estimate the mediating effect on specific kidney disease. Inverse-variance weighted method were used to evaluate the MR estimates for primary analysis.Genetic predisposition to IBD was associated with higher risk of IgA nephropathy (IgAN) (OR, 1.78; 95% CI, 1.45-2.19), but not membranous nephropathy, diabetic nephropathy, glomerulonephritis, nephrotic syndrome, chronic kidney disease, and urolithiasis. CD4 expression on CD4\u2009+\u2009T cell had a significant genetic association with the risk of IgAN (OR, 2.72; 95% CI, 1.10-6.72). Additionally, consistent results were also observed when IBD was subclassified as ulcerative colitis (OR, 1.38; 95% CI, 1.10-1.71) and Crohn\'s disease (OR, 1.37; 95% CI, 1.12-1.68). MR-PRESSO and the MR-Egger intercept did not identify pleiotropic SNPs.This study provides genetic evidence supporting a positive casual association between IBD, including its subclassification as ulcerative colitis and Crohn\'s disease, and the risk of IgAN. However, no casual association was found between IBD and other types of kidney diseases. Further exploration of IBD interventions as potential preventive measures for IgAN is warranted.</ABSTRACT>'}]
2024-01-02 00:26:15,451 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:15,466 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:15,467 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449042, Requested 1169. Please try again in 28ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:15,467 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Microperimetry Findings in Pentosan Polysulfate Maculopathy.\n</ABSTRACT>'}]
2024-01-02 00:26:15,467 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:15,468 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448959, Requested 1720. Please try again in 90ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:15,469 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Acute Kidney Injury from Intravitreal Anti-vascular Endothelial Growth Factor Drugs: A Systematic Review and Meta-analysis of Randomized Controlled Trials.\nSeveral observational studies have reported acute kidney injury from intravitreal anti-vascular endothelial growth factor (anti-VEGF) drugs for retinal diseases. However, systematic reviews and meta-analyses of randomized controlled trials on this critical topic are scant.To evaluate acute kidney injury risk associated with intravitreal anti-VEGF drugs in patients with retinal diseases.We searched PubMed, Embase, and the Cochrane Central Register of Controlled Trials on 12 July, 2023, and included randomized controlled trials reporting acute kidney injury between anti-VEGF drugs (e.g., aflibercept, bevacizumab, brolucizumab, and ranibizumab) and controls for retinal diseases (e.g., age-related macular degeneration, polypoidal choroidal vasculopathy, diabetic retinopathy/diabetic macular edema, retinal vein occlusion, and myopic choroidal neovascularization). Data were synthesized by\xa0a fixed-effects model for pooling odds ratios (ORs) using the Peto method.We included 13 randomized controlled trials (four and nine trials for aflibercept and ranibizumab, respectively) with a total of 4282 participants. The meta-analysis indicated intravitreal anti-VEGF drugs did not increase the acute kidney injury risk, compared with controls (odds ratio [OR]: 1.00, 95% confidence interval [CI] 0.49-2.04, I2: 0%), and no differences in the acute kidney injury risk were observed between different anti-VEGF drugs (OR: 1.10, 95% CI 0.27-4.43, I2: 0% for aflibercept; OR: 0.97, 95% CI 0.42-2.22, I2: 0% for ranibizumab) and between different retinal diseases (OR: 4.61, 95% CI 0.07-284.13, I2: not applicable for age-related macular degeneration; OR: 0.90, 95% CI 0.42-1.93, I2: 0% for diabetic retinopathy/diabetic macular edema; OR: 1.57, 95% CI 0.16-15.88, I2: 0% for retinal vein occlusion).Intravitreal anti-VEGF drugs were not associated with an acute kidney injury risk, regardless of which anti-VEGF drugs (aflibercept or ranibizumab) or retinal diseases (age-related macular degeneration, diabetic retinopathy/diabetic macular edema, or retinal vein occlusion) were involved.PROSPERO CRD42021267854.</ABSTRACT>'}]
2024-01-02 00:26:15,476 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:15,477 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:15,478 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448941, Requested 1162. Please try again in 13ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:15,478 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>NT-proBNP in Cardioembolic Stroke.\n</ABSTRACT>'}]
2024-01-02 00:26:15,480 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448993, Requested 1658. Please try again in 86ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:15,480 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Clinical characteristics and treatment approaches in patients with Susac syndrome: a scoping review of cases.\nSusac syndrome (SuS) is a rare disease characterized by encephalopathy, hearing impairment and visual disturbances. Immunosuppressive treatments are used based on the hypothesis that an autoimmune endotheliopathy drives the disease. However, a solid evidence-based treatment approach is lacking. The aim of this review is to provide an overview of patient characteristics, disease course and treatment patterns related to successful outcome that have been reported in literature since 2013.Three reviewers conducted a systematic literature search in February 2022. The primary outcome was treatment used, derived from cases classified as probable or definite SuS, describing successful treatment outcome (i.e. no signs of disease activity for\u2009\u2265\u20091\xa0month). Secondary outcomes were time-to-relapse and follow-up time. Published case reports and case series were included. Various clinical characteristics and treatment(s) were extracted and categorized into different phases of treatment.A total of 810 records was identified. 120 articles met inclusion criteria and 161 cases were extracted. Of these, 151 cases were classified as probable or definite SuS and included in the final analysis. Number of combinations of treatments used per treatment phase were: 6 empirically, 35 after confirmed diagnosis, 43 for maintenance treatment, 22 after relapse, 18 during maintenance post-relapse. Median follow-up time was 12.3\xa0months (0.5; 120) and median time to relapse was 4\xa0months (1; 120).This scoping review summarizes treatment approaches in patients with SuS, highlighting variability. International efforts to collect clinical, imaging and treatment data from patients with SuS in registries are needed, in order to provide less biased and long-term follow-up information on treatment response, predictors of relapse and patient outcomes. This may lead to more evidence-based therapeutic approaches.</ABSTRACT>'}]
2024-01-02 00:26:15,483 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:15,484 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448846, Requested 1709. Please try again in 74ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:15,484 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Relationship between baseline electrocardiographic measurements and outcomes in patients with high-risk heart failure: Insights from the VerICiguaT Global Study in Subjects with Heart Failure with Reduced Ejection Fraction (VICTORIA) trial.\nWhether electrocardiographic (ECG) measurements predict mortality in chronic heart failure with reduced ejection fraction (HFrEF) is unknown.We studied 4880 patients from the Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction (VICTORIA) trial with a baseline 12-lead ECG. Associations between ECG measurements and mortality were estimated as hazard ratios (HR) and adjusted for the Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC) risk score, N-terminal pro-B-type natriuretic peptide, and index event. Select interactions between ECG measurements, patient characteristics and mortality were examined. Over a median of 10.8\u2009months, there were 824 cardiovascular (CV) deaths (214 sudden) and 1005 all-cause deaths. Median age was 68\u2009years (interquartile range [IQR] 60-76), 24% were women, median ejection fraction was 30% (IQR 23-35), 41% had New York Heart Association class III/IV, and median MAGGIC score was 24 (IQR 19-28). After multivariable adjustment, significant associations existed between heart rate (per 5 bpm: HR 1.02), QRS duration (per 10\u2009ms: HR 1.02), absence of left ventricular hypertrophy (HR 0.64) and CV death, and similarly so with all-cause death (HR 1.02; HR 1.02; HR 0.61, respectively). Contiguous pathologic Q waves were significantly associated with sudden death (HR 1.46), and right ventricular hypertrophy with all-cause death (HR 1.44). The only sex-based interaction observed was for pathologic Q waves on CV (men: HR 1.05; women: HR 1.64, pinteraction \u2009=\u20090.024) and all-cause death (men: HR 0.99; women: HR 1.57; pinteraction \u2009=\u20090.010). Whereas sudden death doubled in females, it did not differ among males (male: HR 1.25, 95% confidence interval [CI] 0.87-1.79; female: HR 2.50, 95% CI 1.23-5.06; pinteraction \u2009=\u20090.141).Routine ECG measurements provide additional prognostication of mortality in high-risk HFrEF patients, particularly in women with contiguous pathologic Q waves.</ABSTRACT>'}]
2024-01-02 00:26:15,485 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:15,492 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:15,493 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:15,494 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448433, Requested 1630. Please try again in 8ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:15,494 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Ocular manifestations of the genetic renal tubulopathies.\nThe genetic tubulopathies are rare and heterogenous disorders that are often difficult to identify. This study examined the tubulopathy-causing genes for ocular associations that suggested their genetic basis and, in some cases, the affected gene.Sixty-seven genes from the Genomics England renal tubulopathy panel were reviewed for ocular features, and for retinal expression in the Human Protein Atlas and an ocular phenotype in mouse models in the Mouse Genome Informatics database. The genes resulted in disease affecting the proximal tubules (n\u2009=\u200924); the thick ascending limb of the loop of Henle (n\u2009=\u200910); the distal convoluted tubule (n\u2009=\u200915); or the collecting duct (n\u2009=\u200918).Twenty-five of the tubulopathy-associated genes (37%) had ocular features reported in human disease, 49 (73%) were expressed in the retina, although often at low levels, and 16 (24%) of the corresponding mouse models had an ocular phenotype. Ocular abnormalities were more common in genes affected in the proximal tubulopathies (17/24, 71%) than elsewhere (7/43, 16%). They included structural features (coloboma, microphthalmia); refractive errors (myopia, astigmatism); crystal deposition (in oxalosis, cystinosis) and sclerochoroidal calcification (in Bartter, Gitelman syndromes). Retinal atrophy was common in the mitochondrial-associated tubulopathies. Structural abnormalities and crystal deposition were present from childhood, but sclerochoroidal calcification typically occurred after middle age.Ocular abnormalities are uncommon in the genetic tubulopathies but may be helpful in recognizing the underlying genetic disease. The retinal expression and mouse phenotype data suggest that further ocular associations may become apparent with additional reports. Early identification may be necessary to monitor and treat visual complications.</ABSTRACT>'}]
2024-01-02 00:26:15,501 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:15,502 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:15,505 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449675, Requested 1605. Please try again in 170ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:15,505 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Impaired Immunomodulatory Properties of the Retina from the Inflammatory Environment of the Damaged Eye.\nThe retina represents a highly specialized structure with the primary function to capture a light signal and to convert it into electrical impulses. Any damage or disease of the retina can cause visual impairment. Since retinal degenerative diseases are generally associated with immune cell infiltration, a local inflammatory reaction, and cytokine burn, there is a need for mechanisms to prevent the retina from damage by a deleterious immune reaction. In this study, we show that mouse retinal explants co-cultivated with stimulated spleen cells, inhibit in a dose-dependent manner the activation of T cells, and suppress the production of cytokines interleukin-2, interleukin-10, and interferon-[Formula: see text]. The immunoregulatory properties of the retina were mainly mediated by a paracrine effect since retinal explants, separated by a semipermeable membrane, or supernatants obtained after the cultivation of retinal explants, inhibited the reactivity of immune cells. A model of retinal damage was established by the application of sodium iodate which selectively destroys photoreceptors, as it was demonstrated by a decrease in the number of rhodopsin-positive cells. This process was accompanied by increased infiltration of the retina with cells of the immune system and by a local inflammatory reaction. The pharmacologically damaged retina had significantly decreased the ability to inhibit T cell activation and production of cytokines by immune cells. Overall, the results showed that the retina possesses immunoregulatory properties and inhibits the activation and functions of T cells. However, the immunomodulatory properties of the retina are decreased if the retina is damaged.</ABSTRACT>'}]
2024-01-02 00:26:15,506 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449932, Requested 1625. Please try again in 207ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:15,506 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Exploring Signs and Symptoms Associated with Meibomian Gland Dysfunction for Use as Clinical Trial Endpoints.\nPurpose: Dry eye disease is attributed to impaired tear production and/or evaporative dry eye. Evaporative dry eye is frequently associated with meibomian gland dysfunction (MGD). The objective of this study was to identify clinical study endpoints related to MGD. Methods: This 22-day, noninterventional, case-control clinical study involved three cohorts with increasing MGD severity: no MGD, mild/moderate MGD, and severe MGD. Symptoms were assessed with an ocular symptom questionnaire grading blurred vision, eye burning, eye dryness, eye pain, light sensitivity, eye itching, eye foreign body sensation, and overall ocular discomfort. Sign assessments included the maximum meibum quality score (MMQS), tear breakup time, Schirmer tear tests, biomicroscopy, and corneal staining. Signs and symptoms were compared between cohorts and study visits. Results: Seventy-five study participants were assigned to the cohorts (25 per cohort). MMQS scores increased with increasing MGD severity, reflecting the selection criteria for the cohorts. Between-visit scores showed a weighted kappa statistic of 0.72 indicating substantial agreement. Mean scores of all assessed symptoms increased with increasing MGD severity. Scores for symptoms showed moderate (\u03ba\u2009=\u20090.41-0.60) to substantial (\u03ba\u2009=\u20090.61-0.80) agreement between visits. Overall ocular discomfort demonstrated the strongest correlation with the MMQS. Conclusion: The MMQS was a reproducible sign of MGD showing good agreement with ocular symptoms. Overall ocular discomfort was well correlated with typical dry eye symptoms and could potentially be used as a single measure of MGD symptoms. The findings from this observational study may inform endpoints for future clinical trials. ClinicalTrials.gov NCT01979887.</ABSTRACT>'}]
2024-01-02 00:26:15,511 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:15,512 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449636, Requested 1810. Please try again in 192ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:15,512 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Glutamate Infusion Reduces Myocardial Dysfunction after Coronary Artery Bypass Grafting According to NT-proBNP: Summary of 2 Randomized Controlled Trials (GLUTAmate for Metabolic Intervention in Coronary Surgery [GLUTAMICS I-II]).\nGlutamate is reported to enhance the recovery of oxidative metabolism and contractile function of the heart after ischemia. The effect appears to be blunted in diabetic hearts. Elevated plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) reflects myocardial dysfunction. In the GLUTAmate for Metabolic Intervention in Coronary Surgery (GLUTAMICS) II trial, the proportion of patients with diabetes had nearly doubled to 47% compared with the cohort used for sample size estimation, and a significant effect on the postoperative rise in NT-proBNP was only observed in patients without diabetes.We aimed to summarize the pooled NT-proBNP results from both GLUTAMICS trials and address the impact of diabetes.Data from 2 prospective, randomized, double-blind multicenter trials with similar inclusion criteria and endpoints were pooled. Patients underwent a coronary artery bypass grafting (CABG)  valve procedure and had a left-ventricular ejection fraction of \u22640.30 or a European System for Cardiac Operative Risk Evaluation II (EuroSCORE II) of \u22653.0 with at least 1 cardiac risk factor. Intravenous infusion of 0.125 M L-glutamic acid or saline at 1.65 mL/kg/h was started 10-20 min before reperfusion and continued for 150 min. The primary endpoint was the difference between preoperative and day 3 postoperative NT-proBNP levels.A total of 451 patients, 224 receiving glutamate and 227 controls, fulfilled the inclusion criteria. Glutamate was associated with a reduced primary endpoint (5344  5104 ng/L and 6662  5606 ng/L in glutamate and control groups, respectively; P = 0.01). Postoperative mortality at \u226430 d was 0.9% and 3.5% (P = 0.11), whereas stroke at \u226424 h was 0.4% and 2.6% in glutamate and control groups, respectively (P = 0.12). No adverse events related to glutamate were observed. A significant interaction regarding the primary endpoint was only detected between glutamate and insulin-treated diabetes groups (P = 0.04). Among patients without insulin-treated diabetes, the primary endpoint was 5047  4705 ng/L and 7001  5830 ng/L in the glutamate and control groups, respectively (P = 0.001).Infusion of glutamate reduced the postoperative rise in NT-proBNP after CABG in medium- to high-risk patients. A significantly blunted effect was observed only in insulin-treated patients with diabetes.This trial was registered at www.gov as NCT02592824.</ABSTRACT>'}]
2024-01-02 00:26:15,516 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:15,518 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449640, Requested 1647. Please try again in 171ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:15,518 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Efficacy and Safety of the Melanocortin Pan-Agonist PL9643 in a Phase 2 Study of Patients with Dry Eye Disease.\nPurpose: The melanocortin receptor pan-agonist PL9643, a potential therapy for ocular diseases, was investigated in a phase 2, 12-week study in patients with dry eye disease (DED). Methods: This was a placebo-controlled study evaluating efficacy and safety of thrice-daily PL9643. Placebo (vehicle) was similar to tears. Primary endpoints were intra-patient changes in inferior corneal fluorescein staining and ocular discomfort after 12 weeks. Secondary endpoints were changes in additional DED signs or symptoms. Multiple secondary endpoints were not adjusted for multiplicity. Patients with moderate or severe DED were analyzed in addition to the overall intent-to-treat (ITT) population. Results: In the ITT population (n\u2009=\u2009160) the PL9643 group did not demonstrate significant treatment difference versus placebo at week 12/day 85 for the primary endpoints (P\u2009>\u20090.05). In patients with moderate or severe DED (n\u2009=\u200953), PL9643 treatment demonstrated either nominally significant (P\u2009<\u20090.05) or trending (P\u2009<\u20090.1) improvement over placebo in mean change from baseline at week 12/day 85 in several sign endpoints, including fluorescein staining in inferior, superior, corneal sum, and total sum regions; Lissamine Green staining in temporal, nasal, conjunctival sum, and total sum regions; and tear film breakup time. Conjunctival redness also showed (nonsignificant) improvement at week 12/day 85. There were no drug-related adverse events (AEs) and no drug-related discontinuations. Conclusions: PL9643 showed no significant efficacy for the ITT population; however, efficacy results across several signs and symptoms in the subpopulation of moderate to severe DED patients, the low number of ocular AEs, and no tolerability issues suggest that PL9643 shows promise as a therapeutic for DED. Clinical Trial Registration number: NCT04268069.</ABSTRACT>'}]
2024-01-02 00:26:15,531 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:15,532 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:15,532 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449471, Requested 1758. Please try again in 163ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:15,532 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Coronary artery calcium scoring for cardiovascular risk assessment in patients with inflammatory bowel disease.\nInflammatory bowel disease (IBD) is associated with higher incidence of atherosclerotic cardiovascular disease (ASCVD). Data investigating the role of coronary artery calcium (CAC) scoring in identifying subclinical atherosclerotic disease in IBD patients is scarce.Using data obtained from the CLARIFY registry, a prospective study of no-charge coronary artery calcium (CAC) testing at University Hospitals, we reviewed patients with ulcerative colitis (UC) or Crohn\'s disease (CD) who underwent CAC scoring from 2014 to 2020. We investigated the concordance between CAC risk and 10-year estimated ASCVD risk by AHA/ACC pooled cohort equation using pre-established thresholds for statin prescription (CAC\u2265100, 10-year ASCVD risk \u22657.5%). We additionally investigated the association between CAC, preventive therapy initiation and Major Adverse Cardiovascular Events (MACE).A total of 369 patients with IBD were included (174 UC, 195 CD), with median age of 60 years. The median CAC score was 14.9 with no significant difference between UC and CD (P\xa0=\xa0.76). Overall, 151 (41%) had CAC of 0, 108 (29%) had CAC 1-99, 61 (17%) had CAC 100 to 399, and 49 (13%) had CAC \u2265400 with no difference in CAC distribution between CD and UC (P\xa0=\xa0.17). There was no difference in median CAC between IBD or age/sex-matched controls (P\xa0=\xa0.34). Approximately half of the patients (52%) with IBD had 10-year estimated ASCVD risk of 7.5% or higher. Among patients with ASCVD risk <7.5% (n\xa0=\xa0163), 29 (18%) had CAC\u2265100 and among patients with ASCVD risk \u22657.5% (n\xa0=\xa0178), 102 (57%) had CAC <100. There was no difference between CAC<100 vs CAC\u2265100 with respect to CRP, use of immunosuppressive or amino-salicylate therapy, IBD severity or complications. CAC score (AUROC 0.67 [0.56-0.78]), but not PCE ASCVD risk (AUROC 0.60 [0.48-0.73]), was predictive of MACE. The best cut-off for CAC score was 76 (sensitivity\xa0=\xa060%, specificity\xa0=\xa069%), and was associated with 4-fold increase in MACE (Hazard Ratio 4.0 [2.0-8.1], P < .001).Subclinical atherosclerosis, as evaluated by CAC scoring, is prevalent in patients with IBD, and is associated with cardiovascular events. Further studies are needed to understand underlying biological processes of increased atherosclerotic disease risk among adults with IBD.</ABSTRACT>'}]
2024-01-02 00:26:15,533 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449391, Requested 1605. Please try again in 132ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:15,534 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Washed microbiota transplantation for Clostridioides difficile infection: A national multicenter real-world study.\nFecal microbiota transplantation (FMT) has been recommended for the treatment of recurrent Clostridioides difficile infection (CDI). We aimed to evaluate the therapeutic efficacy and safety of washed microbiota transplantation (WMT), a new method of FMT, for CDI across various medical settings.This multicenter real-world cohort study included CDI patients undergoing WMT. The primary outcome was the clinical cure rate of CDI within 8\u2009weeks after WMT. Secondary outcomes included the CDI recurrence rate and reduction in total abdominal symptom score (TASS) during the follow-up period. Adverse events related to WMT were recorded.Altogether 90.7% (49/54) of CDI patients achieved clinical cure after treated with WMT. The cure rate was 83.3% for cases with severe and complicated CDI (ScCDI) (n\u2009=\u200930) and 100% for non-ScCDI cases (n\u2009=\u200924) (P\u2009=\u20090.059). No difference was observed in the clinical cure rate between patients with first and recurrent CDI (91.9% vs 88.2%, P\u2009=\u20090.645). One week post-WMT, TASS showed a remarkable decrease compared to that at baseline (P\u2009<\u20090.001). Totally, 8.2% (4/49) of patients suffered CDI recurrence during the follow-up period. A WHO performance score of 4, age\u2009\u226565\u2009years, higher TASS score, and higher Charlson comorbidity index score were potential risk factors for efficacy (P\u2009=\u20090.018, 0.03, 0.01, 0.034, respectively). Four (3.8%) transient adverse events related to WMT were observed.This study emphasizes the attractive value of WMT for CDI. Early WMT may be recommended for CDI, especially for those in serious condition or with complex comorbidities.ClinicalTrials.gov, no. NCT03895593 (registered on\xa027 March 2019).</ABSTRACT>'}]
2024-01-02 00:26:15,536 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:15,536 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:15,538 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449115, Requested 1644. Please try again in 101ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:15,538 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>MAdCAM-1 targeting strategy can prevent colitic cancer carcinogenesis and progression via suppression of immune cell infiltration and inflammatory signals.\nChronic inflammation caused by infiltrating immune cells can promote colitis-associated dysplasia/colitic cancer in ulcerative colitis (UC) by activating inflammatory cytokine signalling through the IL-6/p-STAT3 and TNF\u03b1/NF-\u03baB pathways. Mucosal addressin cell adhesion molecule-1 (MAdCAM-1) expressed on high endothelial venules promotes the migration of immune cells from the bloodstream to the gut via interaction with \u03b14\u03b27 integrin expressed on the immune cells. MAdCAM-1, has therefore drawn interest as a novel therapeutic target for treating active UC. However, the role of MAdCAM-1-positive endothelial cells in immune cell infiltration in dysplasia/colitic cancers remains unclear. We evaluated the expression of MAdCAM-1, CD31 and immune cell markers (CD8, CD68, CD163 and FOXP3) in samples surgically resected from 11 UC patients with dysplasia/colitic cancer and 17 patients with sporadic colorectal cancer (SCRC), using immunohistochemical staining. We used an azoxymethane/dextran sodium sulphate mouse model (AOM/DSS mouse) to evaluate whether dysplasia/colitic cancer could be suppressed with an anti-MAdCAM-1 blocking antibody by preventing immune cell infiltration. The number of MAdCAM-1-positive vessels and infiltrating CD8+ , CD68+ and CD163+ immune cells was significantly higher in dysplasia/colitic cancer than in normal, SCRC and UC mucosa. In AOM/DSS mice, the anti-MAdCAM-1 antibody reduced the number, mean diameter, depth of tumours, Ki67 positivity, number of CD8+ , CD68+ and CD163+ immune cells and the IL-6/p-STAT3 and TNF-\u03b1/NF-\u03baB signalling. Our results indicate that targeting MAdCAM-1 is a promising strategy for controlling not only UC severity but also carcinogenesis and tumour progression by regulating inflammation/immune cell infiltration in patients with UC.</ABSTRACT>'}]
2024-01-02 00:26:15,543 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:15,544 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448994, Requested 1859. Please try again in 113ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:15,544 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Xihuang pill ameliorates colitis in mice by improving mucosal barrier injury and inhibiting inflammatory cell filtration through network regulation.\nThe prevalence of colitis is on the rise, and effective treatment options are currently lacking. Xihuang pill (XHP) is a traditional Chinese medicine formula mentioned in the "Volume 4 of Surgical Evidence and Treatment of the Whole Life" authored by the renowned doctor Hong-Xu Wang during the Qing Dynasty. It is now part of the "Volume 9 of Chinese medicine formula preparation in Drug Standard." XHP and its primary ingredients have been demonstrated anti-inflammatory properties against colitis. However, the specific effects and underlying mechanisms of XHP in treating colitis remain unknown.This study aimed to investigate the potential impact of XHP on colitis and uncover the underlying mechanisms involved.An acute colitis model was developed in C57BL/6N mice, and the effects on weight loss, colon length, the permeability of the colonic mucosa barrier, Claudin-5 and Occludin expression, number of both infiltrating MPO-positive cells and CD68-positive cells, and the content of pro-inflammatory cytokines (IL-6, IL-22, IL-1\u03b2, and TNF-\u03b1) in the colon tissue were investigated. Low-, medium-, and high-dose XHP (0.45, 0.9, and 1.8\xa0g/kg/day) (batch number: z21021222) were administered to the mice by gavage over the course of two weeks. Additionally, the protein expression levels in colon tissue from the control group, colitis group, and XHP low-dose administration group mice were analyzed by quantitative proteomics techniques. The comprehensive profiling and characterization of absorbed components in mice blood following oral administration of XHP were identified by HPLC/Q-TOF-MS techniques, and the absorbed components in blood were combined with proteomics to reveal the mechanism of enteritis inhibition by XHP.Our findings indicated that XHP enhanced weight loss and colonic shortening of colitis mice. Additionally, XHP reduced the increase in permeability of the colonic mucosa barrier and decreased expression of Claudin-5 and Occludin, while significantly reducing the number of infiltrating MPO-positive cells and CD68-positive cells in the colon tissue. We found that XHP reduced the production of pro-inflammatory cytokines, including IL-6, IL-22, IL-1\u03b2, and TNF-\u03b1 in colon tissue. Pharmacokinetic analysis suggested that XHP contained 24 blood-entering prototype ingredients, which improved colitis through the regulation of various proteins (e.g., Ctsb, Sting1, and Abat) linked to mucosal barrier injury and inflammation.XHP improved intestinal mucosal barrier injury and reduced MPO-positive cells and CD68-positive cell infiltration through multiple targets and pathways, providing support for XHP as a promising therapy for colitis.</ABSTRACT>'}]
2024-01-02 00:26:15,560 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:15,565 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:15,566 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448506, Requested 1770. Please try again in 36ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:15,566 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Effects of Compound Danshen Dripping Pills on Ventricular Remodeling and Cardiac Function after Acute Anterior Wall ST-Segment Elevation Myocardial Infarction (CODE-AAMI): Protocol for a Randomized Placebo-Controlled Trial.\nVentricular remodeling after acute anterior wall ST-segment elevation myocardial infarction (AAMI) is an important factor in occurrence of heart failure which additionally results in poor prognosis. Therefore, the treatment of ventricular remodeling needs to be further optimized. Compound Danshen Dripping Pills (CDDP), a traditional Chinese medicine, exerts a protective effect on microcirculatory disturbance caused by ischemia-reperfusion injury and attenuates ventricular remodeling after myocardial infarction.This study is designed to evaluate the efficacy and safety of CDDP in improving ventricular remodeling and cardiac function after AAMI on a larger scale.This study is a multi-center, randomized, double-blind, placebo-controlled, parallel-group clinical trial. The total of 268 patients with AAMI after primary percutaneous coronary intervention (pPCI) will be randomly assigned 1:1 to the CDDP group (n=134) and control group (n=134) with a follow-up of 48 weeks. Both groups will be treated with standard therapy of ST-segment elevation myocardial infarction (STEMI), with the CDDP group administrating 20 tablets of CDDP before pPCI and 10 tablets 3 times daily after pPCI, and the control group treated with a placebo simultaneously. The primary endpoint is 48-week echocardiographic outcomes including left ventricular ejection fraction (LVEF), left ventricular end-diastolic volume index (LVEDVI), and left ventricular end-systolic volume index (LVESVI). The secondary endpoint includes the change in N terminal pro-B-type natriuretic peptide (NT-proBNP) level, arrhythmias, and cardiovascular events (death, cardiac arrest, or cardiopulmonary resuscitation, rehospitalization due to heart failure or angina pectoris, deterioration of cardiac function, and stroke). Investigators and patients are both blinded to the allocated treatment.This prospective study will investigate the efficacy and safety of CDDP in improving ventricular remodeling and cardiac function in patients undergoing pPCI for a first AAMI. Patients in the CDDP group will be compared with those in the control group. If certified to be effective, CDDP treatment in AAMI will probably be advised on a larger scale. (Trial registration No. NCT05000411).</ABSTRACT>'}]
2024-01-02 00:26:15,603 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:15,603 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:15,604 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449803, Requested 1555. Please try again in 181ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:15,604 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Ocular Manifestations and Outcomes in Children With Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Comparison With Adult Patients.\nTo compare the clinical features and visual outcomes in children and adults with Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).Retrospective comparative case series.This retrospective study included 280 eyes of 140 patients (35 children and 105 adults) with SJS/TEN treated between 2010 and 2020. The primary outcome measures were the final best-corrected visual acuity (BCVA) and severity of dry eye. The secondary outcome measure was the medical and surgical therapies used.Among 64 eyes of children recruited in the study, acute ocular involvement was found in 58 eyes (90.6%). The chronic score in pediatric patients was significantly higher than that in adult patients (P\xa0=\xa0.004). The use of antibiotics/nonsteroidal anti-inflammatory drugs (NSAIDs) and Mycoplasma infection were the more common etiologies in children. In all, 75% of eyes in children maintained a visual acuity of 20/40 or better at a mean follow-up time of 4.3 years. The severity of dryness was comparable between the child and adult groups. The proportion of eyes undergoing amniotic membrane and oral mucosa transplantation was significantly higher in children than in adults in the chronic stage, reflecting that children exhibit much more severe complications.Although pediatric SJS/TEN patients have more severe ocular complications than adults, most children maintain long-term good vision. Early intervention and aggressive treatment help to preserve vision.</ABSTRACT>'}]
2024-01-02 00:26:15,605 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449873, Requested 1657. Please try again in 204ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:15,605 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Sex-Related Disparities in Prescription Patterns of Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Type 2 Diabetes and Heart Failure.\nBackground: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) improve cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM) and heart failure (HF). In consideration of emerging evidence that there are clinically relevant sex-related differences in the course of T2DM and subsequent cardiovascular outcomes, it is unknown if SGLT2i therapy is sex-independently utilized in daily clinical practice. Methods: Patients with T2DM and HF admitted to a tertiary academic center between January 2014 and April 2020 were identified through a search of electronic health records. Data on antidiabetic therapy were acquired at discharge and were screened for SGLT2i prescription. Results: Overall, 812 patients (median age 70 years, 29.7% female) were included in the present analysis. Only 17.3% of the study population received an SGLT2i. In comparison between sexes, females show lower rates of SGLT2i prescription (11.2% vs. 19.8%, p\u2009=\u20090.003), despite comparable patient characteristics. Furthermore, male HF patients showed a significantly higher probability of SGLT2i prescription with an adjusted odds ratio of 2.59 (95% confidence interval 1.29-5.19; p\u2009=\u20090.008). Females who did not receive an SGLT2i showed higher rates of chronic kidney disease (25.2% vs. 7.4%, p\u2009=\u20090.039) and greater levels of N-terminal pro b-type natriuretic peptide (NT-proBNP; 2092 vs. 825\u2009pg/mL, p\u2009=\u20090.011) as compared to female SGLT2i recipients, which did not explain the observed sex-related disparities. Conclusion: SGLT2i are potentially underutilized in female patients with HF and T2DM, despite an overall increasing prescription trend during the observation period. Reasons for withholding therapy could not be objectified. The present data indicate a major need to increase awareness of guideline-directed therapy, especially in female HF patients.</ABSTRACT>'}]
2024-01-02 00:26:15,606 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:15,606 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449777, Requested 1626. Please try again in 187ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:15,606 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Risk Factors for Fibrous Ingrowth in Eyes Requiring Primary Keratoplasty.\nThe aim of this study was to define risks for corneal transplantation associated with fibrous ingrowth among first-time transplant recipients.We performed a retrospective case-control study of patients with a histopathologic diagnosis of fibrous ingrowth between 2002 and 2019. Patients with fibrous ingrowth from a first corneal specimen were included. Those with incomplete records were excluded. A 1:2 case-control ratio was used. Controls were matched using surgical indication, surgery year, transplantation method, sex, and age.Seventy-eight eyes (76 patients) were included and matched with 160 control eyes. The incidence of fibrous ingrowth found on a first corneal transplant was 0.6% per year. The most common keratoplasty indications were pseudophakic corneal edema (n = 25, 32%) and aphakic corneal edema (n = 15, 19%). Cases were more likely to have a history of ocular trauma (odds ratio [OR], 2.94; 95% CI, 1.30-6.30; P = 0.007), uveitis (OR, 2.73; 95% CI, 1.12-6.63; P = 0.022), retinal detachment or previous retinal surgery (OR, 2.40; 95% CI, 1.34-4.30; P = 0.003), glaucoma tube-shunt surgery (OR, 2.70; 95% CI, 1.29-5.65; P = 0.007), aphakia (OR, 3.02; 95% CI, 1.61-5.67; P = 0.0004), or iris derangement (OR, 10.52; 95% CI, 5.45-20.30; P <0.0001). A multivariate logistic regression model using iris derangement, history of ocular trauma, history of uveitis, and history of cataract surgery demonstrated 81% sensitivity and 66% specificity in predicting presence of fibrous ingrowth.A history of ocular trauma, uveitis, retinal detachment or previous retinal surgery, glaucoma tube-shunt surgery, aphakia, and iris derangement are risks for detecting fibrous ingrowth among first-time keratoplasty recipients. Patients with these conditions should be monitored closely for corneal decompensation.</ABSTRACT>'}]
2024-01-02 00:26:15,608 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:15,609 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:15,611 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449258, Requested 1595. Please try again in 113ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:15,611 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Diagnostic properties of natriuretic peptides and opportunities for personalized thresholds for detecting heart failure in primary care.\nHeart failure (HF) is a prevalent syndrome with considerable disease burden, healthcare utilization and costs. Timely diagnosis is essential to improve outcomes. This study aimed to compare the diagnostic performance of B-type natriuretic peptide (BNP) and N-terminal proBNP (NT-proBNP) in detecting HF in primary care. Our second aim was to explore if personalized thresholds (using age, sex, or other readily available parameters) would further improve diagnostic accuracy over universal thresholds.A retrospective study was performed among patients without prior HF who underwent natriuretic peptide (NP) testing in the Amsterdam General Practice Network between January 2011 and December 2021. HF incidence was based on registration out to 90 days after NP testing. Diagnostic accuracy was evaluated with AUROC, sensitivity and specificity based on guideline-recommended thresholds (125\u202fng/L for NT-proBNP and 35\u202fng/L for BNP). We used inverse probability of treatment weighting to adjust for confounding.A total of 15,234 patients underwent NP testing, 6,870 with BNP (4.5\u202f% had HF), and 8,364 with NT-proBNP (5.7\u202f% had HF). NT-proBNP was more accurate than BNP, with an AUROC of 89.9\u202f% (95\u202f% CI: 88.4-91.2) vs. 85.9\u202f% (95\u202f% CI 83.5-88.2), with higher sensitivity (95.3 vs. 89.7\u202f%) and specificity (59.1 vs. 58.0\u202f%). Differentiating NP cut-off by clinical variables modestly improved diagnostic accuracy for BNP and NT-proBNP compared with a universal threshold.NT-proBNP outperforms BNP for detecting HF in primary care. Personalized instead of universal diagnostic thresholds led to modest improvement.</ABSTRACT>'}]
2024-01-02 00:26:15,623 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:15,624 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449146, Requested 1576. Please try again in 96ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:15,624 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Identification of novel biomarkers for retinopathy of prematurity in preterm infants by use of innovative technologies and artificial intelligence.\nRetinopathy of prematurity (ROP) is a leading cause of preventable vision loss in preterm infants. While appropriate screening is crucial for early identification and treatment of ROP, current screening guidelines remain limited by inter-examiner variability in screening modalities, absence of local protocol for ROP screening in some settings, a paucity of resources and an increased survival of younger and smaller infants. This review summarizes the advancements and challenges of current innovative technologies, artificial intelligence (AI), and predictive biomarkers for the diagnosis and management of ROP. We provide a contemporary overview of AI-based models for detection of ROP, its severity, progression, and response to treatment. To address the transition from experimental settings to real-world clinical practice, challenges to the clinical implementation of AI for ROP are reviewed and potential solutions are proposed. The use of optical coherence tomography (OCT) and OCT angiography (OCTA) technology is also explored, providing evaluation of subclinical ROP characteristics that are often imperceptible on fundus examination. Furthermore, we explore several potential biomarkers to reduce the need for invasive procedures, to enhance diagnostic accuracy and treatment efficacy. Finally, we emphasize the need of a symbiotic integration of biologic and imaging biomarkers and AI in ROP screening, where the robustness of biomarkers in early disease detection is complemented by the predictive precision of AI algorithms.</ABSTRACT>'}]
2024-01-02 00:26:15,625 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:15,626 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449132, Requested 1568. Please try again in 93ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:15,626 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>The effects of hypercortisolism on the frequency and magnitude of sleep EEG waves in patients with Cushing syndrome: A spectral analysis study.\nOur aim was to investigate the effects of endogenous chronic hypercortisolism on sleep electroencephalogram (EEG) and differences between the adrenocorticotropic hormone (ACTH)-dependent and independent Cushing Syndrome (CS) patients through a sleep spectral analysis program.A total of 32 patients diagnosed as having endogenous CS (12 ACTH-dependent and 20 ACTH-independent) and a control group comprising 16 healthy individuals were included in the study. Polysomnographic analysis was performed. Blood samples were collected at 08:00 AM for analysis of ACTH and basal cortisol, and at 00:00 AM for midnight cortisol levels. The frequency and power of the slow wave activity (SWA), theta, alpha, and beta waves of the first and last non-rapid eye movement (NREM) cycles were measured with a spectral analysis program.The CS patient group had higher SWA power, especially in the first NREM cycle. In the ACTH-dependent group, SWA maximum and mean power values were higher in the frontal channels in the first NREM, compared to the last NREM sleep stage (p<0.05).Cortisol has been found to be associated with SWA waves, making these waves higher in power, especially in the first NREM phase. This difference was much less pronounced in the final NREM sleep stage. The difference between the first and last NREM sleep stages with respect to the power of SWA in the frontal channel in the ACTH-dependent group suggests that not only cortisol but also high levels of ACTH affect the power of slow waves during sleep.</ABSTRACT>'}]
2024-01-02 00:26:15,641 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:15,642 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:15,642 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448959, Requested 1171. Please try again in 17ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:15,642 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Updates in the diagnosis and management of small-bowel Crohn\'s disease.\n</ABSTRACT>'}]
2024-01-02 00:26:15,660 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:15,661 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:15,666 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:15,667 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449330, Requested 1411. Please try again in 98ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:15,667 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Clostridioides difficile Infection in Pediatric Inflammatory Bowel Disease.\nChildren with inflammatory bowel disease (IBD) are at increased risk of C. difficile infection (CDI) and experience worse outcomes associated with an infection. In this article, we review recent research on the incidence, diagnosis, complications, and treatment options for CDI in children with IBD.Children with IBD have an elevated incidence of CDI, but their CDI risk does not associate with established risk factors in adults with IBD. Existing testing methodologies are inadequate at differentiating CDI from C. difficile colonization in children with IBD. Fecal microbiota transplantation offers a durable cure for recurrent CDI. CDI remains a frequent occurrence in children with IBD. Careful clinical monitoring should be used to diagnose CDI and patients with co-occurring IBD and CDI require careful surveillance for worse outcomes. Future research should explore the optimal diagnosis and treatment modalities in this unique patient population.</ABSTRACT>'}]
2024-01-02 00:26:15,674 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:15,676 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:15,678 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449240, Requested 1794. Please try again in 137ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:15,678 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Delayed oculomotor response associates with optic neuritis in youth with demyelinating disorders.\nImpairment in visual and cognitive functions occur in youth with demyelinating disorders such as multiple sclerosis, neuromyelitis optica spectrum disorder, and myelin oligodendrocyte glycoprotein antibody-associated disease. Quantitative behavioral assessment using eye-tracking and pupillometry can provide functional metrics for important prognostic and clinically relevant information at the bedside.Children and adolescents diagnosed with demyelinating disorders and healthy, age-matched controls completed an interleaved pro- and anti-saccade task using video-based eye-tracking and underwent spectral-domain optical coherence tomography examination for evaluation of retinal nerve fiber layer and ganglion cell inner plexiform layer thickness. Low-contrast visual acuity and Symbol Digit Modalities Test were performed for visual and cognitive functional assessments. We assessed saccade and pupil parameters including saccade reaction time, direction error rate, pupil response latency, peak constriction time, and peak constriction and dilation velocities. Generalized Estimating Equations were used to examine the association of eye-tracking parameters with optic neuritis history, structural metrics, and visual and cognitive scores.The study included 36 demyelinating disorders patients, aged 8-18 yrs. (75% F; median\xa0=\xa015.22 yrs., SD\xa0=\xa02.8) and 34 age-matched controls (65% F; median\xa0=\xa015.26 yrs., SD\xa0=\xa02.3). Surprisingly, pro- and anti-saccade performance was comparable between patients and controls, whereas pupil control was altered in patients. Oculomotor latency measures were strongly associated with the number of optic neuritis episodes, including saccade reaction time, pupil response latency, and peak constriction time. Peak constriction time was associated with both retinal nerve fiber layer and ganglion cell inner plexiform layer thickness. Pupil response latency and peak constriction time were associated with visual acuity. Pupil velocity for both constriction and dilation was associated with Symbol Digit Modalities Test scores.The strong associations between oculomotor measures with history of optic neuritis, structural, visual, and cognitive assessments in these cohorts demonstrates that quantitative eye-tracking can be useful for probing demyelinating injury of the brain and optic nerve. Future studies should evaluate their utility in discriminating between demyelinating disorders and tracking disease progression.</ABSTRACT>'}]
2024-01-02 00:26:15,679 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449247, Requested 1644. Please try again in 118ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:15,679 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Purtscher-like retinopathy in systemic lupus erythematosus: clinical features, risk factors and prognosis.\nPurtscher-like retinopathy (PLR) is a rare ocular manifestation in systemic lupus erythematosus (SLE) with poor prognosis, but its clear risk factors and treatment consensus are still lacking.To investigate the clinical features, risk factors and prognosis of PLR in SLE patients.A retrospective analysis was conducted on SLE patients with PLR admitted at Peking Union Medical College Hospital from 2013 to 2022. Clinical data, including demographic characteristics, lupus-related features, laboratory findings and ophthalmologic examinations, were collected and analyzed. The prognosis was evaluated based on best-corrected visual acuity and ophthalmologic outcomes.Seventeen SLE patients (32 eyes) diagnosed with PLR were included, along with a random selection of 100 SLE patients without retinopathy and 100 with retinal microvasculopathy as controls. Patients with PLR had a significantly younger age, a higher proportion of hemolytic anemia, a shorter duration of SLE, a higher SLE disease activity index-2000 (SLEDAI-2K) score, higher erythrocyte sedimentation rate (ESR) values and lower hemoglobin (HGB) values than the group without retinopathy (P\u2009<\u20090.05). They also had a significantly higher SLEDAI-2K score, higher ESR values and higher white blood cell values (P\u2009<\u20090.05) than the Microvasculopathy group. The majority of eyes (22/26, 84.62%) achieved stabilization at the last follow-up, with different therapeutic strategies, while a few (4/26, 15.38%) experienced complications or progression.This is the largest reported case series of PLR in SLE, which was associated with higher disease activity and poor visual prognosis. It was also associated with younger age, shorter SLE duration, concomitant hemolytic anemia, lower HGB and higher ESR value. Early recognition and prompt treatment are crucial for improving visual outcomes.</ABSTRACT>'}]
2024-01-02 00:26:15,690 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:15,715 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:15,716 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448642, Requested 1587. Please try again in 30ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:15,716 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Impact of sarcosine on diabetic retinopathy: Findings based on weighted gene co-expression network analysis and machine learning techniques.\nTo quantify the association between serum sarcosine and diabetic retinopathy (DR) using weighted gene co-expression network analysis (WGCNA).We measured serum metabolites in 69 pairs of type 2 diabetes (T2D) patients with and without DR matched by age, gender, body mass index\uff08BMI and HbA1c, using a propensity score matching-based approach. To identify modules and metabolites linked to DR, pathway analysis was performed using WGCNA, the Kyoto Encyclopedia of Genes and Genomes and Small-Molecule Pathway Database. The association of sarcosine with DR was estimated by restricted cubic spline and conditional logistic regression models. Its joint effects with covariates on DR were also extensively examined.With per interquartile range elevation of sarcosine, the adjusted odds ratio (AOR) of DR significantly decreased by 67% (AOR: 0.33, 95% confidence interval [CI]: 0.19-0.58). Similar results were also found in the tertile analysis. Compared with those in the first tertile of sarcosine, the AOR significantly decreased by 54% (AOR: 0.46, 95% CI: 0.18-1.17) and 78% (AOR: 0.22, 95% CI: 0.08-0.59) for subjects in the second and third tertiles, respectively. Compared with subjects with lower sarcosine and lower HDL-C levels, those with higher sarcosine and lower HDL-C levels had the lowest odds of DR (OR: 0.13, 95% CI: 0.04, 0.43).Serum sarcosine was inversely related to DR, especially in T2D patients with insufficient HDL-C. This study provides insights on a possible novel target for DR precision prevention and control, as well as a better understanding of the DR mechanism.</ABSTRACT>'}]
2024-01-02 00:26:15,730 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:15,732 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448643, Requested 1553. Please try again in 26ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:15,732 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Updates on the diagnosis and management of cryptogenic multifocal ulcerative stenosing enteropathy (CMUSE) and non-steroidal enteropathy.\nCrohn\'s disease and coeliac disease are well-known to induce ulcerations in the small-bowel. However, there is a group of very rare chronic ulcerative conditions of the small intestine that has emerged from the intestinal black box nearly 70 years ago, and that has gained interest with the advent of small-bowel capsule endoscopy and device-assisted enteroscopy. These distinct ulcerative enteropathies have come to our attention, and continue to reveal their aetiology and treatment options. Two distinct entities, called cryptogenic multifocal ulcerative stenosing enteritis/enteropathy (CMUSE) and chronic nonspecific multiple ulcers of the small intestine (CNSU) are gaining more clinical attention. CMUSE was first reported in Europe, whereas CNSU was exclusively diagnosed in Japanese patients. With the identification of susceptibility genes impacting prostaglandin metabolism, CMUSE and CNSU have become two distinct pathologies within the group of prostaglandin-associated enteropathies, to be differentiated from medication-induced enteropathies, especially non-steroidal anti-inflammatory drugs (NSAID)-induced enteropathy with similar intestinal ulcerations due to interference with prostaglandin metabolism. The current review provides an historical overview of CMUSE and CNSU publications, in addition to the currently available diagnostic and treatment options, and how to differentiate these rare enteropathies from NSAID-induced enteropathy.</ABSTRACT>'}]
2024-01-02 00:26:15,736 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:15,737 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:15,745 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:15,751 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449908, Requested 1789. Please try again in 226ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:15,751 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Associations of cardiovascular health assessed by life\'s essential 8 with diabetic retinopathy and mortality in type 2 diabetes.\nVascular complications are the leading causes of reduced life quality and mortality in type 2 diabetes mellitus (T2DM). Life\'s Essential 8 (LE8) is a newly modified measurement of cardiovascular health (CVH) by American Heart Association (AHA). Promoting CVH has been previously shown to improve the prognosis of T2DM. However, studies regarding the effects of CVH by LE8 on diabetic retinopathy (DR), a major microvascular complication, and death from the cardiovascular and overall causes in T2DM are currently lacking. This study aimed to investigate these associations thus providing preliminary evidence.A total of 3192 participants from the National Health and Nutrition Examination Survey (NHANES) were included in the final analysis. Records of mortality during follow-up were obtained by linking to the National Death Index. The multivariable logistic regression and Cox proportional hazard regression with restricted cubic splines were used to estimate the associations. Subgroup analyses were performed to examine the effects of gender, age, and duration of T2DM.648 individuals had DR at baseline. During a median follow-up of 76 months, 645 overall deaths (incidence per 1000 person-years, 26.53%; 95% confidence interval (CI), 26.50-26.56) were ascertained, including 216 from cardiovascular causes (incidence per 1000 person-years, 8.96%; 95% CI, 8.94-8.98). The multivariable-adjusted odds ratio (OR) per 100-point increase of LE8 was 0.80 (95% CI, 0.71-0.90) for DR, and participants with high levels of LE8 were associated with 47% risk reduction (OR, 0.53; 95% CI, 0.40-0.70). The multivariable-adjusted hazard ratio (HR) per 100-point increase of LE8 was 0.71 (95% CI, 0.62-0.81) and 0.68 (95% CI, 0.58-0.85) for all-cause mortality and cardiovascular mortality, respectively. Similar patterns of inverse associations were observed in participants with moderate and high levels of LE8 for all-cause and cardiovascular mortality. Notably, stronger associations between LE8 and mortality were discovered in participants below 60 years (P\xa0<\xa00.05 for interaction). Moreover, LE8 was correlated with all-cause mortality in a linear way (P for nonlinear=0.32).The AHA\'s newly prompted LE8 was strongly and inversely associated with the risk of DR, all-cause mortality, and cardiovascular-specific mortality in T2DM. LE8 may be a feasible and effective approach in the tertiary prevention of T2DM.</ABSTRACT>'}]
2024-01-02 00:26:15,752 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449885, Requested 1774. Please try again in 221ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:15,753 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Identification of Fangji Huangqi Tang as a potential herbal formula for Sjogren syndrome treatment via network pharmacology and experimental validation.\nFangji Huangqi Tang (FHT) is a well-known Chinese herbal formula that is prescribed as treatment for rheumatoid diseases. In this study, we aimed to investigate the potential therapeutic targets, efficacy, and safety of FHT in the treatment of Sjogren\'s syndrome (SS). The Gene Expression Omnibus (GEO) database was used to screen differentially expressed genes (DEGs) in SS. Further, gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were performed to explore the potential biological functions of the DEGs. Subsequently, an FHT-herb-active compound-target network was constructed to identify the relationship between the active compounds in FHT and the related targets. Then, enrichment analysis involving the DEGs and protein-protein interaction (PPI) network analysis were performed to analyze the biological functions of potential targets and screen hub genes. Further, molecular docking was employed to verify the binding affinity between the active compounds and the hub targets, and in vivo experiments involving NOD/LtJ mice were conducted to verify the therapeutic effects of FHT on SS-like symptoms. Finally, inhibition of PIK3CK/Akt pathway by FHT was validated by WB and rt-qPCR. A total of 1836 DEGs were identified in SS based on the GSE159574 dataset, and 114 targets of the active compounds in FHT were screened. Further, via network pharmacology analysis and molecular docking, six active compounds and five hub targets were obtained, and enrichment analysis showed that the anti-SS effect of FHT was predominantly associated with immune cells, such as T cells and neutrophils. In vivo, FHT effectively reduced lymphocyte infiltration foci, increased saliva flow rate, and inhibited increases in the levels of SS-related autoantibodies (anti-SSA and anti-SSB). Furthermore, the biosafety of FHT was verified via the serological examination of liver and kidney function. WB and rt-qPCR analysis confirmed that FHT could inhibit the expression of PIK3CG and the activation of PIK3CG/Akt pathway. Via network pharmacological analysis, molecular docking, and in vivo verification, we demonstrated the multicomponent and multitarget characteristics of FHT in SS treatment, thereby providing novel insights into the pathogenesis of SS and the therapeutic targets of FHT for SS.</ABSTRACT>'}]
2024-01-02 00:26:15,754 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449846, Requested 1641. Please try again in 198ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:15,754 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Development and Validation of the Low Vision Severely Constricted Peripheral Eyesight (LV-SCOPE) Questionnaire.\nTo develop and validate a novel patient-reported outcome (PRO) measure to assess vision-related functioning in individuals with severe peripheral field loss (PFL).Prospective outcome measure development/validation study.A 127-item questionnaire was developed based on a prior qualitative interview study. A total of 116 participants with severe PFL due to retinitis pigmentosa (RP) or glaucoma were recruited at the Kellogg Eye Center and completed the Likert-scaled telephone-administered questionnaire. Included participants had a horizontal extent of their visual field <20 degrees (RP) or a mixed or generalized stage 4 to 5 defect using the Enhanced Glaucoma Staging System (glaucoma) in the better seeing eye (or in 1 eye if the fellow eye visual acuity was <20/200). Response data were analyzed using exploratory factor analysis and Rasch modeling. Poorly functioning items were eliminated, confirmatory factor analysis was used to ensure scale unidimensionality, and the model was refit to produce the final instrument.The final Low Vision Severely Constricted Peripheral Eyesight (LV-SCOPE) Questionnaire contains 53 items across 6 domains: mobility, object localization, object recognition, reading, social functioning, and technology. There were 74 items removed because of high missingness, poor factor loadings, low internal consistency, high local dependency, low item information, item redundancy, or differential item functioning. Using Rasch item calibrations, person ability scores could be calculated for each of the 6 unidimensional LV-SCOPE domains with good test-retest stability.The LV-SCOPE Questionnaire provides a valid and reliable measure of vision-related functioning across 6 key domains relevant to individuals with severe PFL. Findings support the clinical utility of this psychometrically valid instrument.</ABSTRACT>'}]
2024-01-02 00:26:15,766 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:15,766 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:15,767 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:15,770 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449607, Requested 1421. Please try again in 137ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:15,770 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>[The role of Mller cells in the formation and development of macular hole].\nMller cells are important glial cells in the retina, which play important roles in maintaining the stability of the retina by mechanical support, homeostasis, and physiological metabolism, as well as protecting photoreceptor cells and retinal pigment epithelial cells. The degeneration and destruction of Mller cells are often accompanied by various retinal diseases, and the function of Mller cells is changed under pathological conditions. Based on the summary of the morphology, distribution and function of Mller cells, this article analyzes the different manifestations and changes of Mller cells in different stages of macular hole and the closely related mechanisms, aiming to clarify the role of Mller cells in the formation and development of macular hole and to provide reference for the prediction of disease progression and guidance of treatment.(This article was published ahead of print on the official website of Chinese Journal of Ophthalmology on Augest 28, 2023).</ABSTRACT>'}]
2024-01-02 00:26:15,771 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449576, Requested 1853. Please try again in 190ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:15,771 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Biomarkers and cardiovascular events in patients with stable coronary disease in the ISCHEMIA Trials.\nBiomarkers may improve prediction of cardiovascular events for patients with stable coronary artery disease (CAD), but their importance in addition to clinical tests of inducible ischemia and CAD severity is unknown.To evaluate the prognostic value of multiple biomarkers in stable outpatients with obstructive CAD and moderate or severe inducible ischemia.The ISCHEMIA and ISCHEMIA CKD trials randomized 5,956 participants with CAD to invasive or conservative management from July 2012 to January 2018; 1,064 participated in the biorepository.Primary outcome was cardiovascular death, myocardial infarction (MI), or hospitalization for unstable angina, heart failure, or resuscitated cardiac arrest. Secondary outcome was cardiovascular death or MI. Improvements in prediction were assessed by cause-specific hazard ratios (HR) and area under the receiver operating characteristics curve (AUC) for an interquartile increase in each biomarker, controlling for other biomarkers, in a base clinical model of risk factors, left ventricular ejection fraction (LVEF) and ischemia severity. Secondary analyses were performed among patients in whom core-lab confirmed severity of CAD was ascertained by computed cardiac tomographic angiography (CCTA).Baseline levels of interleukin-6 (IL-6), high sensitivity troponin T (hsTnT), growth differentiation factor 15 (GDF-15), N-terminal pro-B-type natriuretic peptide (NT-proBNP), lipoprotein a (Lp[a]), high sensitivity C-reactive protein (hsCRP), Cystatin C, soluble CD 40 ligand (sCD40L), myeloperoxidase (MPO), and matrix metalloproteinase 3 (MMP3).Among 757 biorepository participants, median (IQR) follow-up was 3 (2-5) years, age was 67 (61-72) years, and 144 (19%) were female; 508 had severity of CAD by CCTA available. In an adjusted multimarker model with hsTnT, GDF-15, NT-proBNP and sCD40L, the adjusted HR for the primary outcome per interquartile increase in each biomarker was 1.58 (95% CI 1.22, 2.205), 1.60 (95% CI 1.16, 2.20), 1.61 (95% 1.22, 2.14), and 1.46 (95% 1.12, 1.90), respectively. The adjusted multimarker model also improved prediction compared with the clinical model, increasing the AUC from 0.710 to 0.792 (P < .01) and 0.714 to 0.783 (P < .01) for the primary and secondary outcomes, respectively. Similar findings were observed after adjusting for core-lab confirmed atherosclerosis severity.Among ISCHEMIA biorepository participants, biomarkers of myocyte injury/distension, inflammation, and platelet activity improved cardiovascular event prediction in addition to risk factors, LVEF, and assessments of ischemia and atherosclerosis severity. These biomarkers may improve risk stratification for patients with stable CAD.</ABSTRACT>'}]
2024-01-02 00:26:15,772 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449596, Requested 1365. Please try again in 128ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:15,772 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Therapeutic targeting of the complement system in ocular disease.\nThe complement system is involved in the pathogenesis of several ocular diseases, providing a rationale for the investigation of complement-targeting therapeutics for these conditions. Dry age-related macular degeneration, as characterised by geographic atrophy (GA), is currently the most active area of research for complement-targeting therapeutics, with a complement C3 inhibitor approved in the United States earlier this year marking the first approved therapy for GA. This review discusses the role of complement in ocular disease, provides an overview of the complement-targeting agents currently under development for ocular conditions, and reflects on the lessons that can be learned from the preclinical investigations and clinical trials conducted in this field to date.</ABSTRACT>'}]
2024-01-02 00:26:15,788 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:15,790 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449457, Requested 1503. Please try again in 128ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:15,790 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Human Retinal Organoids in Therapeutic Discovery: A Review of Applications.\nHuman embryonic stem cells (hESCs)- and induced pluripotent stem cells (hiPSCs)-derived retinal organoids (ROs) are three-dimensional laminar structures that recapitulate the developmental trajectory of the human retina. The ROs provide a fascinating tool for basic science research, eye disease modeling, treatment development, and biobanking for tissue/cell replacement. Here we review the previous studies that paved the way for RO technology, the two most widely accepted, standardized protocols to generate ROs, and the utilization of ROs in medical discovery. This review is conducted from the perspective of basic science research, transplantation for regenerative medicine, disease modeling, and therapeutic development for drug screening and gene therapy. ROs have opened avenues for new technologies such as assembloids, coculture with other organoids, vasculature or immune cells, microfluidic devices (organ-on-chip), extracellular vesicles for drug delivery, biomaterial engineering, advanced imaging techniques, and artificial intelligence (AI). Nevertheless, some shortcomings of ROs currently limit their translation for medical applications and pose a challenge for future research. Despite these limitations, ROs are a powerful tool for functional studies and therapeutic strategies for retinal diseases.</ABSTRACT>'}]
2024-01-02 00:26:15,800 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:15,801 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449497, Requested 1464. Please try again in 128ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:15,801 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Susac syndrome: neurological update (clinical features, long-term observational follow-up and management of sixteen patients).\nSusac syndrome is a likely autoimmune microangiopathy affecting the brain, retina and inner ear. Due to the rarity of this condition, diagnosis and treatment can be challenging. Diagnosis is based on the presence of the clinical triad of central nervous system dysfunction, branch retinal artery occlusions and sensorineural hearing loss. Typical MRI findings of callosal and peri-callosal lesions may assist in diagnosis. Clinical course can be monophasic, polycyclic or chronic continuous. It is important to look out for red flags to attain an accurate diagnosis and follow a therapeutic algorithm based on severity of the disease and response to treatment. Patients are treated with steroids and immunosuppressive agents with a variable response. Early aggressive treatment especially in severe cases, may help in preventing relapses and morbidity/disability. This study highlights important diagnostic features and proposes a treatment algorithm based on clinical experience from management of 16 patients from 2 neuroscience centres in the UK since 2007, who were followed up over a long period of 3-15\xa0years.</ABSTRACT>'}]
2024-01-02 00:26:15,834 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:15,836 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:15,837 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449380, Requested 1590. Please try again in 129ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:15,837 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Comparison of two objective methods for measuring postoperative toric intraocular lens orientation under the natural pupil.\nTo evaluate and compare the accuracy of iTrace and CASIA2 in measuring the postoperative orientation of toric intraocular lens (IOL) without mydriasis.Tianjin Medical University Eye Hospital, Tianjin, China.Prospective cohort study.Patients with SN6AT toric IOLs implanted after cataract surgery were enrolled. 1 month after surgery, the toric IOL orientation were measured by iTrace and CASIA2 in non-mydriatic, semi-dark conditions. Then, the toric axis was directly reviewed using the slit-lamp under full mydriasis. Axis measurement differences between each of the 2 devices and the slit-lamp, described as their relative differences (RDs), were calculated and compared. The percentage of RDs within 5 degrees, within 10 degrees and greater than 30 degrees were analyzed.77 eyes of 70 patients were included. Generally, the mean toric axis measurement RDs of CASIA2 and iTrace were 9.24  10.53 degrees and 13.89  15.47 degrees respectively ( P = .04). For CASIA2 (72 eyes), 54.17% (39), 72.22% (52), and 4.17% (3) of eyes had RDs within 5 degrees, within 10 degrees and greater than 30 degrees, compared with 40.00% (28), 61.43% (43) and 12.86% (9) for iTrace (70 eyes). The 95% limits of agreements of CASIA2 with slit-lamp was narrower than that of iTrace with slit-lamp. The median RD of CASIA2 was significantly smaller in eyes with pupil \u22654 mm under dark condition compared with eyes with pupil <4 mm ( P = .03).CASIA2 demonstrates greater precision in measuring toric IOL orientation under non-mydriatic conditions compared with iTrace. Moreover, the accuracy of CASIA2 is enhanced in cases of pupil >4 mm.</ABSTRACT>'}]
2024-01-02 00:26:15,839 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:15,839 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:15,840 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449305, Requested 1512. Please try again in 108ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:15,840 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>The evolving therapeutic landscape of diabetic retinopathy.\nDiabetic retinopathy (DR) is a leading cause of blindness worldwide. Recent decades have seen rapid progress in the management of diabetic eye disease, evolving from pituitary ablation to photocoagulation and intravitreal pharmacotherapy. The advent of effective intravitreal drugs inhibiting vascular endothelial growth factor (VEGF) marked a new era in DR therapy. Sustained innovation has since produced several promising biologics targeting angiogenesis, inflammation, oxidative stress, and neurodegeneration.This review surveys traditional, contemporary, and emerging therapeutics for DR, with an emphasis on anti-VEGF therapies, receptor tyrosine kinase inhibitors, angiopoietin-Tie2 pathway inhibitors, integrin pathway inhibitors, gene therapy \'biofactory\' approaches, and novel systemic therapies. Some of these investigational therapies are being delivered intravitreally via sustained release technologies for extended durability. Other investigational agents are being delivered non-invasively via topical and systemic routes. These strategies hold promise for early and long-lasting treatment of DR.The evolving therapeutic landscape of DR is rapidly expanding our toolkit for the effective and durable treatment of blinding eye disease. However, further research is required to validate the efficacy of novel therapeutics and characterize real world outcomes.</ABSTRACT>'}]
2024-01-02 00:26:15,840 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449334, Requested 1160. Please try again in 65ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:15,840 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Bartonella Neuroretinitis.\n</ABSTRACT>'}]
2024-01-02 00:26:15,841 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449308, Requested 1300. Please try again in 81ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:15,841 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Retinopathy secondary to flare-up of systemic lupus erythematosus.\nSystemic lupus erythematosus (SLE) can have widespread ocular manifestations, and posterior segment involvement may be associated with poor visual outcome. We report a clinical flare-up of SLE presenting as combined vascular occlusion in one eye and drusen-like deposits, which is a newly described entity in both eyes. As an ophthalmologist, a knowledge of such presentations helps us identify and possibly help the rheumatologist titrate treatment accordingly, to prevent severe life-threatening systemic complications.</ABSTRACT>'}]
2024-01-02 00:26:15,861 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:15,862 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449222, Requested 1558. Please try again in 104ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:15,862 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Hyaluronic acid/inulin-based nanocrystals with an optimized ratio of indigo and indirubin for combined ulcerative colitis therapy via immune and intestinal flora regulation.\nIndigo (IND) and indirubin (INB) have demonstrated a synergistic effect in treating ulcerative colitis at a ratio of 7.5:1. However, the colon mucus layer, a critical physiological barrier against external threats, is also a biological barrier, limiting the potential for effective drug delivery to the lamina propria for regulating inflammatory cells. Inspired by the potential of Hyaluronic acid (HA), to enhance cellular uptake by inflammatory cells, and Pluronic F127 (F127), known for overcoming the mucus barrier, this study innovatively developed INB/IND nanosuspensions by co-modifying with F127 and HA. Moreover, inulin serves a dual purpose as a spray protective agent and a regulator of intestinal flora. Therefore, it was incorporated into INB/IND nanosuspensions for subsequent spray drying, resulting in the preparation of INB/IND nanocrystals (INB/IND-NC). The mucus penetration of INB/IND-NC was 24.30 times that of the control group. Besides, INB/IND-NC exhibited enhanced cellular uptake properties proximately twice that of Raw INB/IND. Importantly, INB/IND-NC exhibited improved therapeutic efficacy in DSS-induced mice by regulating the expression of cytokines, regulating immune responses via downregulating the expression of macrophages, neutrophils, and dendritic cells and maintaining intestinal flora homeostasis. Our study provides a new perspective for applying natural products for treating inflammatory diseases.</ABSTRACT>'}]
2024-01-02 00:26:15,863 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:15,865 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449120, Requested 1611. Please try again in 97ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:15,865 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Left atrial appendage flow velocity predicts occult atrial fibrillation in cryptogenic stroke: a CRYPTON-ICM registry.\nAn insertable cardiac monitor (ICM) and transesophageal echocardiography (TEE) are useful for investigating potential embolic sources in cryptogenic stroke, of which atrial fibrillation (AF) is a critical risk factor for stroke recurrence. The association of left atrial appendage flow velocity (LAA-FV) on TEE with ICM-detected AF is yet to be elucidated.CRYPTON-ICM (CRYPTOgenic stroke evaluation in Nippon using ICM) is a multicenter registry of cryptogenic stroke with ICM implantation, and patients whose LAA-FV was evaluated on TEE were enrolled. The primary outcome was the detection of AF (>\u20092\xa0min) on ICM. Receiver operating characteristic (ROC) curve analysis was performed to determine the optimal cut-off of LAA-FV, and factors associated with ICM-detected AF were assessed.A total of 307 patients (age 66.6\u2009\u200912.3\xa0years; 199 males) with median follow-up of 440 (interquartile range 169-726) days were enrolled; AF was detected in 101 patients. The lower-tertile LAA-FV group had older age, more history of congestive heart failure, and higher levels of B-type natriuretic peptide (BNP) or N-terminal proBNP (all P\u2009<\u20090.05). On ROC analysis, LAA-FV\u2009<\u200937.5\xa0cm/s predicted ICM-detected AF with sensitivity of 26.7% and specificity of 92.2%. After adjustment for covariates, the lower tertile of LAA-FV (hazard ratio [HR], 1.753 [1.017-3.021], P\u2009=\u20090.043) and LAA-FV\u2009<\u200937.5\xa0cm/s (HR 1.987 [1.240-3.184], P\u2009=\u20090.004) predicted ICM-detected AF.LAA-FV\u2009<\u200937.5\xa0cm/s predicts AF. TEE is useful not only to evaluate potential embolic sources, but also for long-term detection of AF on ICM by measuring LAA-FV in cryptogenic stroke. http://www.umin.ac.jp/ctr/ (UMIN000044366).</ABSTRACT>'}]
2024-01-02 00:26:15,866 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:15,867 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449005, Requested 1523. Please try again in 70ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:15,867 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Development of experimental treatments for patients with retinitis pigmentosa.\nRetinitis pigmentosa (RP) is a group of inherited diseases that lead to degeneration of the retina and decreased vision. The World Health Organization reports around 1,300 million people affected by some type of visual impairment worldwide. The prevalence is 1 in every 4000 inhabitants and it is the first cause of blindness of genetic origin, frequent in men with a percentage of 60% and 40% in women. There is a lack of information on this pathology in the world, mainly on the existing treatments for this disease, so this bibliographic review aims to update the existing or under-study treatments and inform the limitations of each of these therapies. This review of scientific literature was carried out by consulting databases such as PubMed and Web of science, the search will be limited to articles from the years 2018-2022. There are several types of therapy in studies: gene therapy, transcorneal electrical stimulation, use of neuroprotectors, optogenic therapy, stem cell transplants and oligonucleotide therapy, which will be discussed in this article, both their benefits and the existing barriers in each treatment experimental. In conclusion, each of these therapies promises a viable treatment in the future for selective groups of people with retinitis pigmentosa, however, some therapies have shown benefit at the beginning of the disease, losing their efficacy in the long term.</ABSTRACT>'}]
2024-01-02 00:26:15,877 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:15,880 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448895, Requested 1531. Please try again in 56ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:15,880 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>An update on the safety of long-term vedolizumab use in inflammatory bowel disease.\nVedolizumab (Entyvio) is a humanized monoclonal antibody that disrupts the interaction between \u03b14\u03b27 integrin on circulating T-lymphocytes and MAdCAM-1 on the vascular endothelium to prevent their egress to sites of gut inflammation. It has proven therapeutic efficacy for the treatment of moderate-to-severe Crohn\'s disease, ulcerative colitis, and pouchitis.This narrative review assesses the safety profile of vedolizumab from the registration trial programs, open-label extension studies, observational real-world data, and pooled safety analyses. This includes an evaluation of the long-term overall safety in special populations typically underrepresented in clinical trials.Vedolizumab is an effective therapy for inflammatory bowel disease with a well-established safety profile. No unexpected long-term safety signals have been identified. Safety data in pregnancy, in pediatric and elderly populations, in patients undergoing surgery, and in patients with a prior history of cancer are reassuring. Due to its safety merits, we propose that vedolizumab is an excellent candidate for advanced combination treatment with an anti-cytokine approach using another biologic or novel small molecule inhibitor. This is important in patients with medically refractory IBD, in patients at high risk of developing disease-related complications, or in patients with concomitant uncontrolled immune-mediated inflammatory diseases.</ABSTRACT>'}]
2024-01-02 00:26:15,889 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:15,891 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448747, Requested 1655. Please try again in 53ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:15,891 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Inflammatory Bowel Disease With Chronic Kidney Disease and Acute Kidney Injury.\nIt remains unclear whether inflammatory bowel disease is associated with long-term risk of chronic kidney disease (CKD) and acute kidney injury (AKI) in the general population.A total of 417,302 participants, including 2,940 patients with ulcerative colitis and 1,261 patients with Crohn\'s disease, without previous CKD and AKI at baseline (2006-2010) from the UK Biobank were included. The study outcomes included incident CKD and AKI, ascertained by self-report data and data linkage with primary care, hospital admissions, and death registry records. Analysis was conducted in 2022.During a median follow-up of 12.5 years, 13,564 and 14,331 participants developed CKD and AKI, respectively. Compared with the hazard ratio for non-inflammatory bowel diseases, the hazard ratios for CKD and AKI related to inflammatory bowel diseases were 1.57 (95% CI=1.37, 1.79) and 1.96 (95% CI=1.74, 2.20) after adjustments for age, sex, and race and were 1.32 (95% CI=1.15, 1.51) and 1.70 (95% CI=1.51, 1.91) after further adjustments for biological, behavioral, and socioeconomic factors in addition to mental health and self-rated health. Similar results were found for patients with Crohn\'s disease (adjusted hazard ratio=1.38 (95% CI=1.09, 1.75) for CKD and 1.62 [95% CI=1.30, 2.02] for AKI) and those with ulcerative colitis (adjusted hazard ratio=1.29 (95% CI=1.09, 1.51) for CKD and 1.71 [95% CI=1.49, 1.97] for AKI) in the fully adjusted models. Genetic risks of kidney diseases did not significantly affect the association of inflammatory bowel disease with incident CKD and AKI (both p-interactions>0.05). The association between inflammatory bowel disease and the risk of incident CKD (p-interaction=0.010) and AKI (p-interaction<0.001) were stronger in younger participants than in older participants.Inflammatory bowel disease was associated with higher risks for CKD and AKI, independent of genetic risks of kidney diseases.</ABSTRACT>'}]
2024-01-02 00:26:15,892 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:15,896 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448725, Requested 1648. Please try again in 49ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:15,896 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study.\nThe QUASAR Phase 2b Induction Study evaluated the efficacy and safety of guselkumab, an interleukin-23p19 subunit antagonist, in patients with moderately to severely active ulcerative colitis (UC) with prior inadequate response and/or intolerance to corticosteroids, immunosuppressants, and/or advanced therapy.In this double-blind, placebo-controlled, dose-ranging, induction study, patients were randomized (1:1:1) to receive intravenous guselkumab 200 or 400 mg or placebo at weeks 0/4/8. The primary endpoint was clinical response (compared with baseline, modified Mayo score decrease \u226530% and \u22652 points, rectal bleeding subscore \u22651-point decrease or subscore of 0/1) at week 12. Guselkumab and placebo week-12 clinical nonresponders received subcutaneous or intravenous guselkumab 200 mg, respectively, at weeks 12/16/20 (uncontrolled study period).The primary analysis population included patients with baseline modified Mayo scores \u22655 and \u22649 (intravenous guselkumab 200 mg, n\xa0= 101; 400 mg, n\xa0= 107; placebo, n\xa0= 105). Week-12 clinical response percentage was greater with guselkumab 200 mg (61.4%) and 400 mg (60.7%) vs placebo (27.6%; both P < .001). Greater proportions of guselkumab-treated vs placebo-treated patients achieved all major secondary endpoints (clinical remission, symptomatic remission, endoscopic improvement, histo-endoscopic mucosal improvement, and endoscopic normalization) at week 12. Among guselkumab week-12 clinical nonresponders, 54.3% and 50.0% of patients in the 200- and 400-mg groups, respectively, achieved clinical response at week 24. Safety was\xa0similar among guselkumab and placebo groups.Guselkumab intravenous induction was effective vs placebo in patients with moderately to severely active UC. Guselkumab was safe, and efficacy and safety were similar between guselkumab dose groups.gov number: NCT04033445.</ABSTRACT>'}]
2024-01-02 00:26:15,901 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:15,901 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:15,903 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448630, Requested 1692. Please try again in 42ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:15,903 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Rare genetic forms of obesity in childhood and adolescence, a comprehensive review of their molecular mechanisms and diagnostic approach.\nObesity represents a major health problem in the pediatric population with an increasing prevalence worldwide, associated with cardiovascular and metabolic disorders, and due to both genetic and environmental factors. Rare forms of obesity are mostly monogenic, and less frequently due to polygenic influence. Polygenic form of obesity is usually the common obesity with single gene variations exerting smaller impact on weight and is commonly non-syndromic.Non-syndromic monogenic obesity is associated with variants in single genes typically related to the hypothalamic leptin-melanocortin signalling pathway, which plays a key role in hunger and satiety regulation, thus body weight control. Patients with these genetic defects usually present with hyperphagia and early-onset severe obesity. Significant progress in genetic diagnostic testing has recently made for early identification of patients with genetic obesity, which guarantees prompt intervention in terms of therapeutic management of the disease. What is Known:  Obesity represents a major health problem among children and adolescents, with an increasing prevalence worldwide, associated with cardiovascular disease and metabolic abnormalities, and it can be due to both genetic and environmental factors.  Non-syndromic monogenic obesity is linked to modifications in single genes usually involved in the hypothalamic leptin-melanocortin signalling pathway, which plays a key role in hunger and satiety regulation. What is New:  The increasing understanding of rare forms of monogenic obesity has provided significant insights into the genetic causes of pediatric obesity, and our current knowledge of the various genes associated with childhood obesity is rapidly expanding.  A useful diagnostic algorithm for early identification of genetic obesity has been proposed, which can ensure a prompt intervention in terms of therapeutic management of the disease and an early prevention of the development of associated metabolic conditions.</ABSTRACT>'}]
2024-01-02 00:26:15,904 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448552, Requested 1661. Please try again in 28ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:15,904 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Mirikizumab-Induced Transcriptome Changes in Ulcerative Colitis Patient Biopsies at Week 12 Are Maintained Through Week 52.\nMirikizumab, an anti-interleukin-23p19 monoclonal antibody, demonstrated efficacy in phase 2 and 3 randomized clinical trials of patients with moderate-to-severe ulcerative colitis (UC). Previous results have shown that 12 weeks of mirikizumab treatment downregulated transcripts associated with UC disease activity and tumor necrosis factor inhibitor resistance. We assessed week-52 gene expression from week-12 responders receiving mirikizumab or placebo.In the phase 2 AMAC study (NCT02589665), mirikizumab-treated patients achieving week-12 clinical response were rerandomized to mirikizumab 200 mg subcutaneous every 4 or 12 weeks through week 52 (N = 31). Week-12 placebo responders continued placebo through week 52 (N = 7). The limma R package clustered transcript changes in colonic mucosa biopsies from baseline to week 12 into differentially expressed genes (DEGs). Among DEGs, similarly expressed genes (DEGSEGs) maintaining week-12 expression through week 52 were identified.Of 89 DEGSEGs, 63 (70.8%) were present only in mirikizumab induction responders, 5 (5.6%) in placebo responders, and 21 (23.6%) in both. Week-12 magnitudes and week-52 consistency of transcript changes were greater in mirikizumab than in placebo responders (log2FC > 1). DEGSEG clusters (from 84 DEGSEGs identified in mirikizumab and mirikizumab/placebo responders) correlated to modified Mayo score (26/84 with Pearson correlation coefficient [PCC] >0.5) and Robarts Histopathology Index (55/84 with PCC >0.5), sustained through week 52.Mirikizumab responders had broader, more sustained transcriptional changes of greater magnitudes at week 52 vs placebo. Mirikizumab responder DEGSEGs suggest a distinct molecular healing pathway associated with mirikizumab interleukin-23 inhibition. The cluster\'s correlation with disease activity illustrates relationships between clinical, endoscopic, and molecular healing in UC.</ABSTRACT>'}]
2024-01-02 00:26:15,910 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:15,912 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:15,913 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448633, Requested 1439. Please try again in 9ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:15,913 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Infantile onset encephalomyopathy, retinopathy, optic atrophy, and mitochondrial DNA depletion associated with a novel pathogenic DHX16 variant.\nWe studied a patient with mitochondrial DNA depletion in skeletal muscle and a multiorgan phenotype, including fatal encephalomyopathy, retinopathy, optic atrophy, and sensorineural hearing loss. Instead of pathogenic variants in the mitochondrial maintenance genes, we identified previously unpublished variant in DHX16 gene, a de novo heterozygous c.1360C>T (p. Arg454Trp). Variants in DHX16 encoding for DEAH-box RNA helicase have previously been reported only in five patients with a phenotype called as neuromuscular oculoauditory syndrome including developmental delay, neuromuscular symptoms, and ocular or auditory defects with or without seizures. We performed functional studies on patient-derived fibroblasts and skeletal muscle revealing, that the DHX16 expression was decreased. Clinical features together with functional data suggest, that our patient\'s disease is associated with a novel pathogenic DHX16 variant, and mtDNA depletion could be a secondary manifestation of the disease.</ABSTRACT>'}]
2024-01-02 00:26:15,913 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448530, Requested 1604. Please try again in 17ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:15,913 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Severity of Nocturia and Constipation in Patients With Ulcerative Colitis.\nTo investigate the association between nocturia and constipation in patients with ulcerative colitis (UC). Constipation has recently been recognized as an important symptom in patients with UC. Although nocturia has been associated with constipation in the general population, the association between nocturia and constipation in UC patients is uncertain.Consecutive series of 290 Japanese patients with UC, Information on constipation, nocturia, and lifestyle habits was obtained using self-administered questionnaires. The definition of constipation was based on Rome I criteria and/or current medication for constipation. Patients were divided into three groups based on nighttime urination: (1) no nocturia, (2) mild nocturia (nocturnal urination - one), and (3) serious nocturia (nocturnal urination - two or more). Multivariate logistic regression was used to evaluate the association between nocturia and constipation.Among all of the UC patients, the prevalence of mild nocturia, serious nocturia, and constipation was 35.2%, 26.9%, and 12.4%, respectively. The prevalence of constipation in the none, mild, and serious nocturia groups was 8.2%, 10.8%, and 20.5%, respectively. After adjustment for confounders such as age, sex, current drinking, current smoking, body mass index, and steroid use, nocturia severity was independently and positively associated with constipation (adjusted odds ratio for mild nocturia: 1.55 [95% confidence interval: 0.57-4.28], serious nocturia: 3.19 [95% confidence interval: 1.09-9.81], P for trend=.035).The severity of nocturia is positively associated with constipation, and physicians should consider the interrelationships between nocturia and constipation in managing UC patients.</ABSTRACT>'}]
2024-01-02 00:26:15,922 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:15,931 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:15,931 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449666, Requested 1588. Please try again in 167ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:15,932 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Cell Division Control Protein 42 Facilitates Diabetic Retinopathy Progression by Activating the MEK/ERK Pathway.\nCell division control protein 42 (CDC42) modulates insulin secretion and angiogenesis to participate in the pathology of diabetic complications and retinal vascular-associated diseases. This study intended to explore the role of CDC42 in the progression of diabetic retinopathy, and the underlying mechanism. Human retinal microvascular endothelial cells (hRMECs) were cultured in 5.5 mM glucose (normal glucose) or 25 mM glucose (high glucose; HG) medium, respectively. CDC42 overexpression plasmid and small interference RNA (oe-CDC42 and si-CDC42) or corresponding negative controls (oe-NC and si-NC) were transfected into hRMECs under HG. Then, platelet-activating factor C-16 (C16-PAF) (MEK/ERK pathway activator) was added to si-CDC42 or si-NC transfected hRMECs under HG. Our study showed that HG increased CDC42 mRNA and protein, cell viability, invasive cell count, branch points, and tube length but reduced cell apoptosis in hRMECs. CDC42 upregulation enhanced cell viability, invasive cell count, branch points, tube length, p-MEK, and p-ERK, but attenuated cell apoptosis. Downregulation of CDC42 exhibited opposite trends. In addition, C16-PAF also increased cell viability, invasive cell count, branch points, and tube length, p-MEK, and p-ERK, but retarded cell apoptosis. Notably, C16-PAF diminished the effect of CDC42 downregulation on the above-mentioned functions in hRMECs under HG. Conclusively, CDC42 promotes HG-induced hRMEC viability and invasion, as well as angiogenesis, but inhibits apoptosis by activating the MEK/ERK pathway, which may be responsible for the progression of diabetic retinopathy.</ABSTRACT>'}]
2024-01-02 00:26:15,934 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:15,935 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449678, Requested 1519. Please try again in 159ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:15,935 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Small bowel cancer in a patient with Crohn\'s disease diagnosed preoperatively by double-balloon enteroscopy.\nA 53-year-old female patient, who had been treated for Crohn\'s disease for approximately 20\xa0years, was admitted to our hospital with a chief complaint of persistent bloody stools. Colonoscopy, computed tomography, and magnetic resonance enterography revealed two stenoses of the ileum and multiple enlarged lymph nodes around the oral-side ileal stenosis. We accordingly performed transoral double-balloon enteroscopy and found ileal stenosis with an irregular mucosal surface. Based on pathological examination of the stenosis, adenocarcinoma of the small bowel was diagnosed for the oral-side stenosis. The stenosis on the anal side was benign. The two stenoses were resected simultaneously, and lymph node dissection was performed on the cancerous lesion. The diagnosis of the cancerous lesion was pStage IIIB, and immunohistochemical staining was positive for tumor protein 53. Patients with Crohn\'s disease are at a high risk of small bowel cancer, but no surveillance protocol has been established to date. We encountered a case of Crohn\'s disease in which radical surgery was possible, owing to preoperative pathological diagnosis, by using balloon-assisted enteroscopy. In this paper, we report a case that suggests the importance of performing balloon-assisted enteroscopy when small bowel stenosis is detected in patients with Crohn\'s disease.</ABSTRACT>'}]
2024-01-02 00:26:15,951 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:15,953 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:15,954 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449597, Requested 1715. Please try again in 174ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:15,955 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Clinical and Diagnostic Findings of Acute Macular Neuroretinopathy and Paracentral Acute Middle Maculopathy in the COVID-19 Era.\nGrowing evidence suggests an association between the infection from the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and eye disorders. The aim of this review was to analyze the clinical presentation and diagnostic features of acute macular neuroretinopathy (AMN) and paracentral acute middle maculopathy (PAMM) associated with COVID-19 infection. The features are then compared with previous reports regarding these retinal disorders, to recognize possible specific characteristics and to assess the role of multimodal ophthalmic imaging.A literature search was performed by consulting PubMed, Scopus, and Embase. The following terms were searched: "(COVID-19 OR SARS-CoV-2 OR coronavirus) AND ([acute macular neuroretinopathy] OR [paracentral acute middle maculopathy])." Inclusion criteria were as follows: (1) publication date from January 31, 2020 to January 31, 2022; (2) English language; (3) original research or case report; (4) free full-text availability.Optical coherence tomography (OCT) findings in AMN patients were hyper-reflectivity (HR) of the outer plexiform layer, of the outer nuclear layer, and ellipsoid or interdigitation zones (EZ and IZ, respectively) disruption. In most cases, the presence of HR and EZ/IZ abnormalities resulted combined. When performed, OCT angiography (OCTA) identified attenuation of signal of the deep capillary plexus (DCP). The most common OCT finding in PAMM was an alteration of the inner nuclear layer, associated with other areas of HR, while no signs of EZ/IZ disruption were detected. When performed, OCTA showed the attenuation of signal of both the DCP and the superficial capillary plexus.In this review, we reported a case series of AMN and PAMM in patients with a previous or concomitant infection from SARS-CoV-2. The microvascular changes in these cases are highlighted by the OCTA scans. Even if we are far from the determination of a direct link between COVID-19 and these retinal disorders, we could hypothesize that the vascular alterations associated with SARS-CoV-2 infection could be a possible risk factor for both AMN and PAMM.</ABSTRACT>'}]
2024-01-02 00:26:15,955 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449521, Requested 1610. Please try again in 150ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:15,955 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>CGMP Compliant Microfluidic Transfection of Induced Pluripotent Stem Cells for CRISPR-Mediated Genome Editing.\nInherited retinal degeneration is a term used to describe heritable disorders that result from the death of light sensing photoreceptor cells. Although we and others believe that it will be possible to use gene therapy to halt disease progression early in its course, photoreceptor cell replacement will likely be required for patients who have already lost their sight. While advances in autologous photoreceptor cell manufacturing have been encouraging, development of technologies capable of efficiently delivering genome editing reagents to stem cells using current good manufacturing practices (cGMP) are needed. Gene editing reagents were delivered to induced pluripotent stem cells (iPSCs) using a Zephyr microfluidic transfection platform (CellFE). CRISPR-mediated cutting was quantified using an endonuclease assay. CRISPR correction was confirmed via digital PCR and Sanger sequencing. The resulting corrected cells were also karyotyped and differentiated into retinal organoids. We describe use of a novel microfluidic transfection platform to correct, via CRISPR-mediated homology-dependent repair (HDR), a disease-causing NR2E3 mutation in patient-derived iPSCs using cGMP compatible reagents and approaches. We show that the resulting cell lines have a corrected genotype, exhibit no off-target cutting, retain pluripotency and a normal karyotype and can be differentiated into retinal tissue suitable for transplantation. The ability to codeliver CRISPR/Cas9 and HDR templates to patient-derived iPSCs without using proprietary transfection reagents will streamline manufacturing protocols, increase the safety of resulting cell therapies, and greatly reduce the regulatory burden of clinical trials.</ABSTRACT>'}]
2024-01-02 00:26:15,956 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:15,957 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449566, Requested 1786. Please try again in 180ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:15,957 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>The effects of mydriatic eye drops on cerebral blood flow and oxygenation in retinopathy of prematurity examinations.\nMydriatic eye drops used during retinopathy examination have been associated with cardiovascular, respiratory, and gastrointestinal side effects. The aim of our study was to investigate the effects of the drops used for pupil dilatation on cerebral blood flow and cerebral oxygenation. The study included 62 infants who underwent retinopathy screening exams. Vital signs, heart rate (HR), arterial oxygen saturation (SpO2), and mean arterial pressure (MAP) were recorded. Cerebral oxygenation and middle cerebral artery blood flow velocity were evaluated using near-infrared spectroscopy (NIRS) and Doppler ultrasonography, respectively, and the cerebral metabolic rate of oxygen (CMRO2) was also calculated. The mean gestational age of the infants included was 31.29\u2009\u20091.42\xa0weeks, and the mean birth weight was 1620\u2009\u2009265\xa0g. Heart rate was found to be significantly decreased after mydriatic eye drop instillation; however, there were no significant differences regarding blood pressure and oxygen saturation levels (HR: p\u2009<\u20090.001; MAP: p\u2009=\u20090.851; SpO2: p\u2009=\u20090.986, respectively). After instillation while cerebral regional oxygen saturation (rScO2) measurements were significantly decreased at the 60th minute (p\u2009=\u20090.01), no significant difference was found in Vmax and Vmean of MCA before and after mydriatic eye drop instillation (p\u2009=\u20090.755, p\u2009=\u20090.515, respectively). Regarding CMRO2 measurements, we also did not find any statistical difference (p\u2009=\u20090.442). \xa0 \xa0Conclusion:\xa0Our study has shown that although eye drops may affect heart rate and regional cerebral oxygen saturation, they do not alter cerebral blood flow velocities and metabolic rate of oxygen consumption. Current recommendations for mydriatic eye drop use in retinopathy exam appear to be safe. What is Known:  Mydriatic eye drop installation is recommended for pupil dilatation during ROP screening exams.  It\'s known that mydriatics used in ROP examination have affects on the vital signs, cerebral oxygenation and blood flow. What is New:  This is the first study evaluating the changes in cerebral oxygenation and blood flow velocity after mydriatic drop instillation using NIRS and Doppler US concomitantly.  While the eye drops may affect heart rate and regional cerebral oxygen saturation, they do not alter cerebral blood flow velocities and metabolic rate of oxygen consumption.</ABSTRACT>'}]
2024-01-02 00:26:15,961 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:15,966 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:15,968 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448603, Requested 1645. Please try again in 33ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:15,968 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Changes in smoking status, amount of smoking and their relation to the risk of microvascular complications in men with diabetes mellitus.\nSmoking is a definite risk factor for macrovascular complications in diabetes mellitus (DM). However, the effect of smoking on microvascular complications is inconclusive.Study participants were 26,673 diabetic men who received health check-up both in 2003-2004 and 2009, excluding women. Assessing smoking status (never, quitting and current) at 2003-2004 and 2009, changes in smoking status were categorised into 7 groups (never - never, never - quitting, never - current, quitting-quitting, quitting-current, current-quitting and current-current). Smoking amount was categorised into never, light (0-10 pack years), moderate (10-20 pack years), and heavy smoking (>20 pack years) based on 2009 data. They were followed-up until 2013 to identify incident microvascular complications. We calculated the adjusted hazard ratios (HR) and 95% confidence interval (CI) (adjusted HR [95% CI]) for incident microvascular complications according to changes in smoking status and smoking amount.Current-quitting (1.271 [1.050-1.538]), current-current (1.243 [1.070-1.444]) and heavy smoking (1.238 [1.078-1.422]) were associated with an increased risk of overall microvascular complications. The risk of nephropathy increased in current-current smoking (1.429 [1.098-1.860]) and heavy smoking (1.357 [1.061-1.734]). An increased risk of neuropathy was observed in current-quitting smoking (1.360 [1.076-1.719]), current-current smoking (1.237 [1.025-1.492]) and heavy smoking (1.246 [1.048-1.481]). However, we couldn\'t see the interpretable findings for the association between smoking and retinopathy.Lasting and heavy smoking increases the risk of microvascular complications, including nephropathy and neuropathy. Quitting smoking and reducing smoking amount are imperative in preventing microvascular complications in DM patients.</ABSTRACT>'}]
2024-01-02 00:26:15,978 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:15,980 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:15,981 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449032, Requested 1367. Please try again in 53ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:15,981 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Meibomian gland dysfunction and blepharitis: A common and still unsolved ophthalmic problem.\nBlepharitis and meibomian gland dysfunction (MGD) are very common, usually underdiagnosed and underappreciated diseases. More than 50% of patients seeking ophthalmologic consultations have symptoms and signs indicating one or both entities. We summarize the key points of diagnosis and management of both diseases, comparing the work of Dry Eye Workshop II (2017) with the dry eye blepharitis syndrome unification theory. The impact of MGD/blepharitis on ocular surgery also is described. Although MGD and blepharitis seem to be uncurable, most of the time they can be successfully controlled. Different management options are available, but the key to success remains simple-routine eyelid hygiene and moisturizing with the use of preservative-free lubricants.</ABSTRACT>'}]
2024-01-02 00:26:15,983 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:15,984 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449000, Requested 1599. Please try again in 79ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:15,984 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Current evidence on diagnosis and treatment of parotid gland lymphomas: a systematic review.\nParotid gland lymphoma (PGL) is a rare and challenging diagnosis. Different lymphomas can develop in the parotid gland, with the most common being the mucosa-associated lymphoid tissue (MALT) lymphoma, which originates directly from the glandular parenchyma. Other histologic subtypes arise from both intraglandular and extraglandular parotid lymph nodes. A consensus on diagnosis and treatment of PGL is still lacking, and published data is scarce and heterogeneous.We performed a systematic review of the literature, including studies published after 2001, when the WHO classification of lymphoid tumours was introduced.Twenty retrospective studies were included in the analyses, eight of which focused exclusively on MALT lymphomas. Final analysis included 612 cases of PGL, with a 1.68:1 F/M ratio. MALT lymphoma was the most common histology, followed by follicular and diffuse large B-cell lymphoma. Most cases were low stages (IE/IIE\xa0acc. Ann Arbour, 76.5%) and only 10% of patients presented with symptoms, most commonly pain (4.8%) and B symptoms (2.2%). A high prevalence of associated autoimmune diseases was found, particularly Sjgren\'s syndrome, that affected up to 70% of patients with MALT lymphoma. In most cases diagnosis was achieved through parotidectomy (57.5%), or open biopsy (31.2%). Treatment strategies were either surgical, non-surgical or a combination of modalities. Surgery as a single-modality treatment was reported in about 20% of patients, supposing it might be a valuable option for selected patients.Our review showed that the diagnosis and treatment of PGLs is far from being standardized and needs further, more homogeneous reports to reach consensus.</ABSTRACT>'}]
2024-01-02 00:26:15,984 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:15,985 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448987, Requested 1504. Please try again in 65ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:15,987 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Retinal stroke: research models, targets and experimental drugs.\nRetinal artery occlusion (RAO), often caused by a microembolus and resulting in inner retinal ischemia, could be considered as the retinal analog to cerebral stroke. Although several therapeutic targets have been suggested in animal models of retinal ischemia and several potential treatments have been evaluated on small series of patients, central retinal artery occlusion (CRAO) is still rarely treatable in clinical practice.Here, we review several animal models of RAO, including increased intraocular pressure, laser, vasoconstriction, embolization and clamp. We also review the pathogenic mechanisms that contribute to cell death cascades during ischemia, and the therapeutic strategies targeting these events. These strategies aim to restore blood flow by fibrinolysis, increase the oxygen or glucose supply, decrease the energy demands, restrict ionic leak fluxes or reduce the detrimental effects of glutamate, calcium and free radicals. The current literature suggests that tPA treatment could be effective for CRAO.Eye care professionals must make a rapid and accurate diagnosis and immediately refer patients with acute retinal stroke to specialized centers. CRAO management should also be facilitated by developing local networks to encourage collaboration among ophthalmologists, retina specialists and stroke neurologists.</ABSTRACT>'}]
2024-01-02 00:26:15,987 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449078, Requested 1590. Please try again in 89ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:15,987 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Correlation between physician- and patient-directed disease assessments in ulcerative colitis patients from Saudi Arabia and Kuwait: Data from ICONIC.\nThe aim of the observational, prospective study was to validate a novel, nonverbal assessment tool for perceived disease burden-Pictorial Representation of Illness and Self-Measure (PRISM)-in ulcerative colitis (UC) against established patient health questionnaires. The cumulative burden of patients recently diagnosed (<3 years) with UC was also evaluated."ICONIC" - Understanding the impact of ulcerative colitis and its associated disease burden on patients - was a noninterventional, multicountry, multicenter study performed in a 2-year follow-up format in adult patients with recently diagnosed UC in 33 countries, regardless of disease severity or treatment. Data collection consisted of five visits, scheduled at approximately 6-month intervals. For the current analysis, patient data from Saudi Arabia and Kuwait were evaluated. The collected data comprised demographics, disease-related data, UC treatment, and healthcare resources, as well as physician- and patient-assessed quality-of-life and disease burden questionnaires. Correlations between selected questionnaire scores were performed using Spearman\'s rho.Disease severity at baseline and throughout the study was slightly less favorable in this country analysis compared with the global study cohort. Disease burden was assessed by PRISM and improved within 24 months.The detected moderate correlation between PRISM and other assessment methods supports the validity of PRISM. Differences in perceptions of UC-related burden between physician and patient may reflect to some degree insufficient patient-physician communication.</ABSTRACT>'}]
2024-01-02 00:26:15,991 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:15,992 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448743, Requested 1517. Please try again in 34ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:15,992 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Trimethylated chitosan-coated flexible liposomes with resveratrol for topical drug delivery to reduce blue-light-induced retinal damage.\nLED-related blue-light-induced damage can cause eye diseases. However, drug delivery in patients with ocular diseases is faced with various challenges. In this study, we developed flexible liposomes based on trimethylated chitosan (TMC-Lipo) to deliver resveratrol for the treatment of retinal diseases. Flexible liposomes can easily cross various biological barriers. Chitosan and its derivatives have adhesive properties and are widely used in mucoadhesive drug delivery systems. Therefore, we wrapped flexible liposomes with trimethylated chitosan via electrostatic adsorption. The charge of the flexible liposomes became positive after encapsulation in TMC, and they remained stable in artificial tears. We assessed the safety of TMC-Lipo in cellular and zebrafish experiments and found that it can be safely used. In addition, treatment with TMC-Lipo significantly reduced H2O2-induced damage to ARPE-19 cells, restored mitochondrial membrane potential, and protected the cells. TMC-Lipo more easily reached the posterior ocular segment of the mice than liposome nanoparticles and attenuated blue-light-induced retinal cytopathy. Our study demonstrates that effective eye drop formulations can be developed based on trimethylated chitosan, which provides a promising approach for the treatment of ocular diseases.</ABSTRACT>'}]
2024-01-02 00:26:16,002 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:16,003 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:16,003 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:16,005 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448859, Requested 1582. Please try again in 58ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:16,005 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Increased risk of glaucoma development in patients with central serous chorioretinopathy: results of a 11-year population-based cohort study.\nTo investigate whether patients with central serous chorioretinopathy (CSC) have increased risk of developing glaucoma.Patients diagnosed with CSC between 1 January 2008 and 31 December 2018 were included in this study using data from the Taiwanese National Health Insurance Research Database (NHIRD). The CSC cohort was matched with a non-CSC cohort using the propensity score matching method, based on sex, age (in 10-year intervals), index date year, comorbidities, and steroid use, resulting in equal numbers of patients in both cohorts. Patients were followed up until 31 December 2019 or until they were withdrawn from the NHIRD. The incidence of glaucoma was compared between the two cohorts using the Cox regression model, and the risk of developing glaucoma was estimated using the Kaplan-Meier method.After adjusting for sex, age, comorbidities, and steroid use, the CSC cohort showed a significantly higher risk of developing glaucoma compared to those without CSC (adjusted HR\u2009=\u20093.99; 95% CI\u2009=\u20093.44-4.62). The cumulative incidence of glaucoma in the CSC cohort was also significantly higher than in the non-CSC cohort (log-rank test, p\u2009<\u20090.001). Among the glaucoma subtypes, normal tension glaucoma had the highest risk (adjusted HR\u2009=\u20095.79; 95% CI\u2009=\u20093.41-9.85), followed by primary open-angle glaucoma (adjusted HR\u2009=\u20092.77; 95% CI\u2009=\u20092.12-3.62).In conclusion, our study shows that CSC patients are at a higher risk of developing glaucoma, especially NTG. Awareness and regular glaucoma screenings are essential for patients with CSC.</ABSTRACT>'}]
2024-01-02 00:26:16,014 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:16,015 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:16,016 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449694, Requested 1628. Please try again in 176ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:16,016 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>[Health-related quality of life by IBDQ-32 in colombian patients with inflammatory bowel disease in remission: A cross-sectional study].\nIn Colombia there are no data about perception of quality of life (QoL) in inflammatory bowel disease (IBD). The aim of this study was to determine the perception of QoL by means of the IBDQ-32 questionnaire in patients with IBD from a sample of patients from different referral centers. We carried out a cross-sectional study in adults with IBD in clinical remission, in outpatient follow-up, in 3 institutions in different cities, between June 2022 and November 2022, eligible subjects were identified, information was collected on different dates, about socio-demographic and clinical aspects, and the IBDQ-32 questionnaire was evaluated on one occasion. Descriptive and analytical analysis of the variables evaluated was performed. 80 patients, 70% women, mean age 38.5(range 18-72; SD 13.25) years. 67.5% ulcerative colitis (UC), 32.5% Crohn\'s disease (CD). Moderate QoL involvement (median 150 points, interquartile range118.3-181.5) was found in IBD, in UC median 151 (interquartile range120-174.75) points, while in CD 133 (interquartile range106.25-186.25) points. There was greater involvement in the systemic domain, with median 21 (interquartile range 15.8-27) points, and 18.5 (interquartile range 12.8-25.3) points, for UC and CD, respectively. The least affected corresponded to the digestive domain and social function, in median UC 48.5 (interquartile range 40-58.3), and 27(interquartile range 20.8-33); in median CD 43 (interquartile range 35.5-61.75) and 24.5(interquartile range 18-32.5), respectively. No statistically significant differences were found. This study provides unique information about QoL of patients with IBD in Colombia. It is necessary to continue reinforcing the accompaniment, support, and education of patients with IBD.</ABSTRACT>'}]
2024-01-02 00:26:16,017 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449681, Requested 1561. Please try again in 165ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:16,017 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Latest advances in white spot syndromes: New findings and interpretations.\nWhite spot syndromes (WSS) pose challenges in the field of ophthalmology, particularly in terms of accurate diagnosis and effective management. However, recent advancements in multimodal imaging (MMI) have significantly contributed to our understanding of WSS, allowing for improved characterization of these inflammatory chorioretinopathies. By employing various imaging modalities, including fundus fluorescein angiography, indocyanine green angiography, fundus autofluorescence, optical coherence tomography (OCT), ultra-widefield imaging, and OCT angiography, researchers and clinicians have gained valuable insights into the underlying pathophysiological changes and clinical progression of WSS. Furthermore, MMI has unveiled novel and atypical variants within the spectrum of WSS, expanding our knowledge in this field. Notably, the identification of secondary forms of WSS occurring concurrently with unrelated chorioretinal disorders has suggested a potential autoimmune mechanism underlying these conditions. The introduction of MMI has also facilitated a more comprehensive evaluation of previously ill-defined entities, such as acute zonal occult outer retinopathy, leading to improved diagnostic criteria and enhanced recognition of distinct features. This review paper provides a comprehensive overview of the latest advances and interpretations in WSS. By integrating MMI into the diagnosis and management of these conditions, this review aims to enhance patient outcomes and provide valuable insights into the complexities surrounding WSS.</ABSTRACT>'}]
2024-01-02 00:26:16,027 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:16,028 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:16,028 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449304, Requested 1746. Please try again in 140ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:16,028 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Thermal Pulsation in the Management of Meibomian Gland Dysfunction and Dry Eye: A Report by the American Academy of Ophthalmology.\nTo review the literature to determine the efficacy and safety of thermal pulsation technologies in improving signs or symptoms of meibomian gland dysfunction (MGD) and dry eye compared with no therapy or with conventional warm compress therapy or eyelid hygiene.A literature search was conducted in the PubMed database in June 2022 and again in March 2023 to identify all studies in the English language on the use of thermal pulsation to treat MGD or dry eye. The search yielded 59 citations, and 11 articles met\xa0all of the inclusion criteria. The panel methodologist then assigned a level of evidence rating for each study; 8 studies were rated level I evidence and 3 studies were rated level II evidence.All included studies evaluated a single 12-minute session using the LipiFlow automated thermal pulsation system (TearScience, Inc, or Johnson & Johnson). Improvements were detected in subjective and objective metrics of MGD or dry eye in patients within 1 to 12 months of thermal pulsation treatment compared with nontreatment. Most of the studies (9/11) reported greater efficacy with thermal pulsation than with standard warm compress therapy and eyelid hygiene. Four of these studies showed relevant industry conflicts of interest. Two of the 4 level I studies without direct industry participation concluded that thermal pulsation treatment was not significantly different from conventional hygiene or warm compress therapy control treatments (in symptoms in one of the studies and in objective findings in the second study). No serious adverse events were reported in any of the 11 studies.According to the current literature, a single thermal pulsation session may improve subjective or objective parameters of MGD and dry eye safely. However, industry support and participation were present in 4 of the 8 level I studies. The durability beyond several months and cost efficacy remain uncertain. Because the inclusion parameters of this assessment captured only the LipiFlow system, the conclusions are limited to that product. High-quality independent studies are needed to assess the long-term benefits of this intervention.The author(s) have no proprietary or commercial interest in any materials discussed in this article.</ABSTRACT>'}]
2024-01-02 00:26:16,032 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:16,032 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449166, Requested 1448. Please try again in 81ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:16,032 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>An early onset cone dystrophy due to CEP290 mutation: a case report.\nBiallelic mutations in the CEP290 gene cause early onset retinal dystrophy or syndromic disease such as Senior-Loken or Joubert syndrome. Here, we present an unusual non-syndromic case of a juvenile retinal dystrophy caused by biallelic CEP290 mutations imitating initially the phenotype of achromatopsia or slowly progressing cone dystrophy.We present 13\xa0years of follow-up of a female patient who presented first with symptoms and findings typical for achromatopsia. The patient underwent functional and morphologic examinations, including fundus autofluorescence imaging, spectral-domain optical coherence tomography, electroretinography, color vision and visual field testing.Diagnostic genetic testing via whole genome sequencing and virtual inherited retinal disease gene panel evaluation finally identified two compound heterozygous variants c.4452_4455del;p.(Lys1484Asnfs*4) and c.2414T\u2009>\u2009C;p.(Leu805Pro) in the CEP290 gene.CEP290 mutation causes a wide variety of clinical phenotypes. The presented case shows a phenotype resembling achromatopsia or early onset slowly progressing cone dystrophy.</ABSTRACT>'}]
2024-01-02 00:26:16,067 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:16,071 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449022, Requested 1567. Please try again in 78ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:16,071 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Regulation of epithelial cell differentiation by the Ubiquitous expressed transcript isoform 1 in ulcerative colitis.\nMucosal healing has emerged as a desirable treatment goal for patients with ulcerative colitis (UC). Healing of mucosal wounds involves epithelial cell proliferation and differentiation, and Y-box transcription factor ZONAB has recently been identified as the key modulator of intestinal epithelial restitution.We studied the characteristics of UXT-V1 expression in UC patients using immunohistochemistry and qPCR. The functional role of UXT-V1 in the colonic epithelium was investigated using lentivirus-mediated shRNA in vitro and ex vivo. Through endogenous Co-immunoprecipitation and LC-MS/MS, we identified ZONAB as a UXT-V1-interactive protein.Herein, we report that UXT-V1 promotes differentiation of intestinal epithelial cells by regulating the nuclear translocation of ZONAB. UXT-V1 was upregulated in the intestinal epithelia of UC patients compared with that of healthy controls. Knocking down UXT-V1 in NCM-460 cells led to the enrichment of pathways associated with proliferation and differentiation. Furthermore, the absence of UXT-V1 in cultured intestinal epithelial cells and colonic organoids inhibited differentiation to the goblet cell phenotype. Mechanistically, the loss of UXT-V1 in the intestinal epithelial cells allowed nuclear translocation of ZONAB, wherein it regulated the transcription of differentiation-related genes, including AML1 and KLF4.Taken together, our study reveals a potential role of UXT-V1 in regulating epithelial cell differentiation, proving a molecular basis for mucosal healing in UC.</ABSTRACT>'}]
2024-01-02 00:26:16,082 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:16,091 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:16,094 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449894, Requested 1513. Please try again in 187ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:16,094 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Inter- and intra-observer agreement in the measurement of macular holes by optical coherence tomography.\nA full-thickness macular hole ("FTMH") is a foveal lesion caused by a defect in the full thickness of the neurosensory retina. Its diagnosis and the indication for surgical treatment take into account the measurement of the hole according to the tool provided by the OCT. This measurement can be performed by several ophthalmologists during the follow-up of a patient. The aim of this study is to find out whether there is intra-individual and inter-individual variability in these measurements.Retrospective review of OCT b-scan images with a diagnosis of FTMH. Measurements of the minimum diameter of the FTMH were performed using the hand-held tool available on the DRI-Triton (Topcon, Japan) at 1:1 and 1:2 scales, on different days, by 2 retina specialists and 2 residents. These measurements were compared to assess inter-observer and intra-observer correspondence.Thirty-four images were analysed. For intra-observer variability, a correlation index higher than 0.98 was obtained in all cases. For inter-observer variability, the intra-class correlation coefficient was 0.94 (95% CI: 0.91-0.97) for the 1:1 scale, and 0.94 (95% CI: 0.91-0.97) for the 1:2 scale.OCT-measured AMEC size values are reproducible between ophthalmic specialists and residents and are independent of the imaging scale at which the measurement is made.</ABSTRACT>'}]
2024-01-02 00:26:16,095 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:16,096 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449877, Requested 1303. Please try again in 157ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:16,096 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Cytomegalovirus (CMV) as a cause of exacerbation of ulcerative colitis (UC). An approach to diagnosis and management.\nCytomegalovirus (CMV) reactivation may be a cause of acute exacerbations in patients with severe ulcerative colitis (UC). Patients with exacerbation of symptoms by CMV have greater morbidity and mortality rate. The present study was conducted to evaluate the prevalence of CMV infection in UC patients by endoscopic examination, histopathological examination and CMV DNA PCR of colonic mucosal biopsy tissue and also to identify the associated risk factors and clinical outcomes.</ABSTRACT>'}]
2024-01-02 00:26:16,097 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:16,101 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:16,102 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449662, Requested 1494. Please try again in 154ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:16,102 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>A spotlight on intestinal permeability and inflammatory bowel diseases.\nThe intestinal barrier is a multi-faced structure lining the surface of the intestinal mucosa of the GI tract. To exert its main functions as a physical and immunological defense barrier, several components of the intestinal barrier act in a concerted and cooperative manner.Herein, we first introduce to the basic organization of the intestinal barrier and then summarize different methods to assess barrier function in and ex vivo. Finally, we provide an in-depth overview of the relevance of intestinal barrier dysfunction in inflammatory bowel diseases.In parallel to a more fundamental understanding of the intestinal barrier as a key component for intestinal integrity is the notion that intestinal barrier defects are associated with a variety of diseases such as inflammatory bowel diseases. Recent research has fueled and perpetuated the concept that barrier defects are critical components of disease development, disease behavior, and potentially also an area of therapeutic intervention in IBD patients. Although being far away from standard, new technologies can be used to easily assess barrier healing in IBD and to derive clinical consequences from these findings such as more accurate forecasting of future disease behavior or the identification of novel therapeutic targets.</ABSTRACT>'}]
2024-01-02 00:26:16,115 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:16,116 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449392, Requested 1619. Please try again in 134ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:16,116 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Association among \u03b22-adrenergic receptor autoantibodies and proximal left anterior descending artery lesions in patients with initial ST-segment elevation myocardial infarction.\n\u03b22 -adrenergic receptor autoantibody (\u03b22 -AA) are widely present in patients with many different types of cardiovascular diseases. Proximal left anterior descending (LAD) artery lesions are associated with adverse prognostic events in patients with ST-segment elevation myocardial infarction (STEMI).\u03b22 -AA is associated with the presence of proximal LAD lesions in patients with STEMI.A cohort of 153 patients with STEMI who underwent primary percutaneous coronary intervention (PPCI) was enrolled in the study. Baseline characteristics were compared between the proximal LAD group (n\u2009=\u200962) and the nonproximal LAD group (n\u2009=\u200991). Admission serum of patients was collected to detect the level of \u03b22 -AA. Data for echocardiogram within 24\u2009hours after PPCI and at the 6-month follow-up were recorded.The optical density values and positive rates of \u03b22 -AA in the proximal LAD group were higher than those in the nonproximal LAD group (p\u2009<\u20090.05). \u03b22 -AA positively correlated with high sensitivity C-reactive protein and peak N-terminal pro-B type natriuretic peptide levels in the proximal LAD group, but those were not relevant in the nonproximal LAD group. Multivariate logistic regression analysis revealed that high \u03b22 -AA levels was independently associated with the presence of proximal LAD lesions in patients with STEMI. Furthermore, a receiver operating characteristic curve was used to show the efficiency of \u03b22 -AA levels to detect proximal LAD lesions, and the AUC of the \u03b22-AA OD value was 0.658 (95% confidence interval 0.568-0.749; p\u2009=\u20090.001).The STEMI patients with high \u03b22 -AA levels had a greater possibility having proximal LAD lesions.</ABSTRACT>'}]
2024-01-02 00:26:16,128 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:16,130 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449336, Requested 1519. Please try again in 114ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:16,130 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Peripheral and central retinal vascular changes in asymptomatic family members of patients with familial exudative vitreoretinopathy.\nTo evaluate the peripheral vascular changes and effects of these on macular microvasculature in asymptomatic family members of familial exudative vitreoretinopathy (FEVR) patients.This is a retrospective study including 61 eyes of asymptomatic family members of FEVR patients. Retinal abnormalities were assessed via ultra-widefield fluorescein angiography (UWF-FA) and optical coherence tomography angiography (OCTA). The eyes were grouped into 3: the first group comprised of eyes with normal findings on UWF-FA; the second group comprised of eyes with abnormal findings on UWF-FA but without any retinal ischemia; and the third group involved eyes with retinal ischemia or neovascularization.Best corrected visual acuity (BCVA) was 20/20 in all eyes. Forty eyes (65.6%) had abnormalities on UWF-FA. The most common feature was peripheral vascular looping, increased tortuosity, and anastomosis (63.9%). ODM/ODD ratio was higher in group 3 compared to groups 1 and 2. Deep foveal VD was lower in group 1 compared to groups 2 and 3. The mean FAZ area and perimeter were smaller in groups 2 and 3 compared to group 1.Even asymptomatic family members of FEVR patients may have significant peripheral retinal vascular abnormalities which may be associated with smaller optic disc, macular ectopia, and macular microvascular changes.</ABSTRACT>'}]
2024-01-02 00:26:16,153 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:16,166 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:16,190 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:16,194 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:16,197 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449300, Requested 1612. Please try again in 121ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:16,197 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Sarcopenia assessed by computed tomography or magnetic resonance imaging is associated with the loss of response to biologic therapies in adult patients with Crohn\'s disease.\nSarcopenia occurs in patients with Crohn\'s disease (CD). However, the association between sarcopenia and loss of response (LOR) to biologic agents remains unclear. This study explored such an association in CD patients. This retrospective study included 94 CD patients who received biologic therapy. The skeletal muscle cross-sectional area at the third lumbar was assessed by computed tomography or magnetic resonance imaging for sarcopenia evaluation. A LOR was defined by fecal calprotectin (FC)\u2009<\u2009250\u2009\u03bcg/g or >50% reduction from baseline levels or other factors, such as the used agent being replaced by other biologic agents. The association between sarcopenia and LOR was assessed by logistic regression analysis. LOR was observed in 54 patients (57.4%). The prevalence of sarcopenia in the LOR group was higher than that in response group (70.4% vs. 40.0%, p\u2009=\u20090.003). Sarcopenia (odds ratio [OR]\u2009=\u20093.89, 95% confidence interval [CI]: 1.31-11.54), Montreal L1 type (OR\u2009=\u20090.20, 95% CI: 0.06-0.60), perianal lesions (OR\u2009=\u20094.08, 95% CI: 1.31-12.70), and monocytes percentage (OR\u2009=\u20091.27, 95% CI: 1.02-1.57) at baseline were independent associated factors for LOR. Sarcopenia was also associated with LOR in patients who received infliximab (OR\u2009=\u20093.31, 95% CI: 1.11-9.87). Montreal L1 type, perianal lesions, and monocytes percentage (Model 1), and with additional consideration of sarcopenia (Model 2), were developed to predict LOR. Model 2 showed better performance than Model 1 (area under the curve [AUC] 0.82 vs. 0.75). Sarcopenia was associated with the LOR to biological agents or infliximab in adult patients with CD.</ABSTRACT>'}]
2024-01-02 00:26:16,200 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:16,227 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:16,231 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:16,231 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449642, Requested 1638. Please try again in 170ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:16,232 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Would, early, versus late hydroxocobalamin dose intensification treatment, prevent cognitive decline, macular degeneration and ocular disease, in 5 patients with early-onset cblC deficiency?\nIn early-onset (EO) cblC deficiency (MMACHC), hydroxocobalamin dose-intensification (OHCBL-DI) improved biochemical and clinical outcome. In mammals, Cobalamin is reduced, in a reaction mediated by MMACHC. Pathogenic variants in MMACHC disrupt the synthesis pathway of methyl-cobalamin (MetCbl) and 5\'-deoxy-adenosyl-cobalamin (AdoCbl), cofactors for both methionine synthase (MS) and methyl-malonyl-CoA mutase (MCM) enzymes. In 5 patients (pts.), with EO cblC deficiency, biochemical and clinical responses were studied following OHCbl-DI (mean\xa0\xa0SD 6,5\xa0\xa03,3\xa0mg/kg/day), given early, before age 5\xa0months (pts. 1, 2, 3 and 4) or lately, at age 5\xa0years (pt. 5). In all pts., total homocysteine (tHcy), methyl-malonic acid (MMA) and Cob(III)alamin levels were measured. Follow-up was performed during 74/12 years (pts. 1, 2, 3), 33/12 years (pt. 4) and 34/12 years (pt. 5). OHCbl was delivered intravenously or subcutaneously. Mean\xa0\xa0SD serum Cob(III)alamin levels were 42,2\xa0\xa0106\xa0\xa028, 0\xa0\xa0106\xa0pg/ml (normal: 200-900\xa0pg/ml). In all pts., biomarkers were well controlled. All pts., except pt. 5, who had poor vision, had central vision, mild to moderate nystagmus, and with peri-foveolar irregularity in pts. 1, 2 and 4, yet none had the classic bulls\' eye maculopathy and retinal degeneration characteristic of pts. with EO cblC deficiency. Only pt. 5, had severe cognitive deficiency. Both visual and cognitive functions were better preserved with early than with late OHCBL-DI. OHCBL-DI is suggested to bypass MMACHC, subsequently to be rescued by methionine synthase reductase (MSR) and adenosyl-transferase (ATR) to obtain Cob(I)alamin resulting in improved cognitive and retinal function in pts. with EO cblC deficiency.</ABSTRACT>'}]
2024-01-02 00:26:16,235 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:16,255 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:16,258 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449088, Requested 1611. Please try again in 93ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:16,258 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Assessing Active Bowel Inflammation in Crohn\'s Disease Using Intestinal Ultrasound: Correlation With Fecal Calprotectin.\nTo analyze the correlation between intestinal ultrasound (IUS) and serum and fecal biomarkers, and the characteristics of small bowel disease, for the assessment of active bowel inflammation.Patients with Crohn\'s disease (CD) who underwent an initial IUS examination between July 2018 and November 2022 at our institution were included retrospectively. We divided small and large bowels into seven segments, and recorded the presence of active inflammation according to following criteria: bowel wall thickness \u2265\u2009mm with \u22651 of feature of active disease on IUS. The correlations between IUS-assessed activity and serum C-reactive protein (CRP, mg/dL) and fecal calprotectin (FC, \u03bcg/g) levels were analyzed.A total of 127 patients were included (mean age: 32.42\u2009\u200912.07, M:F\u2009=\u200990:37, median disease duration 6\u2009years [0-35]). Of them, 78 showed active bowel inflammation (61.4%), with inflammation distal to the terminal ileum being the most common disease location (n\u2009=\u200961, 78.2%). FC and serum CRP levels were significantly correlated with the number of segments with active inflammation (rho\u2009=\u20090.58, 0.48), number of segments with complications (r\u2009=\u20090.35, 0.31), and US activity score (r\u2009=\u20090.62, 0.54). With FC cutoff values of 100 and 150\u2009\u03bcg/g, the concordance rates for patients with active small bowel disease were 78.7% (26/33) and 72.7% (24/33), respectively, which were better than those for other disease locations.Disease activity determined by IUS was significantly correlated with the biomarkers, with a better concordance rate in patients with active small bowel disease than in those with other disease locations with FC cut-off values of 100 and 150\u2009\u03bcg/g.</ABSTRACT>'}]
2024-01-02 00:26:16,265 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:16,283 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:16,289 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:16,290 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449732, Requested 1504. Please try again in 164ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:16,290 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>TGF-\u03b21 signaling and Smad7 control T-cell responses in health and immune-mediated disorders.\nTransforming growth factor (TGF)-\u03b21, a member of the TGF-\u03b2 superfamily, is produced by many immune and nonimmune cells and has pleiotropic effects on both innate and adaptive immunity, especially in the control of T-cell differentiation and function. Consistently, loss of TGF-\u03b21 function is associated with exacerbated T-cell-dependent inflammatory responses that culminate in pathological processes in allergic and immune-mediated diseases. In this review, we highlight the roles of TGF-\u03b21 in immunity, focusing mainly on its ability to promote differentiation of regulatory T cells, T helper (Th)-17, and Th9 cells, thus contributing to amplifying or restricting T-cell responses in health and human diseases (e.g., inflammatory bowel diseases, type 1 diabetes, asthma, and MS). In addition, we discuss the involvement of Smad7, an inhibitor of TGF-\u03b21 signaling, in immune-mediated disorders (e.g., psoriasis, rheumatoid arthritis, MS, and inflammatory bowel diseases), as well as the discordant results of clinical trials with mongersen, an oral pharmaceutical compound containing a Smad7 antisense oligonucleotide, in patients with Crohn\'s disease. Further work is needed to ascertain the reasons for such a discrepancy as well as to identify better candidates for treatment with Smad7 inhibitors.</ABSTRACT>'}]
2024-01-02 00:26:16,318 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:16,320 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449516, Requested 1575. Please try again in 145ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:16,320 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>What is the real incidence of right ventricular affection in patients with acute pulmonary embolism?\nEchocardiographic markers of right ventricular dysfunction or pressure overload (RVd/PO) have been used in risk assessment of patients with acute pulmonary embolism (APE). Nevertheless, the role of echocardiography in these patients is incompletely determined. We evaluated the right ventricular function using \'non-conventional\' markers of RVd/PO in patients with APE.This was a prospective, single-arm, single-centre study. Consecutive adult patients hospitalised for APE were included. The RV free wall longitudinal strain (RV-FWLS), the fractional area change (FAC), the ratio tricuspid annular plane systolic excursion (TAPSE)/pulmonary arterial systolic pressure (PASP), and the pulmonary vascular resistance (PVR) were evaluated.One hundred patients (mean age 70.0\u2009\u200913.9\u2009years, female 48%) were screened and 73 had adequate RV-FWLS images. The most common abnormal echocardiographic marker was RV-FWLS (44/73; p\u2009<\u20090.001, for all other echocardiographic indices). Thirty-one patients had either PASP \u2265 36\u2009mmHg or PVR > 2 WU (49.2% of the patients with both indices available). There were significant correlations between RV-FWLS, TAPSE/PASP and PVR with both D-Dimers and B-type natriuretic peptide (BNP), and between FAC and BNP. RF-FWLS differed significantly between patients with a simplified pulmonary embolism severity index (sPESI) score 0 and those with a score \u22651 (p\u2009<\u20090.001).RVd/PO coexists with APE in a large proportion of patients. RV-FWLS is the most abnormal echocardiographic sign and is related to clinical and biochemical prognostic indices.</ABSTRACT>'}]
2024-01-02 00:26:16,350 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:16,353 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449215, Requested 1581. Please try again in 106ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:16,353 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>A Comparison of Treatment Effect Sizes in Matched Phase 2 and Phase 3 Trials of Advanced Therapeutics in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis.\nPhase 2 trials are fundamental to the rational and efficient design of phase 3 trials. We aimed to determine the relationship of treatment effect size estimates from phase 2 and phase 3 clinical trials on advanced therapeutics in inflammatory bowel disease.MEDLINE, EMBASE, CENTRAL, and the Cochrane library were searched from inception to December 19, 2022, to identify paired phase 2 and 3 placebo-controlled induction studies of advanced therapeutics for Crohn\'s disease (CD) and ulcerative colitis (UC). Treatment effect sizes were expressed as a risk ratio (RR) between the active arm and placebo arm. For the same therapeutics, RRs from phase 2 trials were divided by the RR from phase 3 trial to quantify the relationship of effect sizes between phases.Twenty-two studies (9 phase 2 trials, 13 phase 3 trials) were included for CD and 30 studies (12 phase 2 trials, 18 phase 3 trials) for UC. In UC (pooled RR 0.72; 95% confidence interval: 0.58-0.86; RR <1 indicates smaller treatment effect sizes in phase 2 trials), but not CD (pooled RR 1.01; 95% confidence interval: 0.84-1.18), phase 2 trials systematically underestimated treatment effect sizes for the primary endpoint compared with phase 3 trials. The underestimation was observed for clinical, but not endoscopic, endpoints in UC.Treatment effect sizes for the primary and clinical endpoints were similar across clinical trial phases in CD, but not UC, where only endoscopic endpoints were comparable. This will help inform clinical development plans and future trial design.</ABSTRACT>'}]
2024-01-02 00:26:16,398 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:16,406 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:16,443 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:16,482 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:16,518 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:16,920 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:16,925 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:16,999 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:17,003 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:17,066 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:17,103 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:17,134 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:17,176 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:17,200 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:17,261 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:17,284 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:17,300 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:17,308 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:17,319 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:17,320 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:17,334 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:17,367 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:17,393 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:17,425 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:17,524 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:17,535 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:17,584 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:17,600 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:17,668 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:17,742 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:18,173 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:18,256 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:18,282 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:18,333 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:18,418 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:18,730 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:18,736 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:18,750 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:18,771 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:18,786 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:18,861 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:18,933 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:18,994 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:19,120 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:19,142 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:19,320 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:19,542 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:19,788 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:19,986 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:20,058 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:20,242 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:20,324 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:20,376 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:20,484 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:20,495 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:21,183 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:21,190 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:21,726 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:24,544 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,545 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,547 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,548 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,549 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,552 - INFO - Retrying request to /chat/completions in 0.774572 seconds
2024-01-02 00:26:24,553 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,553 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,554 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,554 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,554 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,555 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,555 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,556 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,556 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,557 - INFO - Retrying request to /chat/completions in 0.775445 seconds
2024-01-02 00:26:24,557 - INFO - Retrying request to /chat/completions in 0.840705 seconds
2024-01-02 00:26:24,557 - INFO - Retrying request to /chat/completions in 0.793043 seconds
2024-01-02 00:26:24,557 - INFO - Retrying request to /chat/completions in 0.920799 seconds
2024-01-02 00:26:24,558 - INFO - Retrying request to /chat/completions in 0.994027 seconds
2024-01-02 00:26:24,558 - INFO - Retrying request to /chat/completions in 0.808987 seconds
2024-01-02 00:26:24,560 - INFO - Retrying request to /chat/completions in 0.898190 seconds
2024-01-02 00:26:24,560 - INFO - Retrying request to /chat/completions in 0.969401 seconds
2024-01-02 00:26:24,560 - INFO - Retrying request to /chat/completions in 0.851247 seconds
2024-01-02 00:26:24,560 - INFO - Retrying request to /chat/completions in 0.795917 seconds
2024-01-02 00:26:24,560 - INFO - Retrying request to /chat/completions in 0.801664 seconds
2024-01-02 00:26:24,560 - INFO - Retrying request to /chat/completions in 0.881210 seconds
2024-01-02 00:26:24,561 - INFO - Retrying request to /chat/completions in 0.962699 seconds
2024-01-02 00:26:24,563 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,566 - INFO - Retrying request to /chat/completions in 0.911527 seconds
2024-01-02 00:26:24,566 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,567 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,567 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,567 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,568 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,568 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,569 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,569 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,569 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,570 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,572 - INFO - Retrying request to /chat/completions in 0.901262 seconds
2024-01-02 00:26:24,572 - INFO - Retrying request to /chat/completions in 0.920450 seconds
2024-01-02 00:26:24,573 - INFO - Retrying request to /chat/completions in 0.893374 seconds
2024-01-02 00:26:24,573 - INFO - Retrying request to /chat/completions in 0.967832 seconds
2024-01-02 00:26:24,573 - INFO - Retrying request to /chat/completions in 0.856797 seconds
2024-01-02 00:26:24,574 - INFO - Retrying request to /chat/completions in 0.906062 seconds
2024-01-02 00:26:24,574 - INFO - Retrying request to /chat/completions in 0.900245 seconds
2024-01-02 00:26:24,574 - INFO - Retrying request to /chat/completions in 0.928219 seconds
2024-01-02 00:26:24,574 - INFO - Retrying request to /chat/completions in 0.943565 seconds
2024-01-02 00:26:24,575 - INFO - Retrying request to /chat/completions in 0.832660 seconds
2024-01-02 00:26:24,576 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,580 - INFO - Retrying request to /chat/completions in 0.828267 seconds
2024-01-02 00:26:24,581 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,582 - INFO - Retrying request to /chat/completions in 0.868961 seconds
2024-01-02 00:26:24,586 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,587 - INFO - Retrying request to /chat/completions in 0.757551 seconds
2024-01-02 00:26:24,588 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,589 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,589 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,589 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,590 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,590 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,590 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,591 - INFO - Retrying request to /chat/completions in 0.900525 seconds
2024-01-02 00:26:24,591 - INFO - Retrying request to /chat/completions in 0.863603 seconds
2024-01-02 00:26:24,591 - INFO - Retrying request to /chat/completions in 0.811511 seconds
2024-01-02 00:26:24,591 - INFO - Retrying request to /chat/completions in 0.867949 seconds
2024-01-02 00:26:24,591 - INFO - Retrying request to /chat/completions in 0.971686 seconds
2024-01-02 00:26:24,592 - INFO - Retrying request to /chat/completions in 0.913751 seconds
2024-01-02 00:26:24,592 - INFO - Retrying request to /chat/completions in 0.951206 seconds
2024-01-02 00:26:24,598 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,599 - INFO - Retrying request to /chat/completions in 0.931250 seconds
2024-01-02 00:26:24,602 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,603 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,604 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,604 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,604 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,605 - INFO - Retrying request to /chat/completions in 0.865780 seconds
2024-01-02 00:26:24,605 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,605 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,606 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,607 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,608 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,613 - INFO - Retrying request to /chat/completions in 0.966778 seconds
2024-01-02 00:26:24,613 - INFO - Retrying request to /chat/completions in 0.991985 seconds
2024-01-02 00:26:24,613 - INFO - Retrying request to /chat/completions in 0.885303 seconds
2024-01-02 00:26:24,614 - INFO - Retrying request to /chat/completions in 0.889501 seconds
2024-01-02 00:26:24,614 - INFO - Retrying request to /chat/completions in 0.815194 seconds
2024-01-02 00:26:24,614 - INFO - Retrying request to /chat/completions in 0.973129 seconds
2024-01-02 00:26:24,615 - INFO - Retrying request to /chat/completions in 0.999102 seconds
2024-01-02 00:26:24,615 - INFO - Retrying request to /chat/completions in 0.828952 seconds
2024-01-02 00:26:24,615 - INFO - Retrying request to /chat/completions in 0.902318 seconds
2024-01-02 00:26:24,658 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,662 - INFO - Retrying request to /chat/completions in 0.834893 seconds
2024-01-02 00:26:24,735 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,736 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,736 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,738 - INFO - Retrying request to /chat/completions in 0.873590 seconds
2024-01-02 00:26:24,739 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,739 - INFO - Retrying request to /chat/completions in 0.964330 seconds
2024-01-02 00:26:24,739 - INFO - Retrying request to /chat/completions in 0.956696 seconds
2024-01-02 00:26:24,740 - INFO - Retrying request to /chat/completions in 0.889546 seconds
2024-01-02 00:26:24,763 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,764 - INFO - Retrying request to /chat/completions in 0.950348 seconds
2024-01-02 00:26:24,767 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,767 - INFO - Retrying request to /chat/completions in 0.858193 seconds
2024-01-02 00:26:24,772 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,772 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,774 - INFO - Retrying request to /chat/completions in 0.766764 seconds
2024-01-02 00:26:24,775 - INFO - Retrying request to /chat/completions in 0.771160 seconds
2024-01-02 00:26:24,776 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,778 - INFO - Retrying request to /chat/completions in 0.970299 seconds
2024-01-02 00:26:24,784 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,785 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,786 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,786 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,786 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,788 - INFO - Retrying request to /chat/completions in 0.771632 seconds
2024-01-02 00:26:24,788 - INFO - Retrying request to /chat/completions in 0.775442 seconds
2024-01-02 00:26:24,788 - INFO - Retrying request to /chat/completions in 0.969983 seconds
2024-01-02 00:26:24,788 - INFO - Retrying request to /chat/completions in 0.856665 seconds
2024-01-02 00:26:24,788 - INFO - Retrying request to /chat/completions in 0.871916 seconds
2024-01-02 00:26:24,790 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,791 - INFO - Retrying request to /chat/completions in 0.947577 seconds
2024-01-02 00:26:24,801 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,801 - INFO - Retrying request to /chat/completions in 0.922131 seconds
2024-01-02 00:26:24,818 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,818 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,819 - INFO - Retrying request to /chat/completions in 0.778057 seconds
2024-01-02 00:26:24,819 - INFO - Retrying request to /chat/completions in 0.870861 seconds
2024-01-02 00:26:24,824 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,826 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,826 - INFO - Retrying request to /chat/completions in 0.869402 seconds
2024-01-02 00:26:24,828 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,828 - INFO - Retrying request to /chat/completions in 0.970377 seconds
2024-01-02 00:26:24,828 - INFO - Retrying request to /chat/completions in 0.848191 seconds
2024-01-02 00:26:24,830 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,830 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,831 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,832 - INFO - Retrying request to /chat/completions in 0.871892 seconds
2024-01-02 00:26:24,832 - INFO - Retrying request to /chat/completions in 0.789758 seconds
2024-01-02 00:26:24,833 - INFO - Retrying request to /chat/completions in 0.898845 seconds
2024-01-02 00:26:24,836 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,837 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,838 - INFO - Retrying request to /chat/completions in 0.855368 seconds
2024-01-02 00:26:24,838 - INFO - Retrying request to /chat/completions in 0.794011 seconds
2024-01-02 00:26:24,841 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,841 - INFO - Retrying request to /chat/completions in 0.805402 seconds
2024-01-02 00:26:24,845 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,846 - INFO - Retrying request to /chat/completions in 0.771189 seconds
2024-01-02 00:26:24,848 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,848 - INFO - Retrying request to /chat/completions in 0.964420 seconds
2024-01-02 00:26:24,851 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,851 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,852 - INFO - Retrying request to /chat/completions in 0.761639 seconds
2024-01-02 00:26:24,852 - INFO - Retrying request to /chat/completions in 0.854659 seconds
2024-01-02 00:26:24,855 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,855 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,856 - INFO - Retrying request to /chat/completions in 0.949525 seconds
2024-01-02 00:26:24,856 - INFO - Retrying request to /chat/completions in 0.774346 seconds
2024-01-02 00:26:24,856 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,857 - INFO - Retrying request to /chat/completions in 0.971059 seconds
2024-01-02 00:26:24,859 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,860 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,861 - INFO - Retrying request to /chat/completions in 0.953442 seconds
2024-01-02 00:26:24,862 - INFO - Retrying request to /chat/completions in 0.900522 seconds
2024-01-02 00:26:24,886 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,887 - INFO - Retrying request to /chat/completions in 0.752419 seconds
2024-01-02 00:26:24,925 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,926 - INFO - Retrying request to /chat/completions in 0.953003 seconds
2024-01-02 00:26:24,931 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,931 - INFO - Retrying request to /chat/completions in 0.782625 seconds
2024-01-02 00:26:24,933 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,933 - INFO - Retrying request to /chat/completions in 0.907907 seconds
2024-01-02 00:26:24,948 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,949 - INFO - Retrying request to /chat/completions in 0.808473 seconds
2024-01-02 00:26:24,952 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,954 - INFO - Retrying request to /chat/completions in 0.795244 seconds
2024-01-02 00:26:24,956 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,957 - INFO - Retrying request to /chat/completions in 0.880559 seconds
2024-01-02 00:26:24,959 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,959 - INFO - Retrying request to /chat/completions in 0.891535 seconds
2024-01-02 00:26:24,964 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,965 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,965 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,966 - INFO - Retrying request to /chat/completions in 0.786021 seconds
2024-01-02 00:26:24,966 - INFO - Retrying request to /chat/completions in 0.889841 seconds
2024-01-02 00:26:24,966 - INFO - Retrying request to /chat/completions in 0.942459 seconds
2024-01-02 00:26:24,994 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,994 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:24,998 - INFO - Retrying request to /chat/completions in 0.759434 seconds
2024-01-02 00:26:25,000 - INFO - Retrying request to /chat/completions in 0.797307 seconds
2024-01-02 00:26:25,001 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,005 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,006 - INFO - Retrying request to /chat/completions in 0.901738 seconds
2024-01-02 00:26:25,006 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,007 - INFO - Retrying request to /chat/completions in 0.785204 seconds
2024-01-02 00:26:25,007 - INFO - Retrying request to /chat/completions in 0.769110 seconds
2024-01-02 00:26:25,030 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,032 - INFO - Retrying request to /chat/completions in 0.814761 seconds
2024-01-02 00:26:25,033 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,033 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,035 - INFO - Retrying request to /chat/completions in 0.904828 seconds
2024-01-02 00:26:25,036 - INFO - Retrying request to /chat/completions in 0.956920 seconds
2024-01-02 00:26:25,041 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,042 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,042 - INFO - Retrying request to /chat/completions in 0.921313 seconds
2024-01-02 00:26:25,043 - INFO - Retrying request to /chat/completions in 0.912259 seconds
2024-01-02 00:26:25,051 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,052 - INFO - Retrying request to /chat/completions in 0.841865 seconds
2024-01-02 00:26:25,054 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,056 - INFO - Retrying request to /chat/completions in 0.807073 seconds
2024-01-02 00:26:25,059 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,059 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,061 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,061 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,062 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,063 - INFO - Retrying request to /chat/completions in 0.941896 seconds
2024-01-02 00:26:25,063 - INFO - Retrying request to /chat/completions in 0.997823 seconds
2024-01-02 00:26:25,063 - INFO - Retrying request to /chat/completions in 0.922722 seconds
2024-01-02 00:26:25,063 - INFO - Retrying request to /chat/completions in 0.904238 seconds
2024-01-02 00:26:25,064 - INFO - Retrying request to /chat/completions in 0.759352 seconds
2024-01-02 00:26:25,071 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,073 - INFO - Retrying request to /chat/completions in 0.914029 seconds
2024-01-02 00:26:25,075 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,075 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,076 - INFO - Retrying request to /chat/completions in 0.799794 seconds
2024-01-02 00:26:25,076 - INFO - Retrying request to /chat/completions in 0.957903 seconds
2024-01-02 00:26:25,101 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,103 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,105 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,106 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,108 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,109 - INFO - Retrying request to /chat/completions in 0.947740 seconds
2024-01-02 00:26:25,110 - INFO - Retrying request to /chat/completions in 0.978284 seconds
2024-01-02 00:26:25,110 - INFO - Retrying request to /chat/completions in 0.860202 seconds
2024-01-02 00:26:25,110 - INFO - Retrying request to /chat/completions in 0.885702 seconds
2024-01-02 00:26:25,110 - INFO - Retrying request to /chat/completions in 0.790018 seconds
2024-01-02 00:26:25,115 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,115 - INFO - Retrying request to /chat/completions in 0.803937 seconds
2024-01-02 00:26:25,126 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,128 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,128 - INFO - Retrying request to /chat/completions in 0.913052 seconds
2024-01-02 00:26:25,128 - INFO - Retrying request to /chat/completions in 0.895569 seconds
2024-01-02 00:26:25,131 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,132 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,132 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,133 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,134 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,134 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,134 - INFO - Retrying request to /chat/completions in 0.920468 seconds
2024-01-02 00:26:25,135 - INFO - Retrying request to /chat/completions in 0.778284 seconds
2024-01-02 00:26:25,135 - INFO - Retrying request to /chat/completions in 0.924004 seconds
2024-01-02 00:26:25,135 - INFO - Retrying request to /chat/completions in 0.929806 seconds
2024-01-02 00:26:25,135 - INFO - Retrying request to /chat/completions in 0.994201 seconds
2024-01-02 00:26:25,135 - INFO - Retrying request to /chat/completions in 0.776367 seconds
2024-01-02 00:26:25,153 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,154 - INFO - Retrying request to /chat/completions in 0.787871 seconds
2024-01-02 00:26:25,157 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,160 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,160 - INFO - Retrying request to /chat/completions in 0.867949 seconds
2024-01-02 00:26:25,161 - INFO - Retrying request to /chat/completions in 0.774604 seconds
2024-01-02 00:26:25,167 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,168 - INFO - Retrying request to /chat/completions in 0.827422 seconds
2024-01-02 00:26:25,169 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,170 - INFO - Retrying request to /chat/completions in 0.799639 seconds
2024-01-02 00:26:25,188 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,191 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,193 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,194 - INFO - Retrying request to /chat/completions in 0.927955 seconds
2024-01-02 00:26:25,194 - INFO - Retrying request to /chat/completions in 0.776352 seconds
2024-01-02 00:26:25,194 - INFO - Retrying request to /chat/completions in 0.929403 seconds
2024-01-02 00:26:25,202 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,203 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,204 - INFO - Retrying request to /chat/completions in 0.843426 seconds
2024-01-02 00:26:25,205 - INFO - Retrying request to /chat/completions in 0.821010 seconds
2024-01-02 00:26:25,208 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,208 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,210 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,210 - INFO - Retrying request to /chat/completions in 0.777454 seconds
2024-01-02 00:26:25,211 - INFO - Retrying request to /chat/completions in 0.834990 seconds
2024-01-02 00:26:25,211 - INFO - Retrying request to /chat/completions in 0.782302 seconds
2024-01-02 00:26:25,226 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,227 - INFO - Retrying request to /chat/completions in 0.935361 seconds
2024-01-02 00:26:25,477 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,478 - INFO - Retrying request to /chat/completions in 1.623042 seconds
2024-01-02 00:26:25,479 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,480 - INFO - Retrying request to /chat/completions in 1.951974 seconds
2024-01-02 00:26:25,496 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,496 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,499 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,504 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,504 - INFO - Retrying request to /chat/completions in 1.551815 seconds
2024-01-02 00:26:25,504 - INFO - Retrying request to /chat/completions in 1.995864 seconds
2024-01-02 00:26:25,505 - INFO - Retrying request to /chat/completions in 1.755291 seconds
2024-01-02 00:26:25,505 - INFO - Retrying request to /chat/completions in 1.729081 seconds
2024-01-02 00:26:25,528 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,535 - INFO - Retrying request to /chat/completions in 1.824649 seconds
2024-01-02 00:26:25,563 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,564 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,567 - INFO - Retrying request to /chat/completions in 1.788818 seconds
2024-01-02 00:26:25,567 - INFO - Retrying request to /chat/completions in 1.779202 seconds
2024-01-02 00:26:25,572 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,572 - INFO - Retrying request to /chat/completions in 1.911307 seconds
2024-01-02 00:26:25,586 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,587 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,598 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,598 - INFO - Retrying request to /chat/completions in 1.574009 seconds
2024-01-02 00:26:25,600 - INFO - Retrying request to /chat/completions in 1.614198 seconds
2024-01-02 00:26:25,600 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,601 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,602 - INFO - Retrying request to /chat/completions in 1.815540 seconds
2024-01-02 00:26:25,602 - INFO - Retrying request to /chat/completions in 1.793361 seconds
2024-01-02 00:26:25,602 - INFO - Retrying request to /chat/completions in 1.901849 seconds
2024-01-02 00:26:25,603 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,603 - INFO - Retrying request to /chat/completions in 1.753291 seconds
2024-01-02 00:26:25,654 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,655 - INFO - Retrying request to /chat/completions in 1.722160 seconds
2024-01-02 00:26:25,662 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,663 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,663 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,664 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,664 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,664 - INFO - Retrying request to /chat/completions in 1.530996 seconds
2024-01-02 00:26:25,665 - INFO - Retrying request to /chat/completions in 1.657118 seconds
2024-01-02 00:26:25,665 - INFO - Retrying request to /chat/completions in 1.512382 seconds
2024-01-02 00:26:25,665 - INFO - Retrying request to /chat/completions in 1.601404 seconds
2024-01-02 00:26:25,665 - INFO - Retrying request to /chat/completions in 1.716268 seconds
2024-01-02 00:26:25,676 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,676 - INFO - Retrying request to /chat/completions in 1.855740 seconds
2024-01-02 00:26:25,677 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,678 - INFO - Retrying request to /chat/completions in 1.683010 seconds
2024-01-02 00:26:25,681 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,681 - INFO - Retrying request to /chat/completions in 1.559720 seconds
2024-01-02 00:26:25,687 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,690 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,693 - INFO - Retrying request to /chat/completions in 1.926046 seconds
2024-01-02 00:26:25,693 - INFO - Retrying request to /chat/completions in 1.660348 seconds
2024-01-02 00:26:25,711 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,712 - INFO - Retrying request to /chat/completions in 1.968599 seconds
2024-01-02 00:26:25,721 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,721 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,722 - INFO - Retrying request to /chat/completions in 1.574215 seconds
2024-01-02 00:26:25,722 - INFO - Retrying request to /chat/completions in 1.610573 seconds
2024-01-02 00:26:25,723 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,724 - INFO - Retrying request to /chat/completions in 1.657644 seconds
2024-01-02 00:26:25,733 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,735 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,735 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,736 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,747 - INFO - Retrying request to /chat/completions in 1.759089 seconds
2024-01-02 00:26:25,747 - INFO - Retrying request to /chat/completions in 1.678695 seconds
2024-01-02 00:26:25,748 - INFO - Retrying request to /chat/completions in 1.997894 seconds
2024-01-02 00:26:25,750 - INFO - Retrying request to /chat/completions in 1.854717 seconds
2024-01-02 00:26:25,751 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,751 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,751 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,752 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,752 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,753 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,754 - INFO - Retrying request to /chat/completions in 1.854350 seconds
2024-01-02 00:26:25,754 - INFO - Retrying request to /chat/completions in 1.516283 seconds
2024-01-02 00:26:25,756 - INFO - Retrying request to /chat/completions in 1.644315 seconds
2024-01-02 00:26:25,756 - INFO - Retrying request to /chat/completions in 1.729114 seconds
2024-01-02 00:26:25,757 - INFO - Retrying request to /chat/completions in 1.817813 seconds
2024-01-02 00:26:25,757 - INFO - Retrying request to /chat/completions in 1.881635 seconds
2024-01-02 00:26:25,760 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,760 - INFO - Retrying request to /chat/completions in 1.828261 seconds
2024-01-02 00:26:25,770 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,772 - INFO - Retrying request to /chat/completions in 1.538870 seconds
2024-01-02 00:26:25,780 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,783 - INFO - Retrying request to /chat/completions in 1.668827 seconds
2024-01-02 00:26:25,795 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,795 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,797 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,798 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,799 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,799 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,800 - INFO - Retrying request to /chat/completions in 1.822078 seconds
2024-01-02 00:26:25,801 - INFO - Retrying request to /chat/completions in 1.875803 seconds
2024-01-02 00:26:25,801 - INFO - Retrying request to /chat/completions in 1.728506 seconds
2024-01-02 00:26:25,801 - INFO - Retrying request to /chat/completions in 1.503989 seconds
2024-01-02 00:26:25,801 - INFO - Retrying request to /chat/completions in 1.848018 seconds
2024-01-02 00:26:25,801 - INFO - Retrying request to /chat/completions in 1.513713 seconds
2024-01-02 00:26:25,803 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,805 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,806 - INFO - Retrying request to /chat/completions in 1.764462 seconds
2024-01-02 00:26:25,806 - INFO - Retrying request to /chat/completions in 1.986059 seconds
2024-01-02 00:26:25,815 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,817 - INFO - Retrying request to /chat/completions in 1.716693 seconds
2024-01-02 00:26:25,823 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,823 - INFO - Retrying request to /chat/completions in 1.640564 seconds
2024-01-02 00:26:25,856 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,860 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,860 - INFO - Retrying request to /chat/completions in 1.697020 seconds
2024-01-02 00:26:25,861 - INFO - Retrying request to /chat/completions in 1.560283 seconds
2024-01-02 00:26:25,874 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,875 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,877 - INFO - Retrying request to /chat/completions in 1.955934 seconds
2024-01-02 00:26:25,877 - INFO - Retrying request to /chat/completions in 1.650971 seconds
2024-01-02 00:26:25,879 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,879 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,881 - INFO - Retrying request to /chat/completions in 1.895701 seconds
2024-01-02 00:26:25,882 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,882 - INFO - Retrying request to /chat/completions in 1.882516 seconds
2024-01-02 00:26:25,882 - INFO - Retrying request to /chat/completions in 1.551715 seconds
2024-01-02 00:26:25,888 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,889 - INFO - Retrying request to /chat/completions in 1.590363 seconds
2024-01-02 00:26:25,903 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,903 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,905 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,907 - INFO - Retrying request to /chat/completions in 1.771874 seconds
2024-01-02 00:26:25,908 - INFO - Retrying request to /chat/completions in 1.590073 seconds
2024-01-02 00:26:25,909 - INFO - Retrying request to /chat/completions in 1.534608 seconds
2024-01-02 00:26:25,921 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,923 - INFO - Retrying request to /chat/completions in 1.693803 seconds
2024-01-02 00:26:25,936 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,937 - INFO - Retrying request to /chat/completions in 1.684232 seconds
2024-01-02 00:26:25,949 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,951 - INFO - Retrying request to /chat/completions in 1.571254 seconds
2024-01-02 00:26:25,952 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,952 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,954 - INFO - Retrying request to /chat/completions in 1.663980 seconds
2024-01-02 00:26:25,954 - INFO - Retrying request to /chat/completions in 1.660902 seconds
2024-01-02 00:26:25,960 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,962 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,965 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,965 - INFO - Retrying request to /chat/completions in 1.788049 seconds
2024-01-02 00:26:25,967 - INFO - Retrying request to /chat/completions in 1.854228 seconds
2024-01-02 00:26:25,967 - INFO - Retrying request to /chat/completions in 1.814280 seconds
2024-01-02 00:26:25,968 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,968 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,969 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,972 - INFO - Retrying request to /chat/completions in 1.729122 seconds
2024-01-02 00:26:25,973 - INFO - Retrying request to /chat/completions in 1.511245 seconds
2024-01-02 00:26:25,973 - INFO - Retrying request to /chat/completions in 1.702818 seconds
2024-01-02 00:26:25,978 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,978 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,979 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,980 - INFO - Retrying request to /chat/completions in 1.814830 seconds
2024-01-02 00:26:25,980 - INFO - Retrying request to /chat/completions in 1.627237 seconds
2024-01-02 00:26:25,980 - INFO - Retrying request to /chat/completions in 1.851213 seconds
2024-01-02 00:26:25,994 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,995 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:25,996 - INFO - Retrying request to /chat/completions in 1.655594 seconds
2024-01-02 00:26:25,997 - INFO - Retrying request to /chat/completions in 1.987122 seconds
2024-01-02 00:26:26,019 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:26,022 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:26,023 - INFO - Retrying request to /chat/completions in 1.783207 seconds
2024-01-02 00:26:26,024 - INFO - Retrying request to /chat/completions in 1.909293 seconds
2024-01-02 00:26:26,037 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:26,037 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:26,038 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:26,038 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:26,039 - INFO - Retrying request to /chat/completions in 1.692739 seconds
2024-01-02 00:26:26,040 - INFO - Retrying request to /chat/completions in 1.738977 seconds
2024-01-02 00:26:26,040 - INFO - Retrying request to /chat/completions in 1.742175 seconds
2024-01-02 00:26:26,040 - INFO - Retrying request to /chat/completions in 1.663329 seconds
2024-01-02 00:26:26,044 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:26,048 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:26,048 - INFO - Retrying request to /chat/completions in 1.679981 seconds
2024-01-02 00:26:26,049 - INFO - Retrying request to /chat/completions in 1.843545 seconds
2024-01-02 00:26:26,052 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:26,053 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:26,055 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:26,057 - INFO - Retrying request to /chat/completions in 1.907194 seconds
2024-01-02 00:26:26,060 - INFO - Retrying request to /chat/completions in 1.871305 seconds
2024-01-02 00:26:26,062 - INFO - Retrying request to /chat/completions in 1.524078 seconds
2024-01-02 00:26:26,069 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:26,071 - INFO - Retrying request to /chat/completions in 1.625095 seconds
2024-01-02 00:26:26,076 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:26,077 - INFO - Retrying request to /chat/completions in 1.633618 seconds
2024-01-02 00:26:26,082 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:26,083 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:26,083 - INFO - Retrying request to /chat/completions in 1.657426 seconds
2024-01-02 00:26:26,084 - INFO - Retrying request to /chat/completions in 1.589649 seconds
2024-01-02 00:26:26,085 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:26,085 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:26,086 - INFO - Retrying request to /chat/completions in 1.908105 seconds
2024-01-02 00:26:26,086 - INFO - Retrying request to /chat/completions in 1.923376 seconds
2024-01-02 00:26:26,092 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:26,093 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:26,093 - INFO - Retrying request to /chat/completions in 1.867158 seconds
2024-01-02 00:26:26,093 - INFO - Retrying request to /chat/completions in 1.697611 seconds
2024-01-02 00:26:26,097 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:26,097 - INFO - Retrying request to /chat/completions in 1.935411 seconds
2024-01-02 00:26:26,104 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:26,105 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:26,105 - INFO - Retrying request to /chat/completions in 1.654059 seconds
2024-01-02 00:26:26,105 - INFO - Retrying request to /chat/completions in 1.834595 seconds
2024-01-02 00:26:26,109 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:26,109 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:26,111 - INFO - Retrying request to /chat/completions in 1.843956 seconds
2024-01-02 00:26:26,112 - INFO - Retrying request to /chat/completions in 1.658126 seconds
2024-01-02 00:26:26,123 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:26,123 - INFO - Retrying request to /chat/completions in 1.951848 seconds
2024-01-02 00:26:26,163 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:26,163 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:26,164 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:26,165 - INFO - Retrying request to /chat/completions in 1.782906 seconds
2024-01-02 00:26:26,165 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:26,165 - INFO - Retrying request to /chat/completions in 1.617028 seconds
2024-01-02 00:26:26,165 - INFO - Retrying request to /chat/completions in 1.545315 seconds
2024-01-02 00:26:26,166 - INFO - Retrying request to /chat/completions in 1.983583 seconds
2024-01-02 00:26:26,170 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:26,170 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:26,172 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:26,172 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:26,173 - INFO - Retrying request to /chat/completions in 1.611347 seconds
2024-01-02 00:26:26,173 - INFO - Retrying request to /chat/completions in 1.746404 seconds
2024-01-02 00:26:26,173 - INFO - Retrying request to /chat/completions in 1.996552 seconds
2024-01-02 00:26:26,173 - INFO - Retrying request to /chat/completions in 1.606927 seconds
2024-01-02 00:26:26,189 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:26,190 - INFO - Retrying request to /chat/completions in 1.673062 seconds
2024-01-02 00:26:26,195 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:26,195 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:26,196 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:26,196 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:26,196 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:26,197 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:26,197 - INFO - Retrying request to /chat/completions in 1.597154 seconds
2024-01-02 00:26:26,198 - INFO - Retrying request to /chat/completions in 1.652396 seconds
2024-01-02 00:26:26,198 - INFO - Retrying request to /chat/completions in 1.694744 seconds
2024-01-02 00:26:26,200 - INFO - Retrying request to /chat/completions in 1.950450 seconds
2024-01-02 00:26:26,200 - INFO - Retrying request to /chat/completions in 1.853504 seconds
2024-01-02 00:26:26,200 - INFO - Retrying request to /chat/completions in 1.715784 seconds
2024-01-02 00:26:26,208 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:26,208 - INFO - Retrying request to /chat/completions in 1.927935 seconds
2024-01-02 00:26:26,215 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:26,216 - INFO - Retrying request to /chat/completions in 1.612295 seconds
2024-01-02 00:26:26,216 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:26,216 - INFO - Retrying request to /chat/completions in 1.804172 seconds
2024-01-02 00:26:26,218 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:26,219 - INFO - Retrying request to /chat/completions in 1.648989 seconds
2024-01-02 00:26:26,223 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:26,224 - INFO - Retrying request to /chat/completions in 1.835345 seconds
2024-01-02 00:26:26,226 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:26,226 - INFO - Retrying request to /chat/completions in 1.588820 seconds
2024-01-02 00:26:26,231 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:26,233 - INFO - Retrying request to /chat/completions in 1.674195 seconds
2024-01-02 00:26:26,235 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:26,236 - INFO - Retrying request to /chat/completions in 1.531224 seconds
2024-01-02 00:26:26,251 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:26,252 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:26,254 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:26,255 - INFO - Retrying request to /chat/completions in 1.527077 seconds
2024-01-02 00:26:26,255 - INFO - Retrying request to /chat/completions in 1.833316 seconds
2024-01-02 00:26:26,256 - INFO - Retrying request to /chat/completions in 1.887822 seconds
2024-01-02 00:26:26,256 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:26,257 - INFO - Retrying request to /chat/completions in 1.972977 seconds
2024-01-02 00:26:26,267 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:26,269 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:26,270 - INFO - Retrying request to /chat/completions in 1.580020 seconds
2024-01-02 00:26:26,270 - INFO - Retrying request to /chat/completions in 1.773560 seconds
2024-01-02 00:26:26,275 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:26,275 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:26,276 - INFO - Retrying request to /chat/completions in 1.801270 seconds
2024-01-02 00:26:26,276 - INFO - Retrying request to /chat/completions in 1.806813 seconds
2024-01-02 00:26:26,502 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:26,542 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:26,696 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:26,820 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:26,903 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:26,993 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:27,019 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:27,033 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:27,066 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:27,143 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:27,344 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:27,406 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:27,408 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449603, Requested 1434. Please try again in 138ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:27,408 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Depression in Individuals With Diabetic Retinopathy in the US National Health and Nutrition Examination Survey, 2005-2008.\nTo examine the relationship between diabetic retinopathy (DR) and depression in the United States.Retrospective, cross-sectional study.National Health and Nutrition Examination Survey (NHANES) participants between 2005 and 2008 (ages 40-85 years) were included. Prevalence of major depression among DR stages as determined by retinal imaging was estimated. Multivariable models assessed associations between depression and DR.Depression was more common in those with moderate to severe DR (16%) than in those with no DR (7%), mild nonproliferative diabetic retinopathy (NPDR, 6%), or proliferative DR (5%). In a model with DR stages that adjusted for demographic factors, there was an association between moderate to severe DR and depression (odds ratio [OR], 2.46, 95% CI, 1.03-5.85).Depression was more prevalent in those with moderate to severe NPDR than in those with no DR, mild NPDR, or proliferative DR. This relationship is statistically significant after adjustment for demographic factors.</ABSTRACT>'}]
2024-01-02 00:26:27,411 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:27,413 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:27,414 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449530, Requested 1555. Please try again in 144ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:27,415 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Evaluation of levels of uric acid and lipid profile in hospitalized patients with diabetes.\nDiabetes is the most common metabolic disorder that leads to various complications, and among these complications, disruption in the lipid profile and serum uric acid (SUA) is one of the significant cases that can lead to the deterioration of the health status of patients with diabetes. So, we aimed to evaluate the level of SUA and lipid profiles in patients with diabetes. A total of 230 patients with diabetes who were admitted to Razi Hospital, Rasht, Iran, were enrolled in this study. Demographical data and clinical characteristics of the patients include gender, body mass index (BMI), duration of diabetes, history of smoking, FBS, HbA1c, SUA, Creatinine (Cr), Cholesterol (Chol), low-density lipoprotein (LDL), high-density lipoprotein (HDL), triglycerides (TG), retinopathy, hypertension, ischemic heart disease (IHD), and microalbuminuria were recorded. All data were analyzed using the SPSS version 21 by a significant level\u2009<\u20090.05.According to our results, 70 were male, and 160 were female, with a mean age of 57.36\u2009\u20098.05 years and a mean BMI of 28.10\u2009\u20094.62. The most frequent comorbidities were hypertension, 67%. The serum level of FBS, HBA1c, SUA, Cr, Chol, LDL, HDL, and TG were 191.47\u2009\u200971.66\xa0mg/dL, 7.94\u2009\u20091.21\xa0mg/dL, 5.65\u2009\u20091.95\xa0mg/dL, 0.94\u2009\u20090.16\xa0mg/dL, 167.28\u2009\u200945.22\xa0mg/dL, 95.91\u2009\u200937.03\xa0mg/dL, 39.78\u2009\u200910.44\xa0mg/dL, and 186.75\u2009\u200976.65\xa0mg/dL, respectively. Only UA had a significant relationship with TG level (P\u2009<\u20090.05).</ABSTRACT>'}]
2024-01-02 00:26:27,417 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449461, Requested 1711. Please try again in 156ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:27,418 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Microvascular changes in obese adults detected by Optical Coherence Tomography Angiography.\nAim: The aim of this prospective, controlled, non-randomized study was the comparison of the retinal microvascular parameters of obese and nonobese adults. Methods: 184 eyes of 92 subjects were separated to 3 groups. 68 eyes were in the normal weight group, with a body mass index between 18.5 and 24.5 kg/ m2, 60 eyes were in the overweight group, with a body mass index between 25-29.9 kg/ m2, and 56 eyes were in the obese group, with a body mass index \u2265 30 kg/ m2. All the volunteers were applied visual acuity, ocular motility testing, and slit lamp and mydriatic fundus examination. Optical Coherence Tomography Angiography (OCT-A) scanning was practiced with Optovue (Optovue, Inc; Fremont, CA) on a 6.00 x 6.00 mm macular region, in the central fovea. Results: 184 eyes of ninety-two patients were involved in this prospective study. The vessels\' density (VD) in the optic nerve head (ONH) were significantly lower in the overweight and obese adult volunteers compared to the normal weight control group. However, other OCTA parameters (including macular VDs, Foveal avascular zone (FAZ), choriocapillaris plexus (CCP) area) did not demonstrate any significant difference between groups. Subfoveal choroidal thickness (SCT) was higher in the overweight and obese patients when compared to the normal weight control group. Central macular thickness (CMT) did not reveal any significant difference between groups. Conclusion: Even though clinicians are limited in pointing out any differential findings in obese patients only by fundus examination, OCT-A provides a predictable view of the microvascular changes in the retina and choroid in obese patients. Abbreviations: BMI = Body mass index, WHO = World Health Organization, AMD = Age-related macular degeneration, CT = Choroidal thickness, OCTA = Optical Coherence Tomography Angiography, (W/H) ratio = Waist-hip ratio, ETDRS = Early Treatment Diabetic Retinopathy Study, VD = Vessel density, SCP = Superficial capillary plexus, DCP = Deep capillary plexus, CCP = Flow area of the choriocapillaris, FAZ = Avascular zone, CMT = Central macular thickness, ONH = Optic nerve head.</ABSTRACT>'}]
2024-01-02 00:26:27,423 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:27,424 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:27,426 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:27,427 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449370, Requested 1580. Please try again in 126ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:27,427 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Prevalence and risk factors of diabetic peripheral neuropathy: A population-based cross-sectional study in\xa0China.\nTo assess the prevalence of diabetic peripheral neuropathy (DPN) and its risk factors in the type 2 diabetes mellitus (T2DM) population.This cross-sectional study enroled patients with T2DM between July and December 2017 from 24 provinces in China. Diabetic peripheral neuropathy and its severity were assessed by the Toronto clinical scoring system, neuropathy symptoms score (NSS) and neuropathy disability score. The prevalence of DPN and its risk factors were analysed.A total of 14,908 patients with T2DM were enroled. The prevalence of DPN was 67.6%. Among 10,084 patients with DPN, 4808 (47.7%), 3325 (33.0%), and 1951 (19.3%) had mild, moderate, and severe DPN, respectively. The prevalence of DPN in females was higher than in males (69.0% vs. 66.6%, P\xa0=\xa00.002). The prevalence of DPN increased with age and course of diabetes and decreased with body mass index (BMI) and education level (all P for trend <0.05). The comorbidities and complications in patients with DPN were higher than in those without DPN, including hypertension, myocardial infarction, diabetic retinopathy, and diabetic nephropathy (all P\xa0<\xa00.001). Age, hypertension, duration of diabetes, diabetic retinopathy, diabetic nephropathy, glycated haemoglobin, high-density lipoprotein cholesterol, and lower estimated glomerular filtration rate were positively associated with DPN, while BMI, education level, fasting C-peptide, and uric acid were negatively associated with DPN.Among patients with T2DM in China, the prevalence of DPN is high, especially in the elderly, low-income, and undereducated patients.</ABSTRACT>'}]
2024-01-02 00:26:27,427 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449343, Requested 1471. Please try again in 108ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:27,429 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Displacement of Submacular Hemorrhage With Vitrectomy Combined With Subretinal Balanced Salt Solution and Air.\nTo describe a technique of displacement of submacular hemorrhage (SMH) using subretinal injection of balanced salt solution and filtered air.Patients presenting within 2 weeks of massive SMH (>4 disk diameter) were prospectively included. All patients underwent 25-gauge pars plana vitrectomy, posterior vitreous detachment, injection of subretinal balanced salt solution and filtered air followed by partial fluid air exchange, 20% sulfur hexafluoride tamponade, and heads-up positioning postoperatively. Degree of displacement of SMH was assessed at 1 month and change in best-corrected visual acuity was assessed at 3 months.Ten patients with massive SMH who underwent the aforementioned procedure were included. Complete displacement of bleed from the macula was achieved in nine (90%) of 10 eyes at 1 month. There was significant improvement in best-corrected visual acuity from baseline at 1 month ( P = 0.015) and 3 months ( P = 0.043).Pars plana vitrectomy with injection of subretinal balanced salt solution and filtered air was well-tolerated and efficacious in displacing large and thick SMH in patients operated within 2 weeks of onset of symptoms.</ABSTRACT>'}]
2024-01-02 00:26:27,429 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449302, Requested 1600. Please try again in 120ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:27,429 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>RBP4-based Multimarker Score: A Prognostic Tool for Adverse Cardiovascular Events in Acute Coronary Syndrome Patients.\nRetinol binding protein 4 (RBP4) has been implicated in the progression of cardiovascular diseases. However, its association with major adverse cardiovascular events (MACEs) in patients with acute coronary syndrome (ACS) remains obscure.Here, we examined the prognostic value of baseline RBP4 and its derived multimarker score for MACEs in ACS patients.A total of 826 patients with ACS were consecutively recruited from the department of cardiology and prospectively followed up for a median of 1.95 years (interquartile range, 1.02-3.25 years). Plasma RBP4 was measured using enzyme-linked immunosorbent assay. Adjusted associations between RBP4 and its derived multimarker score (1 point was assigned when RBP4 \u2265 38.18\u03bcg/mL, left ventricular ejection fraction [LVEF] \u2264 55%, N-terminal pro-B-type natriuretic peptide [NT-proBNP] \u2265 450 ng/L, estimated glomerular filtration rate [eGFR] \u2264 90 mL/min/1.73 m2, and age \u226560) with MACEs were analyzed.In total, 269 ACS patients (32.57%) experienced MACEs. When patients were grouped by multimarker score (0-1, n = 315; 2-3, n = 406; 4-5, n = 105), there was a significant graded association between RBP4-based multimarker score and risk of MACEs (intermediate score (2-3): HRadj: 1.80; 95% CI, 1.34-2.41; high score (4-5): HRadj: 3.26; 95% CI, 2.21-4.81) and its components (P < .05 for each). Moreover, the prognostic and discriminative value of the RBP4-derived multimarker score remained robust in ACS patients with various high-risk anatomical or clinical characteristics.The RBP4-derived 5-item score serves as a useful risk stratification and decision support for secondary prevention in patients with ACS.</ABSTRACT>'}]
2024-01-02 00:26:27,442 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:27,446 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449174, Requested 1671. Please try again in 112ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:27,446 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Phloretin suppresses intestinal inflammation and maintained epithelial tight junction integrity by modulating cytokines secretion in in vitro model of gut inflammation.\nUlcerative colitis is a type of inflammatory bowel disease which in long run can lead to colorectal cancer (CRC). Chronic inflammation can be a key factor for the occurrence of CRC thus mitigating an inflammation can be a preventive strategy for the occurrence of CRC. In this study we have explored the anti-inflammatory potential of phloretin, in in vitro gut inflammation model, developed by co-culture of Caco2 (intestinal epithelial) cells and RAW264.7 macrophages (immune cells). Phloretin is a dihydrochalcone present in apple, pear and strawberries. An anti-inflammatory effect of phloretin in reducing LPS induced inflammation and maintenance of transepithelial electric resistance (TEER) in Caco2 cells was examined. Paracellular permeability assay was performed using Lucifer yellow dye to evaluate the effect of phloretin in inhibiting gut leakiness caused by inflammatory mediators secreted by activated macrophages. Phloretin attenuated LPS induced nitric oxide levels, oxidative stress, depolarization of mitochondrial membrane potential in Caco2 cells as evidenced by reduction in reactive oxygen species (ROS), and enhancement of MMP, and decrease in inflammatory cytokines IL8, TNF\u03b1, IL1\u03b2 and IL6. It exhibited anti-inflammatory activity by inhibiting the expression of NF\u03baB, iNOS and Cox2. Phloretin maintained the epithelial integrity by regulating the expression of tight junction proteins ZO1, occludin, Claudin1 and JAM. Phloretin reduced LPS induced levels of Cox2 along with the reduction in Src expression which further regulated an expression of tight junction protein occludin. Phloretin in combination to sodium pyruvate exhibited potential anti-inflammatory activity via targeting NFkB signaling. Our findings paved a way to position phloretin as nutraceutical in preventing the occurrence of colitis and culmination of disease into colitis associated colorectal cancer.</ABSTRACT>'}]
2024-01-02 00:26:27,466 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:27,468 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:27,471 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449088, Requested 1174. Please try again in 34ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:27,472 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>RPGR-Associated Cone-Rod Degeneration and Tapetal-Like Reflex in a Male Patient.\n</ABSTRACT>'}]
2024-01-02 00:26:27,474 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449000, Requested 1374. Please try again in 49ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:27,474 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Retromode imaging in retinal diseases: A systematic review of the literature.\nRetromode scanning laser ophthalmoscopy imaging captures a pseudo-3-dimensional image of the ocular fundus. Retromode scanning laser ophthalmoscopy imaging was introduced first in 2008 using the Nidek F-10 scanning laser ophthalmoscope (F-10; Nidek Co., Gamagori, Japan). At that time, no major role was described for this imaging modality. The interest in retromode scanning laser ophthalmoscopy imaging is reemerging with the recent advent of the Mirante that combines scanning laser ophthalmoscopy and optical coherence tomography (Nidek Co., Gamagori, Japan) that can capture retromode images of the fundus. We summarize the findings and clinical implications of retromode imaging using the Nidek F-10 and the Mirante in retinal diseases with the aim of helping researchers direct their future studies.</ABSTRACT>'}]
2024-01-02 00:26:27,475 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:27,476 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:27,478 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448833, Requested 1516. Please try again in 46ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:27,478 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Appraisal of Cardiovascular Risk Factors, Biomarkers, and Ocular Imaging in Cardiovascular Risk Prediction.\nCardiovascular disease remains a leading cause of death worldwide despite the use of available cardiovascular disease risk prediction tools. Identification of high-risk individuals via risk stratification and screening at sub-clinical stages, which may be offered by ocular screening, is important to prevent major adverse cardiac events. Retinal microvasculature has been widely researched for potential application in both diabetes and cardiovascular disease risk prediction. However, the conjunctival microvasculature as a tool for cardiovascular disease risk prediction remains largely unexplored. The purpose of this review is to evaluate the current cardiovascular risk assessment methods, identifying gaps in the literature that imaging of the ocular microcirculation may have the potential to fill. This review also explores the themes of machine learning, risk scores, biomarkers, medical imaging, and clinical risk factors. Cardiovascular risk classification varies based on the population assessed, the risk factors included, and the assessment methods. A more tailored, standardised and feasible approach to cardiovascular risk prediction that utilises technological and medical imaging advances, which may be offered by ocular imaging, is required to support cardiovascular disease prevention strategies and clinical guidelines.</ABSTRACT>'}]
2024-01-02 00:26:27,478 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448926, Requested 1594. Please try again in 69ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:27,478 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Risk factors for intolerance of oral 5-aminosalicylic acid preparations in pediatric ulcerative colitis.\nNo previous study of Japanese children with ulcerative colitis (UC) has reported the risk factors for intolerance of 5-aminosalicylic acid (5-ASA). We aimed to identify risk factors for intolerance of oral 5-ASA preparations in pediatric UC.Patients with childhood-onset UC who were seen at our hospital between November 2003 and March 2020 were investigated. Intolerance of 5-ASA was defined as having clinical symptoms (pyrexia, abdominal pain, diarrhea, bloody stool) that worsened after starting oral administration of 5-ASA and improved after discontinuation of 5-ASA. Patient sex, age, body size, laboratory data, pediatric UC activity index scores, and colonoscopy-based determinations of the extent and severity of the affected lesion at initiation of 5-ASA of intolerant and tolerant groups were compared.Fifteen patients were in the intolerant group, and 37 were in the tolerant group. The leukocyte count, C-reactive protein level, and erythrocyte sedimentation rate were significantly higher in the intolerant group than the tolerant group; the albumin level in the intolerant group was significantly lower. All intolerant patients and 68% of tolerant patients had pancolitis (Paris classification E4). Patients with a large, affected area (Paris classifications E3 and E4) more frequently had intolerance to 5-ASA than patients with a small lesion. The cumulative Mayo endoscopic subscore (cMES), which is the sum of MES scores for six regions of the large intestine, was significantly higher in the intolerant group.Pediatric UC patients with more intense inflammation and a large lesion could have an increased risk of intolerance for 5-ASA.</ABSTRACT>'}]
2024-01-02 00:26:27,479 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:27,479 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448842, Requested 1531. Please try again in 49ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:27,480 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Use of a Backflush Needle with a Silicone Tip Cannula to Embed Lamellar Hole-Associated Epiretinal Proliferation.\nFor the treatment of lamellar macular hole, the recent development of a lamellar hole-associated epiretinal proliferation (LHEP) embedding technique is likely to improve functional and anatomical results. However, the peeling of LHEP is often technically challenging. We have developed a new technique using a backflush needle with a silicone tip cannula that seems safer and more effective for use in LHEP embedding.A 25-gauge vitrectomy system with an enhancing visual acuity system (D.O.R.C., Zuidland, Netherlands) was used in all cases. After core vitrectomy, triamcinolone acetonide (Wakamoto Pharmaceutical Co., Ltd., Tokyo, Japan) was used to visualize the membrane. A 25-gauge backflush needle with a silicone tip cannula was used to remove the thin preretinal membrane centripetally, leaving an LHEP on the edge of the hole. Brilliant Blue G (internal limiting membrane Blue; D.O.R.C.) was then used to stain the internal limiting membrane.This technique was used in six eyes with lamellar macular holes. In all cases, peeling and embedding of the LHEP was effectively performed without damaging the internal limiting membrane or causing retinal hemorrhage. No other intraoperative or postoperative complications were experienced.Using a silicone-tipped backflush needle with passive aspiration was a simple and effective technique for peeling and embedding of LHEPs in this small series.</ABSTRACT>'}]
2024-01-02 00:26:27,491 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:27,493 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448764, Requested 1578. Please try again in 45ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:27,493 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Assessing Change in Exudative Age-Related Macular Degeneration With Macular Thickness Maps as a Surrogate Strategy for Remote Patient Monitoring.\nTo determine if macular thickness maps (MTMs) are sufficient to guide management of eyes with exudative age-related macular degeneration (eAMD), we compared the ability to detect change using MTMs with the ability to detect change using the entire optical coherence tomography (OCT) scan in patients undergoing therapy.Retrospective, comparative diagnostic analysis.Patients with eAMD were imaged using macula-centered 6\xa0\xa06-mm OCT scans (CIRRUS HD-OCT 5000; Zeiss). In each case, graders were asked to determine if there were changes that warranted a full clinical assessment after viewing 2 consecutive scans using one of 3 different imaging strategies: MTMs alone, individual foveal-centered B scans alone, or 5 macular B scans including the foveal-centered B scan. Graders were told the 2 scans were taken 2 weeks apart. The consensus ground truth was reached by the graders using a CIRRUS review station to evaluate all the information contained within the OCT scans.A total of 53 eyes were included in this study with 1385 imaging sessions. The Fleiss kappa was highest when graders were given MTMs alone compared with the ground truth. When the averages of all 5 graders were compared with the ground truth, the MTMs alone showed the highest level of agreement (90.05%, SD 0.78%) followed by the central B scans (87.87%, SD 1.59%) and the 5-B scan method (86.512%, SD 0.64%).MTMs alone provide sufficient information to easily identify recurrent exudation in patients with eAMD, and these maps may be all that is needed for remote monitoring.</ABSTRACT>'}]
2024-01-02 00:26:27,500 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:27,502 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448710, Requested 1664. Please try again in 49ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:27,502 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Choroidal neovascularization associated with butterfly-shaped pattern dystrophy - a case report.\nThe pattern dystrophies (PDs) are a group of primarily autosomal dominant inherited macular diseases that cause the deposition of lipofuscin in retinal pigment epithelium (RPE) and may lead to significant vision loss in later life. Patients can develop choroidal neovascularization (CNV) and/ or geographic atrophy (GA) and for this reason they are often misdiagnosed as age-related macular degeneration (AMD). We presented a case of a 66-year-old patient complaining of vision loss in the right eye (RE) for 8 months. At the initial examination, his best corrected visual acuity (BCVA) was 0.6 in the RE. Optical coherence tomography angiography (OCTA), fundus autofluorescence (FAF) and fundus fluorescein angiography (FFA) allowed to diagnose butterfly-shaped PD in both eyes with choroidal neovascularization (CNV) in the RE. The patient was treated with three intravitreal anti-vascular epithelial growth factor (anti-VEGF, ranibizumab) injections during six weeks intervals, which improved and stabilized the BCVA of the RE to 0.7 during the over two-year observation period. Our report contributes to the still limited data regarding CNV associated with butterfly-shaped PDs and the results of treatment with ranibizumab. Abbreviations: AMD = age-related macular degeneration, anti-VEGF = anti-vascular epithelial growth factor, AOFVD = adult-onset foveomacular vitelliform dystrophy, BCVA = best corrected visual acuity, CNV = choroidal neovascularization, FAF = fundus autofluorescence, FFA = fundus fluorescein angiography, GA = geographic atrophy, LE = left eye, MIDD = maternally inherited diabetes and deafness, OCT = optical coherence tomography, OCTA = optical coherence tomography angiography, OU = oculus uterque, both eyes, PD = pattern dystrophy, PDSFF = pattern dystrophy simulating fundus flavimaculatus, PDT = photodynamic therapy, PRPH2 = peripherine-2, RE = right eye, RPE = retinal pigment epithelium, VA = visual acuity.</ABSTRACT>'}]
2024-01-02 00:26:27,503 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:27,504 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448682, Requested 1558. Please try again in 32ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:27,505 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Genetic Obesity Disorders: Body Mass Index Trajectories and Age of Onset\xa0of Obesity Compared with Children with Obesity from the General\xa0Population.\nWe sought to assess body mass index trajectories of children with genetic obesity to identify optimal early age of onset of obesity (AoO) cut-offs for genetic screening.This longitudinal, observational study included growth measurements from birth onward of children with nonsyndromic and syndromic genetic obesity and control children with obesity from a population-based cohort. Diagnostic performance of AoO was evaluated.We describe the body mass index trajectories of 62 children with genetic obesity (29 nonsyndromic, 33 syndromic) and 298 controls. Median AoO was 1.2\xa0years in nonsyndromic genetic obesity (0.4 and 0.6\xa0years in biallelic LEPR and MC4R; 1.7 in heterozygous MC4R); 2.0\xa0years in syndromic genetic obesity (0.9, 2.3, 4.3, and 6.8\xa0years in pseudohypoparathyroidism, Bardet-Biedl syndrome, 16p11.2del syndrome, and Temple syndrome, respectively); and 3.8\xa0years in controls. The optimal AoO cut-off was \u22643.9\xa0years (sensitivity, 0.83; specificity, 0.49; area under the curve, 0.79; P\xa0<\xa0.001) for nonsyndromic and \u22644.7\xa0years (sensitivity, 0.82; specificity, 0.37; area under the curve, 0.68; P\xa0=\xa0.001) for syndromic genetic obesity.Optimal AoO cut-off as single parameter to determine which children should undergo genetic testing was \u22643.9\xa0years. In case of older AoO, additional features indicative of genetic obesity should be present\xa0to warrant genetic testing. Optimal cut-offs might differ across different races and ethnicities.</ABSTRACT>'}]
2024-01-02 00:26:27,520 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:27,571 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:27,571 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449767, Requested 1583. Please try again in 180ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:27,572 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Autoimmune pancreatitis associated with inflammatory bowel diseases: A retrospectively bidirectional case-control study in China.\nAutoimmune pancreatitis (AIP) is a rare and enigmatic immune-mediated inflammatory disease. We aimed to investigate the prevalence, characteristics, and associated factors of AIP-inflammatory bowel disease (IBD) in China.A retrospective bidirectional case-control study was performed. The diagnoses of IBD and AIP were made based on the European Crohn\'s and Colitis Organization guidelines and the International Consensus Diagnostic Criteria. IBD controls were matched by age, sex, and IBD type at a ratio of 1:4, while AIP controls were matched by AIP types.The age-standardized prevalence of AIP-IBD patients in the IBD and AIP population were 292.0 and 8151.93 per 100 000 population, respectively. IBD patients had a higher risk of AIP compared to non-IBD patients (odds ratio 8.4, 95% confidence interval 4.7-14.9, P\u2009<\u20090.0001), and AIP patients had a higher risk of developing IBD compared to the general population in China. The mean age at diagnosis of IBD and AIP was 34.83\u2009years and 40.42\u2009years. IBD was diagnosed before AIP in seven cases. The median total IBD and AIP duration was 43.5\u2009months and 13.5\u2009months. Use of mesalamine and tuberculosis were associated with AIP in IBD patients (P\u2009=\u20090.031). And fecal occult blood test was associated with IBD in AIP patients (P\u2009=\u20090.008).Most AIP-IBD patients had ulcerative colitis and type 2 AIP. IBD patients are more likely to develop AIP compared to the general population, and vice versa. Use of mesalamine and tuberculosis infection were associated with AIP, and fecal occult blood test was associated with IBD.</ABSTRACT>'}]
2024-01-02 00:26:27,577 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:27,578 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449716, Requested 1372. Please try again in 145ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:27,578 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Periocular Mass Due to Persistent Secretion Within a Transplanted Parotid Duct.\nA male patient underwent microvascular transplantation of an autologous submandibular gland and its associated (Wharton\'s) duct for management of very severe right keratoconjunctivitis sicca due to Stevens-Johnson syndrome; due to hypersecretion, the gland was later removed in toto. Twenty-two years later, he presented with a nontender, sausage-like mass lying subcutaneously in the right temple. Intraoperatively a fluctuant tubular mass passing from the temporalis fossa to the superotemporal conjunctiva was identified and excised intact. Histology showed a slightly proteinaceous fluid within a duct lined with cuboidal epithelium, this being compatible with Wharton\'s duct. This case highlights that iatrogenic causes should be considered with any history of periocular injury or surgery.</ABSTRACT>'}]
2024-01-02 00:26:27,592 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:27,593 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:27,594 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:27,596 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449745, Requested 1591. Please try again in 178ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:27,596 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Optical coherence tomography angiography in diabetic retinopathy.\nThere remain many unanswered questions on how to assess and treat the pathology and complications that arise from diabetic retinopathy (DR). Optical coherence tomography angiography (OCTA) is a novel and non-invasive three-dimensional imaging method that can visualize capillaries in all retinal layers. Numerous studies have confirmed that OCTA can identify early evidence of microvascular changes and provide quantitative assessment of the extent of diseases such as DR and its complications. A number of informative OCTA metrics could be used to assess DR in clinical trials, including measurements of the foveal avascular zone (FAZ; area, acircularity, 3D para-FAZ vessel density), vessel density, extrafoveal avascular zones, and neovascularization. Assessing patients with DR using a full-retinal slab OCTA image can limit segmentation errors and confounding factors such as those related to center-involved diabetic macular edema. Given emerging data suggesting the importance of the peripheral retinal vasculature in assessing and predicting DR progression, wide-field OCTA imaging should also be used. Finally, the use of automated methods and algorithms for OCTA image analysis, such as those that can distinguish between areas of true and false signals, reconstruct images, and produce quantitative metrics, such as FAZ area, will greatly improve the efficiency and standardization of results between studies. Most importantly, clinical trial protocols should account for the relatively high frequency of poor-quality data related to sub-optimal imaging conditions in DR and should incorporate time for assessing OCTA image quality and re-imaging patients where necessary.</ABSTRACT>'}]
2024-01-02 00:26:27,596 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449705, Requested 1809. Please try again in 201ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:27,596 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Trends in the Diagnosed Prevalence and Incidence of Major Eye Diseases in Medicare Part B Fee-for-Service Beneficiaries 68 Years of Age or Older.\nTo study contemporary trends in the diagnosed prevalence and incidence of age-related eye diseases among Medicare Fee-for-Service (FFS) beneficiaries.Analysis of Medicare administrative claims data.Medicare FFS beneficiaries 68 years of age and older from 2005 through 2020 who were enrolled continuously in both Part A and Part B for 3 years, including the index year and a 2-year lookback period.Annual cross-sectional diagnosed prevalence and incidence rates were calculated. Age standardization was performed using the direct standardization method to account for changes in the age structure of the study population. Rates stratified by demographics (age, sex, race, and ethnicity) also were calculated.Annual prevalence and incidence of diagnosed age-related macular degeneration (AMD), diabetic retinopathy (DR) (among those with diabetes), and glaucoma.At baseline, in 2005, 60% of included beneficiaries were female, 20% were 85 years of age or older, 86% were non-Hispanic White, and one-quarter had a diagnosis of diabetes. From 2005 through 2019, the\xa0prevalence of a diagnosis of any of the conditions studied increased from 16.4% (n = 3 628 996) to 17.9% (n\xa0= 3 731 281). Diagnosed incidence decreased over this period from 4.9% (n = 954 878) in 2005 to 4.2% in 2019 (n\xa0=\xa0757 696). The diagnosed prevalence of AMD increased from 6.8% (n\xa0= 1 504 770) to 9.4% (n\xa0= 1 965 176); the diagnosed prevalence of any DR among those with diabetes decreased from 9.3% (n\xa0= 504 135) to 9.0% (n\xa0=\xa0532 859), although the diagnosed prevalence of vision-threatening DR increased from 2.0% to 3.4%; and the diagnosed prevalence of any diagnosed glaucoma decreased from 8.8% (n\xa0= 1 951 141) to 8.1% (n\xa0= 1 692 837). In 2020, the diagnosed prevalence and incidence of all diagnoses decreased. During the study period, we detected demographic differences in the prevalence and incidence of diagnosis of each condition.This study presents updated data on the prevalence and incidence of diagnosed major chronic, age-related eye diseases among Medicare FFS beneficiaries. Compared with older epidemiologic estimates, we found that the diagnosed prevalence of each condition studied was higher in more recent years. These findings may inform public health and policy planning and resource allocation to address the eye health of an increasingly older United States population.The author(s) have no proprietary or commercial interest in any materials discussed in this article.</ABSTRACT>'}]
2024-01-02 00:26:27,598 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449771, Requested 1180. Please try again in 126ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:27,598 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Erythema induratum in a patient with recurrent oral ulceration: Crohn\'s disease of the esophagus and colon.\n</ABSTRACT>'}]
2024-01-02 00:26:27,602 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:27,603 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:27,604 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449212, Requested 1635. Please try again in 112ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:27,604 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Evolution of macular atrophy in eyes with neovascular age-related macular degeneration compared to fellow non-neovascular eyes.\n\u03a4o evaluate the evolution of macular atrophy (MA) in patients with neovascular AMD (nAMD), compared with their fellow eyes exhibiting dry AMD (dAMD).This retrospective study included 124 patients from three centers treated with anti-VEGF in their nAMD eye and having dAMD in the fellow eye. Patients without MA at baseline were analyzed to study the time to first MA development. Synchronous and unsynchronous time course of MA was also studied. MA was evaluated using near-infrared images, while all available optical coherence tomography (OCT) images were used to confirm the criteria proposed by the Classification of Atrophy Meetings group for complete MA.MA first detection in nAMD eyes increased significantly from year 2 to 6 compared to dAMD eyes. Over the study\'s follow-up, 45.1% of nAMD-E developed MA, compared to 16.5% of fellow eyes (p\u2009<\u20090.001). When MA in the two eyes was compared in a synchronous paired manner over 4\xa0years, nAMD eyes had an average MA progression rate of 0.275\xa0mm/year versus 0.110\xa0mm/year in their fellow dAMD eyes. Multivariate ANOVA revealed significant time (p\u2009<\u20090.001), eye (p\u2009=\u20090.003), and time-eye interaction (p\u2009<\u20090.001) effects. However, when MA did develop in dAMD eyes and was compared in an asynchronous manner to MA of nAMD eyes, it was found to progress faster in dAMD eyes (dAMD: 0.295\xa0mm/year vs. nAMD: 0.176\xa0mm/year) with a significant time-eye interaction (p\u2009=\u20090.015).In this study, a significant difference in MA incidence and progression was documented in eyes with nAMD under treatment, compared to fellow eye exhibiting dAMD. Eyes with nAMD tended to develop more MA compared to fellow dAMD eyes. However, when atrophy did develop in the fellow dAMD eyes, it progressed faster over time compared to MA in nAMD eyes.</ABSTRACT>'}]
2024-01-02 00:26:27,610 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:27,610 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:27,614 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:27,614 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:27,614 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:27,618 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449109, Requested 1169. Please try again in 37ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:27,618 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Hyperviscosity retinopathy from chronic myelogenous leukemia.\n</ABSTRACT>'}]
2024-01-02 00:26:27,619 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449030, Requested 1616. Please try again in 86ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:27,619 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>The impact of an ultrasound atlas for scoring salivary glands in primary Sjgren\'s syndrome: a pilot study.\nThe objective of this pilot study was to assess the impact of a salivary gland ultrasound (SGUS) atlas for scoring parenchymal changes in Sjgren\'s syndrome by assessing the reliability of the scoring system (0-3), without and with the use of the SGUS atlas. Ten participants with varying experience in SGUS contributed to the reliability exercise. Thirty SGUS images of the submandibular and parotid gland with abnormalities ranging from 0 to 3 were scored using the written definitions of the OMERACT SGUS scoring system and using the SGUS atlas based on the OMERACT scoring system. For intra-reader reliability, two rounds were performed without and with the atlas-in the 2nd round the 30 images were rearranged in random order by a physician not included in the scoring. Inter-reader reliability was also determined in both rounds. Without using the atlas, the SGUS OMERACT scoring system showed fair inter-reader reliability in round 1 (mean kappa 0.36; range 0.06-0.69) and moderate intra-reader reliability (mean kappa 0.55; range 0.28-0.81). With the atlas, inter-reader reliability improved in round 1 to moderate (mean kappa 0.52; range 0.31-0.77) and intra-reader reliability to good (mean kappa 0.69; range 0.46-0.86). Higher intra-reader reliability was noted in participants with previous SGUS experience. The SGUS atlas increased both intra- and inter-reader reliability for scoring gland pathology in participants with varying SGUS experience suggesting a possible future role in clinical practice and trials. Key Points  Ultrasonography can detect parenchymal changes in salivary glands in patients with Sjgren\'s disease.  An ultrasound atlas may improve reliability of scoring parenchymal changes in salivary glands.</ABSTRACT>'}]
2024-01-02 00:26:27,620 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449037, Requested 1627. Please try again in 88ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:27,620 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Skeletal muscle quality, measured via phase angle, and cardiorespiratory fitness in patients with obesity and heart failure with preserved ejection fraction.\nCardiorespiratory fitness (CRF) is influenced by body composition quantity and quality in heart failure with preserved ejection fraction (HFpEF) and obesity. Bioelectrical impedance analysis (BIA) provides a noninvasive quantitative and qualitative body composition assessment. The aim of this study was to determine the role of phase angle (PhA), a BIA-measure of skeletal muscle quality and body cell mass, on CRF in patients with obesity and HFpEF.Fifty-nine consecutive outpatients with HFpEF underwent cardiopulmonary exercise testing to measure CRF. Single-frequency segmental BIA was used to measure PhA and body composition quantity. Resting Doppler echocardiography and biomarkers were measured to assess cardiac function and systemic inflammation.Compared with patients with lower PhA, patients with higher PhA (above mean 5.8) presented a greater absolute peak oxygen consumption (VO2; 1.83 [1.3-2.1] versus 1.39 [1.1-1.6] L/min, P = 0.003), VO2 peak adjusted for body weight (17.5 [12.3-18.1] versus 13.3 [12.7-15.2] mL/kg/min, P\xa0=\xa00.040), and a lower edema index (48.7 [2.9] versus 51.4% [2.7], P < 0.001) and N-terminal pro-B-type natriuretic peptide (NT-proBNP; 64 [50-121] versus 183 [68-343.5] pg/dL, P < 0.001). In the overall sample, PhA was correlated with absolute VO2 peak (r\xa0=\xa00.468, P < 0.001), VO2 peak adjusted for body weight (r\xa0=\xa00.368, P = 0.004), VO2 peak adjusted for fat-free mass (r\xa0=\xa00.315, P = 0.015), edema index (r\xa0=\xa0-0.508, P < 0.001), and NT-proBNP (r\xa0=\xa0-0.579, P < 0.001). PhA remained a significant predictor for CRF even after adjustment for potential confounders and HFpEF severity.In patients with obesity and HFpEF, a greater PhA is an independent predictor for favorable CRF.</ABSTRACT>'}]
2024-01-02 00:26:27,621 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449047, Requested 2010. Please try again in 140ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:27,621 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Beyond dry eye: The greater extent of Sjgren\'s systemic disease symptoms, the impact of COVID-19 and perceptions towards telemedicine identified through a patient co-designed study.\nSjgren\'s (\'SHOW-grins\') is a chronic debilitating autoimmune disease characterised by dry eyes and dry mouth, secondary to reduced exocrine function of both the lacrimal and salivary glands. The persistent, severe\xa0and serious systemic complications of Sjgren\'s are poorly understood and often unappreciated, resulting in significant morbidity and treatment burden. This study aimed to explore the experiences of those living with Sjgren\'s, specifically access to healthcare and attitude towards telemedicine. Additionally, we sought to collect information regarding the impact of the pandemic on their quality of life (QoL).One hundred and ninety-four individuals attended an Irish Sjgren\'s Webinar. Attendees were invited to participate in two online surveys after the webinar. The first survey gathered information related to demographics, disease\xa0and experiences during the COVID-19 pandemic. A combination of bespoke items and validated questionnaires (EULAR Sjgren\'s Syndrome Patient Reported Index [ESSPRI], COVID-19 Impact on Quality of Life\xa0[COV19-QoL]) was used. The second survey consisted of a shortened Telehealth Usability Questionnaire. Both were prepared in collaboration with a patient advocate.Survey 1: n\u2009=\u200976; response rate\u2009=\u200939.2%. Thirty-one respondents (41.4%) to survey 1 reported a delay of \u22655 years between the onset of symptoms and diagnosis. Dry mouth was the most common symptom experienced (76.8%, n\u2009=\u200963), followed by dry eye (74.4%, n\u2009=\u200961), fatigue (57.3%, n\u2009=\u200947) and joint pain (53.7%,\xa0n\u2009=\u200944), but a range of other symptoms were also reported. COV19-QoL results indicated that the pandemic had a detrimental effect on participants\' overall QoL (4.0\u2009\u20091.0) and physical health (4.0\u2009\u20090.8) in particular. COV19-QoL and ESSPRI scores were moderately correlated (0.36, p\u2009=\u2009.002). Over 70% of respondents had a medical appointment cancelled, delayed or rescheduled (n\u2009=\u200960). Survey 2: n\u2009=\u200957; response rate\u2009=\u200929.4%. Those that had interacted with telemedicine reported largely positive experiences with the virtual model.Clinicians should be aware of the range of symptoms experienced by patients with Sjgren\'s beyond those of sicca (dry eye and dry mouth) and fatigue. COVID-19 has negatively influenced the self-reported health and well-being of those with Sjgren\'s, particularly those with higher symptom scores. It is vital that optimised telemedicine models are implemented to ensure continuity in the provision of healthcare for those with chronic illness such as Sjgren\'s and in preparation for possible future pandemics.A group of people living with Sjgren\'s co-designed the structure and content of the webinar where the survey was shared. A public and patient involvement\xa0(PPI) contributor also collaborated in the selection of questionnaires used in the study, ensuring that the questions asked would best reflect the priorities of patients. They contributed to the writing of this manuscript as co-authors. Additionally, the research team and Sjgren\'s patients who contributed to this work have gone on to establish Sjgren\'s Research Ireland, a collaboration between patient advocates, researchers\xa0and PPI facilitators.</ABSTRACT>'}]
2024-01-02 00:26:27,621 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448948, Requested 1626. Please try again in 76ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:27,621 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>External Compressive Ischemic Orbitopathy: A Rising Clinical Entity.\nSaturday night retinopathy, the term coined by Jayam et al . in 1974, is a rare condition in which external compression of the orbit during a drug and alcohol stupor causes a unilateral orbitopathy with ophthalmoplegia and ischemic retinopathy. This condition has been increasingly reported in the last decade, correlating with an increasing burden of substance use. This condition mirrors a similar entity typically reported in patients following spinal surgery, where a headrest supporting the patient\'s face compresses the orbit. The current authors combine these 2 entities, entitled external compressive ischemic orbitopathy, and present a comprehensive literature review describing this entity.A systematic review was carried out in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. All related publications of vision loss in the setting of orbital compression were reviewed. Data collected included patient demographics, precipitating circumstances of vision loss, presenting ocular symptoms, outcomes, and ancillary imaging.In total 31 articles were selected for inclusion, yielding 46 patients. A total of 10 patients suffered orbitopathy in the setting of a drug stupor, and 36 following prone-positioned surgery. However, 79% of patients presented with visual acuity of light perception or worse. Also, 86% of patients presented with ophthalmoplegia, 92% with proptosis and orbital edema, and 86% with varying degrees of retinal ischemia. When compared with iatrogenic cases, self-induced stuporous cases demonstrated worse presenting visual acuity, ophthalmoplegia, retinal and choroidal filling, and worse final outcomes.External compressive ischemic orbitopathy is a severe vision-threatening condition that has been increasingly reported in the last decade.</ABSTRACT>'}]
2024-01-02 00:26:27,636 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:27,636 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:27,637 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448728, Requested 1559. Please try again in 38ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:27,637 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Rare case report: a 26-year-old man with Eales\' disease.\nPurpose: To report the case of a 26-year-old male with bilateral Eales\' disease that led to total blindness in the left eye and legal blindness in the right eye in a short time. Methods: A total clinical systemic examination, computed tomography, magnetic resonance imaging, genetic testing, and optical coherence tomography were performed in the reported case. Results: The eye condition was managed by scatter laser treatment, Anti-VEGF injections, anterior chamber paracentesis and trabeculectomy. Non-steroidal eye drops, as well as prostaglandin analogues, beta-blockers, and carbonic anhydrase inhibitors, have been used as local treatment. Systemic treatment included an intravenous methylprednisolone course, oral corticosteroids, azathioprine, mycophenolate mofetil and a total amount of 12 Anti-VEGF injections. Conclusion: Despite the aggressive treatment with oral steroids, immunosuppressants, and anti-VEGF injections, there were many exacerbations, and remission was not achieved. As a result, aggressive neovascular glaucoma developed, which led to total blindness in the left eye and legal blindness in the right eye. Abbreviations: HLA = human leukocyte antigens, Anti-VEGF = vascular endothelial growth factor inhibitors, BCVA = best corrected visual acuity, FA = fundus angiography, HBsAg = hepatitis B surface antigen, Anti-HCV = hepatitis C antibodies, TPHA = Treponema Pallidum hemagglutination assay, PCR = polymerase chain reaction, HSV = Herpes simplex virus, VZV = Varicella zoster virus, CMV = cytomegalovirus, IOP = intraocular pressure.</ABSTRACT>'}]
2024-01-02 00:26:27,638 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448792, Requested 1660. Please try again in 60ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:27,638 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>The Comparative Effectiveness of Ciprofloxacin and Metronidazole for an Initial Episode of Pouchitis: A Propensity-Matched Study.\nThere is minimal evidence regarding the comparative effectiveness of individual antibiotics in the treatment of pouchitis. We sought to evaluate the comparative effectiveness of ciprofloxacin monotherapy, metronidazole monotherapy, and combination therapy (ciprofloxacin and metronidazole) in the treatment of an initial episode of pouchitis after ileal pouch-anal anastomosis for ulcerative colitis (UC).We performed a retrospective cohort study in TriNetX, a global federated research network of electronic health records. Primary outcomes were failure of initial antibiotic therapy and the development of recurrent pouchitis in the first 12 months after an initial episode of pouchitis. One-to-one propensity score matching was performed for age, sex, race, primary sclerosing cholangitis, nicotine dependence, obesity, and previous exposure to tumor necrosis factor inhibitors between the cohorts.Among 271 patients who developed pouchitis (mean age at ileal pouch-anal anastomosis 35.8 years, male sex 57%) and were treated with ciprofloxacin, metronidazole, or combination therapy, 190 (70%) developed recurrent pouchitis. After propensity score matching, there was no significant difference in the odds of early relapse or nonresponse with ciprofloxacin compared with metronidazole monotherapy (adjusted odds ratio 0.56, 95% confidence interval 0.23-1.34) or when either monotherapy was compared with combination therapy. There was also no significant difference in odds of recurrent pouchitis when comparing patients treated with ciprofloxacin with metronidazole monotherapy (adjusted odds ratio 0.86, 95% confidence interval 0.40-1.84) or either monotherapy with combination therapy.In this retrospective cohort study, we demonstrated no significant difference in the real-world effectiveness of ciprofloxacin, metronidazole, or combination therapy for the initial episode of pouchitis.</ABSTRACT>'}]
2024-01-02 00:26:27,663 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:27,664 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:27,665 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:27,665 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:27,669 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:27,669 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:27,670 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:27,670 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:27,672 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448708, Requested 1349. Please try again in 7ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:27,672 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Gene therapy for heart failure and cardiomyopathies.\nGene therapy strategies encompass a range of approaches, including gene replacement and gene editing. Gene replacement involves providing a functional copy of a modified gene, while gene editing allows for the correction of existing genetic mutations. Gene therapy has already received approval for treating genetic disorders like Leber\'s congenital amaurosis and spinal muscular atrophy. Currently, research is being conducted to explore its potential use in cardiology. This review aims to summarize the mechanisms behind different gene therapy strategies, the available delivery systems, the primary risks associated with gene therapy, ongoing clinical trials, and future targets, with a particular emphasis on cardiomyopathies.</ABSTRACT>'}]
2024-01-02 00:26:27,672 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448799, Requested 1480. Please try again in 37ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:27,673 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Recent advances in the treatment of IBD: Targets, mechanisms and related therapies.\nInflammatory bowel disease (IBD), as a representative inflammatory disease, currently has multiple effective treatment options available and new therapeutic strategies are being actively explored to further increase the treatment options for patients with IBD. Furthermore, biologic agents and small molecule drugs developed for ulcerative colitis (UC) and Crohn\'s disease (CD) have evolved toward fewer side effects and more accurate targeting. Novel inhibitors that target cytokines (such as IL-12/23 inhibitors, PDE4 inhibitors), integrins (such as integrin inhibitors), cytokine signaling pathways (such as JAK inhibitors, SMAD7 blocker) and cell signaling receptors (such as S1P receptor modulator) have become the preferred treatment choice for many IBD patients. Conventional therapies such as 5-aminosalicylic acid, corticosteroids, immunomodulators and anti-tumor necrosis factor agents continue to demonstrate therapeutic efficacy, particularly in combination with drug therapy. This review integrates research from chemical, biological and adjuvant therapies to evaluate current and future IBD therapies, highlighting the mechanism of action of each therapy and emphasizing the potential of development prospects.</ABSTRACT>'}]
2024-01-02 00:26:27,673 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448716, Requested 1605. Please try again in 42ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:27,673 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Outcomes of Intentionally Suspending Treatment in Eyes With Advanced Neovascular Age-Related Macular Degeneration.\nTo determine the outcomes of intentionally suspending anti-vascular endothelial growth factor (anti-VEGF) injections in eyes with advanced neovascular age-related macular degeneration (nAMD).Retrospective cohort study.The study sample comprised 93 patients with nAMD and best available Snellen visual acuity (VA) \u226420/400 in which anti-VEGF treatment was suspended by the treating physician. VA and optical coherence tomography (OCT) characteristics were evaluated to determine visual and anatomical outcomes up to 24 months after treatment suspension.A total of 93 eyes from 93 patients who had received a mean of 16 anti-VEGF injections over a mean of 962 (SD 562) days were included. Comparing the treatment suspension visit to 24 months later, no significant change in mean central foveal thickness (163 [SD 118, range 19-704] \u03bcm vs 164 [SD 217, range 19-1468], P\xa0=\xa0.97), greatest lesion diameter (2547 [SD 1294, range 134-5707] \u03bcm vs 2442 [SD 1158, range 421-5305] \u03bcm, P\xa0=\xa0.43), greatest lesion thickness (194 [SD 136, range 0-618] \u03bcm vs 205 [SD 131, range 0-573] \u03bcm, P\xa0=\xa0.40), or VA (1.87 [SD 0.37], 20/1482, vs 1.94 [SD 0.28], 20/1741, P\xa0=\xa0.16) was found. In total, 7 eyes (7.5%) restarted treatment following a mean of 977 (SD 450) days after treatment suspension.Suspension of anti-VEGF injections in eyes with advanced nAMD and VA \u226420/400 may be reasonable in cases where the treating physician deems additional treatment is unlikely to provide benefit. Although the visual and anatomical findings remained stable after treatment suspension in most, a small number restarted anti-VEGF therapy, suggesting that eyes should still be monitored for disease progression.</ABSTRACT>'}]
2024-01-02 00:26:27,674 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448695, Requested 1733. Please try again in 57ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:27,674 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>A population-based nationwide study on total colectomy for ulcerative colitis and risk of ten prevalent inflammatory or autoimmune diseases.\nThere is growing evidence to support a role of the gut microbiome in the development of chronic inflammatory and autoimmune disease (IAD). We used total colectomy (TC) for ulcerative colitis (UC) as a model for a significant disruption in gut microbiome to explore an association with subsequent risk of IAD.We identified all patients with UC and no diagnosis of IAD prior to their UC diagnosis in Denmark from 1988 to 2015. Patients were followed from the date of UC to a diagnosis of IAD, death or end of follow-up, whichever occurred first. We used Cox regression to estimate hazard ratios (HRs) of IAD associated with TC, adjusting for age, sex, Charlson Comorbidity Index, and calendar year of UC diagnosis.30,507 patients with UC (3,155 with TC and 27,352 without) were identified from the Danish National Patient Registry. During 43,266 person-years of follow-up, 2733 patients were diagnosed with an IAD. The risk of any IAD was higher for patients with TC compared to patients without (adjusted HR [aHR] 1.39 (95% CI: 1.24-1.57)). When the analyses were adjusted for exposure to antibiotics, immunomodulatory medicine and biologics (covering 2005-2018), the risk of IAD was still higher for patients with total colectomy (aHR = 1.41 (95% CI: 1.09;1.83)). Disease-specific analyses were weakened by a low number of outcomes.The risk of IAD was higher for patients who underwent TC for UC compared to patients who did not.KEY MESSAGESWhat is already known?o The gut microbiome plays an important role in host immune homeostasis, and changes in gut bacterial diversity and composition may change the individual\'s risk of inflammatory and autoimmune disease (IAD).What is new here?o Patients with ulcerative colitis who undergo total colectomy have a higher risk of being diagnosed with IAD, compared to patients with ulcerative colitis who do not undergo total colectomy.How can this study help patient care?o Future research can help uncover the mechanisms responsible for the higher risk of certain IADs after total colectomy. If the microbiome plays a role, modifying the gut microbiome could prove a viable therapeutic strategy to reduce the risk of developing IADs.</ABSTRACT>'}]
2024-01-02 00:26:27,674 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448649, Requested 1578. Please try again in 30ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:27,674 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Geographic variation in diabetic retinopathy screening within the Veterans Health Administration.\nDiabetic retinopathy (DR) remains the leading cause of vision impairment among working-age adults in the United States. The Veterans Health Administration (VA) supplemented its DR screening efforts with teleretinal imaging in 2006. Despite its scale and longevity, no national data on the VA\'s screening program exists since 1998. Our objective was to determine the influence of geography on diabetic retinopathy screening adherence.Setting: VA national electronic medical records.A national cohort of 940,654 veterans with diabetes (defined as two or more diabetes ICD-9 codes (250.xx)) without a history of DR.125\xa0VA Medical Center catchment areas, demographics, comorbidity burden, mean HbA1c levels, medication use and adherence, as well as utilization and access metrics.Screening for diabetic retinopathy within the VA medical system within a 2-year period.Within a 2-year time frame 74 % of veterans without a history of DR received retinal screenings within the VA system. After adjustment for age, gender, race-ethnic group, service-connected disability, marital status, and the van Walraven Elixhauser comorbidity score, the prevalence of DR screening varied by VA catchment area with values ranging from 27 % to 86 %. These differences persisted after further adjusting for mean HbA1c level, medication use and adherence as well as utilization and access metrics.The wide variability in DR screening across 125\xa0VA catchment areas indicates the presence of unmeasured determinants of DR screening. These results are relevant to clinical decision making in DR screening resource allocation.</ABSTRACT>'}]
2024-01-02 00:26:27,675 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448598, Requested 1521. Please try again in 15ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:27,675 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>The Role of Gut Microbiota in Glaucoma Progression and Other Retinal Diseases.\nAs a rapidly growing field, microbiota research offers novel approaches to promoting ocular health and treating major retinal diseases, such as glaucoma. Gut microbiota changes throughout life; however, certain patterns of population changes have been increasingly associated with specific diseases. It has been well established that a disrupted microbiome contributes to central nervous system diseases, including Alzheimer disease, Parkinson disease, multiple sclerosis, and glioma, suggesting a prominent role of microbiome in neurodegenerative diseases. This review summarizes the progress in identifying significant changes in the microbial composition of patients with glaucoma by compiling studies on the association between microbiota and disease progression. Of interest is the relationship between increased Firmicutes/Bacteroidetes ratio in patients with primary open-angle glaucoma, increased taurocholic acid, decreased glutathione, and a reduction in retinal ganglion cell survival. Connecting these microbes to specific metabolites sheds light on the pathogenic mechanism and novel treatment strategies. In summary, the current review synthesizes the findings of several studies investigating the effects of shifting bacterial population in retinal diseases, particularly glaucoma, with the aim to identify the current direction of treatment and help direct future endeavors.</ABSTRACT>'}]
2024-01-02 00:26:27,675 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449429, Requested 1604. Please try again in 137ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:27,675 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Ferroptosis in the colon epithelial cells as a therapeutic target for ulcerative colitis.\nFerroptosis, a type of programmed cell death triggered by oxidative stress, was suspected to play a role in ulcerative colitis. Indigo naturalis is highly effective against ulcerative colitis, but its mechanism is unclear. This study found that indigo naturalis treatment suppressed ferroptosis.We analyzed 770 mRNA expressions of patients with ulcerative colitis. Suppression of ferroptosis by indigo naturalis treatment was shown using a cell death assay. Malondialdehyde levels and reactive oxygen species were analyzed in CaCo-2 cells treated with indigo naturalis. Glutathione metabolism was shown by metabolomic analysis. Extraction of the ingredients indigo naturalis from the rectal mucosa was performed using liquid chromatograph-mass spectrometry.Gene expression profiling showed that indigo naturalis treatment increased antioxidant genes in the mucosa of patients with ulcerative colitis. In vitro analysis showed that nuclear factor erythroid-2-related factor 2-related antioxidant gene expression was upregulated by indigo naturalis. Indigo naturalis treatment rendered cells resistant to ferroptosis. Metabolomic analysis suggested that an increase in reduced glutathione by indigo naturalis. The protein expression of CYP1A1 and GPX4 was increased in the rectum by treatment with indigo naturalis. The main ingredients of indigo naturalis, indirubin and indigo inhibited ferroptosis. Indirubin was detected in the rectal mucosa of patients with ulcerative colitis who were treated with indigo naturalis.Suppression of ferroptosis by indigo naturalis in the intestinal epithelium could be therapeutic target for ulcerative colitis. The main active ingredient of indigo naturalis may be indirubin.</ABSTRACT>'}]
2024-01-02 00:26:27,678 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:27,679 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449449, Requested 1602. Please try again in 140ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:27,679 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Low Serum Hepcidin Levels in Patients with Ulcerative Colitis - Implications for Treatment of Co-existent Iron-Deficiency Anemia.\nUlcerative colitis (UC) is often associated with anemia. Hepcidin, the central regulator of iron homeostasis, is known to be induced by inflammation and suppressed by anemia. It is not clear how hepcidin is affected in those with UC, when both inflammation and anemia may co-exist.Such knowledge may hold implications for treatment. Hematological and iron-related parameters, C-reactive protein (CRP), growth differentiation factor 15 (GDF-15) and erythroferrone (ERFE) (erythroid regulators of hepcidin) levels were estimated in blood from those with UC and in control subjects. Values for hematological and iron-related parameters showed evidence of iron-deficiency and resultant anemia, in patients with UC. The presence of UC was significantly associated with inflammation. Serum levels of ERFE, but not of GDF-15, were significantly higher in patients with UC than in control patients, while hepcidin levels were significantly lower. Serum hepcidin concentrations in patients with UC correlated positively with serum iron, ferritin and GDF-15, and negatively with serum ERFE. The iron status and serum hepcidin levels in UC patients with co-existent anemia were significantly lower and serum ERFE values significantly higher than in those with UC without anemia. The effect of anemia on hepcidin predominated over that of inflammation in patients with UC, resulting in suppressed hepcidin levels. This effect is possibly mediated through erythroferrone. We suggest that a serum hepcidin-guided approach may be useful to guide use of oral iron supplements to treat co-existent iron-deficiency anemia in patients with UC and other chronic inflammatory diseases.</ABSTRACT>'}]
2024-01-02 00:26:27,686 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:27,689 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449421, Requested 1603. Please try again in 136ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:27,689 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>A retrospective analysis of vitamin B6 deficiency and associated changes of gut microbes in Crohn\'s disease.\nPatients with inflammatory bowel diseases (IBD) are at risk of micronutrient deficiencies, particularly during flares. Vitamin B6 is required for the proper development of brain, nerves, and many other parts of the body. However, limited studies are available to describe the prevalence, relevance and consequences of vitamin B6 deficiencies in IBD. We aim to estimate the prevalence of vitamin B6 deficiencies in Crohn\'s disease (CD) patients, to identify associated risk factors and to explore the alteration of intestinal microbiota related to vitamin B6 status.A total of 360 CD patients and 55 ulcerative colitis (UC) patients from Shanghai Tenth People\'s Hospital of Tongji University were included. Serum vitamin B6 concentrations were collected from the computerized laboratory data. The logistic regression was used for statistical analysis. Fecal-associated microbiota was also analyzed using 16S rRNA sequencing in another 20 CD patients (10 of vitamin B6 normal, 10 of vitamin B6 deficiency).The prevalence of vitamin B6 abnormality was significantly higher in CD than in UC patients. Logistic regression analysis showed that small bowel lesion, ileocolonic lesion (L3), extraintestinal manifestations, ileal resection, and usage of immunosuppressor were independently associated with abnormal vitamin B6 in CD. Interestingly, the microbial structure presented significant differences between two CD groups. PICRUSt2 prediction revealed that some enzymes and metabolic pathways between the two groups were significantly different.Collectively, our analysis showed that vitamin B6 reduction occurred frequently in patients with CD and affected the intestinal flora of patients.</ABSTRACT>'}]
2024-01-02 00:26:27,691 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:27,717 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:27,721 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448824, Requested 1729. Please try again in 73ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:27,721 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Competing risks analysis for neutrophil to lymphocyte ratio as a predictor of diabetic retinopathy incidence in the Scottish population.\nDiabetic retinopathy (DR) is a major sight-threatening microvascular complication in individuals with diabetes. Systemic inflammation combined with oxidative stress is thought to capture most of the complexities involved in the pathology of diabetic retinopathy. A high level of neutrophil-lymphocyte ratio (NLR) is an indicator of abnormal immune system activity. Current estimates of the association of NLR with diabetes and its complications are almost entirely derived from cross-sectional studies, suggesting that the nature of the reported association may be more diagnostic than prognostic. Therefore, in the present study, we examined the utility of NLR as a biomarker to predict the incidence of DR in the Scottish population.The incidence of DR was defined as the time to the first diagnosis of R1 or above grade in the Scottish retinopathy grading scheme from type 2 diabetes diagnosis. The effect of NLR and its interactions were explored using a competing risks survival model adjusting for other risk factors and accounting for deaths. The Fine and Gray subdistribution hazard model (FGR) was used to predict the effect of NLR on the incidence of DR.We analysed data from 23,531 individuals with complete covariate information. At 10\xa0years, 8416 (35.8%) had developed DR and 2989 (12.7%) were lost to competing events (death) without developing DR and 12,126 individuals did not have DR. The median (interquartile range) level of NLR was 2.04 (1.5 to 2.7). The optimal NLR cut-off value to predict retinopathy incidence was 3.04. After accounting for competing risks at 10\xa0years, the cumulative incidence of DR and deaths without DR were 50.7% and 21.9%, respectively. NLR was associated with incident DR in both Cause-specific hazard (CSH\u2009=\u20091.63; 95% CI: 1.28-2.07) and FGR models the subdistribution hazard (sHR\u2009=\u20092.24; 95% CI: 1.70-2.94). Both age and HbA1c were found to modulate the association between NLR and the risk of DR.The current study suggests that NLR has a promising potential to predict DR incidence in the Scottish population, especially in individuals less than 65\xa0years and in those with well-controlled glycaemic status.</ABSTRACT>'}]
2024-01-02 00:26:27,728 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:27,729 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:27,729 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:27,730 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:27,731 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448766, Requested 1699. Please try again in 62ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:27,732 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Gender-Related Differences in Patients with Acute Heart Failure: Observation from the Journey Heart Failure-Turkish Population Study.\nGender-related clinical variations in patients with acute heart failure have been described in previous studies. However, there is still a lack of research on gender differences in patients hospitalized for acute heart failure in Trkiye. The aim of this study is to compare the clinical features, in-hospital approaches, and outcomes of male and female patients hospitalized for acute heart failure.Differences in clinical characteristics, medication prescription, hospital management, and outcomes between males and females with acute heart failure were investigated from the Journey Heart Failure-Turkish Population study.Nine hundred eighteen patients (57.2%) were men and 688 (42.8%) were women. Women were older than men (70.48  13.20 years vs. 65.87  12.82 years; P <.001). The frequency of comorbidities such as hypertension (72.7% vs. 62.4%, P <.001), diabetes (46.5% vs. 38.5%, P =\u2009.001),\u2009 atrial\u2009 fibrillation\u2009 (46.5%\u2009 vs.\u2009 33.4%,\u2009 P <.001), New York Heart Association class III-IV symptoms (80.6% vs. 71.2%, P =.001), and dyspnea in the rest (73.8% vs. 68.3%, P =.044) were more common in women on admission. Male patients were more frequently hospitalized with reduced left ventricular ejection fraction (51.0% vs. 72.4%, P <.001). In-hospital mortality was higher among female patients (9.3% vs. 6.4%, P =.022). Higher\u2009 New\u2009 York\u2009 Heart\u2009 Association\u2009 class,\u2009 lower\u2009 estimated\u2009 glomerular\u2009 filtration\u2009 rate,\u2009higher N-terminal pro-B type natriuretic peptide on admission, and mechanical ventilation usage were the independent parameters of in-hospital mortality, whereas the female gender was not.Our study clearly demonstrated the diversity in presentation, management, and in-hospital outcomes of acute heart failure between male and female patients. Although left ventricular systolic functions were better in female patients, in-hospital mortality was higher. Recognizing these differences in the management of heart failure in different sexes will serve better results in clinical practice.</ABSTRACT>'}]
2024-01-02 00:26:27,735 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448743, Requested 1548. Please try again in 38ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:27,735 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>A Pilot Study of Exercise Training for Children and Adolescents With Inflammatory Bowel Disease: An Evaluation of Feasibility, Safety, Satisfaction, and Efficacy.\nChildren with inflammatory bowel disease (IBD) experience extraintestinal side effects including altered body composition, impaired muscle strength, and aerobic capacity. Exercise training may remedy these issues.To assess the feasibility, safety, participant satisfaction, and efficacy of a training program for youth with IBD.Children with IBD completed 16\xa0weeks of training (2 supervised + 1 home sessions per week). Feasibility was assessed by tracking recruitment, adherence, and compliance rates. Safety was assessed by tracking symptoms and adverse events. Posttraining interviews gauged satisfaction. Circulating inflammatory markers, body composition, muscle strength, aerobic fitness, and habitual physical activity were measured at baseline, midtraining (8\xa0wk), and posttraining.Eleven youth were recruited and 10 completed the study. Participants adhered to 28 (1) of 32 prescribed supervised sessions and 8 (4) of 16 prescribed home sessions. There were no adverse events, and overall feedback on training was positive. Posttraining, we observed an increase in lean mass (+2.4 [1.1]\xa0kg), bone density (+0.0124 [0.015] gcm-2), aerobic fitness (+2.8 [5.7] mLkg\xa0LM-1\xa0min-1), and vigorous physical activity levels (+13.09 [8.95]\xa0minh-1) but no change in inflammation or muscle strength.Supervised exercise training is feasible, safe, and effective for youth with IBD and should be encouraged.</ABSTRACT>'}]
2024-01-02 00:26:27,737 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448683, Requested 1491. Please try again in 23ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:27,737 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Secondhand smoke exposure and ocular health: A systematic review.\nThe toxicology of secondhand smoke (SHS), along with the harm of its exposure to human health, has been generally acknowledged; however, specific evidence is lacking on the association between SHS exposure and ocular health. In this systematic review (PROSPERO registration number: CRD42022247992), we included 55 original articles published by 12 May 2023, which dealt with SHS exposure and ocular disorders, such as eye irritation, conjunctivitis, dry eye diseases, uveitis, myopia, astigmatism, contact lens discomfort, age-related macular degeneration, glaucoma, and thyroid eye disease that addressed the ocular neurovascular structures of the macular, retinal nerve fiber layer, choroid, and corneal biomechanical parameters. We found compelling correlational evidence for eye irritation, conjunctivitis, and dry eye symptoms-supporting that SHS exposure was positively associated with inflammatory and allergic changes in the eyes. Yet, evidence about the associations between SHS exposure and other ocular disorders, structures, and parameters is still limited or controversial. Given the limitations of existing literature, more investigations with high quality and rigorous design are warranted to elucidate the potentially harmful effects of SHS exposure on ocular health.</ABSTRACT>'}]
2024-01-02 00:26:27,745 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:27,755 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:27,757 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449383, Requested 1173. Please try again in 74ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:27,757 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Trends in B-Type Natriuretic Peptide Testing: A Population-Based Cohort Study.\n</ABSTRACT>'}]
2024-01-02 00:26:27,771 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:27,772 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449429, Requested 1751. Please try again in 157ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:27,772 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Hyperreflective Material Boundary Remodeling in Neovascular Age-Related Macular Degeneration: A Post Hoc Analysis of the AVENUE Trial.\nTo describe the spatial and temporal characteristics of hyperreflective material (HRM) on spectral-domain OCT (SD-OCT) in neovascular age-related macular degeneration (nAMD) during antiangiogenic treatment and explore associations with best-corrected visual acuity (BCVA) and macular atrophy (MA).Retrospective regrading of SD-OCT-images from the multicenter, randomized controlled AVENUE trial (NCT02484690, conducted from August 2015 to September 2017).Treatment-naive nAMD patients enrolled from 50 sites in the US.Retrospective regrading and secondary analysis.Spectral-domain OCT images from 207 study eyes that fit criteria for the present analysis were graded for HRM features, its evolution, and associated hypertransmission into choroid (HTC), a proxy for MA. The appearance of a well-defined hyperreflective inner boundary that separated persistent HRM from the neurosensory retina continuous with the adjacent retinal pigment epithelium layer was defined as hyperreflective material boundary remodeling (HRM-BR). Patterns of HRM composition/evolution were defined as follows: (1) no subretinal HRM at baseline, (2) fully resolved, (3) persistent with complete HRM-BR, or (4) partial/absent HRM-BR. Associations of HRM patterns with BCVA and HTC were analyzed. Predictive factors for complete HRM-BR were explored.Of 207 included eyes, subretinal HRM was present in 159 (76.8%) at baseline and persisted until month 9 in 118 (57.0%) eyes. Of these 118 eyes, 44.9% developed complete HRM-BR and had similar BCVA outcomes by month 9 compared with no/fully resolved subretinal HRM. Partial/absent HRM-BR had a strong negative association with BCVA outcome (-6.1 ETDRS letters; P\xa0= 0.016) and a higher frequency of intralesional HTC (69.2%) compared with eyes with complete HRM-BR (20.8%) at month 9. Older age (odds ratio [OR], 0.96; P\xa0= 0.054) and presence of intralesional HTC (OR, 0.06; P\xa0= 0.010) at baseline were associated with lower odds of complete HRM-BR at month\xa09.In nAMD eyes under antiangiogenic treatment, complete HRM-BR occurred frequently and was associated with better BCVA than when HRM-BR was only partial/absent.Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</ABSTRACT>'}]
2024-01-02 00:26:27,778 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:27,783 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449399, Requested 1619. Please try again in 135ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:27,783 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Phase 1 safety, tolerability, pharmacokinetics and pharmacodynamic results of KCL-286, a novel retinoic acid receptor-\u03b2 agonist for treatment of spinal cord injury, in male healthy participants.\nKCL-286 is an orally available agonist that activates the retinoic acid receptor (RAR) \u03b22, a transcription factor which stimulates axonal outgrowth. The investigational medicinal product is being developed for treatment of spinal cord injury (SCI). This adaptive dose escalation study evaluated the tolerability, safety and pharmacokinetics and pharmacodynamic activity of KCL-286 in male healthy volunteers to establish dosing to be used in the SCI patient population.The design was a double blind, randomized, placebo-controlled dose escalation study in 2 parts: a single ascending dose adaptive design with a food interaction arm, and a multiple ascending dose design. RAR\u03b22 mRNA expression was evaluated in white blood cells.At the highest single and multiple ascending doses (100\u2009mg), no trends or clinically important differences were noted in the incidence or intensity of adverse events (AEs), serious AEs or other safety assessments with none leading to withdrawal from the study. The AEs were dry skin, rash, skin exfoliation, raised liver enzymes and eye disorders. There was an increase in mean maximum observed concentration and area under the plasma concentration-time curve up to 24 h showing a trend to subproportionality with dose. RAR\u03b22 was upregulated by the investigational medicinal product in white blood cells.KCL-286 was well tolerated by healthy human participants following doses that exceeded potentially clinically relevant plasma exposures based on preclinical in vivo models. Target engagement shows the drug candidate activates its receptor. These findings support further development of KCL-286 as a novel oral treatment for SCI.</ABSTRACT>'}]
2024-01-02 00:26:27,795 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:27,796 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449288, Requested 1487. Please try again in 103ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:27,796 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Association between diabetic retinopathy and diabetic foot ulcer in patients with diabetes: A meta-analysis.\nThis study aimed to explore the relationship between diabetic retinopathy (DR) and diabetic foot ulcers (DFUs) to provide evidence for the prevention of diabetic complications. PubMed, EMBASE, Web of Science, Cochrane Library, China National Knowledge Infrastructure, Chinese Biomedical Literature Database and Wanfang Data databases were searched from their inception until March 2023 for studies on the relationship between DR and DFU. Two researchers independently screened the literature and extracted data according to the inclusion and exclusion criteria. The meta-analysis was performed using the RevMan 5.3 software. Eleven articles referring to 10\u2009208 patients were included, of whom 2191 patients had DFU and 8017 patients did not have DFU. The meta-analysis results showed that DR significantly increased the incidence of DFU (47.94% vs. 16.38%; OR, 4.13; 95% CI, 2.33-7.33; p\u2009<\u20090.001). The results of this study suggest that patients with DR have a higher risk of developing DFU, highlighting the importance of regular screening for these two complications to prevent serious adverse outcomes of diabetes. However, further high-quality studies are required to validate the conclusions of the present study.</ABSTRACT>'}]
2024-01-02 00:26:27,797 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:27,798 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449324, Requested 1694. Please try again in 135ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:27,798 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Characteristics and management of vascular compromise after an organ transplantation surgery of the head and neck region: Analysis of 220 submandibular glands with autologous transplantation.\nMicrovascular submandibular gland transplantation (SMGT) for severe dry eye disease (DED) has rarely been reported in the literature. The aim of this study was to report a case series of SMGT with the special focus on monitoring and management of postoperative vascular compromise.Using a retrospective single-cohort study design, the investigators enrolled a sample of DED patients undergoing SMGT in a Chinese university hospital during 1999 and 2021. The main outcomes were baseline and surgical data, post-operative manifestations, and surgical results. Descriptive, uni- and bivariate statistics were computed with the significant P < 0.05.During the study period, 220 DED patients (55.9% female) with a mean age of 32.6614.47 years underwent SMGT. Vascular compromises occurred in 27 grafted glands (12.3%; 22 venous compromises and 5 arterial compromises) at a median of 27\xa0h(range, 3.3 to 288\xa0h) after surgery. Harden texture and swelling of the covering skin flap of the donor indicated venous compromises, while some specific sign was absent for arterial compromise. The accompanying vein of the facial artery (FAV) as a donor\'s vein was associated with less vascular compromise compared to the anterior facial vein (AFV). Timely reexploration was performed in 25 glands (92.6%), with a salvaged rate of 48%, and more venous compromises were salvaged compared to artery compromises (54.6% vs. 0%, P\xa0=\xa00.047). Temporary hypersecretion on postoperative 2-5 days was noticed in the grafted glands with no or salvaged vascular compromise (Schirmer\'s test, 35\xa0mm/5\xa0min and 37\xa0mm/5\xa0min, respectively, P\xa0=\xa00.749), while they were absent for the 15 surgically failed grands (Schirmer\'s test 0\xa0mm/5\xa0min, P<0.001).Vascular compromise appears to be a common complication of SMGT. Postoperative hypersecretion of the grafted glands may indicate good circulation, and the use of FAV as the donor\'s vein could help to decrease the risk of vascular compromise.</ABSTRACT>'}]
2024-01-02 00:26:27,801 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:27,802 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449220, Requested 1645. Please try again in 115ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:27,802 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Safety and effectiveness of IV Thrombolysis in retinal artery occlusion: A multicenter retrospective cohort study.\nRetinal artery occlusion (RAO) may lead to irreversible blindness. For acute RAO, intravenous thrombolysis (IVT) can be considered as treatment. However, due to the rarity of RAO, data about IVT safety and effectiveness is limited.From the multicenter database ThRombolysis for Ischemic Stroke Patients (TRISP), we retrospectively analyzed visual acuity (VA) at baseline and within 3\u2009months in IVT and non-IVT treated RAO patients. Primary outcome was difference of VA between baseline and follow up (\u2206VA). Secondary outcomes were rates of visual recovery (defined as improvement of VA\u2009\u2a7e\u20090.3 logMAR), and safety (symptomatic intracranial hemorrhage (sICH) according to ECASS II criteria, asymptomatic intracranial hemorrhage (ICH) and major extracranial bleeding). Statistical analysis was performed using parametric tests and a linear regression model adjusted for age, sex and baseline VA.We screened 200 patients with acute RAO and included 47 IVT and 34 non-IVT patients with complete information about recovery of vision. Visual Acuity at follow up significantly improved compared to baseline in IVT patients (\u2206VA 0.5\u2009\u20090.8, p\u2009<\u20090.001) and non-IVT patients (\u2206VA 0.40\u2009\u20091.1, p\u2009<\u20090.05). No significant differences in \u2206VA and visual recovery rate were found between groups at follow up. Two asymptomatic ICH (4%) and one (2%) major extracranial bleeding (intraocular bleeding) occurred in the IVT group, while no bleeding events were reported in the non-IVT group.Our study provides real-life data from the largest cohort of IVT treated RAO patients published so far. While there is no evidence for superiority of IVT compared to conservative treatment, bleeding rates were low. A randomized controlled trial and standardized outcome assessments in RAO patients are justified to assess the net benefit of IVT in RAO.</ABSTRACT>'}]
2024-01-02 00:26:27,807 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:27,808 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448597, Requested 1620. Please try again in 28ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:27,808 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Major Adverse Cardiovascular Events by Baseline Cardiovascular Risk in Patients with Ulcerative Colitis Treated with Tofacitinib: Data from the OCTAVE Clinical Programme.\nPatients with inflammatory bowel disease have increased risk of atherosclerotic cardiovascular [CV] disease [ASCVD]. Tofacitinib is an oral \ufeffJanus kinase inhibitor for the treatment of ulcerative colitis [UC]. We report major adverse CV events [MACE] in the UC OCTAVE programme, stratified by baseline CV risk.Rates of MACE were analysed by baseline [first tofacitinib exposure] CV risk profile: prior ASCVD, or 10-year ASCVD risk categories [low, borderline, intermediate, high].Of 1157 patients [2814.4 patient-years of exposure; \u22647.8 years\' tofacitinib treatment], 4% had prior ASCVD and 83% had no prior ASCVD and low-borderline baseline 10-year ASCVD risk. Eight [0.7%] patients developed MACE; one had prior ASCVD. Incidence rates [unique patients with events/100 patient-years of exposure; 95% confidence intervals] for MACE were: 0.95 [0.02-5.27] in patients with prior ASCVD; and 1.81 [0.05-10.07], 1.54 [0.42-3.95], 0.00 [0.00-2.85], and 0.09 [0.01-0.32] in patients without prior ASCVD and with high, intermediate, -borderline, and low baseline 10-year ASCVD risk, respectively. For the 5/7 patients with MACE and without prior ASCVD, 10-year ASCVD risk scores were numerically higher [>1%] prior to MACE versus at baseline, primarily due to increasing age.Most patients receiving tofacitinib in the UC OCTAVE programme had low baseline 10-year ASCVD risk. MACE were more frequent in patients with prior ASCVD and higher baseline CV risk. This analysis demonstrates potential associations between baseline CV risk and MACE in patients with UC, suggesting CV risk should be assessed individually in clinical practice.NCT00787202; NCT01465763; NCT01458951; NCT01458574; NCT01470612.</ABSTRACT>'}]
2024-01-02 00:26:27,814 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:27,815 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:27,816 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448739, Requested 1606. Please try again in 46ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:27,816 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>D-amino Acids Ameliorate Experimental Colitis and Cholangitis by Inhibiting Growth of Proteobacteria: Potential Therapeutic Role in Inflammatory Bowel Disease.\nD-amino acids, the chiral counterparts of protein L-amino acids, were primarily produced and utilized by microbes, including those in the human gut. However, little was known about how orally administered or microbe-derived D-amino acids affected the gut microbial community or gut disease progression.The ratio of D- to L-amino acids was analyzed in feces and blood from patients with ulcerative colitis (UC) and healthy controls. Also, composition of microbe was analyzed from patients with UC. Mice were treated with D-amino acid in dextran sulfate sodium colitis model and liver cholangitis model.The ratio of D- to L-amino acids was lower in the feces of patients with UC than that of healthy controls. Supplementation of D-amino acids ameliorated UC-related experimental colitis and liver cholangitis by inhibiting growth of Proteobacteria. Addition of D-alanine, a major building block for bacterial cell wall formation, to culture medium inhibited expression of the ftsZ gene required for cell fission in the Proteobacteria Escherichia coli and Klebsiella pneumoniae, thereby inhibiting growth. Overexpression of ftsZ restored growth of E.\xa0coli even when D-alanine was present. We found that D-alanine not only inhibited invasion of pathological K.\xa0pneumoniae into the host via pore formation in intestinal epithelial cells but also inhibited growth of E.\xa0coli and generation of antibiotic-resistant strains.D-amino acids might have potential for use in novel therapeutic approaches targeting Proteobacteria-associated dysbiosis and antibiotic-resistant bacterial diseases by means of their effects on the intestinal microbiota community.</ABSTRACT>'}]
2024-01-02 00:26:27,819 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:27,832 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:27,833 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:27,834 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449959, Requested 1918. Please try again in 250ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:27,834 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Effect of preoperative ivabradine on hemodynamics during elective off-pump CABG.\nIvabradine is a specific heart rate (HR)-lowering agent which blocks the cardiac pacemaker If channels. It reduces the HR without causing a negative inotropic or lusitropic effect, thus preserving ventricular contractility. The authors hypothesized that its usefulness in lowering HR can be utilized in patients undergoing off-pump coronary artery bypass (OPCAB) surgery.To study the effects of preoperative ivabradine on hemodynamics (during surgery) in patients undergoing elective OPCAB surgery.Fifty patients, New York Heart Association (NYHA) class I and II, were randomized into group I (control, n = 25) and group II (ivabradine group, n = 25). In group I, patients received the usual anti-anginal medications in the preoperative period, as per the institutional protocol. In group II, patients received ivabradine 5 mg twice daily for 3 days before surgery, in addition to the usual anti-anginal medications. Anesthesia was induced with fentanyl, thiopentone sodium, and pancuronium bromide as a muscle relaxant and maintained with fentanyl, midazolam, pancuronium bromide, and isoflurane. The hemodynamic parameters [HR and mean arterial pressure (MAP)] and pulmonary artery (PA) catheter-derived data were recorded at the baseline (before induction), 3 min after the induction of anesthesia at 1 min and 3 min after intubation and at 5 min and 30 min after protamine administration. Intraoperatively, hemodynamic data (HR and MAP) were recorded every 10 min, except during distal anastomosis of the coronary arteries when it was recorded every 5 min. Post-operatively, at 24 hours, the levels of troponin T and brain natriuretic peptide (BNP) were measured. This trial\'s CTRI registration number is CTRI/005858.The HR in group II was lower when compared to group I (range 59.6-72.4 beats/min and 65.8-80.2 beats/min, respectively) throughout the study period. MAP was comparable [range (78.5-87.8 mm Hg) vs. (78.9-88.5 mm Hg) in group II vs. group I, respectively] throughout the study period. Intraoperatively, 5 patients received metoprolol in group I to control the HR, whereas none of the patients in group II required metoprolol. The incidence of preoperative bradycardia (HR <60 beats/min) was higher in group II (20%) vs. group I (8%). There was no difference in both the groups in terms of troponin T and BNP level after 24 hours, time to extubation, requirement of inotropes, incidence of arrhythmias, in-hospital morbidity, and 30-day mortality.Ivabradine can be safely used along with other anti-anginal agents during the preoperative period in patients undergoing OPCAB surgery. It helps to maintain a lower HR during surgery and reduces the need for beta-blockers in the intraoperative period, a desirable and beneficial effect in situations where the use of beta-blockers may be potentially harmful. Further studies are needed to evaluate the beneficial effects of perioperative Ivabradine in patients with moderate-to-severe left ventricular dysfunction.</ABSTRACT>'}]
2024-01-02 00:26:27,836 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449816, Requested 1677. Please try again in 199ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:27,836 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Gut Microbiome-Generated Phenylacetylglutamine from Dietary Protein is Associated with Crohn\'s Disease and Exacerbates Colitis in Mouse Model Possibly via Platelet Activation.\nOur aims were to better understand the interplay of diet and gut microbiota in Crohn\'s disease [CD], taking advantage of a new-onset treatment-nave CD cohort. We focus on phenylacetylglutamine [PAGln], a diet-derived meta-organismal prothrombotic metabolite.We collected faecal and serum samples from a CD cohort [n\u2005=\u2005136] and healthy controls [n\u2005=\u2005126] prior to treatment, and quantified serum PAGln using LC-MS/MS. Diet was assessed using food-frequency questionnaires. Mice [C57BL/6] were fed high/low-protein diets and administered dextran sodium sulphate [DSS] to examine plasma PAGly, thrombosis potential, and colitis severity. PAGly or saline was administered to DSS-induced colitis mice, and colitis severity and colonic tissue gene expression were examined. P-selectin and CD40L expression were determined in human platelet-rich plasma [n\u2005=\u20055-6] after exposure to platelet agonists following PAGln priming. Bioinformatic analysis and bacterial culturing identified the main contributor of PAGln in CD.PAGln, a meta-organismal prothrombotic metabolite, is associated with CD. Administration of PAGly exacerbated colitis in a mouse model and upregulated coagulation-related biological processes. Antiplatelet medicine, dipyridamole, attenuated PAGly-enhanced colitis susceptibility. PAGln enhanced platelet activation and CD40L expression in platelet-rich plasma ex vivo. Further study revealed that high dietary protein intake and increased abundance of phenylacetic acid [PAA]-producing Proteobacteria mediated by phenylpyruvate decarboxylase act in concert to cause the elevated PAGln levels in CD patients.Taken together, ppdc-carrying Proteobacteria-generated PAGln from dietary protein is associated with CD and exacerbates colitis possibly via platelet-induced coagulation and inflammation These results suggest that PAGln is a potential early diagnostic marker and therapeutic target of CD.</ABSTRACT>'}]
2024-01-02 00:26:27,838 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:27,840 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:27,841 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449868, Requested 1536. Please try again in 187ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:27,841 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Why do drug treatments fail in Sjgren\'s disease? Considerations for treatment, trial design and interpretation of clinical efficacy.\nDespite ongoing efforts to develop effective therapeutics, no disease-modifying drugs have been officially licensed for the indication of Sjgren\'s disease (SjD). This is partly due to heterogeneity in disease manifestations, which complicates drug target selection, trial design and interpretation of clinical efficacy in SjD.Here, we summarize developments and comment on challenges in 1) identifying the right target for treatment, 2) selection of the primary study endpoint for trials and definition of clinically relevant response to treatment, 3) inclusion criteria and patient stratification, 4) distinguishing between disease activity and damage and 5) establishing the effect of treatment considering measurement error, natural variation, and placebo or nocebo responses.Targets that are involved in both the immune cell response and dysregulation of glandular epithelial cells (e.g. B-lymphocytes, type-I interferon) are of particular interest to treat both glandular and extra-glandular manifestations of SjD. The recent development of composite study endpoints (CRESS and STAR) may be a crucial step forward in the search for clinically effective systemic treatment of patients with SjD. Important additional areas for future research are symptom-based and/or molecular pathway-based patient stratification, prevention of irreversible damage, and establishing the effect of treatment.</ABSTRACT>'}]
2024-01-02 00:26:27,841 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449827, Requested 1600. Please try again in 190ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:27,841 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Ileal Pouch-anal Anastomosis in Primary Sclerosing Cholangitis-inflammatory Bowel Disease (PSC-IBD): Long-term Pouch and Liver Transplant Outcomes.\nTo compare the effect of liver transplantation (LT) on ileal pouch-anal anastomosis (IPAA) outcomes in patients with primary sclerosing cholangitis and inflammatory bowel disease (PSC-IBD).Patients with PSC-IBD may require both IPAA for colitis and LT for PSC.Patients with PSC-IBD from out institutional pouch registry (1985-2022) were divided according to LT status and timing of LT (before and after IPAA) and their outcomes analyzed.A total of 160 patients were included: 112 (70%) nontransplanted at last follow-up; 48 (30%) transplanted, of which 23 (14%) before IPAA and 25 (16%) after. Nontransplanted patients at IPAA had more laparoscopic procedures [37 (46%) vs 8 (18%), P =0.002] and less blood loss (median 250 vs 400\xa0mL, P =0.006). Morbidity and mortality at 90 days were similar. Chronic pouchitis was higher in transplanted compared with nontransplanted patients [32 (67%) vs 51 (45.5%), P =0.03], but nontransplanted patients had a higher rate of chronic antibiotic refractory pouchitis. Overall survival was similar, but nontransplanted patients had more PSC-related deaths (12.5% vs 2%, P =0.002). Pouch survival at 10 years was 90% for nontransplanted patients and 100% for transplanted patients (log-rank P =0.052). Timing of LT had no impact on chronic pouchitis, pouch failure, or overall survival. PSC recurrence was 6% at 10 years. For transplanted patients, graft survival was similar regardless of IPAA timing.In patients with PSC-IBD and IPAA, LT is linked to an increased pouchitis rate but does not affect overall and pouch survival. Timing of LT does not influence short-term and long-term pouch outcomes.</ABSTRACT>'}]
2024-01-02 00:26:27,844 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:27,844 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449788, Requested 1820. Please try again in 214ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:27,845 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Visual Functioning and Mortality of Age-Related Macular Degeneration Patients in a Colorado Cohort.\nTo investigate the relationship between visual functioning as measured by the National Eye Institute 25-Item Visual Function Questionnaire (VFQ-25) and mortality in patients with various stages of age-related macular degeneration (AMD).Observational cohort study.Patients with AMD enrolled in the University of Colorado AMD Registry between July 9, 2014 and December 31, 2021 were included.Age-related macular degeneration cases were classified into early AMD, intermediate AMD, geographic atrophy, neovascular AMD, or both advanced types of AMD (neovasuclar and geographic atrophy both present) using multimodal imaging and the Beckman and Classification of Atrophy Meetings criteria. Visual Function Questionnaire\xa0-25 composite and subscale scores at the time of study enrollment were calculated. Cox proportional hazards modeling was used to assess time to event for mortality utilizing univariate and multivariable models, which adjusted for all variables significantly associated with mortality. The measures of association were hazard ratios (HRs) and 95% confidence intervals (CIs).All-cause mortality statistics were obtained through a collaborative agreement with the Colorado Department of Public Health and Environment. Death rates through October 19, 2022 were compared by demographics and potential confounders.Analysis was completed on a cohort of 876 patients, of which 180 (20.6%) died during the follow-up period. Average follow-up time for this cohort was 52.5 (standard deviation: 26.6) months. In univariate analysis, composite VFQ-25 score and all subscale scores aside from ocular pain were significantly associated with time to mortality. Additionally, age, AMD category, marital status, history of smoking, and multiple chronic comorbid conditions were significantly associated with time to mortality. In multivariable analysis, for each 10-point increase in a patient\'s VFQ-25 scores for general health and driving, the risk of death decreased with HR of 0.85 (95% CI: 0.80, 0.91; P < 0.0001) and 0.92 (95% CI: 0.87, 0.97; P\xa0= 0.005), respectively. Composite and other subscale scores were not significantly associated with mortality after adjusting for confounding variables.This cohort of AMD patients had a 20% rate of death in the 52.5-month average follow-up time. Better general health and ability to drive, as measured by the VFQ-25, were each separately associated with significantly lower risk of death among individuals with AMD.The author(s) have no proprietary or commercial interest in any materials discussed in this article.</ABSTRACT>'}]
2024-01-02 00:26:27,848 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:27,848 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449754, Requested 1411. Please try again in 155ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:27,848 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Preparing for the next decade of anti-VEGF biosimilars for retinal diseases: a focus on South Asia.\nSouth Asian countries such as India, South Korea, and Japan have played a key role in spearheading the research and development of biosimilars of the anti-vascular endothelial growth factor (anti-VEGF) ranibizumab for retinal diseases. It is important to understand how this region is preparing for the next decade in the field of anti-VEGF biosimilars for retinal diseases.We discuss the existing anti-VEGF ranibizumab biosimilars along with the biosimilars that might receive approval in the coming decade. Furthermore, we discuss the development status of aflibercept biosimilars that might receive approval as soon as the aflibercept patent expires.The South Asian region seems to be well prepared, with multiple ranibizumab and aflibercept biosimilars in the pipeline. However, it has to be seen whether these therapies will have widespread global clearance or will simply obtain approval from the Asian regional authorities.</ABSTRACT>'}]
2024-01-02 00:26:27,883 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:27,884 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449667, Requested 1681. Please try again in 179ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:27,884 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>The Hypothalamus-pituitary-adrenocortical Response to Critical Illness: A Concept in Need of Revision.\nBased on insights obtained during the past decade, the classical concept of an activated hypothalamus-pituitary-adrenocortical axis in response to critical illness is in need of revision. After a brief central hypothalamus-pituitary-adrenocortical axis activation, the vital maintenance of increased systemic cortisol availability and action in response to critical illness is predominantly driven by peripheral adaptations rather than by an ongoing centrally activated several-fold increased production and secretion of cortisol. Besides the known reduction of cortisol-binding proteins that increases free cortisol, these peripheral responses comprise suppressed cortisol metabolism in liver and kidney, prolonging cortisol half-life, and local alterations in expression of 11\u03b2HSD1, glucocorticoid receptor-\u03b1 (GR\u03b1), and FK506 binding protein 5 (FKBP51) that appear to titrate increased GR\u03b1 action in vital organs and tissues while reducing GR\u03b1 action in neutrophils, possibly preventing immune-suppressive off-target effects of increased systemic cortisol availability. Peripherally increased cortisol exerts negative feed-back inhibition at the pituitary level impairing processing of pro-opiomelanocortin into ACTH, thereby reducing ACTH-driven cortisol secretion, whereas ongoing central activation results in increased circulating pro-opiomelanocortin. These alterations seem adaptive and beneficial for the host in the short term. However, as a consequence, patients with prolonged critical illness who require intensive care for weeks or longer may develop a form of central adrenal insufficiency. The new findings supersede earlier concepts such as "relative," as opposed to "absolute," adrenal insufficiency and generalized systemic glucocorticoid resistance in the critically ill. The findings also question the scientific basis for broad implementation of stress dose hydrocortisone treatment of patients suffering from acute septic shock solely based on assumption of cortisol insufficiency.</ABSTRACT>'}]
2024-01-02 00:26:27,912 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:27,914 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449598, Requested 1790. Please try again in 185ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:27,914 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Assessment of lacrimal gland involvement in primary Sjgren\'s syndrome using gray-scale ultrasonography and shear wave elastography.\nThe aim of this study was to assess lacrimal gland involvement in primary Sjgren\'s syndrome (pSS) using lacrimal gland gray-scale ultrasound (LGUS) and two-dimensional shear wave elastography (2D-SWE).Eighty-five pSS patients with a mean age of 51.16\u2009\u200910.61\xa0years and 84 sex- and age-matched healthy subjects with a mean age of 50.94\u2009\u200911.05\xa0years were included in the study. Lacrimal gland parenchymal findings and 2D-SWE values were compared between the two groups and the correlations of LGUS parameters with clinical findings, dry eye tests, and minor salivary gland biopsy (MSGB) were further investigated.LGUS parenchymal grade was 0 in 14 (16.5%), 1 in 45 (52.9%), 2 in 23 (27.1%), and 3 in 3 patients (3.5%) in the pSS group, while in the control group, parenchymal grades were 0 (57.1%) and 1 (42.9%). The mean 2D-SWE value of pSS patients was significantly higher than the control group (p\u2009<\u20090.05) and increased parallel with lacrimal parenchymal grade. The elasticity modulus had a high diagnostic performance in detecting lacrimal gland involvement in pSS patients (AUC 0.901, sensitivity 70.6%, specificity 97.6%), while the diagnostic performance of LGUS was much lower (AUC 0.769, sensitivity 83.5%, specificity 57.1%). LGUS and 2D-SWE values were found to be correlated with dry eye tests and MSGB results (p\u2009<\u20090.05).LGUS and 2D-SWE are both useful for assessing the lacrimal gland involvement in pSS patients; however, 2D-SWE has a better diagnostic performance than LGUS and found to be correlated with dry eye tests.Lacrimal gland US and two-dimensional shear wave elastography (2D-SWE) are imaging modalities that can be used to demonstrate parenchymal involvement of the lacrimal gland in primary Sjgren\'s syndrome (pSS). Gray-scale US and two-dimensional shear wave elastography (2D-SWE) have been widely used in the recent decade to assess gland involvement in patients with primary Sjgren\'s syndrome (pSS).  The elasticity modulus had a high diagnostic performance in detecting lacrimal gland involvement in primary Sjgren\'s syndrome (pSS) patients.  Lacrimal gland US and two-dimensional shear wave elastography (2D-SWE) are both useful for assessing the lacrimal gland in primary Sjgren\'s syndrome (pSS) patients; however, two-dimensional shear wave elastography (2D-SWE) has a better diagnostic performance than lacrimal gland ultrasound (LGUS).</ABSTRACT>'}]
2024-01-02 00:26:27,926 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:27,927 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449574, Requested 1775. Please try again in 179ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:27,927 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Pneumatic Retinopexy for Rhegmatogenous Retinal Detachment in Elderly Patients.\nTo assess clinical outcomes in elderly patients aged \u2265 75 years who underwent pneumatic retinopexy (PnR) for primary rhegmatogenous retinal detachment (RRD).Retrospective cohort study.Patients aged \u2265 75 years with primary RRD undergoing PnR.This study evaluates clinical outcomes among eligible patients who presented from October 1, 2010, to December 31, 2022, with a minimum of 3 months\' follow-up. There were no limitations with respect to the number, size, or location of retinal breaks. Exclusion criteria included significant proliferative vitreoretinopathy or previous retinal detachment repair in the index eye, inability to maintain the postoperative posturing requirements or inability to carry out adequate examination of the peripheral retina because of media opacity. Lens status did not impact the decision to offer PnR.Pneumatic retinopexy primary anatomic reattachment rate and postoperative best corrected visual acuity (BCVA) at 3 months.Eighty patients with a mean age of 80.6  4.6 years were included in this study; 35% (28/80) were phakic and 34% (27/80) presented with a fovea-on RRD. The mean number of breaks in the detached retina was 1.52  1.13, and the mean number of quadrants of detached retina was 2.35  0.93. The primary anatomic reattachment rate at 3 months after PnR was 78.8% (63/80), whereas the remaining 21.2% (17/80) failed PnR and underwent an operating room procedure. There was a statistically significant improvement in logarithm of the minimum angle of resolution (logMAR) BCVA from baseline to 3 months (1.29  0.94 and 0.69  0.67, respectively, P < 0.001). A subgroup analysis that only included patients aged > 80 years was also performed, with a total of 39 patients with a mean age of 84.4  3.5 years. The primary anatomic reattachment rate with PnR in this subgroup was 74.4% (29/39), with a statistically significant improvement in BCVA from baseline to 3\xa0months (1.4  1.05 and 0.77  0.70, respectively; P\xa0= 0.004).Elderly patients treated with PnR for primary RRD had relatively comparable primary anatomic reattachment rates with other surgical techniques such as pars plana vitrectomy and scleral buckle. Pneumatic retinopexy is an effective, minimally invasive office-based procedure that may be desirable for some elderly patients.The authors have no proprietary or commercial interest in any materials discussed in this article.</ABSTRACT>'}]
2024-01-02 00:26:27,940 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:27,945 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:27,946 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449194, Requested 1695. Please try again in 118ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:27,946 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Delayed Ustekinumab Responders in Ulcerative Colitis Have Greater Inflammatory Burden but Similar Outcomes as Early Responders.\nDifferences in 1-year outcomes among early compared with delayed responders to vedolizumab have been shown in ulcerative colitis. However, it is unclear whether similar differences exist with ustekinumab, and what factors differentiate delayed responders from nonresponders.This study was a post hoc analysis of patient-level data from the UNIFI clinical trial. Ustekinumab-treated patients with clinical response, defined as a reduction in total Mayo score of 30% or more\xa0and 3 or more points from baseline with a reduction in their rectal bleeding subscore of 1 or more or a rectal bleeding subscore of 1 or less, at week 8 were deemed early responders and\xa0their outcomes were compared with delayed responders (week 8 nonresponders who\xa0subsequently responded at week 16). The primary outcome assessed was 1-year clinical remission, defined as a total Mayo score of 2 or less and no subscore greater than\xa01.We included 642 ustekinumab-treated patients, including 321 (50%) early responders, 115 (17.9%) delayed responders, and 205 (32.1%) nonresponders. No differences were observed for 1-year clinical remission among early vs delayed responders (132 of 321 [41.1%] vs 40 of 115 [34.8%]; P\xa0= .233), or for other outcomes assessed regardless of induction dose. Compared with early responders, delayed responders had more severe baseline Mayo endoscopic disease (88 of 115 [76.5%] vs 206 of 321 [64.2%]; P\xa0= .015) and abnormal baseline C-reactive protein level greater than 3 mg/L (83 of 115 [72.2%] vs 183 of 321 [57%]; P\xa0= .004). Compared with nonresponders, delayed responders had a significant decrease in C-reactive protein level (F-value [degrees of freedom, mean squares] [4, 844]; P < .0001) and fecal calprotectin level (F[4, 818]; P < .0001) through week\xa016.Compared with early ustekinumab responders, delayed responders had a greater inflammatory burden at baseline. Early and delayed responders had similar 1-year outcomes. Biomarker decline observed in delayed responders can help differentiate them from nonresponders.</ABSTRACT>'}]
2024-01-02 00:26:27,958 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:27,959 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449044, Requested 1537. Please try again in 77ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:27,959 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Diabetic retinopathy: emerging concepts of current and potential therapy.\nDiabetic retinopathy (DR) is one of\xa0the leading causes of permanent central blindness worldwide. Despite the complexity and inadequate understanding of DR pathogenesis, many of the underlying pathways are currently partially understood and may offer potential targets for future treatments. Anti-VEGF medications are currently the main medication for this problem. This article provides an overview of the established pharmacological treatments and those that are being developed to cure DR. We firstly reviewed the widely utilized approaches including pan-retinal photocoagulation therapy, anti-VEGF therapy, corticosteroid therapy, and surgical management of DR. Next, we discussed the mechanisms of action and prospective benefits of novel candidate medications. Current management are far from being a perfect treatment for DR, despite mild-term favorable efficiency and safety profiles. Pharmacological research should work toward developing longer-lasting treatments or new drug delivery systems, as well as on identifying new molecular targets in the pathogenetical mechanism for DR. In order to find a treatment that is specifically designed for each patient, it is also necessary to properly characterize patients, taking into account elements like hereditary factors and intraretinal neovascularization stages for effective utilization of drugs. The current and potential approaches for diabetic retinopathy. Image was constructed using Biorender.com.</ABSTRACT>'}]
2024-01-02 00:26:27,960 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:27,961 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449060, Requested 1661. Please try again in 96ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:27,961 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Quantitative fluid overload in severe aortic stenosis refines cardiac damage and associates with worse outcomes.\nCardiac decompensation in aortic stenosis (AS) involves extra-valvular cardiac damage and progressive fluid overload (FO). FO can be objectively quantified using bioimpedance spectroscopy. We aimed to assess the prognostic value of FO beyond established damage markers to guide risk stratification.Consecutive patients with severe AS scheduled for transcatheter aortic valve implantation (TAVI) underwent prospective risk assessment with bioimpedance spectroscopy (BIS) and echocardiography. FO by BIS was defined as \u22651.0\u2009L (0.0\u2009L\u2009=\u2009euvolaemia). The extent of cardiac damage was assessed by echocardiography according to an established staging classification. Right-sided cardiac damage (rCD) was defined as pulmonary vasculature/tricuspid/right ventricular damage. Hospitalization for heart failure (HHF) and/or death served as primary endpoint. In total, 880 patients (81\u2009\u20097\u2009years, 47% female) undergoing TAVI were included and 360 (41%) had FO. Clinical examination in patients with FO was unremarkable for congestion signs in >50%. A quarter had FO but no rCD (FO+/rCD-). FO+/rCD+ had the highest damage markers, including N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels. After 2.4\u2009\u20091.0\u2009years of follow-up, 236 patients (27%) had reached the primary endpoint (29 HHF, 194 deaths, 13 both). Quantitatively, every 1.0\u2009L increase in bioimpedance was associated with a 13% increase in event hazard (adjusted hazard ratio 1.13, 95% confidence interval 1.06-1.22, p\u2009<\u20090.001). FO provided incremental prognostic value to traditional risk markers (NT-proBNP, EuroSCORE II, damage on echocardiography). Stratification according to FO and rCD yielded worse outcomes for FO+/rCD+ and FO+/rCD-, but not FO-/rCD+, compared to FO-/rCD-.Quantitative FO in patients with severe AS improves risk prediction of worse post-interventional outcomes compared to traditional risk assessment.</ABSTRACT>'}]
2024-01-02 00:26:27,962 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:27,963 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449039, Requested 1556. Please try again in 79ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:27,963 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Intestinal ultrasound in patients with suspected Crohn\'s disease - results of a prospective evaluation by trainees.\nIntestinal ultrasound (IUS) performed by experts is a valuable tool for the diagnostic work-up and monitoring of Crohn\'s disease (CD). However, concern about insufficient training and perceived high inter-observer variability limit the adoption of IUS in CD. We examined the diagnostic accuracy of trainee-performed IUS in patients with suspected CD.Patients recruited to a prospective trial investigating the diagnostic accuracy of magnetic resonance enterocolonography (MREC) in patients with clinically suspected CD underwent IUS performed by trainees. The primary end-point was IUS per-patient sensitivity and specificity for ileocolonic CD determined by ileocolonoscopy.129 patients with clinically suspected CD and a complete IC and IUS were included in the analysis. IUS detected signs of CD in 49 cases (small bowel 31, colon 15, small bowel, and colon 3). The sensitivity and specificity for detection of ileocolonic CD by trainee performed IUS improved during the first to the second half of the study period from 57.1% (CI 34.0-78.2) to 73.1% (CI 52.2-88.4) and 76.5% (CI 58.8-89.3) to 89.7% (CI 72.6-97.8). The overall sensitivity and specificity of diagnosing CD with IUS were 65.4% (CI 50.9-78.0) and 80.5% (CI 69.9-88.7). There was no difference in diagnostic performance between IUS and MREC for the detection of CD.Trainees improved during the study, and IUS performance in disease detection corresponded to expert-evaluated MREC.Registered at ClinicalTrials.gov (NCT03134586).</ABSTRACT>'}]
2024-01-02 00:26:27,968 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:27,970 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448953, Requested 1531. Please try again in 64ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:27,970 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Novel ginsenoside monomer RT4 promotes colitis repair in mice by regulating miR-144-3p/SLC7A11 signaling pathway.\nGinsenoside RT4 (RT4) is a new biologically active compound extracted from ginseng that possesses numerous medicinal and pharmacological properties. However, its potential therapeutic effect of ginsenoside RT4 on ulcerative colitis remains unknown.In this study, we investigated the anti-inflammatory effects of ginsenoside RT4 and its underlying molecular mechanism in the treatment of ulcerative colitis mice induced with dextran sulfate sodium (DSS). Our results demonstrate that ginsenoside RT4 effectively reduced weight, shortening of colonic tract length, colonic bowel damage, and disease activity index (DAI) scores in DSS-induced colitis mice. Additionally, ginsenoside RT4 regulates miR-144-3p expression in DSS-induced colitis mice, and we further confirmed that the solute carrier family 7 member 11 (SLC7A11) was the target gene of miR-144-3p by database analysis. Finally, ginsenoside RT4 inhibits the activation of the miR-144-3p/SLC7A11 signaling pathway, which alleviates colitis. Ginsenoside RT4 significantly decreased the expression of pro-inflammatory cytokines TNF-\u03b1 and IL-1\u03b2 and increased the anti-inflammatory cytokine IL-10.These findings suggest that ginsenoside RT4 may have therapeutic potential for treating ulcerative colitis by downregulating levels of miR-144-3p/SLC7A11 signaling pathway, which are expected to be useful in treating clinical ulcerative colitis.</ABSTRACT>'}]
2024-01-02 00:26:27,982 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:27,983 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448802, Requested 1607. Please try again in 54ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:27,984 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Population outcomes, trends and the future of pouch surgery for ulcerative colitis: a 19-year New South Wales data linkage study.\nIleal pouch-anal anastomosis (IPAA) is considered the gold standard reconstructive option in ulcerative colitis (UC). Recent efforts to improve pouch outcomes have seen a push towards centralisation of surgery. This study aimed to document outcomes following pouch surgery at a population level within New South Wales (NSW), and identify factors associated with, and temporal trends of these outcomes.A retrospective data linkage study of the NSW population over a 19-year period was performed. The primary outcome was pouch failure in patients with UC who underwent IPAA. The influence of hospital level factors (including annual volume) and patient demographic variables on this outcome were assessed using Cox proportional hazards modelling. Temporal trends in annual volume and evidence for centralisation over the studied period were assessed using Poisson regression analysis.The annual volume of UC pouches reduced over the study period. The pouch failure rates were 8.6% (95% CI 6.3-10.8%) and 10.6% (95% CI 8.0-13.1%) at 5- and 10-years, respectively. Increasing age and non-elective admission were associated with higher failure rates. One-third of UC pouches (31.6%) were performed in a single institution, which averaged 6.5 pouches/year throughout the study period. Three-quarters (19/25) of NSW public hospitals who performed pouches performed less than one UC pouch annually.The outcomes following UC pouch surgery in NSW are comparable with global standards. Concentrating IBD pouch surgery with the aim of producing specialist surgical teams may be a reasonable way forward in NSW and would ensure equity of access and facilitate research and training collaboration.</ABSTRACT>'}]
2024-01-02 00:26:27,992 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:27,993 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448793, Requested 1564. Please try again in 47ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:27,993 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Profile of 193 pediatric cancer patients managed with radiation therapy: Challenges and lessons learned.\nSeries on radiotherapy (RT) practice in pediatric malignancies are limited in India as only a few centers practice pediatric RT, particularly under anesthesia. We aimed to study the clinical profile of pediatric cancer patients treated with RT and to analyze various challenges in pediatric RT under anesthesia.The data were prospectively maintained in Microsoft Excel spreadsheets. Pediatric cancer patients aged 0-14 years, registered in the RT department between February 1, 2019 and July 30, 2021were analyzed.A total of 193 pediatric cancer patients (noncentral nervous system) received RT during the said period. Median age at presentation was 5.2 years (range: 9 months to 14 years) with a male-to-female ratio of 1.8:1. The majority of the patients were in the age group of 0-4 years (52.8%) followed by 5-9 years (29.5%) and \u226510 years (17.6%). Most common indications for RT included bone and soft-tissue tumors, retinoblastoma, Wilms tumor, neuroblastoma, and hematological malignancies. One hundred and seventy-nine (92.7%) patients received RT with curative intent, while 14 (7.3%) patients received palliative RT. Thirty (15.5%) patients needed anesthesia for RT. Ten (5.18%) patients required RT interruption due to toxicities with a median gap of 3 days.RT is challenging yet an important aspect of multidisciplinary care in paediatric cancers. Estimating the burden of pediatric patients in the RT department may help in assessing unmet needs, resource development, and prioritization, which may improve the cure rates.</ABSTRACT>'}]
2024-01-02 00:26:28,018 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:28,020 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448711, Requested 1636. Please try again in 46ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:28,020 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Primary Retinal Detachment Repair in Eyes Deemed High Risk for Proliferative Vitreoretinopathy: Surgical Outcomes in 389 Eyes.\nTo evaluate surgical outcomes in eyes with primary rhegmatogenous retinal detachment (RRD) deemed at high risk for postoperative proliferative vitreoretinopathy (PVR).Retrospective, consecutive case cohort study.Eyes undergoing primary RRD repair with pars plana vitrectomy (PPV) or combined PPV with scleral buckling (PPV/SB) between January 1, 2016, and December 30, 2017, at Wills Eye Hospital.Eyes were defined as "high risk" if \u2265 1 of the following risk factors for PVR was present on preoperative examination: preoperative PVR grade A or B, vitreous hemorrhage, RRD involving \u2265 50% of retinal area, presence of \u2265 3 retinal breaks, history of prior cryotherapy, presence of choroidal detachment, or duration of RRD > 2 weeks. Surgical failure was defined as an additional intervention required for the retinal reattachment.Single surgery attachment success (SSAS) rate 3 months after first surgical intervention for primary RRD.Of 2053 reviewed charts, a total of 389 eyes (18.9%) met the definition of high risk and were included in the analysis. Mean patient age was 63.5 years. PPV/SB was performed in 125 (32.1%) eyes and PPV alone in 264 (67.9%) eyes. SSAS rate of the overall cohort was 71.5% at 3 months. SSAS rate was significantly higher in eyes treated with PPV/SB compared with PPV (80.8% vs. 67%, respectively, P\xa0= 0.006). On multivariate analysis, use of PPV/SB was the only feature associated with SSAS (odds ratio, 2.04; 95% confidence interval, 1.12-3.69, P\xa0= 0.019).In eyes with primary RRD and risk factors for PVR, overall SSAS was 71.5% after primary repair. In this cohort, use of PPV/SB was associated with a significantly higher SSAS compared with PPV alone.Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</ABSTRACT>'}]
2024-01-02 00:26:28,027 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:28,028 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449908, Requested 1339. Please try again in 166ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:28,028 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Coats\' Disease in a Patient With Cornelia de Lange Syndrome: Management With Laser and Bevacizumab.\nCornelia de Lange syndrome is a congenital disorder with multisystem abnormalities including multiple ocular findings. The authors report a case of Coats\' disease in a patient with Cornelia de Lange syndrome who was successfully treated with laser and intravitreal bevacizumab. This case demonstrates the importance of fluorescein angiography in making the diagnosis and directing treatment and the efficacy of combined laser with intravitreal anti-vascular endothelial growth factor therapy for persistent vascular leakage associated with Coats\' disease in Cornelia de Lange syndrome. [J Pediatr Ophthalmol Strabismus. 2023;60(4):e45-e48.].</ABSTRACT>'}]
2024-01-02 00:26:28,031 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:28,032 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449932, Requested 1594. Please try again in 203ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:28,032 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Statin Treatment on Cardiovascular Risk After Retinal Artery Occlusion: A Historical Cohort Study.\nRetinal artery occlusion (RAO) is a major cause of acute visual loss and patients with RAO have an increased risk for subsequent cardiovascular events. However, there is little evidence of whether the use of statins is associated with the prevention of cardiovascular events in patients with RAO. We investigated whether statin treatment in patients with RAO is associated with a lower risk of cardiovascular events.This study was a historical cohort study with nested case-control analysis. Using the nationwide health insurance claims database in Korea, we retrospectively established a cohort of newly diagnosed RAO patients without prior cardiovascular events between January 2008 and March 2020. We defined the case group as those who had cardiovascular events (stroke or myocardial infarction) and the control group as RAO patients without primary outcome matched by sex, age, comorbidities, and duration of follow-up (1:2 incidence density sampling). Conditional logistic regression was performed.Among 13,843 patients newly diagnosed with RAO, 1030 patients had cardiovascular events (mean follow-up period of 6.4\u2009\u20093.7\xa0years). A total of 957 cases were matched to 1914 controls. Throughout the study period, the proportion of patients taking statin was less than half. Statin treatment after RAO was associated with a low risk of cardiovascular events (adjusted OR, 0.637; 95% CI 0.520-0.780; P\u2009<\u20090.001). A longer duration of statin exposure was associated with a lower cardiovascular risk.In patients with newly diagnosed RAO, treatment with statins, particularly long-term use, was associated with a low risk of future cardiovascular events.</ABSTRACT>'}]
2024-01-02 00:26:28,043 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:28,044 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:28,046 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449813, Requested 1715. Please try again in 203ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:28,046 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Mitochondrial Genome-Encoded Long Noncoding RNA Cytochrome B and Mitochondrial Dysfunction in Diabetic Retinopathy.\nAims: Mitochondrial dysfunction is closely associated with the development of diabetic complications. In diabetic retinopathy, electron transport chain is compromised and mitochondrial DNA (mtDNA) is damaged, downregulating transcription of mtDNA-encoded cytochrome B (CYTB) and its antisense long noncoding RNA, long noncoding RNA cytochrome B (LncCytB). Our goal was to investigate the role of LncCytB in the regulation of CYTB and mitochondrial function in diabetic retinopathy. Methods: Using human retinal endothelial cells, genetically manipulated for LncCytB (overexpression or silencing), the effect of high glucose (20\u2009mM d-glucose) on LncCytB-CYTB interactions (by chromatin isolation by RNA purification), CYTB gene expression (by real-time quantitative polymerase chain reaction), complex III activity, mitochondrial free radicals, and oxygen consumption rate (OCR, by Seahorse XF analyzer) was investigated. Key results were confirmed in the retinal microvessels from streptozotocin-induced diabetic mice. Results: High glucose decreased LncCytB-CYTB interactions, and while LncCytB overexpression ameliorated glucose-induced decrease in CYTB gene transcripts, complex III activity and OCR and increase in mitochondrial reactive oxygen species, LncCytB-siRNA further attenuated CYTB gene transcription, complex III activity, and OCR. Similar decrease in LncCytB-CYTB interactions and CYTB transcription was observed in diabetic mice. Furthermore, maintenance of mitochondrial homeostasis by overexpressing superoxide dismutase or sirtuin 1 in mice ameliorated diabetes-induced decrease in LncCytB-CYTB interactions and CYTB gene transcripts, and also improved complex III activity and mitochondrial respiration. Innovation and Conclusion: LncCytB downregulation in hyperglycemic milieu downregulates CYTB transcription, which inhibits complex III activity and compromises mitochondrial stability and OCR. Thus, preventing LncCytB downregulation in diabetes has potential of inhibiting the development of diabetic retinopathy, possibly via maintaining mitochondrial respiration. Antioxid. Redox Signal. 39, 817-828.</ABSTRACT>'}]
2024-01-02 00:26:28,048 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:28,048 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449784, Requested 1957. Please try again in 232ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:28,048 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Electrochemical skin conductances values and clinical factors affecting sudomotor dysfunction in patients with prediabetes, type 1 diabetes, and type 2 diabetes: A single center experience.\nSudomotor dysfunction is linked to small fibers damage. We investigated sudomotor dysfunction in a large group of participants with diabetes, prediabetes, and nondiabetic healthy subjects. This study aimed to complete knowledge on sudomotor dysfunction in this population, especially regarding the threshold values for the electrochemical skin conductance (ESC) and factors affecting it.A total of 690 volunteers in four groups were included in the study (type 1 [T1DG]: n\xa0=\xa080, 61.3% women; type 2 diabetes [T2DG]: n\xa0=\xa0438, 63.5% women; prediabetes [Pre-DG]: n\xa0=\xa088, 80.7% women; healthy control [HC-G]: n\xa0=\xa084, 67.5% women). All subjects were investigated for clinical diabetic peripheral polyneuropathy and sudomotor dysfunction. The characteristics of participants obtained from outpatient records were evaluated. We used the Sudoscan device to measure ESC which was normalized for BMI, to improve the discriminative capability of the method.Diabetic polyneuropathy was found in 17.5% of T1DG, 27.4% of T1DG, and 10.2% of Pre-DG. The mean ESC/BMI was lower in subgroups with diabetic polyneuropathy than those without. Mean ESC/BMI was lowest in T2DG and highest in HC-G but comparable in T1DG and Pre-DG. We accepted the "mean ESC/BMI-1\xa0SD" in the HC-G as the threshold for sudomotor dysfunction. Accordingly, the prevalence of sudomotor dysfunction was 18.8%, 44.3%, 59.1%, and 15% in T1DG, T2DG, Pre-DG, and HC-G, respectively. In T2DG, sudomotor dysfunction was found in 66.7% of persons with retinopathy, of which 56.3% had clinical diabetic polyneuropathy. The prevalence of sudomotor dysfunction in subjects with peripheral artery disease, chronic kidney disease, cardiovascular disease, and hypertension was 46.7%, 47.4%, 43.4%, and 50%, respectively, and 42.9%, 38.9%, 45.5%, and 37.3% of whom in the same order detected with clinical diabetic polyneuropathy. Considering the entire group, a logistic regression model demonstrated that the variables associated with SMD were: retinopathy (OR: 2.969; 95% CI: 1.723, 5.114), female gender (OR: 1.952; 95% CI: 1.287, 2.962), and e-GFR (OR: 0.989; 95% CI: 0.981, 0.998). Since the rate of complications was very low in T1DG, excluding this group, a new model similarly revealed that retinopathy and female gender were associated with SMD, however, the association with e-GFR was disappeared.The prevalence of sudomotor dysfunction is high when established peripheral polyneuropathy was present in diabetes. Even though, sudomotor dysfunction can also occur before clinical polyneuropathy in both types of diabetes (T1DG: 18.8%, T2DG 44.3%), prediabetes (59.1%), and nondiabetic healthy subjects (15%). The variables associated with sudomotor dysfunction were retinopathy and female sex. Normalization of ESC for BMI would be a beneficial approach. However, before this method is included in the routine screening programs for diabetic polyneuropathy, large-scale and prospective studies are required to reach a consensus on the pathological threshold values.</ABSTRACT>'}]
2024-01-02 00:26:28,053 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:28,054 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449522, Requested 1177. Please try again in 93ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:28,054 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Technique for treatment of recurrent perianal fistula in Crohn\'s disease using autologous fat.\n</ABSTRACT>'}]
2024-01-02 00:26:28,055 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:28,055 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449340, Requested 1582. Please try again in 122ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:28,055 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Endometriosis of\xa0the Appendix: When Appendicitis Is Less Than Straightforward.\nWe present a case report of a 49-year-old female with a history of ulcerative colitis who originally presented to the general surgery clinic after an incidental finding on computed tomography was concerning for a dilated, fluid-filled appendix. She ultimately underwent a laparoscopic appendectomy. The pathology returned consistent with early acute appendicitis, with endometrial tissue along the outer wall of the appendix. We then performed a literature review regarding appendiceal masses and the occurrence of endometriomas and/or endometriosis of the appendix. A PubMed search was performed using the key words of appendix and appendicitis and endometrioma. Specific articles were examined mentioning the occurrence of endometriomas of the appendix and isolated endometriosis of the appendix. Between 2% and 6% of cases of appendicitis present due to an appendiceal mass, usually an inflammatory phlegmon. A variety of other causes, including primary malignancy, secondary malignancy, and combinations of pathologies, may lead to the eventual removal of the appendix. Specifically, endometriosis of the appendix is reported in less than 1% of females on post-appendectomy pathologic analysis. Although specific symptoms may guide a provider, there are few distinguishing symptoms that would point a provider toward a different etiology, to include malignancy, for appendicitis. Further information is needed to determine when a patient has an increased risk for an underlying pathology when presenting with appendicitis. This information will help drive continued treatment and lead to improved screening for appendiceal masses.</ABSTRACT>'}]
2024-01-02 00:26:28,056 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:28,058 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449399, Requested 1532. Please try again in 124ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:28,058 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Bowel Urgency in Ulcerative Colitis: Current Perspectives and Future Directions.\nBowel urgency (BU), the sudden or immediate need for a bowel movement, is one of the most common and disruptive symptoms experienced by patients with ulcerative colitis (UC). Distinct from the separate symptom of increased stool frequency, BU has a substantial negative impact on quality of life and psychosocial functioning. Among patients with UC, BU is one of the top reasons for treatment dissatisfaction and one of the symptoms patients most want improved. Patients may not discuss BU often due to embarrassment, and healthcare providers may not address the symptom adequately due to the lack of awareness of validated tools and/or knowledge of the importance of assessing BU. The mechanism of BU in UC is multifactorial and includes inflammatory changes in the rectum that may be linked to hypersensitivity and reduced compliance of the rectum. Responsive and reliable patient-reported outcome measures of BU are needed to provide evidence of treatment benefits in clinical trials and facilitate communication in clinical practice. This review discusses the pathophysiology and clinical importance of BU in UC and its impact on the quality of life and psychosocial functioning. Patient-reported outcome measures developed to assess the severity of BU in UC are discussed alongside overviews of treatment options and clinical guidelines. Implications for the future management of UC from the perspective of BU are also explored.</ABSTRACT>'}]
2024-01-02 00:26:28,066 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:28,069 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449295, Requested 1636. Please try again in 124ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:28,069 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Emu Oil and zinc monoglycerolate independently reduce disease severity in a rat model of ulcerative colitis.\nUlcerative colitis is characterized by colonic inflammation. Previously, Emu Oil protected the intestine against experimentally-induced inflammatory intestinal disorders. Zinc monoglycerolate (ZMG) polymer, formed by heating zinc oxide with glycerol, demonstrated anti-inflammatory and wound healing properties. We aimed to determine whether ZMG, alone or in combination with Emu Oil, could reduce acute colitis severity in rats. Male Sprague Dawley rats (n\u2009=\u20098/group) were orally-administered either vehicle, ZMG, Emu Oil (EO) or ZMG combined with EO (ZMG/EO) daily. Rats were provided ad libitum access to drinking water (Groups 1-4) or dextran sulphate sodium (DSS; 2%w/v; Groups 5-8) throughout the trial (days 0-5) before euthanasia on day 6. Disease activity index, crypt depth, degranulated mast cells (DMCs) and myeloperoxidase (MPO) activity were assessed. p\u2009<\u20090.05 was considered significant. DSS increased disease severity (days 3-6) compared to normal controls (p\u2009<\u20090.05). Importantly, in DSS-administered rats, ZMG/EO (day 3) and ZMG (day 6) reduced disease activity index compared to controls (p\u2009<\u20090.05). Following DSS consumption, distal colonic crypts lengthened (p\u2009<\u20090.01), occurring to a greater extent with EO compared to ZMG and ZMG/EO (p\u2009<\u20090.001). DSS increased colonic DMC numbers compared to normal controls (p\u2009<\u20090.001); an effect decreased only by EO (p\u2009<\u20090.05). Colonic MPO activity increased following DSS consumption (p\u2009<\u20090.05); notably, ZMG, EO and ZMG/EO treatments decreased MPO activity compared to DSS controls (p\u2009<\u20090.001). EO, ZMG and ZMG/EO did not impact any parameter in normal animals. Emu Oil and ZMG independently decreased selected indicators of colitic disease severity in rats; however, the combination did not reveal any additional benefit.</ABSTRACT>'}]
2024-01-02 00:26:28,069 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:28,070 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449298, Requested 1380. Please try again in 90ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:28,070 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Retinotomies and retinectomies: A review of indications, techniques, results, and complications.\nRetinotomy refers to "cutting" or "incising" the retina, whereas retinectomy denotes "excising" the retina. Retinotomies and retinectomies aid in tackling traction and retinal shortening that persist following membrane dissection and scleral buckling. We performed a literature search using Google Scholar and PubMed, followed by a review of the references procured. All relevant literature was studied in detail and summarized. We discuss the indications of retinotomies and retinectomies for relaxing retinal stiffness, accessing the subretinal space for choroidal neovascular membrane, hemorrhage and abscess clearance, drainage retinotomies to allow retinal flattening, radial retinotomies to release circumferential traction, harvesting free retinal grafts, and prophylactic chorioretinectomies in trauma.</ABSTRACT>'}]
2024-01-02 00:26:28,076 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:28,078 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449271, Requested 1366. Please try again in 84ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:28,078 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Reversible complete atrioventricular block in a neonate with maternal anti-Sjgren\'s syndrome-associated antibody: atypical phenotype of autoimmune congenital heart block.\nThe fetus of anti-Sjgren\'s syndrome-associated antibody-positive mother developed complete atrioventricular block at 39 weeks of gestation and required urgent ventricular pacing after birth. Unexpectedly, the patient recovered from the atrioventricular block within a few days. Fraction analysis of maternal anti-Sjgren\'s syndrome-associated antibody revealed positivity for isolated anti-Ro/SSA 60 kDa antibody, which is abnormal as most patients with complete atrioventricular block present with anti-Ro/SSA\xa052 kDa positivity, which may indicate a potentially atypical late and reversible manifestation of an autoimmune congenital atrioventricular block in this patient.</ABSTRACT>'}]
2024-01-02 00:26:28,104 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:28,105 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449124, Requested 1508. Please try again in 84ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:28,105 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Stemming the tide with ileocecal Crohn\'s disease: when is pharmacotherapy enough?\nCrohn\'s disease (CD) mostly affects the terminal ileum and ileocecal region and up to 80% of patients end up requiring surgery. Previously reserved for complicated or refractory forms, surgery is now considered as an alternative to medical treatment in localized ileocecal disease.This review examines factors associated with response to medical treatment and those associated with the need for surgery in ileocecal CD to identify the patients\' profile for whom pharmacotherapy might be enough. Factors associated with the recurrence and the postoperative complications are also reviewed to help the clinician identify patients for whom medical therapy might be preferred.LIR!C study long-term follow-up data show that 38% of infliximab-treated patients were still treated with infliximab at the end of their follow-up, while 14% had switched to another biologic or had received immunomodulator or corticosteroid and 48% had CD-related surgery. Only the combination with an immunomodulator was associated with a greater likelihood of continuing infliximab. Patients with ileocecal CD for whom pharmacotherapy might be sufficient are probably those with no risk factors for CD-related surgery.In addition, patients with high risk of recurrence or of post-operative complications may benefit more from medical treatment than from surgery.</ABSTRACT>'}]
2024-01-02 00:26:28,115 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:28,116 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449059, Requested 1664. Please try again in 96ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:28,116 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Quantitative evaluation of retinal and choroidal vascularity in systemic lupus erythematosus by SS-OCT/OCTA.\nTo evaluate changes in retinal and choroidal vascularity using swept-source optical coherence tomography (SS-OCT) and optical coherence tomography angiography (OCTA) in patients with systemic lupus erythematosus (SLE).In this prospective, cross-sectional study, 48 SLE patients and 40 healthy control (group HC) participants were included. The SLE patients were divided into two subgroups: patients with SLE with no ocular disease (group I) and patients with SLE with signs of retinopathy (group II). The superficial vessel density (SVD), deep vessel density (DVD), peripapillary retinal vessel densities (pRVD), choroidal thickness (ChT), and choroidal vascularity including total choroidal area (TCA), luminal area (LA), stromal area (SA), and choroidal vascularity index (CVI) were measured using SS-OCT/OCTA. Physical and ophthalmic examinations as well as the assessments of immunological markers were performed. The results of SS-OCT/OCTA were compared between group I, group II, and group HC, while the correlations among the parameters were analyzed.The SVD, DVD, and pRVD were found to be significantly lower in SLE patients than group HC, especially in SLE patients with signs of retinopathy. ChT were found to be significantly higher in group II. CVI was positively correlated with SVD and DVD in the fovea, as well as the foveal and parafoveal thickness. A significant decrease in SVD and DVD in the fovea among subjects positive for anti-dsDNA antibodies was noted.The application of OCTA in the evaluation of microvasculature may be useful in subclinical changes. Retinal microvascular density decreased in patients with SLE with greater severity of SLE. Disturbed retinal circulation was related to SLE disease activity, disease duration, CVI, and being positive for anti-dsDNA antibodies. The study results also suggest that SLE with signs of retinopathy may affect the choroid with increases in LA, SA, TCA, and ChT.</ABSTRACT>'}]
2024-01-02 00:26:28,118 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:28,118 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:28,120 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448958, Requested 1617. Please try again in 76ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:28,120 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Matrix metalloproteinases are key targets of acupuncture in the treatment of ulcerative colitis.\nThe aim of this study was to elucidate the key targets of acupuncture in the colon of ulcerative colitis (UC) mice model using full-length transcriptome sequencing. 2.5% dextran sodium sulfate (DSS)-induced colitis mice were treated with or without acupuncture. Intestinal pathology was observed, and full transcriptome sequencing and bioinformatic analysis were performed. The results demonstrated that acupuncture treatment reduced the UC symptoms, disease activity index score, and histological colitis score and increased body weight, colon length, and the number of intestinal goblet cells. In addition, acupuncture can also decrease the expression of necrotic biomarker phosphorylates mixed lineage kinase domain-like pseudo kinase (p-MLKL). Full-length transcriptome analysis indicated that acupuncture reversed the expression of 987 of the 1918 upregulated differentially expressed genes (DEGs), and 632 of the 1351 downregulated DEGs induced by DSS. DEGs regulated by acupuncture were mainly involved in inflammatory responses and intestinal barrier pathways. The protein-protein interaction network analysis revealed that matrix metalloproteinases (MMPs) are important genes regulated by acupuncture. Gene set enrichment analysis revealed that extracellular matrix (ECM)-receptor interaction was an important target of acupuncture. In addition, alternative splicing analysis suggested that acupuncture improved signaling pathways related to intestinal permeability, the biological processes of xenobiotics, sulfur compounds, and that monocarboxylic acids are closely associated with MMPs. Overall, our transcriptome analysis results indicate that acupuncture improves intestinal barrier function in UC through negative regulation of MMPs expression.</ABSTRACT>'}]
2024-01-02 00:26:28,120 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448973, Requested 1570. Please try again in 72ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:28,120 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Whole-Exome Sequencing for Identification of Potential Sex-Biased Variants in Kawasaki Disease Patients.\nKawasaki disease (KD) is an autoimmune disease of unknown etiology and has become a main cause of childhood acquired heart disease. KD is more prevalent in males than in females. The reason for this sex bias is unknown. Here, we used whole-exome sequencing (WES) to identify significantly different variants between male and female KD patients. From WES result, a total of 19,500 shared genetic variants in 8421 genes were captured via a series of filters. Further comparisons based on sex were performed to obtain 34 potential sex-biased variants in 34 genes for GO and Reactome Gene Sets enrichment analyses. Moreover, we selected 6 variants associated with immune, cells adhesion, platelet function, homeostasis, and ion channel signaling and expanded the sample size (1247 KD patients containing 713 males and 534 females, 803 healthy population containing 481 males and 322 females) for genotyping validation. From the results, USH2A/rs148135241, LMO7/rs142687160, CEMIP/rs12441101, and EFCC1/rs142391828 presented significant differences of alleles/genotypes frequency distributions between male and female only in KD patients (which were consistent with the result of WES analysis) but not in healthy population. In addition, the result also found that only EFCC1/rs142391828 polymorphism was associated with KD susceptibility. This result suggested that those four variants might play critical roles in sex bias in KD. The study would be in favor of a sex-specific genome atlas establishing and novel sex-specific precision therapies development for KD.</ABSTRACT>'}]
2024-01-02 00:26:28,122 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:28,122 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448936, Requested 1442. Please try again in 50ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:28,122 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>A new retinal OCT-angiography diabetic retinopathy dataset for segmentation and DR grading.\nDiabetic retinopathy (DR) is one of the most common diseases caused by diabetes and can lead to vision loss or even blindness. The wide-field optical coherence tomography (OCT) angiography is non-invasive imaging technology and convenient to diagnose DR.A newly constructed Retinal OCT-Angiography Diabetic retinopathy (ROAD) dataset is utilized for segmentation and grading tasks. It contains 1200 normal images, 1440 DR images, and 1440 ground truths for DR image segmentation. To handle the problem of grading DR, we propose a novel and effective framework, named projective map attention-based convolutional neural network (PACNet).The experimental results demonstrate the effectiveness of our PACNet. The accuracy of the proposed framework for grading DR is 87.5% on the ROAD dataset.The information on ROAD can be viewed at URL https://mip2019.github.io/ROAD. The ROAD dataset will be helpful for the development of the early detection of DR field and future research.The novel framework for grading DR is a valuable research and clinical diagnosis method.</ABSTRACT>'}]
2024-01-02 00:26:28,127 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:28,127 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:28,128 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448872, Requested 1608. Please try again in 64ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:28,128 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Factors affecting optical coherence tomography angiography signal strength index in patients receiving intravitreal injection treatment.\nTo investigate the clinical factors affecting optical coherence tomography angiography (OCTA) signal strength index (SSI) and its change after intravitreal injection treatment in patients with retinal disorders.OCTA data from 186 eyes of 166 patients with various retinal disorders including age-related macular degeneration, diabetic macular edema (DME), and retinal vein occlusions who received intravitreal injections were analyzed. The associations between SSI and clinical factors, including age, best-corrected visual acuity (BCVA), media opacity severity, and central macular thickness (CMT), were evaluated both before and after injection.After injection, BCVA improved and CMT decreased significantly, and SSI increased significantly (p\u2009=\u20090.030). BCVA showed a significant positive correlation with media opacity severity before and after injection and with CMT only before injection. In the multivariate analysis, age, presence of DME, BCVA, and media opacity severity were negatively associated with SSI both before and after injection, while CMT was negatively associated with SSI only before injection. After injection, a negative correlation was found between SSI change and both BCVA and CMT change.Our findings suggest that OCTA SSI is influenced by various clinical factors, including age, visual acuity, media opacity severity, and macular thickening, especially in cases of DME. The results also indicate that SSI may decrease in patients with macular disorders due to the presence of macular edema and the associated decrease in visual acuity. Therefore, it is crucial to consider these factors when interpreting OCTA data and ensure an adequate level of SSI.</ABSTRACT>'}]
2024-01-02 00:26:28,128 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448909, Requested 1600. Please try again in 67ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:28,128 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Respiratory outcomes in preterm infants following intravitreal bevacizumab for retinopathy of prematurity-a 10-year matched case study.\nTo evaluate respiratory outcomes in preterm infants with retinopathy of prematurity (ROP) following intravitreal bevacizumab injection (IVB).This single-centre study enroled preterm infants with a gestational age (GA)\u2009<\u200934 weeks or a birth weight (BW)\u2009<\u20091500\u2009g with bilateral type 1 ROP who received a single IVB, and a treatment-free control group matched by GA, postmenstrual age, and respiratory status at the time of the IVB. The primary outcome was serial respiratory changes in mean airway pressure (MAP), fraction of inspired oxygen (FiO2), and respiratory severity score (RSS, MAP x FiO2) during the 28-day post-IVB/matching period and overall respiratory improvement at day 28 and at discharge. The duration of supplemental oxygen therapy following IVB/matching was documented.A total of 5578 infants were included. Seventy-eight infants were enroled in the IVB group, and another 78 infants were matched as the control group. Both groups had downward trends in the MAP, FiO2, and RSS over the study period (all P\u2009<\u20090.001), but there were no between-group differences in these measures. The percentage of overall respiratory improvement was similar between the IVB and control groups, so was the duration of invasive and in-hospital oxygen ventilation. A lower percentage of oxygen dependence at discharge in the IVB group (P\u2009=\u20090.03) remained significant after adjusting for GA and BW.This is a matched case study to evaluate respiratory outcomes in preterm infants following IVB for ROP. We found that the IVBs did not compromise respiratory outcomes in preterm infants during the 28-day post-IVB period and at discharge.</ABSTRACT>'}]
2024-01-02 00:26:28,145 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:28,146 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449918, Requested 1511. Please try again in 190ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:28,146 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Head-Tilt Perfluorocarbon-Air Exchange Technique With Heads-Up Surgery for Giant Retinal Tear-Associated Retinal Detachments to Prevent Retinal Slippage Without Using Silicone Oil.\nTo report the efficacy of the perfluorocarbon liquid-air exchange with a head tilt toward the area of the giant retinal tear (GRT) using the heads-up surgery system to prevent retinal slippage during vitrectomy for GRT-associated retinal detachments.Eyes with GRT-associated retinal detachments underwent vitrectomy using the heads-up surgery system and perfluorocarbon liquid-air exchange with a head tilt 45 toward the GRT to put the area of the tear in the most dependent position to drain fluid. This technique was evaluated to prevent retinal slippage.Five consecutive cases were evaluated. The mean GRT size was 174 (range, 90-240) and the GRT was located temporally in two eyes, nasally in two eyes, and superiorly in one eye. The tamponade types were air (1 eye), sulfur hexafluoride (3 eyes), and perfluoropropane (1 eye). Our technique was feasible and the slippage did not occur in any eyes. Although the microscope needed to be tilted for optimal fundus visualization, heads-up surgery allowed surgeons to maintain ergonomic postures. Retinal reattachment was achieved with a single surgery in all eyes.The head-tilt perfluorocarbon liquid-air exchange with heads-up surgery is useful in preventing retinal slippage in eyes with GRT.</ABSTRACT>'}]
2024-01-02 00:26:28,162 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:28,163 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449793, Requested 1600. Please try again in 185ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:28,163 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Does corneal epithelial thickness show the severity of psoriasis? SD-OCT study.\nPrevious studies have generally focused on dry eye test abnormalities and ocular involvements such as uveitis, and blepharitis in psoriasis. Psoriasis area severity \u0131ndex (PASI), which is used to assess psoriasis severity, is a time-consuming and complex tool.To evaluate the relationship between disease severity and central corneal epithelial thickness (CCET) in psoriasis.175 eyes of 175 psoriasis patients and 57 eyes of 57 healthy individuals as a control group was included in this study. Psoriasis patients were divided into three subgroups according to PASI score as < 10 mild, 10\u201220 moderate and > 20 severe. CCET was measured by spectral domain-optical coherence tomography (SD-OCT), and mean values were recorded. Mean CCET values were compared between the psoriasis groups and the control group. Additionally, the relationship between PASI score and CCET was examined.The mean CCET value was 58.063.1\u03bcm in the mild group, 60.105.0\u03bcm in the moderate group, 65.756.3\u03bcm in the severe group and 56.163.1\u03bcm in the control group. It was determined that the mean CCET value was significantly higher in all psoriasis groups compared to the control group (p<0.001). The mean CCET value was significantly higher in the moderate psoriasis group than in the mild psoriasis group (p=0.018), and in the severe psoriasis group compared to the moderate psoriasis group (p<0.001). There was a strong positive correlation between PASI score and CCET (p<0.001, r=0.519).Cross-sectional design and a relatively small number of participants.There is a strong positive correlation between psoriasis severity and CCET. Contactless measurement of CCET by SD-OCT can be an indicator of psoriasis severity.</ABSTRACT>'}]
2024-01-02 00:26:28,163 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:28,169 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:28,170 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449419, Requested 1444. Please try again in 115ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:28,170 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>HLA-DQA1*05 and upstream variants of PPARGC1B are associated with infliximab persistence in Japanese Crohn\'s disease patients.\nRecently, the HLA-DQA1*05 (rs2097432) genetic variation has been reported to be linked to early infliximab (IFX) treatment failure in the Caucasian Crohn\'s disease (CD) population, but that evidence is scarce in the Asian population. This study aimed to investigate the relationship between rs2097432 and the cumulative discontinuation-free time of IFX (IFX persistence) in 189 Japanese biologics-naive CD patients. We also performed a genome-wide association study (GWAS) to discover novel genetic predictors for IFX persistence. The C allele of rs2097432 significantly increased the risk of early discontinuation of IFX [Hazard ratio (HR)\u2009=\u20092.23 and P-value\u2009=\u20090.026]. In GWAS, one locus tagged by rs73277969, located upstream of PPARGC1B which attenuates macrophage-mediated inflammation, reached genome-wide significance (HR\u2009=\u20096.04 and P-value\u2009=\u20097.93E-9). Pathway analysis suggested association of signaling by PDGF and FCGR activation signaling with IFX persistence (P-value\u2009=\u20098.56E-5 and 5.80E-4, respectively).</ABSTRACT>'}]
2024-01-02 00:26:28,177 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:28,179 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449485, Requested 1181. Please try again in 88ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:28,179 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Prothrombin 20210A mutation in acute posterior cerebral artery infarction and branch retinal vein occlusion.\n</ABSTRACT>'}]
2024-01-02 00:26:28,191 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:28,192 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:28,193 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449177, Requested 1557. Please try again in 97ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:28,193 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Assessment of the hypothalamic-pituitary-adrenocortical axis function using a vasopressin stimulation test in neonatal foals.\nBacterial sepsis is the leading cause of death in foals and is associated with hypothalamic-pituitary-adrenocortical axis (HPAA) dysfunction. HPAA function can be evaluated by an arginine-vasopressin (AVP) stimulation test.Administration of AVP will stimulate a dose-dependent rise in systemic adrenocorticotropin-releasing hormone (ACTH) and cortisol in neonatal foals. There will be no response seen in corticotropin-releasing hormone (CRH) and baseline AVP will be within reference interval.Twelve neonatal foals, <72\u2009hours old.HPAA function was assessed in foals utilizing 3 doses of AVP (2.5, 5, and 7.5\u2009IU), administered between 24 and 48\u2009hours of age in this randomized cross-over study. Cortisol, ACTH, CRH and AVP were measured at 0 (baseline), 15, 30, 60 and 90\u2009minutes after AVP administration with immunoassays. The fold increase in cortisol and ACTH was calculated at 15 and 30\u2009minutes compared to baseline.All doses of AVP resulted in a significant increase in cortisol concentration over time, and a dose-dependent increase in ACTH concentration over time. ACTH and cortisol were significantly increased at 15 and 30\u2009minutes, respectively after all 3 doses of AVP compared to baseline (P\u2009<\u2009.01). There was no change in endogenous CRH after stimulation with AVP.Administration of AVP is safe and results in a significant rise in ACTH and cortisol in neonatal foals. A stimulation test with AVP (5\u2009IU) can be considered for HPAA assessment in septic foals.</ABSTRACT>'}]
2024-01-02 00:26:28,194 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449222, Requested 1168. Please try again in 52ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:28,194 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Bilateral Spontaneous Release of Vitreomacular Traction.\n</ABSTRACT>'}]
2024-01-02 00:26:28,208 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:28,210 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448929, Requested 1488. Please try again in 55ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:28,210 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Use of tofacitinib as first or second-line therapy is associated with better outcomes in patients with ulcerative colitis: data from a real-world study.\nData regarding the real-world (RW) use of tofacitinib (TOF) in patients with ulcerative colitis (UC) are limited. We aimed to investigate TOF\'s RW efficacy and safety in Italian UC patients.A retrospective assessment of clinical and endoscopic activity was performed according to the Mayo score. The primary endpoints were to evaluate the effectiveness and safety of TOF.We enrolled 166 patients with a median follow-up of 24 (IQR 8-36) weeks. Clinical remission was achieved in 61/166 (36.7%) and 75/166 (45.2%) patients at 8-week and 24-week follow-ups, respectively. The optimization was requested in 27 (16.3%) patients. Clinical remission was achieved more frequently when TOF was used as a first/second line rather than a third/fourth line treatment (p\u2009=\u20090.007). Mucosal healing was reported in 46% of patients at the median follow-up time. Colectomy occurred in 8 (4.8%) patients. Adverse events occurred in 12 (5.4%) patients and severe in 3 (1.8%). One case of simple Herpes Zoster and one of renal vein thrombosis were recorded.Our RW data confirm that TOF is effective and safe in UC patients. It performs remarkably better when used as the first/second line of treatment.</ABSTRACT>'}]
2024-01-02 00:26:28,211 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:28,214 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:28,214 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448844, Requested 1561. Please try again in 54ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:28,215 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Dry eye in the upper blepharoplasty patient: a study comparing orbicularis-sparing versus orbicularis-excising techniques.\nTo compare subjective and objective dry eye syndrome (DES) metrics preoperatively and postoperatively in patients undergoing bilateral upper eyelid blepharoplasty (ULB) using orbicularis-sparing versus orbicularis-excising techniques.A double-blind, randomized clinical trial was conducted on patients without prior DES or other severe conditions who presented to our institution between 2017 and 2019 for routine functional ULB. Patients were randomized into two treatment arms: bilateral ULB using the orbicularis-sparing technique or bilateral ULB using the orbicularis-excising technique. One subjective and seven objective DES assessments were performed on all patients preoperatively and 1 month and 1 year after surgery.A total of 63 patients were recruited for the study. Standard Patient Evaluation of Eye Dryness (SPEED) scores decreased in both treatment groups at 1 month and 1 year postoperatively. This change did not significantly vary based on surgical technique. Objective DES assessments were not significantly changed at both postoperative time points for either group. There was a correlation between the severity of preoperative DES symptoms and the subjective improvement of DES symptoms postoperatively in both groups.ULB with an orbicularis-sparing or orbicularis-excising technique does not worsen subjective or objective DES metrics and so, surgeons may confidently use either surgical technique. These findings may impact postoperative expectations for surgeons and patients alike.</ABSTRACT>'}]
2024-01-02 00:26:28,229 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:28,229 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:28,232 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449851, Requested 1415. Please try again in 168ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:28,232 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Mutation spectrum of retinoblastoma patients in Vietnam.\nRetinoblastoma (RB), an intraocular malignancy commonly diagnosed in children, is mostly caused by inactivating mutations of both alleles of the RB1 gene. Early genetic screening for RB1 gene mutations would greatly improve treatment outcomes and patient management.In this study, both somatic and germline mutations were detected in blood and tumour samples of 42 RB patients using direct sequencing and multiplex ligation-dependent probe amplification.In total, 34 different mutations were found in 36 patients, including 1 SNP, 4 large deletions, 5 splicing sites, 1 missense, 7 frameshifts and 17 nonsense mutations. There were five novel mutations and one unreported which have not been found in large databases such as Leiden Open Variation Database (LOVD) and ClinVar.A higher rate of RB patients carrying heterozygous germline mutation and highly prevalent with pathogenic truncated mutation, hence, early detection of RB is essential for vision salvation and genetic counselling.</ABSTRACT>'}]
2024-01-02 00:26:28,233 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449899, Requested 1630. Please try again in 203ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:28,233 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Efficacy and safety of macitentan for pulmonary hypertension: A meta-analysis.\nOur purpose of this study is to evaluate the effect and safety of macitentan in the treatment of pulmonary hypertension (PH).We retrieved the safety and efficacy of macitentan treatment for PH using PubMed, the Cochrane Library, EMBASE databases and clinicaltrials.gov. The Cochrane Risk of Bias Tool was used for literature screening and quality assessment. Data analysis was conducted using RevMan 5.4.1 and Stata/SE 15.1 software. Results are presented as standardization mean differences (SMDs) and odds ratio (OR).Meta-analysis of seven randomized controlled trial (RCT) studies and four non-RCT studies with 2769 patients was included, involving 723 in the macitentan group and 599 in the placebo group. The results of the study showed that macitentan had effectively decreased pulmonary vascular resistance (PVR) (SMD\u2009=\u2009-0.53, 95% CI: -0.77--0.29, p\u2009<\u20090.05), cardiac index (CI) (SMD\u2009=\u20090.60, 95% CI: 0.37-0.83, p\u2009<\u20090.05) and N-terminal pro-brain natriuretic peptide (NT-proBNP) (SMD\u2009=\u2009-0.22, 95% CI: -0.40--0.03, p\u2009<\u20090.05). Furthermore, macitentan also significantly reduced PVR (SMD\u2009=\u2009-0.58, 95% CI: -0.80--0.35, p\u2009<\u20090.05), 6-min walk distance (6WMD) (SMD\u2009=\u20090.33, 95% CI: 0.15-0.50, p\u2009<\u20090.05), CI (SMD\u2009=\u20090.48, 95% CI: 0.28-0.69, p\u2009<\u20090.05), mean pulmonary arterial pressure (mPAP) (SMD\u2009=\u2009-0.43, 95% CI: -0.64--0.23, p\u2009<\u20090.05) and NT-proBNP (SMD\u2009=\u2009-0.55, 95% CI: -1.07--0.03, p\u2009<\u20090.05) between baseline and follow-up. The adverse reactions to macitentan were mild, with headache, anaemia and bronchitis. Other efficacy and safety outcomes did not reach statistical differences.Macitentan therapy for PH is effective and safe. The effectiveness on PVR, mPAP, mean right atrial pressure (mRAP), mortality and other indicators still needs to be further confirmed.</ABSTRACT>'}]
2024-01-02 00:26:28,240 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:28,246 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:28,246 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:28,246 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:28,248 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:28,248 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449341, Requested 1161. Please try again in 66ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:28,248 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Electrical Shock Retinopathy.\n</ABSTRACT>'}]
2024-01-02 00:26:28,249 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449200, Requested 1543. Please try again in 99ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:28,249 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Effect of the Mediterranean Diet on Progression of Dry Form of Age-related Macular Degeneration.\nThe aim of this study was to investigate the possible effect of the Mediterranean diet (Med Diet) on the progression of age-related macular degeneration (AMD) in patients with early or intermediate stages of dry AMD.The present study included 164 patients with early or intermediate dry AMD. Data collected included demographics, anthropometric data, ophthalmic and medical history. AMD progression was evaluated using patients\' optical coherence tomography (OCT) and visual acuity. Using the MedDietScore, sample\'s attachment to Med Diet was evaluated, and distinguished into high and low. The association of supplement intake and adherence to Med Diet with AMD progression was investigated using logistic regression.Sample\'s mean age was 737.4 years. A positive correlation was found between dietary supplementation and slowing of AMD progression, as well as between high adherence to Med Diet and slowing of AMD progression. In contrast, smokers had 51.4% higher risk of AMD progression (p=0.043). The rate of slowing AMD progression was higher in patients who followed Med Diet and received a dietary supplement, compared to patients who followed one or none of the aforementioned recommendations (p<0.001).Adherence to the Med Diet could have a positive effect on delaying AMD progression in advanced stages, both in patients receiving or not antioxidants. Therefore, our study proposes to strengthen recommendations to AMD patients to follow a Med Diet.</ABSTRACT>'}]
2024-01-02 00:26:28,249 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449194, Requested 1672. Please try again in 115ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:28,249 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Salvianolic acid B ameliorates retinal deficits in an early-stage Alzheimer\'s disease mouse model through downregulating BACE1 and A\u03b2 generation.\nAlzheimer\'s disease (AD) is a neurodegenerative disease with subtle onset, early diagnosis remains challenging. Accumulating evidence suggests that the emergence of retinal damage in AD precedes cognitive impairment, and may serve as a critical indicator for early diagnosis and disease progression. Salvianolic acid B (Sal B), a bioactive compound isolated from the traditional Chinese medicinal herb Salvia miltiorrhiza, has been shown promise in treating neurodegenerative diseases, such as AD and Parkinson\'s disease. In this study we investigated the therapeutic effects of Sal B on retinopathy in early-stage AD. One-month-old transgenic mice carrying five familial AD mutations (5FAD) were treated with Sal B (20\u2009mgkg-1d-1, i.g.) for 3 months. At the end of treatment, retinal function and structure were assessed, cognitive function was evaluated in Morris water maze test. We showed that 4-month-old 5FAD mice displayed distinct structural and functional deficits in the retinas, which were significantly ameliorated by Sal B treatment. In contrast, untreated, 4-month-old 5FAD mice did not exhibit cognitive impairment compared to wild-type mice. In SH-SY5Y-APP751 cells, we demonstrated that Sal B (10\u2009\u03bcM) significantly decreased BACE1 expression and sorting into the Golgi apparatus, thereby reducing A\u03b2 generation by inhibiting the \u03b2-cleavage of APP. Moreover, we found that Sal B effectively attenuated microglial activation and the associated inflammatory cytokine release induced by A\u03b2 plaque deposition in the retinas of 5FAD mice. Taken together, our results demonstrate that functional impairments in the retina occur before cognitive decline, suggesting that the retina is a valuable reference for early diagnosis of AD. Sal B ameliorates retinal deficits by regulating APP processing and A\u03b2 generation in early AD, which is a potential therapeutic intervention for early AD treatment.</ABSTRACT>'}]
2024-01-02 00:26:28,250 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449197, Requested 1448. Please try again in 86ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:28,250 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Retinal alterations in evaluation of rheumatoid arthritis with chloroquine treatment: A new approach.\nTo evaluate the effect of hydroxychloroquine on conjunctival and retinal microvascular density in rheumatoid arthritis (RA) patients.Ten healthy controls, 10 RA patients who had not been treated with hydroxychloroquine, and 10 RA patients who had been treated with chloroquine for more than 5\u2009years were recruited. Optical coherence tomography (OCTA) was used to examine the conjunctival and superficial and deep retinal microvascular density and compared the differences in microvascular density between the three groups.The vascular density in RA group in superficial microvascular was significantly lower than that in control group (p\u2009<\u20090.001). Compared with RA group, the chloroquine group showed statistically significantly lower microvascular (p\u2009<\u20090.001) and deep microvascular (p\u2009=\u20090.018). Superficial microvascular was positively correlated with conjunctival vessel density in RA patients (r\u2009=\u20090.868, p\u2009=\u20090.0048).The use of chloroquine could further reduce the vascular density in the absence of statistical difference in the course of the disease.</ABSTRACT>'}]
2024-01-02 00:26:28,263 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:28,264 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:28,266 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449169, Requested 1769. Please try again in 125ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:28,266 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>The Cost of Standard and Complex Pars Plana Vitrectomy for Retinal Detachment Repair Exceeds Its Reimbursement.\nTo measure the total costs and reimbursements associated with standard and complex pars plana vitrectomy using time-driven activity-based costing (TDABC).Economic analysis at a single academic institution.Patients who underwent standard or complex pars plana vitrectomy (PPV; Current Procedural Terminology codes 67108 and 67113) at the University of Michigan in the calendar year\xa02021.Process flow mapping for standard and complex PPVs was used to determine the operative components. The internal anesthesia record system was used to calculate time estimates, and financial calculations were constructed from published literature and internal sources. A TDABC analysis was used to determine the costs of standard and complex PPVs. Average reimbursement was based on Medicare rates.The primary outcomes were the total costs for standard and complex PPVs and the resulting net margin at current Medicare reimbursement levels. The secondary outcomes were the differential in surgical times, costs, and margin for standard and complex PPV.Over the 2021 calendar year, a total of 270 standard and 142 complex PPVs were included in the analysis. Complex PPVs were associated with significantly increased anesthesia time (52.28 minutes; P < 0.001), operating room time (51.28 minutes; P < 0.0001), surgery time (43.64 minutes; P < 0.0001), and postoperative time (25.95 minutes; P < 0.0001). The total day-of-surgery costs were $5154.59 and $7852.38 for standard and complex PPVs, respectively. Postoperative visits incurred an additional cost of $327.84 and $353.86 for standard and complex PPV, respectively. The institution-specific facility payments were $4505.50 and $4935.14 for standard and complex PPV, respectively. Standard PPV yielded a net negative margin of\xa0-$976.93, whereas complex PPV yielded a net negative margin of\xa0-$3271.10.This analysis demonstrated that Medicare reimbursement is inadequate in covering the costs of PPV for retinal detachment, with a particularly large negative margin for more complex cases. These findings demonstrate that additional steps may be necessary to mitigate adverse economic incentives so that patients continue to have timely access to care to achieve optimal visual outcomes after retinal detachment.The authors have no proprietary or commercial interest in any materials discussed in this article.</ABSTRACT>'}]
2024-01-02 00:26:28,269 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449137, Requested 1535. Please try again in 89ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:28,269 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Necroptosis in human cancers with special emphasis on oral squamous cell carcinoma.\nNecroptosis is a type of caspase independent \'programmed or regulated\' necrotic cell death that has a morphological resemblance to necrosis and mechanistic analogy to apoptosis. This type of cell death requires RIPK1, RIPK3, MLKL, death receptors, toll like receptors, interferons, and various other proteins. Necroptosis is implicated in plethora of diseases like rheumatoid arthritis, Alzheimer\'s disease, Crohn\'s disease, and head and neck cancers including oral squamous cell carcinoma. Oral carcinomas show dysregulation or mutation of necroptotic proteins, mediate antitumoral immunity, activate immune response and control tumor progression. Necroptosis is known to play a dual role (pro tumorigenic and anti-tumorigenic) in cancer progression and targeting this pathway could be an effective approach in cancer therapy. Necroptosis based chemotherapy has been proposed in malignancies, highlighting the importance of necroptotic pathway to overcome apoptosis resistance and serve as a "fail-safe" pathway to modulate cancer initiation, progression, and metastasis. However, there is dearth of information regarding the use of necroptotic cell death mechanism in the treatment of oral squamous cell carcinoma. In this review, we summarise molecular mechanism of necroptosis, and its protumorigenic and antitumorigenic role in cancers to shed light on the possible therapeutic significance of necroptosis in oral squamous cell carcinoma.</ABSTRACT>'}]
2024-01-02 00:26:28,270 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:28,273 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448855, Requested 1497. Please try again in 46ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:28,273 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Effect of mesencephalic astrocyte-derived neurotrophic factor on the inflammatory response in human gingival fibroblasts cells.\nMesencephalic astrocyte-derived neurotrophic factor (MANF) is a unique member of the neurotrophic factor family residing in the endoplasmic reticulum, where it functions as a stress response protein maintaining endoplasmic reticulum homeostasis, in addition to being secreted extracellularly as a neurotrophic factor to bind with receptors to initiate intracellular signal transduction pathways. Interestingly, MANF has shown an important protective role in the inflammatory response of many diseases. In neural stem cells, pancreatic \u03b2 cells, and retinal cells, MANF can inhibit the inflammatory response, modulate the immune response, and promote tissue repair. However, the role of MANF in the periodontal inflammatory response remains unclear. In the present study, we used lipopolysaccharide (LPS) from Porphyromonas gingivalis (Pg) to establish a Pg-LPS-stimulated periodontal inflammatory model in human gingival fibroblasts cells (HGF-1) to investigate the role of MANF in vitro. We found that MANF could inhibit pro-inflammatory cytokine secretion, alleviate the endoplasmic reticulum stress response, promote cell survival, and inhibit cell apoptosis. Therefore, MANF might be a novel promising target for the treatment of periodontitis.</ABSTRACT>'}]
2024-01-02 00:26:28,276 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:28,276 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:28,277 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:28,278 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:28,278 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:28,278 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:28,279 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448868, Requested 1684. Please try again in 73ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:28,279 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Incidence and Risk Factors of Second Eye Involvement in Myopic Macular Neovascularization.\nTo report the cumulative incidence and risk factors of second eye involvement after diagnosis of myopic macular neovascularization (MNV) in the first eye.Retrospective analysis of longitudinal data from a tertiary hospital in the Netherlands.Patients with high myopia (spherical equivalent [SE] \u2264\xa0- 6 diopters [D]), of European ethnicity, who were diagnosed with active MNV lesion in 1 eye between 2005 and 2018. Fellow eyes were free of MNV or macular atrophy at baseline, and data were collected on the SE, axial length, and presence of diffuse or patchy chorioretinal atrophy and lacquer cracks.Incidence rate and 2-, 5-, and 10-year cumulative incidences were calculated; hazard ratios (HRs) of second eye involvement were analyzed for potential risk factors using Cox proportional hazard models.Incidence of second eye involvement after onset of myopic MNV in the first eye.We included 88 patients over a period of 13 years with a mean age of 58  15 years, mean axial length of 30  1.7 mm and SE -14  4 D at baseline. Twenty-four fellow eyes (27%) developed a myopic MNV during follow-up. This resulted in an incidence rate of 4.6 (95% confidence interval [CI], 2.9-6.7) per 100 person-years and a cumulative incidence of 8%, 21%, and 38% at 2, 5, and 10 years, respectively. Mean time until MNV development in the fellow eye was 48  37 months. Patients aged < 40 years at the initial presentation had a 3.8 times higher risk of bilateral myopic MNV (HR, 3.8; 95% CI, 1.65-8.69; P\xa0= 0.002). The presence of lacquer cracks in the second eye seemed to increase risk, but this did not reach statistical significance (HR, 2.25; 95% CI, 0.94-5.39; P\xa0= 0.07).Our study of high myopes of European descent shows very similar incidence rates for second eye myopic MNV compared with Asian studies. Our findings substantiate the importance for clinicians to monitor closely and create awareness, especially in younger patients.The authors have no proprietary or commercial interest in any materials discussed in this article.</ABSTRACT>'}]
2024-01-02 00:26:28,280 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448851, Requested 1560. Please try again in 54ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:28,280 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Relevance of sonographic parameters for inflammatory bowel disease in children.\nIntestinal ultrasound (IUS) is widely used as the first exam in patients with suspected inflammatory bowel disease (IBD). This study investigated the accuracy of several IUS parameters, including increased bowel wall thickening (BWT), in detecting IBD in a paediatric population.The study included an unselected series of 113 patients aged 2-18\xa0years (mean age 10.8\xa0years, 65 male), referred for recurrent abdominal pain or altered bowel habits, without known organic diseases, to perform an IUS as first investigation of a diagnostic workup. Patients with full systematic IUS examination, clinical and biochemical exams, and ileocolonoscopy or an uneventful follow-up at least one year follow up were eligible.23 IBD patients (20.4%; 8 ulcerative colitis, 12 Crohn\'s disease and 3 indeterminate colitis) were diagnosed. We found that increased BWT\u2009>\u20093\xa0mm (OR 5.4), altered IUS bowel pattern (IUS-BP, OR 9.8) and mesenteric hypertrophy (MH, OR 5.2) accurately identified IBD at the multivariate analysis. IUS-BP, MH and BWT\u2009>\u20093\xa0mm had a sensitivity of 78.3%, 65.2% and 69.6% and a specificity of 93.3%, 92.2% and 96.7%, respectively. The combination of these three alterations increased the specificity up to 100%, whilst decreased sensitivity to 56.5%.Among several US parameters suggestive of IBD, the increased BWT, MH and altered echopattern are independent predictors of IBD. The ultrasonographic diagnosis of IBD could be more accurate if relied on combination of different sonographic parameters, than on the sole BWT evaluation.</ABSTRACT>'}]
2024-01-02 00:26:28,281 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448805, Requested 1644. Please try again in 59ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:28,281 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>The diagnostic value of global longitudinal strain combined with cardiac biomarkers on early detection of anthracycline-related cardiac dysfunction.\nCardiac dysfunction associated with anthracyclines is a significant side effect of chemotherapy, and early detection is crucial. We aimed to assess the diagnostic value of combining global longitudinal strain (GLS) with biomarkers for the early detection of anthracycline-related cardiac dysfunction.In a prospective cohort study, 80 consecutive adult patients (mean age 51\u2009\u200911\xa0years; 68.8% females) were screened and underwent 2D echocardiographic assessments and biomarker assessments [high-sensitivity troponin-I (hs-Troponin-I) and NT-pro brain natriuretic peptide (NT-proBNP)] before and after anthracycline-based chemotherapy\'s initial regimen. The patients were followed up for 12\xa0weeks to monitor for the development of cardiotoxicity.Ten patients (12.5%) developed cardiotoxicity at the end of the 12-week follow-up. Baseline values of hs-Troponin-I and NT-proBNP were significantly higher in patients who developed cardiotoxicity compared to those who did not, with a similar pattern observed at the 3-week follow-up. Receiver operating characteristic (ROC) curve analysis demonstrated that a cutoff value of baseline hs-Troponin-I\u2009>\u200911\xa0ng/L, NT-proBNP\u2009>\u200990.1\xa0pg/mL, 3-week left ventricular ejection fraction (LVEF)\u2009\u2264\u200952%, 3-week GLS\u2009\u2265\u2009-\xa014.5%, 3-week hs-Troponin-I\u2009>\u200913.1\xa0ng/L, and 3-week NT-proBNP\u2009>\u2009118.1\xa0pg/mL predicted the occurrence of cardiotoxicity with high sensitivity (range 83-94%) and specificity (range 77-92%).Combination of GLS with biomarkers had a high diagnostic value in early identification of anthracycline-related cardiac dysfunction, with an estimated diagnostic accuracy of over 85%. This information could potentially help in the identification of patients at high risk of developing cardiac dysfunction, allowing for earlier management.</ABSTRACT>'}]
2024-01-02 00:26:28,281 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448756, Requested 1647. Please try again in 53ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:28,281 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Comparison between B-Scan and En Face Images for Incomplete and Complete Retinal Pigment Epithelium and Outer Retinal Atrophy.\nTo evaluate and compare the detection of incomplete retinal pigment epithelium and outer retinal atrophy (iRORA) and complete retinal pigment epithelium and outer retinal atrophy (cRORA) assessed on OCT B-scans versus persistent choroidal hypertransmission defects (hyperTDs) assessed by en face choroidal OCT images.Retrospective, cross-sectional study.Patients with late atrophic age-related macular degeneration imaged on the same day using both Spectralis OCT and Cirrus OCT.Agreement between the B-scan and en face OCT for the detection of hyperTDs, cRORA, and iRORA.Two independent graders examined en face OCT and structural OCT to determine the presence and location of hyperTDs, iRORA, and cRORA.A total of 239 iRORA and cRORA lesions were detected on the B-scans, and 249 hyperTD lesions were identified on the en face OCT images. There was no significant difference (P\xa0= 0.88) in the number of lesions. There was no significant difference in the 134 cRORA lesions identified on B-scans and the 131 hyperTDs detected on en face OCT images (P\xa0= 0.13). A total of 105 iRORA lesions were identified by B-scan assessment; however, 50 of these iRORA lesions met the criteria for persistent hyperTDs on en face OCT images (P < 0.001). When considering the topographic correspondence between B-scan and en face OCT detected lesions, the mean percentage of agreement between B-scan detection of cRORA lesions with en face OCT detection was 97.6 % (P\xa0= 0.13).We observed high overall agreement between cRORA lesions identified on B-scans and persistent hyperTDs identified on en face OCT. However, en face imaging was able to detect iRORA lesions that had a greatest linear dimension \u2265 250 \u03bcm in a nonhorizontal en face dimension.Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</ABSTRACT>'}]
2024-01-02 00:26:28,282 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448761, Requested 1542. Please try again in 40ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:28,282 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>GLP-1 receptor agonists and diabetic retinopathy: A meta-analysis of randomized clinical trials.\nGlucagon-like peptide-1 receptor agonists (GLP-1 RAs) are used to treat type 2 diabetes mellitus. Recent research suggests that GLP-1 RAs may influence diabetic retinopathy (DR). We searched ClinicalTrials.gov for trials comparing FDA-approved GLP-1 RAs to placebo, insulin, or oral antidiabetic medicine. Rates of DR, ocular adverse events, demographics, and clinical characteristics were compared amongst cohorts on 93 trials. GLP-1 RA use was significantly associated with increased risk of early-stage DR (risk ratio (RR)\xa0=\xa01.31, 95% confidence interval (CI) [1.01, 1.68]) and early-stage retinal adverse events (RR\xa0=\xa01.29, 95% CI [1.01, 1.66]) compared to placebo. Compared to insulin, GLP-1 RA use protected against late-stage DR (RR\xa0=\xa00.38, 95% CI [0.15, 0.98]). Analysis of individual GLP-1 RAs showed that albiglutide is responsible for these trends, as it is significantly associated with a higher risk of early-stage DR (RR\xa0=\xa02.18, 95% CI [1.01, 4.67]) compared to placebo and a lower risk of late-stage DR (RR\xa0=\xa00.25, 95% CI [0.09, 0.70]) compared to insulin. Albiglutide similarly affected retinal and ocular adverse events. Demographic analysis revealed significant differences between GLP-1 RA and comparator groups for age, HbA1c, body weight, BMI, duration of diabetes, sex, race, and ethnicity. The influence of GLP-1 RAs on DR and the eye may depend on the specific GLP-1 RA and patient demographic and clinical characteristics.</ABSTRACT>'}]
2024-01-02 00:26:28,282 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448707, Requested 1482. Please try again in 25ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:28,282 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Insulin-like growth factor-1 and retinopathy of prematurity: A systemic review and meta-analysis.\nThe prevalence of retinopathy of prematurity (ROP) is rapidly increasing worldwide. Many researchers have explored the relationship between insulin-like growth factor-1 (IGF-1) and ROP; however, the results are controversial. This meta-analysis evaluates the correlation between IGF-1 and ROP systematically. We searched for PubMed, Web of Science, Embase, the Cochrane Central Register of Controlled Trials, Ovid MEDLINE, SinoMed, ClinicalTrials.gov, and 3 Chinese databases up to June 2022. Then, the meta-regression and subgroup analysis were carried out. Twelve articles with 912 neonates were included in this meta-analysis. The results revealed that 4 of 7 covariates account for significant heterogeneity: location, measurement method of IGF-1 levels, collection time of blood sample, and the severity of ROP. The pooled analysis showed that low IGF-1 levels could serve as a risk factor associated with the development and severity of ROP. Serum IGF-1 monitoring in preterm infants after birth will be helpful in the diagnosis and treatment of ROP, and the reference value of IGF-1 should be standardized according to the measurement of IGF-1 and the region, as well as the postmenstrual age of prematurity.</ABSTRACT>'}]
2024-01-02 00:26:28,291 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:28,292 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448681, Requested 1514. Please try again in 26ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:28,292 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Ulcerative colitis: Addressing the manifestations, the role of fecal microbiota transplantation as a novel treatment option and other therapeutic updates.\nThe prevalence and incidence of Ulcerative Colitis (UC), a recurrent and remitting inflammatory\xa0condition, are rising. Any part of the colon may be affected, beginning with inflammation of the mucosa in the rectum and continuing proximally continuously. Bloody diarrhea, tenesmus, fecal urgency, and stomach pain are typical presenting symptoms. Many patients present with extraintestinal manifestations (EIMs) including musculoskeletal, ocular, renal, hepatobiliary, and dermatological presentation, among others. Most cases are treated with pharmacological therapy including mesalazine and glucocorticoids. Fecal microbiota transplantation (FMT) is a novel procedure that is increasingly being used to treat UC, however, its use yet remains controversial because of uncertain efficacy. FMT can lower gut permeability and consequently disease severity by boosting short-chain fatty acids production, helping in epithelial barrier integrity preservation. Upadacitinib (JAK Kinase inhibitor) is another newer treatment option, which is an FDA-approved drug that is being used to treat UC. This review article provides a comprehensive review of the EIMs of UC, the role of FMT along with various recent clinical trials pertaining to FMT as well as other diagnostic and therapeutic updates.</ABSTRACT>'}]
2024-01-02 00:26:28,306 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:28,307 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449707, Requested 1512. Please try again in 162ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:28,307 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Real-world experience with subcutaneous infliximab: broadening treatment strategies for inflammatory bowel disease.\nThe first subcutaneous (SC) formulation of infliximab (IFX), CT\u2011P13 SC, has been approved in Europe and Australia, including for the treatment of inflammatory bowel disease (IBD).We provide a comprehensive overview of available clinical trial and real-world data for IFX SC treatment of IBD, focusing on the potential benefits of switching from IFX intravenous (IV) to IFX SC. We evaluate emerging evidence for IFX SC treatment for difficult-to-treat IBD, use as monotherapy, and suitability for patients receiving escalated IFX IV doses. Therapeutic drug monitoring approaches and patient and healthcare system perspectives on IFX SC are also discussed.IFX SC represents a significant treatment innovation in the tumor necrosis factor inhibitor class after approximately 20\u2009years of IFX IV availability. Evidence suggests that IFX SC is well tolerated and is associated with high patient acceptance and satisfaction. In addition, effectiveness is maintained in patients with stable disease following switch from IFX IV. Switching may be advisable, given the clinical benefits of IFX SC and its potential to improve healthcare service capacity. There are several areas requiring further research, including the role of IFX SC in difficult-to-treat and refractory disease, and the feasibility of IFX SC monotherapy.</ABSTRACT>'}]
2024-01-02 00:26:28,318 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:28,318 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:28,319 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:28,320 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449636, Requested 1687. Please try again in 176ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:28,320 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Detailed Clinical, Ophthalmic, and Genetic Characterization of ADGRV1-Associated Usher Syndrome.\nTo present the clinical characteristics, retinal features, natural history, and genetics of ADGRV1-Usher syndrome (USH).Multicenter international retrospective cohort study.Clinical notes, hearing loss history, multimodal retinal imaging, and molecular diagnosis were reviewed. Thirty patients (28 families) with USH type 2 and disease-causing variants in ADGRV1 were identified. Visual function, retinal imaging, and genetics were evaluated and correlated, with retinal features also compared with those of the commonest cause of USH type 2, USH2A-USH.The mean age at the first visit was 38.6  12.0 years (range: 19-74 years), and the mean follow-up time was 9.0  7.7 years. Hearing loss was reported in the first decade of life by all patients, 3 (10%) described progressive loss, and 93% had moderate-severe impairment. Visual symptom onset was at 17.0  7.7 years of age (range: 6-32 years), with 13 patients noticing problems before the age of 16. At baseline, 90% of patients had no or mild visual impairment. The most frequent retinal features were a hyperautofluorescent ring at the posterior pole (70%), perimacular patches of decreased autofluorescence (59%), and mild-moderate peripheral bone-spicule-like deposits (63%). Twenty-six (53%) variants were previously unreported, 19 families (68%) had double-null genotypes, and 9 were not-double-null. Longitudinal analysis showed significant differences between baseline and follow-up central macular thickness (-1.25 m/y), outer nuclear layer thickness (-1.19 m/y), and ellipsoid zone width (-40.9 m/y). The rate of visual acuity decline was 0.02 LogMAR (1 letter)/y, and the rate of constriction of the hyperautofluorescent ring was 0.23 mm2/y.ADGRV1-USH is characterized by early-onset, usually non-progressive, mild-to-severe hearing loss and generally good central vision until late adulthood. Perimacular atrophic patches and relatively retained ellipsoid zone and central macular thickness in later adulthood are more often seen in ADGRV1-USH than in USH2A-USH.</ABSTRACT>'}]
2024-01-02 00:26:28,320 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449627, Requested 1588. Please try again in 162ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:28,320 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Alleviation of Photoreceptor Degeneration Based on Fullerenols in rd1 Mice by Reversing Mitochondrial Dysfunction via Modulation of Mitochondrial DNA Transcription and Leakage.\nPoor therapeutic outcomes of antioxidants in ophthalmologic clinical applications, including glutathione during photoreceptor degeneration in retinitis pigmentosa (RP), are caused by limited anti-oxidative capacity. In this study, fullerenols are synthesized and proven to be highly efficient in vitro radical scavengers. Fullerenol-based intravitreal injections significantly improve the flash electroretinogram and light/dark transition tests performed for 28 days on rd1 mice, reduce the thinning of retinal outer nuclear layers, and preserve the Rhodopsin, Gnat-1, and Arrestin expressions of photoreceptors. RNA-sequencing, RT-qPCR, and Western blotting validate that mitochondrial DNA (mt-DNA)-encoded genes of the electron transport chain (ETC), such as mt-Nd4l, mt-Co1, mt-Cytb, and mt-Atp6, are drastically downregulated in the retinas of rd1 mice, whereas nuclear DNA (n-DNA)-encoded genes, such as Ndufa1 and Atp5g3, are abnormally upregulated. Fullerenols thoroughly reverse the abnormal mt-DNA and n-DNA expression patterns of the ETC and restore mitochondrial function in degenerating photoreceptors. Additionally, fullerenols simultaneously repress Flap endonuclease 1 (FEN1)-mediated mt-DNA cleavage and mt-DNA leakage via voltage-dependent anion channel (VDAC) pores by downregulating the transcription of Fen1 and Vdac1, thereby inactivating the downstream pro-inflammatory cGAS-STING pathway. These findings demonstrate that fullerenols can effectively alleviate photoreceptor degeneration in rd1 mice and serve as a viable treatment for RP.</ABSTRACT>'}]
2024-01-02 00:26:28,321 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:28,322 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449130, Requested 1508. Please try again in 85ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:28,322 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Retinal Organoid Models Show Heterozygous Rhodopsin Mutation Favors Endoplasmic Reticulum Stress-Induced Apoptosis in Rods.\nRetinitis pigmentosa (RP) is a prevalent inherited retinal degenerative disease resulting from photoreceptor and pigment epithelial apoptosis. The Rhodopsin (RHO) is the most commonly associated pathogenic gene in RP. However, RHO mutations (c.512C>T P171L) have been infrequently reported, and the RP pathogenesis caused by these mutations remains unclear. The objective of this study was to investigate the impact of RHO (c.512C>T P171L) mutation on retinal cell differentiation and elucidate the underlying mechanisms of RP. An effective retinal organoid induction scheme for inhibiting the Wnt signaling pathway was selected for further experiments, and the established cell line chHES-406 was demonstrated to be heterozygous for RHO c.512C>T, with a normal karyotype and pluripotency potential. Furthermore, the development of chHES-406 organoids may be delayed, and apoptosis detection and co-localization revealed that chHES-406 organoids had more apoptotic cells than chHES-90 in the outer nuclear layer (ONL), mutant RHO protein was mislocalized in the endoplasmic reticulum (ER), and stress-related and apoptotic gene expression increased. Overall, our study elucidated a possible mechanism by which ER stress caused by RHO P171L protein mislocalization may lead to ONL cell apoptosis.</ABSTRACT>'}]
2024-01-02 00:26:28,323 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:28,324 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:28,324 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449139, Requested 1748. Please try again in 118ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:28,324 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Preserved Ratio Impaired Spirometry and Risks of Macrovascular, Microvascular Complications and Mortality Among Individuals With Type 2 Diabetes.\nThe prospective associations of preserved ratio impaired spirometry (PRISm) with new-onset macrovascular and microvascular complications and mortality among individuals with type 2 diabetes (T2D) and whether PRISm enhances the prediction ability of an established office-based risk score remain to be elucidated.Can PRISm be used as a predictor of poor prognosis in individuals with T2D?We included 20,047 study participants with T2D and complete data on spirometry at recruitment from the UK Biobank cohort. Multivariable Cox proportional hazards models were used to assess the associations of baseline PRISm (FEV1 to FVC ratio,\xa0\u2265 0.70; FEV1,\xa0< 80%\xa0predicted) with subsequent risks of incident stroke (any type), ischemic stroke, myocardial infarction, unstable angina, coronary heart disease, diabetic retinopathy, diabetic kidney disease, all-cause mortality, cardiovascular mortality, and respiratory mortality.For this cohort analysis, 4,521 patients (22.55%\xa0of participants with T2D) showed comorbid PRISm at baseline. Over a median follow-up of 11.52 to 11.87 years, patients with T2D with PRISm at baseline showed higher risks than those with normal spirometry findings of various T2D complications developing and mortality; the adjusted hazard ratios for PRISm were 1.413 (95%\xa0CI, 1.187-1.681) for stroke (any type), 1.382 (95%\xa0CI, 1.129-1.690) for ischemic stroke, 1.253 (95%\xa0CI, 1.045-1.503) for myocardial infarction, 1.206 (95%\xa0CI, 1.086-1.339) for coronary heart disease, 1.311 (95%\xa0CI, 1.141-1.506) for diabetic retinopathy, 1.384 (95%\xa0CI, 1.190-1.610) for diabetic kidney disease, 1.337 (95%\xa0CI, 1.213-1.474) for all-cause mortality, 1.597 (95%\xa0CI, 1.296-1.967) for cardiovascular mortality, and 1.559 (95%\xa0CI, 1.189-2.044) for respiratory mortality, respectively. The addition of PRISm significantly improved the reclassification ability, based on the net reclassification index, of an office-based risk score by 15.53%\xa0(95%\xa0CI, 10.14%-19.63%) to 33.60%\xa0(95%\xa0CI, 20.90%-45.79%).Individuals with T2D with comorbid PRISm, accounting for a considerable proportion of the population with T2D, showed significantly increased risks of adverse macrovascular and microvascular complications and mortality.</ABSTRACT>'}]
2024-01-02 00:26:28,329 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:28,329 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448788, Requested 1586. Please try again in 49ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:28,329 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Clinical features of idiopathic epiretinal membrane in children and the factors influencing postoperative visual acuity.\nTo describe the characteristics and surgical outcomes of idiopathic epiretinal membrane (iERM) in children and to determine the factors associated with postoperative visual acuity (VA).We retrospectively reviewed the medical records of 17 patients with iERM (age,\u2009<\u200918\xa0years) who had undergone ERM surgery from 2009 to 2021. Spectral-domain optical coherence tomography features were documented. The eyes with iERMs involving the fovea were assigned to the localized and diffused groups depending on the morphological description of the membrane. Multiple linear regression analysis was used to explore the factors associated with the final VA.The mean age was 9.2\u2009\u20093.8\xa0years. The mean follow-up period was 38.9\u2009\u200945.4\xa0months. After surgery, the central foveal thickness and the best-corrected VA (BCVA) improved significantly (all, P\u2009<\u20090.05). Fourteen eyes with iERMs showed involvement of the foveal area (localized group, six eyes; diffused group, eight eyes). There were no significant differences in the preoperative BCVA between the two groups (P\u2009=\u20090.064). However, the final BCVA was better in the diffused group than in the localized group (P\u2009=\u20090.043). Multiple regression analysis indicated that the localized membrane (P\u2009=\u20090.042) and lower preoperative BCVA (P\u2009=\u20090.043) were factors associated with a worse final VA in pediatric iERMs.Surgical removal of ERM showed a high anatomical and functional success rate in children. In pediatric patients with iERMs involving the fovea, a good VA was more common when the membrane was diffused than when it was localized.</ABSTRACT>'}]
2024-01-02 00:26:28,330 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:28,330 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448771, Requested 1521. Please try again in 38ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:28,330 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Time to incorporate preemptive NUDT15 testing before starting thiopurines in inflammatory bowel disease in Asia and beyond: a review.\nThiopurine toxicity is related to genetic polymorphism. Thiopurine methyltransferase (TPMT) variants do not explain thiopurine toxicity in more than half of patients. Asians, despite the low prevalence of TPMT variants, are more susceptible to thiopurine toxicity. Since 2014, studies from many Asian countries have shown a strong association between nucleoside diphosphate-linked moiety X-type motif (NUDT) 15 polymorphism and thiopurine-induced myelotoxicity.An English language literature search was performed for TPMT and NUDT15 genetic variants in inflammatory bowel disease and other diseases. This article discusses the merits of preemptive NUDT15 and TPMT testing in Asian and non-Asian IBD populations.The NUDT polymorphism occurs in up to 27% of the Asian and Hispanic population. Hematological toxicity occurs in up to one-third of patients with this genetic variant. Given this, preemptive testing for NUDT15 variant is worthwhile and is probably more cost-effective than TPMT testing in these groups. Prevalence of NUDT15 variants is low in non-Finnish European population, but NUDT15 variants have been linked to myelotoxicity along with TPMT genetic variants. NUDT15 preemptive testing should be considered in the migrant Asian population in Europe and North America and in Caucasian populations who develop myelotoxicity.</ABSTRACT>'}]
2024-01-02 00:26:28,340 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:28,344 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:28,345 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449784, Requested 1504. Please try again in 171ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:28,345 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Local progression kinetics of macular atrophy in recessive Stargardt disease.\nTo determine the effect of lesion topography on progression in Stargardt disease (STGD1).Fundus autofluoresence (excitation 488\u2009nm) images of 193 eyes in patients with proven ABCA4 mutation were semi-automatically segmented for autofluoresence changes: (DDAF) and questionably decreased autofluoresence (QDAF), which are proxies for retinal pigment epithelial (RPE) atrophy. We calculated topographic incidence of DDAF and DDAF\u2009+\u2009QDAF, as well as velocity of progression of the border of lesions using Euclidean distance mapping.Incidence of atrophy was highest near the fovea, then decreased in incidence with increased foveal eccentricity. However, the rate of atrophy progression followed the opposite pattern; rate of atrophy increased with distance from foveal center. The mean growth rate 500 microns from the foveal center for DDAF\u2009+\u2009QDAF was 39 microns per year (95% CI\u2009=\u200928-49), whereas the mean growth rate 3000 microns from the foveal center was 342 microns per year (95% CI\u2009=\u2009194-522). No difference in growth rate was noted by axis around the fovea.Incidence and progression of atrophy by fundus autofluorescence follow opposite patterns in STGD1. Further, atrophy progression increases significantly with distance from foveal center, which should be taken into consideration in clinical trials.</ABSTRACT>'}]
2024-01-02 00:26:28,348 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:28,360 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:28,360 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:28,361 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449744, Requested 1470. Please try again in 161ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:28,361 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Nutritional aspects of inflammatory bowel disease.\nThe number of people diagnosed with inflammatory bowel disease (IBD) continues to increase in most parts of the world. Although the exact etiology of this chronic intestinal disease is not fully understood, nutritional factors appear to play key roles. Furthermore, individuals with IBD are at increased risk of adverse nutritional impacts, including micronutrient deficiencies.This review aims to summarize recent reports focusing on nutritional factors relevant to the development of IBD and to also review data on nutritional deficiencies seen in individuals with IBD.The typical western diet, characterized by high-fat/high-sugar foods, along with food additives, appears to contribute to the etiopathogenesis of IBD. In contrast, some reports indicate that some foods are likely protective. However, there are inconsistencies in the currently available data, reflecting study design and other confounding factors. Furthermore, some of the conclusions are inferred from animal or in vitro studies. The presence of IBD can compromise the nutrition of individuals with one of these disorders: ongoing monitoring is critical. Nutrition and diet in the setting of IBD remain key areas for further and ongoing study.</ABSTRACT>'}]
2024-01-02 00:26:28,362 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449716, Requested 1624. Please try again in 178ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:28,362 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Transcatheter closure of atrial septal defect in the elderly: a systematic review and meta-analysis.\nDespite the establishment of transcatheter closure as the treatment of choice in adults with secundum atrial septal defects (ASDs), the effectiveness of this approach in the elderly is disputed. This systematic review and meta-analysis aims to explore the impact of transcatheter ASD closure in patients \u226560 years old.We systematically searched four major electronic databases (PubMed, CENTRAL (Cochrane Central Register of Controlled Trials), Scopus and Web of Science), ClinicalTrials.gov, article references and grey literature. Primary outcomes were the right ventricular end-diastolic diameter (RVEDD) and the New York Heart Association functional class change, whereas secondary outcomes included systolic pulmonary arterial pressure (sPAP), left ventricular end-diastolic diameter (LVEDD), brain natriuretic peptide (BNP), tricuspid valve regurgitation (TR) change, as well as the rate of atrial arrhythmias and all-cause mortality.In total, 18 single-arm cohorts comprising 1184 patients were included. RVEDD was reduced after ASD closure (standardised mean difference (SMD) -0.9, 95% CI -1.2 to -0.7). Elderly patients had 9.5 times higher odds of being asymptomatic after ASD closure (95% CI 5.06 to 17.79). Furthermore, ASD closure improved sPAP (mean difference (MD) -10.8, 95% CI -14.6 to -7), LVEDD (SMD 0.8, 95% CI 0.7 to 1.0), TR severity (OR 0.39, 95% CI 0.25 to 0.60) and BNP (MD -68.3, 95% CI -114.4 to -22.1). There was a neutral effect of ASD closure on atrial arrhythmias.Transcatheter ASD closure is beneficial for the elderly population since it improves functional capacity, biventricular dimensions, pulmonary pressures, TR severity and BNP. However, the incidence of atrial arrhythmias did not change significantly after the intervention.CRD42022378574.</ABSTRACT>'}]
2024-01-02 00:26:28,366 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:28,368 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449666, Requested 2101. Please try again in 235ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:28,368 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Turnbull-Cutait Pull-Through Procedure Is an Alternative to Permanent Ostomy in Patients With Complex Pelvic Fistulas.\nA permanent stoma is frequently recommended in the setting of complex or recurrent rectovaginal fistulas because of the high failure rate of reconstructive procedures. The Turnbull-Cutait pull-through procedure is a salvage operation for motivated patients desiring to avoid permanent fecal diversion.To analyze the cure rates of complex rectovaginal fistulas after the Turnbull-Cutait pull-through procedure based on cause.After the institutional review approval board, a retrospective review of women who underwent the procedure (1993-2018) for a rectovaginal fistula was conducted. Patients\' demographics, cause, and postoperative outcomes were analyzed.Colorectal surgery department at a tertiary center in the United States.Adult women with a rectovaginal fistula who underwent a colonic pull-through procedure were included.Recurrence after the colonic pull-through procedure.There were 81 patients who underwent colonic pull-through; of those, 26 patients had a rectovaginal fistula, had a median age of 51 (43-57) years, and had a mean BMI of 28\u2009\u20093.2\u2009kg/m 2 . A total of 4 patients (15%) had a recurrence and 85% of the patients healed. Ninety-three percent of the patients healed after the prior anastomotic leak. Patients with a Crohn\'s disease-related fistula had a 75% cure rate. The Kaplan-Meier analysis showed a cumulative incidence of recurrence of 8% (95% CI, 0%-8%) within 6 months after surgery and 12% at 12 months.Retrospective design.The Turnbull-Cutait pull-through procedure may be the last option to preserve intestinal continuity and successfully treat rectovaginal fistulas in 85% of cases.ANTECEDENTES:Con frecuencia se recomienda un estoma permanente en el contexto de una fstula rectovaginal compleja o recurrente debido a la alta tasa de fracaso de los procedimientos reconstructivos. El procedimiento de extraccin de Turnbull-Cutait es una operacin de rescate para pacientes motivados que desean evitar la desviacin fecal permanente.OBJETIVO:Analizar las tasas de curacin de la fstula rectovaginal compleja despus del procedimiento de extraccin de Turnbull-Cutait segn la etiologa.DISEO:Despus de la junta de aprobacin de revisin institucional, se realiz una revisin retrospectiva de mujeres que se sometieron a un procedimiento (1993-2018) por fstula rectovaginal. Se analizaron los datos demogrficos, la etiologa y los resultados posoperatorios de los pacientes.AJUSTE:Departamento de ciruga colorrectal en un centro terciario en los Estados Unidos.PACIENTES:Mujeres adultas con fstula rectovaginal que se sometieron a extraccin del colon.RESULTADO PRINCIPAL:recurrencia despus de la extraccin del colon.RESULTADOS:Hubo 81 pacientes que tenan extraccin colnica, de esas 26 fstulas rectovaginales con una mediana de edad de 51 (43 - 57) aos, y un ndice de masa corporal promedio de 28\u2009\u20093,2\u2009kg/m2. Un total de 4 (15%) pacientes tuvieron una recurrencia y el 85% de los pacientes se curaron. El noventa y tres por ciento de los pacientes se curaron despus de la fuga anastomtica previa. Los pacientes con fstula relacionada con EC tuvieron una tasa de curacin del 75%. El anlisis de Kaplan Meier mostr una incidencia acumulada de recurrencia del 8% [95% intervalo de confianza 0%-18%] dentro de los 6 meses posteriores a la ciruga y del 12% a los 12 meses.LIMITACIONES:Diseo retrospectivo.CONCLUSIONES:El procedimiento de extraccin de Turnbull-Cutait puede ser la ltima opcin que se puede ofrecer para preservar la continuidad intestinal y tratar la fstula rectovaginal con xito en el 85% de los casos. (Traduccin-Yesenia.Rojas-Khalil).</ABSTRACT>'}]
2024-01-02 00:26:28,370 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:28,372 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449635, Requested 1645. Please try again in 170ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:28,372 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Serum 21-Deoxycortisol for Diagnosis of Nonclassic Congenital Adrenal Hyperplasia in Women With Androgen Excess.\nNonclassic congenital adrenal hyperplasia (NCCAH) requires exclusion before diagnosing polycystic ovary syndrome (PCOS). Increasing use of liquid chromatography and tandem mass spectrometry (LC-MS/MS) necessitates revision of immunoassay-based criteria for NCCAH. Measurement of 21-deoxycortisol (21DF) may simplify the diagnosis of heterozygosity (HTZ), the presence of 1 affected CYP21A2 allele, which currently relies on complex molecular studies.We aimed to determine LC-MS/MS-specific criteria for NCCAH and HTZ and compare the diagnostic accuracy of 21DF and 17-hydroxyprogesterone (17OHP).A cross-sectional study involving 99 hyperandrogenic females was performed. We identified females who had undergone both a synacthen stimulation test (SST) and CYP21A2 genotyping from 2010 to 2017, and prospectively recruited females referred for an SST to investigate hyperandrogenic symptoms from 2017 to 2021. Steroids were compared between genetically confirmed NCCAH, HTZ, and PCOS. Optimal 17OHP and 21DF thresholds for HTZ and NCCAH were determined by receiver operating characteristic analysis.Basal 17OHP, stimulated 17OHP, and 21DF were measured in 99, 85, and 42 participants, respectively. Optimal thresholds for NCCAH were 3.0 nmol/L and 20.7 nmol/L for basal and stimulated 17OHP, respectively. Basal and stimulated 21DF thresholds of 0.31 nmol/L and 13.3 nmol/L provided 100% sensitivity with specificities of 96.8% and 100% for NCCAH, respectively. Diagnostic thresholds for HTZ of 8.0 nmol/L, 1.0 nmol/L, and 13.6 for stimulated 17OHP, 21DF, and the ratio (21DF + 17OHP)/cortisol each provided 100% sensitivity with specificities of 80.4%, 90.5%, and 85.0%, respectively.LC-MS/MS-specific 17OHP thresholds for NCCAH are lower than those based on immunoassay. LC-MS/MS-quantified 17OHP and 21DF accurately discriminate HTZ and NCCAH from PCOS.</ABSTRACT>'}]
2024-01-02 00:26:28,389 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:28,408 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:28,485 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:28,500 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:28,518 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:28,601 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:28,607 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:28,619 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:28,657 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:28,668 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:28,669 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:28,671 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:28,694 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:28,695 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:28,899 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:28,911 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:28,919 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:28,926 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:28,993 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:29,010 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:29,080 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:29,137 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:29,200 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:29,302 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:29,309 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:29,475 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:29,487 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:29,585 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:29,640 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:29,927 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:30,410 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:30,683 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:30,743 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:30,803 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:30,910 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:30,911 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:31,029 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:31,056 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:31,099 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:31,102 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:31,104 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:31,105 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:31,194 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:31,598 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:31,727 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:32,067 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:32,526 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:32,936 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:32,955 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:33,160 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:33,385 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:34,135 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:34,342 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:37,078 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,083 - INFO - Retrying request to /chat/completions in 0.883838 seconds
2024-01-02 00:26:37,088 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,089 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,090 - INFO - Retrying request to /chat/completions in 0.968162 seconds
2024-01-02 00:26:37,090 - INFO - Retrying request to /chat/completions in 0.932188 seconds
2024-01-02 00:26:37,105 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,108 - INFO - Retrying request to /chat/completions in 0.867381 seconds
2024-01-02 00:26:37,124 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,126 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,126 - INFO - Retrying request to /chat/completions in 0.962483 seconds
2024-01-02 00:26:37,129 - INFO - Retrying request to /chat/completions in 0.945215 seconds
2024-01-02 00:26:37,129 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,130 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,130 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,130 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,131 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,131 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,132 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,132 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,133 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,135 - INFO - Retrying request to /chat/completions in 0.988987 seconds
2024-01-02 00:26:37,135 - INFO - Retrying request to /chat/completions in 0.948129 seconds
2024-01-02 00:26:37,135 - INFO - Retrying request to /chat/completions in 0.853451 seconds
2024-01-02 00:26:37,135 - INFO - Retrying request to /chat/completions in 0.945673 seconds
2024-01-02 00:26:37,135 - INFO - Retrying request to /chat/completions in 0.880446 seconds
2024-01-02 00:26:37,135 - INFO - Retrying request to /chat/completions in 0.893871 seconds
2024-01-02 00:26:37,135 - INFO - Retrying request to /chat/completions in 0.829249 seconds
2024-01-02 00:26:37,136 - INFO - Retrying request to /chat/completions in 0.958330 seconds
2024-01-02 00:26:37,136 - INFO - Retrying request to /chat/completions in 0.786121 seconds
2024-01-02 00:26:37,139 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,140 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,140 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,141 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,141 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,144 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,145 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,145 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,145 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,146 - INFO - Retrying request to /chat/completions in 0.853302 seconds
2024-01-02 00:26:37,146 - INFO - Retrying request to /chat/completions in 0.810957 seconds
2024-01-02 00:26:37,146 - INFO - Retrying request to /chat/completions in 0.863242 seconds
2024-01-02 00:26:37,146 - INFO - Retrying request to /chat/completions in 0.761714 seconds
2024-01-02 00:26:37,147 - INFO - Retrying request to /chat/completions in 0.929365 seconds
2024-01-02 00:26:37,148 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,150 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,150 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,151 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,151 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,153 - INFO - Retrying request to /chat/completions in 0.851046 seconds
2024-01-02 00:26:37,153 - INFO - Retrying request to /chat/completions in 0.834671 seconds
2024-01-02 00:26:37,153 - INFO - Retrying request to /chat/completions in 0.886487 seconds
2024-01-02 00:26:37,154 - INFO - Retrying request to /chat/completions in 0.907065 seconds
2024-01-02 00:26:37,155 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,155 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,156 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,157 - INFO - Retrying request to /chat/completions in 0.946404 seconds
2024-01-02 00:26:37,157 - INFO - Retrying request to /chat/completions in 0.786787 seconds
2024-01-02 00:26:37,157 - INFO - Retrying request to /chat/completions in 0.883101 seconds
2024-01-02 00:26:37,158 - INFO - Retrying request to /chat/completions in 0.957488 seconds
2024-01-02 00:26:37,158 - INFO - Retrying request to /chat/completions in 0.867274 seconds
2024-01-02 00:26:37,159 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,159 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,160 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,161 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,163 - INFO - Retrying request to /chat/completions in 0.843488 seconds
2024-01-02 00:26:37,163 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,163 - INFO - Retrying request to /chat/completions in 0.929159 seconds
2024-01-02 00:26:37,163 - INFO - Retrying request to /chat/completions in 0.872492 seconds
2024-01-02 00:26:37,165 - INFO - Retrying request to /chat/completions in 0.790025 seconds
2024-01-02 00:26:37,165 - INFO - Retrying request to /chat/completions in 0.983675 seconds
2024-01-02 00:26:37,167 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,167 - INFO - Retrying request to /chat/completions in 0.798136 seconds
2024-01-02 00:26:37,168 - INFO - Retrying request to /chat/completions in 0.793601 seconds
2024-01-02 00:26:37,168 - INFO - Retrying request to /chat/completions in 0.800083 seconds
2024-01-02 00:26:37,170 - INFO - Retrying request to /chat/completions in 0.777497 seconds
2024-01-02 00:26:37,174 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,175 - INFO - Retrying request to /chat/completions in 0.835474 seconds
2024-01-02 00:26:37,183 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,183 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,186 - INFO - Retrying request to /chat/completions in 0.896656 seconds
2024-01-02 00:26:37,189 - INFO - Retrying request to /chat/completions in 0.757116 seconds
2024-01-02 00:26:37,191 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,193 - INFO - Retrying request to /chat/completions in 0.767844 seconds
2024-01-02 00:26:37,196 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,196 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,199 - INFO - Retrying request to /chat/completions in 0.824016 seconds
2024-01-02 00:26:37,199 - INFO - Retrying request to /chat/completions in 0.995864 seconds
2024-01-02 00:26:37,265 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,266 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,267 - INFO - Retrying request to /chat/completions in 0.764921 seconds
2024-01-02 00:26:37,268 - INFO - Retrying request to /chat/completions in 0.785303 seconds
2024-01-02 00:26:37,279 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,282 - INFO - Retrying request to /chat/completions in 0.817279 seconds
2024-01-02 00:26:37,302 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,305 - INFO - Retrying request to /chat/completions in 0.802074 seconds
2024-01-02 00:26:37,321 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,322 - INFO - Retrying request to /chat/completions in 0.833464 seconds
2024-01-02 00:26:37,331 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,332 - INFO - Retrying request to /chat/completions in 0.974120 seconds
2024-01-02 00:26:37,340 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,341 - INFO - Retrying request to /chat/completions in 0.802423 seconds
2024-01-02 00:26:37,343 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,344 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,345 - INFO - Retrying request to /chat/completions in 0.937928 seconds
2024-01-02 00:26:37,345 - INFO - Retrying request to /chat/completions in 0.837705 seconds
2024-01-02 00:26:37,369 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,370 - INFO - Retrying request to /chat/completions in 0.833519 seconds
2024-01-02 00:26:37,373 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,374 - INFO - Retrying request to /chat/completions in 0.804127 seconds
2024-01-02 00:26:37,379 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,381 - INFO - Retrying request to /chat/completions in 0.805739 seconds
2024-01-02 00:26:37,382 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,385 - INFO - Retrying request to /chat/completions in 0.827378 seconds
2024-01-02 00:26:37,388 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,389 - INFO - Retrying request to /chat/completions in 0.788838 seconds
2024-01-02 00:26:37,407 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,408 - INFO - Retrying request to /chat/completions in 0.806718 seconds
2024-01-02 00:26:37,412 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,413 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,414 - INFO - Retrying request to /chat/completions in 0.963062 seconds
2024-01-02 00:26:37,415 - INFO - Retrying request to /chat/completions in 0.912396 seconds
2024-01-02 00:26:37,416 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,417 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,418 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,418 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,419 - INFO - Retrying request to /chat/completions in 0.909901 seconds
2024-01-02 00:26:37,420 - INFO - Retrying request to /chat/completions in 0.846041 seconds
2024-01-02 00:26:37,420 - INFO - Retrying request to /chat/completions in 0.761595 seconds
2024-01-02 00:26:37,421 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,421 - INFO - Retrying request to /chat/completions in 0.793132 seconds
2024-01-02 00:26:37,423 - INFO - Retrying request to /chat/completions in 0.822364 seconds
2024-01-02 00:26:37,432 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,432 - INFO - Retrying request to /chat/completions in 0.986945 seconds
2024-01-02 00:26:37,437 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,438 - INFO - Retrying request to /chat/completions in 0.884291 seconds
2024-01-02 00:26:37,440 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,440 - INFO - Retrying request to /chat/completions in 0.911919 seconds
2024-01-02 00:26:37,444 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,445 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,448 - INFO - Retrying request to /chat/completions in 0.812194 seconds
2024-01-02 00:26:37,448 - INFO - Retrying request to /chat/completions in 0.798354 seconds
2024-01-02 00:26:37,449 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,451 - INFO - Retrying request to /chat/completions in 0.994370 seconds
2024-01-02 00:26:37,452 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,453 - INFO - Retrying request to /chat/completions in 0.794055 seconds
2024-01-02 00:26:37,460 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,460 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,461 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,462 - INFO - Retrying request to /chat/completions in 0.854649 seconds
2024-01-02 00:26:37,462 - INFO - Retrying request to /chat/completions in 0.940110 seconds
2024-01-02 00:26:37,462 - INFO - Retrying request to /chat/completions in 0.814407 seconds
2024-01-02 00:26:37,464 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,468 - INFO - Retrying request to /chat/completions in 0.816733 seconds
2024-01-02 00:26:37,473 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,474 - INFO - Retrying request to /chat/completions in 0.913874 seconds
2024-01-02 00:26:37,478 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,478 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,480 - INFO - Retrying request to /chat/completions in 0.774628 seconds
2024-01-02 00:26:37,480 - INFO - Retrying request to /chat/completions in 0.818697 seconds
2024-01-02 00:26:37,486 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,486 - INFO - Retrying request to /chat/completions in 0.819202 seconds
2024-01-02 00:26:37,491 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,491 - INFO - Retrying request to /chat/completions in 0.944455 seconds
2024-01-02 00:26:37,493 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,494 - INFO - Retrying request to /chat/completions in 0.866855 seconds
2024-01-02 00:26:37,517 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,517 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,518 - INFO - Retrying request to /chat/completions in 0.856582 seconds
2024-01-02 00:26:37,518 - INFO - Retrying request to /chat/completions in 0.947190 seconds
2024-01-02 00:26:37,537 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,537 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,538 - INFO - Retrying request to /chat/completions in 0.915698 seconds
2024-01-02 00:26:37,540 - INFO - Retrying request to /chat/completions in 0.997896 seconds
2024-01-02 00:26:37,554 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,555 - INFO - Retrying request to /chat/completions in 0.926854 seconds
2024-01-02 00:26:37,563 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,564 - INFO - Retrying request to /chat/completions in 0.916372 seconds
2024-01-02 00:26:37,575 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,576 - INFO - Retrying request to /chat/completions in 0.901241 seconds
2024-01-02 00:26:37,603 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,604 - INFO - Retrying request to /chat/completions in 0.982615 seconds
2024-01-02 00:26:37,615 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,616 - INFO - Retrying request to /chat/completions in 0.844387 seconds
2024-01-02 00:26:37,616 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,618 - INFO - Retrying request to /chat/completions in 0.751222 seconds
2024-01-02 00:26:37,707 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,708 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,708 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,710 - INFO - Retrying request to /chat/completions in 0.755014 seconds
2024-01-02 00:26:37,710 - INFO - Retrying request to /chat/completions in 0.965020 seconds
2024-01-02 00:26:37,711 - INFO - Retrying request to /chat/completions in 0.912813 seconds
2024-01-02 00:26:37,713 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,714 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,716 - INFO - Retrying request to /chat/completions in 0.935908 seconds
2024-01-02 00:26:37,716 - INFO - Retrying request to /chat/completions in 0.880878 seconds
2024-01-02 00:26:37,721 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,723 - INFO - Retrying request to /chat/completions in 0.758281 seconds
2024-01-02 00:26:37,734 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,734 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,735 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,736 - INFO - Retrying request to /chat/completions in 0.834344 seconds
2024-01-02 00:26:37,736 - INFO - Retrying request to /chat/completions in 0.768675 seconds
2024-01-02 00:26:37,736 - INFO - Retrying request to /chat/completions in 0.751001 seconds
2024-01-02 00:26:37,750 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,751 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,752 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,753 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,754 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,754 - INFO - Retrying request to /chat/completions in 0.984956 seconds
2024-01-02 00:26:37,755 - INFO - Retrying request to /chat/completions in 0.952710 seconds
2024-01-02 00:26:37,755 - INFO - Retrying request to /chat/completions in 0.882537 seconds
2024-01-02 00:26:37,755 - INFO - Retrying request to /chat/completions in 0.910547 seconds
2024-01-02 00:26:37,755 - INFO - Retrying request to /chat/completions in 0.767466 seconds
2024-01-02 00:26:37,763 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,765 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,768 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,770 - INFO - Retrying request to /chat/completions in 0.764314 seconds
2024-01-02 00:26:37,770 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,770 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,771 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,771 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,774 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,775 - INFO - Retrying request to /chat/completions in 0.770336 seconds
2024-01-02 00:26:37,775 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,776 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,776 - INFO - Retrying request to /chat/completions in 0.995402 seconds
2024-01-02 00:26:37,776 - INFO - Retrying request to /chat/completions in 0.889314 seconds
2024-01-02 00:26:37,776 - INFO - Retrying request to /chat/completions in 0.864158 seconds
2024-01-02 00:26:37,776 - INFO - Retrying request to /chat/completions in 0.885897 seconds
2024-01-02 00:26:37,776 - INFO - Retrying request to /chat/completions in 0.875618 seconds
2024-01-02 00:26:37,778 - INFO - Retrying request to /chat/completions in 0.837345 seconds
2024-01-02 00:26:37,778 - INFO - Retrying request to /chat/completions in 0.839533 seconds
2024-01-02 00:26:37,778 - INFO - Retrying request to /chat/completions in 0.757058 seconds
2024-01-02 00:26:37,790 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,790 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,795 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,795 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,796 - INFO - Retrying request to /chat/completions in 0.961842 seconds
2024-01-02 00:26:37,796 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,797 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,797 - INFO - Retrying request to /chat/completions in 0.762880 seconds
2024-01-02 00:26:37,797 - INFO - Retrying request to /chat/completions in 0.828575 seconds
2024-01-02 00:26:37,798 - INFO - Retrying request to /chat/completions in 0.904037 seconds
2024-01-02 00:26:37,798 - INFO - Retrying request to /chat/completions in 0.931004 seconds
2024-01-02 00:26:37,798 - INFO - Retrying request to /chat/completions in 0.897025 seconds
2024-01-02 00:26:37,806 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,807 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,807 - INFO - Retrying request to /chat/completions in 0.836779 seconds
2024-01-02 00:26:37,807 - INFO - Retrying request to /chat/completions in 0.798680 seconds
2024-01-02 00:26:37,812 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,813 - INFO - Retrying request to /chat/completions in 0.835539 seconds
2024-01-02 00:26:37,822 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,823 - INFO - Retrying request to /chat/completions in 0.906471 seconds
2024-01-02 00:26:37,828 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,828 - INFO - Retrying request to /chat/completions in 0.938038 seconds
2024-01-02 00:26:37,843 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,844 - INFO - Retrying request to /chat/completions in 0.773291 seconds
2024-01-02 00:26:37,854 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,857 - INFO - Retrying request to /chat/completions in 0.773034 seconds
2024-01-02 00:26:37,863 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,864 - INFO - Retrying request to /chat/completions in 0.794410 seconds
2024-01-02 00:26:37,869 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,870 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,870 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,872 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,872 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,873 - INFO - Retrying request to /chat/completions in 0.816592 seconds
2024-01-02 00:26:37,873 - INFO - Retrying request to /chat/completions in 0.788921 seconds
2024-01-02 00:26:37,873 - INFO - Retrying request to /chat/completions in 0.903378 seconds
2024-01-02 00:26:37,873 - INFO - Retrying request to /chat/completions in 0.859815 seconds
2024-01-02 00:26:37,873 - INFO - Retrying request to /chat/completions in 0.875883 seconds
2024-01-02 00:26:37,895 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,896 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,898 - INFO - Retrying request to /chat/completions in 0.784520 seconds
2024-01-02 00:26:37,898 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,898 - INFO - Retrying request to /chat/completions in 0.978789 seconds
2024-01-02 00:26:37,898 - INFO - Retrying request to /chat/completions in 0.998536 seconds
2024-01-02 00:26:37,898 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,899 - INFO - Retrying request to /chat/completions in 0.873629 seconds
2024-01-02 00:26:37,903 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:37,904 - INFO - Retrying request to /chat/completions in 0.867340 seconds
2024-01-02 00:26:38,022 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,027 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,031 - INFO - Retrying request to /chat/completions in 1.838783 seconds
2024-01-02 00:26:38,031 - INFO - Retrying request to /chat/completions in 1.506771 seconds
2024-01-02 00:26:38,087 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,088 - INFO - Retrying request to /chat/completions in 1.587157 seconds
2024-01-02 00:26:38,111 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,112 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,112 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,113 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,114 - INFO - Retrying request to /chat/completions in 1.502756 seconds
2024-01-02 00:26:38,115 - INFO - Retrying request to /chat/completions in 1.626528 seconds
2024-01-02 00:26:38,115 - INFO - Retrying request to /chat/completions in 1.588494 seconds
2024-01-02 00:26:38,115 - INFO - Retrying request to /chat/completions in 1.553882 seconds
2024-01-02 00:26:38,116 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,116 - INFO - Retrying request to /chat/completions in 1.770308 seconds
2024-01-02 00:26:38,118 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,119 - INFO - Retrying request to /chat/completions in 1.544324 seconds
2024-01-02 00:26:38,135 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,136 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,136 - INFO - Retrying request to /chat/completions in 1.730528 seconds
2024-01-02 00:26:38,136 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,137 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,137 - INFO - Retrying request to /chat/completions in 1.687727 seconds
2024-01-02 00:26:38,138 - INFO - Retrying request to /chat/completions in 1.895747 seconds
2024-01-02 00:26:38,138 - INFO - Retrying request to /chat/completions in 1.515345 seconds
2024-01-02 00:26:38,141 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,141 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,141 - INFO - Retrying request to /chat/completions in 1.880537 seconds
2024-01-02 00:26:38,143 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,143 - INFO - Retrying request to /chat/completions in 1.669817 seconds
2024-01-02 00:26:38,144 - INFO - Retrying request to /chat/completions in 1.756119 seconds
2024-01-02 00:26:38,144 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,144 - INFO - Retrying request to /chat/completions in 1.760634 seconds
2024-01-02 00:26:38,184 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,185 - INFO - Retrying request to /chat/completions in 1.505516 seconds
2024-01-02 00:26:38,187 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,188 - INFO - Retrying request to /chat/completions in 1.722493 seconds
2024-01-02 00:26:38,189 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,190 - INFO - Retrying request to /chat/completions in 1.568300 seconds
2024-01-02 00:26:38,195 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,195 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,196 - INFO - Retrying request to /chat/completions in 1.989324 seconds
2024-01-02 00:26:38,196 - INFO - Retrying request to /chat/completions in 1.817432 seconds
2024-01-02 00:26:38,203 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,204 - INFO - Retrying request to /chat/completions in 1.979823 seconds
2024-01-02 00:26:38,206 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,206 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,206 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,207 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,207 - INFO - Retrying request to /chat/completions in 1.896658 seconds
2024-01-02 00:26:38,209 - INFO - Retrying request to /chat/completions in 1.940101 seconds
2024-01-02 00:26:38,209 - INFO - Retrying request to /chat/completions in 1.627127 seconds
2024-01-02 00:26:38,209 - INFO - Retrying request to /chat/completions in 1.995182 seconds
2024-01-02 00:26:38,217 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,220 - INFO - Retrying request to /chat/completions in 1.693541 seconds
2024-01-02 00:26:38,222 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,223 - INFO - Retrying request to /chat/completions in 1.724902 seconds
2024-01-02 00:26:38,233 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,237 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,240 - INFO - Retrying request to /chat/completions in 1.754668 seconds
2024-01-02 00:26:38,242 - INFO - Retrying request to /chat/completions in 1.544523 seconds
2024-01-02 00:26:38,256 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,256 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,256 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,258 - INFO - Retrying request to /chat/completions in 1.642015 seconds
2024-01-02 00:26:38,258 - INFO - Retrying request to /chat/completions in 1.558905 seconds
2024-01-02 00:26:38,258 - INFO - Retrying request to /chat/completions in 1.996076 seconds
2024-01-02 00:26:38,259 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,260 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,260 - INFO - Retrying request to /chat/completions in 1.679120 seconds
2024-01-02 00:26:38,260 - INFO - Retrying request to /chat/completions in 1.946893 seconds
2024-01-02 00:26:38,270 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,271 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,274 - INFO - Retrying request to /chat/completions in 1.816357 seconds
2024-01-02 00:26:38,275 - INFO - Retrying request to /chat/completions in 1.638038 seconds
2024-01-02 00:26:38,281 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,283 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,283 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,283 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,286 - INFO - Retrying request to /chat/completions in 1.714605 seconds
2024-01-02 00:26:38,286 - INFO - Retrying request to /chat/completions in 1.950254 seconds
2024-01-02 00:26:38,286 - INFO - Retrying request to /chat/completions in 1.892726 seconds
2024-01-02 00:26:38,286 - INFO - Retrying request to /chat/completions in 1.732235 seconds
2024-01-02 00:26:38,305 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,305 - INFO - Retrying request to /chat/completions in 1.669462 seconds
2024-01-02 00:26:38,322 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,323 - INFO - Retrying request to /chat/completions in 1.609041 seconds
2024-01-02 00:26:38,330 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,330 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,333 - INFO - Retrying request to /chat/completions in 1.873651 seconds
2024-01-02 00:26:38,334 - INFO - Retrying request to /chat/completions in 1.842108 seconds
2024-01-02 00:26:38,335 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,335 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,336 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,336 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,336 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,336 - INFO - Retrying request to /chat/completions in 1.548218 seconds
2024-01-02 00:26:38,338 - INFO - Retrying request to /chat/completions in 1.954810 seconds
2024-01-02 00:26:38,338 - INFO - Retrying request to /chat/completions in 1.868748 seconds
2024-01-02 00:26:38,338 - INFO - Retrying request to /chat/completions in 1.992263 seconds
2024-01-02 00:26:38,338 - INFO - Retrying request to /chat/completions in 1.618188 seconds
2024-01-02 00:26:38,344 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,345 - INFO - Retrying request to /chat/completions in 1.901757 seconds
2024-01-02 00:26:38,348 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,349 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,350 - INFO - Retrying request to /chat/completions in 1.925360 seconds
2024-01-02 00:26:38,351 - INFO - Retrying request to /chat/completions in 1.659345 seconds
2024-01-02 00:26:38,353 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,353 - INFO - Retrying request to /chat/completions in 1.706389 seconds
2024-01-02 00:26:38,373 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,373 - INFO - Retrying request to /chat/completions in 1.755493 seconds
2024-01-02 00:26:38,390 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,391 - INFO - Retrying request to /chat/completions in 1.807401 seconds
2024-01-02 00:26:38,395 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,395 - INFO - Retrying request to /chat/completions in 1.982968 seconds
2024-01-02 00:26:38,399 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,400 - INFO - Retrying request to /chat/completions in 1.952689 seconds
2024-01-02 00:26:38,413 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,414 - INFO - Retrying request to /chat/completions in 1.960852 seconds
2024-01-02 00:26:38,426 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,426 - INFO - Retrying request to /chat/completions in 1.557332 seconds
2024-01-02 00:26:38,430 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,430 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,431 - INFO - Retrying request to /chat/completions in 1.692551 seconds
2024-01-02 00:26:38,431 - INFO - Retrying request to /chat/completions in 1.805245 seconds
2024-01-02 00:26:38,435 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,436 - INFO - Retrying request to /chat/completions in 1.886809 seconds
2024-01-02 00:26:38,439 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,439 - INFO - Retrying request to /chat/completions in 1.864881 seconds
2024-01-02 00:26:38,446 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,447 - INFO - Retrying request to /chat/completions in 1.843783 seconds
2024-01-02 00:26:38,452 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,454 - INFO - Retrying request to /chat/completions in 1.699287 seconds
2024-01-02 00:26:38,454 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,455 - INFO - Retrying request to /chat/completions in 1.813648 seconds
2024-01-02 00:26:38,458 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,460 - INFO - Retrying request to /chat/completions in 1.737384 seconds
2024-01-02 00:26:38,460 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,461 - INFO - Retrying request to /chat/completions in 1.844744 seconds
2024-01-02 00:26:38,469 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,473 - INFO - Retrying request to /chat/completions in 1.996467 seconds
2024-01-02 00:26:38,480 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,480 - INFO - Retrying request to /chat/completions in 1.661476 seconds
2024-01-02 00:26:38,497 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,499 - INFO - Retrying request to /chat/completions in 1.987033 seconds
2024-01-02 00:26:38,503 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,504 - INFO - Retrying request to /chat/completions in 1.617795 seconds
2024-01-02 00:26:38,512 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,512 - INFO - Retrying request to /chat/completions in 1.973666 seconds
2024-01-02 00:26:38,522 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,524 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,525 - INFO - Retrying request to /chat/completions in 1.687463 seconds
2024-01-02 00:26:38,525 - INFO - Retrying request to /chat/completions in 1.724359 seconds
2024-01-02 00:26:38,527 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,527 - INFO - Retrying request to /chat/completions in 1.788235 seconds
2024-01-02 00:26:38,532 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,533 - INFO - Retrying request to /chat/completions in 1.523651 seconds
2024-01-02 00:26:38,543 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,543 - INFO - Retrying request to /chat/completions in 1.711045 seconds
2024-01-02 00:26:38,557 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,557 - INFO - Retrying request to /chat/completions in 1.988713 seconds
2024-01-02 00:26:38,563 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,567 - INFO - Retrying request to /chat/completions in 1.977518 seconds
2024-01-02 00:26:38,573 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,575 - INFO - Retrying request to /chat/completions in 1.543811 seconds
2024-01-02 00:26:38,586 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,586 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,586 - INFO - Retrying request to /chat/completions in 1.779421 seconds
2024-01-02 00:26:38,586 - INFO - Retrying request to /chat/completions in 1.504691 seconds
2024-01-02 00:26:38,612 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,613 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,613 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,613 - INFO - Retrying request to /chat/completions in 1.633326 seconds
2024-01-02 00:26:38,614 - INFO - Retrying request to /chat/completions in 1.856816 seconds
2024-01-02 00:26:38,614 - INFO - Retrying request to /chat/completions in 1.910063 seconds
2024-01-02 00:26:38,619 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,620 - INFO - Retrying request to /chat/completions in 1.770021 seconds
2024-01-02 00:26:38,626 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,629 - INFO - Retrying request to /chat/completions in 1.843607 seconds
2024-01-02 00:26:38,645 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,645 - INFO - Retrying request to /chat/completions in 1.661772 seconds
2024-01-02 00:26:38,649 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,649 - INFO - Retrying request to /chat/completions in 1.564488 seconds
2024-01-02 00:26:38,662 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,664 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,665 - INFO - Retrying request to /chat/completions in 1.886106 seconds
2024-01-02 00:26:38,666 - INFO - Retrying request to /chat/completions in 1.535027 seconds
2024-01-02 00:26:38,673 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,674 - INFO - Retrying request to /chat/completions in 1.843681 seconds
2024-01-02 00:26:38,677 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,677 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,680 - INFO - Retrying request to /chat/completions in 1.525643 seconds
2024-01-02 00:26:38,681 - INFO - Retrying request to /chat/completions in 1.500307 seconds
2024-01-02 00:26:38,698 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,699 - INFO - Retrying request to /chat/completions in 1.717562 seconds
2024-01-02 00:26:38,710 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,715 - INFO - Retrying request to /chat/completions in 1.661596 seconds
2024-01-02 00:26:38,726 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,726 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,728 - INFO - Retrying request to /chat/completions in 1.699764 seconds
2024-01-02 00:26:38,728 - INFO - Retrying request to /chat/completions in 1.510338 seconds
2024-01-02 00:26:38,739 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,740 - INFO - Retrying request to /chat/completions in 1.618110 seconds
2024-01-02 00:26:38,752 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,755 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,756 - INFO - Retrying request to /chat/completions in 1.755497 seconds
2024-01-02 00:26:38,756 - INFO - Retrying request to /chat/completions in 1.777014 seconds
2024-01-02 00:26:38,767 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,767 - INFO - Retrying request to /chat/completions in 1.768595 seconds
2024-01-02 00:26:38,770 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,771 - INFO - Retrying request to /chat/completions in 1.905759 seconds
2024-01-02 00:26:38,771 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,772 - INFO - Retrying request to /chat/completions in 1.826137 seconds
2024-01-02 00:26:38,796 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,797 - INFO - Retrying request to /chat/completions in 1.996366 seconds
2024-01-02 00:26:38,798 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,798 - INFO - Retrying request to /chat/completions in 1.755307 seconds
2024-01-02 00:26:38,810 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,811 - INFO - Retrying request to /chat/completions in 1.689970 seconds
2024-01-02 00:26:38,817 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,817 - INFO - Retrying request to /chat/completions in 1.637705 seconds
2024-01-02 00:26:38,822 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,822 - INFO - Retrying request to /chat/completions in 1.964454 seconds
2024-01-02 00:26:38,831 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,832 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,833 - INFO - Retrying request to /chat/completions in 1.958160 seconds
2024-01-02 00:26:38,833 - INFO - Retrying request to /chat/completions in 1.748141 seconds
2024-01-02 00:26:38,836 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,836 - INFO - Retrying request to /chat/completions in 1.879226 seconds
2024-01-02 00:26:38,852 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,853 - INFO - Retrying request to /chat/completions in 1.765831 seconds
2024-01-02 00:26:38,862 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,863 - INFO - Retrying request to /chat/completions in 1.835449 seconds
2024-01-02 00:26:38,865 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,867 - INFO - Retrying request to /chat/completions in 1.580668 seconds
2024-01-02 00:26:38,879 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,879 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,880 - INFO - Retrying request to /chat/completions in 1.515156 seconds
2024-01-02 00:26:38,880 - INFO - Retrying request to /chat/completions in 1.614391 seconds
2024-01-02 00:26:38,893 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,894 - INFO - Retrying request to /chat/completions in 1.884698 seconds
2024-01-02 00:26:38,895 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,896 - INFO - Retrying request to /chat/completions in 1.899297 seconds
2024-01-02 00:26:38,898 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,899 - INFO - Retrying request to /chat/completions in 1.548299 seconds
2024-01-02 00:26:38,902 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,903 - INFO - Retrying request to /chat/completions in 1.810870 seconds
2024-01-02 00:26:38,912 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,913 - INFO - Retrying request to /chat/completions in 1.784141 seconds
2024-01-02 00:26:38,918 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,918 - INFO - Retrying request to /chat/completions in 1.547282 seconds
2024-01-02 00:26:38,920 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,920 - INFO - Retrying request to /chat/completions in 1.918035 seconds
2024-01-02 00:26:38,927 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,928 - INFO - Retrying request to /chat/completions in 1.667902 seconds
2024-01-02 00:26:38,943 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,944 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,944 - INFO - Retrying request to /chat/completions in 1.819076 seconds
2024-01-02 00:26:38,944 - INFO - Retrying request to /chat/completions in 1.722996 seconds
2024-01-02 00:26:38,960 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,961 - INFO - Retrying request to /chat/completions in 1.513721 seconds
2024-01-02 00:26:38,961 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,962 - INFO - Retrying request to /chat/completions in 1.850813 seconds
2024-01-02 00:26:38,963 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:38,964 - INFO - Retrying request to /chat/completions in 1.916366 seconds
2024-01-02 00:26:39,017 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:39,020 - INFO - Retrying request to /chat/completions in 1.750236 seconds
2024-01-02 00:26:39,021 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:39,022 - INFO - Retrying request to /chat/completions in 1.777944 seconds
2024-01-02 00:26:39,069 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:39,261 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:39,490 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:39,695 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:39,775 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:39,810 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:39,820 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449429, Requested 1650. Please try again in 143ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:39,820 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Real-World Experience With Tofacitinib Dose De-Escalation in Patients With Moderate and Severe Ulcerative Colitis.\nTofacitinib is associated with sustained steroid-free remission in patients with ulcerative colitis (UC), with the lowest effective dose recommended for maintenance therapy. However, there are limited real-world data to guide decisions on the optimal maintenance regimen. We aimed to evaluate predictors and outcomes of disease activity after tofacitinib dose de-escalation in this population.Included were adults with moderate-severe UC treated with tofacitinib between June 2012 and January 2022. The primary outcome was evidence of UC disease activity-related events: hospitalization/surgery, corticosteroid initiation, tofacitinib dose increase, or therapy switch.Among 162 patients, 52% continued 10 mg twice daily while 48% underwent dose de-escalation to 5 mg twice daily. Cumulative incidence rates of UC events at 12 months were similar in patients with and without dose de-escalation (56% vs 58%; P\xa0= .81). In univariable Cox regression among patients with dose de-escalation, an induction course with 10 mg twice daily for more than 16 weeks was protective of UC events (hazard ratio [HR], 0.37; 95% CI, 0.16-0.85) while ongoing severe disease (Mayo 3) was associated with UC events (HR, 6.41; 95% 95% CI, 2.23-18.44), which remained significant after adjusting for age, sex, duration of induction course, and corticosteroid use at dose de-escalation (HR, 6.05; 95% CI, 2.00-18.35). Twenty-nine percent of patients with UC events had their dose re-escalated to 10 mg twice daily, with only 63% able to recapture clinical response at 12 months.In this real-world cohort, we observed a 56% cumulative incidence of UC events at 12 months in patients with tofacitinib dose de-escalation. Observed factors associated with UC events after dose de-escalation included induction course for fewer than 16 weeks and active endoscopic disease 6 months after initiation.</ABSTRACT>'}]
2024-01-02 00:26:39,820 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:39,821 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449429, Requested 1614. Please try again in 139ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:39,821 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Early intervention with biologic therapy in Crohns disease: how early is early?\nEarly biologic therapy within the first 18-24 months after diagnosis is associated with improved clinical outcomes in Crohn\'s disease [CD]. However, the definition of the best time to initiate biologic therapy remains unclear. We aimed to assess if there is an optimal timing for early biologic therapy initiation.This was a multicentre retrospective cohort study including newly diagnosed CD patients who started anti-tumour necrosis factor [TNF] therapy within 24 months from diagnosis. The timing of initiation of biologic therapy was categorised as\u2005\u22646, 7-12, 13-18, and 19-24 months. The primary outcome was CD-related complications defined as a composite of progression of Montreal disease behaviour, CD-related hospitalisations, or CD-related intestinal surgeries. Secondary outcomes included clinical, laboratory, endoscopic, and transmural remission.We included 141 patients where 54%, 26%, 11%, and 9% started biologic therapy at\u2005\u22646, 7-12, 13-18, and 19-24 months after diagnosis, respectively. A total of 34 patients [24%] reached the primary outcome: 8% had progression of disease behaviour, 15% were hospitalised, and 9% required surgery. There was no difference in the time to a CD-related complication according to the time of initiation of biologic therapy within the first 24 months. Clinical, endoscopic, and transmural remission was achieved in 85%, 50%, and 29%, respectively, but no differences were found according to the time of initiation of biologic therapy.Starting anti-TNF therapy within the first 24 months after diagnosis was associated with a low rate of CD-related complications and high rates of clinical and endoscopic remission, although we found no differences with earlier initiation within this window of opportunity.</ABSTRACT>'}]
2024-01-02 00:26:39,832 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:39,837 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:39,839 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449296, Requested 1640. Please try again in 124ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:39,839 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Detection of systemic cardiovascular illnesses and cardiometabolic risk factors with machine learning and optical coherence tomography angiography: a pilot study.\nOptical coherence tomography angiography (OCTA) has been found to identify changes in the retinal microvasculature of people with various cardiometabolic factors. Machine learning has previously been applied within ophthalmic imaging but has not yet been applied to these risk factors. The study aims to assess the feasibility of predicting the presence or absence of cardiovascular conditions and their associated risk factors using machine learning and OCTA.Cross-sectional study. Demographic and co-morbidity data was collected for each participant undergoing 3\u2009\u20093\u2009mm, 6\u2009\u20096\u2009mm and 8\u2009\u20098\u2009mm OCTA scanning using the Carl Zeiss CIRRUS HD-OCT model 5000. The data was then pre-processed and randomly split into training and testing datasets (75%/25% split) before being applied to two models (Convolutional Neural Network and MoblieNetV2). Once developed on the training dataset, their performance was assessed on the unseen test dataset.Two hundred forty-seven participants were included. Both models performed best in predicting the presence of hyperlipidaemia in 3\u2009\u20093\u2009mm scans with an AUC of 0.74 and 0.81, and accuracy of 0.79 for CNN and MobileNetV2 respectively. Modest performance was achieved in the identification of diabetes mellitus, hypertension and congestive heart failure in 3\u2009\u20093\u2009mm scans (all with AUC and accuracy >0.5). There was no significant recognition for 6\u2009\u20096 and 8\u2009\u20098\u2009mm for any cardiometabolic risk factor.This study demonstrates the strength of ML to identify the presence cardiometabolic factors, in particular hyperlipidaemia, in high-resolution 3\u2009\u20093\u2009mm OCTA scans. Early detection of risk factors prior to a clinically significant event, will assist in preventing adverse outcomes for people.</ABSTRACT>'}]
2024-01-02 00:26:39,878 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:39,883 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:39,886 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449568, Requested 1610. Please try again in 157ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:39,886 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>A Comparative Evaluation of the Measurement Properties of Three Histological Indices of Mucosal Healing in Ulcerative Colitis: Geboes Score, Robarts Histopathology Index and Nancy Index.\nTo inform their future use in regulated clinical trials to evaluate treatment efficacy hypotheses, the measurement properties of three histological indices, Geboes Score [GS], Robarts Histopathology Index [RHI] and Nancy Index [NI], were evaluated among patients with ulcerative colitis.Analyses were conducted on data from a Phase 3 clinical trial of adalimumab [M14-033, n\u2005=\u2005491] and focused on evaluating the measurement properties of the GS, RHI and NI. Specifically, internal consistency and inter-rater reliability, convergent, discriminant and known-group validity, and sensitivity to change were assessed at Baseline, and at Weeks 8 and 52.Internal consistency for the RHI showed lower alpha [\u03b1] values at Baseline [\u03b1\u2005=\u20050.62] relative to Weeks 8 [\u03b1\u2005=\u20050.82] and 52 [\u03b1\u2005=\u20050.81]. The inter-rater reliability values of RHI [0.91], NI [0.64] and GS [0.53] were excellent, good and fair, respectively. Regarding validity, Week 52 correlations were moderate to strong between full and partial Mayo scores and Mayo subscale scores and the RHI and GS, and were weak to moderate for the NI. Significant differences between mean scores of all three histological indices were observed across known-groups based on Mayo endoscopy subscores and full Mayo scores at Weeks 8 and 52 [p\u2005<\u20050.001].The GS, RHI and NI are each capable of producing reliable and valid scores that are sensitive to changes in disease activity over time, in patients with moderately to severely active ulcerative colitis. While all three indices demonstrated relatively acceptable measurement properties, the GS and RHI performed better than the NI.</ABSTRACT>'}]
2024-01-02 00:26:39,887 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:39,888 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:39,890 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448961, Requested 1599. Please try again in 74ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:39,890 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Patient and Public Involvement in Research: Lessons for Inflammatory Bowel Disease.\nParticipatory research, also referred to as patient and public involvement, is an approach that involves collaborating with patients affected by the focus of the research, on the design, development and delivery of research to improve outcomes. There are two broad justifications for this: first, that it enhances the quality and relevance of research, and second, that it satisfies the ethical argument for patient inclusion in decisions about them. This synergistic and collaborative effort, which bridges the divide between researchers and participants with the lived condition, is now a mainstream activity and widely accepted as best practice. Although there has been a substantial increase in the literature over the past two decades, little has been published on how participatory research has been used in inflammatory bowel disease [IBD] research and little guidance as to how researchers should go about this. With an increasing incidence and prevalence worldwide, combined with declining study enrolment in an era of perennial unmet need, there are a multitude of benefits of participatory research to IBD patients and investigators, including research output that is informed and relevant to the real world. A key example of participatory research in IBD is the I-CARE study, a large-scale, pan-European observational study assessing the safety of advanced therapies, which had significant patient involvement throughout the study. In this review, we provide a comprehensive overview of the benefits and challenges of participatory research and discuss opportunities of building strategic alliances between IBD patients, healthcare providers and academics to strengthen research outcomes.</ABSTRACT>'}]
2024-01-02 00:26:39,928 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:39,929 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449849, Requested 1883. Please try again in 230ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:39,929 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Bilateral inferior petrosal sinus sampling: Procedural data from a German single-center study.\nTo assess radiation exposure and diagnostic performance of bilateral inferior petrosal sinus sampling for the distinction of pituitary and ectopic adrenocorticotropin-dependent Cushing\'s syndrome.Procedural data of bilateral inferior petrosal sinus procedures were retrospectively evaluated. The analysis included the patients\' clinical and demographic data, procedural radiation exposure, and complication rates, sampling results, clinical course of the patients, and calculation of diagnostic performance data.The cases of 46 patients diagnosed with adrenocorticotropin-dependent Cushing\'s syndrome were evaluated. Bilateral inferior petrosal sinus sampling was successfully performed in 97.8\u200a% of the cases. The overall median procedure-related fluoroscopy time was 7.8\u200amin. (range 3.2-36.2\u200amin.), and the median procedural dose area product was 11.9 Gy*cm2 (range 2.1-73.7 Gy*cm2). Radiation doses due to digital subtraction angiography series for visualization of the inferior petrosal sinus were 3.6 Gy*cm2 (range 1.0-18.1 Gy*cm2). Radiation doses due to fluoroscopy had a higher impact on the overall radiation exposure and were significantly influenced by the patients\' habitus. The sensitivity, specificity, and positive and negative predictive values were 84\u200a%, 100\u200a%, 100\u200a%, and 72\u200a% before stimulation with corticotropin-releasing hormone, and 97\u200a%, 100\u200a%, 100\u200a%, and 93\u200a% after stimulation. Concordance between magnetic resonance imaging studies and bilateral inferior petrosal sinus sampling results was only found in 35.6\u200a% of the cases. The periprocedural complication rate was 2.2\u200a%, with one patient experiencing vasovagal syncope during catheterization.Bilateral inferior petrosal sinus sampling is a safe procedure with high technical success rates und excellent diagnostic performance. The procedure-related radiation exposure shows large variations and depends on the complexity of cannulation as well as the patients\' habitus. Fluoroscopy accounted for the largest proportion of radiation exposure. Acquisition of digital subtraction angiography series for the verification of correct catheter placement appears justified. Bilateral inferior petrosal sinus sampling with CRH stimulation provides high diagnostic performance in the distinction of pituitary and ectopic Cushing\'s syndrome..  The associated radiation exposure is not negligible and is significantly influenced by the use of fluoroscopy and the patients\' habitus..  Digital subtraction angiography contributes less to the overall radiation dose and appears justified for the verification of correct catheter placement.. Augustin A, Detomas M, Hartung V et\u200aal. Bilateral inferior petrosal sinus sampling: Procedural data from a German single-center study. Fortschr Rntgenstr 2023; 195: 1009\u200a-\u200a1017.</ABSTRACT>'}]
2024-01-02 00:26:39,971 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:39,974 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:39,975 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449242, Requested 1296. Please try again in 71ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:39,975 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Expert Perspective: Challenges in Sjgren\'s Disease.\nThe management of Sjgren\'s disease is challenging because of several factors. Indeed, the clinical presentations are heterogeneous, and one must be able to identify prognostic markers to adapt the follow-up. In addition, there is no validated treatment. Nevertheless, international experts have been working for several years to establish recommendations to guide management. Since research in this field is extremely active, we anticipate the development of effective treatments for our patients in the near future.</ABSTRACT>'}]
2024-01-02 00:26:39,975 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:39,976 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449291, Requested 1643. Please try again in 124ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:39,976 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Sacubitril/valsartan ameliorates renal tubulointerstitial injury through increasing renal plasma flow in a mouse model of type 2 diabetes with aldosterone excess.\nAldosterone has been assumed to be one of aggravating factors in diabetic kidney disease (DKD). Natriuretic peptides/guanylyl cyclase-A/cGMP signalling has been shown to ameliorate aldosterone-induced renal injury in mice. Sacubitril/valsartan (SAC/VAL) is used clinically for chronic heart failure and hypertension, in part by augmenting natriuretic peptide bioavailability. The effects of SAC/VAL on renal pathophysiology including in DKD, however, have remained unclarified.Eight-week-old male db/db mice fed on a high-salt diet (HSD) were treated with vehicle or aldosterone (0.2\xa0\u03bcg/kg/min), and divided into four groups: HSD control, ALDO (aldosterone), ALDO\xa0+\xa0VAL (valsartan), and ALDO\xa0+\xa0SAC/VAL group. After 4 weeks, they were analysed for plasma atrial natriuretic peptide (ANP) levels, renal histology, and haemodynamic parameters including glomerular filtration rate (GFR) by FITC-inulin and renal plasma flow (RPF) by para-amino hippuric acid.The ALDO\xa0+\xa0SAC/VAL group showed significantly increased plasma ANP concentration and creatinine clearance, and decreased tubulointerstitial fibrosis and neutrophil gelatinase-associated lipocalin expression compared to ALDO and ALDO\xa0+\xa0VAL groups. SAC/VAL treatment increased GFR and RPF, and suppressed expression of Tgfb1, Il1b, Ccl2, and Lcn2 genes compared to the ALDO group. The percentage of tubulointerstitial fibrotic areas negatively correlated with the RPF and GFR.In a mouse model of type 2 diabetes with aldosterone excess, SAC/VAL increased RPF and GFR, and ameliorated tubulointerstitial fibrosis. Furthermore, RPF negatively correlated well with tubulointerstitial injury, suggesting that the beneficial effects of SAC/VAL could be through increased renal plasma flow with enhanced natriuretic peptide bioavailability.</ABSTRACT>'}]
2024-01-02 00:26:39,992 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:39,993 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:39,994 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448975, Requested 1423. Please try again in 53ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:39,994 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>In vitro laboratory models of proliferative vitreoretinopathy.\nProliferative vitreoretinopathy (PVR), the most common cause of recurrent retinal detachment, is characterized by the formation and contraction of fibrotic membranes on the surface of the retina. There are no Food and Drug Administration (FDA)-approved drugs to prevent or treat PVR. Therefore, it is necessary to develop accurate in vitro models of the disease that will enable researchers to screen drug candidates and prioritize the most promising candidates for clinical studies. We provide a summary of recent in vitro PVR models, as well as avenues for model improvement. Several in vitro PVR models were identified, including various types of cell cultures. Additionally, novel techniques that have not been used to model PVR were identified, including organoids, hydrogels, and organ-on-a-chip models. Novel ideas for improving in vitro PVR models are highlighted. Researchers may consult this review to help design in vitro models of PVR, which will aid in the development of therapies to treat the disease.</ABSTRACT>'}]
2024-01-02 00:26:39,995 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449036, Requested 1521. Please try again in 74ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:39,995 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Protein kinase C delta mediates Pasireotide effects in an ACTH-secreting pituitary tumor cell line.\nClinical control of corticotroph tumors is difficult to achieve since they usually persist or relapse after surgery. Pasireotide is approved to treat patients with Cushing\'s disease for whom surgical therapy is not an option. However, Pasireotide seems to be effective only in a sub-set of patients, highlighting the importance to find a response marker to this approach. Recent studies demonstrated that the delta isoform of protein kinase C (PRKCD) controls viability and cell cycle progression of an in vitro model of ACTH-secreting pituitary tumor, the AtT-20/D16v-F2 cells. This study aims at exploring the possible PRKCD role in mediating Pasireotide effects.It was assessed cell viability, POMC expression and ACTH secretion in AtT20/D16v-F2 cells over- or under-expressing PRKCD.We found that Pasireotide significantly reduces AtT20/D16v-F2 cell viability, POMC expression and ACTH secretion. In addition, Pasireotide reduces miR-26a expression. PRKCD silencing decreases AtT20/D16v-F2 cell sensitivity to Pasireotide treatment; on the contrary, PRKCD overexpression increases the inhibitory effects of Pasireotide on cell viability and ACTH secretion.Our results provide new insights into potential PRKCD contribution in Pasireotide mechanism of action and suggest that PRKCD might be a possible marker of therapeutic response in ACTH-secreting pituitary tumors.</ABSTRACT>'}]
2024-01-02 00:26:40,020 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,022 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448409, Requested 1602. Please try again in 1ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,024 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Incidence of cancer in patients with ulcerative colitis 30 years after diagnosis (the IBSEN study).\nPatients with ulcerative colitis (UC) have shown an increased risk for colorectal cancer, hepatobiliary, hematologic, and skin cancers, but updated long-term data is needed. This study aimed to estimate the risk of cancer in patients with UC compared to the general Norwegian population, in a population-based cohort (the IBSEN study), 30\u2009years after diagnosis; and to identify possible risk factors associated with cancer.The IBSEN cohort prospectively included all incident patients between 1990 and 1993. Cancer incidence data were obtained from the Cancer Registry of Norway. The overall and cancer-specific hazard ratios (HR) were modelled using Cox regression. Standardized incidence ratios were estimated compared to the general population.In total, the cohort included 519 patients, and 83 cases were diagnosed with cancer. There was no statistically significant difference in the overall cancer risk (HR = 1.01, 95% CI: [0.79-1.29]) and colorectal cancer risk (HR = 1.37, 95% CI: [0.75-2.47]) between patients and controls. The incidence of biliary tract cancer was higher than expected (SIR = 9.84, 95%CI: [3.19-20.15]), especially when UC patients suffered from primary sclerosing cholangitis. Male UC patients were also more at risk of being diagnosed with hematologic malignancies (HR = 3.48, 95% CI: [1.55-7.82]). Being prescribed thiopurines was associated with a higher risk of cancer (HR = 2.03, 95% CI: [1.02-4.01]).At 30\u2009years after diagnosis, the risk of all cancer in patients with UC was not significantly increased compared with the general population. However, the risks of biliary tract cancer and hematologic cancers were increased, particularly in male patients.</ABSTRACT>'}]
2024-01-02 00:26:40,027 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,029 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448887, Requested 1522. Please try again in 54ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,029 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Content of Telephone Consultations of Patients With Inflammatory Bowel Disease: A Single-Center Descriptive Study.\nThis study aimed to analyze the specific contents of telephone consultations of patients with inflammatory bowel disease. A medical record survey was conducted at a clinic in Japan for 1 year. Telephone consultation sheets recorded by nurses for calls with the patients or their relatives were reviewed. Content analysis was used to summarize the telephone consultation content. Consultations were categorized into 8 categories. Coding was conducted by 2 independent researchers. Concordance rates were evaluated using kappa coefficients. We analyzed 476 sheets. A total of 229 participants consulted the clinic at least once. The mean number of consultations per person was 2.1. Of these patients, 96 (40.9%) had ulcerative colitis. The kappa coefficient was 0.89. The most frequent consultation was "Consultation on worsening health: Inflammatory bowel disease is likely to have worsened" (42.0%). The second most frequent response was "Consultation or progress report on a worsening health condition: The disease is unlikely to have worsened" (19.8%). For consultations related to worsening the disease, it would be useful to assess symptoms over the phone using a disease activity index to ascertain the degree of worsening and to develop a screening tool for determining whether patients can continue remote support or require face-to-face consultation.</ABSTRACT>'}]
2024-01-02 00:26:40,035 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,036 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,038 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,040 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448703, Requested 1487. Please try again in 25ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,040 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Fundus fluorescein angiography imaging of retinopathy of prematurity in infants: A review.\nFluorescein angiography in retinopathy of prematurity is increasingly utilized over the past decade. The development of ultra-wide-field imaging combined with fluorescein angiography has allowed improved visualization of the peripheral retinal vasculature. Patient cooperation in the pediatric population is particularly challenging, but hand-held digital retinal photography has shown promise and can visualize the infant retina without the need for anesthesia and intravenous access. Many features of retinopathy of prematurity and its response to laser and anti-VEGF treatment can be either exclusively or better visualized on fluorescein angiography compared to indirect ophthalmoscopy or color fundus photography. Disease treatment is gradually shifting from laser photocoagulation to intravitreal anti-VEGF agents, the latter being associated with late-onset vision-threatening sequelae. The role of fluorescein angiography in retinopathy of prematurity monitoring will continue to increase with the longer follow-up required and different clinical behavior seen with anti-VEGF treatment. We highlight the utility, safety, and importance of fluorescein angiography in the diagnosis, treatment, and follow-up of retinopathy of prematurity.</ABSTRACT>'}]
2024-01-02 00:26:40,042 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448727, Requested 1515. Please try again in 32ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,042 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>The evolving role of JAK inhibitors in the treatment of inflammatory bowel disease.\nJanus Kinase inhibitors (JAKi) are a new class of oral therapies for the treatment of moderate-severe ulcerative colitis with additional potential for the treatment of moderate-severe Crohn\'s disease. In contrast to biologic therapies JAKi provide the opportunity for non-immunogenic once or twice daily oral therapies.Janus Kinase inhibitors for the treatment of ulcerative colitis and Crohn\'s disease based on mechanism of action, pharmacokinetics, clinical trial and real-world data regarding safety and efficacy; focusing on regulatory approvals in the U.S. and Europe.Janus Kinase inhibitors are considered among the \'advanced therapies\' for IBD and are approved for the treatment of moderate to severe ulcerative colitis in adults with pending approvals for Crohn\'s disease in the U.S. JAKi offer non-immunogenic, oral options for patient not responding to other conventional agents but, have been \'restricted\' by the FDA to patients with inadequate response to TNF blockers. JAKi offer rapidly acting oral alternatives to biologic agents for moderate-severe ulcerative colitis where the risks of cardiovascular and thrombotic events noted in rheumatoid arthritis have not been observed in IBD clinical trials. Nevertheless, monitoring of infections (primarily herpes zoster) and risk factors for cardiovascular and thrombotic complications is appropriate.</ABSTRACT>'}]
2024-01-02 00:26:40,043 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448781, Requested 1653. Please try again in 57ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,043 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Revised Algorithmic Approach to Differentiate Between Nonspecific and Specific Etiologies of Chronic Terminal Ileitis.\nChronic isolated terminal ileitis (TI) may be seen in Crohn\'s disease (CD) and intestinal tuberculosis (ITB) in addition to other etiologies that may be managed symptomatically. We developed a revised algorithm to distinguish patients with a specific etiology from a nonspecific etiology.Patients with chronic isolated TI followed up from 2007 to 2022 were retrospectively reviewed. A specific (ITB or CD) diagnosis was made based on standardized criteria, and other relevant data were collected. Using this cohort, validation of a previously suggested algorithm was conducted. Furthermore, based on the results of a univariate analysis, a multivariate analysis with bootstrap validation was used to develop a revised algorithm.We included 153 patients (mean age 36.9  14.6 years, males-70%, median duration-1.5 years, range: 0-20 years) with chronic isolated TI of whom 109 (71.2%) received a specific diagnosis (CD-69, ITB-40). On multivariate regression and validation statistics with a combination of clinical, laboratory, radiological, and colonoscopic findings, an optimism corrected c-statistic of 0.975 and 0.958 was obtained with and without histopathological findings, respectively. Revised algorithm, based on these, showed sensitivity, specificity, positive and negative predictive values, and overall accuracy of 98.2% (95% CI: 93.5-99.8), 75.0% (95% CI: 59.7-86.8), 90.7% (95% CI: 85.4-94.2), 94.3% (95% CI: 80.5-98.5) and 91.5%(95% CI:85.9-95.4), respectively. This was more sensitive and specific than the previous algorithm (accuracy 83.9%, sensitivity 95.5%, and specificity 54.6%).We developed a revised algorithm and a multimodality approach to stratify patients with chronic isolated TI into specific and nonspecific etiologies with an excellent diagnostic accuracy, which could potentially avoid missed diagnosis and unnecessary side effects of treatment.</ABSTRACT>'}]
2024-01-02 00:26:40,043 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,045 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448661, Requested 1545. Please try again in 27ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,045 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Five-year outcomes of digital diabetic eye screening in individuals aged 80 and 85 years.\nTo assess the incidence of referable diabetic retinopathy (DR) in patients aged 80 and 85 years to determine whether screening interval can be extended safely in this age group.Patients who were aged 80 and 85 years when they attended digital screening during April 2014-March 2015 were included. Screening results at baseline and over the next four years were analysed.1880 patients aged 80 and 1105 patients aged 85 were included. Patients referred to hospital eye service (HES) for DR ranged from 0.7% to 1.4% in the 80-year-old cohort over 5 years. In this cohort a total of 76 (4%) were referred to HES for DR, of which 11 (0.6%) received treatment. Over the course of the follow up (FU), 403 (21%) died. In the 85-year-old cohort, referral to HES for DR each year ranged from 0.1% to 1.3%. In this cohort a total of 27 (2.4%) were referred to HES for DR, of which 4 (0.4%) received treatment. Over the course of follow-up 541(49%) died. All treated cases were for maculopathy in both cohorts and there were no cases of proliferative diabetic retinopathy requiring treatment.This study showed that the risk of progression of retinopathy is quite low in this age group and only a small proportion of patients developed referable retinopathy requiring treatment. This suggests relooking at the need for screening and ideal screening intervals in patients aged 80 years and over with no referable DR as they can be potentially classed as a group with low risk of sight loss.</ABSTRACT>'}]
2024-01-02 00:26:40,052 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,053 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448530, Requested 1617. Please try again in 19ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,053 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Supervised Machine Learning Classifies Inflammatory Bowel Disease Patients by Subtype Using Whole Exome Sequencing Data.\nInflammatory bowel disease [IBD] is a chronic inflammatory disorder with two main subtypes: Crohn\'s disease [CD] and ulcerative colitis [UC]. Prompt subtype diagnosis enables the correct treatment to be administered. Using genomic data, we aimed to assess machine learning [ML] to classify patients according to IBD subtype.Whole exome sequencing [WES] from paediatric/adult IBD patients was processed using an in-house bioinformatics pipeline. These data were condensed into the per-gene, per-individual genomic burden score, GenePy. Data were split into training and testing datasets [80/20]. Feature selection with a linear support vector classifier, and hyperparameter tuning with Bayesian Optimisation, were performed [training data]. The supervised ML method random forest was utilised to classify patients as CD or UC, using three panels: 1] all available genes; 2] autoimmune genes; 3] \'IBD\' genes. ML results were assessed using area under the receiver operating characteristics curve [AUROC], sensitivity, and specificity on the testing dataset.A total of 906 patients were included in analysis [600 CD, 306 UC]. Training data included 488 patients, balanced according to the minority class of UC. The autoimmune gene panel generated the best performing ML model [AUROC = 0.68], outperforming an IBD gene panel [AUROC = 0.61]. NOD2 was the top gene for discriminating CD and UC, regardless of the gene panel used. Lack of variation in genes with high GenePy scores in CD patients was the best classifier of a diagnosis of UC.We demonstrate promising classification of patients by subtype using random forest and WES data. Focusing on specific subgroups of patients, with larger datasets, may result in better classification.</ABSTRACT>'}]
2024-01-02 00:26:40,056 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,057 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448538, Requested 1594. Please try again in 17ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,057 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Peak Serum Cortisol Cutoffs to Diagnose Adrenal Insufficiency Across Different Cortisol Assays in Children.\nCurrent peak serum cortisol cutoffs for the diagnosis of adrenal insufficiency (AI) after Cosyntropin stimulation have been established using polyclonal antibody (pAb) immunoassays. However, new and highly specific cortisol monoclonal antibody (mAb) immunoassays are being used more widely, which can potentially yield higher false positive rates. Thus, this study aimed to redefine the biochemical diagnostic cutoff points for AI in children when using a highly specific cortisol mAb immunoassay and liquid chromatography tandem mass spectrometry (LC/MS) to avoid unnecessary steroid use.Cortisol levels from 36 children undergoing 1 mcg Cosyntropin stimulation tests to rule out AI were measured using pAb immunoassay (Roche Elecsys Cortisol I), mAB immunoassay (Roche Elecsys Cortisol II), and LC/MS. Logistic regression was used to predict AI using the pAB as the reference standard. A receiver operator characteristic curve, area under the curve (AUC), sensitivity, specificity, and kappa agreement were also calculated.Using a peak serum cortisol cutoff value of 12.5 \u03bcg/dL for the mAb immunoassay provided 99% sensitivity and 94% specificity for diagnosing AI, when compared to the historical pAb immunoassay cutoff of 18 \u03bcg/dL (AUC=0.997). Likewise, a cutoff of value of 14 \u03bcg/dL using the LC/MS, provided 99% sensitivity and 88% specificity when compared to the pAb immunoassay (AUC=0.995).To prevent overdiagnosis of AI in children undergoing 1 mcg Cosyntropin stimulation test, our data support using a new peak serum cortisol cutoff of 12.5 \u03bcg/dL and 14 \u03bcg/dL to diagnose AI when using mAb immunoassays and LC/MS in children, respectively.</ABSTRACT>'}]
2024-01-02 00:26:40,069 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,070 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448424, Requested 1600. Please try again in 3ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,070 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>[Management optimization of neovascular age-related macular degeneration in Spain: Evolution towards proactive treatment models].\nHealthcare resources optimization is crucial to assume the growing demand of neovascular age-related macular degeneration (nAMD). This work provides guidelines and support so that each hospital can lead its change management.The OPTIMUS project (n=10 hospitals) was based on face-to-face interviews with the key staff of the ophthalmology services, and alignment with the main responsible for each centre (nominal group) to identify potential needs for improving nAMD. The OPTIMUS nominal group was expanded to 12 centres (eVOLUTION). Through different remote work sessions, different guides and tools were defined and developed to implement proactive treatment strategies, one-step treatment administration and potential for remote visits (eConsult) in nAMD.The information collected from the OPTIMUS interviews and working groups (n=10 centres) defined roadmaps to promote the development of protocols and proactive treatment strategies, including healthcare workload optimization and one-stop treatment administration in nAMD. With eVOLUTION, processes and tools were developed to promote eConsult: (i) healthcare burden calculator; (ii) definition of potential patients for telematic management; (iii) definition of nAMD management archetypes; (iv) definition of processes for implementation of eConsult by archetype; and (v) key performance indicators for changing evaluation.Managing change is an internal task that requires an adequate diagnosis of processes and feasible implementation roadmaps. OPTIMUS and eVOLUTION provide the basic tools for an autonomous advance of hospitals in the optimization of AMD management, with the available resources.</ABSTRACT>'}]
2024-01-02 00:26:40,087 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,089 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448395, Requested 1681. Please try again in 10ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,089 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Relations between nonmotor manifestations and motor disorders in patients with benign essential blepharospasm.\nTo evaluate the relations between nonmotor manifestations (dry eye, mood disorders, and sleep disturbance) and motor disorders in patients with benign essential blepharospasm (BEB), and to determine whether relieving motor disorders by botulinum neurotoxin can improve the nonmotor manifestations.In this prospective case series study, 123 BEB patients were enrolled for evaluations. Among them, 28 patients underwent botulinum neurotoxin therapy and attended another two postoperative visits at 1\xa0month and 3\xa0months. Motor severity was measured with Jankovic Rating Scale (JRS) and Blepharospasm Disability Index (BSDI). We assessed dry eye using OSDI questionnaire, Schirmer test, tear break-up time (TBUT), tear meniscus height, lipid layer thickness (LLT) and corneal fluorescence staining. Zung\'s Self-rating Anxiety and Depression Scale (SAS, SDS) and Pittsburgh Sleep Quality Index (PSQI) were for mood status and sleep quality evaluations.Patients with dry eye or mood disorders had higher JRS scores (5.78\u2009\u20091.13, 5.97\u2009\u20091.30) than those without (5.12\u2009\u20091.40, 5.50\u2009\u20091.16; P\u2009=\u20090.039, 0.019, respectively). BSDI values of patients with sleep disturbance (14.61\u2009\u20094.71) was higher than those without (11.89\u2009\u20095.44, P\u2009=\u20090.006). Correlations were found between JRS, BSDI and SAS, SDS, PSQI, OSDI, TBUT. Botulinum neurotoxin effectively relieved JRS, BSDI and improved PSQI, OSDI, TBUT, LLT (8.11\u2009\u20095.81, 21.77\u2009\u200915.76, 5.04\u2009\u20092.15\xa0s, 79.61\u2009\u200924.11\xa0nm) at the 1-month visit compared to baseline (9.75\u2009\u20095.60, 33.58\u2009\u200913.27, 4.14\u2009\u20092.21\xa0s, 62.33\u2009\u200922.01\xa0nm; P\u2009=\u20090.006,\u2009<\u20090.001,\u2009=\u20090.027,\u2009<\u20090.001, respectively).The BEB patients with dry eye, mood disorders, or sleep disturbance had more severe motor disorders. Motor severity was associated with the severity of the nonmotor manifestations. Relieving motor disorders by botulinum neurotoxin was effective in improving dry eye and sleep disturbance.</ABSTRACT>'}]
2024-01-02 00:26:40,096 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,098 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449858, Requested 1607. Please try again in 195ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,098 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Peripapillary Vitreous Traction Syndrome: Expanding the Spectrum of Anterior Optic Neuropathies.\nPeripapillary vitreous traction (PVT) occurring without any underlying eye disease has been contemplated as a distinct entity from nonarteritic ischemic optic neuropathy (NAION) for many years and is sometimes difficult to differentiate from classical NAION. We report 6 new cases to analyze the clinical features of PVT syndrome that would expand the clinical spectrum of anterior optic neuropathies.Prospective case series.PVT syndrome seems to affect optic discs with a small area with a small cup-to-disc (C/D) ratio. The C/D ratio does not significantly increase in the chronic stage, as in NAION. Vitreous traction without detachment can either lead to mild retinal nerve fiber layer (RNFL) injury with attendant ganglion cell layer/inner plexiform layer (GCL/IPL) thinning in 29% or no injury at all in 71%. Eighty-six percent had good visual acuity (VA) and had no relative afferent pupillary defect (RAPD), whereas 14% had a transient RAPD; 71% had no color defect. Vitreous detachment after a period of severe and persistent traction can lead to more damage to the optic nerve head and RNFL that may look like NAION. Our hypothesized mechanically induced injury to the superficial optic nerve head may not lead to much visual impairment. In our study, no further therapeutic interventions were required.Based on our analysis of previously published cases and our own prospective case series of 6 patients, the PVT syndrome falls within the spectrum of anterior optic neuropathies, often affecting small optic discs with a small C/D ratio. Vitreous traction can lead to a partial or complete anterior optic neuropathy. The PVT syndrome may be a "more" anterior optic neuropathy distinct from classical NAION.</ABSTRACT>'}]
2024-01-02 00:26:40,105 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,106 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449811, Requested 1633. Please try again in 192ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,106 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Preliminary characterization of a novel form of progressive retinal atrophy in the German Spitz dog associated with a frameshift mutation in GUCY2D.\nTo describe the clinical, preliminary electroretinographic and optical coherence tomography features of a newly identified form of progressive retinal atrophy (PRA) in German Spitzes, and identify the causal gene mutation.Thirty-three client-owned German Spitz dogs were included.All animals underwent a full ophthalmic examination, including vision testing. In addition, fundus photography, ERG, and OCT were performed. A DNA-marker-based association analysis was performed to screen potential candidate genes and the whole genomes of four animals were sequenced.Initial fundus changes were pale papilla and mild vascular attenuation. Oscillatory nystagmus was noted in 14 of 16 clinically affected puppies. Vision was impaired under both scotopic and photopic conditions. Rod-mediated ERGs were unrecordable in all affected dogs tested, reduced cone-mediated responses were present in one animal at 3\xa0months of age and unrecordable in the other affected animals tested. Multiple small retinal bullae were observed in three clinically affected animals (two with confirmed genetic diagnosis). OCT showed that despite loss of function, retinal structure was initially well-preserved, although a slight retinal thinning developed in older animals with the ventral retina being more severely affected. Pedigree analysis supported an autosomal recessive inheritance. A mutation was identified in GUCY2D, which segregated with the disease (NM_001003207.1:c.1598_1599insT; p.(Ser534GlufsTer20)). Human subjects with GUCY2D mutations typically show an initial disconnect between loss of function and loss of structure, a feature recapitulated in the affected dogs in this study.We identified early-onset PRA in the German Spitz associated with a frameshift mutation in GUCY2D.</ABSTRACT>'}]
2024-01-02 00:26:40,116 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,118 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449695, Requested 1464. Please try again in 154ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,118 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>A paradigm shift in the treatment of refractory angle closure glaucoma in a patient with X-linked juvenile retinoschisis.\nX-linked retinoschisis (XLRS) is a rare inherited bilateral retinal degeneration caused by mutations in RS1 gene, occurring exclusively in men. Various ocular complications associated with XLRS are reported, and angle closure glaucoma in these eyes is one such complication that is refractory and needs surgery for intraocular pressure control. Glaucoma surgery in these eyes often results in refractory malignant glaucoma with its serious sequelae. Several surgical modifications to prevent this complication have been tried with no or limited success.In this report, we present a case of XLRS in a young male with a 22-year follow-up. We have described the natural history and progression of retinal disease and glaucoma.Refractory angle closure glaucoma in our patient was treated with core vitrectomy, phacoemulsification with intraocular lens implantation, and irido-zonulo-hyaloido-vitrectomy. This helped in successful deepening of anterior chamber, good IOP control, and preventing malignant glaucoma.Our case highlights the role of vitrectomy in managing the secondary angle closure glaucoma in eyes with X-LRS.</ABSTRACT>'}]
2024-01-02 00:26:40,128 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,129 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449569, Requested 1170. Please try again in 98ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,129 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Meibomian Gland Dysfunction as a Manifestation of IFAP Syndrome.\n</ABSTRACT>'}]
2024-01-02 00:26:40,132 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,133 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449589, Requested 1614. Please try again in 160ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,133 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Understanding the Genetics of Early-Onset Obesity in a Cohort of Children From Qatar.\nMonogenic obesity is a rare form of obesity due to pathogenic variants in genes implicated in the leptin-melanocortin signaling pathway and accounts for around 5% of severe early-onset obesity. Mutations in the genes encoding the MC4R, leptin, and leptin receptor are commonly reported in various populations to cause monogenic obesity. Determining the genetic cause has important clinical benefits as novel therapeutic interventions are now available for some forms of monogenic obesity.To unravel the genetic causes of early-onset obesity in the population of Qatar.In total, 243 patients with early-onset obesity (above the 95% percentile) and age of onset below 10 years were screened for monogenic obesity variants using a targeted gene panel, consisting of 52 obesity-related genes.Thirty rare variants potentially associated with obesity were identified in 36 of 243 (14.8%) probands in 15 candidate genes (LEP, LEPR, POMC, MC3R, MC4R, MRAP2, SH2B1, BDNF, NTRK2, DYRK1B, SIM1, GNAS, ADCY3, RAI1, and BBS2). Twenty-three of the variants identified were novel to this study and the rest, 7 variants, were previously reported in literature. Variants in MC4R were the most common cause of obesity in our cohort (19%) and the c.485C>T p.T162I variant was the most frequent MC4R variant seen in 5 patients.We identified likely pathogenic/pathogenic variants that seem to explain the phenotype of around 14.8% of our cases. Variants in the MC4R gene are the commonest cause of early-onset obesity in our population. Our study represents the largest monogenic obesity cohort in the Middle East and revealed novel obesity variants in this understudied population. Functional studies will be required to elucidate the molecular mechanism of their pathogenicity.</ABSTRACT>'}]
2024-01-02 00:26:40,137 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,138 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449571, Requested 1315. Please try again in 118ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,138 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>RPGR-Related Retinopathy: Clinical Features, Molecular Genetics, and Gene Replacement Therapy.\nRetinitis pigmentosa GTPase regulator (RPGR) gene variants are the predominant cause of X-linked retinitis pigmentosa (XLRP) and a common cause of cone-rod dystrophy (CORD). XLRP presents as early as the first decade of life, with impaired night vision and constriction of peripheral visual field and rapid progression, eventually leading to blindness. In this review, we present RPGR gene structure and function, molecular genetics, animal models, RPGR-associated phenotypes and highlight emerging potential treatments such as gene-replacement therapy.</ABSTRACT>'}]
2024-01-02 00:26:40,144 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,146 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449458, Requested 1175. Please try again in 84ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,146 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Location of Retinal Pigment Epithelial Cells in the Eye Is Critical to Their Function.\n</ABSTRACT>'}]
2024-01-02 00:26:40,158 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,160 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449477, Requested 1541. Please try again in 135ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,160 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Alterations in retrobulbar haemodynamics in thyroid eye disease.\nTo study the orbital perfusion parameters of ophthalmic artery (OA) and central retinal artery (CRA) in inactive TED and the changes following surgical decompression.Non-randomised clinical trial. 24 inactive moderate-to-severe TED orbits of 24 euthyroid cases underwent surgical decompression and examined again at 3 months. The peak systolic velocity (PSV), end-diastolic velocity (EDV), and resistivity index (RI) of OA and CRA were evaluated using colour doppler imaging and normative database was established using 18 healthy controls.The mean age was 39.38\u2009\u200912.56 years and male: female ratio was 1: 1.18. Intraocular pressure was higher, and CRA-PSV, CRA-RI, OA-PSV, and OA-EDV were lower in TED in comparison to heathy orbits. The CRA-PSV, CRA-EDV, OA-PSV, and OA-EDV negatively correlated with proptosis and duration of thyroid disease. The area under curve of OA-PSV (95% CI:0.964-1.000, p\u2009<\u20090.001) and OA-EDV (95% CI:0.699-0.905, p\u2009<\u20090.001) helped in differentiating TED orbits from HC, and in predicting the severity of disease. Post decompression, CRA-PSV, CRA-EDV, OA-PSV, and OA-EDV improved, with decrease in CRA-RI and OA-RI in both lipogenic and MO.The orbital perfusion is reduced in inactive TED. The changes in OA flow velocities can help in differentiating inactive TED from healthy orbits and progression of TED. Sequential orbital CDI of OA and CRA can serve as an objective tool for case selection and monitoring response to surgical decompression.</ABSTRACT>'}]
2024-01-02 00:26:40,166 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:40,167 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,167 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:40,169 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449133, Requested 1651. Please try again in 104ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,169 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Bacterial Oncotraits Rather than Spatial Organization Are Associated with Dysplasia in Ulcerative Colitis.\nColonic bacterial biofilms are frequently present in ulcerative colitis [UC] and may increase dysplasia risk through pathogens expressing oncotraits. This prospective cohort study aimed to determine [1] the association of oncotraits and longitudinal biofilm presence with dysplasia risk in UC, and [2] the relation of bacterial composition with biofilms and dysplasia risk.Faeces and left- and right-sided colonic biopsies were collected from 80 UC patients and 35 controls. Oncotraits [FadA of Fusobacterium, BFT of Bacteroides fragilis, colibactin [ClbB] and Intimin [Eae] of Escherichia coli] were assessed in faecal DNA with multiplex quantitative polymerase chain reaction [qPCR]. Biopsies were screened for biofilms [n\u2005=\u2005873] with 16S rRNA fluorescent in situ hybridiation. Shotgun metagenomic sequencing [n\u2005=\u2005265], and ki67-immunohistochemistry were performed. Associations were determined with a mixed-effects regression model.Biofilms were highly prevalent in UC patients [90.8%] with a median persistence of 3 years (interquartile range [IQR] 2-5 years). Biofilm-positive biopsies showed increased epithelial hypertrophy [p\u2005=\u20050.025] and a reduced Shannon diversity independent of disease status [p\u2005=\u20050.015], but were not significantly associated with dysplasia in UC: adjusted odds ratio [aOR] 1.45, 95% confidence interval [CI] 0.63-3.40. In contrast, ClbB independently associated with dysplasia [aOR 7.16, 95% CI 1.75-29.28], and FadA and Fusobacteriales were associated with a decreased dysplasia risk in UC [aOR 0.23, 95% CI 0.06-0.83, p\u2005<0.01].Biofilms are a hallmark of UC; however, because of their high prevalence are a poor biomarker for dysplasia. In contrast, colibactin presence and FadA absence independently associate with dysplasia in UC and might therefore be valuable biomarkers for future risk stratification and intervention strategies.</ABSTRACT>'}]
2024-01-02 00:26:40,183 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,184 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448646, Requested 1565. Please try again in 28ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,184 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial.\nTo assess the safety and efficacy of avacincaptad pegol (ACP), a C5 inhibitor, for geographic atrophy (GA) secondary to age-related macular degeneration (AMD) over an 18-month treatment course.This study was an international, prospective, randomized, double-masked, sham-controlled, phase 2/3 clinical trial that consisted of 2 parts. In part 1, 77 participants were randomized 1:1:1 to receive monthly intravitreal injections of ACP 1\u2009mg, ACP 2\u2009mg, or sham. In part 2, 209 participants\xa0were randomized 1:2:2 to receive monthly ACP 2\u2009mg, ACP 4\u2009mg, or sham. The mean rate of change of GA over 18 months was measured by fundus autofluorescence.Compared with their respective sham cohorts, monthly ACP treatment reduced the mean GA growth (square root transformation) over 18 months by 28.1% (0.168\u2009mm, 95% CI [0.066, 0.271]) for the 2\u2009mg cohort and 30.0% (0.167\u2009mm, 95% CI [0.062, 0.273]) for the 4\u2009mg cohort. ACP treatment was generally well tolerated over 18 months, with most ocular adverse events (AEs) related to the injection procedure. Macular neovascularization (MNV) was more frequent in both 2\u2009mg (11.9%) and 4\u2009mg (15.7%) cohorts than their respective sham control groups (2.7% and 2.4%).Over this 18-month study, ACP 2\u2009mg and 4\u2009mg showed continued reductions in the progression of GA growth compared to sham and continued to be generally well tolerated. A pivotal phase 3 GATHER2 trial is currently underway to support the efficacy and safety of ACP as a potential treatment for GA.</ABSTRACT>'}]
2024-01-02 00:26:40,188 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,189 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:40,193 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448619, Requested 1649. Please try again in 35ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,193 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Thiopurines Have Longer Treatment Durability than Methotrexate in Adults and Children with Crohn\'s Disease: A Nationwide Analysis from the epi-IIRN Cohort.\nThiopurines and methotrexate have long been used to maintain remission in Crohn\'s disease [CD]. In this nationwide study, we aimed to compare the effectiveness and safety of these drugs in CD.We used data from the epi-IIRN cohort, including all patients with CD diagnosed in Israel. Outcomes were compared by propensity-score matching and included therapeutic failure, hospitalisations, surgeries, steroid dependency, and adverse events.Of the 19264 patients diagnosed with CD since 2005, 3885 [20%] ever received thiopurines as monotherapy and 553 [2.9%] received methotrexate. Whereas the use of thiopurines declined from 22% in 2012-2015 to 12% in 2017-2020, the use of methotrexate remained stable. The probability of sustaining therapy at 1, 3, and 5 years was 64%, 51%, and 44% for thiopurines and 56%, 30%, and 23% for methotrexate, respectively [p\u2005<0.001]. Propensity-score matching, including 303 patients [202 with thiopurines, 101 with methotrexate], demonstrated a higher rate of 5-year durability for thiopurines [40%] than methotrexate [18%; p\u2005<0.001]. Time to steroid dependency [p\u2005=\u20050.9], hospitalisation [p\u2005=\u20050.8], and surgery [p\u2005=\u20050.1] were comparable between groups. These outcomes reflect also shorter median time to biologics with methotrexate (2.2 [IQR 1.6-3.1 years) versus thiopurines (6.6 [2.4-8.5]; p\u2005=\u20050.02). The overall adverse events rate was higher with thiopurines [20%] than methotrexate [12%; p\u2005<0.001], including three lymphoma cases in males, although the difference was not significant [4.8 vs 0 cases/10 000 treatment-years, respectively; p\u2005=\u20050.6].Thiopurines demonstrated higher treatment durability than methotrexate but more frequent adverse events. However, disease outcomes were similar, partly due to more frequent escalation to biologics with methotrexate.</ABSTRACT>'}]
2024-01-02 00:26:40,213 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,215 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,217 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449648, Requested 1451. Please try again in 146ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,217 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Truxima (rituximab-abbs) for Periocular Xanthogranuloma with Adult-Onset Asthma and Systemic IgG4-Related Disease.\nA 58-year-old female with a 3-year history of adult-onset asthma, bilateral blepharoptosis, dry eye, and yellow-orange xanthelasma-like plaques extensively involving both upper eyelids presented with a diagnosis of adult-onset asthma with periocular xanthogranuloma (AAPOX) and systemic IgG4-related disease. Over the next 8 years, she received 10 intralesional triamcinolone injections (40-80\u2009mg) in the right upper eyelid, 7 intralesional triamcinolone injections (30-60\u2009mg) in the left upper eyelid, underwent right anterior orbitotomy twice followed by 4 doses of rituximab (1000\u2009mg intravenous infusion) without regression of the AAPOX. The patient was then treated with 2 monthly doses of Truxima (1000\u2009mg intravenous infusion), a biosimilar to rituximab. At the most recent follow-up, 13 months later, the xanthelasma-like plaques and orbital infiltration had markedly improved. To the best of the authors\' knowledge, this is the first report of Truxima being used to treat AAPOX with systemic IgG4-related disease and to generate a sustained clinical response.</ABSTRACT>'}]
2024-01-02 00:26:40,220 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449696, Requested 1525. Please try again in 162ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,220 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>CXCL8 as a Potential Biomarker for Crohn\'s Disease is Associated with Immune Infiltration and RNA Methylation.\nTRP channels have an important role in regulating the function of gastrointestinal epithelial cells. The aim of this study was to investigate the molecular mechanisms of genes associated with TRP channels in Crohn\'s disease (CD) by bioinformatics approach and to identify potential key biomarkers. In our study, we identified TRP channel-related differentially expressed genes (DEGs) based on the GSE95095 dataset and the TRP channel-related gene set from the GeneCards database. Hub genes (CXCL8, HIF1A, NGF, JUN, IL1A) were identified by the PPI network and validated by the external GSE52746 dataset. Immune infiltration analysis revealed that CXCL8 was significantly correlated with B cells memory, NK cells activated, Mast cells resting, Mast cells activated, and Neutrophils. GSEA of CXCL8 results showed inositol phosphate metabolism, RNA polymerase, propanoate metabolism, MAPK signaling pathway, base excision repair, and Calcium signaling pathway. In addition, we constructed a lncRNA-miRNA-mRNA ceRNA network and a drug-gene interaction network. Finally, we performed in vitro experiments to verify that LPS induced CXCL8 expression in HT-29 cells and that knockdown of CXCL8 inhibited the inflammatory stimulatory effects of LPS. This study reveals that CXCL8 plays an important role in the pathogenesis of Crohn\'s disease and is expected to be a novel biomarker.</ABSTRACT>'}]
2024-01-02 00:26:40,238 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:40,261 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,264 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,266 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449096, Requested 1555. Please try again in 86ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,266 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Tear film lipid layer and corneal oxygenation: a new function?\nThe classic model of tear film is composed of mucin layer, aqueous layer and the outermost tear film lipid layer (TFLL). The complex mixture of different classes of lipids, mainly secreted by meibomian glands, gives the TFLL unique physicochemical properties. Based on these properties, several functions of TFLL have been found and/or proposed such as the resistance to evaporation and facilitating the formation of a thin film. However, the role of TFLL in the oxygenation of the cornea, a transparent avascular tissue, has never been discussed in the literature. The continuous metabolic activity of the corneal surface and the replenishment of atmospheric gas creates an O2 gradient in the tear film. The molecules of O2 must therefore be transferred from the gas phase to the liquid phase through the TFLL. This process is a function of the diffusion and solubility of the lipid layer as well as interface transfer, which is influenced by alterations in the physical state and lipid composition. In the absence of research on TFLL, the present paper aims to bring the topic into the spotlight for the first time based on existing knowledge on O2 permeability of the lipid membranes and evaporation resistance of the lipid layers. The oxidative stress generated in perturbed lipid layers and the consequent adverse effects are also covered. The function of the TFLL proposed here intends to encourage future research in both basic and clinical sciences, e.g., opening new avenues for the diagnosis and treatment of ocular surface conditions.</ABSTRACT>'}]
2024-01-02 00:26:40,269 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449041, Requested 1784. Please try again in 110ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,269 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>A Detailed Review of Molecular Pathways and Mechanisms Responsible for the Development and Aggravation of Neuropathy and Nephropathy in Diabetes.\nDiabetic mellitus is responsible for triggering many conditions, such as neuropathy, nephropathy, and retinopathy. Hyperglycemia leads to the development of oxidative stress conditions, activation of pathways, and generation of metabolites, leading to complications like neuropathy and nephropathy.This paper aims to discuss the mechanism of actions, pathways, and metabolites triggered due to the development of neuropathy and nephropathy post-long-haul diabetes in patients. The therapeutic targets are also highlighted, proving to be a potential cure for such conditions.Research works were searched from international and national databases with keywords like "diabetes," "diabetic nephropathy," "NADPH," "oxidative stress," "PKC," "Molecular mechanisms," " cellular mechanisms," "complications of diabetes," and "factors." The databases searched were PubMed, Scopus, Directory of open access journals, Semantic Scholar, Core, Europe PMC, EMBASE, Nutrition, FSTA- Food Science and Technology, Merck Index, Google Scholar, PubMed, Science Open, MedlinePlus, Indian citation index, World Wide Science, and Shodhganga.Pathways causing protein kinase C (PKC) activation, free radical injury, oxidative stress, and aggravating the conditions of neuropathy and nephropathy were discussed. In diabetic neuropathy and nephropathy, neurons and nephrons are affected to the extent that their normal physiology is disturbed, thus leading to further complications and conditions of loss of nerve sensation in diabetic neuropathy and kidney failure in diabetic nephropathy. Current treatment options available for the management of diabetic neuropathy are anticonvulsants, antidepressants, and topical medications, including capsaicin. According to AAN guidelines, pregabalin is recommended as the first line of therapy, whereas other drugs currently used for treatment are gabapentin, venlafaxine, opioids, amitriptyline, and valproate. Drug targets for treating diabetic neuropathy must suppress the activated polyol pathways, kinase C, hexosamine, and other pathways, which amplify neuroinflammation. Targeted therapy must focus on the reduction of oxidative stress and proinflammatory cytokines and suppression of neuroinflammation, NF-\u03baB, AP-1, etc. Conclusion: Potential drug targets must be considered for new research on the treatment of neuropathy and nephropathy conditions.</ABSTRACT>'}]
2024-01-02 00:26:40,273 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,275 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449062, Requested 1555. Please try again in 82ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,275 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Impact of Vedolizumab on Extraintestinal Manifestations in Inflammatory Bowel Disease: Results From a Descriptive, Retrospective, Real-world Study.\nPatients with inflammatory bowel disease (IBD), including Crohn\'s disease and ulcerative colitis, may develop extraintestinal manifestations (EIMs). The EMOTIVE study aimed to analyze the effect of vedolizumab on EIMs in a real-world cohort of patients with IBD.This multicenter, descriptive, retrospective study was conducted in Belgium, Denmark, Israel, the Netherlands, and Switzerland in adults with moderately to severely active IBD and concurrent active EIMs at vedolizumab initiation (index date), with a \u22656-month follow-up after the index date. The primary endpoint was resolution of all EIMs within 6 months of vedolizumab initiation.In 99 eligible patients, the most frequent EIMs were arthralgia (69.7%), peripheral spondyloarthritis (21.2%), and axial spondyloarthritis (10.1%). Within 6 and 12 months of vedolizumab initiation, 19.2% and 25.3% of patients reported resolution of all EIMs, while 36.5% and 49.5% of all EIMs were reported to be improved (combination of resolution and partial response), respectively. Vedolizumab treatment persistence at 12 months was 82.8%. Adverse events were reported in 18.2% of patients, with the most frequent being arthralgia (4.0%).This real-world study showed resolution of all EIMs in up to one-fourth of patients with IBD and improvement in up to half of EIMs within 12 months of vedolizumab treatment. Overall, vedolizumab was effective on EIMs in patients with IBD and showed a good safety profile.</ABSTRACT>'}]
2024-01-02 00:26:40,278 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,279 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,282 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449091, Requested 1609. Please try again in 93ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,282 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Racial Disparities in Barriers to Care for Patients With Diabetic Retinopathy in a Nationwide Cohort.\nTo ascertain specific barriers of care among patients with diabetic retinopathy (DR) from different racial/ethnic groups.In this cross-sectional study, we included adult participants in the National Institutes of Health All of Us Research Program with DR who answered questions in the Healthcare Access & Utilization survey and Social Determinants of Health (SDoH) survey. Logistic regression was used to study the association between barriers to care and race/ethnicity.Our cohort included 885 DR patients who answered the Healthcare Access & Utilization survey and 385 DR patients who responded to the SDoH survey. After adjusting for confounders, Hispanic individuals were more likely than non-Hispanic White individuals to report delaying getting medical care due to not being able to get child care (odds ratio [OR] = 6.57 [95% confidence interval {CI}, 1.67-27.8]). Furthermore, compared to non-Hispanic White individuals, non-Hispanic Black individuals were significantly more likely to report being treated with less respect (OR = 2.62 [95% CI, 1.15-5.80]), treated with less courtesy (OR = 2.51 [95% CI, 1.01-5.92]), and receive poorer service than other people (OR = 2.85 [95% CI, 1.25-6.34]) when they go to a doctor\'s office or other healthcare provider.We found that Hispanic and non-Hispanic Black individuals with DR reported greater delays/barriers to care compared to non-Hispanic White individuals even after controlling for individualized socioeconomic factors.This study highlights the importance of taking steps to promote health equity, such as increasing access to child care resources and reducing implicit bias among eye care providers, to increase access to care and prevent vision loss from DR.</ABSTRACT>'}]
2024-01-02 00:26:40,284 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448941, Requested 1561. Please try again in 66ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,284 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Mechanical Circulatory Assistance in Children: Clinical Outcome.\nIn countries where organ donation is scarce, mortality in the pediatric heart transplant waiting list is high, and ventricular assist devices (VADs) are therapeutic alternatives in these situations. Berlin Heart EXCOR is currently 1 of the few VADs specific for children.This retrospective study includes pediatric patients who underwent Berlin Heart EXCOR placement in a Brazilian hospital between 2012 and 2021. Clinical and laboratory data at the time of VAD implantation and the occurrence of complications and outcomes (success as a bridge to transplant or death) were analyzed.Eight patients, from 8 months to 15 years, were included: 6 with cardiomyopathy and 2 with congenital heart disease. Six were on Intermacs 1 and 2 on Intermacs 2. The most common complications observed were stroke and right ventricular dysfunction. Six were transplanted, and 2 died. Those submitted to transplant had a higher mean weight than those who died, with no statistically significant difference. The underlying disease had no impact on the outcome. The group undergoing transplant had lower brain natriuretic peptide and lactate values, but no laboratory variable showed a statistically significant difference in the outcome.A VAD is an invasive treatment with potentially serious adverse effects and is still poorly available in Brazil. However, as a bridge to transplant, it is a useful treatment for children in progressive clinical decline. In this study, we did not observe any clinical or laboratory factor at the time of VAD implantation that implied better outcomes.</ABSTRACT>'}]
2024-01-02 00:26:40,294 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,295 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448716, Requested 1664. Please try again in 50ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,295 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Intraocular Pressure and Rates of Macular Thinning in Glaucoma.\nTo evaluate the effect of intraocular pressure (IOP) on the rates of macular thickness (ganglion cell layer [GCL] and ganglion cell-inner plexiform layer [GCIPL]) change over time measured by spectral-domain (SD) OCT.Retrospective cohort study.Overall, 451 eyes of 256 patients with primary open-angle glaucoma.Data were extracted from the Duke Ophthalmic Registry, a database of electronic medical records of patients observed under routine clinical care at the Duke Eye Center, and satellite clinics. All records from patients with a minimum of 6 months of follow-up and at least 2 good-quality Spectralis SD-OCT macula scans were included. Linear mixed models were used to investigate the relationship between average IOP during follow-up and rates of GCL and GCIPL thickness change over time.The effect of IOP on the rates of GCL and GCIPL thickness loss measured by SD-OCT.Eyes had a mean follow-up of 1.8  1.3 years, ranging from 0.5 to 10.2 years. The average rate of change for GCL thickness was\xa0-0.220 \u03bcm/year (95% confidence interval [CI],\xa0-0.268 to\xa0-0.172 \u03bcm/year) and for GCIPL thickness was\xa0-0.231 \u03bcm/year (95% CI,\xa0-0.302 to\xa0-0.160 \u03bcm/year). Each 1-mmHg higher mean IOP during follow-up was associated with an additional loss of\xa0-0.021 \u03bcm/year of GCL thickness (P\xa0= 0.001) and\xa0-0.032 \u03bcm/year of GCIPL thickness (P\xa0= 0.001) after adjusting for potentially confounding factors, such as baseline age, disease severity, sex, race, central corneal thickness, and follow-up time.Higher IOP was significantly associated with faster rates of GCL and GCIPL loss over time measured by SD-OCT, even during relatively short follow-up times. These findings support the use of SD-OCT GCL and GCIPL thickness measurements as structural biomarkers for the evaluation of the efficacy of IOP-lowering therapies in slowing down the progression of glaucoma.Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</ABSTRACT>'}]
2024-01-02 00:26:40,304 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,305 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448780, Requested 2308. Please try again in 145ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,305 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Fetal growth restriction and small for gestational age as predictors of neonatal morbidity: which growth nomogram to use?\nFetal growth nomograms were developed to screen for fetal growth restriction and guide clinical care to improve perinatal outcomes; however, existing literature remains inconclusive regarding which nomogram is the gold standard.This study aimed to compare the ability of 4 commonly used nomograms (Hadlock, International Fetal and Newborn Growth Consortium for the 21st Century, Eunice Kennedy Shriver National Institute of Child Health and Human Development-unified standard, and World Health Organization fetal growth charts) and 1 institution-specific reference to predict small for gestational age and poor neonatal outcomes.This was a retrospective cohort study of all nonanomalous singleton pregnancies undergoing ultrasound at \u226520 weeks of gestation between 2013 and 2020 and delivering at a single academic center. Using random selection methods, the study sample was restricted to 1 pregnancy per patient and 1 ultrasound per pregnancy completed at \u226522 weeks of gestation. Fetal biometry data were used to calculate estimated fetal weight and percentiles according to the aforementioned 5 nomograms. Maternal and neonatal data were extracted from electronic medical records. Logistic regression was used to estimate the association between estimated fetal weight of <10th and <3rd percentiles compared with estimated fetal weight of 10th to 90th percentile as the reference group for small for gestational age and the neonatal composite outcomes (perinatal mortality, hypoxic-ischemic encephalopathy or seizures, respiratory morbidity, intraventricular hemorrhage, necrotizing enterocolitis, hyperbilirubinemia or hypoglycemia requiring neonatal intensive care unit admission, and retinopathy of prematurity). Receiver operating characteristic curve contrast estimation (primary analysis) and test characteristics were calculated for all nomograms and the prediction of small for gestational age and the neonatal composite outcomes. We restricted the sample to ultrasounds performed within 28 days of delivery; moreover, similar analyses were completed to assess the prediction of small for gestational age and neonatal composite outcomes.Among 10,045 participants, the proportion of fetuses classified as <10th percentile varied across nomograms from 4.9% to 9.7%. Fetuses with an estimated fetal weight of <10th percentile had an increased risk of small for gestational age (odds ratio, 9.9 [95% confidence interval, 8.5-11.5] to 12.8 [95% confidence interval, 10.9-15.0]). In addition, the estimated fetal weight of <10th and <3rd percentile was associated with increased risk of the neonatal composite outcome (odds ratio, 2.4 [95% confidence interval, 2.0-2.8] to 3.5 [95% confidence interval, 2.9-4.3] and 5.7 [95% confidence interval, 4.5-7.2] to 8.8 [95% confidence interval, 6.6-11.8], respectively). The prediction of small for gestational age with an estimated fetal weight of <10th percentile had a positive likelihood ratio of 6.3 to 8.5 and an area under the curve of 0.62 to 0.67. Similarly, the prediction of the neonatal composite outcome with an estimated fetal weight of <10th percentile had a positive likelihood ratio of 2.1 to 3.1 and an area under the curve of 0.55 to 0.57. When analyses were restricted to ultrasound within 4 weeks of delivery, among fetuses with an estimated fetal weight of <10th percentile, the risk of small for gestational age increased across all nomograms (odds ratio, 16.7 [95% confidence interval, 12.6-22.3] to 25.1 [95% confidence interval, 17.0-37.0]), and prediction improved (positive likelihood ratio, 8.3-15.0; area under the curve, 0.69-0.75). Similarly, the risk of neonatal composite outcome increased (odds ratio, 3.2 [95% confidence interval, 2.4-4.2] to 5.2 [95% confidence interval, 3.8-7.2]), and prediction marginally improved (positive likelihood ratio, 2.4-4.1; area under the curve, 0.60-0.62). Importantly, the risk of both being small for gestational age and having the neonatal composite outcome further increased (odds ratio, 21.4 [95% confidence interval, 13.6-33.6] to 28.7 (95% confidence interval, 18.6-44.3]), and the prediction of concurrent small for gestational age and neonatal composite outcome greatly improved (positive likelihood ratio, 6.0-10.0; area under the curve, 0.80-0.83).In this large cohort, Hadlock, recent fetal growth nomograms, and a local population-derived fetal growth reference performed comparably in the prediction of small for gestational age and neonatal composite outcomes.</ABSTRACT>'}]
2024-01-02 00:26:40,310 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,314 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448805, Requested 1596. Please try again in 53ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,314 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Park7 protects retinal ganglion cells and promotes functional preservation after optic nerve crush via regulation of the Nrf2 signaling pathway.\nWe aim to investigate the effect of Park7 on mice RGC survival and function following optic nerve crush (ONC), and to explore its potential mechanism.Wild-type male C57BL/6J mice were subjected to optic nerve crush. Six weeks before ONC, mice received rAAV-shRNA (Park7)-EGFP or rAAV-EGFP intravitreally. Western blotting was used to detect Park7 levels. RGC survival was measured using immunofluorescence. Retinal cell apoptosis was detected using terminal deoxynucleotidyl transferase nick-end-labelling. An electroretinogram (ERG) and the optomotor response (OMR) were used to assess RGC function. Kelch-like ECH-associated protein 1 (Keap1), nuclear factor erythroid 2-related factor (Nrf2), and heme oxygenase 1 (HO-1) levels were assessed using western blotting.ONC injury increased the relative expression of Park7 significantly and decreased RGC survival, the amplitude of the photopic negative response (PhNR), and OMR. Intravitreal injection of rAAV-shRNA(Park7)-EGFP downregulated Park7 expression and was clearly demonstrated by the green fluorescence protein in many retinal layers. Moreover, Park7 downregulation aggravated the decrease in RGC survival and amplitude of PhNR as well as the visual acuity after ONC. However, inhibition of Park7 significantly increased Keap1 levels, decreased the total and nuclear Nrf2 levels, and reduced HO-1 levels.Park7 downregulation enhanced RGC injury and decreased retinal electrophysiological response and OMR after ONC in mice via the Keap1-Nrf2-HO-1 signaling pathway. Park7 may have neuroprotective effects and could represent a novel way to treat optic neuropathy.</ABSTRACT>'}]
2024-01-02 00:26:40,344 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,345 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,345 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,348 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,351 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448490, Requested 1629. Please try again in 15ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,351 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Perspectives on the Role of P21-Activated Kinase 1 (PAK1) in the Intestinal Anti-inflammatory and Antitumor Potential of Artepillin C.\nThe Brazilian biodiversity may bring new perspectives to the therapy of Inflammatory Bowel Diseases (IBD) and intestinal cancer. The effect of Brazilian Green Propolis in reducing ulcerative colitis in mice has already been described, as well as high amounts of the prenylated compound Artepellin C (ARC). The search for new pharmacological targets for IBD is also advancing. Among possibilities is the p21-activated kinase (PAK1), overexpressed and activated in the intestinal mucosa during IBD and colitis-associated colorectal cancer (CAC). PAK 1 contributes to tissue inflammation by reducing the expression of peroxisome proliferator-activated receptor type \u03b3 (PPAR47) and increasing activation of nuclear factor (NF)-\u03baB. At least in vitro, inhibition of PAK1 has been reported to mitigate NF-\u03baB-mediated inflammation in intestinal cells and ARC inhibits PAK1 activation. Given this pharmacological potential of ARC and the role of PAK1 in IBD and CAC, this perspective collected information that encourages future research to test the hypothesis that ARC can maintain intestinal integrity under the inflammatory and neoplastic stimulus and that inhibition of PAK1/NF-\u03baB signaling and favoring PPAR-\u03b3 activity is pivotal in this action. Therefore, future studies employing in vitro and in vivo steps, using murine and human enterocytes and rodents submitted to ulcerative colitis and CAC models are incentivized by the data gathered here, favor retirar essas palavras: mostly in vitro studies, before clinical trials. Therefore, the perspective presented here points to an interesting path in the search for a drug useful in inflammatory and neoplastic intestinal diseases, which may have ARC as a prototype, acting on a target not yet explored clinically.</ABSTRACT>'}]
2024-01-02 00:26:40,352 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448491, Requested 1625. Please try again in 15ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,352 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Biomarkers for the Diagnosis of Heart Failure in People with Diabetes: A Consensus Report from Diabetes Technology Society.\nDiabetes Technology Society assembled a panel of clinician experts in diabetology, cardiology, clinical chemistry, nephrology, and primary care to review the current evidence on biomarker screening of people with diabetes (PWD) for heart failure (HF), who are, by definition, at risk for HF (Stage A HF). This consensus report reviews features of HF in PWD from the perspectives of 1) epidemiology, 2) classification of stages, 3) pathophysiology, 4) biomarkers for diagnosing, 5) biomarker assays, 6) diagnostic accuracy of biomarkers, 7) benefits of biomarker screening, 8) consensus recommendations for biomarker screening, 9) stratification of Stage B HF, 10) echocardiographic screening, 11) management of Stage A and Stage B HF, and 12) future directions. The Diabetes Technology Society panel recommends 1) biomarker screening with one of two circulating natriuretic peptides (B-type natriuretic peptide or N-terminal prohormone of B-type natriuretic peptide), 2) beginning screening five years following diagnosis of type 1 diabetes (T1D) and at the diagnosis of type 2 diabetes (T2D), 3) beginning routine screening no earlier than at age 30\xa0years for T1D (irrespective of age of diagnosis) and at any age for T2D, 4) screening annually, and 5) testing any time of day. The panel also recommends that an abnormal biomarker test defines asymptomatic preclinical HF (Stage B HF). This diagnosis requires follow-up using transthoracic echocardiography for classification into one of four subcategories of Stage B HF, corresponding to risk of progression to symptomatic clinical HF (Stage C HF). These recommendations will allow identification and management of Stage A and Stage B HF in PWD to prevent progression to Stage C HF or advanced HF (Stage D HF).</ABSTRACT>'}]
2024-01-02 00:26:40,353 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448487, Requested 1554. Please try again in 5ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,353 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Deep learning in optical coherence tomography: Where are the gaps?\nOptical coherence tomography (OCT) is a non-invasive optical imaging modality, which provides rapid, high-resolution and cross-sectional morphology of macular area and optic nerve head for diagnosis and managing of different eye diseases. However, interpreting OCT images requires experts in both OCT images and eye diseases since many factors such as artefacts and concomitant diseases can affect the accuracy of quantitative measurements made by post-processing algorithms. Currently, there is a growing interest in applying deep learning (DL) methods to analyse OCT images automatically. This review summarises the trends in DL-based OCT image analysis in ophthalmology, discusses the current gaps, and provides potential research directions. DL in OCT analysis shows promising performance in several tasks: (1) layers and features segmentation and quantification; (2) disease classification; (3) disease progression and prognosis; and (4) referral triage level prediction. Different studies and trends in the development of DL-based OCT image analysis are described and the following challenges are identified and described: (1) public OCT data are scarce and scattered; (2) models show performance discrepancies in real-world settings; (3) models lack of transparency; (4) there is a lack of societal acceptance and regulatory standards; and (5) OCT is still not widely available in underprivileged areas. More work is needed to tackle the challenges and gaps, before DL is further applied in OCT image analysis for clinical use.</ABSTRACT>'}]
2024-01-02 00:26:40,353 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448429, Requested 1614. Please try again in 5ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,353 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Female and Male Fertility after Colectomy and Reconstructive Surgery in Inflammatory Bowel Diesase: A National Cohort Study from Sweden.\nColectomy and reconstruction in patients with inflammatory bowel disease [IBD] may adversely affect fertility, but few population-based studies on this subject are available.Fertility was assessed in 2989 women and 3771 men with IBD and prior colectomy during 1964-2014, identified from the Swedish National Patient Register, and in 35 092 matched individuals.Reconstruction with ileoanal pouch anastomosis [IPAA] was as common as ileorectal anastomosis [IRA] in ulcerative colitis [UC] and IBD-unclassified [IBD-U] but rare in Crohn\'s disease [CD]. Compared with the matched reference cohort, women with IBD had lower fertility overall after colectomy (hazard ratio [HR] 0.65, confidence interval [CI] 0.61-0.69), with least impact with leaving the rectum intact [HR 0.79, CI 0.70-0.90]. Compared with colectomy only, fertility in female patients remained unaffected after IRA [HR 0.86, CI 0.63-1.17 for UC, 0.86, CI 0.68-1.08 for IBD-U and 1.07, CI 0.70-1.63 for CD], but was impaired after IPAA, especially in UC [HR 0.67, CI 0.50-0.88], and after completion proctectomy [HR 0.65, CI 0.49-0.85 for UC, 0.68, CI 0.55-0.85 for IBD-U and 0.61, CI 0.38-0.96 for CD]. In men, fertility was marginally reduced following colectomy [HR 0.89, CI 0.85-0.94], regardless of reconstruction.Fertility was reduced in women after colectomy for IBD. The least impact was seen when a deviated rectum was left intact. IRA was associated with no further reduction in fertility, whereas proctectomy and IPAA were associated with the strongest impairment. IRA therefore seems to be the preferred reconstruction to preserve fertility in selected female patients. Fertility in men was only moderately reduced after colectomy.</ABSTRACT>'}]
2024-01-02 00:26:40,361 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,364 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449929, Requested 1610. Please try again in 205ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,364 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Comparison of clinical effectiveness of conbercept and ranibizumab for treating retinopathy of prematurity: a meta-analysis.\nConbercept and ranibizumab have been used to treat retinopathy of prematurity (ROP). However, the clinical effectiveness of conbercept and ranibizumab remains controversial.This meta-analysis aimed to compare the effectiveness of conbercept and ranibizumab for treating ROP.We systematically searched Pubmed, Web of Science, Embase, the Cochrane Library, Ovid, Scopus, China National Knowledge Infrastructure, Wanfang Database, CQVIP, Duxiu Database, SinoMed, and X-MOL to screen relevant studies up to November 2022. Retrospective cohort studies and randomized controlled trials (RCTs) evaluating the effectiveness of conbercept and ranibizumab in treating patients with ROP were selected. The outcomes assessed were the rates of primary cure, ROP recurrence, and retreatment. Statistical analysis was performed using Stata.Seven studies (n\u2009=\u2009989) were selected in the meta-analysis. There were 303 cases (594 eyes) treated with conbercept and 686 patients (1,318 eyes) treated with ranibizumab. Three studies reported the primary cure rate. Compared to ranibizumab, conbercept had a significantly higher primary cure rate (odds ratio [OR] 1.91, 95% confidence interval [CI] 1.05-3.49, P\u2009<\u20090.05). Five studies reported the rate of ROP recurrence, and there were no significant differences between conbercept and ranibizumab (OR 0.62, 95% CI 0.28-1.38, P\u2009>\u20090.05). Three studies reported the rate of retreatment, and the rates were not significantly different between conbercept and ranibizumab (OR 0.78, 95% CI 0.21-2.93, P\u2009>\u20090.05).Conbercept had a higher rate of primary cure in ROP patients. More RCTs are needed to compare the efficacy of conbercept and ranibizumab in treating ROP.</ABSTRACT>'}]
2024-01-02 00:26:40,370 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,371 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,371 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,372 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,372 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,372 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,376 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449948, Requested 1617. Please try again in 208ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,376 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Point-to-point associations of drusen and hyperreflective foci volumes with retinal sensitivity in non-exudative age-related macular degeneration.\nTo evaluate the quantitative impact of drusen and hyperreflective foci (HRF) volumes on mesopic retinal sensitivity in non-exudative age-related macular degeneration (AMD).In a standardized follow-up scheme of every three months, retinal sensitivity of patients with early or intermediate AMD was assessed by microperimetry using a custom pattern of 45 stimuli (Nidek MP-3, Gamagori, Japan). Eyes were consecutively scanned using Spectralis SD-OCT (20\u2009\u200920, 1024\u2009\u200997\u2009\u2009496). Fundus photographs obtained by the MP-3 allowed to map the stimuli locations onto the corresponding OCT scans. The volume and mean thickness of drusen and HRF within a circle of 240\u2009m centred at each stimulus point was determined using automated AI-based image segmentation algorithms.8055 individual stimuli from 179 visits from 51 eyes of 35 consecutive patients were matched with the respective OCT images in a point-to-point manner. The patients mean age was 76.85\u2009\u20096.6 years. Mean retinal sensitivity at baseline was 25.7\u2009dB. 73.47% of all MP-spots covered drusen area and 2.02% of MP-spots covered HRF. A negative association between retinal sensitivity and the volume of underlying drusen (p\u2009<\u20090.001, Estimate -0.991 db/m3) and HRF volume (p\u2009=\u20090.002, Estimate -5.230 db/m3) was found. During observation time, no eye showed conversion to advanced AMD.A direct correlation between drusen and lower sensitivity of the overlying photoreceptors can be observed. For HRF, a small but significant correlation was shown, which is compromised by their small size. Biomarker quantification using AI-methods allows to determine the impact of sub-clinical features in the progression of AMD.</ABSTRACT>'}]
2024-01-02 00:26:40,377 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449845, Requested 1664. Please try again in 201ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,377 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Distinct Alterations in Central Pain Processing of Visceral and Somatic Pain in Quiescent Ulcerative Colitis Compared to Irritable Bowel Syndrome and Health.\nDespite relevance to pain chronicity, disease burden, and treatment, mechanisms of pain perception for different types of acute pain remain incompletely understood in patients with inflammatory bowel disease [IBD]. Building on experimental research across pain modalities, we herein addressed behavioural and neural correlates of visceral versus somatic pain processing in women with quiescent ulcerative colitis [UC] compared to irritable bowel syndrome [IBS] as a patient control group and healthy women [HC].Thresholds for visceral and somatic pain were assessed with rectal distensions and cutaneous thermal pain, respectively. Using functional magnetic resonance imaging, neural and behavioural responses to individually calibrated and intensity-matched painful stimuli from both modalities were compared.Pain thresholds were comparable across groups, but visceral thresholds correlated with gastrointestinal symptom severity and chronic stress burden exclusively within UC. Upon experience of visceral and somatic pain, both control groups demonstrated enhanced visceral pain-induced neural activation and greater perceived pain intensity, whereas UC patients failed to differentiate between pain modalities at both behavioural and neural levels.When confronted with acute pain from multiple bodily sites, UC patients\' responses are distinctly altered. Their failure to prioritise pain arising from the viscera may reflect a lack of adaptive behavioural flexibility, possibly resulting from long-lasting central effects of repeated intestinal inflammatory insults persisting during remission. The role of psychological factors, particularly chronic stress, in visceral sensitivity and disease-specific alterations in the response to acute pain call for dedicated mechanistic research as a basis for tailoring interventions for intestinal and extraintestinal pain symptoms in IBD.</ABSTRACT>'}]
2024-01-02 00:26:40,377 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449856, Requested 1557. Please try again in 188ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,377 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Comparison of the retinal microvasculature between compressive and glaucomatous optic neuropathy.\nTo compare the patterns of retinal microvasculature change in the peripapillary and macular region between compressive optic neuropathy (CON) and glaucomatous optic neuropathy (GON), and to assess the ability of optical coherence tomography angiography (OCTA) in differentiating the two conditions.This cross-sectional study included 108 participants (108 eyes), 36 with CON, 36 with GON, and 36 healthy controls. The CON and GON eyes were matched by the average peripapillary retinal nerve fiber layer (pRNFL) thickness (1:1). Optical coherence tomography (OCT) and OCTA were performed to compare the structural and vascular change of the peripapillary and macular region between groups.Both CON and GON eyes showed more severe structural and vascular damage than the control eyes. The CON eyes had lower pRNFL thickness than the GON eyes in the temporal and nasal quadrants, and thicker pRNFL thickness in the inferior quadrant. The average GCC thickness did not differ between the two groups. The peripapillary vessel density of the CON group was significantly higher in the inferior sectors than that of the GON group. In the macular region, the CON group had significantly higher vessel density in the whole image, the temporal sector in parafovea region, and the temporal, superior, and inferior sectors in perifovea region.To a similar degree of structural damage, CON had less retinal vascular impairment than GON, especially in the macular region, and the significance of the finding needs further evaluation.</ABSTRACT>'}]
2024-01-02 00:26:40,378 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449794, Requested 1650. Please try again in 192ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,378 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Exploring patient acceptability of emerging intravitreal therapies for geographic atrophy: A mixed-methods study.\nThe acceptability of emerging intravitreal therapies for patients with Geographic Atrophy (GA) is currently unknown. This study therefore aimed to investigate the extent to which regular intravitreal injections may be acceptable to GA patients.Thirty UK-based individuals with GA secondary to age-related macular degeneration (AMD), recruited from two London-based hospitals, were interviewed in April-October 2021 regarding acceptability of new GA treatments. Participants responded to a structured questionnaire, as well as open-ended questions in a semi-structured interview.\xa0The Theoretical Framework of Acceptability (TFA) informed framework\xa0analysis of the qualitative data.Twenty participants (67%) were female, and median (interquartile range (IQR)) age was 83 (78, 87) years. 37% of participants had foveal centre-involving GA, and better eye median (IQR) logMAR visual acuity was 0.30 (0.17, 0.58). Data suggested that 18 participants (60% (95% CI: 41-79%)) would accept the treatment, despite awareness of potential drawbacks. Eight participants (27% (95% CI: 10-43%) were ambivalent or undecided about treatment, and four (13%) (95% CI: 0-26%) would be unlikely to accept treatment. Reducing the frequency of injections from monthly to every other month increased the proportion of participants who considered the treatments acceptable. Conversely, factors limiting acceptability clustered around: the limited magnitude of treatment efficacy; concerns about side effects or the increased risk of neovascular AMD; and the logistical burden of regular clinic visits for intravitreal injections. Misunderstandings of potential benefits indicate the need for appropriately-designed patient education tools to support decision-making.Our study suggests a majority of participants would be positive about intravitreal treatment for GA, in spite of potential burdens.</ABSTRACT>'}]
2024-01-02 00:26:40,378 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449889, Requested 1630. Please try again in 202ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,378 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Defining Biological Remission in Crohn\'s Disease: Interest, Challenges and Future Directions.\nIn Crohn\'s disease, the treat-to-target strategy has been greatly encouraged and has become a standard of care. In this context, defining the target [remission] constitutes a major stake and is fuelling the literature. Currently, clinical remission [symptom control] is no longer the only objective of treatments since it does not allow to closely control inflammation-induced tissue damage. The introduction of endoscopic remission as a therapeutic target clearly represented progress but this examination remains invasive, costly, not well accepted by patients and does not allow tight control of disease activity. More fundamentally, morphological techniques [e.g. endoscopy, histology, ultrasonography] are limited since they do not evaluate the biological activity of the disease but only its consequences. Besides, emerging evidence suggests that biological signs of disease activity could better guide treatment decisions than clinical parameters. In this context, we stress the necessity to define a novel treatment target: biological remission. Based on our previous work, we propose a conceptual definition of biological remission which goes beyond the classical normalization of inflammatory markers [C-reactive protein and faecal calprotectin]: absence of biological signs associated with the risk of short-term relapse and mid-/long-term relapse. The risk of short-term relapse seems essentially to be characterized by a persistent inflammatory state while the risk of mid-/long-term relapse implies a more heterogeneous biology. We discuss the value of our proposal [guiding treatment maintenance, escalation or de-escalation] but also the fact that its clinical implementation would require overcoming major challenges. Finally, future directions are proposed to better define biological remission.</ABSTRACT>'}]
2024-01-02 00:26:40,378 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449781, Requested 1724. Please try again in 200ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,378 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Fluorescein Angiography Findings in Susac Syndrome: A Multicenter Retrospective Case Series.\nSusac syndrome is a vasculopathy, resulting in the classic triad of branch retinal artery occlusion (BRAO), inner ear ischemia, and brain ischemia. In this retrospective chart review, we characterize fluorescein angiography (FA) findings and other ancillary studies in Susac syndrome, including the appearance of persistent disease activity and the occurrence of new subclinical disease on FA.This multicenter, retrospective case series was institutional review board-approved and included patients with the complete triad of Susac syndrome evaluated with FA, contrasted MRI of the brain, and audiometry from 2010 to 2020. The medical records were reviewed for these ancillary tests, along with demographics, symptoms, visual acuity, visual field defects, and findings on fundoscopy. Clinical relapse was defined as any objective evidence of disease activity during the follow-up period after initial induction of clinical quiescence. The main outcome measure was the sensitivity of ancillary testing, including FA, MRI, and audiometry, to detect relapse.Twenty of the 31 (64%) patients had the complete triad of brain, retinal, and vestibulocochlear involvement from Susac syndrome and were included. Median age at diagnosis was 43.5 years (range 21-63), and 14 (70%) were women. Hearing loss occurred in 20 (100%), encephalopathy in 13 (65%), vertigo in 15 (75%), and headaches in 19 (95%) throughout the course of follow-up. Median visual acuity at both onset and final visit was 20/20 in both eyes. Seventeen (85%) had BRAO at baseline, and 10 (50%) experienced subsequent BRAO during follow-up. FA revealed nonspecific leakage from previous arteriolar damage in 20 (100%), including in patients who were otherwise in remission. Of the 11 episodes of disease activity in which all testing modalities were performed, visual field testing/fundoscopy was abnormal in 4 (36.4%), MRI brain in 2 (18.2%), audiogram in 8 (72.7%), and FA in 9 (81.8%).New leakage on FA is the most sensitive marker of active disease. Persistent leakage represents previous damage, whereas new areas of leakage suggest ongoing disease activity that requires consideration of modifying immunosuppressive therapy.</ABSTRACT>'}]
2024-01-02 00:26:40,390 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,392 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449715, Requested 1688. Please try again in 187ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,392 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Use of Heavy Silicon Oil as Intraocular Tamponade for Inferior Retinal Detachment Complicated by Proliferative Vitreoretinopathy: A Multicentric Experience.\nThis is a multicentric study on the use of heavy silicon oil (HSO) as an intraocular tamponade for inferior retinal detachment (RD) complicated by proliferative vitreoretinopathy (PVR).139 eyes treated for RD with PVR were included in the study. 10 (7.2%) were affected by primary RD with inferior PVR, while 129 (92.8%) were affected by recurrent RD with inferior PVR. 102 eyes (73.9%) had received a silicon oil (SO) tamponade in a previous intervention prior to receiving HSO. Mean follow-up was 36.5 (standard deviation = 32.3) months.The median interval between HSO injection and removal was 4 months (interquartile range: 3). At the time of HSO removal, the retina was attached in 120 eyes (87.6%), whereas in 17 eyes (12.4%), it had re-detached while the HSO was in situ. 32 eyes (23.2%) showed recurrent RD. A subsequent RD relapse was observed in 14.2% of cases with no RD at the time of HSO removal, and in 88.2% if an RD was present at the time of HSO removal. Advancing age showed a positive association with retinal attachment at the end of follow-up, while the risk of RD relapse at the end of the follow-up showed a significant negative association with HSO tamponade duration and with the use of SO rather than air or gas as post-HSO tamponade materials. Mean best corrected visual acuity was 1.1 logarithm of minimum angle of resolution at all follow-up time points. 56 cases (40.3%) needed treatment for elevated intraocular pressure (IOP), with which no clinically relevant variables were associated during follow-up.HSO represents a safe and effective tamponade in cases of inferior RD with PVR. The presence of RD at the time of HSO removal is a negative prognostic factor for the development of a subsequent RD relapse. According to our findings, in cases of RD at the time of HSO removal, a short-term tamponade should definitely be avoided, in favor of SO. Special attention must be paid to the risk of IOP elevation, and patients should be closely monitored.</ABSTRACT>'}]
2024-01-02 00:26:40,398 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,400 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,401 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449669, Requested 1617. Please try again in 171ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,401 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Prevalence of Deleterious Variants in MC3R in Patients With Constitutional Delay of Growth and Puberty.\nThe melanocortin 3 receptor (MC3R) has recently emerged as a critical regulator of pubertal timing, linear growth, and the acquisition of lean mass in humans and mice. In population-based studies, heterozygous carriers of deleterious variants in MC3R report a later onset of puberty than noncarriers. However, the frequency of such variants in patients who present with clinical disorders of pubertal development is currently unknown.This work aimed to determine whether deleterious MC3R variants are more frequently found in patients clinically presenting with constitutional delay of growth and puberty (CDGP) or normosmic idiopathic hypogonadotropic hypogonadism (nIHH).We examined the sequence of MC3R in 362 adolescents with a clinical diagnosis of CDGP and 657 patients with nIHH, experimentally characterized the signaling properties of all nonsynonymous variants found and compared their frequency to that in 5774 controls from a population-based cohort. Additionally, we established the relative frequency of predicted deleterious variants in individuals with self-reported delayed vs normally timed menarche/voice-breaking in the UK Biobank cohort.MC3R loss-of-function variants were infrequent but overrepresented in patients with CDGP (8/362 [2.2%]; OR = 4.17; P = .001). There was no strong evidence of overrepresentation in patients with nIHH (4/657 [0.6%]; OR = 1.15; P = .779). In 246 328 women from the UK Biobank, predicted deleterious variants were more frequently found in those self-reporting delayed (aged \u226516 years) vs normal age at menarche (OR = 1.66; P = 3.90E-07).We have found evidence that functionally damaging variants in MC3R are overrepresented in individuals with CDGP but are not a common cause of this phenotype.</ABSTRACT>'}]
2024-01-02 00:26:40,402 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449628, Requested 1615. Please try again in 165ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,402 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Symptom-based stratification algorithm for heterogeneous symptoms of dry eye disease: a feasibility study.\nTo test the feasibility of a dry eye disease (DED) symptom stratification algorithm previously established for the general population among patients visiting ophthalmologists.This retrospective cross-sectional study was conducted between December 2015 and October 2021 at a university hospital in Japan; participants who underwent a comprehensive DED examination and completed the Japanese version of the Ocular Surface Disease Index (J-OSDI) were included. Patients diagnosed with DED were stratified into seven clusters using a previously established symptom-based stratification algorithm for DED. Characteristics of the patients in stratified clusters were compared.In total, 426 participants were included (median age [interquartile range]; 63 [48-72] years; 357 (83.8%) women). Among them, 291 (68.3%) participants were diagnosed with DED and successfully stratified into seven clusters. The J-OSDI total score was highest in cluster 1 (61.4 [52.2-75.0]), followed by cluster 5 (44.1 [38.8-47.9]). The tear film breakup time was the shortest in cluster 1 (1.5 [1.1-2.1]), followed by cluster 3 (1.6 [1.0-2.5]). The J-OSDI total scores from the stratified clusters in this study and those from the clusters identified in the previous study showed a significant correlation (r\u2009=\u20090.991, P\u2009<\u20090.001).The patients with DED who visited ophthalmologists were successfully stratified by the previously established algorithm for the general population, uncovering patterns for their seemingly heterogeneous and variable clinical characteristics of DED. The results have important implications for promoting treatment interventions tailored to individual patients and implementing smartphone-based clinical data collection in the future.</ABSTRACT>'}]
2024-01-02 00:26:40,407 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,410 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449637, Requested 1498. Please try again in 151ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,410 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>The adhesion G protein-coupled receptor VLGR1/ADGRV1 controls autophagy.\nVLGR1/ADGRV1 (very large G protein-coupled receptor-1) is the largest known adhesion G protein-coupled receptor. Mutations in VLGR1/ADGRV1 cause Usher syndrome (USH), the most common form of hereditary deaf-blindness, and have been additionally linked to epilepsy. Although VLGR1/ADGRV1 is almost ubiquitously expressed, little is known about the subcellular function and signalling of the VLGR1 protein and thus about mechanisms underlying the development of diseases. Using affinity proteomics, we identified key components of autophagosomes as putative interacting proteins of VLGR1. In addition, whole transcriptome sequencing of the retinae of the Vlgr1/del7TM mouse model revealed altered expression profiles of gene-related autophagy. Monitoring autophagy by immunoblotting and immunocytochemistry of the LC3 and p62 as autophagy marker proteins revealed evoked autophagy in VLGR1-deficient hTERT-RPE1 cells and USH2C patient-derived fibroblasts. Our data demonstrate the molecular and functional interaction of VLGR1 with key components of the autophagy process and point to an essential role of VLGR1 in the regulation of autophagy at internal membranes. The close association of VLGR1 with autophagy helps to explain the pathomechanisms underlying human USH and epilepsy related to VLGR1 defects.</ABSTRACT>'}]
2024-01-02 00:26:40,415 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,415 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,416 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,417 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449589, Requested 1611. Please try again in 160ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,417 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Ocular Surface Metrics in Blepharospasm Patients After Treatment With Botulinum Toxin Injections.\nThe purpose of this study was to assess blepharospasm patients regarding the effect of botulinum toxin in ocular surface parameters.A prospective study was performed in blepharospasm patients treated with onabotulinumtoxinA. A smartphone (iPhone 6S, Apple) and custom-made software were used to record the eyelid movements for 3 minutes in a standardized manner. Optical coherence tomography of the tear meniscus was used to assess the tear meniscus area. Tear break-up time and the Ocular Surface Disease Index questionnaire were also evaluated. Patients were assessed before and 15 days after botulinum toxin injections.Forty eyes of 20 patients were evaluated. The frequency of the spontaneous eyelid movements was significantly reduced after treatment (23.18\u2009\u200912.85 movements/min vs. 9.29\u2009\u20096.87 movements/min; p < 0.0001). Significant increases in the tear meniscus area (0.020\u2009\u20090.015\u2009mm 2 vs. 0.057\u2009\u20090.104\u2009mm 2 ; p = 0.01) and in break-up time (4.2\u2009\u20091.2 seconds vs. 5.1\u2009\u20091.3 seconds; p = 0.03) were observed 15 days after treatment. A significant reduction in the Ocular Surface Disease Index (59.05\u2009\u200919.04 vs. 21.2\u2009\u200919.5; p < 0.0001) was also observed.Significant changes in the tear meniscus area, break-up time, and Ocular Surface Disease Index after treatment reflect the effect of botulinum toxin on the lacrimal pump and in the improvement of dry eye symptoms. Reduction of eyelid spasms after treatment in blepharospasm patients was demonstrated using a smartphone and custom-made software. Thus, beyond relieving eyelid spasms, botulinum toxin injections were associated with subjective and objective improvement of dry eye parameters in patients with blepharospasm.</ABSTRACT>'}]
2024-01-02 00:26:40,417 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449549, Requested 1176. Please try again in 96ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,417 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Reducing time to surgery in patients affected by idiopathic full thickness macular holes.\n</ABSTRACT>'}]
2024-01-02 00:26:40,418 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449550, Requested 1585. Please try again in 151ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,418 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>High 1-h glucose in youths with obesity as marker of prediabetes and cardiovascular risk.\nTesting 1-h glucose (1HG) concentration during oral glucose tolerance test is cost-effective to identify individuals at risk of incident type 2 diabetes. Aim of the study was to define 1HG cutoffs diagnostic of incident impaired glucose tolerance (IGT) in youths with obesity, and to evaluate prevalence and association of cutoffs identified in the cohort and from the literature (133 and 155\xa0mg/dl) to cardiovascular disease (CVD) in a population of youths with obesity.This is a longitudinal study of 154 youths to identify 1HG cutoffs, and cross-sectional study of 2295 youths to estimate prevalence of high 1HG and association to CVD. Receiver-operating characteristic curves (ROC) were used to establish 1HG cutoffs, and univariate regression analyses\xa0to test\xa0association of 1HG to blood pressure, lipids and aminotransferases.ROC analysis identified the 1HG cutoff of 159\xa0mg/dl as having diagnostic accuracy of IGT with area under the ROC 0.82 (95% CI 0.66-0.98), sensitivity 0.86% and specificity 0.79%. In the cross-sectional population, prevalence of high 1HG was 36% and 15% for 133 and 155\xa0mg/dl cutoffs, respectively, and 17% for the 159\xa0mg/dl value. All the examined cutoffs were significantly associated with worse lipid profile, liver function test, reduced insulin sensitivity, secretion and disposition index.High 1HG is marker of persistent IGT and increased risk of metabolic abnormalities in youths. The 155\xa0mg/dl cutoff is a convenient estimate in young people but longitudinal studies with retinopathy and overt diabetes as end points are advised to verify the 1HG cutoff with the best diagnostic accuracy.</ABSTRACT>'}]
2024-01-02 00:26:40,424 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:40,428 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,430 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449021, Requested 1788. Please try again in 107ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,430 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Forecasting Risk of Future Rapid Glaucoma Worsening Using Early Visual Field, OCT, and Clinical Data.\nTo assess whether we can forecast future rapid visual field (VF) worsening using deep learning models (DLMs) trained on early VF, OCT, and clinical data.A retrospective cohort study.In total, 4536 eyes from 2962 patients. Overall, 263 (5.80%) eyes underwent rapid VF worsening (mean deviation slope less than -1 dB/year across all VFs).We included eyes that met the following criteria: (1) followed for glaucoma or suspect status; (2) had at least 5 longitudinal reliable VFs (VF1, VF2, VF3, VF4, and VF5); and (3) had 1 reliable baseline OCT scan (OCT1) and 1 set of baseline clinical measurements (clinical1) at the time of VF1. We designed a DLM to forecast future rapid VF worsening. The input consisted of spatially oriented total deviation values from VF1 (including or not including VF2 and VF3 in some models) and retinal nerve fiber layer thickness values from the baseline OCT. We passed this VF/OCT stack into a vision transformer feature extractor, the output of which was concatenated with baseline clinical data before putting it through a linear classifier to predict the eye\'s risk of rapid VF worsening across the 5 VFs. We compared the performance of models with differing inputs by computing area under the curve (AUC) in the test set. Specifically, we trained models with the following inputs: (1) model V: VF1; (2) VC: VF1+ Clinical1; (3) VO: VF1+ OCT1; (4) VOC: VF1+ Clinical1+ OCT1; (5) V2: VF1\xa0+ VF2; (6) V2OC: VF1\xa0+ VF2\xa0+ Clinical1\xa0+ OCT1; (7) V3: VF1\xa0+ VF2\xa0+ VF3; and (8) V3OC: VF1\xa0+ VF2\xa0+ VF3\xa0+ Clinical1\xa0+ OCT1.The AUC of DLMs when forecasting rapidly worsening eyes.Model V3OC best forecasted rapid worsening with an AUC (95% confidence interval [CI]) of 0.87 (0.77-0.97). Remaining models in descending order of performance and their respective AUC (95% CI) were as follows: (1) model V3 (0.84 [0.74-0.95]), (2) model V2OC (0.81 [0.70-0.92]), (3) model V2 (0.81 [0.70-0.82]), (4) model VOC (0.77 [0.65-0.88]), (5) model VO (0.75 [0.64-0.88]), (6) model VC (0.75 [0.63-0.87]), and (7) model V (0.74 [0.62-0.86]).Deep learning models can forecast future rapid glaucoma worsening with modest to high performance when trained using data from early in the disease course. Including baseline data from multiple modalities and subsequent visits improves performance beyond using VF data alone.Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</ABSTRACT>'}]
2024-01-02 00:26:40,432 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,434 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448985, Requested 1167. Please try again in 20ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,434 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Iris Melanocytoma with Minimal Change over 50 Years.\n</ABSTRACT>'}]
2024-01-02 00:26:40,440 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,442 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,449 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448962, Requested 1626. Please try again in 78ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,449 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Analysis of ocular fluid in patients with ranibizumab-recalcitrant neovascular age-related macular degeneration who have serum anti-ranibizumab antibodies.\nTo evaluate whether anti-drug antibodies (ADAs) are present in the ocular fluid of patients with ranibizumab-recalcitrant neovascular age-related macular degeneration (nAMD).Two serum ADA-positive ranibizumab-recalcitrant patients and two serum ADA-negative controls were recruited from patients with nAMD treated with ranibizumab monotherapy. Recalcitrance was defined as persistent fluid after \u22656 monthly ranibizumab injections. Serum and aqueous humor ADAs were detected by enzyme-linked immunosorbent assay and immunoprecipitation, respectively.Two of 156 ranibizumab-treated patients were ADA-positive. The patients received six and 14 ranibizumab injections, respectively, up to 4 weeks prior to blood collection. The serum ADA concentration was estimated to be approximately 50,000 ng/mL. Neutralizing ADAs were confirmed in both samples. A specific band was detected by immunoprecipitation only in ADA-positive samples, consistent with the results of enzyme-linked immunosorbent assay. Based on an assessment of the degree of sensitivity of commercially available anti-ranibizumab antibodies, it was estimated that the immunoprecipitation method could detect ADA levels >30 ng. Nevertheless, ADAs were not detected in the aqueous humor of either the experimental or control group.In the aqueous humor, ADAs are either not present or are present at a lower concentration than that which can be detected by immunoprecipitation. This presumably reflects the fact that blood ADA is the product of systemic circulation clearance through anterior elimination of intravitreal ranibizumab. Based on our results, ADAs do not return to the eye in sufficient quantities to interfere with the action of ranibizumab in the vitreous cavity.</ABSTRACT>'}]
2024-01-02 00:26:40,450 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,451 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448980, Requested 1593. Please try again in 76ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,451 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Defining the safety of early ileostomy closure after ileal pouch anal anastomosis.\nThe safety of early ileostomy reversal after ileal pouch anal anastomosis (IPAA) has not been established. Our hypothesis was that ileostomy reversal before 8\xa0weeks is associated with negative outcomes.This was a retrospective cohort study from a prospectively maintained institutional database. Patients who underwent primary IPAA with ileostomy reversal between 2000 and 2021 from a Pouch Registry were stratified on the basis of timing of reversal. Those reversed before 8\xa0weeks (early) and those reversed from 8\xa0weeks to 116\xa0days (routine) were compared. The primary outcome was overall complications according to timing and reason for closure.Ileostomy reversal was performed early in 92 patients and routinely in 1908. Median time to closure was 49\xa0days in the early group and 93\xa0days in the routine group. Reasons for early reversal were stoma-related morbidity in 43.3% (n\u2009=\u200939) and scheduled closure in 56.7% (n\u2009=\u200951). The complication rate in the early group was 17.4% versus 11% in the routine group (p\u2009=\u20090.085). When early patients were stratified according to reason for reversal, those reversed early for stoma-related morbidity had an increased complication rate compared to the routine group (25.6% vs. 11%, p\u2009=\u20090.006). Patients undergoing scheduled reversal in the early group did not have increased complications (11.8% vs. 11%, p\u2009=\u20090.9). There was a higher likelihood of pouch anastomotic leak when reversal was performed early for stoma complications compared to routinely (OR 5.13, 95%\xa0CI 1.01-16.57, p\u2009=\u20090.049).Early closure is safe but could be delayed in stoma morbidity as patients may experience increased complications.</ABSTRACT>'}]
2024-01-02 00:26:40,451 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,453 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449019, Requested 1617. Please try again in 84ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,453 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Curcumin attenuates hydroxychloroquine-mediated apoptosis and oxidative stress via the inhibition of TRPM2 channel signalling pathways in a retinal pigment epithelium cell line.\nHydroxychloroquine (HCQ) is used in the treatment of several diseases, such as malaria, Sjgren\'s disease, Covid-19, and rheumatoid arthritis. However, HCQ induces retinal pigment epithelium death via the excessive increase of cytosolic (cROS) and mitochondrial (mROS) free oxygen radical production. The transient receptor potential melastatin 2 (TRPM2) cation channel is stimulated by ADP-ribose (ADPR), cROS, and mROS, although it is inhibited by curcumin (CRC). We aimed to investigate the modulating action of CRC on HCQ-induced TRPM2 stimulation, cROS, mROS, apoptosis, and death in an adult retinal pigment epithelial 19 (ARPE19) cell line model.ARPE19 cells were divided into four groups: control (CNT), CRC (5\xa0M for 24\xa0h), HCQ (60\xa0M for 48\xa0h), and CRC\u2009+\u2009HCQ groups.The levels of cell death (propidium iodide positive cell numbers), apoptosis markers (caspases -3, -8, and -9), oxidative stress (cROS and mROS), mitochondria membrane depolarization, TRPM2 current density, and intracellular free Ca2+ and Zn2+ fluorescence intensity were upregulated in the HCQ group after stimulation with hydrogen peroxide and ADPR, but their levels were downregulated by treatments with CRC and TRPM2 blockers (ACA and carvacrol). The HCQ-induced decrease in retinal live cell count and cell viability was counteracted by treatment with CRC.HCQ-mediated overload Ca2+ influx and retinal oxidative toxicity were induced in an ARPE19 cell line through the stimulation of TRPM2, although they were attenuated by treatment with CRC. Hence, CRC may be a potential therapeutic antioxidant for TRPM2 activation and HCQ treatment-induced retinal oxidative injury and apoptosis.</ABSTRACT>'}]
2024-01-02 00:26:40,454 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448911, Requested 1615. Please try again in 70ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,454 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Implementing a Combined Phone and Mail Recall to Increase Screening Colonoscopy Rates in Adults With Chronic Ulcerative Colitis.\nColon cancer is the third leading cancer nationally. To prevent colon cancer and decrease healthcare costs, high-risk individuals such as adults with chronic ulcerative colitis are recommended to stay up-to-date on screening colonoscopies. Despite these recommendations, screening colonoscopy rates remain low both globally and locally. The purpose of this article is to increase surveillance colonoscopy rates among adult patients with chronic ulcerative colitis. Research supports increasing surveillance colonoscopy rates by implementing a combined phone and mail recall with included educational material on the risks of colon cancer. At a clinic for inflammatory bowel disease patients in Southeast Alabama, participants with chronic ulcerative colitis who were overdue for screening colonoscopies were issued two reminder phone calls and a reminder letter coupled with educational material. Both the calls and letters reminded participants that they were due for a surveillance colonoscopy and provided them with an option to schedule the procedure. A pre- and post-survey was used to evaluate screening colonoscopy rates before and after the intervention. The survey indicated whether a patient had scheduled a colonoscopy, intended to schedule a colonoscopy, or completed a colonoscopy within 3 months of project completion. Survey results revealed an 83% increase in screening colonoscopies post-intervention. A chart audit was also performed 3 months after project completion and results indicated a 70% increase in completed colonoscopy rates. The findings from this evidence-based practice project indicate that implementing a phone and mail recall is successful in increasing screening colonoscopy rates.</ABSTRACT>'}]
2024-01-02 00:26:40,474 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,475 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 450382, Requested 1375. Please try again in 234ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,475 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>The Optic Nerve Crush Injury Paradigm in African Turquoise Killifish to Study Axonal Regeneration in an Aged Environment.\nIn our graying world population, we are increasingly facing brain injuries and age-associated neurodegenerative diseases, which are often characterized by axonal pathology. Here, we propose the killifish visual/retinotectal system as a model for investigating central nervous system repair, more specifically axonal regeneration, in an aging context. We first describe an optic nerve crush (ONC) injury paradigm in killifish to induce and study both de- and regeneration of retinal ganglion cells (RGCs) and their axons. Subsequently, we summarize several methods for mapping different steps of the regenerative process-namely, axonal regrowth and synapse reformation-using retro- and anterograde tracing methods, (immuno)histochemistry, and morphometrical analyses.</ABSTRACT>'}]
2024-01-02 00:26:40,480 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,481 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 450295, Requested 1495. Please try again in 238ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,481 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Identification of miRNA-mRNA Regulatory Networks Associated with Diabetic Retinopathy using Bioinformatics Analysis.\nDiabetic retinopathy (DR) is a major complication of diabetes and a leading cause of visual loss. This study aimed to explore biomarkers for DR that may provide additional reference to DR pathogenesis and development.The differentially expressed genes (DEGs) between the DR and control samples in the GSE53257 dataset were identified. Logistics analyses were performed to identify DR-associated miRNAs and genes, and correlation analysis was performed to determine the correlation between them in GSE160306.A total of 114 DEGs in DR were identified in GSE53257. Three genes, including ATP5A1 (down), DAUFV2 (down), and OXA1L (down), were differentially expressed between DR and control samples in GSE160306. Univariate logistics analysis identified that ATP5A1 (OR=0.007, p = 1.40E-02), NDUFV2 (OR = 0.003, p = 6.40E-03), and OXA1L (OR = 0.093, p = 3.08E-02) were DR-associated genes. ATP5A1 and OXA1L were regulated by multiple miRNAs, of which hsa-let- 7b-5p (OR = 26.071, p = 4.40E-03) and hsa-miR-31-5p (OR = 4.188, p = 5.09E-02) were related to DR. ATP5A1 and OXA1L were closely correlated with each other in DR.The hsa-miR-31-5p-ATP5A1 and hsa-let-7b-5p-OXA1L axes might play novel and important roles in the pathogenesis and development of DR.</ABSTRACT>'}]
2024-01-02 00:26:40,486 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,488 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 450300, Requested 1612. Please try again in 254ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,488 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Video Capsule Endoscopy can Identify Occult Luminal Crohn\'s Disease in Patients with Isolated Perianal Fistulas.\nAccurate tools to distinguish Crohn\'s disease [CD] from cryptoglandular disease in patients with perianal fistulas without detectable luminal inflammation on ileocolonoscopy and abdominal enterography (isolated perianal fistulas [IPF]) are lacking. We assessed the ability of video capsule endoscopy [VCE] to detect luminal inflammation in patients with IPF.We studied consecutive adults [>17 years] with IPF who were evaluated by VCE after a negative ileocolonoscopy and abdominal enterography between 2013 and 2022. We defined luminal CD by VCE as diffuse erythema, three or more aphthous ulcers, or a Lewis score greater than 135. We compared rates of intestinal inflammation in this cohort with age- and sex-matched controls without perianal fistulas, who underwent VCE for other indications. We excluded persons with pre-existing inflammatory bowel disease [IBD] and exposure to non-steroidal anti-inflammatory drugs or immunosuppressive treatments.A total of 45 patients with IPF underwent VCE without complications. Twelve patients [26%] met our definition of luminal CD. Luminal CD was more common in patients with IPF than in controls [26% vs 3%; p\u2005<0.01]. Among patients with IPF, male sex (OR [odds ratio], 9.2; 95% confidence interval [CI] [1.1-79.4]), smoking (OR, 4.5; 95% CI [0.9-21.2]), abscess (OR, 6.3; 95% CI [1.5-26.8]), rectal enhancement on magnetic resonance imaging [MRI] (OR, 9.0; 95% CI [0.8-99.3]), and positive antimicrobial serology (OR, 7.1; 95% CI, [0.7-70.0]) were more common in those with a positive VCE study.VCE detected small intestinal inflammation suggestive of luminal CD in approximately one-quarter of patients with IPF. Larger studies are required to validate these findings.</ABSTRACT>'}]
2024-01-02 00:26:40,489 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,490 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 450275, Requested 1594. Please try again in 249ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,490 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Topical diquafosol versus hyaluronic acid for the treatment of dry eye disease: a meta-analysis of randomized controlled trials.\nDiquafosol enhances fluid transfer and mucin secretion on ocular surface, which has been suggested as an effective treatment for dry eye disease (DED). The aim of the systematic review and meta-analysis was to compare the efficacy and safety of topical diquafosol versus hyaluronic acid (HA) for DED.Relevant randomized controlled trials were obtained via search of electronic including PubMed, Embase, Cochrane Library, and Web of Science. A random-effects model was used to pool the results after incorporating the influence of potential heterogeneity.A total of nine RCTs involving 1295 patients with DED were included in the meta-analysis. Compared to treatment with 0.1% HA, topical treatment with 3% diquafosol significantly improved the Ocular Surface Disease Index (mean difference (MD): -\u20093.59, 95% confidence interval (CI): -\u20094.68 to -\u20092.50, p < 0.001; I2 = 6%), results of Schirmer\'s test (MD: 1.08 mm, 95% CI: 0.41 to 1.76, p = 0.002; I2 = 0%), tear breakup time (MD: 0.60 s, 95% CI: 0.20 to 0.99, p = 0.003; I2 = 63%), corneal fluorescein staining score (MD: -\u20090.20, 95% CI: -\u20090.37 to -\u20090.03, p = 0.02; I2 = 58%), and ocular rose bengal staining score (MD: -\u20090.62, 95% CI: -\u20090.88 to -\u20090.35, p < 0.001; I2 = 15%). No severe adverse events were reported. Topical use of diquafosol was associated with a higher risk of overall adverse events as compared to HA (odds ratio: 1.71, 95% CI: 1.08 to 2.71, p = 0.02; I2 = 18%).Topical treatment with 3% diquafosol may be more effective than 0.1% HA for patients with DED. However, the long-term efficacy and tolerability of diquafosol still need to be determined.</ABSTRACT>'}]
2024-01-02 00:26:40,494 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,495 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 450220, Requested 1169. Please try again in 185ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,495 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Etrasimod for ulcerative colitis: evaluating phase III results.\n</ABSTRACT>'}]
2024-01-02 00:26:40,495 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,496 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 450204, Requested 1592. Please try again in 239ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,496 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>USP14 Regulates ATF2/PIK3CD Axis to Promote Microvascular Endothelial Cell Proliferation, Migration, and Angiogenesis in Diabetic Retinopathy.\nDiabetic retinopathy (DR) is one of the leading causes of blindness in diabetic patients. However, the pathogenesis of DR is complex, and no firm conclusions have been drawn so far. It has become a hot spot in ophthalmology research to deeply study the mechanism of DR pathological changes and find effective treatment options. Human retinal microvascular endothelial cells (HRMECs) were induced by high glucose (HG) to construct DR cell model. CCK-8 assay was used to detect the viability of HRMECs. Transwell assay was used to detect the migration ability of HRMECs. Tube formation assay was used to identify the tube formation ability of HRMECs. The expressions of USP14, ATF2 and PIK3CD were detected by Western blot analysis and qRT-PCR assay. Immunoprecipitation (IP) was used to ascertain the relationship of USP14 and ATF2. To explore the regulatory relationship between ATF2 and PIK3CD by dual-luciferase reporter gene assay and Chromatin immunoprecipitation (ChIP) assay. High glucose treatment promoted the proliferation, migration, and tube formation of HRMEC, and the expressions of USP14, ATF2 and PIK3CD were significantly up-regulated. USP14 or ATF2 knockdown inhibited HG-induced HRMECs proliferation, migration, and tube formation. USP14 regulated the expression of ATF2, and ATF2 promoted PIK3CD expression. PIK3CD overexpression attenuated the inhibitory effectiveness of USP14 knockdown on proliferation, migration and tube formation of DR cell model. Here, we revealed that USP14 regulated the ATF2/PIK3CD axis to promote proliferation, migration, and tube formation in HG-induced HRMECs.</ABSTRACT>'}]
2024-01-02 00:26:40,510 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,511 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,513 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 450120, Requested 1569. Please try again in 225ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,513 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Early Intestinal Ultrasound Predicts Long-Term Endoscopic Response to Biologics in Ulcerative Colitis.\nThe Milan ultrasound criteria [MUC] is a validated score to assess endoscopic activity in ulcerative colitis [UC]. MUC\u2005>\u20056.2 detects Mayo endoscopic score [MES]\u2005>\u20051. In this study we evaluated the predictive value of MUC for biologic treatment response, using colonoscopy [CS] as a reference standard.Consecutive UC patients starting biologic therapy were included, and underwent CS, IUS, clinical assessment and faecal calprotectin [FC] measurement at baseline and within 1 year. In addition, IUS, clinical and FC assessments were performed at week 12. The primary objective was to evaluate whether ultrasound improvement [MUC \u2264 6.2] at week 12 predicted endoscopic improvement at reassessment [MES \u2264 1]. Endoscopic remission was defined as MES\u2005=\u20050.Forty-nine patients were included [59% under infliximab, 29% under vedolizumab, 8% under adalimumab, 4% under ustekinumab]. MUC \u2264 6.2 at week 12 was the only independent predictor for MES \u2264 1 and MES\u2005=\u20050 at reassessment (odds ratio [OR] 5.80, p\u2005=\u20050.010; OR 10.41, p\u2005=\u20050.041; respectively). MUC \u2264 6.2 at week 12 showed a negative predictive value of 96% for detecting MES\u2005=\u20050. A \u22652 reduction of the MUC predicted MES\u2005=\u20050 (area under the curve [AUC] 0.816). MUC \u2264 4.3 was the most accurate cut-off value for MES\u2005=\u20050 [AUC 0.876]. Guyatt\'s responsiveness ratio for the MUC was 1.73 [>0.8].MUC \u2264 6.2 at week 12 predicts long-term endoscopic response. MUC is accurate in monitoring treatment response and may be used in both clinical trials and routine practice.</ABSTRACT>'}]
2024-01-02 00:26:40,514 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 450118, Requested 1560. Please try again in 223ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,515 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Fidaxomicin treatment for Clostridioides difficile infection in patients with inflammatory bowel disease.\nAlthough fidaxomicin is an effective first-line treatment for Clostridioides difficile infection, it has not been well studied in patients with inflammatory bowel disease. We aimed to assess the effectiveness of fidaxomicin for the treatment of C.\xa0difficile infection in patients with inflammatory bowel disease.This was a multicenter retrospective study of adults with inflammatory bowel disease and C.\xa0difficile infection treated with fidaxomicin with at least 3\xa0months of follow up. The primary outcomes were treatment response, defined as resolution of C.\xa0difficile infection-attributed diarrhea and/or negative C.\xa0difficile infection stool test, and time to C.\xa0difficile infection recurrence after fidaxomicin.Thirty-three patients (median age 42\xa0years; 60.6% female) were included. Most patients had ulcerative colitis (26, 78.8%), were receiving treatment with a biologic or small molecule medication (19, 57.6%), and had a prior episode of C.\xa0difficile infection (26, 78.8%, median 2 episodes, range 0-15). Fidaxomicin led to resolution of C.\xa0difficile infection in 20 (60.6%) patients, with 6/20 (30.0%) developing a recurrence at a median of 55\xa0days. Most patients who failed to respond to fidaxomicin underwent fecal microbiota transplantation (10/13, 76.9%) with resolution.In this cohort of patients with inflammatory bowel disease and C.\xa0difficile infection, 60.6% responded to treatment with fidaxomicin. Of those who did not respond, fecal microbiota transplantation was an effective therapy.</ABSTRACT>'}]
2024-01-02 00:26:40,516 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,517 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 450064, Requested 1509. Please try again in 209ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,518 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Deletion of Emc1 in photoreceptor cells causes retinal degeneration in mice.\nThe endoplasmic reticulum membrane protein complex (EMC) plays a critical role in the synthesis of multipass membrane proteins. Genetic studies indicated that mutations in EMC1 gene were associated with retinal degeneration diseases; however, the role of EMC1 in photoreceptor has not been confirmed. Here, we show that Emc1 ablation in the photoreceptor cells of mice recapitulated the retinitis pigmentosa phenotypes, including an attenuated scotopic electroretinogram response and the progressive degeneration of rod cells and cone cells. Histopathological examination of tissues from rod-specific Emc1 knockout mice revealed mislocalized rhodopsin and irregularly arranged cone cells at the age of 2\u2009months. Further immunoblotting analysis revealed decreased levels of membrane proteins and endoplasmic reticulum chaperones in 1-month-old rod-specific Emc1 knockout mice retinae, and this led us to speculate that the loss of membrane proteins is the main cause of the degeneration of photoreceptors. EMC1 most likely regulated the membrane protein levels at an earlier step in the biosynthetic process before the proteins translocated into the endoplasmic reticulum. The present study demonstrates the essential roles of Emc1 in photoreceptor cells, and reveals the mechanism through which EMC1 mutations are linked to retinitis pigmentosa.</ABSTRACT>'}]
2024-01-02 00:26:40,535 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,536 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:40,537 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,537 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,538 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,540 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 450057, Requested 1497. Please try again in 207ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,540 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Single-cell transcriptomics of the ocular anterior segment: a comprehensive review.\nElucidating the cellular and genetic composition of ocular tissues is essential for uncovering the pathophysiology of ocular diseases. Since the introduction of single-cell RNA sequencing (scRNA-seq) in 2009, vision researchers have performed extensive single-cell analyses to better understand transcriptome complexity and heterogeneity of ocular structures. This technology has revolutionized our ability to identify rare cell populations and to make cross-species comparisons of gene expression in both steady state and disease conditions. Importantly, single-cell transcriptomic analyses have enabled the identification of cell-type specific gene markers and signalling pathways between ocular cell populations. While most scRNA-seq studies have been conducted on retinal tissues, large-scale transcriptomic atlases pertaining to the ocular anterior segment have also been constructed in the past three years. This timely review provides vision researchers with an overview of scRNA-seq experimental design, technical limitations, and clinical applications in a variety of anterior segment-related ocular pathologies. We review open-access anterior segment-related scRNA-seq datasets and illustrate how scRNA-seq can be an indispensable tool for the development of targeted therapeutics.</ABSTRACT>'}]
2024-01-02 00:26:40,541 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448953, Requested 1597. Please try again in 73ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,541 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Evaluation of intestinal ultrasound for disease activity assessment in patients with inflammatory bowel disease: A cross-sectional study at a tertiary centre in Malaysia.\nThe use of intestinal ultrasound (IUS) in the management of inflammatory bowel disease (IBD) is emerging. We aim to determine the performance of IUS in the assessment of disease activity in IBD.This is a prospective cross-sectional study of IUS performed on IBD patients in a tertiary centre. IUS parameters including intestinal wall thickness, loss of wall stratification, mesenteric fibrofatty proliferation, and increased vascularity were compared with endoscopic and clinical activity indices.Among the 51 patients, 58.8% were male, with a mean age of 41 years. Fifty-seven percent had underlying ulcerative colitis with mean disease duration of 8.4 years. Against ileocolonoscopy, IUS had a sensitivity of 67% (95% confidence interval (CI): 41-86) for detecting endoscopically active disease. It had high specificity of 97% (95% CI: 82-99) with positive and negative predictive values of 92% and 84%, respectively. Against clinical activity index, IUS had a sensitivity of 70% (95% CI: 35-92) and specificity of 85% (95% CI: 70-94) for detecting moderate to severe disease. Among individual IUS parameters, presence of bowel wall thickening (>3 mm) had the highest sensitivity (72%) for detecting endoscopically active disease. For per-bowel segment analysis, IUS (bowel wall thickening) was able to achieve 100% sensitivity and 95% specificity when examining the transverse colon.IUS has moderate sensitivity with excellent specificity in detecting active disease in IBD. IUS is most sensitive in detecting a disease at transverse colon. IUS can be employed as an adjunct in the assessment of IBD.</ABSTRACT>'}]
2024-01-02 00:26:40,541 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449446, Requested 1745. Please try again in 158ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,541 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>SHED-derived exosomes ameliorate hyposalivation caused by Sjgren\'s syndrome via Akt/GSK-3\u03b2/Slug-mediated ZO-1 expression.\nSjgren\'s syndrome (SS) is an autoimmune disorder characterized by sicca syndrome and/or systemic manifestations. The treatment is still challenging. This study aimed to explore the therapeutic role and mechanism of exosomes obtained from the supernatant of stem cells derived from human exfoliated deciduous teeth (SHED-exos) in sialadenitis caused by SS.SHED-exos were administered to the submandibular glands (SMGs) of 14-week-old non-obese diabetic (NOD) mice, an animal model of the clinical phase of SS, by local injection or intraductal infusion. The saliva flow rate was measured after pilocarpine intraperitoneal injection in 21-week-old NOD mice. Protein expression was examined by western blot analysis. Exosomal microRNA (miRNAs) were identified by microarray analysis. Paracellular permeability was evaluated by transepithelial electrical resistance measurement.SHED-exos were injected into the SMG of NOD mice and increased saliva secretion. The injected SHED-exos were taken up by glandular epithelial cells, and further increased paracellular permeability mediated by zonula occluden-1 (ZO-1). A total of 180 exosomal miRNAs were identified from SHED-exos, and Kyoto Encyclopedia of Genes and Genomes analysis suggested that the phosphatidylinositol 3 kinase (PI3K)/protein kinase B (Akt) pathway might play an important role. SHED-exos treatment down-regulated phospho-Akt (p-Akt)/Akt, phospho-glycogen synthase kinase 3\u03b2 (p-GSK-3\u03b2)/GSK-3\u03b2, and Slug expressions and up-regulated ZO-1 expression in SMGs and SMG-C6 cells. Both the increased ZO-1 expression and paracellular permeability induced by SHED-exos were abolished by insulin-like growth factor 1, a PI3K agonist. Slug bound to the ZO-1 promoter and suppressed its expression. For safer and more effective clinical application, SHED-exos were intraductally infused into the SMGs of NOD mice, and saliva secretion was increased and accompanied by decreased levels of p-Akt/Akt, p-GSK-3\u03b2/GSK-3\u03b2, and Slug and increased ZO-1 expression.Local application of SHED-exos in SMGs can ameliorate Sjgren syndrome-induced hyposalivation by increasing the paracellular permeability of glandular epithelial cells through Akt/GSK-3\u03b2/Slug pathway-mediated ZO-1 expression.</ABSTRACT>'}]
2024-01-02 00:26:40,542 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,542 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449463, Requested 1609. Please try again in 142ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,542 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Managing metastatic Crohn\'s disease: a single center experience, review of the current evidence, and treatment algorithm.\nCrohn\'s disease (CD) is an inflammatory bowel disease (IBD) that, besides gastrointestinal symptoms, may encompass extra-intestinal symptoms, such as dermatological manifestations. Of those, metastatic CD (MCD) is a rare extra-intestinal manifestation for which the management is uncertain.We conducted a retrospective case series of patients with MCD seen at the University hospital Leuven, Belgium, combined with an overview of the recent literature. Electronic medical records were searched from January 2003 till April 2022. For the literature search, Medline, Embase, Trip Database, and The Cochrane Library were searched from inception to April 1, 2022.A total of 11 patients with MCD were retrieved. In all cases noncaseating granulomatous inflammation was found on skin biopsies. Two adults and one child were diagnosed with MCD prior to their diagnosis of CD. Seven patients were treated with steroids (intralesional, topical or systemic). Six patients needed a biological therapy to treat MCD. Surgical excision was performed in three patients. All patients reported a successful outcome and most cases achieved remission. The literature search yielded 53 articles, including three reviews, three systematic reviews, 30 case reports and six case series. A treatment algorithm was generated based on literature and multidisciplinary discussion.MCD remains a rare entity and diagnosis is often difficult. A multidisciplinary approach including skin biopsy is necessary to diagnose and treat MCD efficiently. Outcome is generally favorable, and lesions respond well to steroids and biologicals. We propose a treatment algorithm based on the available evidence and multidisciplinary discussion.</ABSTRACT>'}]
2024-01-02 00:26:40,543 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449468, Requested 1427. Please try again in 119ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,543 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>The validity of hospital diagnostic and procedure codes reflecting morbidity in preterm neonates born <32 weeks gestation.\nTo determine the validity of diagnostic hospital billing codes for complications of prematurity in neonates <32 weeks gestation.Retrospective cohort data from discharge summaries and clinical notes (n\u2009=\u2009160) were reviewed by trained, blinded abstractors for the presence of intraventricular hemorrhage (IVH) grades 3 or 4, periventricular leukomalacia (PVL), necrotizing enterocolitis (NEC), stage 3 or higher, retinopathy of prematurity (ROP), and surgery for NEC or ROP. Data were compared to diagnostic billing codes from the neonatal electronic health record.IVH, PVL, ROP and ROP surgery had strong positive predictive values (PPV\u2009>\u200975%) and excellent negative predictive values (NPV\u2009>\u200995%). The PPVs for NEC (66.7%) and NEC surgery (37.1%) were low.Diagnostic hospital billing codes were observed to be a valid metric to evaluate preterm neonatal morbidities and surgeries except in the instance of more ambiguous diagnoses such as NEC and NEC surgery.</ABSTRACT>'}]
2024-01-02 00:26:40,543 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,545 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449426, Requested 1595. Please try again in 136ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,545 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Fibrosis in neovascular age-related macular degeneration: A review of definitions based on clinical imaging.\nDespite the success of antiangiogenic therapy in controlling exudation in neovascular age-related macular degeneration (nAMD), the involvement of the outer retina in fibrosis results in gradual vision loss over time. The development of drugs that prevent or ameliorate fibrosis in nAMD requires that it is accurately detected and quantified with reliable endpoints and identification of robust biomarkers. Achievement of such an aim is currently challenging due to the lack of a consensus definition of fibrosis in nAMD. As a first step towards the establishment of a clear definition of fibrosis, we provide an extensive overview of the imaging modalities and criteria used to characterize fibrosis in nAMD. We observed variety in the selection of individual and combinations of imaging modalities, and criteria for detection. We also observed heterogeneity in classification systems and severity scales for fibrosis. The most commonly used imaging modalities were color fundus photography, fluorescein angiography and optical coherence tomography (OCT). A multimodal approach was frequently utilized. Our review suggests that OCT offers a more detailed, objective and sensitive characterization than color fundus photography/fluorescein angiography. Thus, we recommend it as a primary modality for fibrosis evaluation. This review provides a basis for future discussions to reach a consensus definition using standardized terms based on a detailed characterization of fibrosis, its presence and evolution, and taking into consideration impact on visual function. Achieving this goal is of paramount importance for the development of antifibrotic therapies.</ABSTRACT>'}]
2024-01-02 00:26:40,554 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,554 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449331, Requested 1504. Please try again in 111ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,554 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Microcephaly and chorioretinopathy associated with TUBGCP4: a case report and a review of the literature.\nMicrocephaly and chorioretinopathy (MCCRP) is a rare autosomal recessive (AR) disorder characterized by microcephaly, developmental delay, chorioretinopathy, and visual impairment. We characterized the long-term phenotype of an additional patient with MCCRP associated with TUBCGP4 pathogenic variants and analysed previously reported cases in the literature.Analysis of clinical and genetic data of a patient with TUBGCP4-related MCCRP followed for more than 19\u2009years and literature search for previously reported patients with TUBCGP4 variants using PubMed, Scopus, and Google Scholar.Molecular diagnosis using exome sequencing demonstrated two TUBCGP4 variants in trans: c.1669C>T (p.Arg557*) and c.1746\u2009G>T (p.Leu582=). Clinical characteristics included microcephaly, microphthalmia, punched-out chorioretinal lesions, vision impairment, nystagmus, Tetralogy of Fallot and neurodevelopmental delay. Another six previously reported cases of TUBCGP4-related MCCRP were identified. Their clinical and genetic characteristics are compared.TUBCGP4-related microcephaly and chorioretinopathy, is a rare autosomal recessive neuro-ophthalmic disorder. Clinical characteristics in our proband have remained stable for two decades. The pathophysiology of this syndrome is not yet fully understood.</ABSTRACT>'}]
2024-01-02 00:26:40,557 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,557 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449268, Requested 1556. Please try again in 109ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,557 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>TFOS Lifestyle: Impact of elective medications and procedures on the ocular surface.\nThe word "elective" refers to medications and procedures undertaken by choice or with a lower grade of prioritization. Patients usually use elective medications or undergo elective procedures to treat pathologic conditions or for cosmetic enhancement, impacting their lifestyle positively and, thus, improving their quality of life. However, those interventions can affect the homeostasis of the tear film and ocular surface. Consequently, they generate signs and symptoms that could impair the patient\'s quality of life. This report describes the impact of elective topical and systemic medications and procedures on the ocular surface and the underlying mechanisms. Moreover, elective procedures performed for ocular diseases, cosmetic enhancement, and non-ophthalmic interventions, such as radiotherapy and bariatric surgery, are discussed. The report also evaluates significant anatomical and biological consequences of non-urgent interventions to the ocular surface, such as neuropathic and neurotrophic keratopathies. Besides that, it provides an overview of the prophylaxis and management of pathological conditions resulting from the studied interventions and suggests areas for future research. The report also contains a systematic review investigating the quality of life among people who have undergone small incision lenticule extraction (SMILE). Overall, SMILE refractive surgery seems to cause more vision disturbances than LASIK in the first month post-surgery, but less dry eye symptoms in long-term follow up.</ABSTRACT>'}]
2024-01-02 00:26:40,566 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:40,595 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,596 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448676, Requested 1538. Please try again in 28ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,596 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Real-world observational cohort study of treatment patterns and safety outcomes of infliximab biosimilar CT-P13 for the treatment of inflammatory bowel disease (CONNECT-IBD).\nThe objective of this non-interventional, observational prospective cohort study (CONNECT-IBD) was to assess the use of CT-P13 (Inflectra) in the treatment of patients with Crohn\'s disease (CD) and ulcerative colitis (UC) in the context of treatment with reference infliximab (IFX; Remicade).Patients (recruited April 2015 to October 2018) at 150 sites across 13 European countries were followed for up to 2\u2009years. Primary outcomes were safety, population characteristics, and drug utilization patterns. Secondary outcomes included clinical assessment of disease activity. Data were analyzed descriptively.Overall, 2543 patients (CD, n\u2009=\u20091676; UC, n\u2009=\u2009867) were included. In the CT-P13 cohort (n\u2009=\u20091522), median disease duration was 63 (0-579) months and 30% of patients were IFX nave; median duration of prior IFX treatment was 5\u2009months. During the observation period, median duration of drug exposure was 14 (0-28) months. 41% of patients reported 912 all-causality treatment-emergent adverse events (TEAEs); 24% experienced treatment-related TEAEs. Most TEAEs were of mild-to-moderate severity. Treatment-emergent serious adverse events were reported by 17% of patients.Safety information for CT-P13 in this large study was consistent with the known safety profile for IFX and did not alter the established benefit-risk profile of CT-P13.</ABSTRACT>'}]
2024-01-02 00:26:40,600 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,601 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449897, Requested 1374. Please try again in 169ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,601 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>A Rare Case of Blindness Caused by Syphilis with Malignant Hypertensive Nephropathy.\nThe number of patients with syphilis has been rapidly increasing. Without treatment, syphilis can damage various organs and become life-threatening. We herein report a 29-year-old woman diagnosed with neurosyphilis, acute hydrocephalus, syphilitic uveitis combined with hypertensive retinopathy, and malignant hypertensive nephropathy. To our knowledge, this is the first report of syphilis complicated with malignant hypertensive nephropathy proven by a renal biopsy. Neurosyphilis was successfully treated with intravenous penicillin G, and severe hypertension subsequently resolved. However, delayed medical examinations and complications of syphilitic uveitis and hypertensive retinopathy resulted in irreversible visual loss. To prevent irreversible organ damage, early treatment is essential.</ABSTRACT>'}]
2024-01-02 00:26:40,612 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,613 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,613 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,615 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449914, Requested 1463. Please try again in 183ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,615 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Late-Onset Hyponatremia in Premature Infants.\nLate-onset hyponatremia (LOH) frequently affects premature infants 2 or more weeks of age due to inadequate sodium intake and excessive kidney loss. Late-onset hyponatremia typically occurs in infants who are physiologically stable and is defined as serum sodium of 132 mEq/L or less or between 133 and 135 mEq/L if receiving sodium supplementation. Recent evidence suggests that spot urine sodium levels may improve the recognition of LOH, as low levels of excreted urine reflect a total body sodium deficit and negative balance. Untreated LOH may result in poor somatic growth, neurodevelopmental delay, higher incidence of bronchopulmonary dysplasia, and more severe retinopathy of prematurity. The primary prevention of LOH is to maintain serum sodium between 135 and 145 mEq/L; however, there are currently no formal protocols guiding sodium supplementation. The purpose of this article is to present on overview of LOH pathophysiology and its effect on somatic growth, neurodevelopment outcomes, and other related sequelae. We further discuss general management strategies and describe a protocol for sodium supplementation that is presently undergoing an evaluation for effectiveness.</ABSTRACT>'}]
2024-01-02 00:26:40,616 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449965, Requested 1181. Please try again in 152ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,616 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>The NOD audit: Insights into the current state of management for neovascular age-related macular degeneration.\n</ABSTRACT>'}]
2024-01-02 00:26:40,617 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449884, Requested 1472. Please try again in 180ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,617 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Vitreous Cortex Remnants Removal With Beveled Vitrectomy Probe During Vitrectomy For Primary Rhegmatogenous Retinal Detachment.\nTo introduce a new surgical technique with a beveled vitrectomy probe for the removal of peripheral vitreous cortex remnants (VCR) in primary rhegmatogenous retinal detachment (RRD).This study was a retrospective case series. From September 2019 to June 2022, 54 patients with complete or partial posterior vitreous detachment who underwent vitrectomy for primary RRD by a single surgeon were enrolled.After staining the vitreous with triamcinolone acetonide, the presence of VCR was assessed in detail. If VCR were present, the macular VCR were removed using surgical forceps, and then, a free flap of peripheral VCR was used as a handle for removing peripheral VCR using the beveled vitrectomy probe. Of the total patients, the presence of VCR was confirmed in 16 patients (29.6%). There were no intraoperative or postoperative complications, except for retinal redetachment caused by proliferative vitreoretinopathy, that occurred in only one eye (1.9%).Using a beveled vitrectomy probe was a practical solution for removing VCR during RRD vitrectomy because additional instruments were not needed and risk of iatrogenic retinal damage was low.</ABSTRACT>'}]
2024-01-02 00:26:40,628 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,628 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,630 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449802, Requested 1607. Please try again in 187ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,630 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Randomized controlled trials in central serous chorioretinopathy: A review.\nCentral serous chorioretinopathy (CSCR), a common chorioretinal disease, presents with a myriad of manifestations. Acute CSCR presents with localized neurosensory detachment whereas chronic CSCR may show widespread retinal pigment epithelium (RPE) changes, chronic shallow subretinal fluid, and\xa0choroidal neovascularization (CNV) suggestive of a variable natural history leading to suboptimal visual outcomes. Even though multiple treatment options including laser photocoagulation, photodynamic therapy, micropulse laser, anti-vascular endothelial growth factors, and systemic drugs (spironolactone, eplerenone, melatonin, mifepristone) are available, there is\xa0an absence of any standardized treatment protocol or gold standard treatment modality. Moreover, their performance compared to observation especially in acute CSCR is still debatable. Compared to other chorioretinal diseases such as age-related macular degeneration, diabetic retinopathy, diabetic macular oedema, and retinal vein occlusion, there is a\xa0relative dearth of randomized controlled trials in CSCR. Multiple inconsistencies including reliance on history of disease duration, variable inclusion criteria/disease descriptors/study endpoints, and availability of multiple treatment modalities lead to difficulties in designing RCTs. A consensus-based treatment protocol, therefore, is still elusive. We reviewed the literature and compiled the list of papers published to date, wherein we analyse and compare the inclusion criteria, imaging modalities, study endpoints, study\xa0duration, and\xa0study results. Correcting these discrepancies and deficiencies will help standardize future study designs, facilitating a next step toward\xa0a standardized treatment protocol.</ABSTRACT>'}]
2024-01-02 00:26:40,631 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449848, Requested 1176. Please try again in 136ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,631 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Endothelial Graft Orientation Marking Impairing Epiretinal Membrane Surgery Visualization.\n</ABSTRACT>'}]
2024-01-02 00:26:40,635 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:40,635 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,637 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449342, Requested 1580. Please try again in 122ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,637 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Early fecal calprotectin levels at week 8 may guide therapeutic decisions on Ustekinumab therapy in patients with Crohn\'s disease.\nResponse evaluation after induction therapy with ustekinumab (UST) in Crohn\'s disease (CD) is important for decisions on maintenance therapy. We aimed to assess the potential of fecal calprotectin (FC) levels to predict endoscopic response at week 16.CD patients with FC >100\u2009g/g and endoscopic active disease (SES-CD> 2, Rutgeerts\' score\u2009\u2265\u2009i2) at initiation of UST therapy were enrolled. FC was determined at weeks 0, 2, 4, 8 and 16 and patients underwent a colonoscopy at week 16. The primary outcome was an endoscopic response at week 16 (SES-CD score \u226550% decrease or a decrease of \u22651 points in Rutgeerts\' score). The optimal cut-off levels of FC and change in FC to predict endoscopic response were determined using ROC statistics.59\u2009CD patients were included. Endoscopic response was observed in 21/59 (36%) patients. The diagnostic accuracy for FC levels at week 8 to predict endoscopic response at week 16 showed a predictive value of 0.71. A decrease in FC levels \u2265500\u2009g/g between baseline at week 8 indicates endoscopic response (PPV = 89%), whereas absence of any decrease indicates endoscopic non-response after induction (NPV = 81%).Continuation of UST therapy without endoscopic response evaluation may be considered in patients with a decrease in FC levels of \u2265500\u2009g/g at week 8. The decision on continuation of UST therapy or therapy optimization needs reconsideration in patients without a decrease of FC level. In all other patients, endoscopic response evaluation of induction therapy remains essential for therapeutic decisions.</ABSTRACT>'}]
2024-01-02 00:26:40,643 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,645 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449287, Requested 1630. Please try again in 122ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,645 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Early Initiation of Dapagliflozin during Hospitalization for Acute Heart Failure Is Associated with a Shorter Hospital Stay.\nObjective Sodium-glucose co-transporter-2 inhibitors (SGLT2is), such as dapagliflozin, have a diuretic effect, and their early initiation to treat acute heart failure (AHF) may improve outcomes; however, the significance of the timing of starting dapagliflozin after hospital admission remains unclear. Methods We performed a post hoc analysis of a prospective, observational registry. Participants were divided into the early (E) group and late (L) group using the median time to the initiation of dapagliflozin (6 days) as the cut-off. We evaluated the relationship between the time to the initiation of dapagliflozin after hospital admission and patient characteristics and the length of the hospital stay. Patients Study subjects were 118 patients with AHF admitted between January 2021 and April 2022 who were started on dapagliflozin treatment (10 mg/day). Results Patients were divided into the E group (n=63) and L group (n=55). The HF severity as evaluated by the New York Heart Association class and the N-terminal pro-brain natriuretic peptide level was not significantly different between the groups. The time to the initiation of dapagliflozin and length of hospital stay showed a significant positive correlation (p<0.001, r=0.46). The hospital stay was significantly shorter in group E [median, 16.5 days; interquartile range (IQR): 13-22 days] than in group L (median, 22 days; IQR: 17-27 days; p=0.002). A multivariate logistic regression analysis showed that the early initiation of dapagliflozin was independently associated with a shorter hospital stay, even after multiple adjustments. Conclusion Early initiation of dapagliflozin after hospital admission is associated with a shorter hospital stay, suggesting it is a key factor for shortening hospital stays.</ABSTRACT>'}]
2024-01-02 00:26:40,655 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,656 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449286, Requested 1827. Please try again in 148ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,656 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Prediction of Acute Myocardial Injury in Noncardiac Surgery in Patients at Risk for Major Adverse Cardiovascular and Cerebrovascular Events: A Multivariable Risk Model.\nThe best use of perioperative cardiac biomarkers assessment is still under discussion. Massive postoperative troponin surveillance can result in untenably high workloads and costs for health care systems and potentially harmful interventions for patients. In a cohort of patients at risk for major adverse cardiovascular and cerebrovascular events (MACCEs), we aimed to (1) determine whether preoperative biomarkers can identify patients at major risk for acute myocardial injury in noncardiac surgery, (2) develop a risk model for acute myocardial injury prediction, and (3) propose an algorithm to optimize postoperative troponin surveillance.Prospective, single-center cohort study enrolling consecutive adult patients (\u226545 years) at risk for MACCE scheduled for intermediate-to-high-risk noncardiac surgery. Baseline high-sensitivity troponin T (hsTnT) and N-terminal fragment of pro-B-type natriuretic peptide (NT-proBNP), as well as hsTnT on the first 3 postoperative days were obtained. The main outcome was the occurrence of acute myocardial injury. Candidate predictors of acute myocardial injury were baseline concentrations of hsTnT \u226514 ng/L and NT-proBNP \u2265300 pg/mL and preoperative and intraoperative variables. A multivariable risk model and a decision curve were constructed.Of 732 patients, 42.1% had elevated hsTnT and 37.3% had elevated NT-proBNP levels at baseline. Acute myocardial injury occurred in 161 patients (22%). Elevated baseline hsTnT, found in 84% of patients with acute myocardial injury, was strongly associated with this outcome: odds ratio (OR), 12.08 (95% confidence interval [CI], 7.78-19.42). Logistic regression identified 6 other independent predictors for acute myocardial injury: age, sex, estimated glomerular filtration rate (eGFR) <45 mLmin -1 1.73 m -2 , functional capacity <4 METs or unknown, NT-proBNP \u2265300 pg/mL, and estimated intraoperative blood loss. The c -statistic for the risk model was 77% (95% CI, 0.73-0.81). The net benefit of the model began at a risk threshold of 7%.Baseline determination of cardiac biomarkers in patients at risk for MACCE shortly before intermediate- or high-risk noncardiac surgery helps identify those with the highest risk for acute myocardial injury. A baseline hsTnT \u226514 ng/L indicates the need for postoperative troponin surveillance. In patients with baseline hsTnT <14 ng/L, our 6-predictor model will identify additional patients at risk for acute myocardial injury who may also benefit from postoperative surveillance.</ABSTRACT>'}]
2024-01-02 00:26:40,658 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,659 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449254, Requested 1524. Please try again in 103ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,659 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Identification of new candidate drugs for primary Sjgren\'s syndrome using a drug repurposing transcriptomic approach.\nTo date, no immunomodulatory drug has demonstrated its efficacy in primary SS (pSS). We sought to analyse potential commonalities between pSS transcriptomic signatures and signatures of various drugs or specific knock-in or knock-down genes.Gene expression from peripheral blood samples of patients with pSS was compared with that of healthy controls in two cohorts and three public databases. In each of the five datasets, we analysed the 150 most up- and downregulated genes between pSS patients and controls with regard to the differentially expressed genes resulting from the biological action on nine cell lines of 2837 drugs, 2160 knock-in and 3799 knock-down genes in the Connectivity Map database.We analysed 1008 peripheral blood transcriptomes from five independent studies (868 patients with pSS and 140 healthy controls). Eleven drugs could represent potential candidate drugs, with histone deacetylases and PI3K inhibitors among the most significantly associated. Twelve knock-in genes were associated with a pSS-like profile and 23 knock-down genes were associated with a pSS-revert profile. Most of those genes (28/35, 80%) were interferon-regulated.This first drug repositioning transcriptomic approach in SS confirms the interest of targeting interferons and identifies histone deacetylases and PI3K inhibitors as potential therapeutic targets.</ABSTRACT>'}]
2024-01-02 00:26:40,660 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,661 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449173, Requested 1612. Please try again in 104ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,661 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>The prevalence and presentation patterns of microcystic macular oedema: a systematic review and meta-analysis of 2128 glaucomatous eyes.\nWe conducted this research to determine the prevalence rate and presentation patterns with microcystic macular oedema (MMO) in glaucoma patients. The protocol was pre-registered on PROSPERO ( CRD42022316367 ). PubMed, Scopus, Web of Science, EMBASE, ProQuest, EBSCOHost, CENTRAL, clinicaltrials.gov, and Google Scholar were searched for articles reporting MMO in glaucoma patients. The primary outcome was the prevalence of MMO, while secondary outcomes included the comparison between MMO and non-MMO in terms of patients\' characteristics (age, gender), glaucoma stage, and ocular parameters (axial length (AL), intraocular pressure, mean deviation, spherical equivalent). Data are reported as mean difference (MD) or log odds ratio (logOR) along with their corresponding 95% confidence intervals (CI) for continuous and dichotomous outcomes, respectively. The quality of included studies was assessed using the NIH tool, and the certainty of evidence was assessed using GRADE framework. Ten studies (2128 eyes) were included, revealing an overall prevalence rate of MMO of 8% (95%CI: 5-12%). When compared to non-MMO group, MMO was associated with lower age (MD\u2009=\u2009-5.91; 95%CI: -6.02: -5.20), greater risk of advanced glaucoma stage (LogOR=1.41; 95%CI: 0.72: 2.09), and lower mean deviation of the visual field (MD\u2009=\u2009-5.00; 95%CI: -7.01: -2.99). No significant difference was noted between both groups in terms of gender, axial length, or spherical equivalent. Three studies had good quality while seven had poor quality. MMO is a prevalent observation in glaucoma patients and is associated with patients\' age and stage of the disease. However, the certainty of evidence remains very low.</ABSTRACT>'}]
2024-01-02 00:26:40,666 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,667 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,668 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449163, Requested 1607. Please try again in 102ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,668 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Phenotypic diversity observed in a Chinese patient cohort with biallelic variants in Bardet-Biedl syndrome genes.\nBardet-Biedl syndrome (BBS) is a rare multisystem ciliopathy. The aim of this study was to describe the clinical and genetic features of a cohort of Chinese patients carrying biallelic BBS gene variants.We recruited 34 patients from 31 unrelated pedigrees who carried biallelic pathogenic variants in BBS genes. All patients underwent ophthalmic and systematic evaluations, as well as comprehensive molecular genetic analyses. Ultimately, 14 patients were followed up over time.We identified 47 diseasing-causing variants in 10 BBS genes; 33 were novel. Diagnosis of BBS and non-syndromic retinitis pigmentosa (RP) were established in 28 patients from 27 pedigrees and 6 patients, respectively. The two most prevalent genes in patients with BBS were BBS2 and BBS4, accounting for 51.8% of the probands. The patients exhibited clinical heterogeneity, from patients with all six primary clinical components to patients suffering from non-syndromic RP. The common components were retinal dystrophy, polydactyly, and obesity, with frequencies of 78.6% to 100%, while renal anomaly frequencies were only 7.1%. Patients exhibited early and severe visual defects and retinal degeneration. Patients with biallelic missense variants in BBS2 suffered fewer clinical symptoms and mild visual impairment. Patients with BBS10 variants tended to have cone dystrophy.Our study defined the mutated gene profiles and established the configuration of the variation frequencies for each BBS gene in Chinese patients. Overall, our patients showed early and severe visual defects and retinal degeneration. Genetic analysis is therefore crucial for diagnosis, genetic counseling, and future gene therapy in these patients.</ABSTRACT>'}]
2024-01-02 00:26:40,668 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449238, Requested 1604. Please try again in 112ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,668 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Comparison of long-term treatment outcomes of laser and anti-VEGF therapy in retinopathy of prematurity: a multicentre study from J-CREST group.\nTo compare real-world, long-term outcomes of laser and anti-vascular endothelial growth factor (VEGF) therapies in patients with retinopathy of prematurity (ROP).This was a multicentre retrospective study. We included 264 eyes of 139 patients treated for type 1 ROP or aggressive ROP (AROP) who were followed for at least 4 years. Laser treatment was initially performed in 187 eyes (the laser group), and anti-VEGF therapy was initially performed in 77 eyes (the anti-VEGF group). We collected data on sex, birth characteristics, zone, stage, and the presence of plus disease at the time of treatment and best-corrected visual acuity (BCVA), spherical equivalent (SE), and ocular complications (amblyopia and strabismus) in patients aged 4-6 years. We investigated the associations between treatment outcomes (BCVA, SE and the presence of amblyopia and strabismus) and influencing factors, including treatment procedure (anti-VEGF or laser therapy), sex, birth characteristics, zone, stage, and the presence of plus disease, using multivariable analysis and logistic regression analyses.The initial treatment procedure was not associated with any specific treatment outcome. Subgroup analysis of patients with zone I ROP revealed that the anti-VEGF-treated eyes had significantly better BCVA and higher SE than laser-treated eyes (p\u2009=\u20090.004, p\u2009=\u20090.009, respectively). Female patients presented significantly better BCVA, less amblyopia and less strabismus than male patients (p\u2009<\u20090.001, p\u2009=\u20090.029, p\u2009=\u20090.008, respectively).In zone I ROP, anti-VEGF therapy led to better visual acuity and less myopic refractive error than laser treatment.</ABSTRACT>'}]
2024-01-02 00:26:40,669 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,669 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449150, Requested 1662. Please try again in 108ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,669 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Comparison of quantitative assessment and efficiency of diabetic retinopathy diagnosis using ETDRS seven-field imaging and two ultra-widefield imaging.\nThis study compared the efficiency of diabetic retinopathy (DR) diagnosis and differences in the relative visible retinal area among the Early Treatment Diabetic Retinopathy Study (ETDRS) seven-field, ultra-widefield (UWF)-Optos, and UWF-Clarus fundus imaging methods.This was a prospective and clinic-based comparative study. All patients underwent three fundus examinations, and all images were graded using the ETDRS severity scale. We compared and analysed the agreement of DR severity and the relative visible retinal area among the three fundus examination methods, and the number and type of lesions outside the ETDRS seven-field (peripheral lesions) between the two UWF imaging methods.A total of 202 patients (386 eyes) were included. Weighted kappa for the agreement between ETDRS seven-field and blinded Optos images was 0.485; between ETDRS seven-field and blinded Clarus images, 0.924; and between blinded Optos and Clarus images, 0.461. Blinded Clarus showed excellent performance when a ETDRS scale was used for grading the images. The relative visible retinal area for ETDRS seven-field images was 195\u2009\u200928 disc area (DA); single Optos images, 371\u2009\u200969 DA; single Clarus images, 261\u2009\u200965 DA; two-montage Clarus images, 462\u2009\u2009112 DA; and four-montage Clarus images, 598\u2009\u2009139 DA. The relative visible retinal area was statistically significant between any two of the imaging systems used. In total, 2015 and 4200 peripheral lesions were detected in single Optos and Clarus images, respectively (P\u2009<\u20090.001). These peripheral lesions on two UWF images suggested a more severe DR level in approximately 10% and 12% of eyes, respectively.UWF-Clarus fundus imaging offers a suitable assessment approach for DR severity; it could improve DR diagnosis and has the potential to replace ETDRS seven-field imaging after additional clinical trials.</ABSTRACT>'}]
2024-01-02 00:26:40,685 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:40,702 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:40,702 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,705 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,705 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,706 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,707 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449452, Requested 1643. Please try again in 146ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,707 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Optical coherence tomography-based misdiagnosis and morphological distinction in pachychoroid neovasculopathy vs. polypoidal choroidal vasculopathy.\nTo evaluate the rate of misdiagnosis of aneurysmatic pachychoroid type 1 choroidal neovascularization/polypoidal choroidal vasculopathy (PAT1/PCV) among cases diagnosed as non-aneurysmatic pachychoroid neovasculopathy (PNV) and to define optical coherence tomography (OCT) features facilitating their distinction.The database of the Department of Ophthalmology, Ludwig-Maximilians University Munich, was screened for patients diagnosed with PNV. Multimodal imaging was screened for the presence of choroidal neovascularization (CNV) and aneurysms/polyps. Imaging features facilitating the diagnosis of PAT1/PCV were analysed.In total, 49 eyes of 44 patients with a clinical PNV diagnosis were included, of which 42 (85.7%) had PNV and 7 (14.3%) represented misdiagnosed PAT1/PCV. SFCT was comparable (PNV: 377\u2009\u200992 vs. PAT1/PCV: 400\u2009\u200983\u2009m; p\u2009=\u20090.39). Whereas no difference was detected in total pigment epithelium detachment (PED) diameter (p\u2009=\u20090.46), maximum PED height was significantly higher in the PAT1/PCV group (199\u2009\u200931 vs. 82\u2009\u200946, p\u2009<\u20090.00001). In a receiver operating characteristic (ROC) analysis, the optimum cutoff for defining "peaking PED" was 158\u2009m with an area under the curve of 0.969, a sensitivity of 1.0 (95% CI: 0.59-1.0), and a specificity of 0.95 (95% CI: 0.84-0.99). Sub-retinal hyperreflective material (SHRM; p\u2009=\u20090.04), sub-retinal ring-like structures (SRRLS; p\u2009<\u20090.00001), and sub-RPE fluid (p\u2009=\u20090.04) were significantly more frequent in eyes with PAT1/PCV.A relevant percentage of eyes diagnosed with PNV might instead suffer from PAT1/PCV. The detection of a maximum PED height ("peaking PED") exceeding approximately 150\u2009m, SHRM, SRRLS, and sub-RPE fluid might greatly aid in the production of a more accurate diagnosis.</ABSTRACT>'}]
2024-01-02 00:26:40,709 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449440, Requested 1601. Please try again in 138ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,709 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Bile acid alterations associated with indolent course of inflammatory bowel disease.\nThe indolent course of treatment-naive patients with inflammatory bowel disease (IBD) is confirmed predictable based on clinical characteristics. Current evidences supported that bile acids (BAs) alteration might be promising biomarkers in the field of IBD. We aimed to analyze the alterations of BAs as the disease progresses and explore their predictive value for indolent course of IBD.The indolent course of IBD was defined as a disease course without need for strict interventions throughout the entire follow-up. A targeted metabolomics method was used to detect the concentration of 27 BAs from serum sample in treatment-naive patients with IBD (Crohn\'s disease [CD], n\u2009=\u200927; ulcerative colitis [UC], n\u2009=\u200950). Patients with CD and UC were individually divided into two groups for further study according to the median time of indolent course. The overall BAs profile and the clinical value of BAs in predicting indolent course of IBD were identified between different groups.For CD, the levels of deoxycholic acid, glycodeoxycholic acid, taurodeoxycholic acid, glycolithocholic acid-3-sulfate disodium salt and iso-lithocholic acid were significantly increased in patients with indolent course > 18\u2009M (p\u2009<\u20090.05). These five BAs owned 83.5% accuracy for predicting indolent course over 18\u2009months in CD. For UC, the concentration of deoxycholic acid and glycodeoxycholic acid were significantly higher, while dehydrocholic acid were lower in patients with indolent course > 48\u2009M (p\u2009<\u20090.05). These three BAs predicted indolent course over 48\u2009months of 69.8% accuracy in UC.The specific BAs alterations might be potential biomarkers in predicting disease course of IBD patients.</ABSTRACT>'}]
2024-01-02 00:26:40,709 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449555, Requested 1612. Please try again in 155ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,709 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Aflibercept monotherapy versus aflibercept with targeted retinal laser to peripheral retinal ischemia for diabetic macular oedema (LADAMO).\nWe tested the hypothesis that targeted retinal laser photocoagulation (TPRP) to peripheral retinal ischaemia reduces the overall burden of aflibercept injections when treating diabetic macular oedema (DMO) over a 24-month period.Prospective, double-masked, multicentre, randomised controlled trial in Australia comparing aflibercept monotherapy, following a treat-and-extend protocol, or combination therapy of aflibercept and TPRP for DMO. The aflibercept monotherapy group received placebo laser. The primary outcome measure was the mean number of intravitreal aflibercept injections for each group at 24 months. Secondary outcome included: mean change in central macular thickness (CMT) and vision at trial completion, the proportion of eyes whose DMO resolved and the mean injection treatment interval. Ocular and systemic adverse events were recorded.We enrolled 48 eyes of 47 patients; 27 eyes were randomised to combination therapy (aflibercept and TPRP) and 21 to aflibercept monotherapy. Thirty-two eyes (67%) completed the 2-year study. The number of intravitreal treatments given were similar for combination therapy (10.5 (SD 5.8) and monotherapy (11.8 (SD5.6)) (P\u2009=\u20090.44). The mean visual improvement (+4.0 (-1.8, 9.8) and +7.8 (2.6, 12.9) letters, P\u2009=\u20090.32), mean decrease in CMT (-154 (-222,-87)\u2009m and -152 (-218,-86)\u2009m, P\u2009=\u20090.96), proportion of eyes with CMT\u2009<\u2009300\u2009m (48% and 67%; P\u2009=\u20090.50) and safety outcomes were similar in both the combination and monotherapy treatment groups (respectively).Laser to areas of ischaemic peripheral retina does not reduce the burden of intravitreal aflibercept injections when treating diabetic macular oedema.</ABSTRACT>'}]
2024-01-02 00:26:40,710 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449434, Requested 1391. Please try again in 110ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,710 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Results of the Eighth Scientific Workshop of ECCO: Prevention and Treatment of Postoperative Recurrence in Patients With Crohn\'s Disease Undergoing an Ileocolonic Resection With Ileocolonic Anastomosis.\nDespite the introduction of biological therapies, an ileocolonic resection is often required in patients with Crohn\'s disease [CD]. Unfortunately, surgery is not curative, as many patients will develop postoperative recurrence [POR], eventually leading to further bowel damage and a decreased quality of life. The 8th Scientific Workshop of ECCO reviewed the available scientific data on both prevention and treatment of POR in patients with CD undergoing an ileocolonic resection, dealing with conventional and biological therapies, as well as non-medical interventions, including endoscopic and surgical approaches in case of POR. Based on the available data, an algorithm for the postoperative management in daily clinical practice was developed.</ABSTRACT>'}]
2024-01-02 00:26:40,711 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,712 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449362, Requested 1820. Please try again in 157ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,712 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Analysis of the Imaging Features and Prognosis of Pulmonary Tuberculosis Complicated with Pulmonary Embolism.\nThis study aimed to explore the imaging characteristics of patients with pulmonary tuberculosis complicated with pulmonary embolism and analyze the prognosis of the condition, thereby reducing the mortality and misdiagnosis rate of complications in this type of pulmonary tuberculosis.In this retrospective study, a total of 70 patients diagnosed with pulmonary embolism by computed tomography pulmonary angiography (CTPA) from January 2016 to May 2021 in Anhui Chest Hospital were included. Among them, 35 patients with pulmonary embolism combined with pulmonary tuberculosis were set as the study group, and the other 35 patients with pulmonary embolism only were set as the control group. The imaging findings of chest CT examination, the incidence of pulmonary hypertension, the level of N-terminal proto-B-type brain natriuretic peptide (NT-proBNP), and the prognosis of patients were compared between the two groups. The incidence of deep venous embolism was evaluated by ultrasonography of the lower extremity.In the study group, the median age of patients was 71 years, and the ratio of males to females was 2.5 to 1. In the control group, the median age was 66 years old, and the male-to-female ratio was 2.2 to 1. There were 16 cases (16/35, 45.71%) in the study group and 10 cases (10/35, 28.57%) in the control group with an increased level of NT-proBNP. Pulmonary hypertension occurred in 10 patients (10/35, 28.57%) in the study group and 7 patients (7/35, 20.00%) in the control group. Patients who lost follow-up included 5 in the study group (5/35, 14.29%) and 3 in the control group (3/35, 8.57%). There were 17 cases (17/35, 48.57%) in the study group and 3 cases (3/35, 8.57%) in the control group with pulmonary artery widening, and the difference was significant (P < 0.001). There were 13 deaths in the study group (13/35, 37.14%) and 1 death in the control group (1/35, 2.86%), and the difference was significant (P <0.001).Special signs of pulmonary artery widening, pulmonary hypertension of varying degrees, and increased levels of NT-proBNP of varying degrees can be found in patients with pulmonary tuberculosis complicated with pulmonary embolism, and the three signs are positively correlated. The mortality of patients with pulmonary tuberculosis complicated with pulmonary embolism is significantly higher than that of patients with pulmonary embolism alone. Pulmonary tuberculosis and pulmonary embolism both occur in the ipsilateral lung, causing clinical symptoms to cover each other, thereby making diagnosis difficult.</ABSTRACT>'}]
2024-01-02 00:26:40,736 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,737 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449212, Requested 1533. Please try again in 99ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,737 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Anisometric Cell/Dysplastic Lipomas in a Retinoblastoma Survivor: Report of a Case with Review of the Literature.\nDifferent authors have recently described a subtype of lipoma characterized by variation of adipocyte size, single cell fat necrosis, and a subset with minimal to mild nuclear atypia, and termed these as anisometric cell/dysplastic lipoma (AC/DL). These lipomas follow a benign course and rarely recur. In 3 examples, AC/DL has occurred in patients with childhood retinoblastoma (RB). We report another such example where multiple AC/DL occurred in the neck and back of a 30-year-old male who had germline RB1 gene deletion and bilateral RB in infancy. On excision, all tumors histologically showed similar morphology of adipocyte anisometry, focal single cell necrosis with surrounding binucleated or multinucleated histiocytes, hyperchromatic and minimally atypical lipocyte nuclei, vacuolated Lockhern change, rare foci of fibromyxoid change, occasional mononuclear cell clusters around capillaries, and loss of RB1 immunostaining. Unequivocal atypical cells, lipoblasts, floret-nucleated or multinucleated giant cells were absent. Molecular analysis of tumor cells showed monoallelic RB1 gene loss without amplification of MDM2 and CDK4 genes. Short-term follow up did not show tumor recurrence. AC/DLs in RB survivors are characterized by multiplicity, unifying histology, and benign course. Their biology appears distinct from ordinary lipomas, spindle cell lipomas, and atypical lipomatous tumors.</ABSTRACT>'}]
2024-01-02 00:26:40,745 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,746 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449039, Requested 1589. Please try again in 83ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,746 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Inflammatory Bowel Disease and Risk of Colorectal Polyps: A Nationwide Population-Based Cohort Study From Sweden.\nInflammatory bowel disease [IBD] has been linked to an increased risk of colorectal neoplasia. However, the types and risks of specific polyp types in IBD are less clear.We identified 41 880 individuals with IBD (Crohn\'s disease [CD: n\u2005=\u200512 850]; ulcerative colitis [UC]: n\u2005=\u200529 030]) from Sweden matched with 41 880 reference individuals. Using Cox regression, we calculated adjusted hazard ratios [aHRs] for neoplastic colorectal polyps [tubular, serrated/sessile, advanced and villous] defined by histopathology codes.During follow-up, 1648 [3.9%] IBD patients and 1143 [2.7%] reference individuals had an incident neoplastic colorectal polyp, corresponding to an incidence rate of 46.1 and 34.2 per 10 000 person-years, respectively. This correlated to an aHR of 1.23 (95% confidence interval [CI] 1.12-1.35) with the highest HRs seen for sessile serrated polyps [8.50, 95% CI 1.10-65.90] and traditional serrated adenomas [1.72, 95% CI 1.02-2.91]. aHRs for colorectal polyps were particularly elevated in those diagnosed with IBD at a young age and at 10 years after diagnosis. Both absolute and relative risks of colorectal polyps were higher in UC than in CD [aHRs 1.31 vs 1.06, respectively], with a 20-year cumulative risk difference of 4.4% in UC and 1.5% in CD, corresponding to one extra polyp in 23 patients with UC and one in 67 CD patients during the first 20 years after IBD diagnosis.In this nationwide population-based study, there was an increased risk of neoplastic colorectal polyps in IBD patients. Colonoscopic surveillance in IBD appears important, especially in UC and after 10 years of disease.</ABSTRACT>'}]
2024-01-02 00:26:40,766 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,769 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,771 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448913, Requested 1383. Please try again in 39ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,771 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Results of the Eighth Scientific Workshop of ECCO: Pathophysiology and Risk Factors of Postoperative Crohn\'s Disease Recurrence after an Ileocolonic Resection.\nPostoperative recurrence [POR] after an ileocolonic resection with ileocolonic anastomosis is frequently encountered in patients with Crohn\'s disease. The 8th Scientific Workshop of ECCO reviewed the available evidence on the pathophysiology and risk factors for POR. In this paper, we discuss published data on the role of the microbiome, the mesentery, the immune system and the genetic background. In addition to investigating the causative mechanisms of POR, identification of risk factors is essential to tailor preventive strategies. Potential clinical, surgical and histological risk factors are presented along with their limitations. Emphasis is placed on unanswered research questions, guiding prevention of POR based on individual patient profiles.</ABSTRACT>'}]
2024-01-02 00:26:40,771 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448909, Requested 1331. Please try again in 32ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,771 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Cell-Based Therapies: Strategies for Regeneration.\nThe neural retina of mammals, like most of the rest of the central nervous system, does not regenerate new neurons after they are lost through damage or disease. The ability of nonmammalian vertebrates, like fish and amphibians, is remarkable, and lessons learned over the last 20 years have revealed some of the mechanisms underlying this potential. This knowledge has recently been applied to mammals to develop methods that can stimulate regeneration in mice. In this review, we highlight the progress in this area, and propose a "wish list" of how the clinical implementation of regenerative strategies could be applicable to various human retinal diseases.</ABSTRACT>'}]
2024-01-02 00:26:40,778 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,779 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448873, Requested 1650. Please try again in 69ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,779 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Visual acuity time in range: a novel concept to describe consistency in treatment response in diabetic macular oedema.\nTo assess \'time in range\' as a novel measure of treatment response in diabetic macular oedema (DMO).This post hoc analysis of the Protocol T randomised clinical trial included 660 individuals with centre-involved DMO and best-corrected visual acuity (BCVA) letter score \u226478-\u226524 (approximate Snellen equivalent 20/32-20/320). Study participants received intravitreal aflibercept 2.0\u2009mg, repackaged (compounded) bevacizumab 1.25\u2009mg, or ranibizumab 0.3\u2009mg given up to every 4 weeks using defined retreatment criteria. Mean time in range was calculated using a BCVA letter score threshold of \u226569 (20/40 or better; minimum driving requirement in many regions), with sensitivity analyses using BCVA thresholds from 100 to 0 (20/10 to 20/800) in 1-letter increments.Time in range was defined as either the absolute or relative duration above a predefined BCVA threshold, measured in weeks or as a percentage of time, respectively. Using a BCVA letter score threshold of \u226569 (20/40 or better), the least squares mean time in range (adjusted for baseline BCVA) in Year 1 was 41.2 weeks with intravitreal aflibercept, 4.0 weeks longer (95% CI: 1.7, 6.3; p\u2009=\u20090.002) than bevacizumab and 3.6 weeks longer (1.3, 5.9; p\u2009=\u20090.004) than ranibizumab. Overall, mean time in range was numerically longer for intravitreal aflibercept for all BCVA letter score thresholds between 92 and 30 (20/20 to 20/250). In the Day 365-728 analysis, time in range was 3.9 (1.3, 6.5) and 2.4 (0.0, 4.9) weeks longer with intravitreal aflibercept vs bevacizumab and vs ranibizumab (p\u2009=\u20090.011 and 0.106), respectively.BCVA time in range may represent another way to describe visual outcomes and potential impact on vision-related functions over time for patients with DMO and provide a better understanding, for physicians and patients, of the consistency of treatment efficacy.</ABSTRACT>'}]
2024-01-02 00:26:40,791 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,792 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448795, Requested 1689. Please try again in 64ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,792 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Skin-Only Versus Skin-Plus-Orbicularis Resection Blepharoplasty: An Elaborated Analysis of Early- and Long-Term Effects on Corneal Nerves, Meibomian Glands, Dry Eye Parameters, and Eyebrow Position.\nTo evaluate the early- and long-term effects of 2 different blepharoplasty techniques on corneal nerves, meibomian gland morphology, clinical parameters of dry eye disease (DED), and eyebrow position.This prospective, interventional study included age-sex-matched blepharoplasty patients who had a skin-only resection (24 eyes of 12 patients; Group-S) or a skin-plus-orbicularis muscle resection (24 eyes of 12 patients; Group-M) procedure. Preoperative and postoperative parameters of in vivo corneal confocal microscopy (IVCCM; corneal nerve fiber density [CNFD], nerve branch density [CNBD], and nerve fiber length), meibomian gland area loss (MGAL), DED (Schirmer I test and noninvasive tear breakup time), and eyebrow heights (lateral [LBH] and central [CBH]) were evaluated and compared between the intervention groups ( ClinicalTrials.gov , NCT05528016).Compared with baseline, the CNBD of Group-S (19.91\u2009\u20097.66 vs. 16.05\u2009\u20097.28 branches/mm 2 , p = 0.049) and CNFD of Group-M (19.52\u2009\u20097.45 vs. 16.80\u2009\u20096.95 fibers/mm 2 , p = 0.028) was significantly decreased at postoperative first week. However, in both groups, IVCCM parameters returned to baseline values at postoperative first month and first year ( p > 0.05). A significant MGAL increase was observed in Group-S (18.47\u2009\u20095.43 vs. 19.94\u2009\u20095.31, p = 0.030) and Group-M (18.86\u2009\u20097.06 vs. 20.12\u2009\u20097.01, p = 0.023) at the postoperative first year, demonstrating meibomian gland atrophy. Only significant changes were observed in Group-M in LBH (16.17\u2009\u20092.45 vs. 16.67\u2009\u20092.28\u2009mm, p = 0.044) and CBH (17.33\u2009\u20092.35 vs. 17.96\u2009\u20092.31\u2009mm, p = 0.004) at postoperative first year.Blepharoplasty with or without orbicularis resection seems to have similar effects on IVCCM, DED, and MGAL parameters. However, incorporating an orbicularis muscle resection in a blepharoplasty operation could slightly elevate the eyebrow position.</ABSTRACT>'}]
2024-01-02 00:26:40,822 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,824 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448678, Requested 1601. Please try again in 37ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,824 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>A randomized, double-blind, placebo-controlled, parallel group study on the effects of a cathepsin S inhibitor in primary Sjgren\'s syndrome.\nPrimary SS (pSS) is a chronic autoimmune disorder characterized by mucosal dryness and systemic symptoms. We tested the effects of inhibition of cathepsin S using the potent and selective inhibitor RO5459072 on disease activity and symptoms of pSS.This was a randomized, double-blind, placebo-controlled, parallel-group, Phase IIA study to investigate the effects of RO5459072 (100\u2009mg twice daily; 200\u2009mg per day). Seventy-five patients with pSS were randomized 1:1 to receive either RO5459072 or placebo for 12\u2009weeks. The primary outcome was the proportion of patients with a \u22653 point reduction from baseline in EULAR SS Disease Activity Index (ESSDAI) score. We also investigated the effects of RO5459072 on quality of life, exocrine gland function, biomarkers related to SS, and safety and tolerability.The proportion of patients showing an improvement in ESSDAI score was not significantly different between the RO5459072 and placebo arms. No clinically meaningful treatment effects were observed in favour of RO5459072 for all secondary outcomes. Analysis of soluble biomarkers indicated target engagement between RO5459072 and cathepsin S. There were modest decreases in the number of circulating B cells and T cells in the RO5459072 group, although these did not reach significance. RO5459072 was safe and well-tolerated.There was no clinically relevant improvement in ESSDAI score (primary endpoint), and no apparent benefit in favour of RO5459072 in any of the secondary clinical endpoints. Further work is needed in order to understand the mechanisms of MHC-II-mediated immune stimulation in pSS.ClinicalTrials.gov; NCT02701985.</ABSTRACT>'}]
2024-01-02 00:26:40,830 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,833 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448678, Requested 1535. Please try again in 28ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,833 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Obefazimod: A First-in-class Drug for the Treatment of Ulcerative Colitis.\nBiologic agents and oral small molecules are the mainstays of inflammatory bowel disease [IBD] management. However, an unmet clinical need remains for additional agents with novel mechanism of action which are effective, safe, and disease-modifying; this is due to the substantial proportion of patients who do not respond, lose response, or develop intolerance to currently marketed products. microRNAs [miRNAs] that play a role in the modulation of signal transduction pathways implicated in the development of IBD hold the potential to be used as therapeutic targets. Recently, a novel first-in-class compound, obefazimod, originally conceived as a human immunodeficiency virus [HIV] infection drug, has shown great promise in phase II induction trials for ulcerative colitis [UC] patients. Findings from the maintenance phases of trials showed that long-term obefazimod treatment provides continued improvement in clinical symptoms of disease, with a substantial proportion of patients in clinical remission, and an overall good safety profile. With a novel mechanism of action, obefazimod is an orally available small molecule with anti-inflammatory properties through the specific and selective upregulation of miR-124 expression. The aim of this paper is to critically review the available evidence related to pharmacokinetics and pharmacodynamics, and to discuss the potential clinical implications of this first-in-class oral small molecule.</ABSTRACT>'}]
2024-01-02 00:26:40,835 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,835 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448538, Requested 1599. Please try again in 18ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,835 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Effect of Accessible Nonmydriatic Retinal Imaging on Diabetic Retinopathy Surveillance Rates.\nPurpose: To evaluate the impact on surveillance rates for diabetic retinopathy (DR) by providing nonmydriatic retinal imaging as part of comprehensive diabetes care at no cost to patients or insurers. Methods: A retrospective comparative cohort study was designed. Patients were imaged from April 1, 2016 to March 31, 2017 at a tertiary diabetes-specific academic medical center. Retinal imaging was provided without additional cost beginning October 16, 2016. Images were evaluated for DR and diabetic macular edema using standard protocol at a centralized reading center. Diabetes surveillance rates before and after no-cost imaging were compared. Results: A total of 759 and 2,080 patients respectively were imaged before and after offering no-cost retinal imaging. The difference represents a 274% increase in the number of patients screened. Furthermore, there was a 292% and 261% increase in the number of eyes with mild DR and referable DR, respectively. In the comparative 6-month period, 92 additional cases of proliferative DR were identified, estimated to prevent 6.7 cases of severe visual loss with annual cost savings of $180,230 (estimated yearly cost of severe vision loss per person: $26,900). In patients with referable DR, self-awareness was low, with no significant difference in the before and after groups (39.4% vs. 43.8%, p\u2009=\u20090.3725). Conclusions: Providing retinal imaging as part of comprehensive diabetes care substantially increased the number of patients identified by nearly threefold. The data suggest that the removal of out-of-pocket costs substantially increased patient surveillance rates, which may translate to improved long-term patient outcomes.</ABSTRACT>'}]
2024-01-02 00:26:40,843 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:40,892 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:40,896 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,897 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448935, Requested 1645. Please try again in 77ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,897 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Retinal Ganglion Cells in a Dish: Current Strategies and Recommended Best Practices for Effective In Vitro Modeling of Development and Disease.\nThe ability to derive retinal ganglion cells (RGCs) from human pluripotent stem cells (hPSCs) provides an extraordinary opportunity to study the development of RGCs as well as cellular mechanisms underlying their degeneration in optic neuropathies. In the past several years, multiple approaches have been established that allow for the generation of RGCs from hPSCs, with these methods greatly improved in more recent studies to yield mature RGCs that more faithfully recapitulate phenotypes within the eye. Nevertheless, numerous differences still remain between hPSC-RGCs and those found within the human eye, with these differences likely explained at least in part due to the environment in which hPSC-RGCs are grown. With the ultimate goal of generating hPSC-RGCs that most closely resemble those within the retina for proper studies of retinal development, disease modeling, as well as cellular replacement, we review within this manuscript the current effective approaches for the differentiation of hPSC-RGCs, as well as how they have been applied for the investigation of RGC neurodegenerative diseases such as glaucoma. Furthermore, we provide our opinions on the characteristics of RGCs necessary for their use as effective in vitro disease models and importantly, how these current systems should be improved to more accurately reflect disease states. The establishment of characteristics in differentiated hPSC-RGCs that more effectively mimic RGCs within the retina will not only enable their use as effective models of RGC development, but will also create a better disease model for the identification of mechanisms underlying the neurodegeneration of RGCs in disease states such as glaucoma, further facilitating the development of therapeutic approaches to rescue RGCs from degeneration in disease states.</ABSTRACT>'}]
2024-01-02 00:26:40,901 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,903 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,904 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448958, Requested 1180. Please try again in 18ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,904 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Diagnostic accuracy of morning serum cortisol concentration in predicting secondary adrenal insufficiency.\n</ABSTRACT>'}]
2024-01-02 00:26:40,906 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448903, Requested 1637. Please try again in 72ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,906 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Tofacitinib for Acute Severe Ulcerative Colitis: A Systematic Review.\nTofacitinib has emerged as a new potential treatment for acute severe ulcerative colitis [ASUC]. We conducted a systematic review to assess efficacy, safety and integration in ASUC algorithms.Systematic searching was done in MEDLINE, EMBASE, Cochrane Library and Clinicaltrials.gov until August 17, 2022, including all studies reporting original observations on tofacitinib for ASUC, preferably defined according to Truelove and Witts criteria. The primary outcome was colectomy-free survival.Of 1072 publications identified, 21 studies were included of which three were ongoing clinical trials. The remaining comprised a pooled cohort originating from 15 case publications [n\u2005=\u200542], a GETAID cohort study [n\u2005=\u200555], a case-control study [n\u2005=\u200540 cases] and a paediatric cohort [n\u2005=\u200511]. Of these 148 reported cases, tofacitinib was used as second-line treatment after steroid failure in previous infliximab failures or third-line after sequential steroid and infliximab or cyclosporine failure, 69 [47%] were female, median age range was 17-34 years and disease duration was 0.7-10 years. Overall, 30-day colectomy-free survival was 85% [n\u2005=\u2005123 of 145; n\u2005=\u20053 without colectomy had follow-up <30 days], 90-day 86% [n\u2005=\u2005113 of 132; n\u2005=\u200516 follow-up <90 days] and 180-day 69% [n\u2005=\u200577 of 112; n\u2005=\u200536 follow-up <180 days]. Tofacitinib persistence at follow-up was 68-91%, clinical remission 35-69% and endoscopic remission 55%. Adverse events occurred in 22 patients, predominantly being infectious complications other than herpes zoster [n\u2005=\u200513], and resulted in tofacitinib discontinuation in seven patients.Tofacitinib appears promising for treatment of ASUC with high short-term colectomy-free survival among refractory patients who are otherwise deemed to require colectomy. However, large high-quality studies are needed.</ABSTRACT>'}]
2024-01-02 00:26:40,912 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,913 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448776, Requested 1639. Please try again in 55ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,913 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>A novel ocular phenotype associated with pathogenic variants in MFSD8 leading to macular dystrophy.\nThe major facilitator superfamily domain-containing protein 8 (MFSD8) pathogenic variants are classically associated with autosomal recessive neuronal ceroid lipofuscinosis-7. Case reports have recently demonstrated an association of MFSD8 variants causing autosomal recessive macular dystrophy with central cone involvement without neurologic sequelae. We report a patient with a novel ocular phenotype associated with MFSD8 pathogenic variants causing macular dystrophy without systemic findings.A 37-year-old female presented with a 20-year history of progressive bilateral vision loss. Fundus examination was notable for a slight pigmentary ring around the fovea in both eyes. Optical coherence tomography (OCT) of the macula showed bilateral subfoveal ellipsoid zone loss without outer retinal changes. Fundus autofluorescence (FAF) demonstrated foveal hypo-autofluorescence (AF) in both eyes as well as hyper-AF nasally to the optic nerve in the perifoveal area. Full-field and multifocal electroretinography demonstrated cone dysfunction with diffuse macular changes in both eyes. Subsequent genetic testing identified two pathogenic MFSD8 variants. The patient had no neurologic symptoms consistent with variant-late infantile neuronal ceroid lipofuscinosis.MFSD8 pathogenic variants are known to cause macular dystrophies. We report a novel MFSD8-associated macular dystrophy phenotype demonstrating foveal-limited disease with cavitary changes on OCT without inner retinal atrophy and foveal-specific changes on FAF. A threshold model can explain how a hypomorphic missense variant heterozygous with a loss-of-function nonsense variant can lead to a predominantly ocular phenotype with preserved neurologic function. We recommend careful monitoring of these patients for future signs of both retinal and systemic disease progression.</ABSTRACT>'}]
2024-01-02 00:26:40,918 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,920 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448827, Requested 1608. Please try again in 58ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,920 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Density of Biopsy Sampling Required to Ensure Accurate Histological Assessment of Inflammation in Active Ulcerative Colitis.\nHistological response to treatment is an important outcome in patients with ulcerative colitis (UC). The accuracy of biopsy-based measurements of inflammation may be limited by error imposed by natural microscopic heterogeneity on the scale of individual biopsies. We determined the magnitude of this error, its histological correlates, and the density of biopsy sampling within mucosal regions of interest required to meet specified benchmarks for accuracy.A total of 994 sequential 1-mm digital microscopic images (virtual biopsies) from consecutive colectomies from patients with clinically severe UC were scored by 2 pathologists. Agreement statistics for Geboes subscores and Nancy (NHI) and Robarts Histological Indices (RHI) between random samples from 1 to 10 biopsies and a reference mean score across a 2-cm region of mucosa were calculated using bootstrapping with 2500 iterations.The agreement statistics improved across all indices as the biopsy density increased, with the largest proportional gains occurring with addition of the second and third biopsies. One biopsy achieved moderate to good agreement with 95% confidence for NHI and RHI corresponding to scale-specific errors of 0.40 (0.25-0.66) and 3.02 (2.08-5.36), respectively; and 3 biopsies achieved good agreement with 95% confidence corresponding to scale-specific errors of 0.22 (0.14-0.39) and 1.87 (1.19-3.25), respectively. Of the individual histological features, erosions and ulcers had the greatest impact on the agreement statistics.In the setting of active colitis, up to 3 biopsy samples per region of interest may be required to overcome microscopic heterogeneity and ensure accurate histological grading.</ABSTRACT>'}]
2024-01-02 00:26:40,922 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,924 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448795, Requested 1575. Please try again in 49ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,924 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Older patients benefit more from sequential courses of washed microbiota transplantation than younger population with ulcerative colitis.\nThe short-term efficacy of fecal microbiota transplantation (FMT) for ulcerative colitis (UC) has increasingly been evaluated. However, few studies have examined the long-term efficacy and its predictors. This study aimed to assess the clinical factors affecting the long-term efficacy of FMT for patients with UC.This is a retrospective analysis of a prospective trial (NCT01790061) for patients with UC undergoing washed microbiota transplantation (WMT), which is the improved methodology of FMT. The long-term clinical efficacy of WMT and the factors affecting efficacy were analyzed.A total of 259 patients were included for analysis. Of 70.7% (183/259) of patients achieved a clinical response at 1 month after WMT and 29.7% (77/259) achieved steroid-free clinical remission 6 months after WMT. Total 44 patients maintained a clinical response for \u226524\u2009months, and 33 (17.1%, 33/193) achieved steroid-free clinical remission for \u226524\u2009months with WMT monotherapy. Patients with age at UC onset of \u226560\u2009years, mild disease severity and undergoing \u22652 courses of WMT during the response within 6 months were more likely to achieve steroid-free clinical remission 6 months after WMT. Besides, independent factors associated with the long-term response of WMT for UC were age at onset of \u226560\u2009years and \u22652 courses of WMT during the response.This study indicated WMT could induce short-term steroid-free clinical remission and maintain long-term response in UC, especially for older patients and patients undergoing sequential courses.</ABSTRACT>'}]
2024-01-02 00:26:40,924 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,925 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448828, Requested 1623. Please try again in 60ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,925 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Senescence-induced alteration of circadian phagocytic activity of retinal pigment epithelium cell line ARPE-19.\nRenewal of retinal photoreceptor outer segments is conducted through daily shedding of distal photoreceptor outer segment tips and subsequent their phagocytosis by the adjacent retinal pigment epithelium (RPE) monolayer. Dysregulation of the diurnal clearance of photoreceptor outer segment tips has been implicated in age-related retinal degeneration, but it remains to be clarified how the circadian phagocytic activity of RPE cells is modulated by senescence. In this study, we used the human RPE cell line ARPE-19 to investigate whether hydrogen peroxide (H2O2)-induced senescence in ARPE-19\xa0cells alters the circadian rhythm of their phagocytic activity. After synchronization of the cellular circadian clock by dexamethasone treatment, the phagocytic activity of normal ARPE-19\xa0cells exhibited significant 24-h oscillation, but this oscillation was modulated by senescence. The phagocytic activity of senescent ARPE-19\xa0cells increased constantly throughout the 24-h period, which still exhibited blunted circadian oscillation, accompanied by an alteration in the rhythmic expression of circadian clock genes and clock-controlled phagocytosis-related genes. The expression levels of REV-ERB\u03b1, a molecular component of the circadian clock, were constitutively increased in senescent ARPE-19\xa0cells. Furthermore, pharmacological activation of REV-ERB\u03b1 by its agonist SR9009 enhanced the phagocytic activity of normal ARPE-19\xa0cells and increased the expression of clock-controlled phagocytosis-related genes. Our present findings extend to understand the role of circadian clock in the alteration of phagocytic activity in RPE during aging. Constitutive enhancement of phagocytic activity of senescent RPE may contribute to age-related retinal degeneration.</ABSTRACT>'}]
2024-01-02 00:26:40,932 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:40,933 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 448685, Requested 1576. Please try again in 34ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:40,933 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Cotinus coggygria Scop. Attenuates Acetic Acid-Induced Colitis in Rats by Regulation of Inflammatory Mediators.\nIn traditional medicine, many medicinal plants are used in the treatment of various diseases caused by inflammation. The objective of the present study is to elucidate for the first time the effects of Cotinus coggygria (CC) ethanol extract (CCE) on colonic structure and inflammation of acetic acid-induced ulcerative colitis in rats. Colonic damage was assessed using disease activity index score, enzyme-linked immunosorbent assay, and hematoxylin-eosin staining. Also, in vitro antioxidant activity of CCE was investigated by ABTS methods. Total phytochemical content of CCE was measured spectroscopically. Acetic acid caused colonic damage according to disease activity index and macroscopic scoring. CCE significantly reversed these damages. While the levels of proinflammatory cytokines TNF-alpha, IL-1beta, IL-6, and TGF-1beta increased in tissue with UC, IL-10 level decreased. CCE increased inflammatory cytokine levels to values close to the sham group. At the same time, while markers indicating disease severity such as VEGF, COX-2, PGE2, and 8-OHdG indicated the disease in the colitis group, these values returned to normal with CCE. Histological research results support biochemical analysis. CCE exhibited significant antioxidant against ABTS radical. Also, CCE was found to have a high content of total polyphenolic compounds. These findings provide evidence that CCE might be benefit as a promising novel therapy in the treatment of UC in humans due to high polyphenol content and justify the use of CC in folkloric medicine for treatment of inflamed diseases.</ABSTRACT>'}]
2024-01-02 00:26:40,962 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:40,968 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:41,010 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:26:41,011 - ERROR - agenerate error: Error code: 429 - {'error': {'message': 'Rate limit reached for gpt-4-1106-preview in organization org-zHtQdHGhKVfrSkZqUztZJjv9 on tokens_usage_based per min: Limit 450000, Used 449128, Requested 1547. Please try again in 90ms. Visit https://platform.openai.com/account/rate-limits to learn more.', 'type': 'tokens_usage_based', 'param': None, 'code': 'rate_limit_exceeded'}}
2024-01-02 00:26:41,011 - ERROR - [{'role': 'system', 'content': 'Please set feature values for the below abstract according to the following instructions. Each abstract has the following list of features:\n\n- pathway_rel [yes, no]: Set to yes if the abstract relates to either the melanocortin or natriuretic metabolic pathway, and otherwise set to no\n\n- disease_rel [yes, no]: Set to yes if the abstract relates to dry eye, ulcerative colitis, crohn\'s disease, retinopathy or retinal disease, and otherwise set to no\n\n- is_systematic [yes, no]: Set to yes if the abstract relates to a systematic review or a meta study and otherwise set to no\n\n- study_type [animal, human RCT, human non-RCT, in vitro, other, not a study]: set to whichever allowed value best matches the study described in the abstract\n\n- study_outcome [effectiveness, safety, bio marker]: return a list of any allowed value that applies to the outcomes targeted in the abstract\n\nReturn your answer in the following JSON format:\n\n{\n  "$schema": "http://json-schema.org/draft-07/schema#",\n  "type": "object",\n  "properties": {\n    "pathway_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to either the melanocortin or natriuretic metabolic pathway, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "disease_rel": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract relates to any of the following diseases and otherwise set to \'no: dry eye, ulcerative colitis, Crohn\'s disease, retinopathy or retinal disease",\n      "enum": ["yes", "no"]\n    },\n    "relevant_pathways": {\n      "type": "array",\n      "description": "List of relevant metabolic pathways if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["melanocortin", "natriuretic"]\n      }\n    },\n    "relevant_diseases": {\n      "type": "array",\n      "description": "List of relevant diseases if the abstract is related.",\n      "items": {\n        "type": "string",\n        "enum": ["dry eye", "ulcerative colitis", "crohn\'s disease", "retinopathy", "retinal disease"]\n      }\n    }\n    "is_systematic": {\n      "type": "string",\n      "description": "Set to \'yes\' if the abstract is a systematic review or a meta-study, otherwise set to \'no\'.",\n      "enum": ["yes", "no"]\n    },\n    "study_type": {\n      "type": "string",\n      "description": "Set to the type of study described in the abstract. Choose from \'animal\', \'human RCT\', \'human non-RCT\', \'in vitro\', \'other\', or \'not a study\'.",\n      "enum": ["animal", "human RCT", "human non-RCT", "in vitro", "other", "not a study"]\n    },\n    "study_outcome": {\n      "type": "array",\n      "description": "List any outcomes targeted in the abstract. Allowed values are \'effectiveness\', \'safety\', \'diagnostic\', and \'biomarker\'.",\n      "items": {\n        "type": "string",\n        "enum": ["effectiveness", "safety", "diagnostic", "biomarker"]\n      }\n    }\n  },\n  "required": ["pathway_rel", "disease_rel", "is_systematic", "study_type", "study_outcome"]\n}<ABSTRACT>Knobloch syndrome - a rare collagenopathy, revealing peripheral avascular retina.\nPediatric rhegmatogenous retinal detachments, especially those presenting at birth or soon afterward, have a high likelihood of syndromic associations that can be confirmed by genetic testing.A 5-month-old child was found to have high myopia in the right eye (RE) with highly tessellated fundus, opalescent vitreous, and peripheral thinning. Left eye had a shallow retinal detachment for which he underwent belt buckling. The baby had an occipital skin tag. A provisional diagnosis of Stickler syndrome was made.On 1-month follow-up, left eye retina was attached and 360 laser barrage was done. Fluorescein angiography was done which revealed peripheral avascular retina in both eyes. MRI and genetic testing were suggestive of syndromic association. Genetic testing revealed pathogenic mutation in COL 18A1 suggestive of Knobloch syndrome in the baby, and both parents were found to be carriers of the same mutation. However, brain MRI showed features not pathognomonic of Knobloch syndrome.Although Knobloch syndrome is associated with vitreoretinal degeneration and high risk of retinal detachment, there seems to be no recommendation for prophylaxis in the other eye and therefore we preferred to observe the RE closely. A unique feature noted in our case was the peripheral avascular zone (PAZ). The PAZ could be contributed by multiple factors such as high myopia, or due to endostatin deficiency (which is a derivative of collagen XVIII) or an underlying WNT signalling abnormality.</ABSTRACT>'}]
2024-01-02 00:26:41,025 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:41,065 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:41,086 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:41,169 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:41,226 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:41,291 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:41,386 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:41,467 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:41,473 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:41,503 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:41,504 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:41,774 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:41,777 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:41,785 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:41,870 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:42,011 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:42,073 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:26:42,197 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:08,406 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-02 00:28:08,406 - INFO - NumExpr defaulting to 8 threads.
2024-01-02 00:28:08,720 - INFO - openai_wrapper loaded
2024-01-02 00:28:09,021 - INFO - Starting
2024-01-02 00:28:09,025 - INFO - file_cache is only supported with oauth2client<4.0.0
2024-01-02 00:28:14,424 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:15,083 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:15,163 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:15,172 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:15,256 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:15,266 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:15,336 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:15,337 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:15,349 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:15,508 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:15,539 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:15,544 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:15,568 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:15,723 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:15,792 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:15,842 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:15,895 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:15,901 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:15,909 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:15,910 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:15,915 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:15,916 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:15,957 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:15,974 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:15,984 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:15,991 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:15,993 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:16,000 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:16,057 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:16,065 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:16,072 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:16,084 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:16,107 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:16,128 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:16,178 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:16,180 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:16,182 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:16,183 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:16,248 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:16,266 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:16,331 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:16,348 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:16,376 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:16,397 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:16,460 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:16,473 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:16,527 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:16,530 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:16,534 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:16,691 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:16,702 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:16,718 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:16,727 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:16,791 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:17,016 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:17,083 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:17,108 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:17,114 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:17,134 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:17,142 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:17,173 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:17,195 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:17,207 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:17,224 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:17,308 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:17,400 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:17,471 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:17,500 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:17,505 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:17,515 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:17,532 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:17,615 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:17,707 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:17,734 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:17,808 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:17,819 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:17,963 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:17,970 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:18,003 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:18,010 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:18,033 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:18,131 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:18,142 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:18,192 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:18,318 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:18,380 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:18,398 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:18,407 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:18,558 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:18,566 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:18,567 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:18,632 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:18,683 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:18,683 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:18,725 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:18,732 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:18,772 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:18,877 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:18,968 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:19,052 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:19,099 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:19,183 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:19,356 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:19,361 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:19,408 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:19,575 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:19,660 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:19,683 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:19,700 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:19,707 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:19,768 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:19,772 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:19,792 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:19,828 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:19,907 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:20,000 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:20,026 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:20,059 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:20,126 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:20,306 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:20,373 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:20,435 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:20,500 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:20,541 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:20,588 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:20,711 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:20,750 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:20,806 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:20,824 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:20,839 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:20,862 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:20,866 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:20,891 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:20,924 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:20,935 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:20,938 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:21,032 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:21,101 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:21,207 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:21,255 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:21,265 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:21,312 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:21,359 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:21,400 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:21,584 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:21,650 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:21,688 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:21,730 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:21,734 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:21,773 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:21,799 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:21,874 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:21,880 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:22,029 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:22,057 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:22,062 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:22,071 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:22,085 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:22,098 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:22,186 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:22,278 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:22,301 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:22,361 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:22,408 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:22,410 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:22,648 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:22,672 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:22,675 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:22,768 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:22,818 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:22,824 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:22,910 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:22,912 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:22,984 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:23,018 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:23,077 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:23,179 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:23,394 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:23,400 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:23,410 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:23,442 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:23,450 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:23,571 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:23,991 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:24,009 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:24,011 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:24,158 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:24,267 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:24,428 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:24,446 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:24,466 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:24,603 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:24,644 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:24,657 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:24,730 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:25,218 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:25,731 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:25,958 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:28:27,627 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:34,460 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 503 Service Temporarily Unavailable"
2024-01-02 00:30:34,463 - INFO - Retrying request to /chat/completions in 0.839532 seconds
2024-01-02 00:30:37,581 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:50,962 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:51,195 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:51,253 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:51,310 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:51,407 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:51,456 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:51,510 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:51,521 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:51,526 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:51,528 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:51,690 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:51,692 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:51,723 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:51,727 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:51,755 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:51,801 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:51,836 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:51,858 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:51,863 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:51,903 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:51,904 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:51,956 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:51,987 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:51,992 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:52,033 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:52,073 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:52,290 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:52,334 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:52,342 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:52,412 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:52,413 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:52,462 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:52,465 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:52,471 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:52,489 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:52,496 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:52,496 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:52,528 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:52,537 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:52,546 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:52,564 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:52,660 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:52,668 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:52,672 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:52,676 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:52,685 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:52,702 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:52,747 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:52,819 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:52,830 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:52,971 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:53,013 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:53,068 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:53,073 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:53,110 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:53,121 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:53,131 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:53,178 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:53,194 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:53,202 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:53,226 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:53,285 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:53,295 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:53,354 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:53,372 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:53,377 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:53,423 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:53,471 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:53,520 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:53,554 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:53,570 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:53,574 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:53,656 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:53,663 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:53,706 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:53,754 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:53,769 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:53,773 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:53,802 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:53,835 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:53,862 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:53,876 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:53,908 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:53,920 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:53,927 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:54,056 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:54,087 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:54,224 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:54,300 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:54,354 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:54,598 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:54,603 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:54,971 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:54,976 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:55,029 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:55,145 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:55,153 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:55,155 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:55,230 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:55,320 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:55,435 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:55,509 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:55,542 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:55,659 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:55,695 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:55,721 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:55,752 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:55,807 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:55,851 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:55,878 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:55,922 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:55,991 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:56,196 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:56,331 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:56,337 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:56,412 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:56,444 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:56,594 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:56,718 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:56,770 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:56,776 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:56,789 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:56,796 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:56,880 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:56,920 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:56,931 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:56,990 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:57,073 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:57,100 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:57,142 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:57,194 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:57,203 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:57,242 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:57,270 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:57,341 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:57,417 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:57,422 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:57,446 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:57,480 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:57,486 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:57,538 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:57,631 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:57,645 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:57,647 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:57,688 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:57,692 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:57,762 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:57,768 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:57,804 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:57,846 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:57,847 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:57,896 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:57,918 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:57,938 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:57,938 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:57,974 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:58,003 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:58,026 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:58,114 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:58,172 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:58,578 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:58,596 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:58,813 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:58,842 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:59,047 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:59,070 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:59,086 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:59,114 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:59,120 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:59,126 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:59,129 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:59,170 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:59,235 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:59,321 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:59,353 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:59,419 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:59,435 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:59,453 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:59,525 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:59,635 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:59,762 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:59,873 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:59,942 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:30:59,967 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:00,083 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:00,255 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:00,268 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:00,325 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:00,417 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:00,427 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:00,467 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:00,647 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:00,775 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:00,878 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:00,998 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:01,430 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:01,520 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:01,823 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:02,016 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:02,869 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:15,587 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:15,761 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:16,116 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:16,139 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:16,282 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:16,427 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:16,452 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:16,482 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:16,516 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:16,525 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:16,556 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:16,657 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:16,677 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:16,684 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:16,708 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:16,724 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:16,751 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:16,756 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:16,798 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:16,802 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:16,848 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:16,859 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:16,920 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:16,927 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:16,950 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:16,968 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:16,975 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:16,976 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:17,044 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:17,059 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:17,119 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:17,124 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:17,251 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:17,265 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:17,266 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:17,284 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:17,344 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:17,348 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:17,367 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:17,394 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:17,403 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:17,476 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:17,500 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:17,541 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:17,564 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:17,604 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:17,630 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:17,659 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:17,711 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:17,712 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:17,717 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:17,733 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:17,784 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:17,878 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:17,890 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:18,010 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:18,018 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:18,051 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:18,103 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:18,148 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:18,154 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:18,256 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:18,277 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:18,323 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:18,388 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:18,397 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:18,488 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:18,576 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:18,586 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:18,621 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:18,661 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:18,668 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:18,674 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:18,793 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:18,802 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:18,899 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:18,915 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:18,927 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:18,958 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:18,974 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:19,009 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:19,078 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:19,083 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:19,105 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:19,134 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:19,138 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:19,198 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:19,218 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:19,307 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:19,329 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:19,469 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:19,606 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:19,648 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:19,703 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:19,766 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:20,042 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:20,086 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:20,134 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:20,266 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:20,317 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:20,332 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:20,375 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:20,576 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:20,618 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:20,623 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:20,701 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:20,705 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:20,711 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:20,869 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:21,026 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:21,159 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:21,186 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:21,215 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:21,234 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:21,364 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:21,409 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:21,412 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:21,434 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:21,549 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:21,584 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:21,595 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:21,632 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:21,685 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:21,688 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:21,715 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:21,759 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:21,761 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:21,777 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:21,816 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:21,916 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:21,974 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:22,011 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:22,140 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:22,198 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:22,290 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:22,311 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:22,315 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:22,333 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:22,335 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:22,460 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:22,475 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:22,564 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:22,579 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:22,640 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:22,842 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:22,844 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:22,847 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:22,850 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:22,951 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:22,990 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:23,008 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:23,097 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:23,142 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:23,204 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:23,250 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:23,256 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:23,356 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:23,400 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:23,482 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:23,491 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:23,565 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:23,681 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:23,808 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:23,893 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:23,917 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:23,966 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:24,050 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:24,266 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:24,298 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:24,488 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:24,642 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:24,738 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:24,751 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:24,802 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:24,804 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:24,840 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:24,846 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:25,165 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:25,291 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:25,373 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:25,447 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:25,932 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:25,946 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:25,962 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:26,082 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:26,093 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:26,131 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:26,211 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:26,212 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:26,273 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:26,373 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:26,437 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:26,446 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:26,489 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:27,009 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:27,185 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:27,576 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:27,669 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:28,687 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:32,874 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:45,777 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:46,274 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:46,308 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:46,378 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:46,445 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:46,474 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:46,545 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:46,753 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:46,813 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:46,820 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:46,820 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:46,831 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:46,842 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:46,875 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:46,976 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:46,983 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:47,014 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:47,034 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:47,035 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:47,044 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:47,073 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:47,086 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:47,109 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:47,199 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:47,213 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:47,219 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:47,227 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:47,263 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:47,267 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:47,298 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:47,317 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:47,461 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:47,469 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:47,516 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:47,533 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:47,552 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:47,604 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:47,610 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:47,617 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:47,628 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:47,633 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:47,663 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:47,667 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:47,678 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:47,844 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:47,849 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:47,874 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:47,876 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:47,939 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:48,055 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:48,169 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:48,178 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:48,210 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:48,240 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:48,244 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:48,281 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:48,282 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:48,324 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:48,475 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:48,509 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:48,592 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:48,686 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:48,720 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:48,724 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:48,731 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:48,765 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:48,799 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:48,811 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:48,846 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:48,869 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:48,910 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:48,933 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:48,956 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:48,976 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:49,015 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:49,035 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:49,053 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:49,101 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:49,109 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:49,117 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:49,275 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:49,308 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:49,322 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:49,410 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:49,436 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:49,463 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:49,499 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:49,516 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:49,576 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:49,592 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:49,623 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:49,732 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:49,798 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:49,817 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:49,843 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:49,876 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:49,925 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:50,008 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:50,292 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:50,326 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:50,342 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:50,596 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:50,685 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:50,710 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:50,902 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:50,939 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:51,049 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:51,079 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:51,082 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:51,110 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:51,169 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:51,235 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:51,364 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:51,412 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:51,558 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:51,629 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:51,700 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:51,742 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:51,799 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:51,836 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:51,854 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:51,860 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:51,864 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:51,878 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:51,881 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:51,892 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:51,913 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:51,981 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:51,984 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:52,053 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:52,119 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:52,158 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:52,178 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:52,235 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:52,340 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:52,342 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:52,387 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:52,405 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:52,415 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:52,556 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:52,631 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:52,660 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:52,675 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:52,728 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:52,800 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:52,884 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:52,898 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:52,953 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:53,067 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:53,091 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:53,095 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:53,140 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:53,143 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:53,160 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:53,166 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:53,168 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:53,201 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:53,229 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:53,232 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:53,283 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:53,336 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:53,468 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:53,551 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:53,603 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:53,717 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:53,733 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:53,760 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:53,823 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:53,976 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:54,025 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:54,029 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:54,041 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:54,134 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:54,171 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:54,200 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:54,239 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:54,284 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:54,305 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:54,493 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:54,543 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:54,695 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:54,700 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:54,749 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:54,922 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:55,006 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:55,046 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:55,110 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:55,158 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:55,273 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:55,278 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:55,884 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:55,915 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:55,984 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:56,400 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:56,401 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:56,616 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:56,685 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:56,725 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:57,333 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:31:57,849 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:10,653 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:10,927 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:11,155 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:11,193 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:11,260 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:11,279 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:11,303 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:11,336 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:11,375 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:11,381 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:11,384 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:11,387 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:11,391 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:11,395 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:11,415 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:11,437 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:11,446 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:11,482 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:11,508 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:11,570 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:11,614 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:11,616 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:11,636 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:11,666 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:11,670 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:11,735 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:11,762 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:11,768 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:11,776 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:11,813 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:11,826 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:11,847 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:11,852 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:11,869 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:11,894 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:11,934 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:11,938 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:11,989 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:11,994 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:11,998 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:12,001 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:12,053 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:12,114 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:12,128 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:12,216 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:12,237 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:12,268 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:12,279 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:12,310 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:12,326 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:12,385 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:12,437 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:12,502 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:12,531 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:12,595 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:12,616 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:12,626 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:12,645 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:12,692 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:12,806 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:12,815 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:12,827 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:12,837 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:12,846 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:12,914 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:12,918 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:12,929 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:13,178 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:13,185 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:13,232 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:13,362 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:13,386 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:13,462 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:13,512 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:13,594 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:13,629 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:13,735 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:13,738 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:13,740 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:13,751 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:13,793 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:13,953 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:14,322 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:14,339 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:14,377 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:14,411 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:14,601 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:14,618 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:14,728 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:14,767 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:14,813 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:14,815 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:14,847 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:14,861 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:14,869 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:14,897 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:14,904 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:14,933 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:14,956 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:15,013 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:15,070 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:15,144 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:15,160 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:15,202 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:15,231 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:15,237 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:15,265 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:15,293 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:15,405 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:15,483 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:15,518 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:15,551 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:15,588 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:15,693 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:15,701 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:15,731 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:15,750 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:15,752 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:15,764 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:15,812 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:15,820 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:15,821 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:15,840 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:15,854 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:15,877 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:15,911 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:15,994 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:16,017 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:16,161 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:16,323 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:16,345 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:16,383 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:16,410 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:16,587 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:16,704 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:16,750 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:16,765 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:17,030 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:17,086 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:17,104 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:17,132 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:17,151 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:17,255 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:17,305 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:17,325 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:17,346 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:17,372 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:17,381 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:17,420 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:17,510 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:17,624 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:17,667 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:17,772 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:17,789 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:17,791 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:17,796 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:17,846 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:18,116 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:18,122 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:18,149 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:18,152 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:18,183 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:18,206 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:18,292 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:18,362 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:18,374 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:18,378 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:18,396 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:18,414 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:18,588 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:18,652 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:18,655 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:18,664 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:18,695 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:18,771 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:18,779 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:18,946 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:18,982 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:19,003 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:19,058 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:19,083 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:19,088 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:19,090 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:19,169 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:19,190 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:19,232 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:19,256 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:19,340 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:19,347 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:19,380 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:19,555 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:19,572 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:19,963 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:20,195 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:20,605 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:21,016 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:21,061 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:21,198 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:21,774 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:22,626 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:35,473 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:35,475 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:35,986 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:36,074 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:36,102 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:36,147 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:36,227 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:36,228 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:36,249 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:36,253 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:36,260 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:36,303 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:36,318 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:36,325 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:36,350 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:36,356 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:36,386 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:36,395 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:36,397 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:36,417 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:36,440 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:36,482 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:36,581 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:36,627 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:36,628 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:36,639 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:36,673 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:36,680 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:36,741 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:36,745 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:36,787 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:36,809 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:36,901 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:36,909 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:36,913 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:36,956 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:37,008 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:37,015 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:37,028 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:37,078 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:37,101 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:37,105 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:37,113 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:37,127 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:37,162 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:37,203 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:37,240 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:37,272 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:37,323 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:37,470 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:37,522 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:37,527 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:37,653 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:37,664 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:37,699 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:37,712 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:37,731 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:37,797 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:37,811 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:38,002 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:38,018 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:38,028 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:38,034 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:38,072 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:38,123 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:38,128 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:38,228 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:38,656 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:38,772 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:38,796 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:38,819 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:38,894 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:38,905 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:38,948 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:38,996 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:38,997 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:39,004 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:39,116 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:39,163 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:39,194 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:39,248 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:39,266 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:39,285 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:39,348 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:39,478 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:39,490 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:39,521 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:39,680 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:39,756 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:39,761 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:39,763 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:39,790 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:39,837 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:39,965 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:40,064 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:40,089 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:40,154 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:40,188 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:40,196 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:40,205 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:40,220 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:40,237 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:40,256 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:40,263 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:40,264 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:40,301 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:40,327 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:40,337 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:40,410 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:40,414 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:40,469 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:40,488 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:40,509 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:40,544 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:40,638 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:40,681 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:40,760 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:40,761 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:40,806 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:40,853 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:40,940 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:41,022 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:41,223 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:41,256 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:41,260 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:41,332 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:41,453 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:41,581 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:41,665 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:41,702 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:41,726 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:41,860 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:41,972 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:42,100 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:42,129 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:42,148 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:42,149 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:42,255 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:42,291 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:42,319 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:42,340 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:42,398 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:42,450 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:42,460 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:42,471 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:42,472 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:42,513 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:42,520 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:42,542 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:42,596 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:42,626 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:42,660 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:42,667 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:42,843 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:42,865 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:42,919 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:42,954 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:42,997 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:43,001 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:43,011 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:43,048 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:43,196 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:43,223 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:43,227 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:43,361 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:43,379 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:43,461 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:43,516 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:43,591 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:43,662 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:43,690 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:43,765 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:43,879 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:43,886 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:43,907 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:43,964 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:44,138 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:44,225 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:44,230 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:44,313 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:44,459 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:44,584 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:44,620 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:44,758 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:44,975 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:45,075 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:45,546 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:46,049 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:46,191 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:46,494 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:46,543 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:47,026 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:47,134 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:47,299 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:47,538 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:48,126 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:48,158 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:49,583 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:50,074 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:32:50,533 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:03,605 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:03,684 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:03,833 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:03,856 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:03,883 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:03,925 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:03,942 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:03,961 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:03,993 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:04,017 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:04,022 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:04,042 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:04,102 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:04,227 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:04,250 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:04,295 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:04,307 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:04,335 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:04,366 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:04,373 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:04,394 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:04,397 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:04,431 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:04,477 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:04,483 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:04,541 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:04,574 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:04,584 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:04,645 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:04,665 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:04,675 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:04,678 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:04,726 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:04,732 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:04,780 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:04,792 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:04,796 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:04,797 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:04,810 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:04,856 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:04,893 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:04,932 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:04,935 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:04,941 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:04,985 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:04,999 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:05,033 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:05,163 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:05,207 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:05,233 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:05,259 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:05,317 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:05,426 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:05,434 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:05,482 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:05,704 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:05,840 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:05,897 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:05,903 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:06,134 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:06,151 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:06,218 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:06,226 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:06,295 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:06,317 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:06,345 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:06,377 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:06,438 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:06,440 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:06,467 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:06,470 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:06,476 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:06,498 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:06,501 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:06,517 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:06,519 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:06,540 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:06,544 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:06,568 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:06,651 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:06,666 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:06,736 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:06,774 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:06,904 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:06,908 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:06,968 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:07,018 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:07,152 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:07,176 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:07,199 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:07,200 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:07,214 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:07,319 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:07,346 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:07,393 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:07,485 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:07,490 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:07,507 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:07,528 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:07,582 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:07,622 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:33:07,623 - INFO - Retrying request to /chat/completions in 0.881634 seconds
2024-01-02 00:33:07,642 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:07,648 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:07,668 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:07,698 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:33:07,699 - INFO - Retrying request to /chat/completions in 0.839444 seconds
2024-01-02 00:33:07,840 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:07,859 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:07,883 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:07,892 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:07,986 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:07,993 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:08,063 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:08,116 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:08,142 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:08,153 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:08,170 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:08,217 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:08,250 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:08,430 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:08,452 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:08,475 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:08,518 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:08,529 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:08,536 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:08,603 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:08,606 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:08,667 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:08,771 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:08,874 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:09,083 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:09,184 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:09,218 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:09,376 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:09,434 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:09,462 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:09,482 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:09,634 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:09,717 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:09,763 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:09,773 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:09,914 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:09,916 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:09,917 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:10,085 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:10,101 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:10,124 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:10,168 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:10,212 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:10,336 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:10,361 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:10,394 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:10,450 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:10,491 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:10,520 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:10,521 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:10,867 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:10,876 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:10,952 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:10,963 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:10,996 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:11,066 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:11,084 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:11,171 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:11,236 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:11,259 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:11,384 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:11,416 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:11,424 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:11,529 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:11,545 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:11,552 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:11,744 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:11,846 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:11,935 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:12,000 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:12,075 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:12,146 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:12,247 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:12,251 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:12,276 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:12,360 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:12,386 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:12,411 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:12,566 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:12,586 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:12,676 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:12,734 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:12,880 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:12,917 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:12,920 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:13,033 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:13,084 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:13,106 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:13,202 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:13,250 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:13,433 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:13,462 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:13,475 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:13,769 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:13,852 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:13,934 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:14,153 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:27,034 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:27,066 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:27,131 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:27,375 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:27,471 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:27,574 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:27,628 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:27,648 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:27,666 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:27,682 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:27,701 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:27,714 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:27,717 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:27,760 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:27,764 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:27,778 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:27,782 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:27,802 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:27,807 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:27,877 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:27,900 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:27,932 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:27,979 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:28,010 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:28,015 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:28,022 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:28,026 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:28,043 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:28,132 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:28,151 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:28,152 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:28,154 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:33:28,159 - INFO - Retrying request to /chat/completions in 0.893668 seconds
2024-01-02 00:33:28,165 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:33:28,166 - INFO - Retrying request to /chat/completions in 0.947144 seconds
2024-01-02 00:33:28,212 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:28,232 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:28,251 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:28,266 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:28,283 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:33:28,284 - INFO - Retrying request to /chat/completions in 0.889050 seconds
2024-01-02 00:33:28,290 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:33:28,290 - INFO - Retrying request to /chat/completions in 0.899964 seconds
2024-01-02 00:33:28,291 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:28,295 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:28,296 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:28,300 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:33:28,301 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:28,303 - INFO - Retrying request to /chat/completions in 0.866151 seconds
2024-01-02 00:33:28,328 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:28,373 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:28,386 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:33:28,387 - INFO - Retrying request to /chat/completions in 0.753715 seconds
2024-01-02 00:33:28,397 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:33:28,398 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:28,400 - INFO - Retrying request to /chat/completions in 0.790574 seconds
2024-01-02 00:33:28,409 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:28,409 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:33:28,410 - INFO - Retrying request to /chat/completions in 0.845256 seconds
2024-01-02 00:33:28,410 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:28,419 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:33:28,420 - INFO - Retrying request to /chat/completions in 0.803436 seconds
2024-01-02 00:33:28,425 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:33:28,425 - INFO - Retrying request to /chat/completions in 0.838259 seconds
2024-01-02 00:33:28,427 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:33:28,428 - INFO - Retrying request to /chat/completions in 0.879137 seconds
2024-01-02 00:33:28,435 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:33:28,435 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:33:28,436 - INFO - Retrying request to /chat/completions in 0.833529 seconds
2024-01-02 00:33:28,436 - INFO - Retrying request to /chat/completions in 0.830561 seconds
2024-01-02 00:33:28,442 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:28,447 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:28,451 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:28,472 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:28,507 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:33:28,508 - INFO - Retrying request to /chat/completions in 0.787136 seconds
2024-01-02 00:33:28,559 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:28,590 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:28,601 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:28,615 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:28,660 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:28,693 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:28,766 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:28,820 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:28,835 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:28,916 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:29,000 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:29,232 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:29,234 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:29,357 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:29,365 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:29,390 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:29,394 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:29,399 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:33:29,400 - INFO - Retrying request to /chat/completions in 1.766671 seconds
2024-01-02 00:33:29,401 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:33:29,402 - INFO - Retrying request to /chat/completions in 1.759482 seconds
2024-01-02 00:33:29,407 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:29,408 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:33:29,409 - INFO - Retrying request to /chat/completions in 1.956159 seconds
2024-01-02 00:33:29,427 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:29,433 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 429 Too Many Requests"
2024-01-02 00:33:29,434 - INFO - Retrying request to /chat/completions in 1.578871 seconds
2024-01-02 00:33:29,704 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:29,726 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:29,751 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:29,763 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:29,784 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:29,816 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:29,863 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:29,867 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:29,869 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:29,877 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:29,969 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:29,976 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:29,999 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:30,042 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:30,076 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:30,122 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:30,184 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:30,292 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:30,410 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:30,414 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:30,451 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:30,713 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:30,840 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:30,866 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:30,963 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:31,061 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:31,081 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:31,126 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:31,195 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:31,215 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:31,282 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:31,391 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:31,442 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:31,472 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:31,506 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:31,526 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:31,607 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:31,726 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:31,741 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:31,761 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:31,770 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:31,844 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:31,851 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:31,881 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:31,893 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:31,932 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:31,981 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:31,983 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:32,191 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:32,384 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:32,483 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:32,694 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:32,753 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:32,810 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:32,851 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:32,911 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:32,915 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:32,950 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:32,978 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:32,980 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:33,380 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:33,424 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:33,426 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:33,430 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:33,535 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:33,657 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:33,809 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:33,885 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:33,891 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:34,285 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:34,323 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:34,328 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:34,652 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:34,783 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:34,794 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:34,894 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:35,031 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:35,033 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:33:41,135 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:35,820 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-02 00:41:35,820 - INFO - NumExpr defaulting to 8 threads.
2024-01-02 00:41:36,136 - INFO - openai_wrapper loaded
2024-01-02 00:41:36,431 - INFO - Starting
2024-01-02 00:41:36,436 - INFO - file_cache is only supported with oauth2client<4.0.0
2024-01-02 00:41:41,814 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:42,106 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:42,344 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:42,460 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:42,701 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:42,708 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:42,824 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:42,833 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:42,851 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:42,873 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:42,905 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:42,932 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:43,050 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:43,069 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:43,122 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:43,251 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:43,258 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:43,306 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:43,393 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:43,400 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:43,438 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:43,450 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:43,458 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:43,473 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:43,506 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:43,519 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:43,525 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:43,554 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:43,721 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:43,758 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:43,855 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:43,913 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:43,940 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:43,966 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:44,006 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:44,029 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:44,064 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:44,100 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:44,124 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:44,125 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:44,168 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:44,170 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:44,200 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:44,221 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:44,266 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:44,340 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:44,350 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:44,394 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:44,423 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:44,500 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:44,521 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:44,562 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:44,580 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:44,583 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:44,588 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:44,672 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:44,685 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:44,715 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:44,766 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:44,919 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:45,026 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:45,055 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:45,208 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:45,215 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:45,251 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:45,259 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:45,285 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:45,288 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:45,325 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:45,387 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:45,420 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:45,425 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:45,499 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:45,525 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:45,632 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:45,634 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:45,688 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:45,727 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:45,757 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:45,773 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:45,901 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:45,934 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:45,941 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:45,993 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:46,024 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:46,122 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:46,226 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:46,240 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:46,297 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:46,335 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:46,336 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:46,362 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:46,401 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:46,420 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:46,457 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:46,462 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:46,471 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:46,488 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:46,574 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:46,659 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:46,664 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:46,681 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:46,688 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:46,993 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:47,166 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:47,207 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:47,297 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:47,309 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:47,380 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:47,394 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:47,417 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:47,422 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:47,486 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:47,576 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:47,586 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:47,587 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:47,622 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:47,728 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:47,875 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:47,907 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:47,941 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:48,084 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:48,088 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:48,154 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:48,321 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:48,353 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:48,365 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:48,386 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:48,412 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:48,447 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:48,471 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:48,525 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:48,539 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:48,553 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:48,606 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:48,898 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:48,938 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:48,956 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:48,996 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:49,030 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:49,038 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:49,050 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:49,058 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:49,064 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:49,166 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:49,190 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:49,204 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:49,342 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:49,372 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:49,385 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:49,420 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:49,437 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:49,517 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:49,553 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:49,583 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:49,615 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:49,617 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:49,656 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:49,678 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:49,692 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:49,717 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:49,731 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:49,756 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:49,805 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:49,822 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:49,831 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:49,955 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:50,025 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:50,036 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:50,112 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:50,126 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:50,128 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:50,158 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:50,160 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:50,202 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:50,492 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:50,503 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:50,789 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:50,848 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:50,856 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:50,857 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:50,929 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:50,933 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:51,088 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:51,165 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:51,182 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:51,216 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:51,378 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:51,938 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:51,993 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:52,130 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:52,434 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:52,523 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:52,655 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:52,722 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:52,992 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:52,995 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:53,199 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:53,537 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:41:53,936 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:06,576 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:06,862 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:06,967 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:07,118 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:07,280 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:07,485 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:07,501 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:07,543 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:07,627 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:07,649 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:07,653 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:07,794 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:07,861 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:08,005 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:08,045 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:08,057 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:08,091 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:08,102 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:08,115 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:08,118 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:08,123 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:08,145 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:08,151 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:08,152 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:08,198 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:08,220 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:08,225 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:08,244 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:08,268 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:08,271 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:08,295 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:08,301 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:08,320 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:08,325 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:08,328 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:08,383 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:08,412 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:08,444 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:08,461 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:08,467 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:08,480 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:08,567 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:08,785 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:08,912 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:08,951 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:08,958 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:09,017 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:09,026 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:09,032 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:09,048 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:09,078 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:09,194 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:09,196 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:09,259 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:09,261 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:09,291 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:09,292 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:09,324 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:09,355 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:09,385 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:09,391 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:09,441 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:09,464 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:09,496 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:09,535 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:09,536 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:09,578 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:09,579 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:09,588 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:09,627 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:09,633 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:09,651 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:09,652 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:09,665 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:09,726 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:09,862 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:10,134 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:10,190 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:10,289 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:10,344 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:10,416 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:10,484 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:10,498 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:10,586 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:10,658 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:10,669 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:10,680 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:10,793 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:10,811 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:10,818 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:10,835 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:10,845 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:10,864 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:10,875 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:10,889 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:10,948 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:11,043 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:11,059 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:11,152 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:11,319 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:11,374 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:11,391 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:11,399 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:11,545 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:11,565 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:11,577 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:11,626 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:11,645 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:11,759 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:11,993 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:12,100 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:12,158 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:12,232 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:12,377 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:12,486 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:12,519 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:12,560 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:12,671 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:12,693 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:12,701 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:12,778 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:12,782 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:12,834 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:12,836 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:12,845 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:12,849 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:12,965 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:12,982 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:12,989 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:13,025 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:13,051 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:13,119 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:13,148 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:13,266 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:13,274 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:13,317 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:13,403 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:13,433 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:13,466 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:13,469 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:13,532 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:13,554 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:13,558 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:13,577 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:13,685 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:13,736 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:13,743 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:13,768 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:13,827 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:13,855 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:13,928 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:14,000 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:14,097 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:14,115 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:14,132 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:14,157 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:14,244 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:14,263 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:14,391 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:14,478 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:14,515 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:14,561 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:14,583 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:14,808 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:14,816 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:14,828 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:15,061 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:15,096 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:15,116 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:15,119 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:15,149 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:15,316 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:15,366 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:15,410 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:15,448 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:15,534 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:15,577 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:15,632 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:15,745 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:15,750 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:15,914 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:16,526 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:16,607 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:16,643 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:16,685 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:17,217 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:17,257 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:17,370 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:17,452 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:17,454 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:17,488 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:18,017 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:18,209 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:18,568 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:19,104 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:19,135 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:20,100 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:20,102 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:21,682 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:21,813 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:35,040 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:35,166 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:35,172 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:35,249 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:35,275 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:35,335 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:35,393 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:35,451 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:35,483 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:35,526 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:35,536 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:35,634 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:35,656 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:35,732 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:35,755 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:35,775 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:35,795 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:35,808 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:35,848 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:35,875 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:35,876 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:35,887 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:35,892 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:35,906 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:35,934 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:35,940 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:35,956 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:35,976 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:35,990 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:36,000 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:36,005 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:36,012 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:36,023 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:36,027 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:36,056 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:36,078 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:36,083 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:36,134 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:36,155 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:36,159 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:36,167 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:36,208 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:36,217 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:36,241 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:36,284 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:36,341 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:36,347 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:36,355 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:36,374 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:36,389 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:36,415 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:36,432 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:36,489 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:36,594 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:36,609 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:36,672 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:36,674 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:36,675 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:36,682 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:36,730 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:36,760 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:36,831 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:36,917 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:36,924 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:37,067 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:37,098 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:37,120 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:37,123 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:37,324 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:37,339 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:37,366 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:37,398 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:37,413 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:37,587 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:37,594 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:37,655 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:37,722 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:37,843 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:37,848 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:37,892 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:37,899 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:37,911 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:37,949 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:37,965 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:37,987 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:38,050 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:38,150 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:38,207 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:38,374 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:38,425 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:38,516 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:38,518 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:38,573 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:38,589 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:38,652 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:38,808 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:38,859 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:38,923 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:39,011 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:39,283 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:39,327 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:39,329 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:39,416 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:39,582 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:39,610 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:39,648 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:39,709 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:39,749 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:39,783 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:39,799 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:39,927 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:40,016 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:40,027 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:40,093 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:40,243 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:40,250 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:40,277 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:40,321 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:40,447 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:40,449 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:40,494 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:40,513 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:40,582 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:40,712 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:40,793 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:40,876 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:40,881 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:40,949 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:40,950 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:40,959 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:41,015 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:41,031 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:41,046 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:41,107 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:41,117 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:41,145 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:41,222 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:41,259 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:41,334 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:41,399 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:41,401 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:41,416 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:41,443 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:41,467 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:41,543 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:41,544 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:41,555 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:41,559 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:41,576 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:41,650 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:41,678 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:41,694 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:41,710 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:41,727 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:41,790 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:41,798 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:41,849 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:41,858 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:41,881 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:42,007 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:42,064 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:42,082 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:42,091 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:42,115 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:42,325 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:42,352 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:42,382 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:42,469 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:42,543 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:42,646 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:42,648 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:42,650 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:42,682 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:42,717 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:42,733 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:42,764 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:42,869 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:43,217 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:43,264 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:43,387 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:43,600 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:43,687 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:43,780 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:43,817 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:44,044 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:44,272 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:44,298 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:44,312 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:44,324 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:44,348 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:44,397 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:44,434 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:45,167 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:45,260 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:45,268 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:45,426 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:45,653 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:45,725 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:46,568 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:42:48,451 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:01,268 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:01,317 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:01,326 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:01,595 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:01,682 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:01,712 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:01,813 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:01,975 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:02,126 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:02,212 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:02,251 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:02,282 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:02,302 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:02,314 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:02,394 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:02,418 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:02,433 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:02,440 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:02,447 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:02,470 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:02,483 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:02,500 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:02,501 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:02,508 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:02,547 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:02,548 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:02,582 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:02,591 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:02,620 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:02,623 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:02,661 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:02,691 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:02,699 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:02,785 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:02,786 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:02,821 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:02,836 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:02,844 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:02,849 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:02,855 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:02,858 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:02,867 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:02,911 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:02,926 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:02,952 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:02,953 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:02,979 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:02,984 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:03,017 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:03,018 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:03,074 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:03,077 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:03,150 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:03,177 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:03,409 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:03,700 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:03,750 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:03,752 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:03,882 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:03,889 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:03,993 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:04,002 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:04,050 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:04,117 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:04,179 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:04,212 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:04,220 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:04,413 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:04,488 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:04,558 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:04,651 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:04,659 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:04,666 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:04,716 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:04,717 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:04,752 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:04,792 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:04,809 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:04,827 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:04,833 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:04,884 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:04,943 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:04,944 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:04,976 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:05,051 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:05,052 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:05,080 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:05,124 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:05,172 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:05,203 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:05,218 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:05,223 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:05,224 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:05,254 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:05,317 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:05,392 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:05,412 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:05,528 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:05,541 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:05,651 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:05,713 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:05,908 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:05,993 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:06,036 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:06,109 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:06,124 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:06,182 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:06,191 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:06,326 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:06,397 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:06,401 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:06,418 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:06,435 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:06,551 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:06,560 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:06,627 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:06,665 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:06,677 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:06,708 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:06,749 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:06,844 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:06,851 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:06,912 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:07,145 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:07,207 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:07,245 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:07,273 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:07,333 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:07,367 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:07,445 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:07,550 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:07,595 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:07,624 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:07,678 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:07,703 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:07,728 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:07,749 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:07,874 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:07,900 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:07,934 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:07,962 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:07,970 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:07,979 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:08,048 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:08,107 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:08,131 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:08,143 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:08,247 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:08,275 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:08,290 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:08,371 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:08,485 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:08,657 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:08,792 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:08,801 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:08,848 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:08,887 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:08,902 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:09,044 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:09,079 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:09,083 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:09,111 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:09,121 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:09,160 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:09,218 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:09,246 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:09,326 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:09,414 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:09,452 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:09,563 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:09,567 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:09,665 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:09,685 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:09,691 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:09,768 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:09,803 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:10,021 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:10,093 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:10,112 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:10,119 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:10,368 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:10,445 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:10,475 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:10,548 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:10,588 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:10,685 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:10,759 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:10,787 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:11,220 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:11,266 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:11,307 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:11,459 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:12,376 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:12,827 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:13,062 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:13,593 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:13,779 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:14,029 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:14,630 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:18,462 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:31,360 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:31,508 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:31,517 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:31,625 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:31,679 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:31,718 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:31,838 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:31,925 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:31,990 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:32,023 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:32,089 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:32,116 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:32,123 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:32,140 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:32,142 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:32,149 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:32,155 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:32,176 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:32,192 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:32,200 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:32,204 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:32,214 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:32,221 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:32,223 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:32,229 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:32,252 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:32,289 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:32,323 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:32,355 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:32,358 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:32,380 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:32,390 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:32,401 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:32,417 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:32,474 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:32,509 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:32,510 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:32,517 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:32,546 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:32,547 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:32,549 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:32,553 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:32,626 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:32,652 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:32,674 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:32,747 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:32,758 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:32,760 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:32,798 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:32,892 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:32,905 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:32,949 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:33,065 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:33,076 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:33,082 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:33,108 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:33,150 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:33,214 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:33,217 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:33,239 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:33,246 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:33,347 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:33,540 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:33,549 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:33,626 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:33,627 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:33,683 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:33,687 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:33,754 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:33,778 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:33,782 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:33,789 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:33,793 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:33,833 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:33,888 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:33,928 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:33,963 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:34,005 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:34,220 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:34,252 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:34,289 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:34,432 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:34,784 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:34,951 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:34,965 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:35,012 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:35,149 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:35,215 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:35,291 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:35,365 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:35,390 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:35,466 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:35,488 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:35,515 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:35,530 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:35,545 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:35,728 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:35,749 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:35,765 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:35,867 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:35,880 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:35,882 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:35,883 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:35,900 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:35,914 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:35,948 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:36,022 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:36,030 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:36,190 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:36,247 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:36,297 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:36,308 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:36,358 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:36,501 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:36,511 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:36,615 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:36,672 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:36,741 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:36,858 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:36,887 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:36,889 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:36,998 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:37,015 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:37,022 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:37,060 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:37,125 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:37,189 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:37,238 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:37,286 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:37,334 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:37,382 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:37,479 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:37,522 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:37,531 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:37,554 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:37,556 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:37,589 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:37,599 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:37,644 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:37,681 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:37,775 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:37,783 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:37,875 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:37,975 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:37,984 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:38,000 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:38,106 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:38,126 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:38,155 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:38,175 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:38,176 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:38,188 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:38,206 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:38,214 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:38,301 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:38,338 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:38,342 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:38,382 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:38,784 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:38,790 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:38,847 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:38,900 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:38,907 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:39,067 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:39,109 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:39,155 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:39,162 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:39,189 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:39,227 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:39,274 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:39,359 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:39,596 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:39,599 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:39,656 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:39,666 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:39,675 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:39,741 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:39,967 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:40,012 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:40,124 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:40,180 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:40,202 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:40,210 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:40,225 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:40,338 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:40,609 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:40,648 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:40,839 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:40,941 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:41,025 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:41,072 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:41,198 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:41,508 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:41,523 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:41,849 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:41,908 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:42,008 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:42,941 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:43,523 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:44,729 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:57,705 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:57,820 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:57,880 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:57,912 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:58,085 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:58,110 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:58,198 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:58,240 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:58,345 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:58,405 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:58,417 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:58,479 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:58,518 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:58,581 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:58,596 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:58,597 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:58,602 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:58,643 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:58,652 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:58,677 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:58,689 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:58,696 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:58,795 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:58,797 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:58,811 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:58,834 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:58,852 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:58,875 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:58,906 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:58,917 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:59,013 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:59,015 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:59,022 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:59,086 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:59,111 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:59,189 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:59,277 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:59,380 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:59,491 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:59,546 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:59,622 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:59,636 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:59,647 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:59,845 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:59,873 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:59,874 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:59,883 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:59,926 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:43:59,950 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:00,063 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:00,064 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:00,073 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:00,112 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:00,135 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:00,204 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:00,219 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:00,260 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:00,319 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:00,354 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:00,362 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:00,370 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:00,398 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:00,413 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:00,413 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:00,420 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:00,471 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:00,504 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:00,596 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:00,597 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:00,703 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:00,720 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:00,790 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:00,805 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:00,930 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:01,027 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:01,094 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:01,140 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:01,209 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:01,218 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:01,293 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:01,389 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:01,457 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:01,472 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:01,486 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:01,515 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:01,524 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:01,595 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:01,626 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:01,650 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:01,727 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:01,900 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:01,947 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:02,020 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:02,064 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:02,066 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:02,120 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:02,130 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:02,139 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:02,238 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:02,331 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:02,441 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:02,454 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:02,514 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:02,645 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:02,677 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:02,686 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:02,704 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:02,791 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:02,817 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:02,867 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:02,941 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:02,990 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:03,209 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:03,221 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:03,253 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:03,261 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:03,330 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:03,411 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:03,459 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:03,510 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:03,610 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:03,618 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:03,620 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:03,639 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:03,653 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:03,738 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:03,813 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:03,861 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:03,878 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:03,886 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:03,927 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:03,977 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:04,021 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:04,079 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:04,131 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:04,231 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:04,304 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:04,436 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:04,440 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:04,498 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:04,565 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:04,575 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:04,671 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:04,710 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:04,718 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:04,742 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:04,830 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:04,953 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:04,978 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:04,979 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:04,997 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:05,012 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:05,021 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:05,071 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:05,073 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:05,080 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:05,088 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:05,111 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:05,217 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:05,293 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:05,345 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:05,394 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:05,461 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:05,521 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:05,575 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:05,593 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:05,604 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:05,689 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:05,728 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:05,881 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:05,931 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:06,080 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:06,083 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:06,144 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:06,265 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:06,390 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:06,521 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:06,570 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:06,629 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:06,720 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:06,764 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:06,784 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:06,941 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:06,968 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:07,019 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:07,144 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:07,218 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:07,314 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:07,452 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:07,479 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:07,493 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:07,886 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:08,380 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:08,464 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:12,803 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:17,967 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:22,211 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:23,853 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:24,400 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:24,486 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:37,096 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:37,431 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:37,469 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:37,594 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:37,738 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:38,146 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:38,180 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:38,195 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:38,209 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:38,348 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:38,355 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:38,361 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:38,428 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:38,437 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:38,512 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:38,534 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:38,556 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:38,570 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:38,579 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:38,635 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:38,641 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:38,683 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:38,684 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:38,711 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:38,712 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:38,717 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:38,727 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:38,770 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:38,777 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:38,800 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:38,807 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:38,828 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:38,852 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:38,863 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:38,885 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:38,894 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:38,900 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:38,919 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:38,980 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:38,988 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:39,060 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:39,061 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:39,162 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:39,197 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:39,230 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:39,240 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:39,244 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:39,270 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:39,340 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:39,362 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:39,387 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:39,464 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:39,486 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:39,514 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:39,529 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:39,552 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:39,665 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:39,790 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:39,798 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:39,873 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:39,875 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:39,878 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:39,895 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:39,912 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:39,935 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:39,976 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:40,011 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:40,064 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:40,071 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:40,246 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:40,253 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:40,354 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:40,384 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:40,411 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:40,437 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:40,447 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:40,464 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:40,543 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:40,549 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:40,549 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:40,585 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:40,611 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:40,639 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:40,696 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:40,748 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:40,943 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:41,063 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:41,212 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:41,473 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:41,569 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:41,632 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:41,687 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:41,694 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:41,762 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:41,814 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:41,829 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:42,124 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:42,163 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:42,421 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:42,455 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:42,471 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:42,515 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:42,520 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:42,556 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:42,605 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:42,689 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:42,690 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:42,816 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:42,910 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:42,944 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:42,980 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:42,988 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:43,019 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:43,187 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:43,196 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:43,263 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:43,341 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:43,391 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:43,398 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:43,480 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:43,496 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:43,611 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:43,683 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:43,707 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:43,709 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:43,755 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:43,781 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:43,790 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:43,807 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:43,812 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:43,830 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:43,864 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:43,873 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:43,910 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:43,917 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:43,923 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:43,960 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:43,982 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:44,028 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:44,095 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:44,120 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:44,138 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:44,247 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:44,265 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:44,287 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:44,417 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:44,456 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:44,501 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:44,515 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:44,527 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:44,553 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:44,562 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:44,572 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:44,576 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:44,579 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:44,641 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:44,706 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:44,715 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:44,821 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:44,860 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:44,888 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:44,912 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:44,965 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:45,046 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:45,098 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:45,120 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:45,145 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:45,207 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:45,211 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:45,263 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:45,332 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:45,358 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:45,379 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:45,380 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:45,478 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:45,621 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:45,650 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:45,705 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:45,873 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:46,132 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:46,279 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:46,313 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:46,398 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:46,584 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:46,706 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:46,798 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:46,859 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:46,947 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:47,044 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:47,096 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:47,358 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:47,380 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:47,521 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:47,795 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:47,965 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:48,100 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:48,758 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:50,012 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:50,137 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:44:50,189 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:02,990 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:03,422 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:03,449 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:03,758 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:03,817 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:03,819 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:03,880 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:03,885 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:03,926 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:03,971 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:03,975 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:03,982 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:03,982 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:03,990 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:04,027 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:04,065 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:04,101 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:04,168 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:04,180 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:04,211 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:04,216 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:04,242 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:04,274 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:04,300 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:04,330 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:04,335 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:04,382 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:04,417 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:04,419 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:04,426 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:04,443 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:04,444 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:04,504 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:04,505 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:04,520 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:04,557 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:04,557 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:04,565 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:04,567 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:04,575 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:04,594 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:04,673 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:04,678 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:04,731 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:04,732 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:04,752 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:04,844 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:04,850 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:04,857 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:04,900 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:05,001 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:05,015 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:05,035 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:05,125 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:05,254 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:05,383 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:05,404 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:05,578 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:05,633 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:05,634 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:05,667 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:05,717 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:05,733 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:05,743 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:05,837 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:05,893 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:05,899 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:05,916 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:05,945 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:05,993 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:06,129 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:06,148 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:06,227 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:06,264 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:06,274 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:06,510 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:06,513 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:06,642 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:06,764 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:06,778 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:06,811 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:06,870 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:06,876 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:06,910 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:06,967 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:06,970 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:07,002 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:07,052 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:07,074 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:07,110 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:07,250 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:07,294 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:07,436 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:07,438 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:07,444 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:07,667 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:07,669 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:07,728 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:07,747 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:07,767 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:07,793 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:07,814 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:07,844 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:07,900 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:07,965 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:07,993 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:08,063 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:08,086 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:08,135 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:08,158 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:08,160 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:08,253 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:08,547 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:08,551 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:08,553 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:08,609 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:08,651 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:08,691 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:08,813 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:08,861 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:08,869 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:09,018 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:09,037 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:09,052 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:09,193 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:09,202 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:09,233 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:09,270 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:09,324 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:09,434 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:09,442 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:09,450 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:09,483 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:10,093 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:10,110 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:10,214 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:10,224 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:10,244 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:10,614 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:11,379 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:12,095 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:12,304 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:13,016 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:13,306 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:13,880 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:45:14,804 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:47:50,859 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-02 00:47:50,859 - INFO - NumExpr defaulting to 8 threads.
2024-01-02 00:47:51,187 - INFO - openai_wrapper loaded
2024-01-02 00:47:51,481 - INFO - Starting
2024-01-02 00:47:51,486 - INFO - file_cache is only supported with oauth2client<4.0.0
2024-01-02 00:47:56,906 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:47:57,527 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:47:57,632 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:47:58,037 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:47:58,051 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:47:58,133 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:47:58,981 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:47:59,174 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:00,301 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:04,041 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:44,411 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-02 00:48:44,411 - INFO - NumExpr defaulting to 8 threads.
2024-01-02 00:48:44,720 - INFO - openai_wrapper loaded
2024-01-02 00:48:45,012 - INFO - Starting
2024-01-02 00:48:45,016 - INFO - file_cache is only supported with oauth2client<4.0.0
2024-01-02 00:48:49,799 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:50,280 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:50,611 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:50,751 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:50,849 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:50,857 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:50,904 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:50,915 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:50,916 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:50,920 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:50,929 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:50,997 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:51,000 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:51,015 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:51,021 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:51,038 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:51,042 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:51,058 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:51,093 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:51,133 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:51,134 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:51,217 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:51,254 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:51,256 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:51,265 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:51,359 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:51,400 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:51,401 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:51,411 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:51,412 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:51,447 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:51,494 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:51,541 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:51,547 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:51,555 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:51,570 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:51,601 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:51,613 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:51,674 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:51,681 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:51,721 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:51,729 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:51,773 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:51,841 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:51,854 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:51,859 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:51,861 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:51,894 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:51,924 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:51,975 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:52,002 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:52,006 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:52,020 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:52,133 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:52,139 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:52,146 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:52,284 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:52,333 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:52,347 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:52,359 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:52,432 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:52,692 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:52,708 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:52,780 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:52,831 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:52,905 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:52,999 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:53,081 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:53,177 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:53,199 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:53,260 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:53,264 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:53,416 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:53,429 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:53,433 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:53,471 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:53,498 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:53,599 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:53,624 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:53,639 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:53,668 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:53,680 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:53,694 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:53,697 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:53,708 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:53,780 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:53,798 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:53,808 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:53,839 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:53,874 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:53,951 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:53,977 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:54,045 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:54,167 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:54,214 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:54,239 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:54,286 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:54,368 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:54,401 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:54,403 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:54,429 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:54,494 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:54,527 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:54,551 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:54,560 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:54,581 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:54,603 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:54,667 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:54,735 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:54,751 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:54,776 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:54,782 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:54,816 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:55,075 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:55,076 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:55,090 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:55,123 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:55,125 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:55,160 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:55,261 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:55,315 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:55,323 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:55,343 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:55,384 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:55,429 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:55,486 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:55,507 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:55,515 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:55,533 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:55,647 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:55,669 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:55,677 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:55,801 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:55,813 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:55,933 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:56,009 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:56,093 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:56,185 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:56,250 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:56,336 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:56,381 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:56,510 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:56,586 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:56,694 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:56,752 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:56,861 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:56,902 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:56,919 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:56,977 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:56,981 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:57,011 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:57,049 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:57,058 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:57,110 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:57,149 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:57,189 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:57,279 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:57,423 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:57,569 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:57,626 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:57,677 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:57,684 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:57,820 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:57,834 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:57,885 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:57,946 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:57,978 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:58,022 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:58,068 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:58,133 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:58,176 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:58,197 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:58,223 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:58,318 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:58,361 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:58,581 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:58,652 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:58,694 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:58,747 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:58,758 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:58,766 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:58,784 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:58,863 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:58,894 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:58,945 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:58,987 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:59,079 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:59,158 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:59,589 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:59,726 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:59,915 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:48:59,917 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:00,223 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:00,387 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:00,507 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:01,515 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:02,102 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:02,207 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:02,492 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:06,750 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:19,602 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:19,616 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:19,733 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:19,736 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:19,791 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:19,852 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:19,859 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:20,165 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:20,502 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:20,573 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:20,582 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:20,594 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:20,627 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:20,642 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:20,643 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:20,692 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:20,708 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:20,712 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:20,718 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:20,731 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:20,741 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:20,774 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:20,776 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:20,785 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:20,789 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:20,830 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:20,848 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:20,869 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:20,877 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:20,883 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:20,911 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:20,918 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:20,924 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:20,934 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:20,938 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:20,968 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:21,024 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:21,032 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:21,093 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:21,094 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:21,124 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:21,175 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:21,184 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:21,202 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:21,219 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:21,319 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:21,383 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:21,408 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:21,489 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:21,536 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:21,617 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:21,725 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:21,751 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:21,788 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:21,801 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:21,834 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:21,865 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:21,886 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:22,098 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:22,203 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:22,229 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:22,460 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:22,589 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:22,652 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:22,654 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:22,718 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:22,765 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:22,840 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:22,854 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:22,901 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:22,936 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:23,073 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:23,082 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:23,085 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:23,153 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:23,238 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:23,394 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:23,427 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:23,434 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:23,439 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:23,474 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:23,487 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:23,524 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:23,537 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:23,542 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:23,584 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:23,602 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:23,633 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:23,691 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:23,752 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:23,757 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:23,770 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:23,786 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:23,787 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:23,996 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:24,137 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:24,203 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:24,376 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:24,408 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:24,621 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:24,626 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:24,628 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:24,669 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:24,695 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:24,735 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:24,746 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:24,765 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:24,772 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:24,786 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:24,791 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:24,817 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:24,859 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:24,966 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:25,015 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:25,064 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:25,067 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:25,077 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:25,083 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:25,133 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:25,237 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:25,346 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:25,504 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:25,542 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:25,604 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:25,658 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:25,750 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:25,777 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:25,836 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:25,852 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:25,902 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:25,921 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:25,936 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:26,067 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:26,128 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:26,176 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:26,190 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:26,212 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:26,328 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:26,352 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:26,421 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:26,451 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:26,493 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:26,528 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:26,571 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:26,603 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:26,713 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:26,754 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:26,764 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:26,855 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:26,926 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:26,970 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:26,991 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:27,032 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:27,051 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:27,126 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:27,209 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:27,234 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:27,377 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:27,460 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:27,472 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:27,475 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:27,521 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:27,621 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:27,650 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:27,730 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:27,783 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:27,827 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:27,873 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:27,887 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:27,892 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:27,977 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:28,055 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:28,169 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:28,214 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:28,244 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:28,338 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:28,354 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:28,389 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:28,392 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:28,584 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:28,620 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:28,627 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:28,678 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:28,778 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:28,866 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:28,986 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:28,999 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:29,202 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:29,395 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:29,625 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:29,638 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:29,684 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:29,980 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:30,170 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:30,372 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:30,432 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:30,921 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:30,934 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:32,653 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:34,254 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:47,131 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:47,274 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:47,347 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:47,826 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:47,894 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:47,908 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:48,013 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:48,052 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:48,097 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:48,154 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:48,164 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:48,168 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:48,254 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:48,292 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:48,305 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:48,308 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:48,322 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:48,327 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:48,327 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:48,361 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:48,369 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:48,388 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:48,451 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:48,465 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:48,553 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:48,554 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:48,611 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:48,636 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:48,861 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:48,964 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:48,987 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:48,995 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:49,009 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:49,062 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:49,075 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:49,128 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:49,268 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:49,312 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:49,352 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:49,396 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:49,444 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:49,598 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:49,617 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:49,694 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:49,747 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:49,760 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:49,761 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:49,774 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:49,784 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:49,814 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:49,867 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:49,919 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:49,953 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:49,957 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:49,985 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:49,994 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:50,008 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:50,088 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:50,120 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:50,123 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:50,161 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:50,162 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:50,162 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:50,219 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:50,247 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:50,299 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:50,300 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:50,332 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:50,411 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:50,419 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:50,504 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:50,589 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:50,595 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:50,612 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:50,638 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:50,728 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:50,780 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:50,824 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:50,857 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:50,977 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:51,054 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:51,135 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:51,154 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:51,504 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:51,589 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:51,634 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:51,718 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:51,743 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:51,864 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:51,887 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:51,979 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:52,123 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:52,134 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:52,145 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:52,184 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:52,220 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:52,262 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:52,325 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:52,387 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:52,393 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:52,437 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:52,438 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:52,460 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:52,525 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:52,707 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:52,726 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:52,729 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:52,745 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:52,887 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:52,903 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:53,012 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:53,094 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:53,103 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:53,156 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:53,181 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:53,242 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:53,253 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:53,271 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:53,272 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:53,362 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:53,409 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:53,426 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:53,488 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:53,529 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:53,554 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:53,620 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:53,659 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:53,673 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:53,721 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:53,762 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:53,886 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:53,893 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:53,901 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:53,946 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:53,951 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:54,007 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:54,025 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:54,078 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:54,144 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:54,153 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:54,188 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:54,236 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:54,239 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:54,261 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:54,322 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:54,336 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:54,361 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:54,395 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:54,488 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:54,495 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:54,496 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:54,599 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:54,609 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:54,620 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:54,788 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:54,817 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:54,930 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:54,934 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:55,120 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:55,210 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:55,245 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:55,267 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:55,276 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:55,378 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:55,403 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:55,446 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:55,474 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:55,563 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:55,642 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:55,659 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:55,769 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:55,858 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:55,868 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:55,938 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:55,996 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:56,055 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:56,087 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:56,345 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:56,456 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:56,488 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:56,575 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:56,670 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:56,678 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:56,736 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:56,836 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:56,957 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:56,995 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:57,051 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:57,342 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:57,785 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:57,786 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:57,867 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:57,868 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:58,050 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:58,305 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:58,429 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:58,539 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:58,614 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:49:59,100 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:06,902 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:20,051 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:20,130 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:20,651 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:20,661 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:20,687 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:20,768 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:20,803 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:20,871 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:20,878 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:20,894 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:20,909 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:20,977 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:21,178 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:21,188 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:21,203 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:21,212 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:21,229 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:21,268 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:21,361 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:21,377 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:21,385 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:21,386 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:21,400 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:21,403 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:21,408 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:21,408 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:21,420 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:21,470 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:21,504 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:21,520 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:21,521 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:21,534 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:21,576 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:21,577 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:21,588 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:21,607 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:21,616 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:21,654 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:21,709 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:21,737 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:21,770 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:21,776 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:21,819 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:21,826 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:21,836 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:21,867 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:21,910 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:21,918 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:22,004 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:22,023 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:22,044 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:22,077 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:22,090 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:22,109 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:22,137 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:22,453 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:22,462 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:22,529 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:22,537 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:22,571 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:22,623 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:22,640 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:22,691 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:22,695 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:22,753 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:22,863 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:22,875 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:22,911 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:23,027 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:23,108 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:23,263 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:23,355 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:23,403 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:23,421 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:23,516 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:23,543 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:23,583 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:23,610 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:23,669 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:23,675 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:23,753 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:23,772 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:23,783 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:23,872 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:23,886 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:24,028 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:24,120 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:24,222 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:24,224 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:24,288 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:24,337 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:24,367 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:24,455 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:24,494 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:24,527 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:24,537 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:24,571 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:24,611 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:24,771 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:24,796 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:24,810 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:24,828 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:24,831 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:24,899 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:24,905 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:24,922 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:24,936 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:25,023 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:25,026 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:25,028 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:25,029 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:25,040 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:25,043 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:25,044 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:25,162 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:25,171 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:25,185 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:25,226 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:25,442 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:25,448 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:25,468 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:25,471 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:25,535 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:25,589 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:25,611 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:25,620 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:25,706 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:25,821 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:25,854 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:25,917 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:26,014 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:26,038 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:26,072 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:26,103 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:26,155 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:26,203 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:26,219 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:26,290 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:26,513 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:26,540 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:26,545 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:26,575 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:26,605 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:26,612 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:26,677 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:26,803 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:26,854 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:26,871 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:26,930 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:26,931 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:27,018 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:27,029 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:27,037 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:27,067 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:27,071 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:27,111 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:27,195 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:27,196 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:27,269 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:27,281 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:27,356 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:27,369 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:27,395 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:27,405 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:27,468 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:27,486 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:27,503 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:27,519 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:27,523 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:27,612 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:27,626 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:27,670 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:27,712 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:27,714 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:27,735 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:27,857 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:27,951 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:28,097 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:28,177 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:28,211 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:28,296 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:28,347 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:28,539 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:28,564 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:28,617 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:28,962 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:29,194 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:29,202 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:29,330 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:29,379 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:29,436 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:29,477 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:29,494 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:29,744 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:29,864 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:30,657 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:31,072 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:31,438 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:32,221 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:37,313 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:49,956 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:50,137 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:50,735 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:50,751 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:50,765 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:50,826 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:50,878 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:50,926 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:50,971 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:51,017 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:51,065 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:51,101 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:51,161 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:51,168 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:51,170 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:51,211 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:51,277 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:51,311 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:51,319 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:51,320 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:51,484 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:51,490 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:51,524 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:51,552 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:51,617 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:51,618 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:51,639 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:51,699 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:51,734 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:51,756 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:51,786 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:51,793 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:51,800 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:51,833 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:51,842 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:51,857 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:51,929 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:51,986 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:52,001 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:52,005 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:52,029 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:52,160 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:52,166 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:52,317 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:52,342 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:52,401 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:52,423 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:52,431 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:52,448 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:52,465 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:52,502 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:52,533 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:52,579 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:52,597 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:52,649 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:52,696 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:52,707 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:52,761 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:52,806 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:52,822 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:52,869 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:52,979 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:53,070 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:53,082 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:53,116 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:53,126 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:53,166 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:53,193 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:53,201 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:53,208 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:53,235 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:53,260 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:53,339 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:53,346 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:53,493 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:53,565 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:53,577 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:53,583 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:53,612 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:53,696 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:53,716 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:53,717 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:53,737 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:53,757 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:53,834 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:53,927 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:53,995 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:54,092 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:54,154 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:54,197 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:54,284 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:54,350 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:54,367 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:54,376 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:54,434 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:54,550 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:54,569 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:54,709 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:54,744 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:54,922 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:54,982 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:55,018 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:55,184 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:55,212 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:55,237 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:55,238 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:55,272 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:55,326 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:55,494 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:55,540 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:55,551 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:55,552 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:55,566 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:55,600 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:55,702 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:55,767 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:55,791 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:55,801 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:56,055 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:56,194 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:56,201 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:56,211 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:56,283 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:56,301 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:56,303 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:56,333 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:56,344 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:56,345 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:56,348 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:56,433 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:56,436 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:56,600 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:56,630 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:56,632 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:56,643 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:56,675 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:56,701 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:56,740 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:56,747 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:56,760 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:56,922 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:57,086 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:57,256 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:57,270 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:57,307 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:57,346 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:57,375 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:57,413 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:57,496 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:57,533 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:57,569 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:57,576 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:57,685 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:57,861 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:57,891 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:57,944 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:57,946 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:58,096 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:58,098 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:58,259 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:58,261 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:58,276 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:58,328 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:58,395 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:58,446 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:58,487 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:58,507 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:58,571 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:58,583 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:58,721 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:58,734 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:58,736 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:58,738 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:58,838 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:58,894 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:58,916 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:58,999 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:59,039 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:59,045 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:59,085 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:59,158 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:59,176 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:59,195 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:59,217 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:59,219 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:59,347 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:59,411 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:59,796 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:59,935 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:50:59,997 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:00,138 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:00,147 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:00,277 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:00,511 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:01,835 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:01,982 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:02,264 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:02,501 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:02,571 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:03,088 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:16,138 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:16,360 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:16,462 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:16,477 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:16,578 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:16,591 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:16,688 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:16,734 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:16,786 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:16,835 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:16,860 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:16,928 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:17,002 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:17,070 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:17,195 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:17,203 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:17,211 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:17,245 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:17,319 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:17,336 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:17,344 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:17,345 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:17,366 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:17,444 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:17,469 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:17,478 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:17,505 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:17,535 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:17,536 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:17,582 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:17,585 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:17,601 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:17,629 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:17,648 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:17,681 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:17,686 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:17,711 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:17,712 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:17,713 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:17,763 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:17,793 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:17,905 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:17,938 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:17,977 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:17,995 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:18,003 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:18,021 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:18,031 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:18,035 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:18,064 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:18,100 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:18,133 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:18,138 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:18,198 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:18,219 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:18,243 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:18,249 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:18,578 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:18,623 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:18,668 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:18,771 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:18,829 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:18,851 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:18,947 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:18,993 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:19,131 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:19,137 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:19,162 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:19,170 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:19,210 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:19,234 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:19,362 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:19,379 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:19,380 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:19,442 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:19,512 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:19,537 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:19,555 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:19,579 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:19,585 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:19,736 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:19,769 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:19,790 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:19,899 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:19,910 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:19,927 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:19,933 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:20,003 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:20,037 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:20,121 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:20,220 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:20,311 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:20,355 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:20,393 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:20,532 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:20,547 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:20,568 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:20,647 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:20,653 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:20,754 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:20,768 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:20,779 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:20,784 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:20,793 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:20,835 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:20,870 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:20,895 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:21,010 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:21,102 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:21,221 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:21,233 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:21,280 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:21,480 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:21,485 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:21,579 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:21,708 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:21,780 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:21,782 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:21,801 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:21,802 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:21,860 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:21,864 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:21,934 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:21,969 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:22,030 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:22,104 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:22,196 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:22,212 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:22,297 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:22,493 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:22,532 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:22,579 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:22,669 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:22,682 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:22,744 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:22,895 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:22,919 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:22,997 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:23,002 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:23,031 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:23,102 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:23,104 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:23,108 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:23,109 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:23,137 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:23,202 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:23,252 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:23,304 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:23,322 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:23,395 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:23,397 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:23,420 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:23,478 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:23,502 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:23,528 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:23,537 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:23,547 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:23,550 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:23,785 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:23,786 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:23,912 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:24,077 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:24,154 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:24,236 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:24,472 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:24,503 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:24,520 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:24,601 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:24,636 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:24,663 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:25,025 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:25,031 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:25,072 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:25,356 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:25,438 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:25,465 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:25,571 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:25,644 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:25,666 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:25,688 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:25,711 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:25,746 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:25,823 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:25,840 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:25,938 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:26,032 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:26,083 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:26,566 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:26,757 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:27,062 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:27,085 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:27,297 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:27,590 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:27,710 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:28,063 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:28,082 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:28,257 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:30,703 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:30,962 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:46,997 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:51:59,841 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:00,092 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:00,172 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:00,187 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:00,341 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:00,413 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:00,466 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:00,640 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:00,703 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:00,766 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:00,778 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:00,795 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:00,829 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:00,853 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:00,854 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:00,871 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:00,887 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:00,946 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:01,012 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:01,014 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:01,015 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:01,097 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:01,157 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:01,171 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:01,184 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:01,207 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:01,208 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:01,214 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:01,273 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:01,278 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:01,328 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:01,474 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:01,529 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:01,534 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:01,608 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:01,616 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:01,645 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:01,690 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:01,737 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:01,761 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:01,771 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:01,825 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:01,874 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:01,921 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:01,929 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:01,930 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:01,988 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:02,081 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:02,330 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:02,482 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:02,505 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:02,520 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:02,570 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:02,581 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:02,624 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:02,644 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:02,650 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:02,662 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:02,800 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:02,808 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:02,889 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:02,897 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:02,904 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:02,996 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:03,008 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:03,056 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:03,101 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:03,223 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:03,238 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:03,265 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:03,280 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:03,327 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:03,332 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:03,361 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:03,397 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:03,631 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:03,649 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:03,756 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:03,822 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:03,858 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:03,881 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:03,964 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:03,974 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:04,079 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:04,087 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:04,121 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:04,262 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:04,265 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:04,270 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:04,371 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:04,378 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:04,390 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:04,447 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:04,723 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:04,730 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:04,849 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:04,856 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:04,873 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:04,933 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:04,944 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:05,000 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:05,038 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:05,050 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:05,065 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:05,133 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:05,146 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:05,195 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:05,291 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:05,298 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:05,383 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:05,473 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:05,476 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:05,649 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:05,679 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:05,700 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:05,745 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:05,746 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:05,771 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:05,819 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:05,845 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:05,855 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:06,025 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:06,072 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:06,125 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:06,130 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:06,141 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:06,237 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:06,333 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:06,383 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:06,408 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:06,416 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:06,514 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:06,587 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:06,614 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:06,649 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:06,676 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:06,724 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:06,748 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:06,751 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:06,780 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:06,789 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:06,816 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:06,870 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:06,933 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:07,004 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:07,056 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:07,079 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:07,136 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:07,191 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:07,335 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:07,339 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:07,373 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:07,423 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:07,484 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:07,621 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:07,637 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:07,744 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:07,750 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:08,033 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:08,053 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:08,066 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:08,131 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:08,214 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:08,248 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:08,280 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:08,308 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:08,399 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:08,431 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:08,440 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:08,556 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:08,588 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:08,776 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:08,841 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:08,904 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:08,934 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:09,202 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:09,213 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:09,221 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:09,288 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:09,356 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:09,372 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:09,585 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:09,755 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:09,972 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:10,141 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:10,196 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:10,215 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:10,263 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:10,309 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:10,348 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:10,434 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:10,465 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:10,643 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:10,657 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:11,230 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:11,374 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:11,462 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:12,157 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:12,951 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:16,160 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:29,369 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:29,459 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:29,753 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:29,850 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:29,859 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:29,868 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:29,873 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:29,908 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:29,975 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:29,993 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:30,004 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:30,061 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:30,073 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:30,082 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:30,126 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:30,134 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:30,147 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:30,216 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:30,265 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:30,291 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:30,319 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:30,366 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:30,373 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:30,432 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:30,485 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:30,517 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:30,544 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:30,592 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:30,682 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:30,697 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:30,702 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:30,733 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:30,736 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:30,741 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:30,757 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:30,819 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:30,825 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:30,835 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:30,841 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:30,897 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:30,920 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:30,930 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:30,964 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:30,973 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:31,005 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:31,015 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:31,029 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:31,033 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:31,039 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:31,083 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:31,114 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:31,146 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:31,236 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:31,326 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:31,443 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:31,460 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:31,485 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:31,507 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:31,523 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:31,543 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:31,557 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:31,568 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:31,685 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:31,719 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:31,759 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:31,789 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:31,806 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:31,842 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:31,873 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:31,952 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:31,958 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:31,984 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:32,135 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:32,137 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:32,152 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:32,158 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:32,159 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:32,366 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:32,383 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:32,393 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:32,452 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:32,535 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:32,537 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:32,618 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:32,620 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:32,639 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:32,725 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:33,023 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:33,034 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:33,066 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:33,259 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:33,294 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:33,301 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:33,370 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:33,374 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:33,402 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:33,481 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:33,515 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:33,523 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:33,635 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:33,757 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:33,806 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:33,858 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:33,991 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:34,083 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:34,100 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:34,183 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:34,252 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:34,576 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:34,649 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:34,819 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:34,857 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:34,889 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:34,916 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:35,025 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:35,103 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:35,114 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:35,172 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:35,209 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:35,247 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:35,249 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:35,269 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:35,274 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:35,332 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:35,334 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:35,370 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:35,436 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:35,439 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:35,655 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:35,665 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:35,795 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:35,840 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:35,984 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:35,991 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:36,050 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:36,094 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:36,124 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:36,165 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:36,236 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:36,241 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:36,318 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:36,323 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:36,657 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:36,766 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:37,593 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 00:52:38,492 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:14:22,327 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-02 01:14:22,328 - INFO - NumExpr defaulting to 8 threads.
2024-01-02 01:14:22,664 - INFO - openai_wrapper loaded
2024-01-02 01:14:22,956 - INFO - Starting
2024-01-02 01:14:53,467 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-02 01:14:53,467 - INFO - NumExpr defaulting to 8 threads.
2024-01-02 01:14:53,777 - INFO - openai_wrapper loaded
2024-01-02 01:14:54,074 - INFO - Starting
2024-01-02 01:15:00,228 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:15:01,275 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:15:01,351 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:15:01,358 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:15:01,519 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:15:03,509 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:15:03,828 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:15:04,136 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:15:04,256 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:15:04,904 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:15:18,031 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:15:18,558 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:15:18,588 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:15:19,240 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:15:20,459 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:15:20,481 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:15:20,785 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:15:21,168 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:15:23,541 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:15:23,873 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:27,365 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-02 01:16:27,365 - INFO - NumExpr defaulting to 8 threads.
2024-01-02 01:16:27,672 - INFO - openai_wrapper loaded
2024-01-02 01:16:27,964 - INFO - Starting
2024-01-02 01:16:32,947 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:33,080 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:33,281 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:33,416 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:33,442 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:33,460 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:33,519 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:33,822 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:33,837 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:33,885 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:33,986 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:34,021 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:34,052 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:34,066 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:34,109 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:34,203 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:34,386 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:34,396 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:34,452 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:34,463 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:34,501 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:34,596 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:34,748 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:34,804 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:34,814 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:34,815 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:34,914 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:34,929 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:34,951 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:34,973 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:34,986 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:35,028 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:35,042 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:35,052 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:35,053 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:35,058 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:35,087 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:35,161 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:35,170 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:35,286 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:35,322 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:35,373 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:35,439 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:35,503 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:35,513 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:35,565 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:35,570 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:35,589 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:35,626 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:35,630 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:35,763 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:35,768 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:35,849 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:35,945 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:36,071 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:36,206 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:36,392 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:36,422 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:36,543 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:36,548 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:36,560 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:36,568 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:36,596 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:36,678 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:36,747 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:36,753 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:36,828 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:36,880 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:36,957 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:37,181 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:37,185 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:37,271 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:37,272 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:37,346 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:37,446 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:37,603 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:37,613 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:37,694 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:37,747 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:37,767 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:37,871 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:37,889 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:38,022 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:38,169 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:38,255 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:38,282 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:38,313 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:38,318 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:38,420 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:38,487 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:38,495 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:38,672 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:38,817 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:38,822 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:38,838 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:38,893 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:38,970 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:39,087 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:39,161 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:39,185 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:39,233 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:39,270 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:39,290 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:39,295 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:39,485 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:39,570 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:39,583 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:39,622 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:39,679 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:39,687 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:39,737 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:39,746 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:39,777 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:39,853 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:39,876 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:39,984 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:40,020 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:40,037 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:40,184 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:40,295 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:40,364 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:40,703 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:40,728 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:40,795 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:40,796 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:40,820 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:40,894 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:40,896 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:41,021 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:41,049 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:41,054 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:41,154 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:41,249 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:41,251 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:41,258 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:41,285 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:41,387 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:41,402 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:41,435 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:41,560 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:41,661 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:41,670 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:41,726 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:41,759 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:41,859 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:41,897 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:41,899 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:41,973 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:41,975 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:42,010 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:42,014 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:42,045 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:42,199 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:42,213 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:42,595 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:42,626 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:42,647 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:42,713 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:42,794 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:42,826 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:42,829 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:42,894 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:42,905 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:42,985 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:43,106 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:43,132 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:43,229 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:43,495 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:43,536 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:43,565 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:43,587 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:43,698 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:43,700 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:43,730 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:43,976 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:44,102 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:44,433 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:44,458 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:44,884 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:45,012 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:45,110 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:45,248 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:45,662 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:45,783 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:45,814 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:46,020 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:46,096 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:46,102 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:46,322 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:46,805 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:46,824 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:47,067 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:47,205 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:47,746 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:48,647 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:49,083 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:49,699 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:49,788 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:50,639 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:16:52,288 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:05,438 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:05,605 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:06,180 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:06,389 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:06,412 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:06,446 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:06,499 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:06,580 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:06,607 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:06,673 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:06,733 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:06,743 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:06,866 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:06,882 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:06,983 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:07,005 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:07,074 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:07,089 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:07,096 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:07,107 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:07,145 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:07,156 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:07,189 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:07,200 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:07,207 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:07,256 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:07,317 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:07,320 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:07,324 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:07,325 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:07,406 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:07,574 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:07,577 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:07,634 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:07,819 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:07,848 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:07,915 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:07,966 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:07,967 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:07,981 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:07,986 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:08,000 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:08,039 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:08,120 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:08,157 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:08,158 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:08,192 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:08,208 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:08,240 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:08,280 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:08,395 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:08,420 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:08,456 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:08,510 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:08,562 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:08,714 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:08,723 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:08,835 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:08,865 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:08,919 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:09,098 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:09,308 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:09,346 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:09,355 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:09,437 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:09,668 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:09,699 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:09,705 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:09,729 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:09,851 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:09,856 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:09,970 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:10,092 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:10,094 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:10,201 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:10,209 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:10,255 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:10,266 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:10,482 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:10,514 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:10,677 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:10,686 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:10,716 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:10,722 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:10,827 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:10,937 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:10,947 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:10,979 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:11,066 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:11,256 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:11,424 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:11,435 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:11,460 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:11,546 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:11,698 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:11,706 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:11,784 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:11,834 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:11,893 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:11,907 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:11,982 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:12,011 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:12,018 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:12,043 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:12,106 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:12,159 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:12,228 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:12,261 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:12,411 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:12,551 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:12,554 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:12,566 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:12,761 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:12,793 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:12,831 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:12,833 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:12,951 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:12,986 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:13,032 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:13,359 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:13,408 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:13,468 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:13,555 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:13,624 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:13,665 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:13,690 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:13,705 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:13,893 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:13,947 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:13,952 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:14,021 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:14,028 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:14,065 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:14,066 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:14,070 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:14,085 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:14,099 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:14,104 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:14,183 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:14,217 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:14,335 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:14,340 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:14,358 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:14,584 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:14,753 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:14,793 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:14,817 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:14,820 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:14,825 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:15,220 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:15,301 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:15,366 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:15,616 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:15,652 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:15,673 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:15,754 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:15,836 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:15,859 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:15,873 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:15,913 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:15,922 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:16,033 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:16,176 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:16,385 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:16,575 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:16,585 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:16,642 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:16,735 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:16,737 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:16,988 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:17,167 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:17,172 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:17,378 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:17,535 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:17,564 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:17,677 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:17,819 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:17,892 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:18,011 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:18,184 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:18,404 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:18,558 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:18,592 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:18,904 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:18,926 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:19,103 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:19,167 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:19,463 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:19,649 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:19,784 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:19,969 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:20,200 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:20,608 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:21,073 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:21,199 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:22,600 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:25,383 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:25,689 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:34,101 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:38,122 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:51,477 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:51,507 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:51,601 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:51,891 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:51,936 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:52,158 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:52,209 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:52,331 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:52,357 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:52,372 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:52,461 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:52,523 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:52,592 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:52,593 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:52,615 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:52,675 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:52,700 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:52,707 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:52,711 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:52,782 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:52,785 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:52,806 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:52,847 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:52,945 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:52,954 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:52,983 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:52,984 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:53,015 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:53,030 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:53,233 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:53,268 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:53,341 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:53,367 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:53,377 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:53,416 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:53,442 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:53,456 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:53,467 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:53,500 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:53,509 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:53,522 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:53,524 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:53,548 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:53,553 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:53,620 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:53,676 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:53,677 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:53,724 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:53,730 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:53,816 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:53,982 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:53,993 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:54,013 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:54,157 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:54,222 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:54,279 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:54,340 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:54,358 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:54,374 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:54,376 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:54,518 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:54,708 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:54,775 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:54,833 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:54,995 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:55,040 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:55,243 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:55,245 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:55,272 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:55,313 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:55,327 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:55,391 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:55,423 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:55,438 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:55,513 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:55,592 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:55,850 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:55,950 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:55,963 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:55,973 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:56,014 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:56,015 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:56,043 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:56,225 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:56,332 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:56,542 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:56,547 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:56,732 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:56,784 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:56,890 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:56,947 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:56,995 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:57,053 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:57,138 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:57,322 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:57,332 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:57,375 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:57,457 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:57,475 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:57,756 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:57,782 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:57,857 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:57,943 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:57,976 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:58,048 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:58,054 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:58,098 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:58,206 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:58,291 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:58,423 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:58,445 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:58,455 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:58,523 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:58,548 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:58,615 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:58,700 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:58,806 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:58,841 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:58,915 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:58,955 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:58,966 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:59,093 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:59,097 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:59,161 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:59,222 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:59,226 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:59,295 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:59,327 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:59,330 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:59,353 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:59,497 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:59,532 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:59,598 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:59,631 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:59,708 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:59,730 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:59,796 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:59,818 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:59,856 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:59,862 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:59,957 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:59,961 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:59,984 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:17:59,997 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:00,055 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:00,071 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:00,167 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:00,242 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:00,255 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:00,552 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:00,553 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:00,564 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:00,609 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:00,612 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:00,718 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:00,833 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:00,871 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:00,989 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:00,998 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:01,030 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:01,175 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:01,456 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:01,514 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:01,530 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:01,539 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:01,595 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:01,672 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:01,720 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:01,752 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:01,841 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:01,889 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:01,943 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:01,955 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:01,982 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:02,084 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:02,147 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:02,298 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:02,383 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:02,437 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:02,924 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:03,012 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:03,074 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:03,249 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:03,254 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:03,571 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:03,639 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:03,706 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:03,736 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:03,838 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:03,865 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:03,978 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:04,097 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:05,175 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:05,563 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:05,628 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:05,689 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:05,774 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:05,866 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:06,331 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:06,588 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:19,483 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:20,213 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:20,580 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:20,716 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:20,719 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:20,822 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:21,004 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:21,017 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:21,138 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:21,139 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:21,225 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:21,251 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:21,269 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:21,370 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:21,391 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:21,402 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:21,473 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:21,501 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:21,552 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:21,561 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:21,582 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:21,613 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:21,618 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:21,625 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:21,632 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:21,657 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:21,686 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:21,789 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:21,808 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:22,051 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:22,083 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:22,168 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:22,174 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:22,175 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:22,208 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:22,212 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:22,226 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:22,385 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:22,563 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:22,736 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:22,823 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:22,870 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:22,871 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:22,891 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:23,004 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:23,053 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:23,071 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:23,075 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:23,194 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:23,201 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:23,210 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:23,252 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:23,253 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:23,386 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:23,426 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:23,443 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:23,461 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:23,622 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:23,637 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:23,640 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:23,684 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:23,832 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:23,837 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:23,850 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:23,915 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:24,150 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:24,156 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:24,213 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:24,217 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:24,275 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:24,416 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:24,495 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:24,583 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:24,684 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:24,741 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:24,825 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:24,826 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:24,876 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:24,928 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:24,942 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:25,035 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:25,100 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:25,173 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:25,209 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:25,294 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:25,295 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:25,359 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:25,542 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:25,758 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:25,771 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:25,869 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:25,875 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:25,975 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:26,034 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:26,098 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:26,135 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:26,239 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:26,318 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:26,384 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:26,445 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:26,469 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:26,474 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:26,479 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:26,509 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:26,627 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:26,825 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:26,850 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:26,921 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:26,966 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:26,974 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:27,004 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:27,077 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:27,124 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:27,127 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:27,161 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:27,212 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:27,291 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:27,509 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:27,520 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:27,724 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:27,738 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:27,866 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:27,953 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:28,122 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:28,137 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:28,227 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:28,360 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:28,436 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:28,442 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:28,477 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:28,568 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:28,641 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:28,670 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:28,744 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:28,817 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:28,820 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:28,843 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:28,958 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:29,051 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:29,052 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:29,153 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:29,170 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:29,220 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:29,271 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:29,307 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:29,378 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:29,442 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:29,552 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:29,575 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:29,577 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:29,583 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:29,586 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:29,590 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:29,619 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:29,624 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:29,702 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:29,707 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:29,806 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:29,869 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:29,916 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:30,010 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:30,111 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:30,161 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:30,207 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:30,225 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:30,259 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:30,361 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:30,503 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:30,748 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:30,759 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:30,782 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:31,271 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:31,284 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:31,328 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:31,443 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:31,458 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:31,587 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:31,688 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:31,769 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:32,224 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:32,541 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:32,545 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:32,665 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:32,762 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:32,776 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:32,893 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:32,983 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:33,024 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:33,409 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:33,469 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:33,550 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:34,011 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:34,225 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:34,287 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:34,385 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:34,625 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:36,069 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:36,217 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:36,504 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:40,598 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:53,335 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:53,927 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:54,133 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:54,698 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:54,709 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:54,769 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:54,787 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:54,935 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:55,140 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:55,189 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:55,365 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:55,382 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:55,460 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:55,484 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:55,509 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:55,518 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:55,527 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:55,532 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:55,621 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:55,630 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:55,638 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:55,765 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:55,853 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:55,954 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:55,955 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:55,965 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:55,978 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:56,081 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:56,086 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:56,172 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:56,190 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:56,343 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:56,404 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:56,585 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:56,711 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:56,714 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:56,733 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:56,738 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:56,755 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:56,765 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:56,843 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:56,944 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:56,977 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:57,209 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:57,219 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:57,335 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:57,390 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:57,554 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:57,616 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:57,785 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:57,800 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:57,825 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:57,831 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:57,851 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:57,886 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:57,919 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:57,971 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:57,985 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:58,019 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:58,188 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:58,204 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:58,313 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:58,325 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:58,336 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:58,402 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:58,473 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:58,602 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:58,645 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:58,659 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:58,769 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:58,779 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:58,846 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:58,882 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:58,894 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:58,921 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:59,050 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:59,104 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:59,163 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:59,205 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:59,226 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:59,293 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:59,407 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:59,413 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:59,414 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:59,442 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:59,474 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:59,486 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:59,495 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:59,499 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:59,643 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:59,648 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:18:59,881 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:00,014 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:00,093 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:00,169 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:00,192 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:00,202 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:00,295 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:00,343 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:00,404 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:00,559 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:00,584 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:00,613 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:00,884 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:00,919 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:00,961 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:01,005 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:01,102 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:01,170 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:01,217 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:01,270 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:01,301 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:01,320 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:01,341 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:01,386 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:01,623 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:01,713 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:01,723 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:01,790 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:01,829 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:01,846 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:01,912 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:01,970 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:02,110 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:02,302 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:02,628 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:02,648 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:02,670 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:02,832 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:02,849 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:02,934 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:02,969 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:02,998 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:03,026 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:03,113 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:03,126 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:03,385 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:03,400 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:03,403 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:03,470 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:03,486 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:03,502 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:03,505 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:03,559 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:03,679 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:03,684 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:03,921 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:04,036 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:04,085 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:04,109 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:04,153 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:04,176 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:04,252 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:04,258 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:04,267 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:04,309 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:04,370 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:04,616 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:04,650 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:05,012 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:05,035 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:05,084 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:05,145 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:05,322 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:05,578 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:05,628 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:05,700 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:05,786 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:06,299 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:06,388 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:06,558 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:06,733 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:06,918 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:06,950 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:07,001 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:07,003 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:07,142 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:07,158 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:07,532 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:07,567 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:07,569 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:07,669 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:07,765 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:07,809 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:07,885 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:07,899 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:07,900 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:08,229 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:08,479 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:08,813 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:09,035 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:09,043 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:09,203 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:09,393 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:09,619 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:09,908 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:11,428 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:11,892 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:15,491 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:16,968 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:29,891 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:30,080 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:30,144 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:30,423 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:30,497 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:30,518 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:30,547 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:30,726 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:30,734 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:30,845 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:30,854 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:31,131 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:31,167 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:31,341 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:31,348 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:31,385 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:31,503 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:31,515 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:31,551 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:31,561 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:31,617 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:31,678 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:31,694 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:31,717 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:31,774 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:31,796 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:31,805 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:31,824 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:31,925 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:31,932 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:31,966 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:31,996 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:32,109 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:32,154 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:32,205 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:32,217 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:32,260 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:32,291 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:32,363 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:32,443 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:32,471 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:32,489 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:32,505 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:32,537 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:32,615 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:32,631 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:32,714 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:32,891 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:32,896 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:32,906 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:32,908 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:32,938 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:32,946 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:33,049 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:33,140 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:33,142 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:33,200 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:33,249 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:33,368 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:33,425 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:33,516 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:33,565 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:33,580 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:33,598 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:33,788 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:33,842 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:33,872 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:34,001 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:34,017 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:34,090 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:34,156 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:34,250 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:34,306 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:34,321 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:34,338 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:34,381 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:34,435 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:34,436 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:34,547 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:34,910 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:34,923 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:35,066 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:35,071 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:35,106 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:35,205 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:35,238 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:35,277 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:35,305 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:35,403 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:35,434 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:35,455 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:35,537 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:35,617 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:35,633 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:35,639 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:35,662 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:35,708 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:35,908 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:35,937 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:36,154 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:36,642 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:36,654 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:36,840 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:36,925 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:36,942 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:36,967 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:37,015 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:37,046 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:37,132 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:37,199 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:37,366 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:37,517 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:37,538 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:37,613 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:37,699 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:37,764 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:37,805 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:37,879 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:37,923 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:38,022 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:38,024 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:38,188 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:38,333 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:38,459 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:38,461 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:38,481 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:38,489 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:38,516 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:38,519 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:38,582 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:38,587 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:38,631 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:38,633 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:38,716 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:38,730 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:38,826 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:38,883 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:38,897 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:38,945 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:38,972 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:39,069 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:39,106 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:39,191 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:39,217 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:39,324 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:39,349 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:39,366 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:39,512 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:39,599 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:39,652 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:39,739 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:39,752 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:39,873 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:40,036 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:40,123 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:40,132 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:40,148 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:40,163 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:40,199 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:40,315 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:40,400 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:40,414 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:40,465 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:40,537 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:40,546 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:40,620 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:40,639 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:40,708 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:40,893 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:40,942 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:41,072 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:41,166 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:41,183 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:41,199 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:41,366 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:41,547 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:41,706 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:42,049 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:42,165 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:42,366 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:42,472 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:42,631 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:42,937 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:42,964 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:43,427 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:43,573 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:43,846 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:44,024 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:44,182 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:44,683 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:44,847 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:45,225 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:45,249 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:45,799 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:46,382 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:46,501 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:46,612 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:46,705 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:46,916 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:19:48,400 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:00,564 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:01,483 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:01,764 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:01,871 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:02,189 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:02,228 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:02,327 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:02,380 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:02,436 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:02,507 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:02,630 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:02,690 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:02,829 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:02,893 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:02,918 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:02,938 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:03,132 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:03,210 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:03,306 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:03,333 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:03,389 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:03,395 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:03,571 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:03,574 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:03,888 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:03,932 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:03,996 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:04,003 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:04,011 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:04,032 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:04,064 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:04,083 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:04,094 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:04,097 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:04,143 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:04,162 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:04,170 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:04,212 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:04,263 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:04,269 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:04,444 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:04,515 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:04,537 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:04,718 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:04,765 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:04,814 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:04,840 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:04,865 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:04,871 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:04,878 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:04,969 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:05,044 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:05,045 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:05,097 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:05,111 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:05,129 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:05,169 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:05,170 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:05,309 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:05,312 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:05,405 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:05,414 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:05,479 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:05,564 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:05,829 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:05,863 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:06,024 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:06,100 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:06,304 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:06,330 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:06,376 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:06,471 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:06,482 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:06,561 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:06,627 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:06,634 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:06,668 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:06,736 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:06,748 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:06,789 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:06,845 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:06,898 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:06,932 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:06,955 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:06,964 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:07,129 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:07,188 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:07,236 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:07,324 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:07,379 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:07,421 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:07,430 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:07,455 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:07,488 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:07,528 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:07,575 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:07,662 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:07,931 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:08,048 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:08,114 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:08,155 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:08,197 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:08,274 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:08,291 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:08,340 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:08,482 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:08,700 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:08,703 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:08,748 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:08,980 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:09,088 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:09,090 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:09,220 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:09,300 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:09,330 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:09,396 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:09,430 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:09,498 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:09,610 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:09,636 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:09,781 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:10,019 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:10,139 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:10,171 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:10,228 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:10,232 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:10,264 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:10,338 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:10,372 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:10,504 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:10,587 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:10,655 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:10,686 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:10,823 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:10,988 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:11,099 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:11,116 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:11,140 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:11,166 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:11,197 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:11,213 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:11,373 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:11,415 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:11,465 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:11,666 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:11,697 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:11,717 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:11,766 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:11,804 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:11,880 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:11,917 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:11,925 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:11,933 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:11,963 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:11,997 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:12,005 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:12,049 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:12,052 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:12,190 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:12,430 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:12,566 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:12,612 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:12,675 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:12,813 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:12,879 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:12,954 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:12,990 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:13,207 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:13,265 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:13,306 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:13,332 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:13,401 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:13,477 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:13,525 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:13,623 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:13,686 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:13,830 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:14,076 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:14,324 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:14,531 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:14,673 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:14,981 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:14,999 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:15,036 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:15,046 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:15,198 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:15,224 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:15,380 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:15,538 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:15,581 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:15,816 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:15,976 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:16,370 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:16,387 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:17,131 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:17,141 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:17,304 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:17,615 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:18,981 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:20,353 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:33,042 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:33,456 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:33,744 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:33,978 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:34,228 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:34,295 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:34,386 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:34,442 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:34,478 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:34,492 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:34,557 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:34,573 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:34,615 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:34,622 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:34,639 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:34,667 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:34,831 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:35,004 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:35,118 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:35,205 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:35,274 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:35,288 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:35,324 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:35,328 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:35,508 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:35,522 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:35,577 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:35,615 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:35,625 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:35,649 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:35,841 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:35,906 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:35,915 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:35,934 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:36,013 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:36,072 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:36,178 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:36,208 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:36,216 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:36,320 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:36,374 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:36,450 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:36,558 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:36,567 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:36,582 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:36,632 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:36,662 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:36,680 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:36,722 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:36,724 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:36,780 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:36,813 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:36,874 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:36,949 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:36,965 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:37,001 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:37,025 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:37,083 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:37,088 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:37,141 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:37,259 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:37,316 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:37,318 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:37,346 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:37,348 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:37,483 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:37,501 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:37,538 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:37,632 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:37,650 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:37,944 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:37,975 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:37,981 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:38,032 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:38,286 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:38,324 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:38,338 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:38,375 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:38,410 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:38,467 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:38,475 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:38,533 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:38,542 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:38,623 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:38,733 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:38,757 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:38,782 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:38,832 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:38,874 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:38,888 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:38,900 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:39,093 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:39,174 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:39,218 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:39,486 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:39,532 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:39,590 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:39,669 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:39,701 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:39,914 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:39,925 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:39,984 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:40,066 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:40,085 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:40,125 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:40,168 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:40,170 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:40,194 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:40,483 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:40,694 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:40,743 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:40,852 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:41,060 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:41,122 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:41,132 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:41,207 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:41,225 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:41,308 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:41,413 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:41,646 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:41,710 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:41,901 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:41,942 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:42,146 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:42,252 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:42,259 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:42,268 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:42,289 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:42,364 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:42,394 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:42,542 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:42,550 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:42,694 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:42,878 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:42,996 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:43,202 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:43,419 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:43,429 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:43,810 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:43,993 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:44,203 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:44,492 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:45,112 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:45,961 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:46,737 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:20:46,776 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 01:25:41,924 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-02 01:25:41,924 - INFO - NumExpr defaulting to 8 threads.
2024-01-02 01:25:42,237 - INFO - openai_wrapper loaded
2024-01-02 01:25:42,525 - INFO - Starting
2024-01-02 01:27:29,900 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-02 01:27:29,900 - INFO - NumExpr defaulting to 8 threads.
2024-01-02 01:27:30,213 - INFO - openai_wrapper loaded
2024-01-02 01:27:30,506 - INFO - Starting
2024-01-02 01:30:31,880 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-02 01:30:31,881 - INFO - NumExpr defaulting to 8 threads.
2024-01-02 01:30:32,198 - INFO - openai_wrapper loaded
2024-01-02 01:30:32,495 - INFO - Starting
2024-01-02 05:57:13,776 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-02 05:57:13,776 - INFO - NumExpr defaulting to 8 threads.
2024-01-02 05:57:14,136 - INFO - openai_wrapper loaded
2024-01-02 05:57:14,440 - INFO - Starting
2024-01-02 06:00:38,231 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-02 06:00:38,231 - INFO - NumExpr defaulting to 8 threads.
2024-01-02 06:00:38,546 - INFO - openai_wrapper loaded
2024-01-02 06:00:38,842 - INFO - Starting
2024-01-02 06:00:48,327 - INFO - "GET /?state=XQUmF6G9ZRndJDk8QoRJCuJVKzOaQ1&code=4/0AfJohXne5HrtWyJ1CqaQQ7fkL82i8D_Azema3HzREkpNEzNSDdCTdJ2vxPROgFhpQGYBew&scope=https://www.googleapis.com/auth/spreadsheets HTTP/1.1" 200 65
2024-01-02 06:00:48,756 - INFO - file_cache is only supported with oauth2client<4.0.0
2024-01-02 06:07:56,933 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-02 06:07:56,933 - INFO - NumExpr defaulting to 8 threads.
2024-01-02 06:07:57,253 - INFO - openai_wrapper loaded
2024-01-02 06:07:57,547 - INFO - Starting
2024-01-02 06:08:36,269 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-02 06:08:36,269 - INFO - NumExpr defaulting to 8 threads.
2024-01-02 06:08:36,589 - INFO - openai_wrapper loaded
2024-01-02 06:08:36,901 - INFO - Starting
2024-01-02 06:08:37,297 - INFO - file_cache is only supported with oauth2client<4.0.0
2024-01-02 06:11:32,869 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-02 06:11:32,869 - INFO - NumExpr defaulting to 8 threads.
2024-01-02 06:11:33,186 - INFO - openai_wrapper loaded
2024-01-02 06:11:33,485 - INFO - Starting
2024-01-02 06:11:33,857 - INFO - file_cache is only supported with oauth2client<4.0.0
2024-01-02 06:11:45,832 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-02 06:11:45,833 - INFO - NumExpr defaulting to 8 threads.
2024-01-02 06:11:46,159 - INFO - openai_wrapper loaded
2024-01-02 06:11:46,456 - INFO - Starting
2024-01-02 06:11:46,818 - INFO - file_cache is only supported with oauth2client<4.0.0
2024-01-02 06:12:01,369 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-02 06:12:01,369 - INFO - NumExpr defaulting to 8 threads.
2024-01-02 06:12:01,690 - INFO - openai_wrapper loaded
2024-01-02 06:12:01,987 - INFO - Starting
2024-01-02 06:12:02,353 - INFO - file_cache is only supported with oauth2client<4.0.0
2024-01-02 06:13:32,743 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-02 06:13:32,743 - INFO - NumExpr defaulting to 8 threads.
2024-01-02 06:13:33,079 - INFO - openai_wrapper loaded
2024-01-02 06:13:33,387 - INFO - Starting
2024-01-02 06:13:33,743 - INFO - file_cache is only supported with oauth2client<4.0.0
2024-01-02 06:16:20,669 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-02 06:16:20,669 - INFO - NumExpr defaulting to 8 threads.
2024-01-02 06:16:20,991 - INFO - openai_wrapper loaded
2024-01-02 06:16:21,290 - INFO - Starting
2024-01-02 06:16:21,666 - INFO - file_cache is only supported with oauth2client<4.0.0
2024-01-02 06:16:41,044 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-02 06:16:41,044 - INFO - NumExpr defaulting to 8 threads.
2024-01-02 06:16:41,363 - INFO - openai_wrapper loaded
2024-01-02 06:16:41,662 - INFO - Starting
2024-01-02 06:16:42,070 - INFO - file_cache is only supported with oauth2client<4.0.0
2024-01-02 06:17:08,543 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-02 06:17:08,544 - INFO - NumExpr defaulting to 8 threads.
2024-01-02 06:17:08,868 - INFO - openai_wrapper loaded
2024-01-02 06:17:09,170 - INFO - Starting
2024-01-02 06:17:09,530 - INFO - file_cache is only supported with oauth2client<4.0.0
2024-01-02 06:17:18,438 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 06:18:43,904 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-02 06:18:43,904 - INFO - NumExpr defaulting to 8 threads.
2024-01-02 06:18:44,261 - INFO - openai_wrapper loaded
2024-01-02 06:18:44,572 - INFO - Starting
2024-01-02 06:18:44,948 - INFO - file_cache is only supported with oauth2client<4.0.0
2024-01-02 06:18:51,451 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-02 06:22:56,094 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-02 06:22:56,094 - INFO - NumExpr defaulting to 8 threads.
2024-01-02 06:22:56,414 - INFO - openai_wrapper loaded
2024-01-02 06:22:56,715 - INFO - Starting
2024-01-02 06:22:57,140 - INFO - file_cache is only supported with oauth2client<4.0.0
2024-01-02 06:23:03,410 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-01-03 12:40:34,173 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-03 12:40:34,173 - INFO - NumExpr defaulting to 8 threads.
2024-01-03 12:40:37,374 - INFO - openai_wrapper loaded
2024-01-03 12:40:37,705 - INFO - Starting
2024-01-03 12:41:19,795 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-03 12:41:19,795 - INFO - NumExpr defaulting to 8 threads.
2024-01-03 12:41:20,117 - INFO - openai_wrapper loaded
2024-01-03 12:41:20,413 - INFO - Starting
2024-01-03 12:41:53,488 - INFO - Note: NumExpr detected 16 cores but "NUMEXPR_MAX_THREADS" not set, so enforcing safe limit of 8.
2024-01-03 12:41:53,488 - INFO - NumExpr defaulting to 8 threads.
2024-01-03 12:41:53,810 - INFO - openai_wrapper loaded
2024-01-03 12:41:54,115 - INFO - Starting
